



# Effective Health Care Program

---

Comparative Effectiveness Review  
Number 117

## **Pulmonary Arterial Hypertension: Screening, Management, and Treatment**



Agency for Healthcare Research and Quality  
Advancing Excellence in Health Care • [www.ahrq.gov](http://www.ahrq.gov)

# *Comparative Effectiveness Review*

---

Number 117

## **Pulmonary Arterial Hypertension: Screening, Management, and Treatment**

### **Prepared for:**

Agency for Healthcare Research and Quality  
U.S. Department of Health and Human Services  
540 Gaither Road  
Rockville, MD 20850  
[www.ahrq.gov](http://www.ahrq.gov)

**Contract No. 290-2007-10066-I**

### **Prepared by:**

Duke Evidence-based Practice Center  
Durham, NC

### **Investigators:**

Douglas C. McCrory, M.D., M.H.S.  
Remy R. Coeytaux, M.D., Ph.D.  
Kristine M. Schmit, M.D., M.P.H.  
Bryan Kraft, M.D.  
Andrzej S. Kosinski, Ph.D.  
Alicia M. Mingo, M.D.  
Lisa M. Vann, M.D.  
Daniel L. Gilstrap, M.D.  
C. William Hargett, M.D.  
Njira L. Lugogo, M.D.  
Brooke L. Heidenfelder, Ph.D.  
Rachael Posey, M.S.L.S.  
R. Julian Irvine, M.C.M.  
Liz Wing, M.A.  
Karen Pendergast, M.P.H.  
Rowena J. Dolor, M.D., M.H.S.

**AHRQ Publication No. 13-EHC087-EF  
April 2013**

This report is based on research conducted by the Duke Evidence-based Practice Center (EPC) under contract to the Agency for Healthcare Research and Quality (AHRQ), Rockville, MD (Contract No. 290-2007-10066-I). The findings and conclusions in this document are those of the authors, who are responsible for its contents; the findings and conclusions do not necessarily represent the views of AHRQ. Therefore, no statement in this report should be construed as an official position of AHRQ or of the U.S. Department of Health and Human Services.

The information in this report is intended to help health care decisionmakers—patients and clinicians, health system leaders, and policymakers, among others—make well-informed decisions and thereby improve the quality of health care services. This report is not intended to be a substitute for the application of clinical judgment. Anyone who makes decisions concerning the provision of clinical care should consider this report in the same way as any medical reference and in conjunction with all other pertinent information, i.e., in the context of available resources and circumstances presented by individual patients.

This report may be used, in whole or in part, as the basis for development of clinical practice guidelines and other quality enhancement tools, or as a basis for reimbursement and coverage policies. AHRQ or U.S. Department of Health and Human Services endorsement of such derivative products may not be stated or implied.

This document is in the public domain and may be used and reprinted without permission except those copyrighted materials that are clearly noted in the document. Further reproduction of those copyrighted materials is prohibited without the specific permission of copyright holders.

Persons using assistive technology may not be able to fully access information in this report. For assistance contact [EffectiveHealthCare@ahrq.hhs.gov](mailto:EffectiveHealthCare@ahrq.hhs.gov).

None of the investigators have any affiliations or financial involvement that conflicts with the material presented in this report.
---

**Suggested citation:** McCrory DC, Coeytaux RR, Schmit KM, Kraft B, Kosinski AS, Mingo AM, Vann LM, Gilstrap DL, Hargett CW, Lugogo NL, Heidenfelder BL, Posey R, Irvine RJ, Wing L, Pendergast K, Dolor RJ. Pulmonary Arterial Hypertension: Screening, Management, and Treatment. Comparative Effectiveness Review No. 117. (Prepared by the Duke Evidence-based Practice Center under Contract No. 290-2007-10066-I.) AHRQ Publication No. 13-EHC087-EF. Rockville, MD: Agency for Healthcare Research and Quality. April 2013. [www.effectivehealthcare.ahrq.gov/reports/final.cfm](http://www.effectivehealthcare.ahrq.gov/reports/final.cfm).

## Preface

The Agency for Healthcare Research and Quality (AHRQ), through its Evidence-based Practice Centers (EPCs), sponsors the development of systematic reviews to assist public- and private-sector organizations in their efforts to improve the quality of health care in the United States. These reviews provide comprehensive, science-based information on common, costly medical conditions, and new health care technologies and strategies.

Systematic reviews are the building blocks underlying evidence-based practice; they focus attention on the strength and limits of evidence from research studies about the effectiveness and safety of a clinical intervention. In the context of developing recommendations for practice, systematic reviews can help clarify whether assertions about the value of the intervention are based on strong evidence from clinical studies. For more information about AHRQ EPC systematic reviews, see [www.effectivehealthcare.ahrq.gov/reference/purpose.cfm](http://www.effectivehealthcare.ahrq.gov/reference/purpose.cfm).

AHRQ expects that these systematic reviews will be helpful to health plans, providers, purchasers, government programs, and the health care system as a whole. Transparency and stakeholder input are essential to the Effective Health Care Program. Please visit the Web site ([www.effectivehealthcare.ahrq.gov](http://www.effectivehealthcare.ahrq.gov)) to see draft research questions and reports or to join an email list to learn about new program products and opportunities for input.

We welcome comments on this systematic review. They may be sent by mail to the Task Order Officer named below at: Agency for Healthcare Research and Quality, 540 Gaither Road, Rockville, MD 20850, or by email to [epc@ahrq.hhs.gov](mailto:epc@ahrq.hhs.gov).

Carolyn M. Clancy, M.D.  
Director  
Agency for Healthcare Research and Quality

Jean Slutsky, P.A., M.S.P.H.  
Director, Center for Outcomes and Evidence  
Agency for Healthcare Research and Quality

Stephanie Chang M.D., M.P.H.  
Director, EPC Program  
Center for Outcomes and Evidence  
Agency for Healthcare Research and Quality

Elisabeth U. Kato, M.D., M.R.P.  
Task Order Officer  
Center for Outcomes and Evidence  
Agency for Healthcare Research and Quality

## Acknowledgments

The authors thank Megan von Isenburg, M.S.L.S., for help with the literature search and retrieval.

## Key Informants

In designing the study questions, the EPC consulted several Key Informants who represent the end-users of research. The EPC sought the Key Informant input on the priority areas for research and synthesis. Key Informants are not involved in the analysis of the evidence or the writing of the report. Therefore, in the end, study questions, design, methodological approaches, and/or conclusions do not necessarily represent the views of individual Key Informants.

Key Informants must disclose any financial conflicts of interest greater than \$10,000 and any other relevant business or professional conflicts of interest. Because of their role as end-users, individuals with potential conflicts may be retained. The TOO and the EPC work to balance, manage, or mitigate any conflicts of interest.

The list of Key Informants who participated in developing this report follows:

Neil C. Jensen, M.H.A., M.B.A.  
Director, Cardiology Networks  
United Healthcare  
Edina, MN

Lewis J. Rubin, M.D.  
Critical Care Medicine  
University of California, San Diego  
La Jolla, CA

Vallerie V. McLaughlin, M.D.  
Director, Pulmonary Hypertension Program  
University of Michigan  
Ann Arbor, MI

Sharad Vora, M.D.  
Carolina Pulmonary Medicine  
Cary, NC

Debjani Mukherjee, M.P.H.  
Associate Director, Evidence-Based  
Medicine, Science & Quality  
ACCF/AHA Guideline Staff  
Washington, DC

## Technical Expert Panel

In designing the study questions and methodology at the outset of this report, the EPC consulted several technical and content experts. Broad expertise and perspectives were sought. Divergent and conflicted opinions are common and perceived as healthy scientific discourse that results in a thoughtful, relevant systematic review. Therefore, in the end, study questions, design, methodologic approaches, and/or conclusions do not necessarily represent the views of individual technical and content experts.

Technical Experts must disclose any financial conflicts of interest greater than \$10,000 and any other relevant business or professional conflicts of interest. Because of their unique clinical or content expertise, individuals with potential conflicts may be retained. The TOO and the EPC work to balance, manage, or mitigate any potential conflicts of interest identified.

The list of Technical Experts who participated in developing this report follows:

James Klinger, M.D.  
Associate Professor of Medicine  
Brown University  
Providence, RI

Jonathan R. Lindner, M.D.  
Cardiology  
Oregon Health & Science University  
Portland, OR

Vallerie V. McLaughlin, M.D.  
Director, Pulmonary Hypertension Program  
University of Michigan  
Ann Arbor, MI

Stuart Rich, M.D.  
Clinical Professor of Medicine  
University of Chicago Medicine  
Chicago, IL

Lewis J. Rubin, M.D.  
Critical Care Medicine  
University of California, San Diego  
La Jolla, CA

Nelson B. Schiller, M.D.  
Professor in Residence, Department of  
Medicine (Cardiology)  
University of California, San Francisco  
San Francisco, CA

Rubin Tudor, M.D.  
Director, Program in Translational Lung  
Research  
University of Colorado, Denver  
Denver, CO

C. Michael White, Pharm.D.  
Professor and Head, Department of  
Pharmacy Practice  
University of Connecticut  
Storrs, CT

## Peer Reviewers

Prior to publication of the final evidence report, EPCs sought input from independent Peer Reviewers without financial conflicts of interest. However, the conclusions and synthesis of the scientific literature presented in this report does not necessarily represent the views of individual reviewers.

Peer Reviewers must disclose any financial conflicts of interest greater than \$10,000 and any other relevant business or professional conflicts of interest. Because of their unique clinical or content expertise, individuals with potential non-financial conflicts may be retained. The TOO and the EPC work to balance, manage, or mitigate any potential non-financial conflicts of interest identified.

The list of Peer Reviewers follows:

Nicholas Hill, M.D.  
Pulmonary and Critical Care Division  
New England Medical Center  
Tufts University School of Medicine  
Boston, MA

Bryan H. Ristow, M.D.  
Internal Medicine, Cardiovascular Disease  
California Pacific Medical Center  
San Francisco, CA

Alan L. Hinderliter, M.D.  
Cardiologist and Internist  
Associate Professor of Medicine  
University of North Carolina School of  
Medicine  
Chapel Hill, NC

# Pulmonary Arterial Hypertension: Screening, Management, and Treatment

## Structured Abstract

**Objectives.** Pulmonary arterial hypertension (PAH) is a rare and progressive disease associated with increased pulmonary vascular resistance that, if unrelieved, progresses to right ventricular pressure overload, dysfunction, right heart failure, and premature death. PAH is more prevalent in some populations, thereby warranting screening of asymptomatic individuals. This review seeks to evaluate the comparative validity, reliability, and feasibility of echocardiography and biomarker testing for the screening, diagnosis, and management of PAH; to clarify whether the use of echocardiography or biomarkers affects decisionmaking and clinical outcomes; and to determine which medications are effective for treating PAH and whether combination therapy is more effective than monotherapy.

**Data sources.** We searched PubMed®, Embase®, and the Cochrane Database of Systematic Reviews for relevant English-language comparative studies.

**Review methods.** Two investigators screened each abstract and full-text article for inclusion, abstracted data, rated quality and applicability, and graded the strength of evidence. Random-effects models were used to compute summary estimates of effect where several similar studies provided estimates.

**Results.** Sixty studies involving 7,096 patients evaluated biomarker tests, echocardiography, or both to screen for PAH. Symptom status of study populations consisted of asymptomatic (3 studies; 481 patients), symptomatic (41 studies; 4,394 patients), mixed (8 studies; 1,186 patients), and symptoms not described (8 studies; 1,035 patients). N-terminal pro-B-type natriuretic peptide (NT-proBNP) showed moderate correlation with right heart catheterization (RHC) hemodynamic measures and a great deal of variability between studies in its diagnostic accuracy and discrimination; however, one good-quality prospective cohort study suggested that biomarker testing with NT-proBNP might be useful in ruling out PAH in patients with symptoms suggestive of PAH who have elevated systolic pulmonary artery pressure (sPAP) by echocardiography. No data are available regarding combined echocardiography and biomarker screening in asymptomatic patients at high risk for PAH. Echocardiography estimates of pulmonary artery pressures (sPAP, tricuspid gradient [TG], and tricuspid regurgitant jet velocity [TRV]) and PVR (TRV/velocity-time integral of right ventricular outflow tract [VTI<sub>RVOT</sub>]) demonstrated good accuracy in screening for PAH, but accuracy varied with the prevalence of PAH in study populations.

Ninety-nine studies involving 8,655 patients evaluated biomarker tests, echocardiography, or both to evaluate severity or prognosis and followed progression of disease or response to therapy. B-type natriuretic peptide (BNP) showed moderate correlation with most RHC measures (mean pulmonary artery pressure [mPAP], PVR, cardiac index, right atrial pressure [RAP]) and clinical measures of disease severity (6-minute walk distance [6MWD]) and showed weak correlation with pulmonary capillary wedge pressure (PCWP), indicating that BNP levels alone could not serve as an accurate surrogate marker for disease severity. Echocardiography-derived



sPAP showed strong correlation with RHC-sPAP with a precise summary effect estimate, although there was a great deal of heterogeneity of results among individual studies. BNP level (summary hazard ratio [HR] 2.42; 95% confidence interval [CI], 1.72 to 3.41) and presence of pericardial effusion were strong predictors of mortality (summary HR 2.43; 95% CI, 1.57 to 3.77) RA size and uric acid were also predictive of mortality, but fractional area change (FAC) showed no significant ability to predict mortality, and data on TAPSE were insufficient.

Thirty-seven studies involving 4,192 patients assessed the effectiveness of drug treatments for PAH in adults. Few deaths were observed in these limited duration studies, leading to wide CIs and lack of statistical power to detect a mortality difference associated with treatment. All drug classes demonstrated increases in 6MWD when compared with placebo, but comparisons between agents were inconclusive. Combination therapy also showed improved 6MWD compared with monotherapy, but the diversity of treatment regimens and the small number of combination therapy trials again make comparisons between specific regimens inconclusive. The odds ratio (OR) of hospitalization was lower in patients taking endothelin receptor antagonists or phosphodiesterase-5 inhibitors compared with placebo (OR 0.34 and 0.48, respectively), while the reduction in patients taking prostanoids compared with placebo was similar but not statistically significant. Each drug class showed a favorable impact on at least two of the three hemodynamic outcomes: cardiac index, mPAP, and PVR.

The applicability of these findings is limited by the relative lack of diagnostic studies among asymptomatic patients and, in prognostic and diagnostic studies, inadequate description and apparent diversity of disease etiology and severity.

**Conclusions.** Further confirmation is needed to determine if the combination of echocardiography and the biomarker NT-proBNP is sufficiently accurate to rule out PAH when testing symptomatic patients. In asymptomatic populations, more research is needed to permit conclusions regarding their effectiveness for screening. BNP, RA size, presence of pericardial effusion, and uric acid had prognostic value in patients with PAH, but other echocardiographic parameters and biomarkers either were not predictive or had insufficient data. Although no studies were powered to detect a mortality reduction, monotherapy was associated with improved 6MWD and reduced hospitalization rates. Comparisons of different drug combinations were inconclusive regarding a mortality reduction but suggested an improvement in 6MWD when a second drug was added to existing monotherapy.

# Contents

<b>Executive Summary .....</b>	<b>ES-1</b>
<b>Introduction.....</b>	<b>1</b>
Background.....	1
Epidemiology and Etiology of Pulmonary Arterial Hypertension .....	1
Screening and Diagnosis.....	2
Treatment Strategies .....	4
Scope and Key Questions .....	5
Scope of the Review .....	5
Key Questions.....	5
<b>Methods.....</b>	<b>8</b>
Topic Refinement and Review Protocol.....	8
Literature Search Strategy.....	8
Sources Searched .....	8
Inclusion and Exclusion Criteria.....	9
Study Selection .....	11
Data Extraction .....	11
Quality (Risk-of-Bias) Assessment of Individual Studies.....	12
Data Synthesis.....	13
Strength of the Body of Evidence.....	14
Applicability .....	14
Peer Review and Public Commentary .....	15
<b>Results .....</b>	<b>16</b>
Results of Literature Searches .....	16
Description of Included Studies.....	18
KQ 1: Screening for PAH.....	19
Key Points.....	19
Description of Included Studies.....	19
Detailed Synthesis.....	20
Summary Strength of Evidence for KQ 1.....	56
KQ 2: Management of PAH .....	58
Key Points.....	58
Description of Included Studies.....	59
Detailed Synthesis.....	60
Summary Strength of Evidence for KQ 2.....	94
KQ 3: Pharmacotherapy for PAH.....	96
Key Points.....	96
Description of Included Studies.....	97
Detailed Synthesis of Randomized Controlled Trials.....	108
Summary Strength of Evidence for KQ 3.....	128
<b>Discussion.....</b>	<b>134</b>
Key Findings and Strength of Evidence .....	134
KQ 1: Screening for PAH.....	134
KQ 2: Management of PAH .....	136
KQ 3: Pharmacotherapy for PAH.....	138

Findings in Relation to What is Already Known.....	140
Applicability .....	142
Implications for Clinical and Policy Decisionmaking .....	143
Limitations of the Comparative Effectiveness Review Process .....	144
Limitations of the Evidence Base .....	144
Research Gaps.....	147
KQ 1: Screening for PAH.....	147
KQ 2: Management of PAH .....	147
KQ 3: Pharmacotherapy for PAH.....	148
<b>Conclusions</b> .....	148
<b>References</b> .....	150
<b>Abbreviations</b> .....	163

## Tables

Table A. Clinical classification of pulmonary hypertension .....	ES-1
Table B. Summary of strength of evidence and effect estimates for echocardiography versus echocardiography plus biomarkers as screening modalities for PAH (KQ 1) .....	ES-13
Table C. Summary of strength of evidence and effect estimates for the use of echocardiography or biomarkers in the management of PAH (KQ 2) .....	ES-17
Table D. Summary of strength of evidence and effect estimates for the use of echocardiography or biomarkers in the prediction of mortality (KQ 2) .....	ES-18
Table E. Summary of strength of evidence and effect estimates for monotherapy versus combination therapy for PAH (KQ 3) .....	ES-20
Table 1. Updated clinical classification of pulmonary hypertension (Dana Point, 2008) .....	1
Table 2. Inclusion and exclusion criteria .....	9
Table 3. Definitions of overall quality ratings .....	13
Table 4. Strength of evidence required domains .....	14
Table 5. Diagnostic accuracy of biomarkers for PAH.....	22
Table 6. Biomarker levels by diagnostic group .....	26
Table 7. Correlations of biomarkers with RHC in PAH.....	29
Table 8. Diagnostic accuracy of echocardiographic parameters for diagnosis of PAH .....	31
Table 9. Sensitivity analysis of echocardiography sPAP by study characteristics .....	38
Table 10. Echocardiographic parameter values by diagnostic group .....	40
Table 11. Correlation of echocardiographic parameters with RHC in PAH .....	47
Table 12. Further data on accuracy of echocardiographic estimates of sPAP compared with RHC, described as percentage of patients within a specified threshold .....	55
Table 13. Summary strength of evidence for KQ 1: Echocardiography sPAP with NT-proBNP versus echocardiography sPAP in symptomatic patients.....	56
Table 14. Summary strength of evidence for KQ 1: NT-proBNP compared with RHC .....	57
Table 15. Summary strength of evidence for KQ 1: TRV/TG/sPAP compared with RHC .....	57
Table 16. Summary strength of evidence for KQ 1: TRV/VTI <sub>RVOT</sub> compared with RHC.....	58
Table 17. Hazard ratio table for KQ 2 .....	69
Table 18. Studies reporting changes in mean values over time .....	81
Table 19. Studies reporting changes in median levels over time.....	88
Table 20. Studies reporting mean or median change from baseline .....	91

Table 21. Summary strength of evidence for KQ 2: assessment of prognostic value .....	94
Table 22. Summary strength of evidence for KQ 2: assessment of predictive value .....	95
Table 23. Study characteristics table for KQ 3 (RCTs) .....	99
Table 24. Study characteristics table for KQ 3 (nonrandomized studies) .....	106
Table 25. Summary strength of evidence for KQ 3: Mortality .....	128
Table 26. Summary strength of evidence for KQ 3: 6MWD .....	130
Table 27. Summary strength of evidence for KQ 3: Hospitalization .....	130
Table 28. Summary strength of evidence for KQ 3: Pulmonary vascular resistance .....	131
Table 29. Summary strength of evidence for KQ 3: Mean pulmonary artery pressure .....	131
Table 30. Summary strength of evidence for KQ 3: Cardiac index .....	132
Table 31. Summary strength of evidence for KQ 3: Adverse events .....	132
Table 32. Summary of strength of evidence and effect estimates for echocardiography vs. echocardiography plus biomarkers as screening modalities for PAH (KQ 1) .....	135
Table 33. Summary of strength of evidence and effect estimates for the use of echocardiography or biomarkers in the management of PAH (KQ 2) .....	137
Table 34. Summary of strength of evidence and effect estimates for the use of echocardiography or biomarkers in the prediction of mortality (KQ 2) .....	138
Table 35. Summary of strength of evidence and effect estimates for monotherapy versus combination therapy for PAH (KQ 3) .....	140

## Figures

Figure A. Analytic framework for KQs 1 and 2 .....	ES-6
Figure B. Analytic framework for KQ 3 .....	ES-7
Figure C. Literature flow diagram .....	ES-11
Figure 1. Analytic framework for KQs 1 and 2 .....	6
Figure 2. Analytic framework for KQ 3 .....	7
Figure 3. Literature flow diagram .....	17
Figure 4. Sensitivity and specificity of NT-proBNP levels for predicting development of PAH .....	24
Figure 5. Sensitivity and specificity of NT-proBNP for diagnosis of PAH .....	25
Figure 6. Summary sensitivity and specificity values for echocardiography sPAP diagnosis of PH .....	37
Figure 7. Sensitivity and specificity of echocardiography sPAP for diagnosis of PAH .....	38
Figure 8. Sensitivity and specificity of TRV/VTI <sub>RVOT</sub> for diagnosis of PAH .....	39
Figure 9. Forest plot of correlation between BNP and RHC-mPAP .....	62
Figure 10. Forest plot of correlation between BNP and RHC-PVR .....	63
Figure 11. Forest plot of correlation between BNP and RHC-RAP .....	64
Figure 12. Forest plot of correlation between BNP and RHC-CI .....	65
Figure 13. Forest plot of correlation between BNP and 6MWD .....	66
Figure 14. Forest plot of correlation between BNP and RHC-PCWP .....	67
Figure 15. Forest plot of correlation between echocardiography-sPAP and RHC-sPAP .....	68
Figure 16. Forest plot of hazard ratio for log-transformed BNP and mortality .....	76
Figure 17. Forest plot of hazard ratio for BNP (without mention of log-transformation) and mortality .....	76
Figure 18. Forest plot of hazard ratio for pericardial effusion and mortality .....	77
Figure 19. Forest plot of hazard ratio for RA size and mortality .....	77

Figure 20. Forest plot of hazard ratio for FAC and mortality .....	78
Figure 21. Forest plot of hazard ratio for serum uric acid level and mortality .....	79
Figure 22. Forest plot of hazard ratio for TAPSE and mortality .....	79
Figure 23. Forest plot of odds ratio for mortality—ambrisentan versus placebo .....	109
Figure 24. Forest plot of odds ratio for mortality—bosentan versus placebo .....	110
Figure 25. Forest plot of odds ratio for mortality—intravenous epoprostenol versus standard therapy .....	110
Figure 26. Forest plot of odds ratio for mortality—aerosolized iloprost versus placebo .....	111
Figure 27. Forest plot of odds ratio for mortality—treprostinil versus placebo .....	111
Figure 28. Forest plot of odds ratio for mortality by drug class .....	113
Figure 29. Forest plot of effects of therapy by drug class on 6MWD .....	115
Figure 30. Forest plot of effects of therapy by drug class on hospitalization .....	117
Figure 31. Forest plot of effects of therapy by drug class on pulmonary vascular resistance .....	118
Figure 32. Forest plot of effects of therapy by drug class on mean pulmonary artery pressure .....	119
Figure 33. Forest plot of effects of therapy by drug class on cardiac index .....	120
Figure 34. Forest plot of effects of therapy by drug class on headache.....	121
Figure 35. Forest plot of effects of therapy by drug class on dizziness.....	122
Figure 36. Forest plot of effects of therapy by drug class on diarrhea .....	123
Figure 37. Forest plot of effects of therapy by drug class on peripheral edema.....	124
Figure 38. Forest plot of effects of therapy by drug class on jaw pain.....	125
Figure 39. Forest plot of effects of therapy by drug class on flushing .....	126
Figure 40. Forest plot of effects of therapy by drug class on cough.....	127
Figure 41. Forest plot of effects of therapy by drug class on infections.....	128
Figure 42. Regression of functional class on log odds ratio .....	142

## Appendixes

Appendix A. Exact Search Strings
Appendix B. Data Abstraction Elements
Appendix C. List of Included Studies
Appendix D. Quality and Applicability of Included Studies
Appendix E. List of Excluded Studies
Appendix F. Study Characteristics Tables (KQ 1 and KQ 2)
Appendix G. Correlation Table for KQ 2

# Executive Summary

## Background

### Epidemiology and Etiology of Pulmonary Arterial Hypertension

Pulmonary arterial hypertension (PAH), a subcategory of pulmonary hypertension (PH), is a rare and progressive disease whose prevalence is estimated to be between 15 and 50 cases per 1 million adults.<sup>1</sup> While the pathophysiology is not well understood, both genetic and environmental factors have been found to contribute to changes in the pulmonary vasculature, causing increased pulmonary vascular resistance. This increased resistance, if unrelieved, progresses to right ventricular pressure overload, dysfunction, and ultimately right heart failure and premature death.<sup>2</sup> The causes of PAH are numerous and are listed in Table A, taken from the Fourth World Symposium on PAH (2008).<sup>3</sup> Before the availability of disease-specific therapy in the mid-1980s, the median life expectancy at the time of diagnosis was 2.8 years.<sup>1,4</sup>

**Table A. Updated clinical classification of pulmonary hypertension (Dana Point, 2008)<sup>a</sup>**

<b>1.</b>	<b>Pulmonary arterial hypertension (PAH)</b>
1.1	Idiopathic PAH
1.2	Heritable
1.2.1	BMPR2
1.2.2	ALK1, endoglin (with or without hereditary hemorrhagic telangiectasia)
1.2.3	Unknown
1.3	Drug and toxin-induced
1.4	Associated with:
1.4.1	Connective tissue disease
1.4.2	HIV infection
1.4.3	Portal hypertension
1.4.4	Congenital heart diseases
1.4.5	Schistosomiasis
1.4.6	Chronic hemolytic anemia
1.5	Persistent pulmonary hypertension of the newborn
<b>1'.</b>	<b>Pulmonary veno-occlusive disease (PVOD) and/or pulmonary capillary hemangiomatosis (PCH)</b>
<b>2.</b>	<b>Pulmonary hypertension owing to left heart disease</b>
2.1	Systolic dysfunction
2.2	Diastolic dysfunction
2.3	Valvular disease
<b>3.</b>	<b>Pulmonary hypertension owing to lung diseases and/or hypoxemia</b>
3.1	Chronic obstructive pulmonary disease
3.2	Interstitial lung disease
3.3	Other pulmonary diseases with mixed restrictive and obstructive pattern
3.4	Sleep-disordered breathing
3.5	Alveolar hypoventilation disorders
3.6	Chronic exposure to high altitude
3.7	Developmental abnormalities
<b>4.</b>	<b>Chronic thromboembolic pulmonary hypertension (CTEPH)</b>

**Table A. Updated clinical classification of pulmonary hypertension (Dana Point, 2008)<sup>a</sup>  
(continued)**

<b>5.</b>	<b>Pulmonary hypertension with unclear multifactorial mechanisms</b>
5.1	Hematologic disorders: myeloproliferative disorders, splenectomy
5.2	Systemic disorders: sarcoidosis, pulmonary Langerhans cell histiocytosis: lymphangioleiomyomatosis, neurofibromatosis, vasculitis
5.3	Metabolic disorders: glycogen storage disease, Gaucher disease, thyroid disorders
5.4	Others: tumoral obstruction, fibrosing mediastinitis, chronic renal failure on dialysis

ALK1 = activin receptor-like kinase type 1; BMPR2 = bone morphogenetic protein receptor type 2; HIV = human immunodeficiency virus

<sup>a</sup>Fourth World Symposium on PAH in Dana Point, CA (2008).

Table reprinted from the Journal of the American College of Cardiology, Vol 54, No. 1, Suppl S, Simonneau G, Robbins IM, Beghetti M, et al., Updated Clinical Classification of Pulmonary Hypertension, Pages No. S43-54, Copyright 2009, with permission from Elsevier.<sup>3</sup>

## Screening and Diagnosis

There are two separate populations for which screening for PAH needs to be considered. First, there are patients with symptoms that raise the suspicion of PAH. The symptoms of PAH can be insidious and nonspecific and may include shortness of breath, fatigue, weakness, chest pain, syncope, leg swelling, and abdominal distention. Symptoms that are present at rest suggest advanced disease.<sup>1</sup> Since these symptoms are nonspecific, screening may be necessary to help the physician decide whether the patient should undergo a diagnostic workup for PAH, or whether other conditions should be considered. The other population is patients with medical conditions that put them at risk for PAH. In these patients screening tests may be used to identify patients with asymptomatic elevation of pulmonary artery pressures, who might be more closely monitored for the development of symptoms or progressive disease or offered a diagnostic workup for PAH and possibly treatment for early disease.

Once screening indicates the possibility of PAH, diagnostic tests are necessary to confirm the presence of elevated right-sided heart pressures and to exclude valvular, primary myocardial, chronic lung disease, thromboembolic disease, and miscellaneous other causes of pulmonary hypertension (PH). The reference standard for diagnosing PAH is right heart catheterization (RHC), which is invasive but generally safe. In a retrospective and prospective study by Hoeper et al.,<sup>5</sup> the rate of serious complications in patients undergoing RHCs for evaluation of pulmonary hypertension was 1.1 percent and included bleeding, vasovagal reactions, systemic hypotension, arterial injury, hypertensive crisis, pneumothorax, and cardiac arrhythmias. The procedure-related mortality was 0.055 percent.<sup>5</sup>

RHC not only confirms the diagnosis of PAH but also provides prognostic hemodynamic information (mean right atrial pressure [mRAP], pulmonary vascular resistance)<sup>6</sup> to direct treatment decisions. A small subset of patients with PAH, when challenged with a short-acting pulmonary vasodilator, will experience a drop in mean pulmonary artery pressure of at least 10 mmHg (20%) to below 40 mmHg while maintaining cardiac output; this predicts a favorable long-term response to calcium channel blockers.<sup>1</sup>

Since PAH is a progressive disease, regular reassessment is needed to monitor response to treatment and adjust prognosis. In addition to the assessment of clinical symptoms, RHC has traditionally been the means by which patients' clinical course is monitored; however, transthoracic echocardiography has emerged as a possible alternative monitoring mechanism because of its availability, safety, and relatively low cost. The number of echocardiographic modalities has increased substantially, providing unique insights into the structure and function

of the right heart in patients with pulmonary hypertension.<sup>7</sup> However, this test has not been definitively validated as a substitute for RHC in patients with PAH. Finally, the role of biomarkers has not been fully established in the management and prognosis of PAH. Defining whether biomarkers alone or biomarkers plus echocardiography might be superior to echocardiography alone for informing treatment decisions is a necessary first step in establishing a noninvasive, multifaceted approach to the management of PAH.

## **Role of Echocardiography**

The role of echocardiography in the diagnosis and management of patients with PAH has evolved over time, and has been proposed for screening, assessing prognosis and evaluating response to treatment. Screening high-risk individuals for PAH generally begins with a transthoracic echocardiogram.<sup>8</sup> Echocardiography can estimate the right ventricular systolic pressure and identify other signs of PH including increased right-sided chamber size and wall thickness. Most often, the peak velocity of the tricuspid regurgitant (TR) jet is measured by Doppler and—along with an estimate of right atrial pressure (RAP) based on inspiratory collapse and size of the inferior vena cava—TR jet is used to estimate the systolic pulmonary artery pressure (sPAP). However, a significant proportion of patients have no measureable TR jet. Estimates are often inaccurate compared with RHC; up to 60 percent of echocardiography estimates were more than 10 mmHg off from RHC measurement in one large multicenter registry of PAH patients.<sup>9</sup>

Furthermore, sPAP is dependent on right ventricle (RV) systolic function and stroke volume. In later stages of PH, RV function deteriorates, which can lessen the degree of sPAP elevation and lead to an underestimate of pulmonary vascular resistance (PVR). More recent echocardiographic-based methods have focused on evaluating RV systolic function. Therefore, although transthoracic echocardiography is the standard screening test for PAH, it is less than completely accurate and there is uncertainty as to which echocardiographic measurements are most useful.

Several studies have investigated the use of echocardiography in establishing prognosis in PAH. In a study of patients with systemic sclerosis (n=155), 3-year survival rates were lower in 47 patients with right ventricular systolic pressure (RVSP)  $\geq 36$  mmHg as calculated by Doppler echocardiography compared with patients with RVSP  $< 36$  mmHg (67% vs. 86%,  $p < 0.01$ ).<sup>10</sup> Another study of patients with PAH (n=80) using echocardiography to calculate right ventricular free wall strain found that patients with strain worse than -12.5 percent were associated with increased 6-month disease progression and increased mortality at 1 year (unadjusted hazard ratio 6.2).<sup>11</sup> Uncertainty remains regarding which echocardiographic measure(s) have prognostic value, although tricuspid annular plane systolic excursion (TAPSE) and pericardial effusion have been proposed.<sup>12</sup>

Traditionally, RHC assessment of hemodynamics is recommended to demonstrate treatment response;<sup>12</sup> echocardiography has seldom been studied in this role.

## **Role of Biomarkers**

Because of the limitations of echocardiography, the potential role of biomarkers in screening for and managing of PAH has been the subject of increasing interest over the last decade. Brain natriuretic peptide (BNP) and N-terminal proBNP (NT-proBNP) are two biological substances found in the blood that have been studied as a screening test in patients at risk for PAH and which have been shown to correlate well with the presence of disease.<sup>13,14</sup> Other biomarkers



currently under investigation include atrial natriuretic peptide, endothelin-1, uric acid, troponin T, nitric oxide, asymmetric dimethylarginine, cyclic guanosine monophosphate, D-dimer, and serotonin. Several of these biomarkers have been shown to correlate with prognosis and mortality, either alone or in conjunction with other traditional measurements such as the 6-minute walk distance (6MWD) test, functional class assessment, and pulmonary hemodynamics.<sup>15</sup> Select biomarkers may even be superior to traditional testing. Patients with idiopathic and familial PAH were shown to exhibit dysregulation over a broad range of inflammatory cytokines, such as tumor necrosis factor-alpha and interleukin-6, when compared with healthy controls, findings which correlated better with prognosis than 6MWD and pulmonary hemodynamics.<sup>16</sup> It remains uncertain to what extent the correlations and case-control comparisons offer valid prognostic information for individual patients and can be used to make better management decisions.

## **Treatment Strategies**

### **Medications**

There has been rapid development and approval of vasodilator medications for PAH over the past three decades. Currently, there are four main classes of medications used to treat PAH:<sup>17</sup>

- Calcium channel blockers:
  - Amlodipine
  - Diltiazem
  - Nifedipine
- Prostacyclin analogues:
  - Epoprostenol
  - Iloprost
  - Treprostinil
- Endothelin receptor antagonists:
  - Bosentan
  - Ambrisentan
- Phosphodiesterase type 5 inhibitors:
  - Sildenafil
  - Tadalafil

These PAH medications have been shown to improve dyspnea, 6MWD, pulmonary hemodynamics, and functional class. Calcium channel blockers are associated with long-term (>1 year) improvements in hemodynamics and functional status in most of those patients who show acute vasoreactivity testing response; however, acute vasoreactivity is seen in a minority of patients tested.<sup>18</sup> The limited usefulness of calcium antagonists—as well as the poor prognosis and diminished quality of life associated with PAH—reinforces the need for new drug therapies and improved delivery of current medications. Limited data suggest that epoprostenol and bosentan may provide a survival benefit; however, this end point has not been studied consistently between the medications.<sup>19</sup> The three medications most recently approved by the U.S. Food and Drug Administration for PAH are: (1) inhaled treprostinil, a new delivery system for this prostacyclin analogue, (2) tadalafil, a new phosphodiesterase type 5 inhibitor, and (3) ambrisentan, an endothelin receptor antagonist. With the exception of tadalafil, these new medications were discussed in the Expert Consensus Document on Pulmonary Hypertension released in 2009 by the American College of Cardiology Foundation and the American Heart

Association.<sup>19</sup> Since then, however, numerous studies have been published regarding the safety and efficacy of these new medications. Also, more data have been published on the older medications for PAH. These new data may clarify any effect on mortality and gauge the comparative effectiveness of these drugs.

Additionally, combination drug therapy (using multiple drugs with different mechanisms of action) is an important area of research and may be the most promising way to improve clinical outcomes although at higher cost.<sup>2</sup> Combination therapy was addressed in the 2009 ACCF/AHA publication, and several studies have since been published on this topic. In order to optimize PAH care, newer information regarding the latest drugs and combination therapies should be systematically reviewed.<sup>17</sup>

## Scope and Key Questions

This comparative effectiveness review was funded by the Agency for Healthcare Research and Quality (AHRQ). It was designed to evaluate the comparative validity, reliability, and feasibility of echocardiography and biomarker testing for the diagnosis and management of PAH in addition to clarifying whether the use of echocardiography and biomarkers affects decisionmaking and clinical outcomes. We also wanted to address which medications are effective for treating PAH and how the newer medications compare with older ones and with each other. Further, there was a need for clarity about whether combination therapy is more effective than monotherapy and what effect monotherapy or combination therapy has on intermediate-term and long-term outcomes.

The Key Questions (KQs) considered in this comparative effectiveness review were:


**KQ 1:** For patients with suspected pulmonary arterial hypertension (PAH) and asymptomatic patients at high risk for PAH, what are the comparative effectiveness and safety of echocardiography versus echocardiography plus biomarkers as screening modalities before right heart catheterization to establish the diagnosis of PAH (i.e., what is their comparative diagnostic accuracy efficacy)?

**KQ 2:** For patients with PAH, what are the comparative effectiveness and safety of (a) echocardiography versus biomarkers and (b) echocardiography versus echocardiography plus biomarkers in managing PAH and on intermediate-term ( $\leq 90$  days) and long-term ( $> 90$  days) patient outcomes?

**KQ 3:** For patients with PAH, what are the comparative effectiveness and safety of monotherapy or combination therapy for PAH using calcium channel blockers, prostanoids, endothelin receptor antagonists, or phosphodiesterase inhibitors on intermediate-term and long-term patient outcomes?

Figures A and B show the analytic framework for this comparative effectiveness review.

**Figure A. Analytic framework for KQs 1 and 2**




KQ = Key Question; PAH = pulmonary arterial hypertension

<sup>a</sup>Fryback DG, Thornbury JR. The efficacy of diagnostic imaging. Med Decis Making 1991;11(2):88-94.

<sup>b</sup>In conjunction with routine clinical assessment (functional class, dyspnea, 6-minute walk).

**Figure B. Analytic framework for KQ 3**



KQ = Key Question; PAH = pulmonary arterial hypertension

## Methods

The methods for this comparative effectiveness review follow those suggested in the AHRQ “Methods Guide for Effectiveness and Comparative Effectiveness Reviews” (available at [www.effectivehealthcare.ahrq.gov/methodguide.cfm](http://www.effectivehealthcare.ahrq.gov/methodguide.cfm); hereafter referred to as the Methods Guide).<sup>20</sup>

## Input From Stakeholders

During the topic refinement stage, we solicited input from Key Informants representing clinicians (in pulmonology, cardiology, and pathology), patients, scientific experts, and Federal agency officials, to help define the KQs. The KQs were then posted for public comment for 30 days, and the comments received were considered in the development of the research protocol. We next convened a Technical Expert Panel (TEP), comprising clinical, content, and methodological experts, to provide input in defining populations, interventions, comparisons, or outcomes as well as in identifying particular studies or databases to search. The Key Informants and members of the TEP were required to disclose any financial conflicts of interest greater than \$10,000 and any other relevant business or professional conflicts of interest. Any potential conflicts of interest were balanced or mitigated. Neither Key Informants nor members of the TEP did analysis of any kind or contribute to the writing of the report.

## **Literature Search Strategy**

To identify the relevant published literature, we searched PubMed<sup>®</sup>, Embase<sup>®</sup>, and the Cochrane Database of Systematic Reviews. We limited the search to English-language studies conducted from 1995 to the present for KQs 1 and 2, and 1990 to the present for KQ 3; prior to 1990, newer drug treatments were not available and prior to 1995 older echocardiographic and biomarker testing technology was less applicable. We supplemented the electronic searches with a manual search of citations from a set of key primary and review articles. All citations were imported into an electronic database (EndNote<sup>®</sup> X4; Thomson Reuters, Philadelphia, PA).

We also searched the gray literature of study registries and conference abstracts for relevant articles from completed studies. Gray literature databases included ClinicalTrials.gov; metaRegister of Controlled Trials; ClinicalStudyResults.org; World Health Organization International Clinical Trials Registry Platform Search Portal; and ProQuest COS Conference Papers Index. Scientific information packets were requested from the manufacturers of medications and devices and reviewed for relevant articles from completed studies not previously identified in the literature searches.

## **Inclusion and Exclusion Criteria**

Criteria used to screen articles for inclusion/exclusion at both the title-and-abstract and full-text screening stages are detailed in the full report. For KQ 1, the search focused on studies that reported the accuracy of echocardiography, biomarkers, or the combination of these tests for diagnosis of PAH in patients suspected of having PAH or in asymptomatic patients at high risk for PAH. For KQ 2, the search focused on English-language studies describing data on how echocardiographic or biomarker testing among patients with PAH was related to diagnostic thinking efficacy and therapeutic efficacy (clinician judgment about diagnosis or prognosis or choice of treatment) and patient outcome efficacy (prognosis related to intermediate and long term outcomes, including hemodynamic parameters, dyspnea, 6MWD, functional status, and mortality). For KQ 3, the search focused on the effect of pharmacotherapy with prostanoids (epoprostenol, treprostinil, iloprost), endothelin receptor antagonists (bosentan, ambrisentan) or phosphodiesterase inhibitors (sildenafil, tadalafil) on intermediate-term and long-term outcomes as well as adverse effects in patients with PAH. For KQ 3, we chose not to use composite endpoints such as time to clinical worsening (TTCW) due to weighting issues and lack of comparability among studies.

## **Study Selection**

Using the prespecified inclusion and exclusion criteria, two reviewers independently examined titles and abstracts for potential relevance to the KQs. Articles included by any reviewer underwent full-text screening. At the full-text screening stage, two independent reviewers read each article to determine if it met eligibility criteria. Disagreements were resolved by discussion or by a third-party arbitrator, if needed. Relevant systematic review articles, meta-analyses, and methods articles were flagged for hand-searching and cross-referencing against the library of citations identified through electronic database searching. All screening decisions were made and tracked in a Distiller SR database (Evidence Partners, Inc., Manotick, ON, Canada).

## Data Extraction

The investigative team created data abstraction forms and evidence table templates. Based on clinical and methodological expertise, two investigators were assigned to the research questions to abstract data from the eligible articles. One investigator abstracted the data, and the second overread the article and the accompanying abstraction to check for accuracy and completeness. Disagreements were resolved by consensus or by obtaining a third reviewer's opinion if consensus was not reached between the first two investigators.

## Quality Assessment of Individual Studies

We evaluated the quality of individual studies using the approach described in the Methods Guide.<sup>20</sup> To assess methodological quality, we employed the Methods Guide strategy to: (a) apply predefined criteria for quality and critical appraisal and (b) arrive at a summary judgment of the study's quality. To indicate the summary judgment of the quality of the individual studies, we used the summary ratings of good, fair, or poor. For studies of diagnostic tests (KQ 1 and KQ 2), we used QUADAS-2,<sup>21</sup> a tool for the quality assessment of studies of diagnostic accuracy included in systematic reviews. QUADAS-2 describes risk of bias in four key domains: patient selection, index test(s), reference standard, and flow and timing; each domain is rated as having high, low, or unclear risk of bias. For studies of pharmacotherapies, we used the Cochrane Risk of Bias tool, which evaluates random sequence generation, allocation concealment, blinding of participant and personnel, blinding of outcome assessment, completeness of outcome data, completeness of outcome reporting, and other indications that the studies are unbiased.

Two raters independently evaluated each study and resolved differences by consensus; if they could not reach consensus, they rated the item as unclear, and the rationale for each differing assessment was described. They described results for individual domains. If the distribution of ratings permitted, they examined methodological domains for association with the effects obtained in meta-analysis.

To indicate the summary judgment of the quality of the individual studies, we used the summary ratings of good, fair, or poor based on the studies' adherence to well accepted standard methodologies and the adequacy of their reporting.

## Data Synthesis

Quantitative synthesis (i.e., meta-analysis) was done when we found multiple studies of similar design, population, intervention, comparator, and outcome that reported sufficient data for analysis. When a meta-analysis was appropriate, we used random-effects models to quantitatively synthesize the available evidence. We use meta-analyses both to quantify and to attempt to explain between-study variation as well as to calculate summary estimates. When a meta-analysis was not appropriate we described the reasons, presented data in tabular form, and summarized studies either individually or qualitatively.

For sensitivity and specificity data, we used a binomial model to calculate summary estimates of sensitivity and specificity and associated confidence intervals and summary receiver operating characteristic (ROC) curve using SAS statistical software. Sensitivity analyses were conducted using summary ROC meta-analysis using the diagnostic odds ratio with dr-ROC software (Diagnostic Research Design and Reporting; Glenside, PA). For meta-analysis of correlation coefficients and hazard ratios for observational studies, we used a random effects

model implemented in SAS (SAS Institute Inc.; Cary, NC). For treatment effects meta-analysis, we used a random effects model meta-analysis implemented in Comprehensive Meta-Analysis Software (Version 2.2.064, Biostat; Englewood, NJ). We tested for heterogeneity using graphical displays and test statistics (Q and  $I^2$  statistics), while recognizing that the ability of statistical methods to detect heterogeneity may be limited, particularly when the number of studies is small. We present summary estimates and confidence intervals in our data synthesis.

## **Strength of the Body of Evidence**

The strength of evidence for each KQ was assessed using the approach described in the Methods Guide.<sup>22</sup> In brief, the approach requires assessment of four domains: risk of bias, consistency, directness, and precision. Additional domains were used when appropriate: dose-response association, impact of plausible residual confounders, strength of association (magnitude of effect), and publication bias. These domains were considered qualitatively, and a summary rating of high, moderate, or low strength of evidence was assigned after discussion by two reviewers. A grade of insufficient was assigned when no evidence was available or when evidence on the outcome was too weak, sparse, or inconsistent to permit any conclusion to be drawn.

Diagnostic evaluation studies (KQs 1 and 2) are generally indirect, as the link between the test intervention and outcome is mediated by prognosis, management, and the effectiveness of treatments. As a rule of thumb, we considered correlation coefficients greater than 0.7 as strong association, 0.40 to 0.69 as moderate, and less than 0.40 as weak. In our summary strength of evidence assessments for KQs 1 and 2, lack of directness was weighed less heavily and risk of bias most heavily. Thus, we allowed high strength of evidence levels despite the lack of directness among these studies.

## **Applicability**


We assessed applicability across our KQs using the PICOTS format as described in the Methods Guide.<sup>20,23</sup> We used these data to evaluate the applicability to clinical practice, paying special attention to study eligibility criteria, demographic features of the enrolled population (such as age, ethnicity, and sex) in comparison with the target population, the version or characteristics of the intervention used in comparison with therapies currently in use (such as specific components of treatments considered to be supportive therapy), and the clinical relevance and timing of the outcome measures. We summarized issues of applicability qualitatively. Because applicability issues may differ for different users, we reported across a range of potential applicability issues.

In assessing the applicability of diagnostic evaluation studies, we were particularly concerned about the prevalence of PAH versus PH in the study populations compared, the spectrum of underlying type of PAH, and the assessment of adverse events associated with testing. In assessing PAH drug trials, we were particularly concerned with whether the researchers had assessed the severity of illness; the use of run-in periods; attrition before randomization; the use of surrogate or combined outcome measures; short study duration; the reporting of adverse events, in particular including those related to administration or monitoring of treatment; whether the sample size was sufficient to assess minimally important differences from a patient perspective; and the use of intention-to-treat-analysis.

## Results

Figure C depicts the flow of articles through the literature search and screening process. Searches of PubMed®, the Cochrane Database of Systematic Reviews, and Embase® yielded 8,256 citations, 1,626 of which were duplicate citations. Manual searching identified 46 additional citations, for a total of 6,676 citations. After applying inclusion/exclusion criteria at the title-and-abstract level, 1,324 full-text articles were retrieved and screened. Of these, 1,127 were excluded at the full-text screening stage, leaving 197 articles (representing 186 studies) for data abstraction. (Article counts by KQ do not add to 197 because some studies were included for multiple KQs.)

**Figure C. Literature flow diagram**



KQ = Key Question

Note: Some studies were included for multiple KQs.



## KQ 1: Screening for Pulmonary Arterial Hypertension

Key Points from the Results chapter are:

- For patients suspected of having PAH with elevated sPAP by echo, additional testing with the biomarker NT-proBNP may identify more patients who do not have PAH, compared with echo sPAP alone (based on one good-quality prospective cohort study) (low strength of evidence).
- For patients suspected of PAH, echocardiographic estimation of RVSP (or TG) by TRV, sPAP by TRV and RAP, and PVR by  $(TRV/VTI_{RVOT})$  shows reasonably good accuracy, compared with RHC (moderate strength of evidence).
- Both for asymptomatic patients at high risk for PAH and for symptomatic patients suspected of PAH, natriuretic peptide testing (with either BNP or NT-proBNP) shows highly variable sensitivity and specificity estimates (not simultaneously high) for pulmonary hypertension (PH) or PAH diagnosis (low strength of evidence) and moderate correlation with hemodynamic measures by RHC (moderate strength of evidence).
- There were no studies of the safety of biomarker and echocardiography testing, nor were there any studies of combined echocardiographic and biomarker screening of asymptomatic patients at high risk for PAH (insufficient strength of evidence).

We identified one good-quality study involving 372 patients that compared echocardiography with echocardiography plus biomarkers in patients with suspected PAH, most of whom were symptomatic. There were no other studies that directly compared combinations of echocardiographic and biomarker testing. In order to draw inferences about the comparative effectiveness of other tests, we reviewed the diagnostic accuracy of independent echocardiographic or biomarker testing compared with RHC. By evaluating the relative diagnostic performance of these tests versus a reference standard of RHC, one can impute the comparative effectiveness via indirect comparisons. We identified 60 unique studies involving a total of 7,096 patients that describe the effectiveness of echocardiography or biomarkers in patients with suspected PAH, or in asymptomatic patients at high risk for PAH, as screening modalities before RHC to establish the diagnosis of PAH. Symptom status of study populations consisted of asymptomatic (3 studies; 481 patients), symptomatic (41 studies; 4,394 patients), mixed (8 studies; 1,186 patients), and symptoms not described (8 studies; 1,035 patients). Table B summarizes the findings of our review and the strength of evidence ratings for the available outcomes of sensitivity, specificity, correlation coefficients, and adverse effects of biomarker and echocardiographic tests. Details about the specific components of these ratings (risk of bias, consistency, directness, and precision) are available in the full report. Among biomarker studies, natriuretic peptide (BNP, NT-proBNP) was the only biomarker reported in more than one study; therefore it is the only biomarker for which we generated a strength of evidence table. Limited data on cyclic GMP, asymmetric dimethylarginine (ADMA) and endothelin-1 were reported in one study each. Likewise, the echocardiographic estimates of sPAP and PVR ( $TRV/VTI_{RVOT}$ ) were the only echocardiographic parameters reported in a sufficient number of studies to support strength of evidence rating. Limited data on FAC, RA size, RIMP, RV size, tricuspid lateral annular systolic velocity ( $S'$ ), and TAPSE are described in the full report.

**Table B. Summary of strength of evidence and effect estimates for echocardiography versus echocardiography plus biomarkers as screening modalities for PAH (KQ 1)<sup>a</sup>**

Test	Sensitivity	Specificity	Correlation With RHC
<b>Echo sPAP with NT-proBNP vs. Echo sPAP in symptomatic patients</b>	SOE = Insufficient (1 study, 121 patients)  NT-proBNP >80 pg/mL has a low false negative rate compared with RHC reference standard; the serial testing study design did not allow for NT-proBNP testing to improve sensitivity beyond that of echo sPAP alone.	SOE = Low (1 study, 121 patients)  NT-proBNP ≤80 pg/mL ruled out PAH in 9–16% of patients with elevated echo sPAP ≥36 mmHg.	SOE = Insufficient (No studies)
<b>Echo sPAP with NT-proBNP vs. Echo sPAP in asymptomatic patients</b>	SOE = Insufficient (No studies)	SOE = Insufficient (No studies)	SOE = Insufficient (No studies)
<b>NT-proBNP compared with RHC</b>	SOE = Low (3 studies, 198 patients)  NT-proBNP has variable sensitivity (range, 56% to 100%) for diagnosing PAH; uncertain performance for ruling out PAH.	SOE = Low (3 studies, 198 patients)  NT-proBNP has variable specificity (range, 24% to 95%); uncertain performance for ruling in PAH.	SOE = Moderate (3 studies, 176 patients)  Correlation of NT-proBNP and RHC is only moderate (range, 0.43 to 0.72).
<b>TRV/TG/sPAP compared with RHC</b>	SOE = Moderate (19 studies, 2,459 patients)  Echocardiographic estimate of sPAP showed variable sensitivity ranging from 58% to 100%, with lower prevalence studies finding higher sensitivity.	SOE = Moderate (19 studies, 2,459 patients)  Echocardiographic estimate of sPAP showed variable specificity ranging from 50% to 98%, with lower prevalence studies finding higher specificity.	SOE = Moderate (23 studies, 4,217 patients)  Echocardiographic estimates of sPAP showed moderate to strong correlation (range, 0.38 to 0.96) with RHC and were on average unbiased, but were limited by imprecision and by a significant minority of patients in whom TRV was not measurable.
<b>TRV/VTI<sub>RVOT</sub> compared with RHC</b>	SOE = Moderate (6 studies, 196 patients)  Echocardiographic estimate of PVR showed reasonably high sensitivity (range, 89% to 100%) for ruling in PAH.	SOE = Moderate (6 studies, 196 patients)  Echocardiographic estimate of PVR showed variable specificity (range, 50% to 97%), with better specificity in lower prevalence studies (range, 94% to 97%).	SOE = High (6 studies, 196 patients)  Showed strong correlation between echocardiographic estimates of PVR and PVR by RHC (range, 0.74 to 0.84).

NT-proBNP = N-terminal pro-B-type natriuretic peptide; PVR = pulmonary vascular resistance; RHC = right heart catheterization; SOE = strength of evidence; sPAP = systolic pulmonary artery pressure; TRV = tricuspid regurgitant jet velocity; VTI<sub>RVOT</sub> = velocity-time integral of right ventricular outflow tract

<sup>a</sup>Shaded background indicates insufficient strength of evidence.

One good-quality study evaluated the diagnostic value of serum NT-proBNP in a noninvasive diagnostic decision algorithm that also used data from electrocardiography and echocardiography. Among 69 patients without RV strain on ECG, serum NT-proBNP level  $>80$  pg/mL had 100 percent sensitivity and 24 percent specificity. Taken in combination with the decision algorithm, and in patients with echocardiographic estimates of sPAP  $\geq 36$  mmHg, the presence of either RV strain on ECG or serum NT-proBNP  $>80$  pg/mL had a sensitivity of 100 percent and specificity of 19 percent for diagnosis of PAH based on the RHC reference standard. By using this decision algorithm to exclude precapillary PH, the investigators concluded that 9 percent of referred patients with elevated sPAP by echocardiography ( $\geq 36$  mmHg) could avoid undergoing invasive RHC. After excluding patients with RV strain, serum NT-proBNP testing would have avoided RHC in 16 percent of patients.

Fourteen studies (4 good quality, 7 fair, and 3 poor) evaluated biomarkers in patients both with and without PAH. Most studies were of natriuretic peptide (serum NT-proBNP or BNP); we found one study each for urinary cGMP, ADMA, and plasma endothelin-1 (ET-1). Sensitivity and specificity estimates associated with natriuretic peptide among four studies that permitted their calculation were highly variable, presumably reflecting differences in study populations because differences in test thresholds did not result in the expected direction of change in sensitivity and specificity. The remaining 10 studies reported statistically significant correlation coefficients between natriuretic peptide levels and hemodynamic measures CO, mPAP, PVR, and sPAP.

Nineteen studies (6 good, 10 fair, 3 poor) reported the diagnostic accuracy of echocardiographic estimates of pulmonary pressures based on TRV measurement, with or without estimate of RAP, compared with a reference standard diagnosis based on RHC. Summary estimates for sensitivity (0.90; 95% CI, 0.80 to 0.96) and specificity (0.87; 95% CI, 0.80 to 0.92) showed moderate heterogeneity ( $I^2=61.9\%$ ). Studies with lower prevalence of PH (less than 15% of study subjects) showed greater homogeneity than studies with higher prevalence of PH (sensitivity 0.84 [95% CI, 0.72 to 0.91]; specificity 0.84 [95% CI, 0.72 to 0.91]). The 10 low-prevalence studies (sensitivity 0.91 [95% CI, 0.85 to 0.94]; specificity 0.91 [95% CI, 0.85 to 0.94]) included 4 studies of liver transplant patients (which had complete verification of test-negative subjects) and 6 studies that had high degrees of verification bias.

Seven studies (3 good, 3 fair, 1 poor) evaluated the echocardiographic estimation of PVR using  $TRV/VTI_{RVOT}$  against RHC diagnosis of elevated PVR. Three of these studies included patients with known PH. Two studies used a threshold for PVR much higher than that used for diagnosis (8 Wood units vs. 2 Wood units), with the goal of distinguishing more severe PAH; these studies also used a higher test threshold of 0.2 and 0.38 compared with 0.14 to 0.175. Sensitivity ranged from 57 to 94 percent, while specificity ranged from 57 to 100 percent. Because of clinical heterogeneity no meta-analysis was performed.

Six studies correlated  $TRV/VTI_{RVOT}$  with PVR by RHC. Correlation coefficients indicated strong correlation ranging from 0.73 to 0.84, with bias ranging from 0 to 6.1, and standard deviations ranging from 1.9 to 4.3 Wood units.

We found no studies describing the safety (or harms) of echocardiography or biomarker testing.

## KQ 2: Management of PAH

Key points from the Results chapter are:

- No data are available regarding the comparative effectiveness of echocardiography versus biomarkers or echocardiography versus echocardiography plus biomarkers with respect to the management of PAH or patient outcomes (insufficient strength of evidence).
- sPAP estimated by echocardiography shows good correlation with sPAP from RHC (low strength of evidence).
- BNP level shows moderate correlation with these RHC measures: mPAP (moderate strength of evidence), PVR (low strength of evidence), RAP (moderate strength of evidence), cardiac index (low strength of evidence), and clinical outcomes such as the 6MWD test (moderate strength of evidence).
- BNP level shows poor correlation with RHC pulmonary capillary wedge pressure (PCWP) (low strength of evidence).
- BNP level alone is not an accurate surrogate marker for disease severity (high strength of evidence).
- Increase in level of log-transformed BNP is a strong predictor of mortality (moderate strength of evidence).
- Presence of pericardial effusion is a strong predictor of mortality, although there was wide variability in results for this measure (moderate strength of evidence).
- Right atrial (RA) size correlates with increased risk of mortality (moderate strength of evidence).
- FAC is a poor predictor of mortality, but results are variable across studies (moderate strength of evidence).
- Serum uric acid level appears to predict mortality (low strength of evidence).
- TAPSE has inconsistent association with mortality (insufficient strength of evidence).
- We found no studies addressing diagnostic thinking efficacy, therapeutic efficacy, or harms (insufficient strength of evidence).

We identified 99 unique observational studies, involving a total of 8,655 patients, that evaluated the use of biomarkers or echocardiographic parameters in the management of PAH or as predictors of patient outcomes. Of these studies, 68 were rated good quality, 29 fair quality, and 2 poor quality. We did not find any studies that assessed the comparative effectiveness of echocardiography versus biomarkers, or echocardiography versus echocardiography plus biomarkers, as outlined in our original KQ. Instead, we focus on available studies that evaluated the ability of echocardiography or biomarkers to assess the severity of PAH, to predict events such as lung transplantation or death, or to assess a patient's response to therapy. By evaluating the independent association of biomarkers or echocardiography, one can impute the comparative effectiveness via indirect comparison. The most common biomarker evaluated was BNP (59 studies), followed by uric acid (9), endothelin-1 (6), troponin T (4), nitric oxide (2), cGMP (2) and ANP (1). We found no studies assessing D-dimer or asymmetric dimethylarginine to evaluate their ability to assess severity of disease, response to therapy, or outcome.

Thirty-nine studies evaluated several echocardiographic parameters. These included sPAP (17 studies), RIMP/MPI/Tei (14), RA size (11), pericardial effusion (11), RV size (9), FAC (8), mPAP (8), TAPSE (6), TR jet (4), TRV/VTI<sub>RVOT</sub> (3), RVEF (2), echocardiography-derived cardiac index (2), and RVSP (2).

For the comparators, we focused on RHC hemodynamics, 6MWD, and functional class (FC) as the reference standards for assessing severity of disease. Thirty-four studies used RHC as a reference test, 15 studies used 6MWD as a reference test, and 10 studies used FC as a reference test.

Thirty-nine studies looked at correlation between biomarkers and/or echocardiographic parameters and the comparators. Twenty-three studies evaluated hazard ratios (HR) for death, two studies evaluated HR for a composite outcome of death or lung transplant, and one study evaluated HR for lung transplant alone. Twenty-three studies evaluated changes in mean values in response to therapy, and four studies evaluated changes in median values in response to therapy. Eight studies assessed mean or median change from baseline in response to therapy.

In studies evaluating correlation of the above measures with RHC measures or a commonly used measure of disease severity (6MWD) studies were too underpowered to give reliable results. However, by combining studies looking at the same parameters and performing a meta-analysis we were able to increase the power for seven different comparisons: (1) BNP versus RHC-mPAP, (2) BNP versus RHC-PVR, (3) BNP versus RHC-CI, (4) BNP versus RHC-RAP, (5) BNP versus RHC-PCWP, (6) BNP versus 6MWD, and (7) echocardiography-derived sPAP versus RHC-sPAP. BNP showed moderate correlation with most RHC measures (mPAP, PVR, cardiac index, RAP) and clinical measures of disease severity (6MWD) and showed weak correlation with PCWP. Most effect estimates were precise (mPAP, PVR, cardiac index, RAP, 6MWD), but estimates for PCWP were imprecise, making it difficult to interpret the clinical importance of the findings for this measure. For the other measures, correlation with BNP was only moderate, indicating that BNP levels alone could not serve as an accurate surrogate marker for disease severity. Echocardiography-derived sPAP showed strong correlation with RHC-sPAP, although there was a great deal of heterogeneity among these studies and only moderate strength of evidence to support the use of this measure.

In studies evaluating the ability of biomarkers or echocardiographic measures to predict mortality, we were able to perform a meta-analysis on six measures: BNP, pericardial effusion, RA size, FAC, uric acid and TAPSE. BNP level and pericardial effusion were strong predictors of mortality. RA size was also predictive of mortality. Data on uric acid suggested an association with mortality, while fractional area change (FAC) showed uncertain association with mortality.

The strength of evidence ratings for the most commonly reported biomarkers and echocardiographic parameters are summarized in Table C (management of PAH) and Table D (prediction of patient outcomes).

**Table C. Summary of strength of evidence and effect estimates for the use of echocardiography or biomarkers in the management of PAH (KQ 2)**

Comparison	Number of Studies (Patients)	Summary Correlation Coefficient Estimate (95% CI)	SOE and Findings
<b>BNP compared with RHC-mPAP</b>	14 (606)	0.39 (0.31 to 0.47)	SOE = Moderate  Serum BNP level shows moderate correlation with mPAP.
<b>BNP compared with RHC-PVR</b>	13 (684)	0.46 (0.31 to 0.59)	SOE = Low  Serum BNP level shows moderate correlation with PVR.
<b>BNP compared with RHC-RAP</b>	12 (645)	0.47 (0.40 to 0.54)	SOE = Moderate  Serum BNP level shows moderate correlation with RAP.
<b>BNP compared with RHC-CI</b>	10 (550)	-0.42 (-0.54 to -0.28)	SOE = Low  Serum BNP level shows negative moderate correlation with cardiac index.
<b>BNP compared with RHC-PCWP</b>	5 (319)	0.16 (0.01 to 0.31)	SOE = Low  Serum BNP level shows poor correlation with PCWP.
<b>BNP compared with 6MWD (absolute)</b>	9 (484)	-0.46 (-0.55 to -0.35)	SOE = Moderate  Serum BNP level shows negative moderate correlation with 6MWD.
<b>Echocardiography-derived sPAP compared with RHC-sPAP</b>	9 (362)	0.76 (0.53 to 0.89)	SOE = Low  sPAP estimated by echocardiography shows good correlation with sPAP from RHC.

6MWD = 6-minute walk distance; BNP = B-type natriuretic peptide; CI = confidence interval; FAC = fractional area change; PCWP = pulmonary capillary wedge pressure; PVR = pulmonary vascular resistance; RA = right atrium; RAP = right atrial pressure; RHC = right heart catheterization; SOE = strength of evidence; sPAP=systolic pulmonary artery pressure

**Table D. Summary of strength of evidence and effect estimates for the use of echocardiography or biomarkers in the prediction of mortality (KQ 2)<sup>a</sup>**

Marker	Number of Studies (Patients)	Summary Hazard Ratio Estimate (95% CI)	SOE and Findings
<b>BNP</b>	6 (407)	2.42 (1.72 to 3.41)	SOE = Moderate  Increase in log-transformed BNP level is a good predictor of mortality.
<b>Pericardial effusion</b>	8 (2,590)	2.43 (1.57 to 3.77)	SOE = Moderate  Presence of pericardial effusion is a strong predictor of mortality, although there was wide variability in results for this measure.
<b>RA size</b>	4 (242)	1.06 (1.01 to 1.10)	SOE = Moderate  RA size is a predictor of mortality.
<b>FAC</b>	4 (242)	0.98 (0.96 to 1.01)	SOE = Moderate  FAC is a poor predictor of mortality.
<b>Uric acid</b>	4 (246)	1.01 (1.00 to 1.01)	SOE = Low  Small increase in mortality but imprecision of estimates limit these data.
<b>TAPSE</b>	4 (251)	0.94 (0.82 to 1.08)	SOE = Insufficient  Inconsistent results between studies lead to uncertainty.

BNP = B-type natriuretic peptide; CI = confidence interval; FAC = fractional area change; RA = right atrium; RAP = right atrial pressure; SOE = strength of evidence; TAPSE = tricuspid annular plane systolic excursion

<sup>a</sup>Shaded background indicates insufficient strength of evidence.

### **KQ 3: Pharmacotherapy for Pulmonary Arterial Hypertension**

Key Points from the Results chapter are:

- In patients who have been receiving monotherapy, combination therapy appears to be moderately more effective than continuation of monotherapy for improving 6-minute walk distance (6MWD), with a magnitude of effect that is approximately equal to the estimated minimal important difference (MID) for PAH, of 6MWD of 33 meters (low strength of evidence).
- We did not identify any eligible studies that evaluated the comparative effectiveness of calcium channel blockers on intermediate-term and long-term patient outcomes, or that randomized treatment-naïve patients to monotherapy versus combination therapy, or that directly compared two drug classes.
- Although we did not intend to exclude studies of children, the inclusion criterion requiring reporting intermediate-term and long-term patient outcomes had the effect of eliminating randomized clinical trials of children with PAH.
- Prostanoids were associated with lower mortality when compared with standard therapy or placebo (low strength of evidence). Current evidence is inconclusive regarding a reduction in mortality associated with treatment with endothelin antagonists or phosphodiesterase inhibitors (insufficient strength of evidence).
- Endothelin antagonists, phosphodiesterase inhibitors, and prostanoids were all associated with improved 6MWD after 8 to 16 weeks of therapy, with a magnitude of effect that is

approximately equal to the estimated minimal important difference (MID) for PAH of 6MWD of 33 meters (moderate strength of evidence).

- Endothelin antagonists and phosphodiesterase inhibitors were associated with lower incidence of hospitalization when compared with standard therapy or placebo (moderate strength of evidence). Current evidence is inconclusive regarding a reduction in hospitalization associated with treatment with prostanoids (insufficient strength of evidence).
- Endothelin antagonists, phosphodiesterase inhibitors, and prostanoids were associated with statistically significant improvements in most or all hemodynamic measures such as PVR, mPAP, and cardiac index (low strength of evidence), compared with placebo or standard therapy. The clinical significance of the magnitude of the observed changes in these intermediate outcomes is unclear.
- Among commonly reported adverse events, there was a higher incidence of jaw pain associated with aerosolized prostanoid treatment compared with placebo (high strength of evidence) and cough associated with aerosolized prostanoids versus placebo (high strength of evidence). In addition, headache was associated with phosphodiesterase inhibitors compared with placebo or standard therapy (moderate strength of evidence), and flushing was associated with phosphodiesterase inhibitors (moderate strength of evidence) and aerosolized prostanoids (moderate strength of evidence), compared with placebo or standard therapy.

Twenty-eight RCTs involving 3,613 patients evaluated the comparative effectiveness and safety of monotherapy or combination therapy for PAH. Of these RCTs, 18 (64%) were rated good quality, 9 (32%) fair quality, and 1 (4%) poor quality. Nineteen studies (68%) were funded by industry, one by private foundation, one by government and private funding, one by private and industry funding, one by industry and “other” funding, and five did not report funding sources.

The mean patient ages ranged from 28 to 50 years old. Twenty studies enrolled patients with PAH, four studies enrolled patients with PAH associated with systemic sclerosis (formerly scleroderma), and two studies enrolled patients with Eisenmenger syndrome. Two studies enrolled a minority of patients with PH other than PAH: one included patients with chronic thromboembolic PH (28%), and another included patients with PH owing either to lung disease or to chronic thromboembolic PH (37%).

Twenty-one studies compared a single drug (monotherapy) with placebo or standard therapy and included the following drugs: bosentan (6 studies), sildenafil (2), iloprost (2), epoprostenol (3), tadalafil (3), ambrisentan (2), treprostinil (3), and vardenafil (1). For the purposes of this analysis, the standard therapy arms were grouped with the placebo arms. Standard therapies included supportive therapy (diuretics, oxygen, digoxin, oral anticoagulants) with or without calcium channel blockers, but not including newer specific vasodilator medications. One study was a head-to-head comparison of bosentan and sildenafil. The remaining five studies compared combination therapy with monotherapy: (1) intravenous (IV) epoprostenol plus bosentan versus IV epoprostenol plus placebo, (2) sildenafil plus IV epoprostenol versus IV epoprostenol plus placebo, (3) bosentan plus aerosolized iloprost versus bosentan, (4) bosentan plus aerosolized iloprost versus bosentan plus placebo, and (5) aerosolized treprostinil plus bosentan or sildenafil versus bosentan or sildenafil plus placebo. We did not identify any eligible studies published after 1990 that evaluated the safety or efficacy of calcium channel blockers on intermediate-term and long-term patient outcomes.



Most studies (85%) were multicenter trials; three were single-center trials, and four did not report the number of centers. The studies reported the following outcomes: 6MWD (27 studies), mortality (21), dyspnea (17), right heart catheterization indices (18), functional class (13), hospitalization for worsening PAH (10), quality of life (11), lung transplantation (5), right heart failure or right ventricular dysfunction (4), and brain natriuretic peptide (4). Twenty-one studies reported harms or adverse events. Table E summarizes the strength of evidence ratings for the key outcomes of mortality, 6MWD, and hospitalization. Details about the specific components of these ratings (risk of bias, consistency, directness, and precision) and information on other outcomes are available in the full report.

**Table E. Summary of strength of evidence and effect estimates for monotherapy versus combination therapy for PAH (KQ 3)<sup>a</sup>**

Intervention	Mortality	6MWD (m)	Hospitalization
Endothelin antagonist vs. placebo	SOE = Insufficient (6 studies, 838 patients)  Inconclusive benefit (few studies, few deaths lead to wide CI)  OR 0.60 (95% CI, 0.23 to 1.59)	SOE = Moderate (6 studies, 663 patients)  Improved 6MWD with endothelin antagonists compared with placebo  Mean difference 39.9 (95% CI, 21.4 to 58.4)	SOE = Moderate (3 studies, 606 patients)  Reduced risk of hospitalization  OR 0.34 (95% CI, 0.17 to 0.69)
Phosphodiesterase inhibitors vs. placebo	SOE = Insufficient (4 studies, 1,011 patients)  Inconclusive benefit (few studies, few deaths lead to wide CI)  OR 0.30 (95% CI, 0.08 to 1.11)	SOE = Moderate (4 studies, 991 patients)  Improved 6MWD with PDE5 therapy compared with placebo or standard therapy  Mean difference 38.9 (95% CI, 22.0 to 55.9)	SOE = Moderate (4 studies, 1,011 patients)  Reduced risk of hospitalization  OR 0.48 (95% CI, 0.25 to 0.91)
Prostanoids vs. placebo or standard therapy	SOE = Low (8 studies, 1,229 patients)  Lower mortality with prostanoids, but inconsistent results and wide confidence intervals  OR 0.52 (95% CI, 0.29 to 0.95)	SOE = Moderate (7 studies, 933 patients)  Improved 6MWD with prostanoid therapy compared with placebo  Mean difference 27.9 (95% CI, 10.3 to 45.4)	SOE = Insufficient (2 studies, 301 patients)  Inconclusive benefit (few studies, wide CI)  OR 0.42 (95% CI, 0.06 to 3.08)
Combination vs. monotherapy	SOE = Insufficient (3 studies, 566 patients)  Inconclusive benefit (few studies, few deaths lead to wide CI)  OR 0.37 (95% CI, 0.04 to 3.32)	SOE = Low (3 studies, 363 patients)  Improved 6MWD with combination therapy compared with monotherapy  Mean difference 23.9 (95% CI, 8.0 to 39.9)	SOE = Insufficient (3 studies, 566 patients)  Inconclusive benefit (few studies, wide CI)  OR 0.64 (95% CI, 0.31 to 1.36)

6MWD = 6-minute walk distance; CI = confidence interval; NS = not statistically significant; OR = odds ratio; SOE = strength of evidence

<sup>a</sup>Shaded background indicates insufficient strength of evidence.

## Discussion

### Key Findings and Strength of Evidence

A single study compared the combination of biomarker tests and echocardiography with echocardiography alone to screen for PAH (KKQ 1). This good-quality prospective cohort study of 372 patients suggested that biomarker testing with NT-proBNP may be useful in ruling out PAH among those suspected of PH who also have elevated sPAP by echocardiography;<sup>24</sup> however, this finding is limited by the lack of replication, small sample size (wide confidence limits) and confounding with RV strain on ECG. No data are available regarding combined echocardiography and biomarker screening in asymptomatic patients at high risk for PAH. In the absence of other direct comparative trials, we attempted to address this question by evaluating the efficacy of biomarker and echocardiography independently for screening and diagnosis of PAH. We reviewed 60 studies involving 7,096 patients that evaluated biomarker tests, echocardiography, or both, to screen for PAH. The associations between natriuretic peptide testing and PAH diagnosis is insufficiently strong to support its use alone as a screening test in either asymptomatic or symptomatic patients suspected of PAH. Data on biomarker testing were essentially limited to a single test—NT-proBNP—which showed moderate correlation with RHC hemodynamic measures and a great deal of variability between studies in its diagnostic accuracy and discrimination.

We found that echocardiography estimates of pulmonary artery pressures (sPAP, TG, and TRV) and pulmonary vascular resistance ( $TRV/VTI_{RVOT}$ ) demonstrated good accuracy in screening for PAH. In low-prevalence populations (<10%), negative predictive value of a normal sPAP is high, suggesting that echocardiography with a low threshold may be an appropriate test in asymptomatic high-risk populations or in patients with symptoms suggesting PAH. (This is shown in studies of liver transplant patients with complete verification).

Our findings suggest that echocardiographic estimation of sPAP is sufficiently accurate to justify its role in screening for PAH in symptomatic patients suspected of having PH. However, this conclusion has several important caveats. First, echocardiography in a small but significant number of patients may not produce an estimate of sPAP because of poor-quality Doppler visualization of the tricuspid regurgitant jet. Second, echocardiographic estimates of sPAP often over- or under-estimate pulmonary artery pressure enough to result in misclassification according to PAH diagnostic threshold—hence the selection of a test threshold is critical for the aim of screening. A single test threshold is insufficient to perform with simultaneously high sensitivity and specificity (or simultaneously high positive and negative predictive values), especially in populations with higher risk or higher prevalence (more symptomatic), where echocardiography cannot be relied upon to exclude pulmonary hypertension if pretest probability is high. In asymptomatic patients at high risk for PH, echocardiography seems to perform with similar sensitivity and specificity; however, these studies suffer from verification bias, which likely inflates both the sensitivity and specificity estimates. For example, consider two prospective studies that show that approximately 10 percent of asymptomatic patients with systemic sclerosis and normal sPAP develop PH when serially retested with echocardiography. These findings are consistent with either misclassification at baseline echocardiographic screening or prospective development of PH. This ambiguity suggests that if echocardiographic screening of asymptomatic patients with a high-risk diagnosis were to be undertaken, then serial testing would be necessary.

We reviewed 99 studies, involving 8,655 patients, that evaluated biomarker tests or echocardiography to diagnose and follow progression of disease as well as response to therapy for PAH (KQ 2). Our review found that BNP showed only moderate correlation with most RHC measures (mPAP, PVR, cardiac index, RAP) and clinical measures of disease severity (6MWD) and showed weak correlation with PCWP. Most effect estimates were precise (mPAP, PVR, cardiac index, RAP, 6MWD), but estimates for PCWP were imprecise, making it difficult to interpret the clinical importance of the findings for this measure. For the other measures, correlation with BNP was moderate, indicating that BNP levels alone could not serve as an accurate surrogate marker for disease severity. Alternatively, echocardiography-derived sPAP showed strong correlation with RHC-sPAP with a precise effect estimate, and may be useful as an alternative to RHC to assess disease severity. However, there was a great deal of heterogeneity among these studies.

BNP level and the presence of pericardial effusion were predictors of mortality and may be useful clinically, though results were not highly precise. RA size and uric acid were also associated with mortality, but studies were less consistent than for BNP. FAC showed no significant ability to predict mortality; data on TAPSE were too inconsistent to be conclusive.

Our findings do not support any recommendations for replacing existing measurement tools to assess disease severity, prognosis, or response to therapy. Echocardiography-derived sPAP shows promise as a possible surrogate marker for RHC-sPAP, but it is unclear whether or not this measure alone is adequate to assess disease severity, prognosis, or response to therapy.

We reviewed 37 studies involving 4,192 patients that assess the effectiveness of drug treatment for PAH in adults. Our review found inconclusive evidence regarding mortality reduction for 11 of the 12 drug treatment comparisons: (1) ambrisentan versus placebo (OR 0.40; 95% CI, 0.10 to 1.51), (2) bosentan versus placebo (OR 0.72; CI, 0.14 to 3.60), (3) epoprostenol versus placebo or standard therapy (OR 0.33; CI, 0.07 to 1.50), (4) iloprost versus placebo (OR 0.43; CI, 0.08 to 2.47), (5) sildenafil versus placebo (OR 1.01; CI, 0.10 to 9.92), (6) tadalafil versus placebo (OR 0.50; CI, 0.05 to 5.63), (7) treprostinil versus placebo (OR 0.50; CI, 0.12 to 2.12), (8) vardenafil versus placebo (OR 0.08; CI, 0.00 to 1.82), (9) endothelin antagonists versus placebo (OR 0.60; CI, 0.23 to 1.59), (10) phosphodiesterase inhibitors versus placebo (OR 0.30; CI, 0.08 to 1.11), and (11) combination therapy versus monotherapy (OR 0.37; CI, 0.04 to 3.32).

Few deaths were observed in these limited-duration studies, leading to wide confidence intervals and lack of statistical power to detect a difference in mortality; however, a consistent direction of effect and demonstrated improvements in other outcomes, including functional and hemodynamic measures, support that a mortality reduction might exist.

Increases in 6MWD ranging from 27.9 meters (95% CI, 10.3 to 45.4) to 39.9 meters (CI, 21.4 to 58.4) were observed in trials of all drug classes when compared with placebo or standard therapy; however, comparisons between agents are inconclusive. The magnitude of these statistically significant improvements in 6MWD associated with treatment are very close to a recently published estimate of 33 meters for the minimal important difference for the 6MWD in patients with PAH.<sup>25</sup> Combination therapy in patients already on monotherapy also showed improved 6MWD compared with continuation of monotherapy (OR 23.9; CI, 8.0 to 39.9), but the diversity of treatment regimens and the small number of combination therapy trials again make comparisons between specific regimens inconclusive. In studies evaluating hospitalization, endothelin receptor antagonists and phosphodiesterase-5 inhibitor treatment was associated with lower odds of hospitalization compared with placebo (OR 0.34 and 0.48, respectively). The

magnitude of the odds ratio associated with prostanoids was similar (OR 0.42), but the 95% confidence interval included 1.0, thereby making this finding not statistically significant. Combination therapy compared with monotherapy also showed a similar nonsignificant effect on hospitalizations (OR 0.64). Endothelin antagonists, phosphodiesterase inhibitors, and prostanoids each had favorable effects on most hemodynamic outcomes including cardiac index, mPAP, and PVR.

In studies reporting adverse effects, we found that phosphodiesterase-5 inhibitors were more likely than endothelin receptor antagonists to cause headache, and endothelin antagonists still were more likely than placebo to cause headache. Drugs did not significantly differ in their odds of causing dizziness or diarrhea. Aerosolized prostanoids were much more likely to cause jaw pain and cough compared with placebo. Phosphodiesterase-5 inhibitors and prostanoids were associated with flushing, while data on endothelin receptor antagonists were inconclusive. Phosphodiesterase-5 inhibitors had a significant association with peripheral edema, while data on prostanoids and endothelin receptor antagonists were inconclusive.

The findings from our meta-analyses of the few studies that compared combination therapy with monotherapy suggest, but do not prove, that combination therapy confers more benefit than does monotherapy in the treatment of PAH. These findings are generally consistent with the European Society of Cardiology (ESC)/European Respiratory Society (ERS) guideline recommendation for monotherapy as initial treatment, with combination treatment reserved for patients who have an inadequate clinical response to monotherapy.

## Applicability

The principal limitations to applicability of data on the diagnosis of PAH all relate to the patient populations studied. First, the studies may not be applicable to the screening of asymptomatic patients. None of the study populations consisted entirely of asymptomatic patients, and although many studies included some patients without symptoms, they were not reported separately in terms of outcomes. Some studies of populations in whom PAH was suspected failed to adequately describe the basis for a clinical suspicion of PAH, whether symptoms of dyspnea, clinical signs, or other test results, such as diffusion capacity of the lung for carbon monoxide (DLCO), thus the applicability of these studies for screening symptomatic patients was also limited.

A second kind of limitation resulted from the fact that the spectrum of disease among study populations was often skewed, particularly in case-control studies, by selection criteria that selected from patients with known PAH (cases) and patients known not to have PAH (controls). Such studies usually excluded participants with other conditions that might be confused with PAH such as PH due to left-sided heart failure, thrombotic disease, or chronic obstructive pulmonary disease.

A third limitation was that participants in many studies had a wide range of disease severity, particularly those cases in case-control design studies, making these studies a poor match for the question at hand. Other applicability issues identified in the KQ 1 studies were less frequent and judged to be less severe.

Our findings in KQ 2 assessing the prognostic or predictive value of biomarkers and echocardiography may not be applicable to all PAH populations. The greatest concern is that studies reviewed in KQ 2 included participants at widely differing points in the natural history of disease, who had widely differing degrees of disease severity and different underlying etiologies of PAH. There was also concern that the population was not adequately described to assess

applicability, included patients with conditions other than PAH, or in general did not match the review question. Applicability may also be limited by the use of surrogate markers that may not be clinically relevant; also by insufficient followup time. In a few studies, it was also felt that the intervention arm or cointerventions did not adequately reflect current clinical practice or that the study setting was widely divergent from the current typical U.S. setting. Finally, there is concern that some studies did not provide adequate information about adverse events.

Applicability considerations were somewhat different for KQ 3 than for the KQs about screening and management of PAH. Most of the studies included in this review for KQ 3 were RCTs with generally good internal validity. Patient populations, however, differed between studies; variation in eligibility criteria resulted in differences between study populations in severity of illness, underlying etiology of PAH, comorbid conditions, and prior and concurrent treatment. Many different countries were represented, thereby introducing potential differences in clinical practice and care delivery settings relative to current practice in typical settings in the United States. There was also concern that the population was not always adequately described to assess applicability, with few studies exploring potential differences in response to treatment among different patient subgroups. Finally, the studies that compared combination therapy with monotherapy were all of similar design, randomizing patients who had previously received monotherapy to either continued monotherapy with that drug or continued therapy with that drug plus the addition of a second drug. While we considered these studies to represent a comparison of combination therapy with monotherapy, we do so with the understanding that this study design does not address the question of whether initiating two drugs is superior to initiating a single drug to treatment-naïve patients.

## Research Gaps

The available evidence leaves numerous gaps and areas for potential future research. We used the framework recommended by Robinson et al.<sup>26</sup> to identify gaps in evidence and describe why these gaps exist. Results are as follows:

### **KQ 1: Screening for PAH**

- Patients at elevated risk for PAH, other than those with systemic sclerosis, have seldom been studied in screening test studies.
  - Consider cohort studies of testing for PH among high-risk populations other than those with systemic sclerosis; including patients with HIV, sickle cell anemia or trait portal hypertension, family history of PAH, or catecholaminergic drug use.
  - Different populations may have different risks of PAH and different benefits from screening; in studies where heterogeneous populations are included, the effectiveness of screening should be examined according to risk factor.
- Relatively few data exist on screening of asymptomatic patients with a combination of echocardiography and biomarker testing.
  - Consider cohort studies that apply echocardiography and biomarker screening in a coordinated or algorithmic way, and studies that verify diagnosis in at least a sample of test-negative patients by RHC or lengthy followup.
  - Future tests of the added value of biomarkers should use well validated echocardiography parameters as a screening test, including estimates of pulmonary artery pressures (sPAP, TG, and TRV) and pulmonary vascular resistance (TRV/VTI<sub>RVOT</sub>).

- Studies of echocardiography for diagnosis of PH have focused on the association of single measures or parameters at a time rather than an integrated diagnostic assessment based on an entire examination and multiple echocardiographic measures or parameters.
  - Consider studies that evaluate a global echocardiographic assessment based not only on sPAP but also on right heart chamber size wall thickness and function, estimated PVR, and left heart measures.
  - Consider further development of data on the use of echocardiography to measure exercise response to sPAP.
  - Consider further development of echocardiographic estimation of mPAP, which would better align with the diagnostic criteria for PAH.
  - Consider studies of additional promising measures such as end diastolic pulmonary regurgitation gradient, mean tricuspid regurgitation gradient, and Doppler tissue imaging of the tricuspid annulus.

#### **KQ 2: Management of PAH**

- Echocardiographically guided and BNP-guided treatment strategies have not been explicitly tested.
  - Consider cohort studies evaluating prognosis, as well as treatment trials examining association of baseline echocardiographic parameters and BNP levels with response to treatment.
- Other imaging modalities, such as magnetic resonance imaging, have been little studied as alternative noninvasive tests to assess RV function.
- Cardiopulmonary exercise testing and exercise echocardiography have yielded relatively few data, and their clinical utility and relationship to PH diagnostic criteria are uncertain.
  - Consider validation studies to demonstrate prognostic value, particularly for patients with normal resting echocardiography but abnormal exercise echocardiography.

#### **KQ 3: Pharmacotherapy for PAH**

- Relatively few data exist on the efficacy of treating PAH early in the disease course (WHO functional class I-II).
  - Improved data on efficacy of early PAH treatment would strengthen linkage to data on efficacy of screening testing.
  - Consider treatment trials in early-stage PAH, particularly among patients identified by case finding or screening interventions.
- Relatively few data exist on children with persistent PH or congenital heart disease.
  - Consider controlled trials in children.
- Few treatment trials address direct comparison of alternative drug treatments, particularly for PAH patients early in the disease course.
  - Consider trials designed to compare clinical alternative treatments to permit more evidence-based treatment selection, such as head-to-head treatment comparisons rather than placebo-control, or combination versus monotherapy trials.
- The majority of RCTs have been too short and small to generate definitive data on major patient-centered outcomes. Although surrogate markers have limitations, more complete collection, analysis, and correlation of these markers with patient-centered outcomes may not only help to validate surrogate outcomes but also provide more practical outcome measures.

- Consider including biomarker and imaging techniques with conventional clinical outcomes to improve data on validity and responsiveness of surrogate outcomes.
- Few data are available from trials about differences in response to treatment based on patient characteristics.
  - Consider subgroup analysis of treatment efficacy by WHO functional class, underlying etiology, and other patient-level factors.
- Data on the efficacy of combination treatments are limited.
  - Consider more combination treatment trials, in particular trials with clear criteria for starting combination therapy, and trials in patients who have not failed monotherapy.
- The duration of controlled trial efficacy data are limited.
  - Consider, particularly for clinically relevant comparisons (e.g., head-to-head treatment or combo versus monotherapy trials), longer term followup studies that retain randomized group comparisons while assessing long-term efficacy.

## Conclusions

Further research is needed to confirm the single good-quality study suggesting that echocardiography and the biomarker NT-proBNP in combination may be sufficiently accurate to rule out PAH when testing symptomatic patients. In asymptomatic populations, more research is needed to draw conclusions regarding the effectiveness for screening. BNP, RA size, the presence of pericardial effusion and uric acid had prognostic value in patients with PAH, but other echocardiographic parameters and biomarkers either were not predictive or had insufficient data. Although no treatments demonstrate a strong and consistent mortality reduction, many are associated with improved 6MWD and reduced hospitalization rates. Comparisons of different drug combinations are inconclusive regarding mortality reduction but suggest an improvement in 6MWD compared with continuation of monotherapy.

# References

1. Galie N, Torbicki A, Barst R, et al. Guidelines on diagnosis and treatment of pulmonary arterial hypertension. The Task Force on Diagnosis and Treatment of Pulmonary Arterial Hypertension of the European Society of Cardiology. *Eur Heart J*. 2004;25(24):2243-78. PMID: 15589643.
2. Badesch DB, Abman SH, Simonneau G, et al. Medical therapy for pulmonary arterial hypertension: updated ACCP evidence-based clinical practice guidelines. *Chest*. 2007;131(6):1917-28. PMID: 17565025.
3. Simonneau G, Robbins IM, Beghetti M, et al. Updated clinical classification of pulmonary hypertension. *J Am Coll Cardiol*. 2009;54(1 Suppl):S43-54. PMID: 19555858.
4. D'Alonzo GE, Barst RJ, Ayres SM, et al. Survival in patients with primary pulmonary hypertension. Results from a national prospective registry. *Ann Intern Med*. 1991;115(5):343-9. PMID: 1863023.
5. Hoeper MM, Lee SH, Voswinckel R, et al. Complications of right heart catheterization procedures in patients with pulmonary hypertension in experienced centers. *J Am Coll Cardiol*. 2006;48(12):2546-52. PMID: 17174196.
6. Benza RL, Miller DP, Gomberg-Maitland M, et al. Predicting survival in pulmonary arterial hypertension: insights from the Registry to Evaluate Early and Long-Term Pulmonary Arterial Hypertension Disease Management (REVEAL). *Circulation*. 2010;122(2):164-72. PMID: 20585012.
7. Cacciapuoti F. Echocardiographic evaluation of right heart function and pulmonary vascular bed. *Int J Cardiovasc Imaging*. 2009;25(7):689-97. PMID: 19634000.
8. Barst RJ, McGoon M, Torbicki A, et al. Diagnosis and differential assessment of pulmonary arterial hypertension. *J Am Coll Cardiol*. 2004;43(12 Suppl S):40S-47S. PMID: 15194177.
9. Farber HW, Foreman AJ, Miller DP, et al. REVEAL Registry: correlation of right heart catheterization and echocardiography in patients with pulmonary arterial hypertension. *Congest Heart Fail*. 2011;17(2):56-64. PMID: 21449993.
10. Kiatchoosakun S, Wongvipaporn C, Nanagara R, et al. Right ventricular systolic pressure assessed by echocardiography: a predictive factor of mortality in patients with scleroderma. *Clin Cardiol*. 2011;34(8):488-93. PMID: 21717471.
11. Sachdev A, Villarraga HR, Frantz RP, et al. Right ventricular strain for prediction of survival in patients with pulmonary arterial hypertension. *Chest*. 2011;139(6):1299-309. PMID: 21148241.
12. Galie N, Hoeper MM, Humbert M, et al. Guidelines for the diagnosis and treatment of pulmonary hypertension: the Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS), endorsed by the International Society of Heart and Lung Transplantation (ISHLT). *Eur Heart J*. 2009;30(20):2493-537. PMID: 19713419.
13. Bernal V, Pascual I, Esquivias P, et al. N-terminal brain natriuretic peptide as a diagnostic test in cirrhotic patients with pulmonary arterial hypertension. *Transplant Proc*. 2009;41(3):987-8. PMID: 19376405.
14. Cavagna L, Caporali R, Klersy C, et al. Comparison of brain natriuretic peptide (BNP) and NT-proBNP in screening for pulmonary arterial hypertension in patients with systemic sclerosis. *J Rheumatol*. 2010;37(10):2064-70. PMID: 20634241.
15. Aubert JD. Biochemical markers in the management of pulmonary hypertension. *Swiss Med Wkly*. 2005;135(3-4):43-9. PMID: 15729606.
16. Soon E, Holmes AM, Treacy CM, et al. Elevated levels of inflammatory cytokines predict survival in idiopathic and familial pulmonary arterial hypertension. *Circulation*. 2010;122(9):920-7. PMID: 20713898.



17. Macchia A, Marchioli R, Tognoni G, et al. Systematic review of trials using vasodilators in pulmonary arterial hypertension: why a new approach is needed. *Am Heart J*. 2010;159(2):245-57. PMID: 20152223.
18. Sitbon O, Humbert M, Jais X, et al. Long-term response to calcium channel blockers in idiopathic pulmonary arterial hypertension. *Circulation*. 2005;111(23):3105-11. PMID: 15939821.
19. McLaughlin VV, Archer SL, Badesch DB, et al. ACCF/AHA 2009 expert consensus document on pulmonary hypertension a report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents and the American Heart Association developed in collaboration with the American College of Chest Physicians; American Thoracic Society, Inc.; and the Pulmonary Hypertension Association. *J Am Coll Cardiol*. 2009;53(17):1573-619. PMID: 19389575.
20. Agency for Healthcare Research and Quality. Methods Guide for Effectiveness and Comparative Effectiveness Reviews. Rockville, MD: Agency for Healthcare Research and Quality. [www.effectivehealthcare.ahrq.gov/index.cfm/search-for-guides-reviews-and-reports/?pageaction=displayproduct&productid=318](http://www.effectivehealthcare.ahrq.gov/index.cfm/search-for-guides-reviews-and-reports/?pageaction=displayproduct&productid=318). Accessed March 19, 2012.
21. Whiting PF, Rutjes AW, Westwood ME, et al. QUADAS-2: A Revised Tool for the Quality Assessment of Diagnostic Accuracy Studies. *Ann Intern Med*. 2011;155(8):529-36. PMID: 22007046.
22. Owens DK, Lohr KN, Atkins D, et al. AHRQ series paper 5: Grading the strength of a body of evidence when comparing medical interventions--Agency for Healthcare Research and Quality and the Effective Health-Care Program. *J Clin Epidemiol*. 2010;63(5):513-23. PMID: 19595577.
23. Atkins D, Chang SM, Gartlehner G, et al. Assessing applicability when comparing medical interventions: AHRQ and the Effective Health Care Program. *J Clin Epidemiol*. 2011;64(11):1198-207. PMID: 21463926.
24. Bonderman D, Wexberg P, Martischniig AM, et al. A noninvasive algorithm to exclude pre-capillary pulmonary hypertension. *Eur Respir J*. 2011;37(5):1096-103. PMID: 20693249.
25. Mathai SC, Puhan MA, Lam D, et al. The minimal important difference in the 6-minute walk test for patients with pulmonary arterial hypertension. *Am J Respir Crit Care Med*. 2012;186(5):428-33. PMID: 22723290.
26. Robinson KA, Saldanha IJ, Mckoy NA. Frameworks for Determining Research Gaps During Systematic Reviews. Methods Future Research Needs Report No. 2. (Prepared by the Johns Hopkins University Evidence-based Practice Center under Contract No. 290-2007-10061-I.) AHRQ Publication No. 11-EHC043-EF. Rockville, MD: Agency for Healthcare Research and Quality. June 2011. [www.effectivehealthcare.ahrq.gov/reports/final.cfm](http://www.effectivehealthcare.ahrq.gov/reports/final.cfm). Accessed May 22, 2012.

## Glossary

6MWD	6-minute walk distance
AHRQ	Agency for Healthcare Research and Quality
BID	two times per day
BNP	B-type natriuretic peptide
CI	confidence interval
CHF	congestive heart failure
COPD	chronic obstructive pulmonary disease
CTEPH	chronic thromboembolic pulmonary hypertension
CVD	collagen vascular disease
FAC	fractional area change
FC	functional class
HR	hazard ratio
HRQOL	health-related quality of life
IQR	interquartile range
KQ	Key Question
MI	myocardial infarction
mo	month/months
mPAP	mean pulmonary artery pressure
MPI	myocardial performance index
NA	not applicable
NR	not reported
NT-proBNP	N-terminal pro-B-type natriuretic peptide
OR	odds ratio
PAH	pulmonary arterial hypertension
PADP	pulmonary artery diastolic pressure
PASP	pulmonary artery systolic pressure
PCWP	pulmonary capillary wedge pressure
PH	pulmonary hypertension
PPH	primary pulmonary hypertension
PVR	pulmonary vascular resistance
QOL	quality of life
RA	right atrium
RAP	right atrial pressure
RHC	right heart catheterization
RIMP	right index of myocardial performance
RR	risk ratio
RV	right ventricle
RVEF	right ventricle ejection fraction
SD	standard deviation
SEM	standard error of the mean
SOE	strength of evidence
sPAP	systolic pulmonary artery pressure
SSc	systemic sclerosis
TAPSE	tricuspid annular plane systolic excursion

TEP	Technical Expert Panel
TRV	tricuspid regurgitant jet velocity
VSD	ventricular septal defect
VTI <sub>RVOT</sub>	velocity-time integral of right ventricular outflow tract
yr	year/years

# Introduction

## Background

### Epidemiology and Etiology of Pulmonary Arterial Hypertension

Pulmonary arterial hypertension (PAH), a subcategory of pulmonary hypertension (PH), is a rare and progressive disease whose prevalence is estimated to be between 15 and 50 cases per million adults.<sup>1</sup> While the pathophysiology is not well understood, both genetic and environmental factors have been found to contribute to changes in the pulmonary vasculature, causing increased pulmonary vascular resistance. This increased resistance, if unrelieved, progresses to right ventricular pressure overload, dysfunction, and ultimately right heart failure and premature death.<sup>2</sup> The causes of PAH are numerous and are listed in Table 1, taken from the Fourth World Symposium on PAH (2008).<sup>3</sup> Before the availability of disease-specific therapy in the mid-1980s, the median life expectancy at the time of diagnosis was 2.8 years.<sup>1,4</sup>

**Table 1. Updated clinical classification of pulmonary hypertension (Dana Point, 2008)<sup>a</sup>**

<b>1.</b>	<b>Pulmonary arterial hypertension (PAH)</b>
1.1	Idiopathic PAH
1.2	Heritable
1.2.1	BMPR2
1.2.2	ALK1, endoglin (with or without hereditary hemorrhagic telangiectasia)
1.2.3	Unknown
1.3	Drug and toxin-induced
1.4	Associated with:
1.4.1	Connective tissue disease
1.4.2	HIV infection
1.4.3	Portal hypertension
1.4.4	Congenital heart diseases
1.4.5	Schistosomiasis
1.4.6	Chronic hemolytic anemia
1.5	Persistent pulmonary hypertension of the newborn
<b>1'.</b>	<b>Pulmonary veno-occlusive disease (PVOD) and/or pulmonary capillary hemangiomatosis (PCH)</b>
<b>2.</b>	<b>Pulmonary hypertension owing to left heart disease</b>
2.1	Systolic dysfunction
2.2	Diastolic dysfunction
2.3	Valvular disease
<b>3.</b>	<b>Pulmonary hypertension owing to lung diseases and/or hypoxemia</b>
3.1	Chronic obstructive pulmonary disease
3.2	Interstitial lung disease
3.3	Other pulmonary diseases with mixed restrictive and obstructive pattern
3.4	Sleep-disordered breathing
3.5	Alveolar hypoventilation disorders
3.6	Chronic exposure to high altitude
3.7	Developmental abnormalities
<b>4.</b>	<b>Chronic thromboembolic pulmonary hypertension (CTEPH)</b>
<b>5.</b>	<b>Pulmonary hypertension with unclear multifactorial mechanisms</b>
5.1	Hematologic disorders: myeloproliferative disorders, splenectomy
5.2	Systemic disorders: sarcoidosis, pulmonary Langerhans cell histiocytosis: lymphangioleiomyomatosis, neurofibromatosis, vasculitis

**Table 1. Updated clinical classification of pulmonary hypertension (Dana Point, 2008)<sup>a</sup> (continued)**

5.3	Metabolic disorders: glycogen storage disease, Gaucher disease, thyroid disorders
5.4	Others: tumoral obstruction, fibrosing mediastinitis, chronic renal failure on dialysis

<sup>a</sup> Fourth World Symposium on PAH in Dana Point, CA (2008).

Table reprinted from the Journal of the American College of Cardiology, Vol 54, No. 1, Suppl S, Simonneau G, Robbins IM, Beghetti M, et al., Updated Clinical Classification of Pulmonary Hypertension, Pages No. S43-S54, Copyright 2009, with permission from Elsevier.<sup>3</sup>

## Screening and Diagnosis

There are two separate populations where screening for PAH needs to be considered. First, there are patients with symptoms that raise the suspicion of PAH. The symptoms of PAH can be insidious and nonspecific and may include shortness of breath, fatigue, weakness, chest pain, syncope, leg swelling and abdominal distention. Symptoms that are present at rest suggest advanced disease.<sup>1</sup> Since these symptoms are nonspecific, screening may be necessary to help decide whether the patient should undergo a diagnostic workup for PAH, or whether other conditions should be considered. The other population is patients with medical conditions that put them at risk for PAH. In these patients screening tests may be used to identify patients with asymptomatic elevation of pulmonary artery pressures, who might be more closely monitored for the development of symptoms or progressive disease or offered a diagnostic workup for PAH, and possibly treatment for early disease.

Once screening indicates the possibility of PAH, diagnostic tests are necessary to confirm the presence of elevated right-sided heart pressures and to exclude valvular, primary myocardial, chronic lung disease, thromboembolic, and miscellaneous other causes of pulmonary hypertension (PH). The reference standard for diagnosing PAH is right heart catheterization (RHC), which is invasive but generally safe. In a retrospective and prospective study by Hoeper et al.,<sup>5</sup> the rate of serious complications in patients undergoing RHCs for evaluation of pulmonary hypertension was 1.1 percent and included bleeding, vasovagal reactions, systemic hypotension, arterial injury, hypertensive crisis, pneumothorax, and cardiac arrhythmias. The procedure-related mortality was 0.055 percent.<sup>5</sup>

RHC not only confirms the diagnosis of PAH but also provides prognostic hemodynamic information (mean right atrial pressure, pulmonary vascular resistance)<sup>6</sup> to direct treatment decisions. A small subset of patients with PAH, when challenged with a short-acting pulmonary vasodilator, will experience a drop in mean pulmonary artery pressure of at least 10 mmHg (20%) to below 40 mmHg while maintaining cardiac output; this predicts a favorable long-term response to calcium channel blockers.<sup>1</sup>

Since PAH is a progressive disease, regular reassessment is needed to monitor response to treatment and adjust prognosis. RHC has traditionally been the means by which patients' clinical course is monitored; however, transthoracic echocardiography has emerged as a possible alternative because of its availability, safety, and cost. The number of echocardiographic modalities has increased substantially, providing unique insight into the structure and function of the right heart in patients with pulmonary hypertension.<sup>7</sup> However, this test has not been definitively validated as a substitute for RHC in patients with PAH. Finally, the role of biomarkers has not been fully established in the management and prognosis of PAH. Defining whether biomarkers alone or biomarkers plus echocardiography might be superior to echocardiography alone for informing treatment decisions is a necessary first step in establishing a noninvasive, multifaceted approach to the management of PAH.

## Role of Echocardiography

The role of echocardiography in the diagnosis and management of patients with PAH has evolved over time, and has been proposed for screening, assessing prognosis, and evaluating response to treatment. Screening high-risk individuals for PAH generally begins with a transthoracic echocardiogram.<sup>8</sup> Echocardiography can estimate the right ventricular systolic pressure and identify other signs of PH including increased right-sided chamber size and wall thickness. Most often, the peak velocity of the tricuspid regurgitant (TR) jet is measured by Doppler and—along with an estimate of right atrial pressure based on inspiratory collapse and size of the inferior vena cava—TR jet is used to estimate the systolic pulmonary artery pressure (sPAP). However, a significant proportion of patients have no measureable TR jet. Estimates are often inaccurate compared with RHC; up to 60 percent of echocardiography estimates were more than 10 mmHg off from RHC measurements in one large multicenter registry of PAH patients.<sup>9</sup> Furthermore, sPAP is dependent on right ventricle (RV) systolic function and stroke volume. In later stages of PH, RV function deteriorates, which can lessen the degree of sPAP elevation and lead to an underestimate of pulmonary vascular resistance (PVR). More recent echocardiographic-based methods have focused on evaluating RV systolic function. Therefore, although transthoracic echocardiography is the standard screening test for PAH, it is less than completely accurate and there is uncertainty as to which echocardiographic measurements are most useful.

Several studies have investigated the use of echocardiography in establishing prognosis in PAH. In a study of patients with systemic sclerosis (n=155), calculation of the right ventricular systolic pressure (RVSP) using Doppler echocardiography identified 47 patients (36.4%) with RVSP  $\geq 36$  mmHg who had decreased 3-year survival rates compared with patients with RVSP  $< 36$  mmHg (67% versus 86%,  $p < 0.01$ ).<sup>10</sup> Another study of patients with PAH (n=80) using echocardiography to calculate right ventricular free wall strain found that patients with strain worse than -12.5 percent were associated with increased 6-month disease progression and increased mortality at 1 year (unadjusted hazard ratio 6.2).<sup>11</sup> There remains uncertainty regarding which echocardiographic measure(s) have prognostic value although tricuspid annular plane systolic excursion (TAPSE) and pericardial effusion have been proposed.<sup>12</sup> Traditionally, RHC assessment of hemodynamics is recommended to demonstrate treatment response;<sup>12</sup> echocardiography has been seldom studied in this role.

## Role of Biomarkers

Because of the limitations of echocardiography, the potential role of biomarkers in screening for and managing of PAH has been the subject of increasing interest over the last decade. Brain natriuretic peptide (BNP) and N-terminal BNP (NT-proBNP) are two biological substances found in the blood that have been studied as a screening test in patients at risk for PAH and which have been shown to correlate well with the presence of disease.<sup>13,14</sup> Other biomarkers currently under investigation include atrial natriuretic peptide, endothelin-1, uric acid, troponin T, nitric oxide, asymmetric dimethylarginine, cyclic guanosine monophosphate, D-dimer, and serotonin. Several of these biomarkers have been shown to correlate with prognosis and mortality, either alone or in conjunction with other traditional measurements such as the 6-minute walk distance (6MWD) test, functional class assessment, and pulmonary hemodynamics.<sup>15</sup> Select biomarkers may even be superior to traditional testing. Patients with idiopathic and familial PAH were shown to exhibit dysregulation over a broad range of inflammatory cytokines, such as tumor necrosis factor-alpha and interleukin-6, when compared

with healthy controls, which correlated better with prognosis than 6MWD and pulmonary hemodynamics.<sup>16</sup>

## Treatment Strategies

### Medications

The goal of medical treatment for PAH is both to improve patients' symptomatic status and to slow the rate of clinical deterioration. In addition to supportive therapy (diuretics, oxygen, digoxin, oral anticoagulants), specific drug therapy is recommended. There has been rapid development and approval of vasodilator medications for PAH over the past three decades. Currently, there are four main classes of medications used to treat PAH, as shown in the bulleted list below.<sup>17</sup> Calcium channel blockers are indicated for the minority of patients who have positive acute vasoreactivity testing and demonstrate a sustained response. Most patients are candidates for treatment with one of the other three classes of medications.

- Calcium channel blockers:
  - Amlodipine
  - Diltiazem
  - Nifedipine
- Prostacyclin analogues:
  - Epoprostenol
  - Iloprost
  - Treprostinil
- Endothelin receptor antagonists:
  - Bosentan
  - Ambrisentan
- Phosphodiesterase type 5 inhibitors:
  - Sildenafil
  - Tadalafil

These PAH medications have been shown to improve dyspnea, 6MWD, pulmonary hemodynamics, and functional class. Calcium channel blockers are associated with long-term (>1 year) improvements in hemodynamics and functional status in most of those patients who show acute vasoreactivity testing response; however, acute vasoreactivity is seen in a minority of patients tested.<sup>18</sup> The limited usefulness of calcium antagonists—as well as the poor prognosis and diminished quality of life associated with PAH—reinforces the need for new drug therapies and improved delivery of current medications. Limited data suggest that epoprostenol and bosentan may provide a survival benefit; however, this end point has not been studied consistently between the medications.<sup>19</sup> The three medications most recently approved by the U.S. Food and Drug Administration for PAH are: (1) inhaled treprostinil, a new delivery system for this prostacyclin analogue, (2) tadalafil, a new phosphodiesterase type 5 inhibitor, and (3) ambrisentan, an endothelin receptor antagonist. With the exception of tadalafil, these new medications were discussed in the Expert Consensus Document on Pulmonary Hypertension released in 2009 by the American College of Cardiology Foundation and the American Heart Association.<sup>19</sup> Since then, however, numerous studies have been published regarding the safety and efficacy of these new medications. Also, more data have been published on the older medications for PAH. These new data may clarify any effect on mortality and gauge the comparative effectiveness of these drugs.

Additionally, combination drug therapy (using multiple drugs with different mechanisms of action) is an important area of research and may be the most promising way to improve clinical outcomes although at higher cost.<sup>2</sup> Combination therapy was addressed in the 2009 ACCF/AHA publication, and several studies have since been published on this topic. In order to optimize PAH care, newer information regarding the latest drugs and combination therapies should be systematically reviewed.<sup>17</sup>

## **Scope and Key Questions**

### **Scope of the Review**

This comparative effectiveness review was funded by the Agency for Healthcare Research and Quality (AHRQ). It was designed to evaluate the comparative validity, reliability, and feasibility of echocardiography and biomarker testing for the diagnosis and management of PAH in addition to clarifying whether the use of echocardiography and biomarkers affects decisionmaking and clinical outcomes. We also wanted to address which medications are effective for treating PAH and how the newer medications compare with older ones and with each other. Further, there was a need for clarity about whether combination therapy is more effective than monotherapy and what effect monotherapy or combination therapy has on intermediate-term and long-term outcomes.

### **Key Questions**

With input from our Key Informants, we constructed Key Questions (KQs) using the general approach of specifying the population of interest, the interventions, comparators, outcomes, timing of outcomes, and settings (PICOTS; see the section on “Inclusion and Exclusion Criteria” in the Methods section for details). The KQs considered in this comparative effectiveness review were:


- KQ 1: For patients with suspected pulmonary arterial hypertension (PAH) and asymptomatic patients at high risk for PAH, what is the comparative effectiveness and safety of echocardiography versus echocardiography plus biomarkers as screening modalities before right heart catheterization to establish the diagnosis of PAH (diagnostic accuracy efficacy)?
- KQ 2: For patients with PAH, what is the comparative effectiveness and safety of (a) echocardiography versus biomarkers and (b) echocardiography versus echocardiography plus biomarkers in managing PAH and on intermediate-term ( $\leq 90$  days) and long-term ( $> 90$  days) patient outcomes?
- KQ 3: For patients with PAH, what is the comparative effectiveness and safety of monotherapy or combination therapy for PAH using calcium channel blockers, prostanoids, endothelin receptor antagonists, or phosphodiesterase inhibitors on intermediate-term and long-term patient outcomes?

### **Analytic Framework**

Figures 1 and 2 show the analytic framework for this comparative effectiveness review.



**Figure 1. Analytic framework for KQs 1 and 2**




KQ = Key Question; PAH = pulmonary arterial hypertension

<sup>a</sup>Fryback DG, Thornbury JR. The efficacy of diagnostic imaging. Med Decis Making 1991;11(2):88-94.

<sup>b</sup>In conjunction with routine clinical assessment (functional class, dyspnea, 6-minute walk).

**Figure 2. Analytic framework for KQ 3**



KQ = Key Question; PAH = pulmonary arterial hypertension

# Methods

The methods for this comparative effectiveness review follow those suggested in the AHRQ “Methods Guide for Effectiveness and Comparative Effectiveness Reviews” (available at [www.effectivehealthcare.ahrq.gov/methodsguide.cfm](http://www.effectivehealthcare.ahrq.gov/methodsguide.cfm); hereafter referred to as the Methods Guide).<sup>20</sup> The main sections in this chapter reflect the elements of the protocol established for the systematic review; certain methods map to the PRISMA checklist.<sup>21</sup> All methods and analyses were determined a priori.

## Topic Refinement and Review Protocol

During the topic refinement stage, we solicited input from Key Informants representing clinicians (pulmonology, cardiology, pathology), patients, scientific experts, and Federal agencies, to help define the Key Questions. The Key Questions were then posted for public comment for 30 days, and the comments received were considered in the development of the research protocol. We next convened a Technical Expert Panel (TEP), comprising clinical, content, and methodological experts, to provide input in defining populations, interventions, comparisons, or outcomes as well as identifying particular studies or databases to search. The Key Informants and members of the TEP were required to disclose any financial conflicts of interest greater than \$10,000 and any other relevant business or professional conflicts of interest. Any potential conflicts of interest were balanced or mitigated. Neither Key Informants nor members of the TEP did analysis of any kind and did not contribute to the writing of the report. Members of the TEP were invited to provide feedback on an initial draft of the review protocol, which was then refined based on their input, reviewed by AHRQ, and posted for public access at the AHRQ Effective Health Care Web site.<sup>22</sup>

## Literature Search Strategy

### Sources Searched

Our search strategy used the National Library of Medicine’s medical subject headings (MeSH) keyword nomenclature developed for MEDLINE<sup>®</sup> and adapted for use in other databases. In consultation with our research librarians, we searched PubMed<sup>®</sup>, Embase<sup>®</sup>, and the Cochrane Database of Systematic Reviews (Appendix A). We limited the search to English-language studies conducted from 1995 to the present for KQs 1 and 2, and 1990 to the present for KQ 3; prior to 1990, newer drug treatments were not available, and prior to 1995 older echocardiographic and biomarker testing technology is less applicable. Where possible, we used existing validated search filters (such as the Clinical Queries Filters in PubMed<sup>®</sup>). We supplemented the electronic searches with a manual search of citations from a set of key primary and review articles. The reference list for identified pivotal articles was hand-searched and cross-referenced against our library, and additional manuscripts were retrieved. All citations were imported into an electronic database (EndNote<sup>®</sup> X4; Thomson Reuters, Philadelphia, PA).

We also searched the gray literature of study registries and conference abstracts for relevant articles from completed studies. Gray literature databases included ClinicalTrials.gov; metaRegister of Controlled Trials; ClinicalStudyResults.org; WHO: International Clinical Trials Registry Platform Search Portal; and ProQuest COS Conference Papers Index. Scientific information packets were requested from the manufacturers of medications and devices and

reviewed for relevant articles from completed studies not previously identified in the literature searches.

Although this was not an exhaustive strategy, the search of ClinicalTrials.gov was also used as a mechanism to ascertain publication bias by identifying completed but unpublished studies. During peer and public review of the draft report, we updated all database searches and included any eligible studies identified either through that search or through suggestions from peer and public reviewers.

## Inclusion and Exclusion Criteria

The PICOTS criteria used to screen articles for inclusion/exclusion at both the title-and-abstract and full-text screening stages are detailed in Table 2.

**Table 2. Inclusion and exclusion criteria**

<b>Study Characteristic</b>	<b>Inclusion Criteria</b>	<b>Exclusion Criteria</b>
Population	<ul style="list-style-type: none"> <li>• KQ 1: Patients with suspected pulmonary arterial hypertension (PAH) or asymptomatic patients at high risk for PAH (e.g., patients with a collagen vascular disorder such as scleroderma)</li> <li>• KQs 2 and 3: Patients with PAH</li> </ul>	<p>KQ 1: Patients have neither (1) a condition associated with a high risk of undiagnosed PAH (e.g., a collagen vascular disorder) nor (2) signs or symptoms suspicious for PAH</p> <p>KQ 2 and KQ 3: No patients have PAH</p>
Interventions	<ul style="list-style-type: none"> <li>• KQ 1 (screening): Echocardiography plus biomarkers including natriuretic peptides (e.g., atrial natriuretic peptide, brain natriuretic peptide), endothelin-1, uric acid, troponin T, nitric oxide, asymmetric dimethylarginine, cyclic guanosine monophosphate, D-dimer, and serotonin</li> <li>• KQ 2 (management): <ul style="list-style-type: none"> <li>○ Biomarkers plus clinical assessment (e.g., history, physical exam, functional status)</li> <li>○ Echocardiography plus biomarkers plus clinical assessment</li> </ul> </li> <li>• KQ 3 (pharmacotherapies): <ul style="list-style-type: none"> <li>○ Calcium channel blockers (amlodipine, diltiazem, nifedipine, verapamil)</li> <li>○ Prostanoids (epoprostenol, treprostinil, iloprost)</li> <li>○ Endothelin antagonists (bosentan, ambrisentan)</li> <li>○ Phosphodiesterase inhibitors (sildenafil, tadalafil)</li> </ul> </li> </ul>	<p>Study does not include a comparison of echocardiography or biomarkers for screening, diagnosis, or management of PAH, or does not include a comparison of monotherapy with combination therapy for PAH</p>

**Table 2. Inclusion and exclusion criteria (continued)**

Study Characteristic	Inclusion Criteria	Exclusion Criteria
Comparators	<ul style="list-style-type: none"> <li>• KQ 1: Echocardiography vs. echocardiography plus biomarkers</li> <li>• KQ 2: <ul style="list-style-type: none"> <li>○ Echocardiography vs. biomarkers (direct comparison)</li> <li>○ Echocardiography vs. echocardiography plus biomarkers (direct comparison)</li> <li>○ Echocardiography vs. clinical assessment (indirect comparison)</li> <li>○ Biomarkers vs. clinical assessment (indirect comparison)</li> </ul> </li> <li>• KQ 3: <ul style="list-style-type: none"> <li>○ One pharmacotherapy vs. another pharmacotherapy</li> <li>○ Monotherapy vs. combination therapy</li> </ul> </li> </ul>	Study does not include a comparison of echocardiography or biomarkers for screening, diagnosis, or management of PAH, or does not include a comparison of monotherapy with combination therapy for PAH
Outcomes	<ul style="list-style-type: none"> <li>• KQ 1: Test-associated outcomes: Diagnostic accuracy efficacy (sensitivity, specificity, positive predictive value/negative predictive value); verification by right heart catheterization for test positive patients was required (incomplete verification of test negative patients was allowed)</li> <li>• KQ 2: Efficacy outcomes: <ul style="list-style-type: none"> <li>○ Diagnostic thinking efficacy and therapeutic efficacy (clinician judgment about diagnosis/prognosis, choice of treatment)</li> <li>○ Patient outcome efficacy for intermediate-term outcomes (hemodynamic parameters, dyspnea, and 6-minute walk) and long-term outcomes (functional class, quality of life, right heart failure, and mortality)</li> </ul> </li> <li>• KQ 3: Effectiveness of pharmacotherapies: <ul style="list-style-type: none"> <li>○ Intermediate-term outcomes such as hemodynamic parameters, dyspnea, and 6-minute walk</li> <li>○ Long-term outcomes such as functional class, quality of life, right heart failure or right ventricular dysfunction, and mortality</li> </ul> </li> </ul>	No primary or secondary outcomes of interest are reported
Outcomes (safety)	<ul style="list-style-type: none"> <li>• KQs 1 and 2: Adverse effects of echocardiography and biomarkers, such as bleeding, bruising, infection, and transient ischemic attack</li> <li>• KQ 3: Adverse effects of pharmacotherapies (liver function abnormalities, headache, flushing, cough, epistaxis, dyspepsia, diarrhea, peripheral edema, nausea, nasal congestion, dizziness, syncope, hypoxia, increased international normalized ratio or prothrombin time) and parenteral therapy (line infection, site pain, abrupt catheter occlusion)</li> </ul>	None
Timing	Intermediate-term ( $\leq 120$ days) and long-term ( $> 120$ days)	None

**Table 2. Inclusion and exclusion criteria (continued)**

<b>Study Characteristic</b>	<b>Inclusion Criteria</b>	<b>Exclusion Criteria</b>
Setting	<ul style="list-style-type: none"> <li>• Inpatient and outpatient</li> <li>• Specialty (pulmonary, cardiology, rheumatology) and primary care</li> </ul>	None
Study design	<ul style="list-style-type: none"> <li>• Randomized controlled trial, prospective or retrospective observational study, or registry</li> <li>• Original data (or related methodology paper of an included article) for any of the screening or diagnostic tests listed in the KQs, or original data with intermediate-term or long-term outcomes associated with monotherapy or combination therapy for PAH</li> <li>• Relevant systematic review or meta-analysis (used for background only)</li> <li>• All sample sizes</li> </ul>	Not a clinical study (e.g., editorial, nonsystematic review, letter to the editor, case series)
Publications	<ul style="list-style-type: none"> <li>• English-language only</li> <li>• Peer-reviewed article</li> <li>• KQs 1 and 2: Published January 1, 1995, to present</li> <li>• KQ 3: Published January 1, 1990, to present</li> </ul>	Given the high volume of literature available in English-language publications (including the majority of known important studies), non-English articles are excluded <sup>b</sup>

KQ = Key Question; PAH = pulmonary arterial hypertension

## Study Selection

Using the prespecified inclusion and exclusion criteria, titles and abstracts were examined independently by two reviewers for potential relevance to the Key Questions. Articles included by any reviewer underwent full-text screening. At the full-text screening stage, paired researchers independently reviewed the articles and indicated a decision to include or exclude the article for data abstraction. When the paired reviewers arrived at different decisions, we reconciled the difference through review and discussion or through a third-party arbitrator, if needed. Articles meeting eligibility criteria were included for data abstraction. Relevant systematic review articles, meta-analyses, and methods articles were flagged for hand-searching and cross-referencing against the library of citations identified through electronic database searching. All screening decisions were made and tracked in the DistillerSR database (Evidence Partners, Inc., Manotick, ON, Canada).

## Data Extraction

The investigative team created data abstraction forms and evidence table templates. Based on clinical and methodological expertise, two investigators were assigned to the research questions to abstract data from the eligible articles. One investigator abstracted the data, and the second overread the article and the accompanying abstraction to check for accuracy and completeness. Disagreements were resolved by consensus or by obtaining a third reviewer's opinion if consensus was not reached between the first two investigators. To aid in both reproducibility and standardization of data collection, investigators received data abstraction instructions directly on each form created specifically for this project with the DistillerSR data synthesis software program (Evidence Partners Inc., Manotick, ON, Canada). Data reported only in graphs were

estimated quantitatively using Engauge Digitizer version 4.1 software (www.digitizer.sourceforge.net).

We designed the data abstraction forms for this project to collect data required to evaluate the specified eligibility criteria for inclusion in this review, as well as demographic and other data needed for determining outcomes (intermediate outcomes, health outcomes, and safety outcomes). Although we recorded time to clinical worsening (TTCW) as an outcome, we did not analyze it separately in lieu of individual outcomes. As a composite outcome, we found TTCW problematic to assess because it (1) is reported only in relatively few recent studies, (2) is defined differently in different studies, and (3) assigns equal importance to different events in the composite (mortality, hospitalization, transplant). The safety outcomes were framed to help identify adverse events, including bleeding, bruising, infection, liver function abnormalities, headache, flushing, epistaxis, dyspepsia, diarrhea, peripheral edema, nausea, nasal congestion, dizziness, syncope, increased international normalized ratio or prothrombin time.

Data necessary for assessing quality and applicability, as described in the *Methods Guide*,<sup>20</sup> were also abstracted. Before they were used, abstraction form templates were pilot tested with a sample of included articles to ensure that all relevant data elements were captured and that there was consistency and reproducibility between abstractors. Forms were revised as necessary before full abstraction of all included articles. Appendix B lists the elements used in the data abstraction forms. Appendix C contains a bibliography of all articles/studies included in this review, organized alphabetically by author.

## **Quality (Risk-of-Bias) Assessment of Individual Studies**

We evaluated the quality of individual studies by using the approach described in the *Methods Guide*.<sup>20</sup> For studies of diagnostic tests (KQ 1 and KQ 2), we used QUADAS-2,<sup>23</sup> a tool for the quality assessment of studies of diagnostic accuracy included in systematic reviews. QUADAS-2 describes risk of bias in four key domains: patient selection, index test(s), reference standard, and flow and timing; each domain is rated as high, low, or unclear risk of bias. For studies of pharmacotherapies, we used the Cochrane Risk of Bias tool, which evaluates random sequence generation, allocation concealment, blinding of participant and personnel, blinding of outcome assessment, incompleteness of outcome data, selective outcome reporting, and other bias.

Two raters independently evaluated each study and differences were resolved by consensus; if consensus could not be reached, then the item was rated as unclear, and the rationale for each differing assessment was described. Results were described for individual domains. If the distribution of ratings permits, methodological domains were examined for association with effects in meta-analysis.

To indicate the summary judgment of the quality of the individual studies, we used the summary ratings of good, fair, or poor based on their adherence to well-accepted standard methodologies and adequate reporting (Table 3).

**Table 3. Definitions of overall quality ratings**

Quality Rating	Description
Good	A study with the least bias; results are considered valid. A good study has a clear description of the population, setting, interventions, and comparison groups; uses a valid approach to allocate patients to alternative treatments; has a low dropout rate; and uses appropriate means to prevent bias, measure outcomes, and analyze and report results.
Fair	A study that is susceptible to some bias but probably not enough to invalidate the results. The study may be missing information, making it difficult to assess limitations and potential problems. As the fair-quality category is broad, studies with this rating vary in their strengths and weaknesses. The results of some fair-quality studies are possibly valid, while others are probably valid.
Poor	A study with significant bias that may invalidate the results. These studies have serious errors in design, analysis, or reporting; have large amounts of missing information; or have discrepancies in reporting. The results of a poor-quality study are at least as likely to reflect flaws in the study design as to indicate true differences between the compared interventions.

Included meta-analyses were appraised according to criteria adapted from the PRISMA Statement.<sup>21</sup> Grading was outcome-specific; thus, a given study may have been graded of different quality for two individual outcomes reported within that study. Study design also was considered when grading quality. RCTs were graded as good, fair, or poor. Observational studies were graded separately, also as good, fair, or poor. Appendix D summarizes our assessment of the quality and applicability for each included study.

## Data Synthesis

Quantitative synthesis (i.e., meta-analysis) was done when we found multiple studies of similar design, population, intervention, comparator and outcome that reported sufficient data for analysis. When a meta-analysis was appropriate, we used random-effects models to quantitatively synthesize the available evidence. We use meta-analyses both to quantify and to attempt to explain between-study variation as well as to calculate summary estimates. When a meta-analysis was not appropriate, we described the reasons, presented data in tabular form, and summarized studies either individually or qualitatively.

For sensitivity and specificity data, we used a binomial model to calculate summary estimates of sensitivity and specificity and associated confidence intervals and summary ROC curve using SAS. Sensitivity analyses were conducted using summary receiver operating characteristic meta-analysis using the diagnostic odds ratio with dr-ROC software (Diagnostic Research Design and Reporting; Glenside, PA). For meta-analysis of correlation coefficients and hazard ratios for observational studies, we used a random effects model implemented in SAS (SAS Institute Inc.; Cary, NC). For treatment effects meta-analysis, we used a random effects model meta-analysis implemented in Comprehensive Meta-Analysis Software (Version 2.2.064, Biostat; Englewood, NJ). We tested for heterogeneity using graphical displays and test statistics ( $Q$  and  $I^2$  statistics), while recognizing that the ability of statistical methods to detect heterogeneity may be limited, particularly when the number of studies is small. We present summary estimates and confidence intervals in our data synthesis.



## Strength of the Body of Evidence

The strength of evidence for each Key Question was assessed using the approach described in the Methods Guide.<sup>24</sup> The evidence was evaluated using the four required domains: risk of bias, consistency, directness, and precision (Table 4).

**Table 4. Strength of evidence required domains**

Domain	Rating	How Assessed
Risk of bias	Low Medium High	Assessed primarily through study design (RCT versus observational study) and aggregate study quality
Consistency	Consistent Inconsistent Unknown/not applicable	Assessed primarily through whether effect sizes are generally on the same side of “no effect” and the overall range of effect sizes
Directness	Direct Indirect	Assessed by whether the evidence involves direct comparisons or indirect comparisons through use of surrogate outcomes or use of separate bodies of evidence
Precision	Precise Imprecise	Based primarily on the size of the confidence intervals of effect estimates

Additionally, when appropriate, the studies were evaluated for dose-response association, the presence of confounders that would diminish an observed effect, strength of association (magnitude of effect), and publication bias. These domains were considered qualitatively, and a summary rating of high, moderate, or low strength of evidence was assigned after discussion by two reviewers. In some cases, high, moderate, or low ratings were impossible or imprudent to make; for example, when evidence on the outcome was too weak, sparse, or inconsistent to permit any conclusion to be drawn. In these situations, a grade of insufficient was assigned. This four-level rating scale consists of the following definitions:

- **High**—High confidence that the evidence reflects the true effect. Further research is very unlikely to change our confidence in the estimate of effect.
- **Moderate**—Moderate confidence that the evidence reflects the true effect. Further research may change our confidence in the estimate of effect and may change the estimate.
- **Low**—Low confidence that the evidence reflects the true effect. Further research is likely to change the confidence in the estimate of effect and is likely to change the estimate.
- **Insufficient**—Evidence either is unavailable or does not permit estimation of an effect.

Diagnostic evaluation studies (KQs 1 and 2) are generally indirect, as the link between the test intervention and outcome is mitigated by prognosis, management, and the effectiveness of treatments. As a rule of thumb, we considered correlation coefficients greater than 0.7 as strong association, 0.40 to 0.69 as moderate, and less than 0.40 as weak. In our summary strength of evidence assessments for KQs 1 and 2, lack of directness was weighed less heavily and risk of bias most heavily. Thus, we allowed high strength of evidence levels despite the lack of directness among these studies.

## Applicability

We assessed applicability across our KQs using the PICOTS format as described in the Methods Guide.<sup>20,25</sup> We used these data to evaluate the applicability to clinical practice, paying special attention to study eligibility criteria, demographic features of the enrolled population (such as age, ethnicity, and sex) in comparison with the target population, version or

characteristics of the intervention used in comparison with therapies currently in use (such as specific components of treatments considered to be supportive therapy), and clinical relevance and timing of the outcome measures. We summarized issues of applicability qualitatively. Because applicability issues may differ for different users, we reported across a range of potential applicability issues (Appendix D).

In diagnostic evaluation studies, we were particularly concerned with the prevalence of PAH versus PH in the study populations compared, the spectrum of underlying type of PAH, and the assessment of adverse events associated with testing. In PAH drug trials, we were particularly concerned with assessing the severity of illness; use of run-in periods and attrition before randomization; use of surrogate or combined outcome measures; short study duration; reporting of adverse events, in particular including those related to administration or monitoring of treatment; sample size sufficient to assess minimally important differences from a patient perspective; and use of intention-to-treat-analysis.

## **Peer Review and Public Commentary**

The peer review process is our principal external quality-monitoring device. Nominations for peer reviewers were solicited from several sources, including the TEP and interested Federal agencies. Experts in cardiology, radiology, vascular surgery, general medicine, and nursing, along with individuals representing stakeholder and user communities, were invited to provide comments; AHRQ and an associate editor also provided comments. The draft report was posted on the AHRQ Web site for 4 weeks, from August 31 to September 28, 2012. We have addressed reviewer comments, revising the report as appropriate, and have documented our responses in a disposition of comments report available on the AHRQ Web site. A list of peer reviewers is given in the preface of this report.


## Results

In what follows, we begin by presenting the results of our literature searches. The remainder of the chapter is organized by Key Question (KQ). Under each KQ, we begin by listing the key points of the findings, followed by a brief description of included studies and a study characteristics table, followed by a more detailed synthesis of the evidence. We conducted quantitative analyses (i.e., meta-analyses) where possible, as described in the Methods chapter. Results of these analyses are presented graphically in the form of forest plots and in tabular format. A list of abbreviations and acronyms used in this chapter is provided at the end of the report.

### Results of Literature Searches

Figure 3 depicts the flow of articles through the literature search and screening process. Searches of PubMed<sup>®</sup>, the Cochrane Database of Systematic Reviews, and Embase<sup>®</sup> yielded 8256 citations, 1626 of which were duplicate citations. Manual searching identified 46 additional citations, for a total of 6676 citations. After applying inclusion/exclusion criteria at the title-and-abstract level, 1324 full-text articles were retrieved and screened. Of these, 1127 were excluded at the full-text screening stage, leaving 197 articles (representing 186 studies) for data abstraction. Appendix C provides a detailed listing of included articles as well as a key to study groupings of primary and companion articles. Appendix E provides a complete list of articles excluded at the full-text screening stage, with reasons for exclusion.

**Figure 3. Literature flow diagram**



KQ = Key Question

\*Article counts by KQ do not add to 197 because some studies were included for multiple KQs.

## Description of Included Studies

Overall, we included 186 studies represented by 197 articles: 60 studies were relevant to KQ 1, 99 studies to KQ 2, and 37 studies to KQ 3. Studies were conducted wholly or partly in continental Europe (37%), the United States or Canada (32%), the United Kingdom (7%), Asia (24%), South or Central America (4%), Australia or New Zealand (7%), and other locations (3%). In 11 studies, the location was not reported. Further details on the studies included for each KQ are provided in the relevant results sections below and in Appendix F.

As described in the Methods chapter, we searched ClinicalTrials.gov to identify completed but unpublished studies as a mechanism for ascertaining publication bias. Our search yielded 552 trial records, 257 of which were completed at least 1 year prior to our search of the database and review of the published literature. A single reviewer identified 35 of these records as potentially relevant. We identified and screened publications for 23 of the 35 trial records. Of the 12 trial records for which we did not identify publications, one was considered potentially relevant to KQ 2, and 11 were potentially relevant to KQ 3.

The one study potentially relevant to KQ 2 is an interventional study in patients diagnosed with PAH that was verified as completed with 75 patients in June 2011. It was designed to assess the correlation between plasma brain natriuretic peptide (BNP) and migration inhibitory factor (MIF) levels, both before and after exercise, with 6-minute walk distance (6MWD) and echocardiographic parameters as markers of PAH severity. This study remains unpublished, but if findings are available in the future, the data would add to the BNP correlations with 6MWD and echocardiographic parameters reported here. Although MIF was not in the list of commonly studied biomarkers that we focused on in this report, our findings support the need for additional research into alternative biomarkers that may more effectively assess disease severity.

Of the 11 studies potentially relevant to KQ 3, one was terminated when the drug sitaxsentan was withdrawn from the market, and another study focused on oral treprostinil, which was recently rejected by the FDA. Two more studies were terminated due to slow enrollment, and we could not find any published results. Of the seven remaining studies, four have data uploaded to ClinicalTrials.gov but have yet to be published in the peer-reviewed literature. These studies consist of a dose response study of oral sildenafil that was terminated, the EPITOME-1 and EPITOME-1 Extension studies comparing two types of injectable epoprostenol, and the ATHENA-1 study investigating the addition of ambrisentan to phosphodiesterase-5 (PDE5) inhibitor therapy. These four unpublished trials could potentially provide additional evidence on the comparative safety and effectiveness of pharmacological therapies for PAH in 197 patients. Note that the 37 studies included for KQ 3 involved data for 4192 patients.

The final three studies are either still recruiting, or their true status is unknown. One study, on the effect of treprostinil plus tadalafil versus tadalafil alone, was confirmed as still recruiting in February 2011 and would add to our knowledge of monotherapy versus combination therapy. The final two unpublished studies have not been updated in ClinicalTrials.gov in the last 2 years, and both are studies of novel drug treatments for PAH. One of these studies focuses on the safety and efficacy of fluoxetine, while the other focuses on an endothelin named BQ-123.

Based on our search of ClinicalTrials.gov and the 12 trial records without publications in peer-reviewed literature, we do not believe that there is significant publication bias in the evidence base that would impact our overall findings.

## KQ 1: Screening for PAH

KQ 1: For patients with suspected pulmonary arterial hypertension (PAH) and asymptomatic patients at high risk for PAH, what are the comparative effectiveness and safety of echocardiography versus echocardiography plus biomarkers as screening modalities before right heart catheterization to establish the diagnosis of PAH (diagnostic accuracy efficacy)?

### Key Points

- For patients suspected of having PAH with elevated systolic pulmonary artery pressure (sPAP) by echocardiography, additional testing with the biomarker N-terminal pro-B-type natriuretic peptide (NT-proBNP) may identify patients who do not have PAH compared with echocardiography sPAP alone (based on one good-quality prospective cohort study) (low strength of evidence).
- For patients suspected of PAH, echocardiographic estimation of right ventricular systolic pressure (RVSP) (or tricuspid gradient [TG]) by tricuspid regurgitation jet velocity (TRV), sPAP by TRV and right atrial pressure (RAP), and pulmonary vascular resistance (PVR) by TRV/velocity-time integral right ventricular outflow tract (VTI<sub>RVOT</sub>) show reasonably good accuracy compared with right heart catheterization (RHC) (moderate strength of evidence).
- For both asymptomatic patients at high risk for PAH or symptomatic patients suspected of PAH, natriuretic peptide testing (with either BNP or NT-proBNP) shows highly variable sensitivity and specificity estimates (not simultaneously high) for pulmonary hypertension (PH) or PAH diagnosis (low strength of evidence) and moderate correlation with hemodynamic measures by RHC (moderate strength of evidence).
- There were no studies of the safety of biomarker and echocardiography testing, nor were there any studies of combined echocardiographic and biomarker screening of asymptomatic patients at high risk for PAH (insufficient strength of evidence).

### Description of Included Studies

We identified 60 unique studies involving a total of 7,096 patients that described the effectiveness of echocardiography or biomarkers in patients with suspected PAH, or in asymptomatic patients at high risk for PAH, as screening modalities before right heart catheterization to establish the diagnosis of PAH.<sup>9,14,26-83</sup> We identified one good-quality study<sup>26</sup> involving 372 patients that compared echocardiography with echocardiography plus biomarkers in patients with suspected PAH, most of whom were symptomatic. There were no other studies directly comparing combinations of echocardiographic and biomarker testing. In order to draw inferences about the comparative effectiveness of other tests, we reviewed the diagnostic accuracy of independent echocardiographic or biomarker testing compared with RHC. By evaluating the relative diagnostic performance of these tests versus a reference standard of RHC, one can impute the comparative effectiveness via indirect comparisons.

Of the 60 included studies, 18 (30%) were rated good quality, 33 (55%) fair quality, and 9 (15%) poor quality. Echocardiographic parameters evaluated were right ventricular (RV) size,

right atrium (RA) size, fractional area change (FAC), tricuspid annular plane systolic excursion (TAPSE), tricuspid lateral annular systolic velocity (S'), right ventricular index of myocardial performance (RIMP), myocardial performance index (MPI), Tei index, systolic pulmonary artery pressure (sPAP), mean pulmonary artery pressure (mPAP), tricuspid regurgitation jet velocity (TRV), velocity-time integral right ventricular outflow tract (VTI<sub>RVOT</sub>), right ventricular ejection fraction (RVEF), right ventricular systolic pressure (RVSP), and pericardial effusion. Biomarkers evaluated were natriuretic peptides, endothelin-1, uric acid, troponin T, nitric oxide, asymmetric dimethylarginine, cyclic guanosine monophosphate, and D-dimer.

## Study Characteristics

Table F-1 in Appendix F summarizes the patient population, study size, test measures, study objectives, and quality rating for each study relevant to KQ 1. Of these studies, 26 were conducted in Europe (including the United Kingdom),<sup>14,26-30,32,35,36,39-41,46,54,55,57,58,60,66,68,70,71,73,76-78</sup> 17 in the United States,<sup>9,33,37,43,45,51-53,56,59,61,65,67,75,80,83</sup> 12 in Asia,<sup>38,47-49,62-64,69,72,79,82</sup> 5 in Australia/New Zealand,<sup>31,42,44,50,81</sup> and 1 in South America.<sup>34</sup> The vast majority of studies included only adults; exceptions were five studies that included only children<sup>45,63,64,74,82</sup> and three studies that included both children and adults.<sup>65,69,79</sup> In studies that reported the sex of participants, a total of 4020 participants were female and 1275 were male. Symptom status of study populations consisted of asymptomatic (3 studies; 481 patients), symptomatic (41 studies; 4394 patients), mixed (8 studies; 1186 patients), and symptoms not described (8 studies; 1035 patients). Of the included studies, 14 compared biomarker levels, 49 evaluated echocardiographic parameters, and 1 assessed echocardiography plus biomarkers as a testing or screening modality in patients with suspected PAH or asymptomatic patients at high risk for developing PAH. BNP and NT-proBNP were the most commonly evaluated biomarkers. The most commonly reported echocardiographic parameters compared with RHC were FAC, mPAP, RIMP, TRV/VTI<sub>RVOT</sub>, S', sPAP, TRV, and TAPSE.

## Detailed Synthesis

### Echocardiography Plus Biomarkers for Screening for PAH

We identified only one study (good quality) that gave data on the use of echocardiography and biomarkers in screening patients suspected of having PAH.<sup>26</sup> This study used retrospective data on patients referred for evaluation of precapillary PH to develop a noninvasive diagnostic decision algorithm. This diagnostic algorithm was subsequently tested and validated in a prospective study using data from electrocardiography, serum NT-proBNP, and echocardiography. The goal was to use the aforementioned assessment to distinguish between patients in whom precapillary PH was likely versus those in whom precapillary PH could be excluded with the goal of avoiding unnecessary, invasive RHC procedures. Patients with neither RV strain on ECG (defined as ST-segment deviation and T-wave inversions in leads V1-V3) nor elevated serum NT-proBNP (>80 pg/mL) were considered to have the diagnosis of precapillary PH excluded despite elevated sPAP ( $\geq 36$  mmHg) by echocardiography.

In 121 patients prospectively evaluated with this algorithm, 44 demonstrated RV strain, which alone had a sensitivity of 66 percent and specificity of 96 percent for identifying patients with precapillary PH. Among the remaining 69 patients, serum NT-proBNP level >80 pg/mL had 100 percent sensitivity and 24 percent specificity. Taken in combination with the decision algorithm, and in patients with echocardiographic estimates of sPAP  $\geq 36$  mmHg, the presence of

either RV strain on ECG or serum NT-proBNP >80 pg/mL had a sensitivity of 100 percent and specificity of 19 percent for diagnosis of PAH based on RHC reference standard. By using this decision algorithm to exclude precapillary PH, the investigators concluded that 9 percent of referred patients with elevated sPAP by echocardiography ( $\geq 36$  mmHg) could avoid undergoing invasive RHC. Excluding patients with RV strain on ECG, serum NT-proBNP testing would have avoided RHC in 16 percent of patients.

## **Biomarkers for Screening for PAH**

Fourteen studies (4 good quality, 7 fair, and 3 poor) evaluated biomarkers in patients with and without PAH.<sup>14,26-28,35,43,58,63,64,68,71,73,79,81</sup> Most studies were of natriuretic peptide (serum NT-proBNP or BNP); we found one study each for urinary cGMP,<sup>28</sup> asymmetric dimethylarginine (ADMA)<sup>79</sup> and plasma endothelin-1 (ET-1).<sup>64</sup> Two studies evaluated biomarkers at baseline for an association with incident diagnosis of PAH,<sup>27,35</sup> while the remaining studies evaluated concurrent biomarker and reference data.<sup>14,26,43,58,63,68,71,73,79,81</sup> Five of these studies were case-control design.<sup>58,68,73,79,81</sup> Four studies permitted calculation of sensitivity and specificity (of a NT-proBNP diagnostic threshold) for diagnosis of PAH (Table 5).<sup>26,58,68,81</sup> One study permitted calculation of sensitivity and specificity of ADMA for diagnosis of PAH.<sup>79</sup> The remaining studies were divided between those reporting biomarker group mean (or median) and standard deviation (or interquartile range) for groups with or without PAH (Table 6) and those reporting the correlation between biomarker level and hemodynamic measures from RHC in the form of a correlation coefficient ( $n=3$ )<sup>14,43,63</sup> (Table 7).



**Table 5. Diagnostic accuracy of biomarkers for PAH**

Study Population (N) Quality	Biomarker	Test Threshold	Reference Diagnostic Criterion	TP	FN	FP	TN	Sensitivity (95% CI)	Specificity (95% CI)	Prevalence
Allanore, 2008 <sup>27</sup>  SSc patients with echocardiography sPAP<40 mmHg and no NYHA III/IV symptoms (N=101)  Good	NT-proBNP	>97 <sup>th</sup> percentile for age/sex	mPAP ≥25 mmHg	6	3	16	77	67 (35 to 88)	83 (74 to 89)	8.8%
Bonderman, 2011 <sup>26</sup>  Referred for evaluation of suspected PAH; more than half had NYHA III/IV symptoms (N=372)  Good	NT-proBNP	>80pg/mL	mPAP >25 mmHg, PCWP <15 mmHg	23	0	35	11	100 (88 to 100)	24 (13 to 39)	33%
Frea, 2011 <sup>35</sup>  SSc patients with no signs or symptoms of PAH (N=76)  Fair	NT-proBNP	>97 <sup>th</sup> percentile for age/sex	mPAP ≥25 mmHg	1	3	6	28	25 (4.6 to 70)	82 (67 to 92)	10.5%
Simeoni, 2008 <sup>58</sup>  Known SSc-associated PAH and controls with SSc but no PAH (N=20)  Poor	NT-proBNP	≥125 pg/mL	mPAP	9	1	3	7	90 (55 to 100)	70 (35 to 93)	50%
Thakkar, 2012 <sup>81</sup>  SSc patients with PAH, at high risk for PAH, with ILD, or SSc controls without PAH (N=94)  Fair	NT-proBNP	≥209.8 pg/mL	mPAP ≥25 mmHg, PCWP ≤15 mmHg	14 13	1 2	0 0	30 19	93 (81 to 100) 87 (70 to 100)	100 (90 to 100) 100 (84 to 100)	33% (PAH vs. SSc controls) 44% (PAH vs. ILD)

**Table 5. Diagnostic accuracy of biomarkers for PAH (continued)**

Study Population (N) Quality	Biomarker	Test Threshold	Reference Diagnostic Criterion	TP	FN	FP	TN	Sensitivity (95% CI)	Specificity (95% CI)	Prevalence
Williams, 2006 <sup>68</sup>  SSc patients with PAH and controls with SSc but without PAH (N=109)  Fair	NT-proBNP	>91 pg/mL	mPAP >25mmHg at rest or >30mmHg with exercise, PCWP <15 mmHg	38	30	2	39	56 (43 to 68)	95 (83 to 99)	62%
Sanli, 2012 <sup>79</sup>  Children with unrepaired CHD with or without PAH and healthy controls (N=70)  Fair	ADMA	>17 µmol/L	mPAP ≥25 mmHg, PCWP ≤15 mmHg	21	9	10	10	70 (54 to 86)	50 (28 to 72)	60%


ADMA = asymmetric dimethylarginine; CHD = congenital heart disease; FN = false negative; FP = false positive; ILD = interstitial lung disease; mmHg = millimeter of mercury; mPAP = mean pulmonary artery pressure; NT-proBNP = N-terminal pro-B-type natriuretic peptide; NYHA = New York Heart Association; PAH = pulmonary arterial hypertension; PCWP = pulmonary capillary wedge pressure; SSc = systemic sclerosis; sPAP = systolic pulmonary artery pressure; TN = true negative; TP = true positive

## Predicting Incidence of PAH

Two studies of patients with systemic sclerosis reported NT-proBNP levels measured at baseline among patients subsequently diagnosed with PAH.<sup>27,35</sup> At baseline, patients were either without any signs or symptoms suggesting PAH<sup>35</sup> or with no NYHA class III or IV symptoms and echocardiographic estimate of sPAP less than 40 mmHg.<sup>27</sup> In both studies, patients were followed over time for development of symptoms or echocardiographic evidence of elevated sPAP. In followup ranging between 12 mo<sup>35</sup> and 36 mo,<sup>27</sup> approximately 10 percent of patients developed PAH in each study (Table 6).

Mean NT-proBNP levels at baseline were significantly higher among patients subsequently diagnosed with PAH in one study,<sup>27</sup> but not significantly so in the other.<sup>35</sup> This may be related to smaller numbers of patients with PAH or use of a lower mPAP threshold for diagnosis of PAH (25mmHg rather than 35mmHg). Applying a diagnostic threshold based on the 97<sup>th</sup> percentile by sex and age group in healthy subjects, these two studies found nearly identical specificity, around 83 percent, but sensitivity estimates that are lower with wide confidence limits (Figure 4).

**Figure 4. Sensitivity and specificity of NT-proBNP levels for predicting development of PAH**




CI = confidence interval; FN = false negative; FP = false positive; TN = true negative; TP = true positive

## Diagnosis of Prevalent PAH

Four studies evaluated NT-proBNP for diagnosing PAH; three studies used a case-control design among patients with systemic sclerosis, comparing cases with known PAH to controls with systemic sclerosis but no PAH (Figure 5).<sup>58,68,81</sup> The fourth study included patients referred for evaluation of suspected PAH, but without a specific high-risk diagnosis.<sup>26</sup> Thresholds for NT-proBNP ranged from 80 to 360 pg/mL; except for one study,<sup>81</sup> thresholds were set relatively low compared with the normal ranges. Estimates of the sensitivity and specificity are quite different among these three studies. Differences between sensitivity and specificity estimates among these studies likely stem from both the inclusion criteria and the designs of the study by Bonderman et al.,<sup>26</sup> in which patients were included only if they had elevated sPAP (>36 mmHg) by echocardiography, leading to a population with a high proportion of patients who had elevated NT-proBNP levels. Furthermore, all patients were first screened for evidence of RVH on ECG, before results of NT-proBNP testing were assessed.

**Figure 5. Sensitivity and specificity of NT-proBNP for diagnosis of PAH**



CI = confidence interval; FN = false negative; FP = false positive; TN = true negative; TP = true positive

Eight studies reported biomarker levels by PAH diagnosis.<sup>14,26,58,68,71,73,79,81</sup> Five studies included patients with systemic sclerosis,<sup>14,58,68,71,81</sup> one included children with congenital heart disease,<sup>79</sup> one included HIV-positive patients,<sup>73</sup> and one (previously described) included patients referred for suspicion of PAH without a specific high-risk diagnosis.<sup>26</sup> Although serum BNP and NT-proBNP levels were consistently more elevated in patients with PAH than those without PAH in these studies, this was represented by a wide range of mean values between studies (Table 6). Three studies reported on a single biomarker each.<sup>28,64,79</sup> ADMA levels were higher among children with PAH and unrepaired congenital heart disease (CHD) than among healthy controls ( $p<0.0001$ ) but not statistically different between those with PAH and unrepaired CHD versus controls with unrepaired CHD but no PAH ( $p>0.05$ ).<sup>79</sup> Urinary cGMP levels were significantly higher among patient with PPH than controls with acute asthma ( $p<0.001$ ) or healthy controls ( $p<0.001$ ).<sup>28</sup> Among children with congenital heart disease with left-to-right shunt, the ratio of pulmonary venous to systemic venous plasma endothelin-1 level distinguished those with PH from those without ( $p<0.01$ ).<sup>64</sup>

**Table 6. Biomarker levels by diagnostic group**

Study Population (N) Quality	Biomarker	Reference Diagnostic Criterion for PAH	Patients With PAH		Patients Without PAH		Summary Measure
			N	Mean (SD) (pg/mL)	N	Mean (SD) (pg/mL)	Criteria for Verification by RHC
Allanore, 2008 <sup>27a</sup>  SSc patients with echocardiography sPAP <40 mmHg and no NYHA III/IV symptoms (N=101)  Good	NT-proBNP	mPAP ≥25 mmHg, PCWP ≤15 mmHg	8	413 (304)	93	127 (135)	sPAP >40 mmHg, DLCO <50% predicted without pulmonary fibrosis or unexplained dyspnea, negative CT, D-dimer
Bonderman, 2011 <sup>26</sup>  Referred for evaluation of suspected PAH; more than half had NYHA III/IV symptoms (N=372)  Good	NT-proBNP	mPAP >25 mmHg, PCWP <15 mmHg	64	3648 (6541)	57	1489 (3518)	sPAP ≥36 mmHg
Cavagna, 2010 <sup>14</sup>  SSc patients; symptoms not described (N=135)  Good	NT-proBNP	mPAP >25 mmHg, PCWP <15 mmHg	20	189 (44 to 665) <sup>a</sup>	115	84 (39 to 181) <sup>b</sup>	sPAP ≥36 mmHg
Frea, 2011 <sup>35a</sup>  SSc patients with no signs or symptoms of PAH (N=76)  Fair	NT-proBNP	mPAP ≥25 mmHg, PCWP ≤15 mmHg	4	211 (134)	34	127 (100)	TRV ≥3 m/s or sPAP ≥40 mmHg
Ghio, 2004 <sup>73</sup>  HIV and confirmed PAH; controls with HIV and no known cardiac or pulmonary disease (N=93)  Fair	NT-proBNP	NR	16	1412 (574 to 2326) <sup>a</sup>	77	29 (7 to 48) <sup>b</sup>	NR (case-control design)

**Table 6. Biomarker levels by diagnostic group (continued)**

Study Population (N) Quality	Biomarker	Reference Diagnostic Criterion for PAH	Patients With PAH		Patients Without PAH		Summary Measure Criteria for Verification by RHC
			N	Mean (SD) (pg/mL)	N	Mean (SD) (pg/mL)	
Simeoni, 2008 <sup>58</sup>  Known SSc-associated PAH and controls with SSc but no PAH (N=20)  Poor	NT-proBNP	NR	10	198	10	103	NR (case-control design)
Thakkar, 2012 <sup>81</sup>  SSc patients with PAH, at high risk for PAH, with ILD, or SSc controls without PAH (N=94)  Fair	NT-proBNP	mPAP $\geq$ 25 mmHg, PCWP $\leq$ 15 mmHg	15	1818 (2367)	19 (ILD) 30 (SSc) 30 (risk)	133 (87) 72 (38) 278 (243)	Echo sPAP $\geq$ 40 mmHg or DLCO $\leq$ 50% predicted with FVC $>$ 85%, DLCO $\geq$ 20% or unexplained dyspnea
Williams, 2006 <sup>68</sup>  SSc patients with PAH and controls with SSc but without PAH (N=109)  Fair	NT-proBNP	NR, but PCWP $\leq$ 15 mmHg required	68	1474 (2642)	41	139 (150)	NA (case-control design; all patients had RHC)
Cavagna, 2010 <sup>14</sup>  SSc patients; symptoms not described (N=135)  Good	BNP	mPAP $\geq$ 25 mmHg, PCWP $<$ 15 mmHg	20	74.5 (29 to 196) <sup>a</sup>	115	30 (18 to 49) <sup>b</sup>	sPAP $\geq$ 36 mmHg, DLCO $<$ 50%pred, 20% decrease DLCO in 1 yr in absence of pulmonary fibrosis, or unexplained dyspnea, negative CT
Gialafos, 2008 <sup>71</sup>  SSc patients; some symptomatic (N=106)  Fair	BNP	NR	37	163 (159)	69	33 (23)	sPAP $>$ 40 mmHg (18/37 patients verified by RHC)

**Table 6. Biomarker levels by diagnostic group (continued)**

Study Population (N) Quality	Biomarker	Reference Diagnostic Criterion for PAH	Patients With PAH		Patients Without PAH		Summary Measure Criteria for Verification by RHC
			N	Mean (SD) (pg/mL)	N	Mean (SD) (pg/mL)	
Sanli, 2012 <sup>79</sup>  Children with unrepaired CHD with or without PAH and healthy controls (N=70)  Fair	ADMA	mPAP≥25 mmHg, PCWP ≤ 15 mmHg	30	23.1 (9.2)	20  20	19.6 (7.4) (CHD controls)  17.1 (5.6) (healthy controls)	All patients verified by RHC
Bogdan, 1998 <sup>28</sup>  PAH patients (N=19) and controls (N=30)  Poor	Urinary cGMP	NR	19	251 (26) nmol/mmol creatinine	30  7	51 (4) healthy controls  71 (8) asthmatic controls	NR (case-control design)
Tutar 1999 <sup>64</sup>  Children with left-to-right shunt (N=23) and healthy controls (N=11)  Fair	Plasma endothelin-1 (ratio of pulmonary venous and systemic venous level)	Ratio of simultaneous mPAP to aortic mean pressure > 0.5	9	1.10 (0.35)	14	0.90 (0.16)	NR (case-control design)

ADMA = asymmetric dimethylarginine; CHD = congenital heart disease; CT = computed tomography; DLCO = diffusion capacity of the lung for carbon monoxide; FVC = forced vital capacity; ILD = interstitial lung disease; mmHg = millimeter of mercury; mPAP = mean pulmonary artery pressure; m/s = meters per second; NT-proBNP = N-terminal pro-B-type natriuretic peptide; NYHA = New York Heart Association; PAH = pulmonary arterial hypertension; PCWP = pulmonary capillary wedge pressure; RHC = right heart catheterization; SD = standard deviation; sPAP = systolic pulmonary artery pressure; RHC = right heart catheterization; yr = year/years

<sup>a</sup>Studies that assessed baseline NT-proBNP as predictors of future development of PAH.

<sup>b</sup>Median interquartile range.

Four studies examined the correlation between either serum BNP or NT-proBNP levels and hemodynamic parameters measured at RHC. Statistically significant correlations were found between the biomarker level and CO, mPAP, PVR, mean right atrial pressure (mRAP), and sPAP; these correlations were of moderate strength for all parameters (Table 7). One study of ADMA found no correlation between ADMA levels and mPAP, sPAP, or PVR.<sup>79</sup> One study each of urinary cGMP<sup>28</sup> and plasma endothelin-1<sup>64</sup> reported isolated positive correlations among many negative correlations for which incomplete data were reported.

**Table 7. Correlations of biomarkers with RHC in PAH**

Study Population (N) Quality	Biomarker	RHC Parameter	Total N	Correlation (p-value)
Machado, 2006 <sup>43</sup>  Sickle cell disease (N=416)  Poor	NT-proBNP	CO	37	-0.43 (0.006)
	NT-proBNP	mPAP	37	0.43 (0.006)
	NT-proBNP	PVR (NR)	37	0.51 (0.001)
	NT-proBNP	sPAP	37	0.59 (0.002)
Thakkar, 2012 <sup>81</sup>  SSc patients with PAH, at high risk for PAH, with ILD or SSc controls without PAH (N=94)  Fair	NT-proBNP	mPAP	15	0.63 (0.013)
	NT-proBNP	mRAP	15	0.77 (0.006)
	NT-proBNP	PVR	15	0.76 (0.005)
	NT-proBNP	sPAP	94	0.65 (<0.0001)
Cavagna, 2010 <sup>14</sup>  SSc patients; symptoms not described (N=135)  Good	NT-proBNP	mPAP	115	0.61 (0.001)
	BNP	mPAP	135	0.72 (0.002)
Toyono, 2008 <sup>63</sup>  Children with VSD and severe PH (N=24)  Good	BNP	PVR (Fick)	24	0.56 (0.004)
Sanli, 2012 <sup>79</sup>  Children with unrepaired CHD with or without PAH and healthy controls (N=70)  Fair	ADMA	mPAP	30	-0.10 (>0.05)
	ADMA	sPAP	30	-0.02 (>0.05)
	ADMA	PVR	30	-0.19 (>0.05)
Bogdan, 1998 <sup>28</sup>  PAH patients (N=19) and controls (N=30)  Poor	Urinary cGMP	Cardiac Index	19	-0.65 (0.003)
Tutar 1999 <sup>64</sup>  Children with left-to-right shunt (N=23) and healthy controls (N=11)  Fair	Plasma endothelin-1 level (ratio of pulmonary to systemic venous)	mPAP	23	0.57 (<0.005)

ADMA = asymmetric dimethylarginine; BNP = B-type natriuretic peptide; CO = cardiac output; mPAP = mean pulmonary artery pressure; mRAP = mean right atrial pressure; NR = not reported; NT-proBNP = N-terminal pro-B-type natriuretic peptide; PAH = pulmonary arterial hypertension; sPAP = systolic pulmonary artery pressure; PVR = pulmonary vascular resistance; RHC = right heart catheterization



## Echocardiography for Diagnosing PAH

Twenty-six studies assessed echocardiography in evaluating patients suspected of PAH. All studies reported data that compared a single hemodynamic parameter at a time. Nineteen studies (6 good quality, 10 fair, 3 poor) reported the diagnostic accuracy of echocardiographic estimates of pulmonary pressures based on TRV measurement, with or without estimate of RAP, compared with a reference standard diagnosis based on RHC (Table 8).<sup>29,30,32,34,36-40,42,46,50,51,59,60,75,77,78,83</sup>

Six studies used a variable estimate of RAP (based on inferior vena cava size and inspiratory variation or jugular venous pressure) to calculate sPAP;<sup>29,32,38,40,51,83</sup> five studies calculated sPAP using a fixed value for RAP;<sup>37,50,59,60,78</sup> and eight studies used TG or TRV.<sup>30,34,36,39,42,46,75,77</sup>

Eleven of these studies were of patients with systemic sclerosis (or other collagen vascular disease) with suspected PAH based on symptoms.<sup>30,32,36,37,39,40,46,50,59,77,78</sup> Four studies evaluated liver transplant candidates;<sup>29,38,51,60</sup> two studies included patients with sickle cell disease;<sup>34,75</sup> and two studies had patients referred for evaluation of suspected PAH without a single high-risk condition.<sup>42,83</sup>

**Table 8. Diagnostic accuracy of echocardiographic parameters for diagnosis of PAH**

Study Population (N) Quality	Test Parameter	Test Threshold	Reference Diagnostic Criterion	TP	FN	FP	TN	Sensitivity (95% CI)	Specificity (95% CI)	Prevalence
Hua, 2008 <sup>38</sup>  Liver transplant candidates (N=105)  Good	sPAP 4 * TRV <sup>2</sup> + RAP	≥30 mmHg	mPAP ≥25 mmHg (PVR ≥240 dyne*sec/cm <sup>5</sup> PCWP <15 mmHg	4	0	18	83	100 (47 to 100)	82 (73 to 89)	4%
Torregrosa, 2001 <sup>60</sup>  Liver transplant candidates (N=94)  Fair	sPAP 4 * TRV <sup>2</sup> + 10  sPAP, PAT	≥40 mmHg  sPAP ≥40 mmHg or PAT <100 ms	mPAP ≥25 mmHg or PVR >120 dynes*s/cm <sup>5</sup>	4  5	1  0	3  5	35  33	80 (45 to 100)  100 (40 to 100)	92 (84 to 96)  87 (76 to 98)	12%
Phung, 2009 <sup>50</sup>  SSc patients referred with or without suspicion of PAH; 10% had NYHA III/IV symptoms (N=184)  Good	sPAP 4 * TRV <sup>2</sup> + 10	>40 mmHg	mPAP ≥25 mmHg	23	0	18	119	100 (88 to 100)	87 (80 to 92)	14%
Pilatis, 2000 <sup>51</sup>  Liver transplant candidates (N=55)  Fair	sPAP 4 * TRV <sup>2</sup> + RAP	>40 mmHg	mPAP ≥25 mmHg	5	3	1	46	62 (24 to 91)	98 (89 to 100)	14%
Ruiz-Irastorza, 2012 <sup>78</sup>  SLE patients in cohort study, regardless of symptoms of dyspnea (N=245)  Fair	sPAP 4 * TRV <sup>2</sup> + 5	≥40 mmHg  ≥30 mmHg  ≥40 mmHg *2	mPAP ≥25 mmHg	12  12  12	0  0  0	19  110  5	212  121  226	100 (75 to 100)  100 (75 to 100)  100 (75 to 100)	92 (88 to 95)  52 (46 to 59)  98 (96 to 100)	5%  5%  5%

**Table 8. Diagnostic accuracy of echocardiographic parameters for diagnosis of PAH (continued)**

Study Population (N) Quality	Test Parameter	Test Threshold	Reference Diagnostic Criterion	TP	FN	FP	TN	Sensitivity (95% CI)	Specificity (95% CI)	Prevalence
Steen, 2008 <sup>59</sup>  SSc patients with suspected PAH based on symptoms or signs (N=54)  Fair	sPAP $4 * TRV^2 + 10$	>20 mmHg increase over resting	mPAP >25 mmHg (rest) or >30 mmHg (exercise)	21	5	3	25	81 (61 to 93)	89 (72 to 98)	48%
Colle, 2003 <sup>29</sup>  Liver transplant candidates (N=165)  Good	sPAP $4 * TRV^2 + RAP$	≥30 mmHg	mPAP >25 PCWP <15 PVR >120 dynes*s/cm <sup>5</sup>	8	2	6	149	80 (44 to 97)	96 (92 to 99)	6%
Hsu, 2008 <sup>37</sup>  SSc patients with dyspnea or other clinical features suggestive of PAH (N=49)  Good	sPAP $4 * TRV^2 + 10$	>47 mmHg	sPAP>25 mmHg	14	10	1	24	58 (37 to 78)	96 (80 to 100)	49%
Denton, 1997 <sup>32</sup>  SSc patients suspected of PAH, most due to reduced DLCO (N=93)  Fair	sPAP $4 * TRV^2 + JVP$	≥30 mmHg	sPAP ≥30 mmHg “provided PCWP was normal”	19	2	3	9	90 (70 to 99)	75 (43 to 95)	64%
Kovacs, 2010 <sup>40</sup>  Patients with CVD some with symptoms (N=52)  Good	sPAP $4 * TRV^2 + RAP$	>40 mmHg	sPAP >40 mmHg with exercise and PCWP ≤20 mmHg	11	5	10	18	69 (41 to 89)	64 (44 to 81)	36%

**Table 8. Diagnostic accuracy of echocardiographic parameters for diagnosis of PAH (continued)**

Study Population (N) Quality	Test Parameter	Test Threshold	Reference Diagnostic Criterion	TP	FN	FP	TN	Sensitivity (95% CI)	Specificity (95% CI)	Prevalence
Arcasoy, 2003 <sup>83</sup>  Advanced lung disease, undergoing evaluation for lung transplantation (N=374)  Good	sPAP  RV finding	≥45 mmHg  RVH, dilation or systolic dysfunction	sPAP ≥45 by RHC	51  78	9  17	48  120	58  157	85 (73 to 93)  82 (73 to 89)	55 (45 to 64)  57 (51 to 62)	36%  27%
Mukerjee, 2004 <sup>46</sup>  SSc patients with suspected PAH, symptoms of exercise limitation and reduced DLCO (N=137)  Fair	TG 4 * TRV <sup>2</sup>	≥40 mmHg	mPAP>25mmHg or resting PVR>200 dyne*sec/cm <sup>5</sup> mPAP>30mmHg with exercise	57	42	5	33	58 (47 to 67)	87 (72 to 96)	72%
Condliffe, 2011 <sup>30</sup>  SSc patients with suspected PAH; symptoms not described (N=89)  Fair	TRV	≥35 mmHg (≥2.96 m/s)	mPAP ≥ 25 mmHg and PCWP ≤15 mmHg	42	5	10	10	89 (77 to 96)	50 (27 to 73)	70%
Fitzgerald, 2012 <sup>75</sup>  Adults with SCD (N=75)  Poor	TRV	≥ 2.5 m/s	mPAP ≥ 25 mmHg  mPAP≥25 mmHg and PCWP ≤15 mmHg	9  3	0  0	16  22	50  50	100 (67 to 100)  100 (0 to 100)	76 (65 to 86)  69 (59 to 80)	12%  4%
Fonseca, 2012 <sup>34</sup>  Sickle cell disease; symptoms not described (N=80)  Fair	TRV	>2.5 m/s	mPAP ≥25 mmHg  mPAP ≥25 mmHg and PCWP ≤15 mmHg	8  3	0  0	18  23	48  48	100 (62 to 100)  100 (0 to 100)	73 (62 to 84)  68 (57 to 78)	11%  4%

**Table 8. Diagnostic accuracy of echocardiographic parameters for diagnosis of PAH (continued)**

Study Population (N) Quality	Test Parameter	Test Threshold	Reference Diagnostic Criterion	TP	FN	FP	TN	Sensitivity (95% CI)	Specificity (95% CI)	Prevalence
Hachulla, 2005 <sup>36</sup>  SSc patients; some symptomatic (N=599)  Poor	TRV	≥3 m/s or ≥2.5 m/s with unexplained dyspnea	mPAP ≥25 mmHg rest or ≥30 mmHg with exercise and PCWP ≤15 mmHg	18	0	15	419	100 (85 to 100)	97 (94 to 98)	4%
Jansa, 2011 <sup>39</sup>  SSc patients some with dyspnea (N=203)  Fair	TRV	>30 mmHg (>2.74 m/s)	mPAP ≥25 mmHg and PCWP ≤15 mmHg	6	0	10	186	100 (61 to 100)	95 (91 to 98)	3%
Low, 2011 <sup>42</sup>  Referred for evaluation of suspected or definite PAH, most with symptoms (N=200)  Poor	TRV	≥36 mmHg (≥3 m/s)	mPAP >25 mmHg PCWP, LAP or LVEDP ≤15 mmHg PVR >3WU	58	0	8	128	100 (95 to 100)	94 (89 to 97)	30%
Rajaram, 2012 <sup>77</sup>  CTD suspected of PH based on symptoms or screening tests (N=81)  Fair	TRV	NR  ≥ 30 mmHg (≥2.74 m/s)  ≥40 mmHg (≥3.16 m/s)  ≥50 mmHg (≥3.54 m/s)	mPAP ≥25 mmHg and PCWP ≤15 mmHg	27  52  47  39	28  3  8  16	4  13  4  1	18  9  18  21	49 (36 to 62)  95 (89 to 100)  86 (76 to 95)  71 (59 to 83)	82 (66 to 98)  41 (20 to 62)  82 (66 to 98)  95 (87 to 100)	71%

**Table 8. Diagnostic accuracy of echocardiographic parameters for diagnosis of PAH (continued)**

Study Population (N) Quality	Test Parameter	Test Threshold	Reference Diagnostic Criterion	TP	FN	FP	TN	Sensitivity (95% CI)	Specificity (95% CI)	Prevalence
Dahiya, 2010 <sup>31</sup>  Referred for evaluation of suspected PH; all patients had dyspnea (N=114)  Good	TRV/VTI <sub>RVOT</sub>	>0.16	PVR >2 WU	47	3	2	20	94 (83 to 99)	91 (71 to 99)	69%
Lindqvist, 2011 <sup>41</sup>  Patients with PH undergoing RHC (N=30)  Fair	TRV/VTI <sub>RVOT</sub>	>0.175	PVR >3 WU	16	2	1	6	88 (65 to 99)	86 (42 to 100)	72%
Rajagopalan, 2009 <sup>52</sup>  Known pulmonary hypertension (N=52)  Fair	TRV/VTI <sub>RVOT</sub>	>0.16	PVR >2 WU	41	4	0	7	91 (79 to 98)	100 (65 to 100)	87%
Roule, 2010 <sup>55</sup>  Known PH (N=37)  Good	TRV/VTI <sub>RVOT</sub>	>0.14	PVR >2 WU	28	2	3	4	93 (78 to 99)	57 (18 to 90)	81%
Vlahos, 2007 <sup>65</sup>  Known or suspected pulmonary hypertension (N=12)  Fair	TRV/VTI <sub>RVOT</sub>	>0.38	PVR >8 WU	6	2	0	4	75 (35 to 97)	100 (47 to 100)	67%


**Table 8. Diagnostic accuracy of echocardiographic parameters for diagnosis of PAH (continued)**

Study Population (N) Quality	Test Parameter	Test Threshold	Reference Diagnostic Criterion	TP	FN	FP	TN	Sensitivity (95% CI)	Specificity (95% CI)	Prevalence
Ajami, 2011 <sup>68,69</sup>  Children and young adults with congenital heart disease referred for RHC (N=20)  Good	TRV/VTI <sub>RVOT</sub>	>0.2	PVR >8 WU	9	1	1	9	90 (55 to 100)	90 (55 to 100)	50%
Cevik, 2012 <sup>74</sup>  Children with CHD and healthy controls (N=70)  Fair	RVMPI  S'  sPAP/VTI <sub>RVOT</sub>	NR	mPAP ≥25 mmHg and PCWP ≤15 mmHg	14  21  17	16  9  13	2  2  5	38  38  35	47 (29 to 64)  70 (54 to 86)  57 (39 to 74)	95 (88 to 100)  95 (88 to 100)  88 (77 to 98)	43%
Rajagopalan, 2009 <sup>52</sup>  Known pulmonary hypertension (N=52)  Fair	S'	< 10 cm/s	sPAP >75 mmHg	10	5	2	15	67 (43 to 90)	88 (73 to 100)	47%

CHD = congenital heart disease; CI = confidence interval; cm/s = centimeters per second; CTD = connective tissue disease; FAC = fractional area change; FN = false negative; FP = false positive; JVP = jugular venous pressure; LVEDP = left ventricular end-diastolic pressure; mmHg = millimeter of mercury; mPAP = mean pulmonary artery pressure; MPI = myocardial performance index; NR = not reported; NT-proBNP = N-terminal pro-B-type natriuretic peptide; PAH = pulmonary arterial hypertension; PAT = pulmonary acceleration time; PCWP = pulmonary capillary wedge pressure; PH = pulmonary hypertension; PPH = primary pulmonary hypertension; PVR = pulmonary vascular resistance; RA = right atrium; RIMP = right index of myocardial performance; RV = right ventricle; RVH = right ventricular hypertrophy; RVMPI = right ventricular myocardial performance index; S' = tricuspid lateral annular systolic velocity; sPAP = systolic pulmonary artery pressure; SSc = systemic sclerosis; TAPSE = tricuspid annular plane systolic excursion; TG = tricuspid gradient; TN = true negative; TP = true positive; TRV = tricuspid regurgitant jet velocity; VSD = ventricular septal defect; VTI<sub>RVOT</sub> = velocity-time integral of right ventricular outflow tract; WU = Wood unit

Sensitivity of estimates ranged from 58 to 100 percent, while specificity estimates ranged from 55 to 98 percent. The paired sensitivity and specificity values are shown in Figure 6 in receiver operating curve space. The studies with the greatest degree of verification bias (large proportion of test-negative patients with no RHC verification of disease status) tend to have both high specificity and sensitivity estimates. Four studies of liver transplant candidates were the only ones to have complete RHC verification, and these studies had sensitivity estimates from 62 to 100 percent and specificity estimates from 82 to 98 percent.<sup>29,38,51,60</sup>

**Figure 6. Summary sensitivity and specificity values for echocardiography sPAP diagnosis of PH**




CI = confidence interval



Meta-analysis of the 19 studies yielded summary estimates for sensitivity and specificity of 88 percent, with confidence region as shown in Figure 7. There was moderate heterogeneity ( $I^2=61.9\%$ ). In an effort to explain the between-study variation, we undertook a sensitivity analysis based on features we suspected might account for variation and that had suitable distributions among the studies. The results of the sensitivity analyses are shown in Table 9.

**Figure 7. Sensitivity and specificity of echocardiography sPAP for diagnosis of PAH**



CI = confidence interval; FN = false negative; FP = false positive; TN = true negative; TP = true positive

**Table 9. Sensitivity analysis of echocardiography sPAP by study characteristics**


Study Characteristic	Number of Studies (Patients)	Summary Sensitivity (95% CI)	Summary Specificity (95% CI)	$I^2$
<b>Prevalence</b>				
Less than 15%	10 (1638)	90.6 (84.9 to 94.2)	90.8 (85.2 to 94.4)	0
15% or more	9 (821)	83.7 (71.8 to 91.2)	83.6 (71.7 to 91.1)	62.7%
<b>Diagnosis</b>				
Liver transplant	4 (432)	79.7 (72.5 to 85.4)	93.8 (91.1 to 95.8)	0
Systemic sclerosis	10 (1474)	88.7 (82.2 to 93.1)	89.7 (83.6 to 93.7)	52.5%
Other (SSD, CVD)	5 (553)	90.3 (71.8 to 97.2)	73.2 (42.7 to 90.9)	73.6%
<b>RAP Method</b>				
None or fixed	13 (1891)	89.9 (84.5 to 93.6)	88.9 (83.1 to 92.9)	56.1%
Variable	6 (561)	81.4 (70.1 to 89.1)	85.0 (75.3 to 91.4)	63.8%

CI = confidence interval; CVD = collagen vascular disease; RAP = right atrial pressure; sPAP = systolic pulmonary artery pressure; SSD = sickle cell disease

Studies with lower prevalence of PH (less than 15% of study subjects) showed greater homogeneity than studies with higher prevalence of PH. These 10 low-prevalence studies included the four studies of liver transplant patients (which had complete verification of test-negative subjects) and 6 studies that had high degree of verification bias. The studies among liver transplant patients had no important heterogeneity compared with 10 studies of systemic sclerosis patients or studies in patients with other diagnoses. The method of correction for RAP (fixed or none versus variable estimate) did not explain between-study heterogeneity.

Seven studies (three good quality, three fair, 1 poor) evaluated the echocardiographic estimation of PVR using  $TRV/VTI_{RVOT}$  against RHC diagnosis of elevated PVR (Figure 8).<sup>31,41,52,55,65,69,74</sup> Three of these studies included patients with known PH.<sup>41,52,55</sup> Two studies used a threshold for PVR much higher than that used for diagnosis (8 Wood units versus 2 Wood units)<sup>65,69</sup> with the goal of distinguishing more severe PAH; these studies also used a higher test threshold of 0.2 and 0.38 compared with 0.14 to 0.175. Sensitivity ranged from 57 to 94 percent, while specificity ranged from 57 to 100 percent.

**Figure 8. Sensitivity and specificity of  $TRV/VTI_{RVOT}$  for diagnosis of PAH**



CI = confidence interval; FN = false negative; FP = false positive; TN = true negative; TP = true positive

## Echocardiographic Parameters by Diagnostic Group

Fifteen studies reported data on the mean (or median) and standard deviation (or interquartile range) for specific echocardiographic parameters for patients with and without PAH (Table 10). Two of these studies reported echocardiographic values at baseline for prospectively identified incident cases of PAH.<sup>27,35</sup> In one study, the diagnostic categories distinguished between primary PAH and chronic thromboembolic pulmonary hypertension.<sup>48</sup>

**Table 10. Echocardiographic parameter values by diagnostic group**

Study Population (N) Quality	Echocardiographic Parameter	Criteria for Verification by RHC	Reference Diagnostic Criterion	Patients With PAH		Patients Without PAH		P-value
				N	Mean (SD)	N	Mean (SD)	
Ruan, 2007 <sup>56</sup>  Known PAH and healthy controls (N=180)  Fair	FAC	NR (case-control design)	NR	70	19 (10)	35	53 (10)	NR
Fukuda, 2011 <sup>72</sup>  Patients with known PH (N=67)  Fair	FAC	NR (case-control design)	mPAP > 25 mmHg	45	37 (13)	22	51 (1)	<0.001
Rajagopalan, 2009 <sup>52</sup>  Known pulmonary hypertension (N=52)  Fair	FAC	NR (case-control design)		32	31 (12)	15	52 (5)	<0.05
Bonderman, 2011 <sup>26</sup>  Referred for evaluation of suspected PAH; more than half had NYHA III/IV symptoms (N=372)  Good	RA size	sPAP ≥36 mmHg	mPAP >25 mmHg, PCWP <15 mmHg	64	58.7 (10.9)	57	59.1 (11.5)	0.87
Hachulla, 2005 <sup>36</sup>  SSc patients; some symptomatic (N=599)  Poor	RA size (transverse)  RA size (longitudinal)	NR (case-control design)	mPAP ≥25 mmHg rest or ≥30 mmHg with exercise and PCWP ≤15 mmHg	18	38.7 (8.3)  48.3 (7.2)	548	34.3 (7.0)  42.1 (7.2)	0.01  0.0001
Fukuda, 2011 <sup>72</sup>  Patients with known PH (N=67)  Fair	RIMP	NR (case-control design)	mPAP >25 mmHg	45	0.4 (0.1)	22	0.2 (0.1)	<0.001

**Table 10. Echocardiographic parameter values by diagnostic group (continued)**

Study Population (N) Quality	Echocardiographic Parameter	Criteria for Verification by RHC	Reference Diagnostic Criterion	Patients With PAH		Patients Without PAH		P-value
				N	Mean (SD)	N	Mean (SD)	
Tei, 1996 <sup>61</sup>  Known PPH and health controls (N=53)  Poor	RIMP	NR (case-control design)	NR	26	0.89 (0.25)	37	0.28 (0.04)	<0.001
Gialafos, 2008 <sup>71</sup>  SSc patients. Some were symptomatic (N=106)  Fair	RIMP	sPAP >40 mmHg (18/37 patients verified by RHC)	NR	37	0.41 (0.03)	69	0.37 (0.02)	<0.001
Bonderman, 2011 <sup>26</sup>  Referred for evaluation of suspected PAH; more than half had NYHA III/IV symptoms (N=372)  Good	RV size	sPAP ≥36 mmHg	mPAP >25 mmHg, PCWP <15 mmHg	64	44 (9.2)	57	38.2 (6.9)	<0.001
Hachulla, 2005 <sup>36</sup>  SSc patients; some symptomatic (N=599)  Poor	RV size	NR (case-control design)	mPAP ≥25 mmHg rest or ≥30 mmHg with exercise and PCWP ≤15 mmHg	18	33.0 (5.9)	548	30.0 (6.6)	0.061
Rajagopalan, 2009 <sup>52</sup>  Known pulmonary hypertension (N=52)  Fair	RV size (end- diastolic area)	NR (case-control design)		32	27 (11)	15	20 (4)	<0.05
	RV size (end systolic area)				19 (9)		9 (3)	<0.05
Ruan, 2007 <sup>56</sup>  Known PAH and healthy controls (N=180)  Fair	RV size	NR (case-control design)	NR	70	28 (9)	35	14 (6)	NR

**Table 10. Echocardiographic parameter values by diagnostic group (continued)**

Study Population (N) Quality	Echocardiographic Parameter	Criteria for Verification by RHC	Reference Diagnostic Criterion	Patients With PAH		Patients Without PAH		P-value
				N	Mean (SD)	N	Mean (SD)	
Fukuda, 2011 <sup>72</sup>  Patients with known PH (N=67)  Fair	S'	NR (case-control design)	mPAP >25 mmHg	45	11.8 (2.9)	22	14.1 (2.4)	<0.001
Rajagopalan, 2009 <sup>52</sup>  Known pulmonary hypertension (N=52)  Fair	S'	NR	NR	32	10.9 (2.9)	15	13.8 (2.8)	<0.01
Ruan, 2007 <sup>56</sup>  Known PAH and healthy controls (N=180)  Fair	S'	NR (case-control design)	NR	70	8 (3)	35	15.8 (5.5)	<0.05
Bonderman, 2011 <sup>26</sup>  Referred for evaluation of suspected PAH; more than half had NYHA III/IV symptoms (N=372)  Good	sPAP	sPAP ≥36 mmHg	mPAP >25 mmHg PCWP <15 mmHg	64	82.6 (24.3)	57	55.2 (16.3)	<0.001
Ruan, 2007 <sup>56</sup>  Known PAH and healthy controls (N=180)  Fair	sPAP	NR (case-control design)	NR	70	73 (6)	35	21 (6)	NR
Torregrosa, 2001 <sup>60</sup>  Liver transplant candidates (N=94)  Fair	sPAP	NA (all patients had RHC)	mPAP ≥25 mmHg PVR >120 dyne*sec/cm <sup>5</sup>	5	54 (15)	102	36 (5)	<0.001

**Table 10. Echocardiographic parameter values by diagnostic group (continued)**

Study Population (N) Quality	Echocardiographic Parameter	Criteria for Verification by RHC	Reference Diagnostic Criterion	Patients With PAH		Patients Without PAH		P-value
				N	Mean (SD)	N	Mean (SD)	
Fukuda, 2011 <sup>72</sup>  Patients with known PH (N=67)  Fair	sPAP	NR (case-control design)	mPAP >25 mmHg	45	67 (23)	22	20 (10)	0.0001
Fitzgerald, 2012 <sup>75</sup>  Adults with SCD (N=75)  Poor	TRV	TRV ≥2.5	mPAP ≥25 mmHg, PCWP ≤15 mmHg	9	2.7 (0.16)	16	3.1 (0.68)	0.12
Hammerstingl, 2012 <sup>76</sup>  Patients with PH undergoing RHC (N=155)  Fair	sPAP	sPAP >30 mmHg, all patients had RHC	mPAP ≥25 mmHg, PCWP ≤15 mmHg	36	58.3 (23.6)	119	49.9 (14.2)	0.009
	RVDs			36	2.4 (1.2)	119	2.4 (1.1)	0.8
	RVDd			36	3.4 (1.6)	119	3.3 (1.3)	0.88
Fukuda, 2011 <sup>72</sup>  Patients with known PH (N=67)  Fair	TAPSE	NR (case-control design)	mPAP >25 mmHg	45	18 (4)	22	21 (3)	<0.001
Cevik, 2012 <sup>74</sup>  Children with CHD and healthy controls (N=70)  Fair	RVMPI/RIMP	NA (all patients had CHD)	mPAP ≥25 mmHg, PCWP ≤15 mmHg	30	0.45 (0.14)	40	0.35 (0.08)	<0.001
	S' (Ts')				0.13 (0.09-0.58)		0.13 (0.10-0.18)	0.42
	TAPSE				1.96 (1.03-3.22)		2.53 (1.1-4.25)	0.10
	sPAP/VTI <sub>RVOT</sub>				1.3 (0.0-8.8)		0.5 (0.0-1.2)	<0.001
	sPAP/VTI <sub>RVOT</sub>				1.0 (0.0-9.0)		0.6 (0.01-1.0)	0.015

**Table 10. Echocardiographic parameter values by diagnostic group (continued)**

Study Population (N) Quality	Echocardiographic Parameter	Criteria for Verification by RHC	Reference Diagnostic Criterion	Patients With PAH		Patients Without PAH		P-value
				N	Mean (SD)	N	Mean (SD)	
Sanli, 2012 <sup>79</sup>  Children with unrepaired CHD with or without PAH and healthy controls (N=70)  Fair	RVMPI/RIMP	NA (all patients had RHC)	mPAP $\geq$ 25 mmHg, PCWP $\leq$ 15 mmHg	30	0.30 (0.10)	20	0.22 (0.03)	<0.001
	TAPSE			30	1.90 (0.24)	20	2.42 (0.21)	<0.0001
	RVD/RV size			30	4.40 (0.74)	20	4.15 (0.62)	>0.05
Takatsuki, 2012 <sup>82</sup>  Children with iPAH (N=51) and healthy controls (N=51) (total N=102)  Fair	RVDd	NA (case-control design; 88% had RHC)	mPAP $\geq$ 25 mmHg, PCWP $\leq$ 15 mmHg	51	23.5 (6.0)	51	18.1 (4.9)	<0.001
	RVMPI			51	0.63 (0.30)	51	0.21 (0.10)	<0.001
	TRV			51	4.1 (0.8)	51	2.2 (0.2)	<0.001
	S'			51	11.3 (2.4)	51	13.6 (2.8)	<0.001
Ruan, 2007 <sup>56</sup>  Known PAH and healthy controls (N=180)  Fair	TRV/VTI <sub>RVOT</sub>	NA (case-control design)	NR	70	0.66 (0.13)	35	0.13 (0.11)	<0.01
Frea, 2011 <sup>35a</sup>  SSc patients with no signs or symptoms of PAH (N=76)  Fair	FAC	TRV $\geq$ 3m/s or sPAP $\geq$ 40mmHg	mPAP $\geq$ 25 mmHg, PCWP $\leq$ 15 mmHg	4	41.25 (2.22)	34	43.7 (4.5)	0.29
	RIMP	TRV $\geq$ 3 m/s or sPAP $\geq$ 40 mmHg	mPAP $\geq$ 25 mmHg, PCWP $\leq$ 15 mmHg	4	0.32 (0.16)	34	0.26 (0.07)	0.14
	RV size	TRV $\geq$ 3 m/s or sPAP $\geq$ 40 mmHg	mPAP $\geq$ 25 mmHg, PCWP $\leq$ 15 mmHg	4	35.2 (30)	34	33 (3.5)	0.24
	TRV/VTI <sub>RVOT</sub>	TRV $\geq$ 3 m/s or sPAP $\geq$ 40 mmHg	mPAP $\geq$ 25mmHg, PCWP $\leq$ 15mmHg	4	0.157 (0.033)	34	0.122 (0.022)	0.01
Frea, 2011 <sup>35a</sup>  SSc patients with no signs or symptoms of PAH (N=76)  Fair	TAPSE	TRV $\geq$ 3 m/s or sPAP $\geq$ 40 mmHg	mPAP $\geq$ 25 mmHg, PCWP $\leq$ 15 mmHg	4	23 (1.63)	34	22.3 (2.19)	0.54

**Table 10. Echocardiographic parameter values by diagnostic group (continued)**

Study Population (N) Quality	Echocardiographic Parameter	Criteria for Verification by RHC	Reference Diagnostic Criterion	Patients With PAH		Patients Without PAH		P-value
				N	Mean (SD)	N	Mean (SD)	
Allanore, 2008 <sup>27a</sup>  SSc patients with echocardiography sPAP <40 mmHg and no NYHA III/IV symptoms (N=101)  Good	sPAP	sPAP >40 mmHg, DLCO <50% predicted without pulmonary fibrosis or unexplained dyspnea, negative CT, D-dimer	mPAP ≥25 mmHg, PCWP ≤15 mmHg	8	38.2 (9.4)	93	31.2 (5.9)	0.001
Nakayama, 1998 <sup>48b</sup>  Patients with known, symptomatic CTEPH or PPH (N=35)  Fair	mPAP	NA (all patients had RHC)	NR but includes negative V/Q scan	19	41 (10)	16	54 (9)	

CTEPH = chronic thromboembolic pulmonary hypertension; DLCO = diffusion capacity of the lung for carbon monoxide; iPAH = idiopathic pulmonary arterial hypertension; mmHg = millimeter of mercury; mPAP = mean pulmonary artery pressure; MPI = myocardial performance index; NT-proBNP = N-terminal pro-B-type natriuretic peptide; PAH = pulmonary arterial hypertension; PH = pulmonary hypertension; PPH = primary pulmonary hypertension; PVR = pulmonary vascular resistance; RA = right atrium; RHC = right heart catheterization; RIMP = right index of myocardial performance; RV = right ventricle; RVD = right ventricular dysfunction; RVDd = right ventricular dysfunction (diastolic); RVDs = right ventricular dysfunction (systolic); sPAP = systolic pulmonary artery pressure; SD = standard deviation; SSc = systemic sclerosis; TRV = tricuspid regurgitant jet velocity; V/Q = ventilation perfusion scan; VSD = ventricular septal defect; VTI<sub>RVOT</sub> = velocity-time integral of right ventricular outflow tract

<sup>a</sup>Studies that assessed baseline NT-proBNP as predictors of future development of PAH.

<sup>b</sup>Study attempted to distinguish primary PAH from CTEPH (rather than no PAH).



In the two studies that examined echocardiographic predictors of later development of PAH, TRV/VTI<sub>RVOT</sub> and sPAP at baseline showed statistically significant differences among those who later developed PAH compared with those who did not (Table 10). Other parameters examined, including FAC, RIMP, RV size and TAPSE, failed to show statistically significant differences; however, the number of cases in this study was small (n=4), suggesting this analysis lacks sensitivity. Likewise the number of parameters examined for association is large relative to the number of cases, suggesting the possibility of finding significant associations by chance.

Thirteen studies evaluated concurrent echocardiography measurement with diagnosis of PAH and provided data on seven different echocardiographic parameters: sPAP (or TRV), RIMP, RV size, RA size, S', TAPSE, TRV/VTI<sub>RVOT</sub> and FAC. Seven of the studies used a case-control design; four used elevated sPAP by echocardiography to select patients for diagnostic verification; three studies verified all participants' diagnosis with RHC:

- For FAC, three case-control studies showed reasonably large differences, statistically significant in both studies that reported a statistical comparison.
- For RA size, findings in two studies were inconsistent: one case-control study reported statistically significant differences, but a cohort study found no difference.
- For RIMP, all six studies reported statistically significant differences.
- For RV size, three of eight studies reported statistically significant differences, four did not detect a difference, and one study did not report a statistical test for differences.
- For S', four of five studies reported statistically significant differences.
- For TAPSE, two of three studies reported statistically significant differences.
- For TRV/VTI<sub>RVOT</sub> or the related sPAP/VTI<sub>RVOT</sub>, both studies showed statistically significant differences.

Four studies indicated large differences in echocardiography sPAP between patients with PAH and those without PAH with differences in means ranging from 18 to 52 mmHg. These differences, while highly significant, reflect incorporation bias since the diagnostic classification is based on mPAP, which is highly correlated with sPAP.

## **Accuracy and Precision of Echocardiography Versus RHC**

Twenty-eight studies reported the correlation or agreement between echocardiographic measurements and corresponding hemodynamic parameters measured at RHC (Table 11). The correlation coefficient between echocardiography sPAP and RHC sPAP ranged from 0.15 to 0.96. Two studies reported correlation of echocardiography sPAP with both simultaneous and nonconcurrent RHC; in each case, correlations were improved when echocardiography was performed simultaneously with RHC; however, the improvement in correlation was only 0.03 to 0.06.

**Table 11. Correlation of echocardiographic parameters with RHC in PAH**

Study Population (N) Quality	Echocardiographic Parameter	Measurement Details	RHC Parameter	Total N (N Not Estimable)	Correlation (p-Value)	Bias (SD)
Fukuda, 2011 <sup>72</sup>  Patients with known PH (N=67)  Fair	FAC	(RV end-diastolic area – RV end-systolic area) / RV end-diastolic area * 100%	mPAP  PVR (Fick)	45  45	-0.47 (0.001)  -0.46 (0.002)	
Selimovic, 2007 <sup>57</sup>  Patients with suspected pulmonary vascular disease; 37 of 42 NYHA III/IV (N=42)  Good	mPAP  mPAP  sPAP	PADP + 0.33(PASP – PADP)  Simultaneous with RHC  4 * TRV <sup>2</sup> + RAP (5, 10, 15)	mPAP  mPAP  sPAP	56 (4)  20 (0)  56 (4)	0.91 (0.04)  0.95 (0.31)  0.88 (0.3)	-2.0 (7.2)  1.4 (5.8)  -1.7 (12.3)
Tian, 2011 <sup>62</sup>  Suspected PH based on symptoms (N=42)  Fair	mPAP		mPAP	42 (0)	0.88(0.0001)	-5.7 (0.84)
Vonk, 2007 <sup>66</sup>  Connective tissue diseases; one-third NYHA III/IV (N=98)  Fair	RIMP		mPAP	35 (2)	0.46 (0.01)	
Fukuda, 2011 <sup>72</sup>  Patients with known PH (N=67)  Fair	RIMP		mPAP  PVR (Fick)	45 (0)  45 (0)	-0.21 (0.174)  -0.26 (0.12)	

**Table 11. Correlation of echocardiographic parameters with RHC in PAH (continued)**

Study Population (N) Quality	Echocardiographic Parameter	Measurement Details	RHC Parameter	Total N (N Not Estimable)	Correlation (p-Value)	Bias (SD)
Vonk, 2007 <sup>66</sup>  Connective tissue diseases; one-third NYHA III/IV (N=98)  Fair	RIMP		PVR (TD)	35 (2)	0.33 (0.08)	
Fukuda, 2011 <sup>72</sup>  Patients with known PH (N=67)  Fair	RIMP		PVR (Fick)	45 (0)	-0.26 (0.12)	
Cevik, 2012 <sup>74</sup>  Children with CHD (N=30) and healthy controls (N=40) (total N=70)  Fair	RVMPI		sPAP  mPAP	30 (NR)  30 (NR)	0.54 (0.002)  0.53 (0.003)	
Fukuda, 2011 <sup>72</sup>  Patients with known PH (N=67)  Fair	S'		mPAP  PVR (Fick)	45 (0)  45	-0.39 (0.009)  -0.41 (0.013)	
Dahiya, 2010 <sup>31</sup>  Referred for evaluation of suspected PH; all patients had dyspnea (N=114)  Good	TRV/VTI <sub>RVOT</sub>		PVR (TD)	50	0.77 (0.001)	1.8 (3.3)
Lindqvist, 2011 <sup>41</sup>  Patients with PH undergoing RHC (N=30)  Fair	TRV/VTI <sub>RVOT</sub>		PVR (TD)	25 (5)	0.78 (0.001)	6.1 (4.0)

**Table 11. Correlation of echocardiographic parameters with RHC in PAH (continued)**

Study Population (N) Quality	Echocardiographic Parameter	Measurement Details	RHC Parameter	Total N (N Not Estimable)	Correlation (p-Value)	Bias (SD)
Rajagopalan, 2009 <sup>52</sup>  Known pulmonary hypertension (N=52)  Fair	TRV/VTI <sub>RVOT</sub>		PVR (Fick)	52	0.73 (0.001)	0 (4.3)
Roule, 2010 <sup>55</sup>  Known PH (N=37)  Good	TRV/VTI <sub>RVOT</sub>		PVR (TD)	37 (NR)	0.76 (0.0001)	0 (1.9)
Vlahos, 2008 <sup>65</sup>  Known or suspected pulmonary hypertension (N=12)  Poor	TRV/VTI <sub>RVOT</sub>		PVR (Fick)	12 (0)	0.843 (NR)	
Ajami, 2011 <sup>69</sup>  Children & young adults with congenital heart disease referred for RHC (N=20)  Good	TRV/VTI <sub>RVOT</sub>		PVR (Fick)	20 (0)	0.73 (NR)	
Rajaram, 2012 <sup>77</sup>  CTD suspected of PH based on symptoms or screening tests (N=81)  Fair	TG	4 * TRV <sup>2</sup>	mPAP  PVR	81 (NR)  81 (NR)	0.84 (0.001)  0.76 (0.001)	

**Table 11. Correlation of echocardiographic parameters with RHC in PAH (continued)**

Study Population (N) Quality	Echocardiographic Parameter	Measurement Details	RHC Parameter	Total N (N Not Estimable)	Correlation (p-Value)	Bias (SD)
Arcasoy, 2003 <sup>83</sup>  Advanced lung disease, undergoing evaluation for lung transplantation (N=374)  Good	sPAP	4 * TRV <sup>2</sup> + RAP	sPAP	166 (208)	0.69 (<0.0001)	
Denton, 1997 <sup>32</sup>  SSc patients suspected of PAH, most due to reduced DLCO (N=93)  Fair	sPAP	4 * TRV <sup>2</sup> + JVP	sPAP	20 (13)	0.83 (0.001)	11.4 (9.8)
Farber, 2011 <sup>9</sup>  Patients with PAH (N=1883)  Fair	sPAP	4 * TRV <sup>2</sup> + RAP	sPAP	1360 (NR)	0.56 (0.001)	
Hammerstingl, 2012 <sup>76</sup>  Patients with PH undergoing RHC (N=155)  Fair	sPAP sPAP		mPAP sPAP	155 (NR)	0.43 (<0.0001) 0.15 (0.06)	
Hsu, 2008 <sup>37</sup>  SSc patients with dyspnea or other clinical features suggestive of PAH (N=49)  Good	sPAP	4 * TRV <sup>2</sup> + 10	sPAP	49 (NR)	0.71 (NR)	

**Table 11. Correlation of echocardiographic parameters with RHC in PAH (continued)**

Study Population (N) Quality	Echocardiographic Parameter	Measurement Details	RHC Parameter	Total N (N Not Estimable)	Correlation (p-Value)	Bias (SD)
Fisher, 2009 <sup>33</sup>  Patients undergoing RHC for known or suspected PAH; symptoms not described (N=65)  Good	sPAP	4 * TRV <sup>2</sup> + RAP	sPAP	59 (NR)	0.66 (0.001)	-0.6 (20)
Kovacs, 2010 <sup>40</sup>  Patients with CVD some with symptoms (N=52)  Good	sPAP	4 * TRV <sup>2</sup> + RAP	sPAP	28 (9)		0.3 (7.6)
Nogami, 2009 <sup>49</sup>  Suspected pulmonary hypertension; all patients symptomatic (N=29)  Good	sPAP	4 * TRV <sup>2</sup> + RAP (5, 15)	sPAP	20 (0)	0.86 (0.01)	-5.9 (14.1)
Rich, 2011 <sup>53</sup>  Patients with both RHC and Doppler echo (N=183)  Good	sPAP	4 * TRV <sup>2</sup> + RAP (5, 10, 15 or 20)	sPAP	160 (EXCL)	0.68 (0.001)	2.2 (18.6)
		With simultaneous RHC	sPAP	23 (EXCL)	0.71 (0.01)	8.0 (8.8)
Roeleveld, 2005 <sup>54</sup>  Known PH (N=47)  Fair	sPAP	4 * TRV <sup>2</sup> + RAP (5, 10, 15)	sPAP	35 (9)	0.375 (0.026)	-5 (30.1)
		With simultaneous RHC	sPAP	22 (1)	0.94 (0.69)	0.7 (7.8)
Selby, 2012 <sup>80</sup>  HIV-infected patients (N=422)  Fair	sPAP	4 * TRV <sup>2</sup> + RAP	sPAP	76 (NR)	0.49 (<0.0001)	1.75 (7.0)

**Table 11. Correlation of echocardiographic parameters with RHC in PAH (continued)**

Study Population (N) Quality	Echocardiographic Parameter	Measurement Details	RHC Parameter	Total N (N Not Estimable)	Correlation (p-Value)	Bias (SD)
Tian, 2011 <sup>62</sup>  Suspected PH based on symptoms (N=42)  Fair	sPAP	4 * TRV <sup>2</sup> + RAP (4, 10, 14)	sPAP	42 (EXCL)	0.96 (0.0001)	-1.8 (1.8)
Vonk, 2007 <sup>66</sup>  Connective tissue diseases. One-third NYHA III/IV (N=98)  Fair	sPAP	4 * TRV <sup>2</sup> + RAP	sPAP	35 (0)	NR (0.001)	
Willens, 2008 <sup>67</sup>  Patients with known PH and elevated sPAP and controls with CHF and elevated sPAP (N=47)  Fair	sPAP	4 * TRV <sup>2</sup> + RAP	sPAP	44 (3)	0.75 (0.001)	
Rajagopalan, 2009 <sup>52</sup>  Known pulmonary hypertension (N=52)  Fair	sPAP S' S' S'	4 * TRV <sup>2</sup> + RAP	sPAP PVR (Fick) CO TG	32 (0)	0.87 (0.001) -0.79 (<0.0001) 0.78 (<0.001) 0.72 (<0.001)	
Murata, 1997 <sup>47</sup>  SSc patients. Symptoms not described, but most had reduced DLCO (N=135)  Fair	sPAP	4 * TRV <sup>2</sup> + 10	sPAP	19 (6)	0.41 (NR)	-0.53 (12.1)

**Table 11. Correlation of echocardiographic parameters with RHC in PAH (continued)**

Study Population (N) Quality	Echocardiographic Parameter	Measurement Details	RHC Parameter	Total N (N Not Estimable)	Correlation (p-Value)	Bias (SD)
Fukuda, 2011 <sup>72</sup>  Patients with known PH (N=67)  Fair	TAPSE	Total excursion of tricuspid annulus during systole	mPAP  PVR (Fick)	45 (0)  45 (0)	-0.33 (0.027)  -0.49 (0.002)	
Condliffe, 2011 <sup>30</sup>  SSc patients with suspected PAH; symptoms not described (N=89)  Fair	TRV  TRV	4 * TRV <sup>2</sup>  4 * TRV <sup>2</sup>	mPAP  PVR (TD)	70 (0)  70 (0)	0.64 (0.001)  0.76 (0.001)	
Fisher, 2009 <sup>33</sup>  Patients undergoing RHC for known or suspected PAH; symptoms not described (N=65)  Good	TRV  CO	4 * TRV <sup>2</sup>	sPAP  CO (TD)	59 (NR)  65 (NR)	  0.74 (<0.001)	-1.8 (18.1)  -0.1 (1.2)
Fonseca, 2011 <sup>34</sup>  Sickle cell disease; symptoms not described (N=80)  Fair	TRV	4 * TRV <sup>2</sup>	sPAP	26 (0)	0.77 (0.001)	
Mourani, 2008 <sup>45</sup>  Children under 2 years of age undergoing RHC for chronic lung disease (N=25)  Fair	TRV	4 * TRV <sup>2</sup>	sPAP	19 (12)	0.19 (0.43)	



**Table 11. Correlation of echocardiographic parameters with RHC in PAH (continued)**

Study Population (N) Quality	Echocardiographic Parameter	Measurement Details	RHC Parameter	Total N (N Not Estimable)	Correlation (p-Value)	Bias (SD)
Mukerjee, 2004 <sup>46</sup>  SSc patients with suspected PAH, symptoms of exercise limitation and reduced DLCO (N=137)  Fair	TRV	TG calculated from TRV using “standard templates”	sPAP	137 (NR)	0.67 (NR)	
Roule, 2010 <sup>55</sup>  Known PH (N=37)  Good	TRV	$4 * TRV^2$	sPAP	37 (0)	0.8 (NR)	

CO = cardiac output; EXCL = excluded from study; JVP = jugular venous pressure; mPAP = mean pulmonary artery pressure; MPI = myocardial performance index; NR = not reported; NT-proBNP = N-terminal pro-B-type natriuretic peptide; PAH = pulmonary arterial hypertension; PADP = pulmonary artery diastolic pressure; PASP = pulmonary artery systolic pressure; PH = pulmonary hypertension; PPH = primary pulmonary hypertension; PVR = pulmonary vascular resistance; RAP = right atrial pressure; RHC = right heart catheterization; RIMP = right index of myocardial performance; RV = right ventricle; SD = standard deviation; sPAP = systolic pulmonary artery pressure; SSc = systemic sclerosis;

TAPSE = tricuspid annular plane systolic excursion; TG = tricuspid gradient; TRV = tricuspid regurgitant jet velocity; VSD = ventricular septal defect; VTI<sub>RVOT</sub> = velocity-time integral of right ventricular outflow tract

Bias in measurement was estimated by examining the difference between two tests measured on the same scale using the method of Bland and Altman. In nine studies comparing sPAP values, the average bias varied between a 5.9 mmHg underestimate and an 11.4 mmHg overestimate by echocardiography. The standard deviation of the bias measurements ranged from 1.8 to 30.1, with a median of 9.3. With a standard deviation of this magnitude, one would expect about 70 percent of echocardiography sPAP readings to fall within 10 mmHg of RHC sPAP; however, the large REVEAL registry<sup>9</sup> found that only 39.8 percent of echocardiographic estimates of sPAP were within 10mmHg of same-day RHC-measured sPAP, corresponding to a standard deviation of approximately 19 mmHg. The remaining 60 percent were approximately equally divided between overestimates (greater than 10 mmHg) and underestimates (greater than 10 mmHg). Three additional studies reported the percentage of patients in which echocardiography sPAP and RHC sPAP readings were within 10 mmHg of each other. Two studies found this to be 48 percent,<sup>33,83</sup> which would suggest a standard deviation of approximately 15 mmHg. The third study reported 80 percent,<sup>80</sup> which would suggest a standard deviation of approximately 7.8. In one study, divergence between echocardiography and RHC was greater than 20 mmHg in 28 percent of patients and greater than 30 mmHg in 9 percent of patients,<sup>83</sup> both suggesting a standard deviation of approximately 18. These estimates assume a normal distribution and a bias of zero (Table 12).

**Table 12. Further data on accuracy of echocardiographic estimates of sPAP compared with RHC, described as percentage of patients within a specified threshold**

Study	Percentage of Echocardiographic Estimates Within Threshold			Standard Deviation	
	10 mmHg	20 mmHg	30 mmHg	Estimated	Reported
Farber, 2011 <sup>9</sup>	39.8%	—	—	19.2	NR
Fisher, 2009 <sup>33</sup>	48%	—	—	15.4	20
Arcasoy, 2003 <sup>83</sup>	48%	—	—	15.4	NR
	—	72%	—	18.5	NR
	—	—	91%	17.6	NR
Selby, 2012 <sup>80</sup>	80%	—	—	7.8	7.0

mmHg = millimeter of mercury; NR = not reported

Four studies reported correlation between echocardiography transtricuspid gradient and sPAP, with estimates ranging from 0.19 to 0.80. The low outlier was a small study of young children with chronic lung disease. One other study found negligible bias but a large standard deviation of difference between echocardiography and RHC measures.<sup>33</sup> Two additional studies correlated TG and mPAP with estimates of 0.64 and 0.84, respectively.<sup>30,77</sup>

Six studies correlated TRV/VTI<sub>RVOT</sub> with PVR by RHC. Correlation coefficients indicated strong correlation ranging from 0.73 to 0.84, with bias ranging from 0 to 6.1, and standard deviations ranging from 1.9 to 4.3 Wood units.

Two studies reported strong correlations between echocardiographic estimates of mPAP with RHC-measured mPAP. Correlation coefficients were 0.88 and 0.91 but increased to 0.95 when echocardiography was simultaneous with RHC. The estimates of bias of a 2 and 5.7 mmHg underestimate improved to a 1.4 mmHg overestimate when echocardiography was performed simultaneously with RHC; the standard deviations of difference between echocardiography and RHC ranged from 0.84 to 7.2.

Low to moderate correlations were observed between RIMP and mPAP, RIMP and PVR, TAPSE and mPAP, FAC and mPAP, and FAC and PVR. Two studies found a strong correlation between TG and PVR.<sup>30,77</sup>

Two studies correlated S' with RHC hemodynamic measures and reported moderate to strong correlation of S' with PVR (Fick), CO, and TG.<sup>52,72</sup>

## Summary Strength of Evidence for KQ 1

Results for these outcomes and comparisons, along with ratings for strength of evidence are shown in Tables 13–16.

**Table 13. Summary strength of evidence for KQ 1: Echocardiography sPAP with NT-proBNP versus echocardiography sPAP in symptomatic patients**

Parameter	Number of Studies (Patients)	Domains				Strength of Evidence Effect Estimate (95% CI)
		Risk of Bias	Consistency	Directness	Precision	
<b>Sensitivity</b>	1 (121)	High	NA	Direct	Imprecise	<b>SOE = Insufficient</b> NT-proBNP >80 pg/mL has a low false-negative rate compared with RHC reference standard; the serial testing study design did not allow for NT-proBNP testing to improve sensitivity beyond that of echo sPAP alone
<b>Specificity</b>	1 (121)	Moderate	NA	Direct	Imprecise	<b>SOE = Low</b> NT-proBNP ≤80 pg/mL ruled out PAH in 9–16% of patients with elevated echo sPAP ≥36 mmHg
<b>Correlation</b>	0 (0)	NA	NA	NA	NA	<b>SOE = Insufficient</b> NA
<b>Adverse effects</b>	0 (0)	NA	NA	NA	NA	<b>SOE = Insufficient</b> NA

CI = confidence interval; echo = echocardiography; NA = not applicable; NT-proBNP = N-terminal pro-B-type natriuretic peptide; PAH = pulmonary arterial hypertension; RHC = right heart catheterization; SOE = strength of evidence; sPAP = systolic pulmonary artery pressure

**Table 14. Summary strength of evidence for KQ 1: NT-proBNP compared with RHC**

Parameter	Number of Studies (Patients)	Domains				Strength of Evidence Effect Estimate (95% CI)
		Risk of Bias	Consistency	Directness	Precision	
<b>Sensitivity</b>	3 (198)	Moderate	Inconsistent	Indirect	Imprecise	<b>SOE = Low</b> Range 56% to 100% NT-proBNP has variable sensitivity for diagnosing PAH; uncertain performance for ruling out PAH
<b>Specificity</b>	3 (198)	Moderate	Inconsistent	Indirect	Imprecise	<b>SOE = Low</b> Range 24% to 95% NT-proBNP has variable specificity; uncertain performance for ruling in PAH
<b>Correlation</b>	3 (176)	Moderate	Consistent	Indirect	Imprecise	<b>SOE = Moderate</b> Range 0.43 to 0.72 Correlation of NT-proBNP and RHC is only moderate
<b>Adverse effects</b>	0 (0)	NA	NA	NA	NA	<b>SOE = Insufficient</b> NA

CI = confidence interval; NT-proBNP = N-terminal pro-B-type natriuretic peptide; PAH = pulmonary arterial hypertension; RHC = right heart catheterization; SOE = strength of evidence

**Table 15. Summary strength of evidence for KQ 1: TRV/TG/sPAP compared with RHC**

Parameter	Number of Studies (Patients)	Domains				Strength of Evidence Effect Estimate (95% CI)
		Risk of Bias	Consistency	Directness	Precision	
<b>Sensitivity</b>	19 (2459)	Moderate	Consistent	Indirect	Imprecise	<b>SOE = Moderate</b> Range 58% to 100% Echocardiographic estimate of sPAP showed variable sensitivity, with lower prevalence studies finding higher sensitivity
<b>Specificity</b>	19 (2459)	Moderate	Consistent	Indirect	Imprecise	<b>SOE = Moderate</b> Range 50% to 98% Echocardiographic estimate of sPAP showed variable specificity, with lower prevalence studies finding higher specificity
<b>Correlation</b>	23 (4217)	Low	Inconsistent	Indirect	Imprecise	<b>SOE = Moderate</b> Range 0.38 to 0.96 Echocardiographic estimate of sPAP showed moderate to strong correlation with RHC and were on average unbiased, but were limited by imprecision and by a significant minority of patients in whom TRV was not measurable
<b>Adverse effects</b>	0 (0)	NA	NA	NA	NA	<b>SOE = Insufficient</b> NA

CI = confidence interval; PAH = pulmonary arterial hypertension; RHC = right heart catheterization; SOE = strength of evidence; sPAP = systolic pulmonary artery pressure; TG = tricuspid gradient; TRV = tricuspid regurgitant jet velocity

**Table 16. Summary strength of evidence for KQ 1: TRV/VTI<sub>RVOT</sub> compared with RHC**

Parameter	Number of Studies (Patients)	Domains				Strength of Evidence Effect Estimate (95% CI)
		Risk of Bias	Consistency	Directness	Precision	
<b>Sensitivity</b>	6 (196)	Moderate	Consistent	Indirect	Precise	<b>SOE = Moderate</b> Range 89% to 100% Echocardiographic estimate of PVR showed reasonably high sensitivity for ruling in PAH
<b>Specificity</b>	6 (196)	Moderate	Consistent	Indirect	Imprecise	<b>SOE = Moderate</b> Range 50% to 97% Echocardiographic estimate of PVR showed variable specificity, with better specificity in lower prevalence studies (range, 94% to 97%)
<b>Correlation</b>	6 (196)	Low	Consistent	Indirect	Precise	<b>SOE = High</b> Range 0.74 to 0.84 Strong correlation between echocardiographic estimates of PVR and PVR by RHC
<b>Adverse effects</b>	0 (0)	NA	NA	NA	NA	<b>SOE = Insufficient</b> NA

CI = confidence interval; PAH = pulmonary arterial hypertension; PVR = pulmonary vascular resistance; RHC = right heart catheterization; SOE = strength of evidence; TRV = tricuspid regurgitant jet velocity; VTI<sub>RVOT</sub> = velocity-time integral of right ventricular outflow tract

## KQ 2: Management of PAH

For patients with PAH, what are the comparative effectiveness and safety of (a) echocardiography versus biomarkers and (b) echocardiography versus echocardiography plus biomarkers in managing PAH and on intermediate-term ( $\leq 90$  days) and long-term ( $> 90$  days) patient outcomes ?

### Key Points

- No data are available regarding the comparative effectiveness of echocardiography versus biomarkers or echocardiography versus echocardiography plus biomarkers in the management of PAH or patient outcomes (insufficient strength of evidence).
- Systolic pulmonary artery pressure (sPAP) estimated by echocardiography shows good correlation with sPAP from RHC (low strength of evidence).
- Serum brain natriuretic peptide (BNP) level shows only moderate correlation with these RHC measures: mean pulmonary artery pressure (mPAP) (moderate strength of evidence), pulmonary vascular resistance (low strength of evidence), right atrial pressure (moderate strength of evidence), cardiac index (low strength of evidence), and clinical outcomes such as the 6-minute walk distance (6MWD) test (moderate strength of evidence).
- BNP level shows poor correlation with RHC pulmonary capillary wedge pressure (PCWP) (low strength of evidence).

- BNP level alone is not an accurate surrogate marker for disease severity (high strength of evidence).
- Increase in level of log-transformed BNP is a strong predictor of mortality (moderate strength of evidence).
- Presence of pericardial effusion is also a strong predictor of mortality although there was wide variability in results for this measure (moderate strength of evidence).
- Right atrial (RA) size correlates with increased risk of mortality (moderate strength of evidence).
- Fractional area change (FAC) is a poor predictor of mortality, but results are variable across studies (moderate strength of evidence).
- Serum uric acid level appears to predict mortality (low strength of evidence)
- Tricuspid annular plane systolic excursion (TAPSE) has inconsistent association with mortality (insufficient strength of evidence).
- We found no studies addressing diagnostic thinking efficacy, therapeutic efficacy, or harms (insufficient strength of evidence).

## Description of Included Studies

We identified 99 unique studies involving a total of 8655 patients that evaluated the use of biomarkers or echocardiographic parameters in the management of PAH or as predictors of patient outcomes.<sup>6,43,58,68,84-178</sup> Of these studies, 68 were rated good quality, 29 fair quality, and 2 poor quality. Biomarkers evaluated were natriuretic peptides, endothelin-1, uric acid, troponin T, nitric oxide, asymmetric dimethylarginine, cyclic guanosine monophosphate, and D-dimer. Echocardiographic parameters evaluated were right ventricular (RV) size, RA size, FAC, TAPSE, right ventricular index of myocardial performance (RIMP), myocardial performance index (MPI), Tei index, sPAP, mPAP, tricuspid regurgitation (TR) jet, tricuspid regurgitation jet velocity/velocity-time integral right ventricular outflow tract (TRV/VTI<sub>RVOT</sub>), right ventricular ejection fraction (RVEF), right ventricular systolic pressure (RVSP), and pericardial effusion. We found no studies addressing diagnostic thinking efficacy or therapeutic efficacy.

## Study Characteristics

Table F-2 in Appendix F summarizes the study location, patient population, study size, sex ratio, index test, comparator, type of result reported, and the quality for each study relevant to KQ 2. Of the 95 studies that reported sex, there were a total of 3972 women and 1618 men. Of the 93 studies that reported age, 72 studies included adults,<sup>6,58,68,84,85,88-94,96,97,100-104,106-121,124,125,127,128,130-134,137,139-145,147-152,154,156,157,159,160,162,164,166,167,170,171,174,175,178</sup> 9 studies included children,<sup>87,98,122,129,136,153,172,173,177</sup> and 12 studies included both adults and children.<sup>86,99,105,138,146,158,161,163,165,168,169,176</sup> Study locations included Asia (23 studies), Europe (36), United States or Canada (29), Africa (1), Australia/New Zealand (1), South America (1), multiple geographic locations (3), and unreported or unclear setting (5).

We did not find any studies that assessed the comparative effectiveness of echocardiography versus biomarkers or echocardiography versus echocardiography plus biomarkers as outlined in our original Key Question. We did find one recent validation study by Benza et al.<sup>179</sup> of a PAH risk calculator that incorporates biomarkers, echocardiographic findings, and clinical assessment to predict survival. Previously, this team had developed the risk calculator based on known prognosticators of survival in patients with PAH. These variables include World Health Organization subgroup demographics (sex and age), renal disease, functional class, vital signs,

6MWD test, BNP level, presence of pericardial effusion, pulmonary function tests, and findings on RHC, each of which were assigned point values based on presence or level. This recent study validated the risk calculator using prospectively collected independent data from patients with newly diagnosed class I PAH and showed good discriminatory ability. This was the only predictive model we found that both incorporated multiple risk factors, including biomarkers and echocardiographic parameters, and was prospectively validated. However, this report does not permit the assessment of the combination of biomarker and echocardiographic data compared with other routine clinical assessment alone.

Because of the lack of data directly addressed in the key question, we instead focus the remainder of this section on the available studies that evaluate the ability of echocardiography or biomarkers to assess the severity of PAH, to predict events such as lung transplantation or death, or to assess a patient's response to therapy. By evaluating the independent association of biomarkers or echocardiography, one can impute the comparative effectiveness via indirect comparison. The most common biomarker evaluated was BNP (59 studies), followed by uric acid (9), endothelin-1 (6), troponin T (4), nitric oxide (2), cGMP (2) and ANP (1). We found no studies assessing D-dimer or asymmetric dimethylarginine to evaluate their ability to assess severity of disease, response to therapy, or outcome.

Thirty-nine studies evaluated several echocardiographic parameters. These included sPAP (17 studies), RIMP/MPI/Tei (14), RA size (11), pericardial effusion (11), RV size (9), FAC (8), mPAP (8), TAPSE (6), TR jet (4), TRV/VTI<sub>RVOT</sub> (3), RVEF (2), echocardiography-derived cardiac index (2), and RVSP (2).

For the comparators, we focused on RHC hemodynamics, 6-minute walk distance (6MWD), and functional class (FC) as the reference standards for assessing severity of disease. Thirty-four studies used RHC as a reference test, 15 studies used 6MWD as a reference test, and 10 studies used FC as a reference test.

Thirty-nine studies evaluated the correlation between biomarkers and/or echocardiographic parameters and the comparators. Twenty-three studies evaluated hazard ratios (HR) for death, two studies evaluated HR for a composite outcome of death or lung transplant, and one study evaluated HR for lung transplant alone. Twenty-three studies evaluated changes in mean values in response to therapy, and four studies evaluated changes in median values in response to therapy. Eight studies assessed mean or median change from baseline in response to therapy.

## **Detailed Synthesis**

### **Evaluation of Prognostic Value of Biomarkers and Echocardiography as Assessed by Correlation With Outcomes With Known Prognostic Ability**

Table G-1 in Appendix G outlines the 39 studies that reported the correlation between a biomarker or echocardiographic parameter result and a hemodynamic or clinical outcome. The included studies consisted of a total of 1243 patients. Of studies with adults reporting age, the mean age ranged from 37 to 64 years. Two studies evaluating children reported a median age range of 7.0 to 10 years. The following were the most common comparisons encountered in the studies and included in our analysis:

- BNP versus RHC-mPAP (14 studies, 606 patients)
- BNP versus RHC-PVR (13 studies, 684 patients)
- BNP versus RHC-RAP (12 studies, 645 patients)

- BNP versus RHC-CI (10 studies, 550 patients)
- BNP versus 6MWD (9 studies, 437 patients)
- BNP versus RHC-PCWP (5 studies, 319 patients)
- Echocardiography sPAP versus RHC-sPAP (9 studies, 362 patients)

## Meta-analysis of Correlation Studies


There appeared to be excessive heterogeneity in correlations that seemed to be explained by temporal differences between noninvasive assessment and outcome measures, whether hemodynamic at RHC or functional assessment. Therefore, we decided to limit our meta-analysis of correlation studies to those assessing correlation between baseline values at a given time. We did not include studies that correlated change in values between two tests due to the small number of these studies. To improve the robustness of the results, we also limited our meta-analysis to those comparisons that were evaluated in at least four studies. One study<sup>177</sup> included data for both BNP and NT-proBNP and so is included twice in several analyses.

## BNP Versus RHC-mPAP

Figure 9 shows the forest plot of the correlation between BNP and RHC-mPAP from 14 studies (606 patients) with values ranging from 0.16 to 0.62. The summary correlation coefficient was 0.39 (95% CI, 0.31 to 0.47), indicating moderate correlation between the two tests. There was moderate heterogeneity, with a Q-value of 18.8 for 14 degrees of freedom,  $I^2=25.52\%$ ,  $p=0.17$ . In these studies, heterogeneity was introduced in part by different study populations. While all studies evaluated patients with PAH, there was a variety of etiologies included with some studies evaluating a specific etiology<sup>43,68,135,139,148</sup> and others assessing a mixture of PAH etiologies.<sup>84,87,93,95,102,107,110,115,177</sup> In addition, two studies<sup>87,177</sup> focused on a pediatric population while the others focused on adult populations. Further, studies evaluated different BNP measurements, which may add to heterogeneity. Some studies reported results for BNP,<sup>87,93,95,110,115,135</sup> and others reported results for NT-proBNP,<sup>43,68,84,102,107,139,148</sup> while the Takatsuki study reported results for both.<sup>177</sup> Some studies reported log-transformed values,<sup>68,87,93,102,135,139,148</sup> and others reported non-log-transformed values.<sup>43,84,95,107,110,115,177</sup> Most studies included patients receiving a variety of PAH treatments, while the Chin study focused on patients treated with epoprostenol.<sup>95</sup> The strength of evidence is rated moderate based on most studies with low risk of bias, consistent results of an indirect outcome, and precise estimates.



**Figure 9. Forest plot of correlation between BNP and RHC-mPAP**




CI=confidence interval

## BNP Versus RHC-PVR

Figure 10 shows the forest plot of the correlation between BNP and RHC-PVR from 13 studies (684 patients) with values ranging from 0.06 to 0.81. The summary correlation coefficient was 0.46 (95% CI, 0.31 to 0.59), indicating moderate correlation between the two tests. There was high heterogeneity, with a Q-value of 71.76 for 13 degrees of freedom,  $I^2=81.88\%$ ,  $p<0.001$ . In these studies, heterogeneity was also introduced by different study populations with some studies evaluating a specific etiology,<sup>43,68,135,139,144,148</sup> and others assessing a mixture of PAH etiologies.<sup>84,87,95,102,107,115,177</sup> In addition, two studies<sup>87,177</sup> focused on a pediatric population while the others focused on adult populations. As with the above comparison, studies evaluated different biomarker measurements. Some studies reported results for BNP,<sup>87,95,115,135</sup> and others reported results for NT-proBNP<sup>43,68,84,102,107,139,144,148</sup> while one study reported outcomes for both BNP and NT-proBNP.<sup>177</sup> Some studies reported log-transformed values,<sup>68,87,102,135,139,144,148</sup> and others reported non-log-transformed values.<sup>43,84,95,107,115,177</sup> Further, three studies reported PVR as an index value corrected for body size using cardiac index and PCWP,<sup>87,107,177</sup> while the remainder reported absolute PVR value. The strength of evidence is rated low based on most studies with low risk of bias, inconsistent results of an indirect outcome, and precise estimates.

**Figure 10. Forest plot of correlation between BNP and RHC-PVR**




CI = confidence interval

## BNP Versus RHC-RAP

Figure 11 shows the forest plot of the correlation between BNP and RHC-RAP from 12 studies (645 patients) with values ranging from 0.28 to 0.68. The summary correlation coefficient was 0.47 (95% CI, 0.40 to 0.54), indicating moderate correlation between the two tests. There was moderate heterogeneity, with a Q-value of 15.5 for 12 degrees of freedom,  $I^2=22.58\%$ ,  $p=0.22$ . In these studies, heterogeneity was again introduced by different study populations with a focus on specific PAH etiology in some studies<sup>68,135,144,148</sup> and others evaluating a mixture of PAH etiologies.<sup>84,87,93,95,107,115,177,180</sup> As with the previous comparisons, two studies<sup>87,177</sup> focused on a pediatric population while the others focused on adult populations. Also as before, studies evaluated different biomarker measurements, with some studies reporting results for BNP,<sup>87,93,95,115,135</sup> others reporting results for NT-proBNP,<sup>68,84,102,107,144,148</sup> and the Takatsuki study reporting on both.<sup>177</sup> Some studies reported log-transformed values,<sup>68,87,93,102,135,144,148</sup> and others reported non-log-transformed values.<sup>84,95,107,115,177</sup> The strength of evidence is rated moderate based on all but one study with low risk of bias, consistent results of an indirect outcome, and precise estimates.

**Figure 11. Forest plot of correlation between BNP and RHC-RAP**




CI = confidence interval

## BNP Versus RHC-CI

Figure 12 shows the forest plot of the correlation between BNP and RHC-CI from 10 studies (550 patients) with values ranging from -0.70 to -0.01. The summary correlation coefficient was -0.42 (95% CI, -0.54 to -0.28), indicating negative moderate correlation between the two tests. There was moderate heterogeneity, with a Q-value of 32.60 for 10 degrees of freedom,  $I^2=69.33\%$ ,  $p<0.001$ . Again, heterogeneity was likely introduced by different study populations. While all studies evaluated patients with PAH, there was a variety of etiologies included, with some studies looking at a specific etiology,<sup>68,144,148</sup> and others looking at a mixture of PAH etiologies.<sup>84,87,93,102,107,115,177</sup> Two studies<sup>87,177</sup> focused on a pediatric population while the others focused on adult populations. Further, studies evaluated different biomarker measurements. Some studies reported results for BNP,<sup>87,93,115</sup> others reported results for NT-proBNP,<sup>68,84,102,107,144,148</sup> and one reported on both BNP and NT-proBNP.<sup>177</sup> Some studies reported log-transformed values,<sup>68,87,93,102,144,148</sup> and others reported non-log-transformed values.<sup>84,107,115,177</sup> The strength of evidence is rated low based on most studies with low risk of bias, inconsistent results of an indirect outcome, and precise estimates.

**Figure 12. Forest plot of correlation between BNP and RHC-CI**




CI=confidence interval

## BNP Versus 6MWD

Figure 13 shows the forest plot of the correlation between BNP and 6MWD from 9 studies (484 patients) with values ranging from -0.60 to -0.22. The summary correlation coefficient was -0.46 (95% CI, -0.55 to -0.35), indicating negative moderate correlation between the two tests. There was moderate heterogeneity, with a Q-value of 16.18 for 9 degrees of freedom,  $I^2=44.37\%$ ,  $p=0.06$ . The above studies included those that focused on a certain etiology of PAH<sup>43,144,148</sup> or a mixture of PAH etiologies.<sup>95,102,107,115,153</sup> Two studies<sup>153,177</sup> focused on a pediatric population while the others focused on adult populations. Studies evaluated different biomarker measurements. Some studies reported results for BNP,<sup>95,115</sup> others reported results for NT-proBNP,<sup>43,102,107,144,148,153</sup> while one reported on both.<sup>177</sup> Some studies reported log-transformed values,<sup>102,144,148,153</sup> and others reported non-log-transformed values.<sup>43,95,107,115,177</sup> The strength of evidence is rated moderate based on most studies with low risk of bias, inconsistent results of a direct outcome, and precise estimates.

**Figure 13. Forest plot of correlation between BNP and 6MWD**




CI = confidence interval

## BNP Versus RHC-PCWP

Figure 14 shows the forest plot of the correlation between BNP and RHC-PCWP from 5 studies (319 patients) with values ranging from -0.03 to 0.32. The summary correlation coefficient was 0.16 (95% CI, 0.01 to 0.31), indicating poor correlation between the two tests. There was moderate heterogeneity, with a Q-value of 6.46 for 4 degrees of freedom,  $I^2=38.04\%$ ,  $p=0.17$ . Heterogeneity in this group of studies was also introduced by differing populations, with some studies looking at populations with a specific etiology of PAH,<sup>43,144</sup> some looking at populations with a mixture of PAH etiologies,<sup>135, 369, 595</sup> and the Bernus study<sup>87</sup> focused on a pediatric population. Studies evaluated different BNP values, with some studies reporting results for BNP<sup>87,95,135</sup> and others reporting results for NT-proBNP.<sup>43,144</sup> Some studies reported log-transformed values<sup>87,135,144</sup> and others reported non-log-transformed values.<sup>43,95</sup> There is not enough information in the Rhodes study<sup>144</sup> regarding how variables were measured to adequately explain why this study found a negative correlation between the two markers. The strength of evidence is rated low based on most studies with low risk of bias, consistent results of an indirect outcome, and imprecise estimates.

**Figure 14. Forest plot of correlation between BNP and RHC-PCWP**




CI=confidence interval

### **Echocardiography sPAP Versus RHC-sPAP**

Figure 15 shows the forest plot of the correlation between echocardiography sPAP and RHC-sPAP from 9 studies (362 patients) with values ranging from 0.33 to 0.97. The summary correlation coefficient was 0.76 (95% CI, 0.53 to 0.89), indicating high correlation between the two tests. There was high heterogeneity, with a Q-value of 110.59 for 8 degrees of freedom,  $I^2=92.77\%$ ,  $p<0.001$ . These studies used a variety of methods to estimate sPAP by echocardiography including Bernoulli equation without correction,<sup>100,105,126</sup> Bernoulli equation plus estimated RAP,<sup>110,113,176</sup> and Bernoulli equation plus a fixed value for RAP;<sup>116,118</sup> one study did not report how sPAP was estimated.<sup>112</sup> In addition, there was variability in timing between the catheterization study and the echocardiography study. In three studies it appears that right heart catheterization and echocardiography were done during the initial evaluation.<sup>113,116,118,176</sup> In one study, the tests were done within 30 days of each other<sup>105</sup> and in another done within 4 to 9 months of each other.<sup>126</sup> Two studies were retrospective chart reviews that evaluated the most recent catheterization or echocardiography results,<sup>110,112</sup> and one prospective study did not specify a time frame between the tests.<sup>102</sup> Most studies included patients with a wide range of disease severity, but the Homma study focused only on patients undergoing evaluation for lung transplantation.<sup>118</sup> The strength of evidence is rated low based on most studies with low risk of bias, inconsistent results of an indirect outcome, and precise estimates.

**Figure 15. Forest plot of correlation between echocardiography-sPAP and RHC-sPAP**



CI = confidence interval

## Evaluation of Predictive Value of Biomarkers and Echocardiography as Assessed by Hazard Ratios

Table 17 summarizes the 25 studies that reported the association between a biomarker or echocardiographic parameter and a future clinical outcome in the form of a hazard ratio. Studies evaluating a hazard ratio consisted of 4624 patients, with a female-to-male ratio of 1396 to 517 in those studies reporting sex. Mean age ranged from 33 to 61 years. Included studies evaluated hazard ratios for the following outcomes:

- Mortality (17 studies reporting mean duration of 2 years, one study reporting mean duration of 9 years; 3 studies reporting median duration of 2 years) evaluating BNP (13 studies), pericardial effusion (8), RA size (5), FAC (4), RIMP/MPI/Tei index (5), TAPSE (4), uric acid (4), RV size (2), troponin T (2), peak TRV (2), mPAP (1), sPAP (1), ANP (1)
- Composite outcome of death or lung transplantation (2 studies with one reporting median duration of 4 years and the other reporting mean duration of 3 years) evaluating BNP (1 study), RA size (1), uric acid (1), peak TRV (1), pericardial effusion (1), FAC (1), RV size (1)
- Lung transplantation (one study with mean duration of 2 years) evaluating RA size
- Hospitalization (one study with mean duration of 3.7 years) evaluating BNP and uric acid

**Table 17. Hazard ratio table for KQ 2**

Study Population (N) Quality	Age (Variability)	Duration of Followup	Index Test	Comparator	N <sup>a</sup>	Result	95% CI	P-value
Benza, 2010 <sup>6</sup>  Adults with PAH (N=2716)  Good	Mean 50.4 (SD 16.8)	Mean followup ~18 mo	Pericardial effusion	Mortality	2105	1.35		0.014
Brierre, 2010 <sup>90</sup>  Adults with PAH (N=79)  Good	Median 61.4 (IQR 46.0 to 74.1)	Mean duration 12 mo	mPAP	Mortality	79	3.94	1.34 to 11.5	0.012
			Pericardial effusion	Mortality	79	5.18	1.85 to 14.5	0.002
			RIMP/MPI/ Tei Index ≥0.98	Mortality	79	5.41	1.12 to 26.1	0.035
			TAPSE	Mortality	79	0.84	0.72 to 0.98	0.024
Bustamante-Labarta, 2002 <sup>91</sup>  Adults with PPH (N=25)  Good	Mean 37.6 (SD 12.7)	Mean followup 29 mo	RA size (RA area)	Transplant (survival from)	25	1.1		0.0004
Fijalkowska, 2006 <sup>102</sup>  Adults with PH (N=55)  Good	Mean 41 (SD 15.1)	Mean followup 770 ± 336 days	FAC	Mortality	55	0.98	0.93 to 1.03	NS
			BNP	Mortality	55	3.0	1.45 to 6.18	0.002
			Pericardial effusion	Mortality	55	3.8	1.46 to 9.93	0.006
			RA size (RA area)	Mortality	55	1.02	0.97 to 1.07	NS
			RIMP/MPI/ Tei index	Mortality	55	1.01	0.34 to 3.01	NS
			RV size (RV diameter)	Mortality	55	1.08	0.99 to 1.17	NS
			cTnT (detectable)	Mortality	55	4.5	1.56 to 12.92	0.005
Forfia, 2006 <sup>104</sup>  Adults with PH (N=63)  Good	Mean 55 (SD 15)	Mean followup 19.3 mo	TAPSE	Mortality	63	1.17	1.04 to 1.32	0.006



**Table 17. Hazard ratio table for KQ 2 (continued)**

Study Population (N) Quality	Age (Variability)	Duration of Followup	Index Test	Comparator	N <sup>a</sup>	Result	95% CI	P-value
Ghio, 2010 <sup>108</sup> Adults with IPAHA (N=59) Good	Mean 46.4 (SD 16.1)	Mean followup 52 mo	Pericardial effusion	Mortality	59	0.79	0.18 to 3.4	0.75
			RIMP/MPI/Tei Index	Mortality	59	2.61	0.52 to 13.03	0.26
			sPAP (transtricuspid gradient)	Mortality	59	0.99	0.98 to 1.02	0.92
			TAPSE	Mortality	59	0.91	0.83 to 0.99	0.026
Hampole, 2009 <sup>114</sup> Adults with PH (N=162) Good	Mean 53 (SD 15)	Mean followup 2.1 ± 0.8 yr	BNP (log)	Mortality	162	1.62	1.01 to 2.60	0.044
Heresi, 2010 <sup>115</sup> Adults with PPH (N=40) Good	Mean 44 (SD 14)	23.5 ± 13.5 mo	BNP	Mortality	40	1.20	0.11 to 13.28	0.88
Lorenzen, 2011 <sup>125</sup> Adults with PAH (N=70) Good	Mean 42 (IQR 48 to 59)	3 mo	BNP (ln)	Mortality	25	1.9	1.2 to 2.9	<0.001
			Uric acid	Mortality	25	1.9	1.5 to 2.6	<0.001
Machado, 2006 <sup>43</sup> Patients with sickle cell disease (N=230) Poor	Median 33 (IQR 27 to 44)	Median followup 31 mo	BNP (log) (75 <sup>th</sup> percentile vs. 25 <sup>th</sup> percentile)	Mortality	230	2.1	1.4 to 2.9	<0.001
Mahapatra, 2006 <sup>127</sup> Adults with PH (N=54) Fair	Mean 52 (SD 11)	250 person yr	RIMP/MPI/Tei Index	Mortality	54	1.66	1.05 to 2.6	0.04

**Table 17. Hazard ratio table for KQ 2 (continued)**

Study Population (N) Quality	Age (Variability)	Duration of Followup	Index Test	Comparator	N <sup>a</sup>	Result	95% CI	P-value
Mathai, 2011 <sup>128</sup>  Adults with known or suspected PAH (N=50)  Fair	Mean 61 (SD 11)	Median followup 15.7 mo	FAC (RVFAC)	Mortality	50	0.99	0.95 to 1.03	0.47
			Peak TRV	Mortality	50	0.58	0.31 to 1.10	0.10
			Pericardial effusion	Mortality	50	1.11	0.75 to 1.64	0.59
			RA size (RA area indexed)	Mortality	50	1.11	1.02 to 1.19	0.01
			TAPSE	Mortality	50	0.87	0.78 to 0.96	<0.01
Nagaya, 2000 <sup>135</sup>  Patients with PPH (N=60)  Good	Mean 38 (Range 15 to 69)	Mean followup 24 ± 2 mo	BNP	Mortality	60	6.983	1.923 to 23.357	0.0031
			BNP (log)	Mortality	53	29.310	5.294 to 162.275	0.0001
			ANP (log)	Mortality	53	19.676	3.834 to 100.978	0.0004
			ANP	Mortality	60	4.641	1.347 to 15.986	0.0150
Nickel, 2008 <sup>140</sup>  Adults with IPAH (N=76)  Fair	Mean 52 (Range 44 to 63)	Median followup 48 mo	BNP (ln)	Composite outcome (death or lung transplant)	76	2.62	1.78 to 3.86	<0.001
			Uric acid	Composite outcome (death or lung transplant)	76	1.56	1.27 to 1.96	<0.001
Nickel, 2012 <sup>162</sup>  Adults with IPAH (N=109)  Fair	Median 55 (IQR 42 to 68)	Median 38 mo	BNP	Mortality	84	1.3	1.1 to 1.6	0.04
			Uric acid	Mortality	104	1.1	1.0 to 1.6	0.01

**Table 17. Hazard ratio table for KQ 2 (continued)**

Study Population (N) Quality	Age (Variability)	Duration of Followup	Index Test	Comparator	N <sup>a</sup>	Result	95% CI	P-value
Raymond, 2002 <sup>143</sup>  Adults with PPH (N=81)  Fair	Mean 40 (SD 15)	Mean followup 36.9 ± 15.4 mo	FAC	Composite outcome (death or lung transplant)	81	0.86	0.57 to 1.28	0.454
			FAC	Mortality	81	0.70	0.39 to 1.25	0.225
			Peak TRV	Composite outcome (death or lung transplant)	81	1.00	0.77 to 1.30	0.981
			Peak TRV	Mortality	81	0.90	0.62 to 1.31	0.591
			Pericardial effusion	Composite outcome (death or lung transplant)	81	2.08	1.12 to 3.86	0.017
			Pericardial effusion	Mortality	81	3.89	1.49 to 10.14	0.003
			RA size (RA area indexed)	Composite outcome (death or lung transplant)	81	1.33	1.06 to 1.66	0.012
			RA size (RA area indexed)	Mortality	81	1.54	1.13 to 2.10	0.005
			RV size (RVED area index)	Composite outcome (death or lung transplant)	81	1.26	0.95 to 1.66	0.110
			RV size (RVED area index)	Mortality	81	1.34	0.90 to 1.98	0.148
Rhodes, 2011 <sup>144</sup>  Adults with IPAH (N=139)  Good	Mean 47.6 (SD 15.8)	2 yr	BNP (square root)	Mortality	139	1.038	1.018 to 1.058	<0.001

**Table 17. Hazard ratio table for KQ 2 (continued)**

Study Population (N) Quality	Age (Variability)	Duration of Followup	Index Test	Comparator	N <sup>a</sup>	Result	95% CI	P-value
Sadushi-Kolici, 2012 <sup>160</sup> Adults with PH (N=111) Fair	Mean 52 (SD 17)	9 yrs	Pericardial effusion	Mortality	105	6.361		0.003
Takeda, 2010 <sup>149</sup> Adults with PAH (N=37) Good	Mean 49 (SD 18)	635 ± 510 days	BNP (log)	Mortality	37	2.79	1.55 to 5.04	0.001
Torbicki, 2003 <sup>150</sup> Adults with PAH (N=56) Good	Mean 41 (SD 15)	Mean followup 17 ± 8.5 mo	FAC	Mortality	56	0.999	0.94 to 1.06	0.96
			BNP >median (1647 pg/mL)	Mortality	56	1.84	0.89 to 5.45	0.32
			Pericardial effusion	Mortality	56	2.77	0.89 to 8.59	0.08
			RA size (RA area)	Mortality	56	1.03	0.97 to 1.09	0.39
			cTnT (detectable)	Mortality	56	5.47	1.62 to 18.46	0.003
Utsunomiya, 2011 <sup>151</sup> Adults with chronic PH (N=50) Good	Mean 46 (SD 13)		BNP	Mortality	50			0.006
			RA size (RA end systolic area indexed)	Mortality	50			0.005
			RIMP/MPI/Tei index	Mortality	50			0.005
Williams, 2006 <sup>68</sup> Adults with systemic sclerosis (N=109) Fair	Mean 60 (SD 10)	1 yr	BNP (10-fold increase FROM baseline)	Mortality	68	3.82	1.46 to 9.96	0.006
			BNP (10-fold increase IN baseline)	Mortality	68	4.82	1.29 to 18.05	0.002
Yamada, 2012 <sup>161</sup> Patients with IPAH (N=41) Good	Mean 39 (SD 14)	45 ± 25 mo	BNP	Mortality	41	1.00	1.00 to 1.00	0.197
			Uric acid	Mortality	41	1.38	0.95 to 2.00	0.087
			BNP	Hospitalization	41	1.00	1.00 to 1.00	0.129
			Uric acid	Hospitalization	41	1.25	0.98 to 1.59	0.075

**Table 17. Hazard ratio table for KQ 2 (continued)**

Study Population (N) Quality	Age (Variability)	Duration of Followup	Index Test	Comparator	N <sup>a</sup>	Result	95% CI	P-value
Yanagisawa, 2012 <sup>159</sup>  Adults with PAH (N=46)  Good	Mean 42 (SD 14)	44 ± 26 mo	BNP	Mortality	46	1.00	0.99 to 1.00	NS
Zhao, 2012 <sup>163</sup>  Patients with IPAH (N=76)  Good	Mean 37 (SD 11)	Mean 24 ± 9 mo	Uric acid	Mortality	76	1.003	1.000 to 1.006	0.049

ANP = A-type natriuretic peptide; BNP = B-type natriuretic peptide; CO = cardiac output; cTnT = cardiac troponin T; CVD = collagen vascular disease; FAC = fractional area change; IQR = interquartile range; mPAP = mean pulmonary artery pressure; mo = month/months; MPI = myocardial performance index; NR = not reported; PVR = pulmonary vascular resistance; RA = right atrium; RIMP = right index of myocardial performance; RV = right ventricle; SD = standard deviation; SEM = standard error of the mean; sPAP = systolic pulmonary artery pressure; TAPSE = tricuspid annular plane systolic excursion; TRV = tricuspid regurgitant jet velocity; yr = year/years

<sup>a</sup>Number of patients who had the index test and comparator measured.

## Meta-Analysis of Hazard Ratio Studies


There were too few studies to permit meta-analysis assessing hazard ratios for a composite outcome. Our analysis focused on those studies that evaluated biomarkers or echocardiographic parameters as predictors of mortality. To improve the robustness of the analysis, we included only index tests that were evaluated in at least four different studies. We also concentrated on univariate hazard ratios as each study that created a multivariate model adjusted for different variables. We did not include those studies that evaluated a biomarker or echocardiographic parameter as a dichotomous outcome since these studies tended use markedly different thresholds across studies.

### BNP and Mortality

Figures 16 and 17 show forest plots of the hazard ratios for BNP and mortality from 11 studies (757 patients), with values ranging from 1.62 to 6.98. Studies differed in whether and how BNP values, which tend to have a skewed distribution, were transformed for use in their analyses. Most studies used log-transformation of BNP values, while others did not describe any transformation or used a different transformation method (e.g., square root in one study). We segregated our analysis according to whether BNP values were log-transformed and found that this explained a great deal of the statistical heterogeneity of results—reducing the initial Q-value of 73.2 for 10 degrees of freedom,  $I^2=86.34$ , to Q-value of 7.78 for 5 degrees of freedom,  $I^2=35.72\%$ ,  $p=0.17$ , among studies using log-transformed BNP values, and Q-value of 26.10 for 4 degrees of freedom,  $I^2=84.68\%$ ,  $p<0.001$ , for studies using no transformation method or a different transformation method.


Given the reduction in heterogeneity, we analyzed those studies reporting a log-transformed value for BNP separately from the other studies. For those studies that analyzed log-transformed values for BNP, the summary hazard ratio was 2.42 (95% CI, 1.72 to 3.41), indicating that higher levels of BNP are associated with higher mortality (Figure 16). Studies differed in study population, with some looking at populations with a specific etiology for PAH<sup>68,125</sup> and others looking at mixed populations.<sup>102,114,135,149</sup> Studies evaluated either BNP<sup>135,149</sup> or NT-proBNP.<sup>68,102,114,125</sup> For those studies in which BNP values were not log-transformed, the summary hazard ratio was 1.01 (95% CI, 0.99 to 1.03), suggesting no association with mortality (Figure 17); however, we believe that these analyses suffer from limited statistical power to detect any effect and perhaps obscure any observed effect through rounding error (e.g., one study reported a hazard ratio of 1 with 95% CI from 1.0 to 1.0). Studies differed in study population, with some evaluating populations with a specific etiology for PAH<sup>144,161,162</sup> and others evaluating mixed populations.<sup>115,159</sup> Studies evaluated either BNP<sup>115,159,161</sup> or NT-proBNP.<sup>144,162</sup> We based our assessment primarily on the studies that used log-transformed BNP values. Overall for BNP, the strength of evidence is moderate based on most studies with low risk of bias, consistent results of a direct outcome, and imprecise estimates.

**Figure 16. Forest plot of hazard ratio for log-transformed BNP and mortality**



CI = confidence interval

**Figure 17. Forest plot of hazard ratio for BNP (without mention of log-transformation) and mortality**




CI = confidence interval

## Pericardial Effusion and Mortality

Figure 18 shows the forest plot of the hazard ratio for presence of pericardial effusion and mortality from 8 studies (2590 patients) with values ranging from 0.79 to 6.36. The summary hazard ratio was 2.43 (95% CI, 1.57 to 3.77), indicating that the presence of pericardial effusion is associated with higher mortality. There was moderate heterogeneity, with a Q-value of 20.79 for 7 degrees of freedom,  $I^2=66.32\%$ ,  $p<0.001$ . The two studies that reported an effect estimate smaller than the summary estimate<sup>108,128</sup> reported the pericardial effusion value as a combined value incorporating both presence and grade or severity. The other six studies reported only presence of effusion. The strength of evidence is rated moderate based on five studies with low risk of bias and three with moderate risk of bias, inconsistent results of a direct outcome, and imprecise estimates.

**Figure 18. Forest plot of hazard ratio for pericardial effusion and mortality**




CI = confidence interval

### RA Size and Mortality

Figure 19 shows the forest plot of the hazard ratio for RA size and mortality from 4 studies (242 patients) with values ranging from 1.02 to 1.11 per 1 cm<sup>2</sup> increment in RA size or per 1 cm<sup>2</sup>/m increment in RA index. The summary hazard ratio was 1.06 (95% CI, 1.01 to 1.10), indicating that increased RA size is associated with increased mortality. There was moderate heterogeneity, with a Q-value of 5.04 for 3 degrees of freedom,  $I^2=40.51\%$ ,  $p=0.17$ . Some of the heterogeneity may be explained by the fact that both the Raymond study<sup>143</sup> and the Mathai study<sup>128</sup> reported RA area indexed to patient height while the others did not. We could find no other significant differences in the studies to explain the heterogeneity. The strength of evidence is rated moderate based on two studies with low risk of bias and two with moderate risk of bias, consistent results of a direct outcome, and precise estimates.

**Figure 19. Forest plot of hazard ratio for RA size and mortality**




CI = confidence interval



## FAC and Mortality

Figure 20 shows the forest plot of the hazard ratio for FAC and mortality from 4 studies (242 patients) with values ranging from 0.96 to 1.0 per 0.01 (1%) increment in FAC. The summary hazard ratio was 0.98 (95% CI, 0.96 to 1.01), indicating that differences in FAC had no relationship to mortality. There was low heterogeneity, with a Q-value of 0.79 for 3 degrees of freedom,  $I^2=0$ ,  $p=0.85$ . The strength of evidence is rated moderate based on two studies with low risk of bias and two with moderate risk of bias, consistent results of a direct outcome, and precise estimates.

**Figure 20. Forest plot of hazard ratio for FAC and mortality**




CI = confidence interval

## Uric Acid and Mortality

Figure 21 shows the forest plot of the hazard ratio for uric acid and mortality from 4 studies (246 patients) with values ranging from 1.00 to 1.10 per 1  $\mu\text{mol/L}$  increment in serum uric acid level. The summary hazard ratio was 1.01 (95% CI, 1.00 to 1.01), suggesting that differences in serum uric acid level had a small but detectable effect on risk of mortality. There was moderate heterogeneity, with a Q-value of 11.65 for 3 degrees of freedom,  $I^2=74.25\%$ ,  $p=0.01$ . Heterogeneity in these studies may have been introduced by different scales of measurements across studies and different populations. Lorenzen et al.<sup>125</sup> reported a statistically significant hazard ratio of 1.9 (CI, 1.5 to 2.6) for a 100  $\mu\text{mol/L}$  increment in serum uric acid level; however, other studies reported hazard ratios calculated for 1  $\mu\text{mol/L}$  or 1 mg/dL increments, and rounding error in the estimates precluded adjustment to a larger (clinically important) increment. Three studies<sup>161-163</sup> evaluated patients with IPAH, while the Lorenzen study evaluated patients with PAH from multiple etiologies.<sup>125</sup> The strength of evidence is rated low based on three studies with low risk of bias and one with moderate risk of bias, inconsistent results of a direct outcome, and imprecise estimates.

**Figure 21. Forest plot of hazard ratio for serum uric acid level and mortality**




CI = confidence interval

## TAPSE and Mortality

Figure 22 shows the forest plot of the hazard ratio for TAPSE and mortality from 4 studies (251 patients) with values ranging from 0.84 to 1.17. The summary hazard ratio was 0.94 (95% CI, 0.82 to 1.08), indicating that differences in TAPSE had no significant relationship to mortality. There was moderate heterogeneity, with a Q-value of 17.9 for 3 degrees of freedom,  $I^2=83.24\%$ ,  $p<0.001$ . Heterogeneity in these studies may have been introduced by different scales of measurements across studies and different populations. The strength of evidence is rated insufficient based on three studies with low risk of bias and one with moderate risk of bias, inconsistent results of a direct outcome, and precise estimates.

**Figure 22. Forest plot of hazard ratio for TAPSE and mortality**



CI = confidence interval

## Evaluation of Responsiveness of Biomarkers and Echocardiography as Assessed by Changes in Mean or Median Levels

In our review, we focused only on those studies that measured mean or median values for biomarkers or echocardiographic parameters at two or more different time points or reported as a change from baseline, in order to evaluate whether changes in these measures could serve as a potential surrogate marker for response to therapy. Tables 17–19 show means, medians, and changes in either mean or median from baseline.

- Twenty-three studies including 1051 patients evaluated changes in mean values in response to therapy for a subset of 913 patients evaluating BNP (13 studies), sPAP (5), RV size (5), RIMP/MPI/Tei index (3), TRV (3), TAPSE (1), FAC (1), mPAP (1), nitric oxide (1), endothelin-1 (1) and RA size (1).

- Four studies with a total of 37 patients evaluated changes in median in response to therapy evaluating BNP (4 studies), Endothelin-1 (1), RIMP/MPI/Tei index (1), sPAP (1), FAC (1), RVEF (1).
- Eight studies with a total 935 patients evaluated mean or median change from baseline in response to therapy for a subset of 610 patients evaluating BNP (5 studies), mPAP (3), RV size (2), FAC (1), TRV (1), RIMP/MPI/Tei index (1), RA size (1) and cardiac index (1).
- Response to therapy was evaluated for the following drugs: ambrisentan (6 studies), bosentan (11), epoprostenol (10), iloprost (2), sildenafil (1), tadalafil (2), and treprostinil (3).

Due to the small number and heterogeneity of these studies in regard to index test and type of therapy, we were unable to perform meta-analysis on these data. While a few studies found changes in biomarkers or echocardiographic parameters in response to various treatments, there were insufficient data to quantitatively assess overall response or to recommend use of these markers as surrogate outcomes measures. Many of these studies also evaluated changes in patient outcomes in response to therapy, but there were no data to correlate change in biomarkers or echocardiographic parameters with these changes in outcomes.

Of the 13 studies that assessed mean values of BNP in response to various therapies (prostanoids, sildenafil, endothelin receptor antagonists, or “standard therapy”), most showed a decrease in BNP levels by approximately half after 3 to 6 months of therapy (Table 18).<sup>93,96,106,119,124,130,133,136,167,168</sup> Studies with longer followup times showed that the lower BNP levels remained stable throughout the course of followup.<sup>93,119,136</sup> One study with mean followup of 9 months showed no change in BNP levels in response to tadalafil.<sup>172</sup> Another study actually showed an increase in BNP levels after a mean followup duration of 20 months when patients were transitioned from bosentan to ambrisentan but a decrease in levels when ambrisentan was started as the first line endothelin receptor antagonist therapy.<sup>173</sup>

Four of five studies assessing changes in mean sPAP showed decreased values in response to tadalafil after 1 month of followup,<sup>88</sup> bosentan after 9 months of followup,<sup>165</sup> or epoprostenol after 6 to 24 months of followup.<sup>137,146</sup> One study showed no change in mean sPAP levels for unspecified monotherapy after 18 month followup or combination therapy after 12 months of followup.<sup>121</sup>

In three studies, mean RIMP/MPI/Tei index did not change appreciably over time following treatment with bosentan/iloprost<sup>101</sup> or epoprostenol<sup>137,146</sup> after 5 to 23 months of followup. Five studies showed no change in mean RV size after treatment with epoprostenol for 15 to 23 months of followup,<sup>93,137</sup> bosentan for 24 months of followup,<sup>165</sup> iloprost after 18 months of followup,<sup>169</sup> or tadalafil after 9 months of followup.<sup>172</sup> Mean TRV decreased slightly in one study after 22 months of treatment with epoprostenol.<sup>137</sup> Two studies showed no change in mean TRV over 6 months of treatment with either bosentan or ambrisentan<sup>133</sup> or 9 months of treatment with tadalafil.<sup>172</sup> There was a slight decrease in mean TAPSE value following 15 months of epoprostenol therapy in one study.<sup>93</sup> Studies showed no change in mean levels of endothelin-1 in response to epoprostenol after 3 months,<sup>123</sup> FAC in response to epoprostenol after 15 months,<sup>93</sup> or RA size after epoprostenol or bosentan for 24 months.<sup>138,165</sup> In one study, mean nitric oxide level decreased significantly over 1 year of treatment with bosentan.<sup>92</sup>

**Table 18. Studies reporting changes in mean values over time**

Study Population (N) Quality	Age (Variability)	Timing	Index Test	N	Mean	Variability	Clinical Scenario
Bharani, 2007 <sup>88</sup>  Adults and children with suspected or symptomatic PAH (N=8)  Fair	Mean 28 (SD 9.38)	Baseline	sPAP	8	114.12	SD 23.14	Response to tadalafil
		1 mo	sPAP	8	88.75	SD 23.26	Response to tadalafil
Campana, 2004 <sup>93</sup>  Adults with precapillary PH (N=22)  Good	Mean 50 (SD 11)	Baseline	FAC	22	0.26	SD 0.10	Response to epoprostenol
		Mean followup 15 ± 4 mo	FAC	22	0.23	SD 0.08 p=0.8	Response to epoprostenol
		Baseline	BNP	22	246	SD 162	Response to epoprostenol
		Mean followup 15 ± 4 mo	BNP	22	256	SD 180 p=0.9	Response to epoprostenol
		Baseline	RV size (RV end diastolic diameter)	22	36	SD 7.5	Response to epoprostenol
		Mean followup 15 ± 4 mo	RV size (RV end diastolic diameter)	22	39	SD 7.3 p=0.09	Response to epoprostenol
		Baseline	TAPSE	22	17.3	SD 4.4	Response to epoprostenol
		Mean followup 15 ± 4 mo	TAPSE	22	15.2	SD 4.4 p=0.04	Response to epoprostenol
Cella, 2009 <sup>92</sup>  Adults with PAH associated with CTD (N=18)  Good	Mean 53.8 (SD 13.1)	Baseline	Nitric oxide	18	24.05	SD 6.04	Response to bosentan
		1 yr	Nitric oxide	18	13.92	SD 3.40 p<0.001	Response to bosentan
D'Alto, 2010 <sup>96</sup>  Adults with PAH due to CHD (N=32)  Fair	Mean 37.1 (SD 13.7)	Baseline	BNP	32	760	SD 943	Response to bosentan + sildenafil
		6 mo	BNP	32	303	SD 366 p=0.008	Response to bosentan + sildenafil

**Table 18. Studies reporting changes in mean values over time (continued)**

Study Population (N) Quality	Age (Variability)	Timing	Index Test	N	Mean	Variability	Clinical Scenario
Feliciano, 2004 <sup>101</sup>  Adults with severe PAH (N=11)  Good	Mean 42 (SD 18)	Baseline	RIMP/MPI/Tei index	11	0.8	SD 0.6	Bosentan or iloprost
		11.3 ± 7.9 mo	RIMP/MPI/Tei index	11	0.7	SD 0.4 p=0.02 (compared with baseline)	Bosentan or iloprost
Galie, 2008 <sup>106</sup>  Adults with PAH (N=201)  Good	NR	Baseline	BNP	394	122.92	95% CI 93.30 to 160.82	Response to ambrisentan 5mg (Aries I)
		12 wk	BNP	394	85.75	95% CI 66.01 to 111.23	Response to ambrisentan 5mg (Aries I)
		Baseline	BNP	394	132.07	95% CI 89.72 to 193.86	Response to ambrisentan 10mg (Aries I)
		12 wk	BNP	394	72.29	95% CI 53.50 to 98.72	Response to ambrisentan 10mg (Aries I)
		Baseline	BNP	394	129.94	95% CI 89.49 to 188.22	Response to ambrisentan 2.5mg (Aries II)
		12 wk	BNP	394	92.68	95% CI 69.43 to 124.84	Response to ambrisentan 2.5mg (Aries II)
		Baseline	BNP	394	89.81	95% CI 58.92 to 137.58	Response to ambrisentan 5mg (Aries II)
		12 wk	BNP	394	62.74	95% CI 42.36 to 93.63	Response to ambrisentan 5mg (Aries II)
Jacobs, 2009 <sup>119</sup>  Adults with idiopathic PAH (N=16)  Fair	Mean 37.0 (SD 2.8)	Baseline	BNP	11	2830	SEM 818	Response to prostanoids
		Mean followup 37.0 ± 4.4 mo	BNP	11	1574	SEM 447 p=0.049	Response to prostanoids

**Table 18. Studies reporting changes in mean values over time (continued)**

Study Population (N) Quality	Age (Variability)	Timing	Index Test	N	Mean	Variability	Clinical Scenario
Kaya, 2012 <sup>165</sup>  Patients with Eisenmenger syndrome (N=23)  Good	Mean 31 (SD 12)	Baseline	RV size	23	35.3	SD 10.5	Response to bosentan
		Mean followup 24 ± 9 mo	RV size	23	31.8	SD 10.3 p=0.066	Response to bosentan
		Baseline	RA size	23	40.5	SD 4.5	Response to bosentan
		Mean followup 24 ± 9 mo	RA size	23	35.4	5.2 p=0.14	Response to bosentan
		Baseline	sPAP	23	118	SD 22	Response to bosentan
		Mean followup 24 ± 9 mo	sPAP	23	111	SD 19 p=0.044	Response to bosentan
		Baseline	s-prime	23	6.7	SD 1.5	Response to bosentan
		Mean followup 24 ± 9 mo	s-prime	23	8.8	SD 1.7 p=0.003	Response to bosentan
Keogh, 2011 <sup>121</sup>  Adults with PAH (N=112)  Fair	Mean 51.4 (SD 17.8)	Baseline (at start of monotherapy)	sPAP	101	83	SD 23	Response to monotherapy
		Mean followup 18.7 ± 13.4 mo on monotherapy	sPAP	103	86	SD 25	Response to monotherapy
		1 yr after starting combination therapy	sPAP	112	77	SD 22	Response to combo therapy
Knirsch, 2011 <sup>129</sup>  Children with heart disease (N=103)  Good	Mean 6.4 (SD 5.2)	Baseline	BNP	4	980.5	SD 994.9	Before treatment in patients with IPAH
		Baseline	BNP	6	665.2	SD 1371	Before treatment in patients with PAH 2/2 CHD
		No followup time specified	BNP	8	25.6	SD 13.2 p<0.05	Response to standardized protocol in patients with IPAH
		No followup time specified	BNP	15	152.9	SD 224.4 p<0.05	Response to standardized protocol in patients with PAH 2/2 CHD

**Table 18. Studies reporting changes in mean values over time (continued)**

Study Population (N) Quality	Age (Variability)	Timing	Index Test	N	Mean	Variability	Clinical Scenario
Langleben, 1999 <sup>123</sup> Patients with PPH (N=18) Good	NR	Baseline	Endothelin-1	11	1.62	SEM 0.35	Response to epoprostenol
		3 mo	Endothelin-1	11	1.84	SEM 0.41	Response to epoprostenol
Leuchte, 2005 <sup>124</sup> Adults with PAH (N=30) Good	Mean 46.93 (SEM 2.8)	Baseline	BNP	30	45.51	SEM 7.52	Comparison to therapy (nonspecific)
		Mean followup 12.6 ± 1.5 mo	BNP	30	58.2	SEM 11.4	Comparison to therapy (nonspecific)
Minniti, 2009 <sup>133</sup> Adults with SCD and PH (N=14) Poor	Mean 48.9	Baseline	BNP	14	407	SD 172	Response to bosentan or ambrisentan
		2 mo	BNP	14	286	SD 63	Response to bosentan or ambrisentan
		3 mo	BNP	14	224	SD 46	Response to bosentan or ambrisentan
		Baseline	TRV	14	3.4	SD 0.1	Response to bosentan or ambrisentan
		2 mo	TRV	14	3.4	SD 0.1	Response to bosentan or ambrisentan
		3 mo	TRV	14	3.3	SD 0.1	Response to bosentan or ambrisentan
		6 mo	TRV	14	3.3	SD 0.2	Response to bosentan or ambrisentan
Morishita, 2009 <sup>138</sup> Adults and children with PAH (N=7) Good	Median 34.6 (Range 15 to 49)	1 mo	RA size (RA area indexed)	7	18.6	SD 10.4	Response to epoprostenol
		3 mo	RA size (RA area indexed)	7	19.4	SD 10.7	Response to epoprostenol
		6 mo	RA size (RA area indexed)	7	14.6	SD 5.4	Response to epoprostenol
		1 yr	RA size (RA area indexed)	7	14.5	SD 5.8	Response to epoprostenol

**Table 18. Studies reporting changes in mean values over time (continued)**

Study Population (N) Quality	Age (Variability)	Timing	Index Test	N	Mean	Variability	Clinical Scenario
Nakayama, 2007 <sup>136</sup>  Patients with PPH (N=60)  Good	Mean 10.7 (SD 3.5)	3 mo	BNP	27	187.0	SD 221.4	Response to epoprostenol
		1 yr	BNP	27	86.6	SD 133.9	Response to epoprostenol
		2 yr	BNP	27	85.3	SD 206.1	Response to epoprostenol
Nath, 2005 <sup>137</sup>  Adults with PPH (N=20)  Good	Mean 46 (SD 11)	Baseline	RIMP/MPI/Tei index	20	0.6	SD 0.3	Response to epoprostenol
		22.7 ± 9.3 mo	RIMP/MPI/Tei index	20	0.6	SD 0.3 p=0.54	Response to epoprostenol
		Baseline	RV size	20	2.1	SD 0.9	Response to epoprostenol
		22.7 ± 9.3 mo	RV size	20	1.8	SD 1.5 p=0.07	Response to epoprostenol
		Baseline	sPAP	20	87	SD 26	Response to epoprostenol
		22.7 ± 9.3 mo	sPAP	20	75	SD 24 p=0.02	Response to epoprostenol
		Baseline	TRV	20	4.2	SD 0.6	Response to epoprostenol
		22.7 ± 9.3 mo	TRV	20	3.8	SD 0.7 p=0.02	Response to epoprostenol
Ogawa, 2012 <sup>167</sup>  Patients with pulmonary veno-occlusive disease or pulmonary capillary hemangiomatosis (N=8)  Fair	Mean 26.0 (SD 3.1)	Baseline	BNP	8	381.3	SD 136.8	Response to epoprostenol
		12 mo	BNP	8	55.2	14.4 p=0.05	Response to epoprostenol



**Table 18. Studies reporting changes in mean values over time (continued)**

Study Population (N) Quality	Age (Variability)	Timing	Index Test	N	Mean	Variability	Clinical Scenario
Sebbag, 2001 <sup>146</sup>  Adults and children with PPH (N=16)  Good	Mean 43 (SD 16)	Baseline	RIMP/MPI/Tei index	16	0.72	SD 0.22	Response to epoprostenol
		5.9 ± 4.6 mo	RIMP/MPI/Tei index	16	0.64	SD 0.17 p=0.05	Response to epoprostenol
		Baseline	sPAP	16	108	SD 19	Response to epoprostenol
		5.9 ± 4.6 mo	sPAP	16	94	SD 22 p=0.03	Response to epoprostenol
Simeoni, 2008 <sup>58</sup>  Adults with systemic sclerosis and PH (N=20)  Good	Median 55 (Range 40 to 70)	Baseline	BNP	10	23.4 pmol/L	Range 11.1 to 38	Response to bosentan
		3 mo	BNP	10	26	Range 4.54 to 144 p=0.953	Response to bosentan
		7 mo	BNP	10	15.7	Range 6 to 79 p=0.600	Response to bosentan
Taguchi, 2012 <sup>168</sup>  Patients with IPAH (N=65)  Good	Mean 40 (SD 13)	Baseline	BNP	65	248	SD 327	Response to combination therapy
		Mean followup 37 ± 17 mo	BNP	65	46	SD 59 p=0.085	Response to combination therapy
Takatsuki, 2012 <sup>172</sup>  Children with PAH (N=33)  Good	Median 10 (Range 4 to 18)	Baseline	TRJ velocity	21	4.1	SD 0.7	Response to tadalafil
		9.0 ± 7.2 mo	TRJ velocity	21	3.9	SD 0.8 p=NS	Response to tadalafil
		Baseline	RV size	19	24.5	SD 10.1	Response to tadalafil
		9.0 ± 7.2 mo	RV size	19	23.6	SD 8.8 p=NS	Response to tadalafil
		Baseline	BNP	24	102.2	SD 283.3	Response to tadalafil
		9.0 ± 7.2 mo	BNP	24	100.2	SD 160 p=NS	Response to tadalafil

**Table 18. Studies reporting changes in mean values over time (continued)**

Study Population (N) Quality	Age (Variability)	Timing	Index Test	N	Mean	Variability	Clinical Scenario
Takatsuki, 2012 <sup>173</sup> Children with PAH (N=38) Good	Median 11 (Range 2-18)	Baseline	BNP	15	49	SD 34	Response to transition to ambrisentan
		Median followup 20 mo	BNP	15	72	SD 47 p=NS	Response to transition to ambrisentan
		Baseline	BNP	23	81	SD 105	Response to the addition of ambrisentan
		Median followup 20 mo	BNP	23	53	SD 41 p=NS	Response to the addition of ambrisentan
Yang, 2012 <sup>169</sup> Patients with Eisenmenger syndrome (N=12) Fair	Mean 33.2 (SD 12.1)	Baseline	RV size	12	53.7	SD 4.8	Response to iloprost
		Mean followup 18.6 ± 7.4 mo	RV size	12	51.4	SD 3.9 p=0.068	Response to iloprost
		Baseline	mPAP	12	62.8	SD 13.7	Response to iloprost
		Mean followup 18.6 ± 7.4 mo	mPAP	12	58.9	SD 11.7 p=0.059	Response to iloprost

ANP = A-type natriuretic peptide; BNP = B-type natriuretic peptide; CHD = congenital heart disease; CTD = connective tissue disease; CO = cardiac output; cTnT = cardiac troponin T; CVD = collagen vascular disease; FAC = fractional area change; mPAP = mean pulmonary artery pressure; mo = month/months; MPI = myocardial performance index; NR = not reported; PVR = pulmonary vascular resistance; RA = right atrium; RIMP = right index of myocardial performance; RV = right ventricle; SD = standard deviation; SEM = standard error of the mean; sPAP = systolic pulmonary artery pressure; TAPSE = tricuspid annular plane systolic excursion; TRV = tricuspid regurgitant jet velocity; wk=week/weeks; yr=year/years

The four studies that assessed change in median levels of BNP in response to therapy with bosentan showed decrease by approximately half after 3 to 12 months of therapy (Table 19).<sup>97,120,164,166</sup> However, one of these studies subsequently showed increasing levels of BNP after 30 months of therapy.<sup>120</sup> One study showed an overall moderate decrease in median RIMP/MPI/Tei index levels after 30 months of therapy but no significant change in median values of sPAP, FAC, or RVEF after 30 months of therapy.<sup>120</sup>

**Table 19. Studies reporting changes in median levels over time**

Study Population (N) Quality	Age (Variability)	Timing	Index Test	N	Median	Variability (Range)	Clinical Scenario
Dimitroulas, 2007 <sup>97</sup>  Adults with PAH associated with scleroderma (N=10)  Good	Median 58 (Range 39 to 74)	Baseline	Natriuretic peptides/BNP	10	474		Response to bosentan
		20 wk	Natriuretic peptides/BNP	10	238	198-335 (p=0.002 compared with baseline)	Response to bosentan
Halank, 2011 <sup>164</sup>  Adults with portopulmonary hypertension (N=14)  Fair	Median 57 (Range 46 to 63)	Baseline	NT-proBNP	11	1226 pg/mL	113 to 2521	Response to ambrisentan
		12 mo	NT-proBNP	11	224	59 to 583	Response to ambrisentan
Ho, 2009 <sup>120</sup>  Adults with PAH (N=6)  Good	Mean 33 (NR)	Baseline	RIMP/MPI/Tei index	6	0.85	0.49 to 1.75	Response to bosentan
		6 mo	RIMP/MPI/Tei index	6	0.55	0.22 to 0.81	Response to bosentan
		1 yr	RIMP/MPI/Tei index	6	0.63	0.33 to 1.49	Response to bosentan
		18 mo	RIMP/MPI/Tei index	4	0.70	0.26 to 1.10	Response to bosentan
		2 yr	RIMP/MPI/Tei index	4	0.73	0.62 to 1.08	Response to bosentan
		30 mo	RIMP/MPI/Tei index	4	0.67	0.45 to 1.16	Response to bosentan
		Baseline	sPAP	6	98	50 to 163	Response to bosentan
		6 mo	sPAP	6	103	37 to 142	Response to bosentan
		1 yr	sPAP	6	92	42 to 127	Response to bosentan
		18 mo	sPAP	4	118	28 to 143	Response to bosentan
		2 yr	sPAP	4	118	61 to 136	Response to bosentan
		30 mo	sPAP	4	108	87 to 117	Response to bosentan
		Baseline	Fractional area change	6	22	13 to 28	Response to bosentan
		6 mo	Fractional area change	6	27	15 to 54	Response to bosentan

**Table 19. Studies reporting changes in median levels over time (continued)**

Study Population (N) Quality	Age (Variability)	Timing	Index Test	N	Median	Variability (Range)	Clinical Scenario
Ho, 2009 <sup>120</sup>  Adults with PAH (N=6)  Good (continued)		1 yr	Fractional area change	6	26	9 to 49	Response to bosentan
		18 mo	Fractional area change	4	35	26 to 53	Response to bosentan
		2 yr	Fractional area change	4	27	16 to 33	Response to bosentan
		30 mo	Fractional area change	4	21	19 to 45	Response to bosentan
		Baseline	Natriuretic peptides/BNP	6	224	20 to 169	Response to bosentan
		6 mo	Natriuretic peptides/BNP	6	111	13 to 231	Response to bosentan
		1 yr	Natriuretic peptides/BNP	6	136	5 to 249	Response to bosentan
		18 mo	Natriuretic peptides/BNP	4	215	14 to 352	Response to bosentan
		2 yr	Natriuretic peptides/BNP	4	193	92 to 293	Response to bosentan
		30 mo	Natriuretic peptides/BNP	4	203	81 to 376	Response to bosentan
		Baseline	RVEF	6	30	14 to 35	Response to bosentan
		6 mo	RVEF	6	39	17 to 71	Response to bosentan
		1 yr	RVEF	6	35	15 to 60	Response to bosentan
		1 yr	RVEF	6	32	15 to 83	Response to bosentan
		18 mo	RVEF	4	45	31 to 77	Response to bosentan
		2 yr	RVEF	4	38	20 to 50	Response to bosentan
		30 mo	RVEF	4	28	24 to 62	Response to bosentan
Kopeck, 2012 <sup>166</sup>  Adults with Eisenmenger syndrome (N=7)  Fair	Median 40.0 (Range 30.0 to 56.0)	Baseline	Natriuretic peptides/BNP	7	260.8	190.6 to 502.9	Response to bosentan
		3 mo	Natriuretic peptides/BNP	7	169	144.9 to 341.8 p=0.02	Response to bosentan
		Baseline	Endothelin-1	7	2.5	1.7 to 2.8	Response to bosentan
		3 mo	Endothelin-1	7	4.5	2.6 to 5.3 p=0.02	Response to bosentan

BNP = B-type natriuretic peptide; mo = month/months; NR = not reported; RVEF = right ventricle ejection fraction;  
wk = week/weeks; yr = year/years

Seven studies assessed mean change from baseline for BNP or various echocardiographic parameters (Table 20). One study evaluated response to therapy with epoprostenol over 3 months and showed mild increase in RV size, decrease in FAC, and minimal decrease in TR jet velocity.<sup>116</sup> Another study evaluated response to 4 months of therapy with bosentan or sildenafil and showed—in response to bosentan—decrease in RV size, minimal increase in CI, minimal decrease in RIMP/MPI/Tei index, increase in RA size, decrease in BNP, and decrease in RV size, and—in response to sildenafil—greater decrease in RV size, RIMP/MPI/Tei index and BNP and decrease in RA size but similar response in CI.<sup>156</sup> Another study showed decrease in mean BNP levels after 6 months of therapy with ambrisentan.<sup>171</sup> Two studies showed decrease in median levels of BNP in response to treprostinil after 6 weeks with some attenuation of response after 3 months<sup>131</sup> and after 6 months of therapy with ambrisentan.<sup>131</sup> Three studies showed a decrease from baseline for mean levels of mPAP, one after 3 months therapy with bosentan,<sup>94</sup> one after 3 months therapy with epoprostenol<sup>85</sup> and one with persistently declining levels during 3 years of therapy with ambrisentan.<sup>174</sup>

**Table 20. Studies reporting mean or median change from baseline**

Study Population (N) Quality	Age (Variability)	Timing	Result	Index Test	N	Results	Variability	Clinical Scenario
Badesch, 2012 <sup>171</sup> Adults with PAH (N=224) Good	Mean 55 (SD 16)	Baseline	Mean	Natriuretic peptides/ BNP	224	335	SD 413	Response to ambrisentan
		6 mo	Mean change	Natriuretic peptides/ BNP	224	-26	95% CI -34 to -16	Response to ambrisentan
Barst, 1996 <sup>85</sup> Adults with PPH (N=81) Good	NR for cohort	3 mo	Mean change	mPAP	41	-4.8	SE 1.3	Response to epoprostenol
Channick, 2001 <sup>94</sup> Adults with PPH or PAH associated with scleroderma (N=32) Good	NR for cohort	3 mo	Mean change	mPAP	20	-1.6	SE 1.2	Response to bosentan
Hinderliter, 1997 <sup>116</sup> Adults with PPH (N=81) Fair	NR for cohort	Baseline	Mean	RV size	38	21.2	SE 0.7	Response to epoprostenol
		Baseline	Mean	Fractional area change	38	19.2	SE 1.2	Response to epoprostenol
		Baseline	Mean	TR jet velocity	36	4.3	SE 0.1	Response to epoprostenol
		3 mo	Median change	RV size	33	0.4		Response to epoprostenol
		3 mo	Median change	Fractional area change	33	-2.2		Response to epoprostenol
		3 mo	Median change	TR jet velocity	32	-0.04		Response to epoprostenol
McLaughlin, 2010 <sup>131</sup> Adults with PAH (N=235) Good	Mean 54 (Range 18 to 75)	6 wk	Median change	Natriuretic peptides/ BNP	86	-71	p<0.0003	Response to treprostinil
		3mo	Median change	Natriuretic peptides/ BNP	73	-57	IQR -396.0 to 34.0	Response to treprostinil

**Table 20. Studies reporting mean or median change from baseline (continued)**

Study Population (N) Quality	Age (Variability)	Timing	Result	Index Test	N	Results	Variability	Clinical Scenario
Wilkins, 2005 <sup>156</sup>  Adults with IPAH or PAH associated with CTD (N=26)  Good	NR for cohort	4 mo	Mean change	RV size	12	-3	95% CI -7.5 to 1.5	Response to bosentan
		4 mo	Mean change	Cardiac Index	12	0.3	95% CI 0.1 to 0.4 p=0.01	Response to bosentan
		4 mo	Mean change	RIMP/MPI/Tei Index	12	-0.02	95% CI -0.1 to 0.11	Response to bosentan
		4 mo	Mean change	RA size	12	4	95% CI -16 to 23	Response to bosentan
		4 mo	Mean change	Natriuretic peptides/ BNP	12	-5.9	95% CI -35 to 24	Response to bosentan
		4 mo	Mean change	RV size	13	-8.8	95% CI -16 to -2 p=0.05	Response to sildenafil
		4 mo	Mean change	Cardiac Index	13	0.3	95% CI 0.1 to 0.4 p=0.01	Response to sildenafil
		4 mo	Mean change	RIMP/MPI/Tei Index	13	-0.11	95% CI -0.23 to 0.01	Response to sildenafil
		4 mo	Mean change	RA size	13	-4	95% CI -19 to 12	Response to sildenafil
		4 mo	Mean change	Natriuretic peptides/ BNP	13	-19.4	95% CI -34 to -5	Response to sildenafil

**Table 20. Studies reporting mean or median change from baseline (continued)**

Study Population (N) Quality	Age (Variability)	Timing	Result	Index Test	N	Results	Variability	Clinical Scenario
Yoshida, 2012 <sup>174</sup>  Adults with PAH (N=21)  Fair	Mean 45.6 (SD 12.6)	Baseline	Mean	Natriuretic peptides/	21	191.1	SD 241.4	Response to ambrisentan
		Baseline	Mean	mPAP	20	48.1	SD 17	Response to ambrisentan
		6 mo	Mean change	Natriuretic peptides/	20	-109.5	SD 170.5	Response to ambrisentan
		6 mo	Mean change	mPAP	21	-10	SD 7.4 95% CI -13.5 to -6.4	Response to ambrisentan
		1 yr	Mean change	Natriuretic peptides/	21	-70.4	SD 211.5	Response to ambrisentan
		1 yr	Mean change	mPAP	19	-7.1	SD 10.1 95% CI -11.9 to -2.2	Response to ambrisentan
		2 yr	Mean change	Natriuretic peptides/	19	-117.1	SD 183.8	Response to ambrisentan
		2 yr	Mean change	mPAP	16	-10.9	SD 10.8 95% CI -16.6 to -5.1	Response to ambrisentan
		3 yr	Mean change	Natriuretic peptides/	6	-146.5	SD 218.6	Response to ambrisentan
		3 yr	Mean change	mPAP	6	-13.9	SD 8.9 95% CI -23.2 to -4.5	Response to ambrisentan

BNP = B-type natriuretic peptide; CI = confidence interval; IQR = interquartile range; mPAP = mean pulmonary artery pressure; mo = month/months; MPI = myocardial performance index; NR = not reported; PVR = pulmonary vascular resistance; RA = right atrium; RIMP = right index of myocardial performance; RV = right ventricle; RVEF = right ventricle ejection fraction; SD = standard deviation; SEM = standard error of the mean; sPAP = systolic pulmonary artery pressure; TAPSE = tricuspid annular plane systolic excursion; TRV = tricuspid regurgitant jet velocity; wk = week/weeks; yr = year/years



## Summary Strength of Evidence for KQ 2

The strength of evidence ratings for the most commonly reported biomarkers and echocardiographic parameters are summarized in Table 21 (assessment of prognostic value) and Table 22 (assessment of predictive value).

**Table 21. Summary strength of evidence for KQ 2: assessment of prognostic value**

Comparison	Number of Studies (Patients)	Domains				Strength of Evidence Correlation Coefficient (95% CI)
		Risk of Bias	Consistency	Directness	Precision	
<b>BNP compared with RHC-mPAP</b>	14 (606)	Low (12) Moderate (1) High (1)	Consistent	Indirect	Precise	<b>SOE = Moderate</b> 0.39 (0.31 to 0.47) Serum BNP level shows moderate correlation with mPAP
<b>BNP compared with RHC-PVR</b>	13 (684)	Low (11) Moderate (1) High (1)	Inconsistent	Indirect	Precise	<b>SOE = Low</b> 0.46 (0.31 to 0.59) Serum BNP level shows moderate correlation with PVR
<b>BNP compared with RHC-RAP</b>	12 (645)	Low (11) Moderate (1)	Consistent	Indirect	Precise	<b>SOE = Moderate</b> 0.47 (0.40 to 0.54) Serum BNP level shows moderate correlation with RAP
<b>BNP compared with RHC-CI</b>	10 (550)	Low (9) Moderate (1)	Inconsistent	Indirect	Precise	<b>SOE = Low</b> -0.42 (-0.54 to -0.28) Serum BNP level shows negative moderate correlation with cardiac index
<b>BNP compared with RHC-PCWP</b>	5 (319)	Low (4) High (1)	Consistent	Indirect	Imprecise	<b>SOE = Low</b> 0.16 (0.01 to 0.31) Serum BNP level shows poor correlation with PCWP
<b>BNP compared with 6MWD (absolute)</b>	9 (484)	Low (8) High (1)	Inconsistent	Direct	Precise	<b>SOE = Moderate</b> -0.46 (-0.55 to -0.35) Serum BNP level shows negative moderate correlation with 6MWD
<b>Echocardiography-derived sPAP compared with RHC-sPAP</b>	9 (362)	Low (6) Moderate (3)	Inconsistent	Indirect	Precise	<b>SOE = Low</b> 0.76 (0.53 to 0.89) sPAP estimated by echocardiography shows good correlation with sPAP from RHC

6MWD = 6-minute walk distance; BNP = B-type natriuretic peptide; CI = confidence interval; PCWP = pulmonary capillary wedge pressure; PVR = pulmonary vascular resistance; RAP = right atrial pressure; RHC = right heart catheterization; SOE = strength of evidence; sPAP = systolic pulmonary artery pressure

**Table 22. Summary strength of evidence for KQ 2: assessment of predictive value**

Comparison	Number of Studies (Patients)	Domains				Strength of Evidence Hazard Ratio (95% CI)
		Risk of Bias	Consistency	Directness	Precision	
<b>BNP (log-transformed)</b>	6 (407)	Low (5) Moderate (1)	Consistent	Direct	Imprecise	<b>SOE = Moderate</b> 2.42 (1.72 to 3.41)) Increase in log-transformed BNP level is a good predictor of mortality
<b>Pericardial effusion</b>	8 (2590)	Low (5) Moderate (3)	Inconsistent	Direct	Imprecise	<b>SOE = Moderate</b> 2.43 (1.57 to 3.77) Presence of pericardial effusion is a strong predictor of mortality, although there was wide variability in results for this measure
<b>RA size</b>	4 (242)	Low (2) Moderate (2)	Inconsistent	Direct	Precise	<b>SOE = Moderate</b> 1.06 (1.01 to 1.10) RA size is a predictor of mortality
<b>FAC</b>	4 (242)	Low (2) Moderate (2)	Consistent	Direct	Precise	<b>SOE = Moderate</b> 0.98 (0.96 to 1.01) FAC is a poor predictor of mortality
<b>Uric acid</b>	4 (246)	Low (3) Moderate (1)	Inconsistent	Direct	Imprecise	<b>SOE = Low</b> 1.01 (1.00 to 1.01) Small increase in mortality but imprecision of estimates limit these data
<b>TAPSE</b>	4 (251)	Low (3) Moderate (2)	Inconsistent	Direct	Imprecise	<b>SOE = Insufficient</b> Inconsistent results between studies lead to uncertainty

BNP = B-type natriuretic peptide; CI = confidence interval; FAC = fractional area change; RA = right atrium; RAP = right atrial pressure; SOE=strength of evidence

## KQ 3: Pharmacotherapy for PAH

For patients with PAH, what are the comparative effectiveness and safety of monotherapy or combination therapy for PAH using calcium channel blockers, prostanoids, endothelin antagonists, or phosphodiesterase inhibitors on intermediate-term and long-term patient outcomes?

### Key Points

- In patients who have been receiving monotherapy, combination therapy appears to be moderately more effective than continuation of monotherapy for improving 6-minute walk distance (6MWD), with a magnitude of effect that is approximately equal to the estimated minimal important difference (MID) of 6MWD for PAH of 33 meters (low strength of evidence).
- We did not identify any eligible studies that evaluated the comparative effectiveness of calcium channel blockers on intermediate-term and long-term patient outcomes, or that randomized treatment-naïve patients to monotherapy versus combination therapy, or that directly compared two drug classes.
- Although we did not intend to exclude studies of children, the inclusion criterion requiring reporting intermediate-term and long-term patient outcomes had the effect of eliminating randomized clinical trials of children with PAH.
- Prostanoids were associated with lower mortality when compared with standard therapy or placebo (low strength of evidence). Current evidence is inconclusive regarding a reduction in mortality associated with treatment with endothelin antagonists or phosphodiesterase inhibitors (insufficient strength of evidence).
- Endothelin antagonists, phosphodiesterase inhibitors, and prostanoids were all associated with improved 6MWD after 8 to 16 weeks of therapy with a magnitude of effect that is approximately equal to the estimated minimal important difference (MID) of 6MWD for PAH of 33 meters (moderate strength of evidence).
- Endothelin antagonists and phosphodiesterase inhibitors were associated with lower incidence of hospitalization when compared with standard therapy or placebo (moderate strength of evidence). Current evidence is inconclusive regarding a reduction in hospitalization associated with treatment with prostanoids (insufficient strength of evidence).
- Endothelin antagonists, phosphodiesterase inhibitors, and prostanoids were associated with statistically significant improvements in most or all hemodynamic measures such as PVR, mPAP, and cardiac index (low strength of evidence) compared with placebo or standard therapy. The clinical significance of the magnitude of the observed changes in these intermediate outcomes is unclear.
- Among commonly reported adverse events, there was a higher incidence of jaw pain associated with aerosolized prostanoid treatment compared with placebo (high strength of evidence) and cough associated with aerosolized prostanoids versus placebo (high strength of evidence). In addition, headache was associated with phosphodiesterase inhibitors compared with placebo or standard therapy (moderate strength of evidence), and flushing was associated with phosphodiesterase inhibitors (moderate strength of evidence).

evidence) and aerosolized prostanoids (moderate strength of evidence) compared with placebo or standard therapy.

## Description of Included Studies

We identified 37 unique studies involving a total of 4192 patients that evaluated the comparative effectiveness and safety of monotherapy or combination therapy for PAH. Of these studies, 28 were RCTs and 9 were nonrandomized comparative observational studies. We describe the findings from these studies separately by study design below.

## Study Characteristics

### Randomized Controlled Trials

Twenty-eight RCTs involving a total of 3613 patients evaluated the comparative effectiveness and safety of monotherapy or combination therapy for PAH.<sup>85,88,94,106,131,156,181-200</sup> Of these, 28 RCTs, 18 (64%) were rated good quality, 9 (32%) fair quality, and 1 (4%) was poor quality. Nineteen studies (68%) were funded by industry, one by private foundation, one by government and private funding, one by private and industry funding, one by industry and “other” funding, and five did not clearly report funding sources.

Study characteristics for each of the 28 RCTs relevant to KQ 3 are presented in Table 23. Studies are organized alphabetically by drug and include patient population, size, and quality; study arms and size; trial duration and followup; and outcome measures. The mean patient ages ranged from 28 to 50 years old. Twenty studies enrolled patients with PAH,<sup>85,88,106,131,156,181,182,184,186-189,192,193,196-200</sup> four studies enrolled patients with PAH associated with systemic sclerosis (formerly scleroderma),<sup>94,185,194</sup> and two studies enrolled patients with Eisenmenger syndrome.<sup>183,195</sup> Two studies enrolled a minority of patients with PH other than PAH: one included patients with chronic thromboembolic PH (28%);<sup>190</sup> and another included patients with PH owing either to lung disease or chronic thromboembolic PH (37%).<sup>191</sup>

Twenty-one studies compared a single drug (monotherapy) with placebo or standard therapy and included the following drugs: bosentan (6 studies), sildenafil (2), iloprost (2), epoprostenol (3), tadalafil (3), ambrisentan (2), treprostinil (3), and vardenafil (1). For the purposes of this analysis, the standard therapy arms were grouped with the placebo arms. Standard therapies included supportive therapy (diuretics, oxygen, digoxin, oral anticoagulants) with or without calcium channel blockers, but not including newer specific vasodilator medications. One study was a head-to-head comparison of bosentan and sildenafil. The remaining five studies randomized patients who had previously received monotherapy to either continued monotherapy with that drug or continued therapy with that drug plus the addition of a second drug. For the purpose of this report, we consider these studies to represent a comparison of combination therapy with monotherapy—with the understanding that this study design does not address the question of whether initiating two drugs is superior to initiating a single drug to treatment-naïve patients.

The remaining five studies compared combination therapy with monotherapy: intravenous (IV) epoprostenol plus bosentan versus IV epoprostenol plus placebo, sildenafil plus IV epoprostenol versus IV epoprostenol plus placebo, bosentan plus aerosolized iloprost versus bosentan, bosentan plus aerosolized iloprost versus bosentan plus placebo, and aerosolized treprostinil plus bosentan or sildenafil versus bosentan or sildenafil plus placebo. We did not

identify any eligible studies published after 1990 that evaluated the safety or efficacy of calcium channel blockers on intermediate-term or long-term patient outcomes.

Most studies (85%) were multicenter trials; three were single-center trials, and four did not report the number of centers. Study locations included Europe (19 studies), United States (15), Asia (8), Canada (6), Australia or New Zealand (6), United Kingdom (4), South America (4), Israel (3), Mexico (3), Central America (2), Africa (1), and unreported or unclear setting (6).

The studies reported the following outcomes: 6MWD (27 studies), mortality (21), dyspnea (17), RHC indices (18), functional class (13), hospitalization for worsening PAH (10), quality of life (11), lung transplantation (5), right heart failure or right ventricular dysfunction (4), and brain natriuretic peptide (4). Twenty-one studies reported harms or adverse events.

**Table 23. Study characteristics table for KQ 3 (RCTs)**

Study Population (N) Quality	Study Arms (N)	Trial Duration (Weeks)	Followup Assessments (Weeks)	Outcome Measures
<b>AMBRISENTAN</b>				
<i>Individual Drug Studies</i>				
Galie, 2008 <sup>106</sup> ARIES-1 (US, Mexico, South America, Australia, and Europe)  PAH (N=201)  Good	<ul style="list-style-type: none"> <li>• Ambrisentan 5 mg daily (N=67)</li> <li>• Ambrisentan 10 mg daily (N=67)</li> <li>• Placebo (N=67)</li> </ul>	12	4, 8, 12, 48	<ul style="list-style-type: none"> <li>• Mortality</li> <li>• 6MWD</li> <li>• Dyspnea</li> <li>• Functional class</li> <li>• Quality of life</li> <li>• Hospitalization</li> <li>• BNP</li> <li>• Adverse events</li> </ul>
Galie, 2008 <sup>106</sup> ARIES-2 (Europe, Israel, and South America)  PAH (N=192)  Good	<ul style="list-style-type: none"> <li>• Ambrisentan 2.5 mg daily (N=64)</li> <li>• Ambrisentan 5 mg daily (N=63)</li> <li>• Placebo (N=65)</li> </ul>	12	4, 8, 12, 48	<ul style="list-style-type: none"> <li>• Mortality</li> <li>• 6MWD</li> <li>• Dyspnea</li> <li>• Functional class</li> <li>• Quality of life</li> <li>• Hospitalization</li> <li>• BNP</li> <li>• Adverse events</li> </ul>
<b>BOSENTAN</b>				
<i>Individual Drug Studies</i>				
Barst, 2010 <sup>185</sup> ASSET-1  SCD with PAH (N=14)  Fair	<ul style="list-style-type: none"> <li>• Bosentan 62.5 mg 2 times daily, then 125 mg 2 times daily (N=6)</li> <li>• Placebo (N=8)</li> </ul>	16	16	<ul style="list-style-type: none"> <li>• Mortality</li> <li>• 6MWD</li> <li>• RHC</li> </ul>
Barst, 2010 <sup>185</sup> ASSET-2  PH (N=12)  Fair	<ul style="list-style-type: none"> <li>• Bosentan 62.5 mg 2 times daily, then 125 mg 2 times daily (N=5)</li> <li>• Placebo (N=7)</li> </ul>	16	16	<ul style="list-style-type: none"> <li>• Mortality</li> <li>• 6MWD</li> <li>• RHC</li> </ul>
Channick, 2001 <sup>94</sup>  PPH or PH due to SCD (N=32)  Good	<ul style="list-style-type: none"> <li>• Bosentan 62.5 mg 2 times daily, then 125 mg 2 times daily (N=21)</li> <li>• Placebo (N=11)</li> </ul>	12	4, 8, 12, 20, 28	<ul style="list-style-type: none"> <li>• 6MWD</li> <li>• Dyspnea</li> <li>• Functional class</li> <li>• Transplantation</li> <li>• RHC</li> <li>• Adverse events</li> </ul>

**Table 23. Study characteristics table for KQ 3 (RCTs) (continued)**

Study Population (N) Quality	Study Arms (N)	Trial Duration (Weeks)	Followup Assessments (Weeks)	Outcome Measures
<b>BOSENTAN (continued)</b>				
<b>Individual Drug Studies</b>				
Galie, 2006 <sup>183</sup> BREATHE-5  Eisenmenger syndrome (N=54)  Good	<ul style="list-style-type: none"> <li>• Bosentan 62.5 mg 2 times daily, then 125 mg 2 times daily (N=37)</li> <li>• Placebo (N=17)</li> </ul>	4	4	<ul style="list-style-type: none"> <li>• 6MWD</li> <li>• Functional class</li> <li>• RHC</li> <li>• Adverse events</li> </ul>
Galie, 2008 <sup>184</sup> EARLY  PAH (N=185)  Good	<ul style="list-style-type: none"> <li>• Bosentan 62.5 mg 2 times daily, then 125 mg 2 times daily (N=93)</li> <li>• Placebo (N=92)</li> </ul>	24	24	<ul style="list-style-type: none"> <li>• Mortality<sup>a</sup></li> <li>• 6MWD<sup>a</sup></li> <li>• Dyspnea<sup>a</sup></li> <li>• Functional class<sup>a</sup></li> <li>• Quality of life<sup>a</sup></li> <li>• Hospitalization<sup>a</sup></li> <li>• RHC<sup>a</sup></li> <li>• Adverse events<sup>a</sup></li> </ul>
Rubin, 2002 <sup>182</sup> BREATHE  PAH (N=213)  Good	<ul style="list-style-type: none"> <li>• Bosentan 62.5 mg 2 times daily, then 125 mg 2 times daily (N=74)</li> <li>• Bosentan 62.5 mg 2 times daily, then 250 mg 2 times daily (N=70)</li> <li>• Placebo (N=69)</li> </ul>	12	4, 8, 16	<ul style="list-style-type: none"> <li>• Mortality</li> <li>• 6MWD</li> <li>• Dyspnea</li> <li>• Functional class</li> <li>• Hospitalization</li> <li>• Echocardiography</li> <li>• Adverse events</li> </ul>
<b>Direct Drug Comparison Studies</b>				
Wilkins, 2005 <sup>156</sup> SERAPH  PAH (N=26)  Good	<ul style="list-style-type: none"> <li>• Bosentan 62.5 mg 2 times daily, then 125 mg 2 times daily (N=12)</li> <li>• Sildenafil 50 mg 2 times daily, then 50 mg 3 times daily (N=14)</li> </ul>	16	16	<ul style="list-style-type: none"> <li>• Mortality</li> <li>• 6MWD</li> <li>• Quality of life</li> <li>• Right ventricular dysfunction</li> <li>• Echocardiography</li> <li>• BNP</li> </ul>

**Table 23. Study characteristics table for KQ 3 (RCTs) (continued)**

Study Population (N) Quality	Study Arms (N)	Trial Duration (Weeks)	Followup Assessments (Weeks)	Outcome Measures
<b>BOSENTAN (continued)</b>				
<b>Combination Drug Studies</b>				
Humbert, 2004 <sup>186</sup> BREATHE-2  PAH (N=33)  Good	<ul style="list-style-type: none"> <li>• Epoprostenol + bosentan 62.5 mg 2 times daily, then 125 mg 2 times daily (N=22)</li> <li>• Epoprostenol + placebo (N=11)</li> </ul>	16	16	<ul style="list-style-type: none"> <li>• 6MWD</li> <li>• Dyspnea</li> <li>• Functional class</li> <li>• Hospitalization</li> <li>• Right heart failure</li> <li>• RHC</li> <li>• Adverse events</li> </ul>
<b>EPOPROSTENOL</b>				
<b>Individual Drug Studies</b>				
Badesch, 2000 <sup>194</sup>  PH associated with SCD spectrum of disease (N=111)  Fair	<ul style="list-style-type: none"> <li>• Epoprostenol <math>\leq 2</math> ng/kg, then adjusted (N=56)</li> <li>• Conventional therapy only (N=55)</li> </ul>	12	1, 6, 12	<ul style="list-style-type: none"> <li>• Mortality</li> <li>• 6MWD</li> <li>• Dyspnea</li> <li>• RHC</li> <li>• Adverse events</li> </ul>
Barst, 1996 <sup>85</sup>  PPH (N=81)  Good	<ul style="list-style-type: none"> <li>• Epoprostenol 4 ng/kg, then adjusted (N=41)</li> <li>• Conventional therapy only (N=40)</li> </ul>	12	1, 6, 12	<ul style="list-style-type: none"> <li>• Mortality</li> <li>• 6MWD</li> <li>• Quality of life</li> <li>• Transplantation</li> <li>• RHC</li> <li>• Adverse events</li> </ul>
Rubin, 1990 <sup>181</sup>  PPH (N=23)  Good	<ul style="list-style-type: none"> <li>• Intravenous epoprostenol 1–2 ng/kg per minute initially, then increased as tolerated (N=11)</li> <li>• Conventional therapy (N=12)</li> </ul>	8	8	<ul style="list-style-type: none"> <li>• Mortality</li> <li>• 6MWD</li> <li>• RHC</li> <li>• Adverse events</li> </ul>



**Table 23. Study characteristics table for KQ 3 (RCTs) (continued)**

Study Population (N) Quality	Study Arms (N)	Trial Duration (Weeks)	Followup Assessments (Weeks)	Outcome Measures
<b>ILOPROST</b>				
<b>Individual Drug Studies</b>				
Olschewski, 2002 <sup>190</sup>  Severe PAH or chronic thromboembolic PH (N=203)  Good	<ul style="list-style-type: none"> <li>• Aerosolized iloprost (N=101)</li> <li>• Placebo (N=102)</li> </ul>	12	4, 8, 12	<ul style="list-style-type: none"> <li>• Mortality</li> <li>• 6MWD</li> <li>• Dyspnea</li> <li>• Functional class</li> <li>• Quality of life</li> <li>• Transplantation</li> <li>• Right ventricular dysfunction</li> <li>• RHC</li> <li>• Adverse events</li> </ul>
Olschewski, 2010 <sup>191</sup> AIR  IPAH or other PH (N=63)  Fair	<ul style="list-style-type: none"> <li>• Aerosolized iloprost (N=30)</li> <li>• Conventional therapy only (N=33)</li> </ul>	12	12, 104	<ul style="list-style-type: none"> <li>• Mortality</li> <li>• 6MWD</li> <li>• Dyspnea</li> <li>• Functional class</li> <li>• Quality of life</li> <li>• Right heart failure</li> <li>• RHC</li> <li>• Adverse events</li> </ul>
<b>Combination Drug Studies</b>				
Hoeper, 2006 <sup>192</sup> COMBI  IPAH (N=40)  Fair	<ul style="list-style-type: none"> <li>• Bosentan 125 mg 2 times daily + aerosolized iloprost (N=19)</li> <li>• Bosentan 125 mg (N=21)</li> </ul>	12	6, 12	<ul style="list-style-type: none"> <li>• 6MWD</li> <li>• Adverse events</li> </ul>
McLaughlin, 2006 <sup>193</sup>  PAH (N=67)  Good	<ul style="list-style-type: none"> <li>• Bosentan + aerosolized iloprost (N=34)</li> <li>• Bosentan + placebo (N=33)</li> </ul>	12	4, 8, 12	<ul style="list-style-type: none"> <li>• 6MWD</li> <li>• Dyspnea</li> <li>• Functional class</li> <li>• Hospitalization</li> <li>• RHC</li> <li>• Adverse events</li> </ul>

**Table 23. Study characteristics table for KQ 3 (RCTs) (continued)**

Study Population (N) Quality	Study Arms (N)	Trial Duration (Weeks)	Followup Assessments (Weeks)	Outcome Measures
<b>SILDENAFIL</b>				
<b>Individual Drug Studies</b>				
Barst, 2011 <sup>188</sup> STARTS-1  PAH (N=234)  Fair	<ul style="list-style-type: none"> <li>• Low-dose sildenafil (N=42)</li> <li>• Medium-dose sildenafil (N=55)</li> <li>• High-dose sildenafil (N=77)</li> <li>• Placebo (N=60)</li> </ul>	16	16, >156	<ul style="list-style-type: none"> <li>• Mortality</li> <li>• Functional class</li> <li>• Quality of life</li> <li>• RHC</li> <li>• Adverse events</li> </ul>
Galie, 2005 <sup>187</sup> SUPER  PAH (N=277)  Good	<ul style="list-style-type: none"> <li>• Sildenafil 20 mg 3 times daily (N=69)</li> <li>• Sildenafil 40 mg 3 times daily (N=67)</li> <li>• Sildenafil 80 mg 3 times daily (N=71)</li> <li>• Placebo (N=70)</li> </ul>	12	4, 8, 12, 52, 156	<ul style="list-style-type: none"> <li>• Mortality</li> <li>• 6MWD</li> <li>• Dyspnea</li> <li>• Hospitalization</li> <li>• Adverse events</li> <li>• RHC</li> </ul>
<b>Combination Drug Studies</b>				
Simonneau, 2008 <sup>189</sup> PACES  PAH (N=267)  Good	<ul style="list-style-type: none"> <li>• Sildenafil 20 mg 3 times daily + epoprostenol, then up to 80 mg 3 times daily + epoprostenol (N=134)</li> <li>• Placebo + epoprostenol (N=133)</li> </ul>	16	4, 8, 12, 16	<ul style="list-style-type: none"> <li>• Mortality</li> <li>• Dyspnea</li> <li>• Quality of life</li> <li>• Hospitalization</li> <li>• Transplantation</li> <li>• Adverse events</li> </ul>
<b>TADALAFIL</b>				
<b>Individual Drug Studies</b>				
Bharani, 2007 <sup>88</sup>  PAH (N=11)  Fair	<ul style="list-style-type: none"> <li>• Tadalafil 20 mg daily (N=11)</li> <li>• Placebo 20 mg daily (N=11)</li> </ul>	4	4	<ul style="list-style-type: none"> <li>• 6MWD<sup>a</sup></li> <li>• Dyspnea<sup>a</sup></li> <li>• Functional class<sup>a</sup></li> <li>• Echocardiography<sup>a</sup></li> </ul>
Galie, 2009 <sup>196</sup> PHIRST  PAH (N=405)  Good	<ul style="list-style-type: none"> <li>• Tadalafil 2.5 mg daily (N=82)</li> <li>• Tadalafil 10 mg daily (N=82)</li> <li>• Tadalafil 20 mg daily (N=80)</li> <li>• Tadalafil 40 mg daily (N=79)</li> <li>• Placebo (N=82)<sup>b</sup></li> </ul>	16	4, 8, 12, 16	<ul style="list-style-type: none"> <li>• Mortality</li> <li>• 6MWD</li> <li>• Functional class</li> <li>• Hospitalization</li> <li>• RHC</li> <li>• Adverse events</li> </ul>

**Table 23. Study characteristics table for KQ 3 (RCTs) (continued)**

Study Population (N) Quality	Study Arms (N)	Trial Duration (Weeks)	Followup Assessments (Weeks)	Outcome Measures
<b>TADALAFIL (continued)</b>				
<b>Individual Drug Studies (continued)</b>				
Mukhopadhyay, 2011 <sup>195</sup>  Eisenmenger syndrome (N=28)  Fair	<ul style="list-style-type: none"> <li>Tadalafil 40 mg daily (N=28)</li> <li>Placebo (N=28)</li> </ul>	6	6	<ul style="list-style-type: none"> <li>6MWD<sup>a</sup></li> <li>RHC<sup>a</sup></li> </ul>
<b>TREPROSTINIL</b>				
<b>Individual Drug Studies</b>				
Hiremath, 2010 <sup>199</sup> TRUST  PAH (N=44)  Fair	<ul style="list-style-type: none"> <li>Intravenous treprostinil 4 ng/kg/min, then adjusted (N=30)</li> <li>Placebo (N=14)</li> </ul>	12	12	<ul style="list-style-type: none"> <li>Mortality</li> <li>6MWD</li> <li>Dyspnea</li> <li>Functional class</li> <li>Adverse events</li> </ul>
McLaughlin, 2003 <sup>198</sup>  PPH (N=26)  Poor	<ul style="list-style-type: none"> <li>Subcutaneous treprostinil 2.5-5.0 ng/kg/min, then adjusted (N=17)</li> <li>Placebo (N=9)</li> </ul>	8	8	<ul style="list-style-type: none"> <li>6MWD<sup>a</sup></li> <li>Dyspnea<sup>a</sup></li> <li>Adverse events<sup>a</sup></li> </ul>
Simonneau, 2002 <sup>197</sup>  PAH (N=470)  Good	<ul style="list-style-type: none"> <li>Subcutaneous treprostinil 1.25 ng/kg/min, then adjusted (N=233)</li> <li>Placebo (N=236)</li> </ul>	12	12	<ul style="list-style-type: none"> <li>Mortality</li> <li>6MWD</li> <li>Dyspnea</li> <li>Quality of life</li> <li>Transplantation</li> <li>Adverse events</li> </ul>

**Table 23. Study characteristics table for KQ 3 (RCTs) (continued)**

Study Population (N) Quality	Study Arms (N)	Trial Duration (Weeks)	Followup Assessments (Weeks)	Outcome Measures
<b>TREPROSTINIL (continued)</b>				
<b>Combination Drug Studies</b>				
McLaughlin, 2010 <sup>131</sup> TRIUMPH 1  Severe PAH (N=235)  Good	<ul style="list-style-type: none"> <li>Aerosolized treprostinil 18 mcg 4 times daily, gradually increased to 54 mcg+ bosentan/ sildenafil (N=115)</li> <li>Placebo + bosentan/sildenafil (N=120)</li> </ul>	12	6, 12	<ul style="list-style-type: none"> <li>Mortality</li> <li>6MWD</li> <li>Dyspnea</li> <li>Functional class</li> <li>Quality of life</li> <li>Hospitalization</li> <li>Transplantation</li> <li>BNP</li> <li>Adverse events</li> </ul>
<b>VARDENAFIL</b>				
<b>Individual Drug Studies</b>				
Jing, 2011 <sup>200</sup> EVALUATION  PAH (N=66)  Good	<ul style="list-style-type: none"> <li>Vardenafil 5 mg daily, then 5 mg 2 times daily (N=44)</li> <li>Placebo (N=22)</li> </ul>	12	12, 24	<ul style="list-style-type: none"> <li>Mortality</li> <li>6MWD</li> <li>Dyspnea</li> <li>Functional class</li> <li>Hospitalization</li> <li>RHC</li> <li>Adverse events</li> </ul>

6MWD = 6 minute walk distance; IPAH = idiopathic PAH; mg = milligram; PAH = pulmonary arterial hypertension; PH = pulmonary hypertension; PPH = Primary pulmonary hypertension; RHC = right heart catheterization; SCD = scleroderma

<sup>a</sup>Outcome not assessed at 12 or 16 weeks.

<sup>b</sup>53 percent of patients received bosentan as background therapy.

## Nonrandomized Comparative Observational Studies

We identified 9 nonrandomized observational studies involving 579 patients.<sup>119,201-208</sup> Of these, all were case series studies rated fair quality (Table 24). Four studies were retrospective, and five collected data prospectively. Epoprostenol was evaluated in six studies; iloprost, bosentan, treprostinil, and sildenafil in two studies each. Four studies directly compared two different monotherapies: one study compared bosentan with iloprost, two studies compared epoprostenol with treprostinil, and one study compared epoprostenol with iloprost. One study compared the combination of first-line epoprostenol and bosentan with epoprostenol monotherapy.

We do not discuss these nonrandomized comparative studies further in this report because the size and quality of the nonrandomized comparative studies compared poorly with the randomized trial data we identified. Although these studies offer the potential to address certain between-treatment comparisons that were not evaluated in RCTs and, in some cases, describe a longer duration of followup beyond that reported in the randomized trials, we assessed their limitations of poorly specified comparison (control) treatments and selection bias in treatment allocation combined with a lack of power from small size so severe as to make these data unusable.

**Table 24. Study characteristics table for KQ 3 (nonrandomized studies)**

Study Study Type Population (N) Quality	Study Arms (N)	Study Review Range	Followup Assessments (Months)	Outcome Measures
Higenbottam, 1993 <sup>208</sup>  Prospective case series  Severe pulmonary hypertension  Fair	<ul style="list-style-type: none"> <li>Epoprostenol, initial mean dose 5.2 (0.5) ng/kg/min, then titrated up to mean 18.7 (4.5) ng/kg/min (N=25)</li> <li>No epoprostenol (N=19)</li> </ul>	6-year period before 1993	12, 24, 36, 48	<ul style="list-style-type: none"> <li>Mortality</li> <li>Progression to transplant</li> </ul>
Fix, 2007 <sup>201</sup>  Retrospective case series  Porto-pulmonary hypertension (N=36)  Fair	<ul style="list-style-type: none"> <li>Epoprostenol 1 ng/kg/min, then titrated to mean dose of 29 ng/kg/min (N=19)</li> <li>Non-epoprostenol (N=17)</li> </ul>	1998–2005	2 to 95	<ul style="list-style-type: none"> <li>Mortality</li> <li>RHC</li> <li>Adverse events</li> </ul>
Hoepfer, 2007 <sup>202</sup>  Retrospective case series  Porto-pulmonary hypertension and cirrhosis (N=31)  Fair	<ul style="list-style-type: none"> <li>Bosentan 62.5 mg 2 times daily x 4 weeks, then 125 mg 2 times daily thereafter (N=18)</li> <li>Aerosolized iloprost 5 mcg 6 times daily (N=13)</li> </ul>	1999–2004	3, 6, 12, 18, 24, 30, 36	<ul style="list-style-type: none"> <li>Mortality</li> <li>6MWD</li> <li>Functional class</li> <li>Event-free survival</li> <li>RHC</li> <li>Adverse events</li> </ul>

**Table 24. Study characteristics table for KQ 3 (nonrandomized studies) (continued)**

Study Study Type Population (N) Quality	Study Arms (N)	Study Review Range	Followup Assessments (Months)	Outcome Measures
Sastry, 2007 <sup>204</sup>  Prospective case series  IPAH (N=178)  Fair	<ul style="list-style-type: none"> <li>Conventional therapy (historical control) (N=39)</li> <li>Conventional therapy + sildenafil 25-50 mg 3 times daily (N=139)</li> </ul>	1999–2005	12, 24, 36, 48, 60	<ul style="list-style-type: none"> <li>Mortality</li> </ul>
Jacobs, 2009 <sup>119</sup>  Prospective case series  IPAH (N=16)  Fair	<ul style="list-style-type: none"> <li>Epoprostenol titrated to 6-8 ng/kg/min after 1 week (N=6)</li> <li>Treprostinil gradually increased to 10 ng/kg/min after 1 week, then 20 ng/kg/min after 6 weeks (N=10)</li> </ul>	2002–2007	4, 6	<ul style="list-style-type: none"> <li>Mortality</li> <li>6MWD</li> <li>Functional class</li> <li>Natriuretic peptides</li> <li>Adverse events</li> </ul>
Reichenberger, 2011 <sup>203</sup>  Prospective case series  IPAH, PAH, portopulmonary hypertension (N=24)  Fair	<ul style="list-style-type: none"> <li>Epoprostenol gradually increased to maximum tolerated dose (N=12)</li> <li>Aerosolized iloprost gradual titration up to 20 mcg per breath, maximum 120 mcg total daily dose (N=12)</li> </ul>	NR	3, 12, 18, 20	<ul style="list-style-type: none"> <li>Mortality</li> <li>6MWD</li> <li>Functional class</li> <li>RHC</li> <li>Progression to transplant</li> <li>Adverse events</li> </ul>
Zeng, 2011 <sup>205</sup>  Retrospective case series  IPAH (N=77)  Fair	<ul style="list-style-type: none"> <li>Conventional therapy (N=26)</li> <li>Sildenafil 25 mg 3 times daily (N=51)</li> </ul>	2005–2009	12, 24, 36	<ul style="list-style-type: none"> <li>Mortality</li> <li>6MWD</li> <li>Dyspnea</li> <li>RHC</li> <li>BNP</li> </ul>
Kemp, 2012 <sup>206</sup>  Retrospective case series  Idiopathic, heritable, or anorexigen- associated PAH (N=69)  Fair	<ul style="list-style-type: none"> <li>Epoprostenol/bosentan combined (n=23)</li> <li>Epoprostenol monotherapy (n=46)</li> </ul>	2001–2008	96	<ul style="list-style-type: none"> <li>Mortality</li> <li>6MWD</li> <li>Functional class</li> <li>RHC</li> </ul>
Rich, 2012 <sup>207</sup>  Prospective cohort  PAH (N=120)  Fair	<ul style="list-style-type: none"> <li>IV Treprostinil in Epoprostenol diluent (n=25)</li> <li>IV Epoprostenol in Epoprostenol diluent (n=61)</li> <li>IV Treprostinil in native diluent (n=34)</li> </ul>	2009–2010	NR (56,563 treatment days)	<ul style="list-style-type: none"> <li>Adverse events</li> </ul>

6MWD = 6 minute walk distance; BNP = brain natriuretic peptide; IPAH = idiopathic PAH; IV = intravenous; mcg=microgram; NR = not reported; PAH = pulmonary arterial hypertension; RHC = right heart catheterization

## Detailed Synthesis of Randomized Controlled Trials

We report on the outcomes of mortality, 6MWD, hospitalization, PVR, mPAP, cardiac index, and certain adverse reactions (headache, dizziness, diarrhea, peripheral edema, jaw pain, flushing, cough, and infections) for the following comparative analyses of pharmacotherapies:

- Head-to-head comparisons by individual drug, when available
- Monotherapy versus placebo (or monotherapy plus standard therapy vs. standard therapy alone) by individual drug
- Monotherapy versus placebo (or monotherapy plus standard therapy vs. standard therapy alone) by class of drug
- Combination therapy versus monotherapy by individual drug

The latter three comparative analyses are reported in tabular and graphic form in a single forest plot for each outcome. We also conducted meta-analyses and reported summary measures for the analyses by individual drug (e.g., studies of bosentan vs. placebo) and class of drug (e.g., prostacyclin-analogues vs. placebo or standard therapy) whenever there were two or more studies with comparable study arms.

We use the term background treatment for cointerventions that are preexisting and applied to both study arms of an RCT in which a second (new) drug is added to one arm (experimental) but not the other (control). Thus, the trial of iloprost plus bosentan versus bosentan (e.g., COMBI<sup>192</sup>) would be described as a trial of iloprost with bosentan background therapy and can be construed to examine the efficacy of combination versus monotherapy; it is also relevant to the efficacy of iloprost. In our meta-analyses, we would infer efficacy of iloprost from controlled trials of iloprost both with and without background therapy. This, however, assumes independent and additive effects of the experimental drug relative to any or all of the other background therapies received by the patients enrolled in the trial (including, but not limited to, other PAH-specific drugs, supplemental oxygen, vasodilators, etc.). We did not identify any eligible studies that randomized treatment-naïve patients to monotherapy versus combination therapy, or that randomized treatment-naïve patients to combination therapy versus placebo or standard therapy. In each of the five combination therapy versus monotherapy studies included in this report, combination therapy refers to the step-wise addition of a second drug to existing monotherapy.

## Mortality


We identified a single head-to-head, double-blind RCT that compared bosentan with sildenafil in patients with PAH.<sup>156</sup> One of the 14 patients in the sildenafil group died during the fourteenth week of treatment. There were no deaths among the 12 patients in the bosentan group during the 16-week intervention period. A total of 20 RCTs reported the effects of monotherapy or compared to placebo, standard therapy, or combination therapy for PAH on mortality outcomes. For two of the studies<sup>188,193</sup> (including ASSET-2, but not including ASSET-1, both of which were reported in the paper by Barst et al.<sup>188</sup>), no deaths were reported, so an odds ratio for mortality could not be calculated. Therefore, 18 studies (14 monotherapy and 4 combination therapy) consisting of a total of 3077 patients were included for analysis, as follows:

- 2 studies (represented by 1 article) compared ambrisentan with placebo<sup>106</sup>
- 3 studies compared bosentan with placebo<sup>182,184,185</sup>
- 3 studies compared IV epoprostenol with standard therapy<sup>85,181,194</sup>
- 2 studies compared aerosolized iloprost with placebo<sup>190,191</sup>
- 1 study compared sildenafil with placebo<sup>187</sup>
- 1 study compared 4 doses of tadalafil with placebo, with 53% of patients receiving bosentan as background therapy<sup>196</sup>
- 2 studies compared IV or subcutaneous treprostinil with placebo<sup>197,199</sup>
- 1 study compared vardenafil with placebo<sup>200</sup>
- 3 studies compared combination therapy with monotherapy<sup>131,186,189</sup>

## Ambrisentan Versus Placebo

Figure 23 shows the forest plot of the odds ratio for mortality for treatment with ambrisentan versus placebo from 2 studies (393 patients). Each of these studies involved two active doses of ambrisentan between 2.5 mg to 10 mg daily with a 5 mg dose used in both studies. Our analysis combined active doses in each study. The duration of treatment was 12 weeks in both studies. The individual odds ratios for the two studies were 0.33 and 0.49, with a summary odds ratio of 0.40 (95% CI, 0.10 to 1.51). The comparative efficacy of ambrisentan in reducing mortality compared with placebo is inconclusive given the small number of trials, the wide confidence intervals, and the observation that the confidence interval includes 1.0.

**Figure 23. Forest plot of odds ratio for mortality—ambrisentan versus placebo**




CI = confidence interval

## Bosentan Versus Placebo

Figure 24 shows the forest plot of the odds ratio for mortality for treatment with bosentan versus placebo from 3 studies (411 patients). The dosages of bosentan across the trials were similar (62.5 mg two times daily titrated up to 125–250 mg two times daily). The duration of treatment ranged from 16 to 32 weeks. The individual odds ratios ranged from 0.23 to 4.09, with a summary odds ratio of 0.72 (95% CI, 0.14 to 3.60). The comparative efficacy of bosentan in reducing mortality compared with placebo is inconclusive given the small number of trials, wide confidence intervals, and the observation that the confidence interval includes 1.0.



**Figure 24. Forest plot of odds ratio for mortality—bosentan versus placebo**




CI = confidence interval

## Epoprostenol Versus Standard Therapy

Figure 25 shows the forest plot of the odds ratio for mortality for treatment with intravenous epoprostenol versus standard therapy from three studies (215 patients). The duration of therapy ranged from 8 to 12 weeks. The individual odds ratios ranged from 0.05 to 0.77, with a summary odds ratio of 0.33 (95% CI, 0.07 to 1.50). The comparative efficacy of epoprostenol in reducing mortality compared with standard therapy is inconclusive given the small number of trials, the wide confidence intervals, and the observation that the confidence interval includes 1.0.

**Figure 25. Forest plot of odds ratio for mortality—intravenous epoprostenol versus standard therapy**




CI = confidence interval

## Iloprost Versus Placebo

Figure 26 shows the forest plot of the odds ratio for mortality for treatment with aerosolized iloprost versus placebo from two studies (266 patients). Both studies contained patient groups diagnosed with non-Class 1 PH. The duration of therapy was 12 weeks in both studies. The doses of aerosolized iloprost were between 2.5 and 5.0 micrograms delivered from six to nine times daily with dosage and schedules individualized based on a predetermined algorithm. The individual odds ratios for the two studies were 0.24 and 1.10, with a summary odds ratio of 0.43 (95% CI, 0.08 to 2.47). The comparative efficacy of iloprost in reducing mortality compared with placebo is inconclusive given the small number of trials, the wide confidence intervals, and the observation that the confidence interval includes 1.0.

**Figure 26. Forest plot of odds ratio for mortality—aerosolized iloprost versus placebo**



CI = confidence interval

## Sildenafil Versus Placebo

A single eligible study compared sildenafil with placebo.<sup>187</sup> The SUPER study was a good-quality, 4-arm RCT that compared three dosages of sildenafil (20 mg, 40 mg, and 80 mg daily) with placebo. The 4 deaths among 277 patients reported over the course of the 3-month study were distributed relatively evenly across the 4 study arms.


## Tadalafil Versus Placebo

A single eligible study compared tadalafil with placebo.<sup>196</sup> The PHIRST study was a good-quality, five-arm RCT that compared four doses of tadalafil (2.5 mg, 10 mg, 20 mg, and 40 mg daily) with placebo. Fifty-three percent of patients in this study also received bosentan as background therapy; limited data were reported for this subgroup of patients which prevented including this study as a test of combination versus monotherapy<sup>209</sup>. Three deaths were reported within the first 16 weeks of treatment among the 405 patients in this study: 1 in the placebo group, 1 in the 10 mg tadalafil group; and 1 in the 20 mg tadalafil group.

## Treprostinil Versus Placebo

Figure 27 shows the forest plot of the odds ratio for mortality for treatment with treprostinil versus placebo from two studies (513 patients). The duration of treatment was 12 weeks in both studies. The method of infusion was different between the studies (intravenous versus subcutaneous). The individual odds ratios were 0.20 and 0.91, with a summary odds ratio of 0.50 (95% CI, 0.12 to 2.12). The comparative efficacy of treprostinil in reducing mortality compared with placebo is inconclusive given the small number of trials, the wide confidence intervals, and the observation that the confidence interval includes 1.0.

**Figure 27. Forest plot of odds ratio for mortality—treprostinil versus placebo**



CI = confidence interval


## Vardenafil Versus Placebo

A single eligible study compared vardenafil with placebo.<sup>200</sup> The EVALUATION study was a good-quality, RCT that compared vardenafil 5 mg daily (later increased to 5 mg 2 times daily) with placebo. Over the course of the 3-month study period, two deaths were observed among the 20 patients in the placebo arm, compared with zero deaths among the 44 patients in the active treatment arm.

## Mortality by Drug Class

Figure 28 shows the forest plot of the odds ratio for mortality by drug class. Incidence of death after 8 to 16 weeks of treatment was decreased by treatment with prostanoids compared with standard therapy or placebo (OR 0.52; 95% CI, 0.29 to 0.95). Similar point estimates for odds ratios were observed for endothelin antagonists (OR 0.60; CI, 0.23 to 1.59) and phosphodiesterase inhibitors (OR 0.30; CI, 0.08 to 1.11), but the confidence intervals were wide and included 1.0. There was little evidence of statistical heterogeneity among the six studies of endothelin antagonists, with a Q-value of 3.33 for 5 degrees of freedom,  $I^2=0$ ,  $p=0.65$ ; among the four studies of phosphodiesterase inhibitors, with a Q-value of 3.11 for 3 degrees of freedom,  $I^2=3\%$ ,  $p=0.38$  or among the 8 studies of prostanoids, with a Q-value of 6.75 for 7 degrees of freedom,  $I^2=0$ ,  $p=0.46$ .

**Figure 28. Forest plot of odds ratio for mortality by drug class**



Aer = aerosolized; Bos = bosentan; CI = confidence interval; Epo = epoprostenol; ERA = endothelin receptor antagonist; IV = intravenous; PDE5 = phosphodiesterase type 5 inhibitor; SC = subcutaneous; Sil = sildenafil; Trep = treprostinil

## Combination Therapy Versus Monotherapy


Three studies representing 566 patients evaluated mortality associated with combination therapy versus mortality associated with monotherapy. The therapies differed between studies: sildenafil plus IV epoprostenol versus IV epoprostenol plus placebo, bosentan plus IV epoprostenol versus IV epoprostenol plus placebo, and bosentan or sildenafil plus aerosolized treprostinil versus bosentan or sildenafil plus placebo. The duration of treatment ranged from 12 to 16 weeks. The individual odds ratios ranged from 0.06 to 2.80, with a summary odds ratio of 0.37 (95% CI, 0.04 to 3.32). The comparative efficacy of combination therapy in reducing mortality compared with monotherapy is inconclusive given the small number of trials, the wide confidence intervals, and the observation that the confidence interval includes 1.0.

## 6-Minute Walk Distance (6MWD)

A total of 17 RCTs representing 2587 patients reported the effects of monotherapy or combination therapy for PAH on 6MWD at 8 to 16 weeks after initiating treatment.<sup>94,106,181,182,185,187,189,190,192-194,196-198,200</sup> In addition, one study compared bosentan with sildenafil.<sup>156</sup> Two studies compared bosentan with placebo.<sup>94,182</sup> One article reporting the results of two studies compared ambrisentan with placebo.<sup>187</sup> Two studies compared sildenafil with placebo,<sup>187,189</sup> one study compared tadalafil with placebo,<sup>196</sup> one study compared vardenafil with placebo,<sup>200</sup> and three studies compared iloprost with placebo.<sup>190,192,193</sup> Three of the 12 studies evaluated combination therapy versus monotherapy: 1 sildenafil study was conducted in patients with epoprostenol as background therapy,<sup>189</sup> and 2 iloprost studies were conducted in patients with bosentan as background therapy.<sup>192,193</sup> Twelve of the 17 studies were rated good quality, 4 were rated fair quality, and 1<sup>192</sup> was rated poor quality.

The single small, head-to-head comparison of bosentan versus sildenafil showed no statistically significant difference in 6MWD in an intention-to-treat analysis.<sup>156</sup> Figure 29 shows the forest plot of a meta-analysis of the 17 remaining studies. The analysis revealed a statistically significant improvement in 6MWD associated with each of the 3 drug classes. Endothelin antagonists, as a class, were associated with an improvement in 6MWD of 39.9 m (95% CI, 21.4 to 58.4) whereas phosphodiesterase inhibitors and prostanoids were associated with improvements of 38.9 m (CI, 22.0 to 55.9) and 27.9 m (CI, 10.3 to 45.4), respectively. There was moderate heterogeneity among these studies, with a Q-value of 7.68 for 5 degrees of freedom,  $I^2=34.89$ ,  $p=0.17$  for endothelin antagonists, a Q-value of 10.09 for 3 degrees of freedom,  $I^2=70.28$ ,  $p=0.018$  for phosphodiesterase inhibitors, and a Q-value of 11.02 for 6 degrees of freedom,  $I^2=45.57$ ,  $p=0.088$  for prostanoids.

**Figure 29. Forest plot of effects of therapy by drug class on 6MWD**



CI = confidence interval; ERA = endothelin receptor antagonist; PDE5 = phosphodiesterase type 5 inhibitor

Two good-quality studies<sup>189,193</sup> and one fair-quality study<sup>192</sup> involving 363 patients evaluated changes in 6MWD associated with combination therapy versus monotherapy. One study evaluated the efficacy of sildenafil with epoprostenol as background therapy, and two evaluated the efficacy of iloprost with bosentan as background therapy. The summary estimate of the difference in means for these 3 studies was 23.9 (95% CI, 8.0 to 39.9). This finding suggests a moderate improvement in 6MWD associated with combination therapy compared with monotherapy.

A fourth study provides additional information about the comparison of combination therapy versus monotherapy. Barst et al.<sup>209</sup> conducted a subgroup analysis of the PHIRST study, which was a 5-arm RCT that compared 4 doses of tadalafil with placebo. Of the 405 patients enrolled in that study, 215 (53%) were on bosentan as background therapy. The investigators reported mean change from baseline in 6MWD for the placebo arm and the study arm that received tadalafil 40 mg per day at 8, 12, and 16 weeks, for both the patients on background bosentan and the patients who were treatment-naïve patients (only the 40 mg/day dose of tadalafil was reported because that was the only dose that showed significant differences in primary and secondary efficacy analyses). At the 16-week assessment, the mean change in 6MWD was 40.2 m (95% CI, 23.1 to 57.2) among patients on background therapy who received tadalafil 40 mg per day; 18.8 m (CI, 0.5 to 37.2) for patients on background therapy who received placebo; 42.2 m (CI, 26.7 to 57.5) for treatment-naïve patients on tadalafil 40 mg per day; and -2.9 m (CI, -22.8 to 17.1) for treatment-naïve patients on placebo. This corresponds to a placebo-corrected difference of 21.4 m among patients on background bosentan and 45.1 m

among treatment-naïve patients. This non-randomized comparison (without testing for statistical significance testing) tentatively suggests that 6MWD improvement associated with monotherapy with 40 mg per day of tadalafil after 16 weeks of treatment may be greater than the improvement in 6MWD associated with adding tadalafil to an existing treatment regimen that includes bosentan. These limited and potentially confounded data suggest that monotherapy may have a greater effect on 6MWD relative to adding a second treatment to existing background therapy. Interpretation of these findings is further complicated by important differences between groups at baseline, including the observation that 74 percent of treatment-naïve patients had a duration of PAH of less than 2 years compared with 38 percent of patients on bosentan background therapy.


We created a funnel plot that included the 17 RCTs reported in Figure 29. Visual inspection of this funnel plot suggested an absence of publication bias. We used 6MWD to evaluate for possible publication bias because it is the outcome that was most commonly reported among the studies included in this report.

## Hospitalization

A total of 9 RCTs representing 1918 patients reported the effects of monotherapy or combination therapy for PAH on hospitalization for worsening of PAH within 8 to 16 weeks after initiating treatment (Figure 30).<sup>106,131,182,187,189,193,196,200</sup> One study compared bosentan with placebo,<sup>182</sup> one article reporting the results of two studies compared ambrisentan with placebo,<sup>106</sup> two studies compared sildenafil with placebo<sup>187,189</sup> (one with epoprostenol as background therapy), one study compared tadalafil with placebo,<sup>196</sup> one study compared vardenafil with placebo,<sup>200</sup> one study compared iloprost with placebo with bosentan as background therapy<sup>193</sup> and one study compared treprostinil with placebo.<sup>131</sup> All nine studies were rated good quality. Meta-analysis of these studies revealed a statistically significant reduction in hospitalization associated with endothelin antagonists (OR 0.34; 95% CI, 0.17 to 0.69) and phosphodiesterase inhibitors (OR 0.48; CI, 0.25 to 0.91) while data on prostanoids were inconclusive (OR 0.42; CI, 0.06 to 3.08). There was little evidence of statistical heterogeneity among the 4 studies involving endothelin antagonists, with a Q-value of 2.34 for 3 degrees of freedom,  $I^2=0$ ,  $p=0.51$ .

Three good-quality studies<sup>131,189,193</sup> involving 566 patients evaluated hospital admissions due to worsening PAH symptoms associated with combination therapy versus monotherapy. One study evaluated the efficacy of sildenafil with epoprostenol as background therapy, one evaluated the efficacy of iloprost with bosentan as background therapy, and one evaluated the efficacy of treprostinil with bosentan or sildenafil as background therapy. The summary estimate of the odds ratios for these 3 studies was 0.64 (95% CI, 0.31 to 1.36). This represents insufficient evidence to conclude whether combination therapy and monotherapy differ in their effects on hospitalization incidence during the first 2 to 4 months of treatment.

**Figure 30. Forest plot of effects of therapy by drug class on hospitalization**



CI = confidence interval; ERA = endothelin receptor antagonist; PDE5 = phosphodiesterase type 5 inhibitor

## Pulmonary Vascular Resistance


A total of 11 RCTs representing 877 patients reported the effects of monotherapy or combination therapy for PAH on PVR as assessed by right heart catheterization at 8 to 16 weeks after initiating treatment (Figure 31).<sup>85,94,181,183,185-187,190,193,194</sup>

Four studies compared bosentan with placebo,<sup>94,183,185</sup> one study compared bosentan plus epoprostenol to epoprostenol plus placebo,<sup>186</sup> one study compared iloprost with placebo,<sup>190</sup> one study compared iloprost plus bosentan with bosentan plus placebo,<sup>193</sup> four studies compared epoprostenol with standard therapy,<sup>85,181,194</sup> and one study compared sildenafil with placebo.<sup>187</sup> Eight studies were rated good quality and three fair quality.<sup>185,194</sup>

Figure 31 shows the forest plot of the 11 RCTs with meta-analysis by drug class. Meta-analysis of the five studies that evaluated an endothelin antagonist as the active treatment showed a summary estimate of -217.5 mm Hg/liter/min (95% CI, -424.4 to -10.7). Heterogeneity was very high, with a Q-value of 15.87 for 3 degrees of freedom,  $I^2=74.79\%$ ,  $p=0.003$ . The single study that evaluated a phosphodiesterase inhibitor (sildenafil) reported an improvement in PVR associated with active treatment of -224.7 mm Hg/liter/min (CI, -339.6 to -109.8). Meta-analysis of the five studies that evaluated a prostanoid as the active treatment demonstrated an improvement in PVR associated with active treatment of -256.2 mm Hg/liter/min (CI, -440.4 to -71.9). Heterogeneity was very high, with a Q-value of 27.96 for 4 degrees of freedom,  $I^2=85.7\%$ ,  $p<0.001$ . Only two studies compared combination therapy with monotherapy using PVR as assessed by right heart catheterization as an outcome at 8 to 16 weeks after initiating treatment. The summary estimate of the difference in means for these two studies was -33.2 (CI, -149.5 to 83.1).



**Figure 31. Forest plot of effects of therapy by drug class on pulmonary vascular resistance**




CI = confidence interval; ERA = endothelin receptor antagonist; PDE5 = phosphodiesterase type 5 inhibitor

## Mean Pulmonary Artery Pressure

Thirteen RCTs representing 1559 patients reported mPAP as assessed by RHC 8 to 16 weeks after initiation of treatment.<sup>85,94,181,183,185-188,190,193,194,197</sup> Six studies evaluated an endothelin antagonist, two studies evaluated the phosphodiesterase inhibitor sildenafil, and five studies evaluated a prostanoid. Two studies were combination therapy studies: one compared bosentan plus epoprostenol with placebo and epoprostenol,<sup>186</sup> and one compared iloprost plus bosentan with placebo plus bosentan.<sup>193</sup> Nine studies were rated good quality and four fair quality.

Figure 32 shows the forest plot of a meta-analysis by drug class, which revealed significant improvement in mPAP for all three drug classes. The summary change in mean arterial pressures were -3.5 mmHg (95% CI, -6.5 to -0.5) for endothelin antagonists, -3.6 mmHg (CI, -5.2 to -2.0) for phosphodiesterase inhibitors (sildenafil only), and -3.2 mmHg for prostanoids (CI, -5.6 to -0.8). There was high heterogeneity among the 6 studies of endothelin antagonists, with a Q-value of 23.3 for 5 degrees of freedom,  $I^2=78.5\%$ ,  $p<0.001$ , and high heterogeneity among the 5 studies of prostanoids, with a Q-value of 13.85 for 4 degrees of freedom,  $I^2=71.13\%$ ,  $p=0.008$ . Only two studies compared combination therapy with monotherapy using mPAP as an outcome at 8 to 16 weeks after initiating treatment. The summary estimate of the difference in means for these two studies was -4.1 (95% CI, -7.6 to -0.6).

**Figure 32. Forest plot of effects of therapy by drug class on mean pulmonary artery pressure (mPAP)**




Bos = bosentan; CI = confidence interval; Epo = epoprostenol; ERA = endothelin receptor antagonist; PDE5 = phosphodiesterase type 5 inhibitor

## Cardiac Index

A total of 6 RCTs representing 982 patients reported cardiac index assessed 8 to 16 weeks after initiation of treatment compared with placebo or standard therapy (Figure 33).<sup>85,94,156,187,194,197</sup> One good-quality study compared bosentan with placebo,<sup>94</sup> one good-quality study compared bosentan plus epoprostenol with epoprostenol plus placebo,<sup>186</sup> one good-quality and one fair-quality study compared epoprostenol with standard therapy,<sup>85,194</sup> one good-quality study compared three doses of sildenafil with each other and with placebo,<sup>187</sup> and one good quality study compared subcutaneous treprostinil with placebo.<sup>197</sup> An additional good-quality study was a head-to-head trial that compared bosentan with sildenafil.<sup>156</sup>

The single RCT that compared bosentan with placebo demonstrated a significant improvement in cardiac index of 1.0 L per minute per meter-squared (95% CI, 0.6 to 1.4) at 12 weeks, in favor of bosentan. The single study that compared sildenafil with placebo permitted dose comparisons; each of the 3 doses (20, 40, and 80 mg three times daily) was associated with statistically significant improvement in cardiac index. Combining the data from all three sildenafil doses generated a summary estimate of an improvement in cardiac index associated with sildenafil versus placebo at 12 weeks of 0.3 L per minute per meter-squared (CI, 0.1 to 0.5). Meta-analysis of the three studies that evaluated a prostanoid generated a summary estimate for improvement in cardiac index of 0.4 L per minute per meter-squared (CI, 0.1 to 0.7) at 12 weeks.

**Figure 33. Forest plot of effects of therapy by drug class on cardiac index**



CI = confidence interval; Epo = epoprostenol; ERA = endothelin receptor antagonist; PDE5 = phosphodiesterase type 5 inhibitor

## Adverse Events

Adverse events that occurred during the first 8 to 16 weeks after initiation of treatment were reported in 21 of the 28 RCTs that compared an endothelin antagonist, phosphodiesterase inhibitor, or prostanoid with either placebo or standard therapy. Adverse events were not reported in the single RCT that compared two active therapies.<sup>156</sup> The most commonly assessed and reported adverse events were headache, dizziness, diarrhea, peripheral edema, jaw pain, flushing, and cough.

For these studies, we computed a summary estimate for the odds ratio for each of three classes of drugs: (1) endothelin antagonists, (2) phosphodiesterase inhibitors, and (3) prostanoids. We computed separate summary estimates for the odds ratio of all prostanoids versus prostanoids delivered via an aerosolized route of administration. An odds ratio greater than 1.0 indicates a higher incidence of adverse events associated with active treatment, and an odds ratio less than 1.0 indicates a lower incidence of adverse events associated with active treatment. When combination therapy was compared with monotherapy, an odds ratio greater than 1.0 indicates a higher incidence of adverse events associated with monotherapy.

## Headache


A total of 16 RCTs representing 2899 patients assessed the incidence of headache within the first 8 to 16 weeks of initiating therapy (Figure 34).<sup>94,106,131,182,183,186-190,193,196,197,199,200</sup> Fourteen studies were rated good quality and two fair quality. There was moderate heterogeneity among these studies, with a Q-value of 36.3 for 14 degrees of freedom,  $I^2=61.4\%$ ,  $p<0.001$ . Meta-analysis of 6 good-quality studies of endothelin antagonists involving 780 patients yielded a summary odds ratio of 1.16 (95% CI, 0.77 to 1.77). There was a two-fold higher incidence of headache among patients treated with phosphodiesterase inhibitors compared with placebo or standard therapy (OR 1.98; CI, 1.18 to 3.32). The 95-percent confidence interval for the summary odds ratio associated with all prostanoids includes 1.0 (CI, 0.93 to 4.53), but there was a significantly higher incidence of headache among patients treated with aerosolized prostanoids (OR 2.35; CI, 1.50 to 3.70).

There was little evidence of statistical heterogeneity among the 6 studies of endothelin antagonists, with a Q-value of 4.7 for 5 degrees of freedom,  $I^2=0$ ,  $p<0.45$  and high heterogeneity among both the 4 studies of phosphodiesterase inhibitors, with a Q-value of 10.13 for 4 degrees

of freedom,  $I^2=60.51\%$ ,  $p<0.038$ , and the 4 studies of prostanoids, with a Q-value of 25.68 for 4 degrees of freedom,  $I^2=84.42\%$ ,  $p<0.001$ .

Three good-quality studies<sup>186,189,193</sup> involving 356 patients evaluated the incidence of headache associated with combination therapy versus monotherapy. One study evaluated the efficacy of bosentan with epoprostenol as background therapy, one compared sildenafil with placebo with epoprostenol as background therapy, and one evaluated the efficacy of iloprost with bosentan as background therapy. We did not estimate a summary estimate for the odds ratio for headache associated with combination therapy compared with monotherapy because of the high degree of heterogeneity between studies, including the use of different drugs for both active and background therapy.

**Figure 34. Forest plot of effects of therapy by drug class on headache**




CI = confidence interval; ERA = endothelin receptor antagonist; PDE5 = phosphodiesterase type 5 inhibitor

## Dizziness

A total of 11 RCTs representing 1872 patients assessed the incidence of dizziness within the first 8 to 16 weeks of initiating therapy (Figure 35).<sup>131,182,183,186,188-190,193,197,199,200</sup> Nine studies were rated good quality and two fair quality. With the exception of one small study<sup>186</sup> that reported a higher incidence of dizziness in the in the epoprostenol plus bosentan study arm compared with the epoprostenol plus placebo arm, there were no statistically significant differences in the proportion of patients reporting adverse events between active and control groups across in any of the individual studies, or within drug class. Meta-analysis of 3 good-quality studies of endothelin antagonists involving 300 patients yielded a summary odds ratio of 0.45 (95% CI, 0.24 to 0.85). There was no apparent association between treatment of phosphodiesterase inhibitors (OR 1.04; CI, 0.60 to 1.81) or prostanoids (OR 0.97; CI, 0.66 to 1.44) and incidence of dizziness. There was little evidence of statistical heterogeneity among the 5 studies of prostanoids, with a Q-value of 2.26 for degrees of freedom,  $I^2=0$ ,  $p=0.85$ .

Three good-quality studies<sup>186,189,193</sup> involving 356 patients evaluated the incidence of dizziness associated with combination therapy versus monotherapy. One study evaluated the efficacy of bosentan with epoprostenol as background therapy, one compared sildenafil with placebo with epoprostenol as background therapy, and one evaluated the efficacy of iloprost with bosentan as background therapy. We did not estimate a summary estimate for the odds ratio for dizziness associated with combination therapy compared with monotherapy because of the high degree of clinical heterogeneity between studies, including the use of different drugs for both active and background therapy.

**Figure 35. Forest plot of effects of therapy by drug class on dizziness**



CI = confidence interval; ERA = endothelin receptor antagonist; PDE5 = phosphodiesterase type 5 inhibitor


## Diarrhea

A total of 11 RCTs representing 2331 patients assessed the incidence of diarrhea within the first 8 to 16 weeks of initiating therapy (Figure 36).<sup>131,186-190,194,196,197,199,200</sup> Eight studies were

rated good quality and three fair quality. Meta-analysis of these studies revealed no statistically significant differences in the proportion of patients reporting adverse events between active and control groups within any of the three drug class (OR 3.20; 95% CI, 0.67 to 15.38 for endothelin antagonists; OR 1.25; CI, 0.84 to 1.88 for phosphodiesterase inhibitors; and OR 1.77; CI, 0.57 to 5.53 for prostanoids). There was little evidence of statistical heterogeneity among the five studies of phosphodiesterase inhibitors, with a Q-value of 1.39 for 4 degrees of freedom,  $I^2=0$ ,  $p<0.85$ , and high heterogeneity among the five studies of prostanoids, with a Q-value of 27.89 for 4 degrees of freedom,  $I^2=85.66\%$ ,  $p<0.001$ .

Two good-quality studies<sup>186,189</sup> involving 289 patients evaluated the incidence of diarrhea associated with combination therapy versus monotherapy. One study evaluated the efficacy of bosentan with epoprostenol as background therapy, one compared sildenafil with placebo with epoprostenol as background therapy, and one evaluated the efficacy of tadalafil with bosentan as background therapy. We did not estimate a summary estimate for the odds ratio for diarrhea associated with combination therapy compared with monotherapy because of the high degree of heterogeneity between studies, including the use of different drugs for both active and background therapy.

**Figure 36. Forest plot of effects of therapy by drug class on diarrhea**




CI = confidence interval; ERA = endothelin receptor antagonist; PDE5 = phosphodiesterase type 5 inhibitor

## Peripheral Edema

A total of 9 RCTs representing 1880 patients assessed the incidence of peripheral edema within the first 8 to 16 weeks of initiating therapy (Figure 37).<sup>106,183,186,189,190,193,196,197</sup> All nine studies were rated good quality. Meta-analysis by drug class yielded statistically significantly increased odds ratios for phosphodiesterase inhibitors (OR 3.32; 95% CI, 1.40 to 7.87), but the results for endothelin antagonists (OR 1.93; CI, 0.64 to 5.85) and prostanoids (OR 1.85; CI, 0.81 to 4.21) were inconclusive. This finding, however, does not necessarily indicate that phosphodiesterase inhibitors are associated with a higher incidence of peripheral edema relative to endothelin receptor antagonists or prostanoids. There was moderate heterogeneity among the 4 studies of endothelin antagonists, with a Q-value of 7.33 for 3 degrees of freedom,  $I^2=59.07\%$ ,  $p=0.062$ .

Three good-quality studies<sup>186,189,193</sup> involving 356 patients evaluated the incidence of peripheral edema associated with combination therapy versus monotherapy. One study evaluated the efficacy of bosentan with epoprostenol as background therapy, one compared sildenafil with placebo with epoprostenol as background therapy, and one evaluated the efficacy of iloprost with bosentan as background therapy. We did not calculate a summary estimate for the odds ratio for peripheral edema associated with combination therapy compared with monotherapy because of the high degree of heterogeneity between studies, including the use of different drugs for both active and background therapy.

**Figure 37. Forest plot of effects of therapy by drug class on peripheral edema**




CI = confidence interval; ERA = endothelin receptor antagonist; PDE5 = phosphodiesterase type 5 inhibitor

## Jaw Pain

A total of 7 RCTs assessed the incidence of jaw pain within the first 8 to 16 weeks of initiating therapy (Figure 38).<sup>186,189,190,193,194,197,199</sup> Five studies were rated good quality and two fair quality. Of these, 5 RCTs representing 894 patients compared intravenous, subcutaneous, or aerosolized prostanoids with placebo or standard therapy. Meta-analysis of these 5 studies yielded a summary estimate of the odds ratio of 6.68 (95% CI, 2.28 to 19.62). There was moderate heterogeneity among these 5 studies, with a Q-value of 10.01 for 4 degrees of freedom,  $I^2=60.04\%$ ,  $p=0.04$ . Aerosolized prostanoids were also associated with a significantly increased risk of jaw pain (OR 4.32; CI, 1.67 to 11.17).

Three good-quality studies<sup>186,189,193</sup> involving 356 patients evaluated the incidence of jaw pain associated with combination therapy versus monotherapy. One study evaluated the efficacy of bosentan with epoprostenol as background therapy, one compared sildenafil with placebo with epoprostenol as background therapy, and one evaluated the efficacy of iloprost with bosentan as background therapy. We did not calculate a summary estimate for the odds ratio for jaw pain associated with combination therapy compared with monotherapy because of the high degree of clinical heterogeneity between studies, including the use of different drugs for both active and background therapy.

**Figure 38. Forest plot of effects of therapy by drug class on jaw pain**



CI = confidence interval; ERA = endothelin receptor antagonist; PDE5 = phosphodiesterase type 5 inhibitor


## Flushing

A total of 10 RCTs representing 2113 patients assessed the incidence of flushing within the first 8 to 16 weeks of initiating therapy (Figure 39).<sup>106,131,182,187,189,190,193,196,200</sup> All 10 studies were rated good quality. Meta-analysis of these studies suggest an approximately two-fold increase in the risk of flushing associated with both endothelin antagonists (OR 2.63; 95% CI, 0.94 to 7.40) and phosphodiesterase inhibitors (OR 2.46; CI, 1.27 to 4.75), but the 95-percent confidence interval of the summary estimate for endothelin antagonists includes 1.0. The risk of flushing was also elevated with aerosolized prostanoids (OR 4.72; CI, 2.13 to 10.42). There was moderate heterogeneity among the 4 studies of phosphodiesterase inhibitors, with a Q-value of 4.05 for 3 degrees of freedom,  $I^2=25.9\%$ ,  $p=0.26$ .

Two good-quality studies<sup>189,193</sup> involving 323 patients evaluated the incidence of flushing associated with combination therapy versus monotherapy. One study compared sildenafil with placebo with epoprostenol as background therapy and one compared iloprost with placebo with bosentan as background therapy. We did not estimate a summary estimate for the odds ratio for flushing associated with combination therapy compared with monotherapy because of the high degree of clinical heterogeneity between studies, including the use of different drugs for both active and background therapy.



**Figure 39. Forest plot of effects of therapy by drug class on flushing**




CI = confidence interval; ERA = endothelin receptor antagonist; PDE5 = phosphodiesterase type 5 inhibitor

## Cough

A total of 8 RCTs representing 1306 patients assessed the incidence of cough within the first 8 to 16 weeks of initiating therapy (Figure 40).<sup>131,182,186-188,190,193,199</sup> Six studies were rated good quality and two fair quality. There was moderate heterogeneity among the 8 studies, with a Q-value of 12.6 for 7 degrees of freedom,  $I^2=44\%$ ,  $p=0.08$ . Meta-analysis of these studies revealed no statistically significant differences in the proportion of patients reporting adverse events between active and control groups for endothelin antagonists and phosphodiesterase inhibitors.

Prostanoids, however, are associated with a higher incidence of cough compared with placebo or standard therapy. The summary estimate of the odds ratio for cough associated with all prostanoids (aerosolized or intravenous) is 2.34 (95% CI, 1.62 to 3.37). There was little evidence of statistical heterogeneity among these 4 studies, with a Q-value of 1.93 for 3 degrees of freedom,  $I^2=0$ ,  $p=0.59$ . Among the 3 studies that used an aerosolized route of administration for prostanoids, the summary estimate of the odds ratio for cough was 2.42 (CI, 1.66 to 3.53). Two good-quality studies<sup>186,193</sup> involving 100 patients evaluated the incidence of cough associated with combination therapy versus monotherapy. One study evaluated the efficacy of bosentan with epoprostenol as background therapy, and one evaluated the efficacy of iloprost with bosentan as background therapy. We did not estimate a summary estimate for the odds ratio for cough associated with combination therapy compared with monotherapy because of the high degree of heterogeneity between studies, including the use of different drugs for both active and background therapy.

**Figure 40. Forest plot of effects of therapy by drug class on cough**




CI = confidence interval; ERA = endothelin receptor antagonist; PDE5 = phosphodiesterase type 5 inhibitor

## Infections

A total of 8 RCTs representing 1210 patients assessed the incidence of infections within the first 8 to 16 weeks of initiating therapy (Figure 41).<sup>186,188,189,192-194,196,200</sup> Five studies were rated good quality and three fair quality. There was low heterogeneity among these studies, with a Q-value of 8.0 for 7 degrees of freedom,  $I^2=12.8\%$ ,  $p=0.33$ . The single study that compared an endothelin antagonist (bosentan) with placebo with epoprostenol as background therapy did not demonstrate an association between treatment and incidence of infection (OR 0.45; 95% CI, 0.05 to 3.72). Meta-analysis of 4 studies demonstrated an increase in incidence of infections associated with phosphodiesterase inhibitors (OR 2.17; CI, 1.20 to 3.94). There was little evidence of statistical heterogeneity among these 4 studies, with a Q-value of 3.94 for 3 degrees of freedom,  $I^2=0$ ,  $p=0.73$ . Meta-analysis of 3 studies did not demonstrate an association between prostanoid treatment and incidence of infection (OR 1.12; CI, 0.13 to 9.87).

Three good-quality studies<sup>186,189,193</sup> and one fair-quality study<sup>192</sup> involving 396 patients evaluated the incidence of infections associated with combination therapy versus monotherapy. We did not calculate a summary estimate for the odds ratio for infections associated with combination therapy compared with monotherapy because of the high degree of heterogeneity between studies, including the use of different drugs for both active and background therapy.

**Figure 41. Forest plot of effects of therapy by drug class on infections**



CI = confidence interval; ERA = endothelin receptor antagonist; PDE5 = phosphodiesterase type 5 inhibitor

## Summary Strength of Evidence for KQ 3

Results for these outcomes and comparisons, along with ratings for strength of evidence (SOE) are shown in Tables 25–31.

**Table 25. Summary strength of evidence for KQ 3: Mortality**

Comparison	Number of Studies (Patients)	Domains				Strength of Evidence Effect Estimate (95% CI)
		Risk of Bias	Consistency	Directness	Precision	
<b>Ambrisentan vs. placebo</b>	2 (393)	Low (2)	Consistent	Direct	Imprecise	<b>SOE = Insufficient</b> OR 0.40 (0.10 to 1.51) Inconclusive benefit (few studies, few deaths lead to wide CI)
<b>Bosentan vs. placebo</b>	3 (411)	Low (2) Moderate (1)	Inconsistent	Direct	Imprecise	<b>SOE = Insufficient</b> OR 0.72 (0.14 to 3.60) Inconclusive benefit (few studies, few deaths lead to wide CI)
<b>Epoprostenol vs. placebo or standard therapy</b>	3 (215)	Low (2) Moderate (1)	Inconsistent	Direct	Imprecise	<b>SOE = Insufficient</b> OR 0.33 (0.07 to 1.50) Inconclusive benefit (few studies, few deaths lead to wide CI)
<b>Iloprost vs. placebo</b>	2 (266)	Low (1) Moderate (1)	Inconsistent	Direct	Imprecise	<b>SOE = Insufficient</b> OR 0.43 (0.08 to 2.47) Inconclusive benefit (few studies, few deaths lead to wide CI)
<b>Sildenafil vs. placebo</b>	1 (277)	Low (1)	NA	Direct	Imprecise	<b>SOE = Insufficient</b> OR 1.01 (0.10 to 9.92) Inconclusive benefit (single study, wide CI)

**Table 25. Summary strength of evidence for KQ 3: Mortality (continued)**

Comparison	Number of Studies (Patients)	Domains				Strength of Evidence Effect Estimate (95% CI)
		Consistency	Directness	Precision	Consistency	
<b>Tadalafil vs. placebo</b>	1 (405)	Low (1)	NA	Direct	Imprecise	<b>SOE = Insufficient</b> OR 0.50 (0.05 to 5.63) Inconclusive benefit (single study, wide CI)
<b>Treprostinil vs. placebo</b>	2 (513)	Low (1) Moderate (1)	Consistent	Direct	Imprecise	<b>SOE = Insufficient</b> OR 0.50 (0.12 to 2.12) Inconclusive benefit (few studies, few deaths lead to wide CI)
<b>Vardenafil vs. placebo</b>	1 (64)	Low (1)	NA	Direct	Imprecise	<b>SOE = Insufficient</b> OR 0.08 (0.00 to 1.82) Inconclusive benefit (single study, wide CI)
<b>Endothelin antagonists vs. placebo</b>	6 (838)	Low (5) Moderate (1)	Inconsistent	Direct	Imprecise	<b>SOE = Insufficient</b> OR 0.60 (0.23 to 1.59) Inconclusive benefit (few studies, few deaths lead to wide CI)
<b>Phosphodiesterase inhibitors vs. placebo</b>	4 (1011)	Low (4)	Inconsistent	Direct	Imprecise	<b>SOE = Insufficient</b> OR 0.30 (0.08 to 1.11) Inconclusive benefit (few studies, few deaths lead to wide CI)
<b>Prostanoids vs. placebo or standard therapy</b>	8 (1229)	Low (5) Moderate (3)	Inconsistent	Direct	Precise	<b>SOE = Low</b> OR 0.52 (0.29 to 0.95) Favors prostanoids
<b>Combination therapy vs. monotherapy</b>	3 (566)	Low (3)	Inconsistent	Indirect	Imprecise	<b>SOE = Insufficient</b> OR 0.37 (0.04 to 3.32) Inconclusive benefit (few studies, few deaths lead to wide CI)

CI = confidence interval; NA = not applicable; OR = odds ratio; SOE = strength of evidence

Note: No eligible studies compared tadalafil or vardenafil monotherapy with either placebo or standard therapy.

**Table 26. Summary strength of evidence for KQ 3: 6MWD**

Comparison	Number of Studies (Patients)	Domains				Strength of Evidence Effect Estimate (95% CI)
		Risk of Bias	Consistency	Directness	Precision	
Endothelin antagonists vs. placebo	6 (663)	Low (4) Moderate (2)	Consistent	Direct	Imprecise	<b>SOE = Moderate</b> Mean difference 39.9 (21.4 to 58.4) Favors endothelin antagonists
Phosphodiesterase inhibitors vs. placebo	4 (991)	Low (4)	Consistent	Direct	Imprecise	<b>SOE = Moderate</b> Mean difference 38.9 (22.0 to 55.9) Favors PDE inhibitors
Prostanoids vs. placebo or standard therapy	7 (933)	Low (4) Moderate (2) High (1)	Consistent	Direct	Imprecise	<b>SOE = Moderate</b> Mean difference 27.9 (10.3 to 45.4) Favors prostanoids
Combination therapy vs. monotherapy	3 (363)	Low (2) Moderate (1)	Consistent	Indirect	Imprecise	<b>SOE = Low</b> Mean difference 23.9 (8.0 to 39.9) Favors combination therapy

CI = confidence interval; OR = odds ratio; SOE = strength of evidence

**Table 27. Summary strength of evidence for KQ 3: Hospitalization**

Comparison	Number of Studies (Patients)	Domains				Strength of Evidence Effect Estimate (95% CI)
		Risk of Bias	Consistency	Directness	Precision	
Endothelin antagonists vs. placebo	3 (606)	Low (3)	Consistent	Direct	Precise	<b>SOE = Moderate</b> OR 0.34 (0.17 to 0.69) Favors endothelin antagonists
Phosphodiesterase inhibitors vs. placebo	4 (1011)	Low (4)	Consistent	Direct	Precise	<b>SOE = Moderate</b> OR 0.48 (0.25 to 0.91) Favors PDE inhibitors
Prostanoids vs. placebo or standard therapy	2 (301)	Low (2)	Inconsistent	Direct	Imprecise	<b>SOE = Insufficient</b> OR 0.42 (0.06 to 3.08) Inconclusive benefit (few studies, wide CI)
Combination therapy vs. monotherapy	3 (566)	Low (3)	Inconsistent	Indirect	Imprecise	<b>SOE = Insufficient</b> OR 0.64 (0.31 to 1.36) Inconclusive benefit (few studies, wide CI)

CI = confidence interval; OR = odds ratio; SOE = strength of evidence

**Table 28. Summary strength of evidence for KQ 3: Pulmonary vascular resistance**

Comparison	Number of Studies (Patients)	Domains				Strength of Evidence Effect Estimate (95% CI)
		Risk of Bias	Consistency	Directness	Precision	
<b>Endothelin antagonists vs. placebo</b>	5 (139)	Low (3) Moderate (2)	Inconsistent	Indirect	Precise	<b>SOE = Low</b> Mean difference -217.5 (-424.4 to -10.7) Favors endothelin antagonists
<b>Phosphodiesterase inhibitors vs. placebo</b>	1 (263)	Low (1)	NA	Indirect	Precise	<b>SOE = Low</b> Mean difference -224.7 (-339.6 to -109.8) Favors PDE inhibitors
<b>Prostanoids vs. placebo or standard therapy</b>	5 (475)	Low (4) Moderate (1)	Consistent	Indirect	Precise	<b>SOE = Low</b> Mean difference -256.2 (-440.4 to -71.9) Favors prostanoids
<b>Combination therapy vs. monotherapy</b>	2 (90)	Low (2)	Inconsistent	Indirect	Imprecise	<b>SOE = Insufficient</b> Mean difference -33.2 (-149.5 to 83.1) Inconclusive benefit (few studies, wide CI)

CI = confidence interval; NA = not applicable; OR = odds ratio; SOE = strength of evidence

**Table 29. Summary strength of evidence for KQ 3: Mean pulmonary artery pressure**

Comparison	Number of Studies (Patients)	Domains				Strength of Evidence Effect Estimate (95% CI)
		Risk of Bias	Consistency	Directness	Precision	
<b>Endothelin antagonists vs. placebo</b>	6 (219)	Low (4) Moderate (2)	Consistent	Indirect	Precise	<b>SOE = Low</b> Mean difference -3.5 (-6.5 to -0.5) Favors endothelin antagonists
<b>Phosphodiesterase inhibitors vs. placebo</b>	2 (481)	Low (1) Moderate (1)	Consistent	Indirect	Precise	<b>SOE = Low</b> Mean difference -3.6 (-5.2 to -2.0) Favors PDE inhibitors
<b>Prostanoids vs. placebo or standard therapy</b>	5 (859)	Low (4) Moderate (1)	Consistent	Indirect	Precise	<b>SOE = Low</b> Mean difference -3.2 (-5.6 to -0.8) Favors prostanoids
<b>Combination therapy vs. monotherapy</b>	2 (90)	Low (2)	Inconsistent	Indirect	Precise	<b>SOE = Low</b> Mean difference -4.1 (-7.6 to -0.6) Favors combination therapy

CI=confidence interval; OR=odds ratio; SOE=strength of evidence

**Table 30. Summary strength of evidence for KQ 3: Cardiac index**

Comparison	Number of Studies (Patients)	Domains				Strength of Evidence Effect Estimate (95% CI)
		Risk of Bias	Consistency	Directness	Precision	
Endothelin antagonists vs. placebo	2 (63)	Low (2)	Inconsistent	Indirect	Imprecise	<b>SOE = Insufficient</b> Mean difference 0.6 (-0.2 to 1.4) Inconclusive benefit (few studies, wide CI)
Phosphodiesterase inhibitors vs. placebo	1 (258)	Low (1)	NA	Indirect	Precise	<b>SOE = Low</b> Mean difference 0.3 (0.1 to 0.5) Favors PDE inhibitors
Prostanoids vs. placebo or standard therapy	3 (661)	Low (2) Moderate (1)	Consistent	Indirect	Precise	<b>SOE = Low</b> Mean difference 0.4 (0.1 to 0.7)
Combination therapy vs. monotherapy	1 (33)	Low (1)	NA	Indirect	Imprecise	<b>SOE = Insufficient</b> Mean difference 0.2 (-0.4 to 0.8) Inconclusive benefit (single study, wide CI)

CI = confidence interval; NA = not applicable; OR = odds ratio; SOE = strength of evidence

**Table 31. Summary strength of evidence for KQ 3: Adverse events<sup>a</sup>**

Comparison	Number of Studies (Patients)	Domains				Strength of Evidence Effect Estimate (95% CI)
		Risk of Bias	Consistency	Directness	Precision	
Endothelin antagonists vs. placebo: Dizziness	3 (300)	Low (3)	Consistent	Direct	Precise	<b>SOE = Low</b> OR 0.45 (0.24 to 0.85)
Phosphodiesterase inhibitors vs. placebo: Peripheral edema	2 (661)	Low (2)	Consistent	Direct	Precise	<b>SOE = Moderate</b> OR 3.32 (1.40 to 7.87)
Phosphodiesterase inhibitors vs. placebo: Infections	4 (959)	Low (3) Moderate (1)	Inconsistent	Direct	Precise	<b>SOE = Low</b> OR 2.17 (1.20 to 3.94)
Phosphodiesterase inhibitors vs. placebo: Headache	5 (1156)	Low (4) Moderate (1)	Consistent	Direct	Precise	<b>SOE = High</b> OR 1.98 (1.18 to 3.32) Favors placebo
Phosphodiesterase inhibitors vs. placebo: Flushing	4 (1002)	Low (4)	Consistent	Direct	Precise	<b>SOE = Moderate</b> OR 2.46 (1.27 to 4.75) Favors placebo
Prostanoids (aerosolized) vs. placebo: Headache	3 (505)	Low (3)	Consistent	Direct	Precise	<b>SOE = High</b> OR 2.35 (1.50 to 3.70)

**Table 31. Summary strength of evidence for KQ 3: Adverse events<sup>a</sup> (continued)**

Comparison	Number of Studies (Patients)	Domains				Strength of Evidence Effect Estimate (95% CI)
		Risk of Bias	Consistency	Directness	Precision	
<b>Prostanoids (aerosolized) vs. placebo: Jaw pain</b>	2 (270)	Low (2)	Consistent	Direct	Precise	<b>SOE = High</b> OR 4.32 (1.67 to 11.17) Favors placebo
<b>Prostanoids (aerosolized) vs. placebo or standard therapy: Flushing</b>	3 (505)	Low (3)	Consistent	Direct	Precise	<b>SOE = Moderate</b> OR 4.72 (2.13 to 10.42) Favors placebo
<b>Prostanoids (aerosolized) vs. placebo: Cough</b>	3 (505)	Low (3)	Consistent	Direct	Precise	<b>SOE = High</b> OR 2.42 (1.66 to 3.53) Favors placebo

CI = confidence interval; OR = odds ratio; SOE = strength of evidence

<sup>a</sup>Only meta-analyses that generated a summary estimate with 95% confidence intervals that did not cross 1.0 or were too imprecise to conclude no difference between groups are included in this table.



# Discussion

## Key Findings and Strength of Evidence

In this comparative effectiveness review, we included 60 studies involving 7096 patients that evaluated biomarker tests, echocardiography, or both, to screen for PAH (KQ 1); 99 studies involving 8655 patients that evaluated biomarker tests, echocardiography, or both, to diagnose and follow progression of disease as well as response to therapy for PAH (KQ 2); and 37 studies involving 4192 patients that assessed the effectiveness of drug treatments for PAH in adults.

### KQ 1: Screening for PAH

We found 1 study involving 372 patients that evaluated the combination of biomarker tests and echocardiography to echocardiography alone to screen for PAH (Key Question [KQ] 1). Based on one good-quality prospective cohort study, biomarker testing with NT-proBNP may be useful in ruling out PAH among those suspected of PH who also have elevated sPAP by echocardiography;<sup>26</sup> however, no data are available regarding combined echocardiography and biomarker screening in asymptomatic patients at high risk for PAH. In the absence of other direct comparative trials, we attempted to address this question by evaluating the efficacy of biomarker and echocardiography independently for screening and diagnosis of PAH. We reviewed 60 studies involving 7096 patients that evaluated biomarker tests, echocardiography, or both, to screen for PAH. The associations between natriuretic peptide testing and PAH diagnosis is insufficiently strong to support its use alone as a screening test in either asymptomatic or symptomatic patients suspected of PAH. Data on biomarker testing were essentially limited to a single test—NT-proBNP—which showed only moderate correlation with RHC hemodynamic measures and showed a great deal of variability between studies in its diagnostic accuracy and discrimination.

We found that echocardiography estimates of pulmonary artery pressures (sPAP, TG, and TRV) and pulmonary vascular resistance ( $TRV/VTI_{RVOT}$ ) demonstrated good accuracy in screening for PAH. In low prevalence populations (<10%), negative predictive value of a normal sPAP is high, suggesting that echocardiography with a low threshold may be an appropriate test in asymptomatic high-risk populations or in patients with symptoms suggesting PAH. (This is shown in studies of liver transplant studies with complete verification).

Our findings suggest that echocardiographic estimation of sPAP may be sufficiently accurate to justify its role in screening for PAH in symptomatic patients suspected of having PH. However, this conclusion has several important caveats. First, echocardiography in a small, but significant, number of patients may not produce an estimate of sPAP because of poor-quality Doppler visualization of the tricuspid regurgitant jet. Second, echocardiographic estimates of sPAP often over- or under-estimate pulmonary artery pressure enough to result in misclassification according to PAH diagnostic threshold—hence the selection of a test threshold is critical for the aim of screening. A single test threshold is insufficient to perform with simultaneously high sensitivity and specificity (or PPV and NPV), especially in populations with higher risk or higher prevalence (more symptomatic), where echocardiography cannot be relied upon to exclude pulmonary hypertension if pretest probability is high. In asymptomatic patients at high risk for PH, echocardiography seems to perform with similar sensitivity and specificity; however, these studies suffer from verification bias, which likely inflates both the sensitivity and specificity estimates. Two prospective studies that show approximately 10 percent of

asymptomatic patients with systemic sclerosis and normal sPAP develop PH when serially retested with echocardiography are consistent with either misclassification at baseline echocardiographic screening or prospective development of PH. This would suggest that if echocardiographic screening of asymptomatic patients with a high-risk diagnosis were to be undertaken, then serial testing would be necessary.

Table 32 summarizes the findings of our review and the strength of evidence (SOE) for the available outcomes of sensitivity, specificity, correlation coefficients, and adverse effects of biomarker and echocardiographic tests.

**Table 32. Summary of strength of evidence and effect estimates for echocardiography vs. echocardiography plus biomarkers as screening modalities for PAH (KQ 1)<sup>a</sup>**

Test	Sensitivity	Specificity	Correlation with RHC
<b>Echo sPAP with NT-proBNP versus Echo sPAP in symptomatic patients</b>	SOE = Insufficient (1 study, 121 patients)  NT-proBNP >80 pg/mL has a low false negative rate compared with RHC reference standard; the serial testing study design did not allow for NT-proBNP testing to improve sensitivity beyond that of echo sPAP alone	SOE = Low (1 study, 121 patients)  NT-proBNP ≤80 pg/mL ruled out PAH in 9–16% of patients with elevated echo sPAP ≥36 mmHg	SOE = Insufficient (No studies)
<b>Echo sPAP with NT-proBNP versus Echo sPAP in asymptomatic patients</b>	SOE = Insufficient (No studies)	SOE = Insufficient (No studies)	SOE = Insufficient (No studies)
<b>NT-proBNP compared with RHC</b>	SOE = Low (3 studies, 198 patients)  NT-proBNP has variable sensitivity (range, 56% to 100%) for diagnosing PAH; uncertain performance for ruling out PAH	SOE = Low (3 studies, 198 patients)  NT-proBNP has variable specificity (range, 24% to 95%); uncertain performance for ruling in PAH	SOE = Moderate (3 studies, 176 patients)  Correlation of NT-proBNP and RHC is only moderate (range, 0.43 to 0.72)
<b>TRV/TG/sPAP compared with RHC</b>	SOE = Moderate (19 studies, 2459 patients)  Echocardiographic estimate of sPAP showed variable sensitivity ranging from 58% to 100%, with lower prevalence studies finding higher sensitivity	SOE = Moderate (19 studies, 2459 patients)  Echocardiographic estimate of sPAP showed variable specificity ranging from 50% to 98%, with lower prevalence studies finding higher specificity	SOE = Moderate (23 studies, 4217 patients)  Echocardiographic estimates of sPAP showed moderate to strong correlation (range, 0.38 to 0.96) with RHC and were on average unbiased, but were limited by imprecision and by a significant minority of patients in whom TRV was not measurable

**Table 32. Summary of strength of evidence and effect estimates for echocardiography vs. echocardiography plus biomarkers as screening modalities for PAH (KQ 1)<sup>a</sup> (continued)**

Test	Sensitivity	Specificity	Correlation with RHC
TRV/VTI <sub>RVOT</sub> compared with RHC	SOE = Moderate (6 studies, 196 patients)  Echocardiographic estimate of PVR showed reasonably high sensitivity (range, 89% to 100%) for ruling in PAH	SOE = Moderate (6 studies, 196 patients)  Echocardiographic estimate of PVR showed variable specificity (range, 50% to 97%), with better specificity in lower prevalence studies (range, 94% to 97%)	SOE = High (6 studies, 196 patients)  Strong correlation between echocardiographic estimates of PVR and PVR by RHC (range, 0.74 to 0.84)

NT-proBNP = N-terminal pro-B-type natriuretic peptide; RHC = right heart catheterization; SOE = strength of evidence; sPAP = systolic pulmonary artery pressure; TRV = tricuspid regurgitant jet velocity; VTI<sub>RVOT</sub> = velocity-time integral of right ventricular outflow tract

<sup>a</sup>Gray background indicates insufficient SOE.

## KQ 2: Management of PAH

Currently, right heart catheterization (RHC) is the reference standard for diagnosing and monitoring progression of PAH. Several biomarkers and echocardiographic parameters have been proposed as potential alternatives to frequent RHC monitoring. In KQ 2 we reviewed studies that evaluated the most commonly studied biomarkers (natriuretic peptides, endothelin-1, uric acid, troponin T, nitric oxide, asymmetric dimethylarginine, cyclic guanosine monophosphate, and D-dimer) and echocardiographic parameters (RV size, RA size, FAC, TAPSE, RIMP/MPI/Tei index, sPAP, mPAP, TR jet, peak TR jet, RVOT, RVEF, RVSP or pericardial effusion) to determine the ability of these measures to assess severity of disease, predict mortality or lung transplantation, or assess response to therapy.

In studies evaluating correlation of the above measures with RHC measures or a commonly used measure of disease severity (6MWD) studies were too underpowered to give reliable results. However, by combining studies looking at the same parameters and performing a meta-analysis we were able to increase the power for seven different comparisons: (1) BNP versus RHC-mPAP, (2) BNP versus RHC-PVR, (3) BNP versus RHC-CI, (4) BNP versus RHC-RAP, (5) BNP versus RHC-PCWP, (6) BNP versus 6MWD, and (7) echocardiography-derived sPAP versus RHC-sPAP. BNP showed only moderate correlation with most RHC measures (mPAP, PVR, cardiac index, RAP) and clinical measures of disease severity (6MWD) and showed weak correlation with PCWP. Most effect estimates were precise (mPAP, PVR, CI, RAP, 6MWD), but estimates for PCWP were imprecise, making it difficult to interpret the clinical importance of the findings for this measure. For the other measures, correlation with BNP was moderate, indicating that BNP levels alone could not serve as an accurate surrogate marker for disease severity. Echocardiography-derived sPAP showed strong correlation with RHC-sPAP, although there was a great deal of heterogeneity among these studies and only moderate strength of evidence to support the use of this measure.

In studies evaluating the ability of biomarkers or echocardiographic measures to predict mortality, we were able to perform a meta-analysis on six measures: BNP, pericardial effusion, RA size, FAC, uric acid and TAPSE. BNP level and pericardial effusion were strong predictors of mortality. RA size was also predictive of mortality. Data on uric acid suggested an association with mortality, while fractional area change (FAC) showed uncertain association with mortality.

The remaining studies that were not included in the meta-analyses were considered to provide insufficient evidence due to small size and poor quality.

Several studies evaluated mean or median levels of biomarkers or echocardiographic parameters at various points in time or as a change from baseline to evaluate response to therapy. Due to the small number and heterogeneity of these studies, we were unable to perform meta-analysis on these data. While a few studies found changes in biomarkers or echocardiographic parameters in response to various treatments, there were insufficient data to quantitatively assess overall response or to recommend use of these markers as surrogate outcomes measures.

We found no studies addressing diagnostic thinking efficacy, therapeutic efficacy, or safety concerns with echocardiography or biomarkers.

The strength of evidence (SOE) ratings for the most commonly reported biomarkers and echocardiographic parameters are summarized in Table 33 (management of PAH) and Table 34 (prediction of patient outcomes).

**Table 33. Summary of strength of evidence and effect estimates for the use of echocardiography or biomarkers in the management of PAH (KQ 2)**

Comparison	Number of Studies (Patients)	Summary Correlation Coefficient Estimate (95% CI)	SOE and Findings
<b>BNP compared with RHC-mPAP</b>	14 (606)	0.39 (0.31 to 0.47)	SOE = Moderate  Serum BNP level shows moderate correlation with mPAP
<b>BNP compared with RHC-PVR</b>	13 (684)	0.46 (0.31 to 0.59)	SOE = Low  Serum BNP level shows moderate correlation with PVR
<b>BNP compared with RHC-RAP</b>	12 (645)	0.47 (0.40 to 0.54)	SOE = Moderate  Serum BNP level shows moderate correlation with RAP
<b>BNP compared with RHC-CI</b>	10 (550)	-0.42 (-0.54 to -0.28)	SOE = Low  Serum BNP level shows negative moderate correlation with cardiac index
<b>BNP compared with PCWP</b>	5 (319)	0.16 (0.01 to 0.31)	SOE = Low  Serum BNP level shows poor correlation with PCWP
<b>BNP compared with 6MWD (absolute)</b>	9 (484)	-0.46 (-0.55 to -0.35)	SOE = Moderate  Serum BNP level shows negative moderate correlation with 6MWD
<b>Echocardiography-derived sPAP compared with RHC-sPAP</b>	9 (362)	0.76 (0.53 to 0.89)	SOE = Low  sPAP estimated by echocardiography shows good correlation with sPAP from RHC

6MWD = 6-minute walk distance; BNP = B-type natriuretic peptide; CI = confidence interval; FAC = fractional area change; PCWP = pulmonary capillary wedge pressure; PVR = pulmonary vascular resistance; RA = right atrium; RAP = right atrial pressure; RHC = right heart catheterization; SOE = strength of evidence; sPAP = systolic pulmonary artery pressure

**Table 34. Summary of strength of evidence and effect estimates for the use of echocardiography or biomarkers in the prediction of mortality (KQ 2)<sup>a</sup>**

Marker	Number of Studies (Patients)	Summary Hazard Ratio Estimate (95% CI)	SOE and Findings
<b>BNP</b>	6 (407)	2.42 (1.72 to 3.41)	SOE = Moderate  Increase in log-transformed BNP level is a good predictor of mortality
<b>Pericardial effusion</b>	8 (2590)	2.43 (1.57 to 3.77)	SOE = Moderate  Presence of pericardial effusion is a strong predictor of mortality, although there was wide variability in results for this measure
<b>RA size</b>	4 (242)	1.06 (1.01 to 1.10)	SOE = Moderate  RA size is a predictor of mortality
<b>FAC</b>	4 (242)	0.98 (0.96 to 1.01)	SOE = Moderate  FAC is a poor predictor of mortality
<b>Uric acid</b>	4 (246)	1.01 (1.00 to 1.01)	SOE = Low Small increase in mortality but imprecision of estimates limit these data
<b>TAPSE</b>	4 (251)	0.94 (0.82 to 1.08)	SOE = Insufficient Inconsistent results between studies lead to uncertainty

BNP = B-type natriuretic peptide; CI = confidence interval; FAC = fractional area change; RA=right atrium; RAP = right atrial pressure; SOE = strength of evidence

<sup>a</sup>Gray background indicates insufficient SOE.

### KQ 3: Pharmacotherapy for PAH

The treatment options for PAH currently are based on three main classes of drugs: endothelin receptor antagonists (ambrisentan, bosentan); phosphodiesterase-5 inhibitors (sildenafil, tadalafil); and prostacyclin-analogues (epoprostenol, iloprost, treprostinil). Few RCTs have been performed to date to fully evaluate the efficacy of these drugs—individually or in combination.

We reviewed 28 RCTs studies involving 3613 patients and 9 nonrandomized observational studies involving 579 patients that assessed the effectiveness of drug treatment for PAH in adults. Our review found inconclusive evidence regarding mortality reduction for 11 of the 12 drug treatment comparisons:

- Ambrisentan versus placebo (OR 0.40; 95% CI, 0.10 to 1.51)
- Bosentan versus placebo (OR 0.72; CI, 0.14 to 3.60)
- Epoprostenol versus placebo or standard therapy (OR 0.33; CI, 0.07 to 1.50)
- Iloprost versus placebo (OR 0.43; CI, 0.08 to 2.47)
- Sildenafil versus placebo (OR 1.01; CI, 0.10 to 9.92)
- Tadalafil versus placebo (OR 0.50; CI, 0.05 to 5.63)
- Treprostinil versus placebo (OR 0.50; CI, 0.12 to 2.12)
- Vardenafil versus placebo (OR 0.08; CI, 0.00 to 1.82)
- Endothelin antagonists versus placebo (OR 0.60; CI, 0.23 to 1.59)

- Phosphodiesterase inhibitors versus placebo (OR 0.30; CI, 0.08 to 1.11)
- Combination therapy versus monotherapy (OR 0.37; CI, 0.04 to 3.32)

However, for prostanoids versus placebo or standard therapy, there was a statistically significant improvement in mortality (OR 0.52; CI, 0.29 to 0.95, low strength of evidence). Few deaths were observed in these limited-duration studies, leading to wide confidence intervals and lack of statistical power to detect a difference; however, a consistent direction of effect and demonstrated improvements in other outcomes, including functional and hemodynamic measures, support that a mortality reduction might exist.

The combination therapy analyzed included three different combinations of drugs: sildenafil plus IV epoprostenol versus IV epoprostenol plus placebo; bosentan plus IV epoprostenol versus IV epoprostenol plus placebo; and bosentan or sildenafil plus inhaled treprostinil versus bosentan or sildenafil plus placebo. Our results are similar to a recent meta-analysis by Fox et al.,<sup>210</sup> which found no significant change in mortality with combination therapy compared with monotherapy for PAH (OR 0.42; 95% CI, 0.08 to 2.26). Clearly more studies are needed in this area.

In studies evaluating 6MWD, we performed four meta-analyses: (1) endothelin receptor antagonists versus placebo, (2) phosphodiesterase-5 inhibitors versus placebo, (3) prostanoids versus placebo or standard therapy, and (4) combination therapy versus monotherapy. Increases in 6MWD ranging from 27.9 meters (95% CI, 10.3 to 45.4) to 39.9 meters (CI, 21.4 to 58.4) were observed in trials of all drug classes when compared with placebo or standard therapy; however, comparisons between agents are inconclusive. The magnitude of these statistically significant improvements in 6MWD associated with treatment are very close to a recently published estimate of 33 meters for the minimal important difference for the 6MWD in patients with PAH.<sup>211</sup> Combination therapy also showed improved 6MWD compared with monotherapy (OR 23.9; CI, 8.0 to 39.9), but the diversity of treatment regimens and the small number of combination therapy trials again make comparisons between specific regimens inconclusive.

In studies evaluating hospitalization, we performed four meta-analyses: (1) endothelin receptor antagonists versus placebo, (2) phosphodiesterase-5 inhibitors versus placebo, (3) prostanoids versus placebo, and (4) combination therapy versus monotherapy. In patients taking the endothelin receptor antagonists and phosphodiesterase-5 inhibitors, the odds ratio of hospitalization was lower compared with placebo (OR 0.34 and 0.48, respectively). The magnitude of the odds ratio associated with prostanoids was similar (OR 0.42), but the 95% confidence interval included 1.0, thereby making this finding not statistically significant and inconclusive. Combination therapy compared with monotherapy also showed a similar nonsignificant effect on hospitalization (OR 0.64).

In studies using right heart catheterization to follow response to therapy, we performed meta-analyses on the following outcomes: (1) pulmonary vascular resistance, (2) mean pulmonary artery pressure, and (3) cardiac index. We found modest improvements in all three measures associated with phosphodiesterase inhibitors and prostanoids and improvements in two measures (mPAP and cardiac index) associated with endothelin antagonists. The clinical significance of the magnitude of the observed changes is unclear. Meta-analysis of two studies that compared combination therapy with monotherapy revealed a modest but statistically significant improvement in mPAP associated with combination therapy and insufficient evidence for PVR and cardiac index.

In studies reporting adverse effects, we found that phosphodiesterase-5 inhibitors were more likely to cause headache than endothelin receptor antagonists were, and endothelin antagonists still were more likely to cause headache than placebo. Drugs did not significantly differ in their

odds of causing dizziness or diarrhea. Aerosolized prostanoids were much more likely to cause jaw pain and cough compared with placebo. Phosphodiesterase-5 inhibitors and prostanoids were associated with flushing, while data on endothelin receptor antagonists were inconclusive. Phosphodiesterase-5 inhibitors had a significant association with peripheral edema while data on prostanoids and endothelin receptor antagonists were inconclusive.

The strength of evidence (SOE) ratings are summarized in Table 35.

**Table 35. Summary of strength of evidence and effect estimates for monotherapy versus combination therapy for PAH (KQ 3)<sup>a</sup>**

Intervention	Mortality	6MWD (m)	Hospitalization
<b>Endothelin antagonist vs. placebo</b>	SOE = Insufficient (6 studies, 838 patients)  Inconclusive benefit (few studies, few deaths lead to wide CI)  OR 0.60 (95% CI, 0.23 to 1.59)	SOE = Moderate (6 studies, 663 patients)  Improved 6MWD with endothelin antagonists compared with placebo  Mean difference 39.9 (95% CI, 21.4 to 58.4)	SOE = Moderate (3 studies, 606 patients)  Reduced risk of hospitalization  OR 0.34 (95% CI, 0.17 to 0.69)
<b>Phosphodiesterase inhibitors vs. placebo</b>	SOE = Insufficient (4 studies, 1,011 patients)  Inconclusive benefit (few studies, few deaths lead to wide CI)  OR 0.30 (95% CI, 0.08 to 1.11)	SOE = Moderate (4 studies, 991 patients)  Improved 6MWD with PDE5 therapy compared with placebo or standard therapy  Mean difference 38.9 (95% CI, 22.0 to 55.9)	SOE = Moderate (4 studies, 1,011 patients)  Reduced risk of hospitalization  OR 0.48 (95% CI, 0.25 to 0.91)
<b>Prostanoids vs. placebo or standard therapy</b>	SOE = Low (8 studies, 1,229 patients)  Lower mortality with prostanoids, but inconsistent results and wide CI  OR 0.52 (95% CI, 0.29 to 0.95)	SOE = Moderate (7 studies, 933 patients)  Improved 6MWD with prostanoid therapy compared with placebo  Mean difference 27.9 (95% CI, 10.3 to 45.4)	SOE = Insufficient (2 studies, 301 patients)  Inconclusive benefit (few studies, wide CI)  OR 0.42 (95% CI, 0.06 to 3.08)
<b>Combination vs. monotherapy</b>	SOE = Insufficient (3 studies, 566 patients)  Inconclusive benefit (few studies, few deaths lead to wide CI)  OR 0.37 (95% CI, 0.04 to 3.32)	SOE = Low (3 studies, 363 patients)  Improved 6MWD with combination therapy compared with monotherapy  Mean difference 23.9 (95% CI, 8.0 to 39.9)	SOE = Insufficient (3 studies, 566 patients)  Inconclusive benefit (few studies, wide CI)  OR 0.64 (95% CI, 0.31 to 1.36)

6MWD = 6-minute walk distance; CI = confidence interval; NS = not statistically significant; OR = odds ratio; SOE=strength of evidence

<sup>a</sup>Gray background indicates insufficient SOE.

## Findings in Relation to What is Already Known

Two previous meta-analyses of echocardiography for diagnosing pulmonary hypertension, focusing solely on sPAP, drew similar conclusions to our review, despite methodological

differences, suggesting that our findings are robust. Zhang et al.<sup>212</sup> analyzed six studies, finding a summary sensitivity of 0.82 (95% CI; 0.76 to 0.88) and summary specificity of 0.68 (95% CI, 0.64 to 0.72). These estimates are somewhat lower than our findings. Despite inclusion criteria that seem to be similar, Zhang et al.<sup>212</sup> included fewer eligible studies than our review even taking into account the date range. Another more recent analysis that included more studies had broader inclusion criteria including patients with COPD and heart failure who were not suspected of having PAH.<sup>213</sup> Summary estimates of sensitivity of 0.83 (CI, 0.73 to 0.90) and specificity of 0.72 (CI, 0.53 to 0.85) were closer to our findings. This study found significant heterogeneity and, given larger numbers of included studies, was able to undertake various sensitivity analyses to explore the reasons for heterogeneity; however, none of the characteristics examined—including prospective studies, study year, population (cardiac versus lung), interval between echocardiography and RHC, and method of RAP estimate—revealed a source for the heterogeneity. Both reviews concluded that echocardiography has acceptable accuracy for use as the initial measure of pulmonary pressures in evaluating patients in whom PH is suspected, but not sufficient accuracy to diagnose PH without RHC.


KQ 2 focused on determining whether echocardiographic parameters and/or biomarkers have value in the management of PAH. The current guidelines for diagnosis and treatment of pulmonary hypertension have identified the presence of pericardial effusion, indexed right atrial area, LV eccentricity index, and RV Doppler index (RIMP/MPI/Tei index) as the echocardiographic parameters having the best prognostic value. TAPSE has also been reported to have some prognostic value.<sup>12</sup> Our findings confirm that pericardial effusion and right atrial size were strong predictors of mortality; however, we found TAPSE did not predict mortality, and we had insufficient data to evaluate the prognostic value of LV eccentricity index or RV Doppler index. These guidelines have also reported that uric acid, ANP, BNP, and troponin T have prognostic value in PAH. In our review, BNP level was associated with mortality and also showed moderate correlation with hemodynamic measures such as RAP and PVR as well as clinical outcomes such as the 6MWD, which have all been reported by the current guidelines to be strong predictors of prognosis. Prior studies also have attempted to determine an optimal cutoff point for BNP levels to most accurately predict prognosis, but we had insufficient data to make any such determination. We also had insufficient data to determine the prognostic significance of other biomarkers. We did find that echocardiography-derived sPAP correlated strongly with RHC-sPAP, but given that sPAP is considered less important than mPAP in terms of prognostic value for PAH, this correlation may be of limited clinical utility.

For KQ 3, our results are similar to a recent meta-analysis by Fox et al.,<sup>210</sup> which found no significant change in mortality with combination therapy compared with monotherapy for PAH (RRR 0.42; 95% CI, 0.08 to 2.26). Our assessment resulted in minor differences that did not impact the conclusions of the study, including a reversal of the effect direction in one study of 6MWD<sup>192</sup> and inability to reproduce the mortality data from another study.<sup>209</sup> Our findings are consistent with those of another meta-analysis of similar scope that also reported a significant effect of prostanoids on mortality.<sup>214</sup>

Another finding from Fox et al. suggested a relationship between the efficacy of treatment on mortality and functional class severity in individual trials. A meta-regression showed greater reduction in mortality in trials with higher proportions of functional class III or IV patients ( $R^2=0.51$ ). We reexamined this hypothesis in our set of data, which included several more trials with lower proportions of functional class III or IV patients. We found no significant association ( $p=0.82$ ) (Figure 42).



Figure 42. Regression of functional class on log odds ratio



## Applicability

The principal limitations to applicability of data on the diagnosis of PAH all relate to the patient populations studied. First, the studies may not be applicable to the screening of asymptomatic patients. None of the study populations consisted entirely of asymptomatic patients and, although many studies included some patients without symptoms, they were not reported separately in terms of outcomes. Some studies of populations in whom PAH was suspected failed to adequately describe the basis for a clinical suspicion of PAH, whether symptoms of dyspnea, clinical signs, or other test results, such as diffusion capacity of the lung for carbon monoxide (DLCO), thus also limiting the applicability of these studies for screening symptomatic patients. Second, the spectrum of disease among study populations was often skewed, particularly in case-control studies, by selection criteria that selected from patients with known PAH (cases) and patients known not to have PAH (controls). Such studies usually excluded participants with other conditions that might be confused with PAH such as PH due to left-sided heart failure, thrombotic disease, or chronic obstructive pulmonary disease. Third, participants in many studies had a wide range of disease severity, particularly those cases in case-control design studies, which is a poor match for the question at hand. Other applicability issues identified in the KQ 1 studies were less frequent and judged to be less severe.

Our findings in KQ 2 assessing the prognostic or predictive value of biomarkers and echocardiography may not be applicable to all PAH populations. The greatest concern is that studies in KQ 2 included participants at widely differing points in the natural history of disease, who had widely differing degrees of disease severity and different underlying etiologies of PAH. There was also concern that the population was not adequately described to assess applicability, included patients with conditions other than PAH, or in general did not match the review question. Applicability may also be limited by the use of surrogate markers that may not be clinically relevant and insufficient followup time. In a few studies, it was also felt that the

intervention arm or cointerventions did not adequately reflect current clinical practice or that the study setting was widely divergent from the current typical U.S. setting. Finally, there is concern that some studies did not provide adequate information about adverse events.

Applicability considerations were somewhat different for KQ 3 than for the Key Questions about screening and management of PAH. Most of the studies included in this review for KQ 3 were RCTs with generally good internal validity. Patient populations, however, differed between studies; variation in eligibility criteria resulted in differences between study populations in severity of illness, underlying etiology of PAH, comorbid conditions, and prior and concurrent treatment. Many different countries were represented, thereby introducing potential differences in clinical practice and care delivery settings relative to current practice in typical settings the U.S. There was also concern that the population was not always adequately described to assess applicability, with few studies exploring potential differences in response to treatment among different patient subgroups.

## Implications for Clinical and Policy Decisionmaking

With regard to screening for PH with echocardiography, our findings are generally consistent with the approach used in the guidelines from the European Society of Cardiology (ESC)/European Respiratory Society (ERS),<sup>12,215</sup> which describe a stratification based on echocardiographic TRV or sPAP and other echocardiographic variables suggestive of pulmonary hypertension (PH):

- PH unlikely: TRV  $\leq 2.8$  m/s or sPAP  $\leq 36$  mmHg and no additional echocardiographic variable suggestive of PH
- PH possible: TRV  $\leq 2.8$  m/s or sPAP  $\leq 36$  mmHg but with additional echocardiographic variable suggestive of PH or TRV 2.9–3.4 m/s or sPAP 37–50 mmHg
- PH likely: TRV  $> 3.4$  m/s or sPAP  $> 50$  mmHg

The additional echocardiographic variables include increased velocity of pulmonary valve regurgitation and a short acceleration time of RV ejection into the PA. The guideline noted that RA and RV dilation, abnormal septum shape or function, increased RV wall thickness, and dilated main PA occur late in the course of PH and thus have questionable value in screening.

The guideline specifically recommends against screening to identify mild, asymptomatic PH because of the high frequency of both underestimation and overestimation of pulmonary artery pressures by echocardiography. Hence, the thresholds are set high. This guideline recommends that echocardiography always be performed when PH is suspected. Also recommended is echocardiographic screening of patients who are candidates for liver transplantation and symptomatic patients with liver disease, connective tissue diseases, HIV infection, and lung disease. The only suggestion for screening asymptomatic patients is for patients with the scleroderma spectrum of diseases, in whom screening “may be considered.” The lack of direct comparisons between assessment strategies, and the lack of measures of clinical outcomes associated with screening diagnostic or prognostic testing, would not seem to support more directive recommendations regarding testing modalities.

Our findings support using echocardiography or biomarkers to assess disease severity, prognosis, or response to therapy. Echocardiography-derived sPAP shows promise as a possible surrogate marker for RHC-sPAP, but whether or not this measure alone is adequate to assess disease severity, prognosis, or response to therapy is unclear, and so this evidence is insufficient to support recommendations regarding policy changes.

The findings from our meta-analyses of the few studies that compared combination therapy with monotherapy suggest, but do not prove, that combination therapy confers more benefit than does monotherapy in the treatment of PAH. These findings are generally consistent with the ESC/ERS guideline recommendation for monotherapy as initial treatment, with combination treatment reserved for patients who have an inadequate clinical response to monotherapy.<sup>12,215</sup>

## **Limitations of the Comparative Effectiveness Review Process**

The process of a comparative effectiveness review calls for specifying the scope and methods a priori. In this review, certain decisions made in designing the review resulted in limitations to this report. First, although we did not intend to exclude studies of children, some of the inclusion criteria we established had the effect of eliminating much of the literature on children with PAH. These criteria included the requirement for RHC verification of diagnoses of PAH and, for therapy trials, a minimum followup of 3 months. Studies in children, particularly newborns with PPHN, often omitted RHC and reported outcomes in shorter followup intervals. Second, we anticipated better quality data for the questions about screening and diagnosis (KQ 1) and prognosis (KQ 2) than we actually found.

For KQ 3, certain limitations existed in our search criteria, which may have limited the analysis. First, as with all meta-analyses, there is the potential for bias due to analyzing published studies, which are more likely to have positive results. We investigated this possibility by creating a funnel plot that included 17 of the 28 RCTs that met eligibility criteria for KQ 3 and that reported 6MWD as an outcome at 8 to 16 weeks after randomization to treatment. Visual inspection of the funnel plot suggests an absence of publication bias. We selected studies that reported 6MWD for this assessment of possible publication bias because this is the major outcome that was most commonly reported, and because there were too few studies that consistently reported other outcomes to reliably assess for possible publication bias. Another limitation is that we pooled the lower doses of drug with the higher doses, thereby possibly diluting any treatment effects—either beneficial or harmful—seen in the higher doses. We also may have missed lower doses that were less efficacious. Our analysis of the 6MWD outcome was also hindered by the heterogeneity in the ways studies were reported (mean versus median, and standard deviation versus standard error); we addressed this by converting medians to means and interquartile ranges to standard errors, but this required us to make assumptions about normal distribution of data.

## **Limitations of the Evidence Base**

Current evidence has several important limitations that preclude a firm conclusion about the effectiveness of echocardiography and biomarker screening for PAH. First, studies have most often assembled populations that reflect referral-filter bias and which inadequately document the presence of symptoms and signs related to PAH or to an alternative diagnosis such as congestive heart failure (CHF) or pulmonary fibrosis, etc. In such studies, we found that the diagnostic performance of echocardiographic testing varied with PAH prevalence such that higher prevalence was associated with poorer diagnostic performance. We believe this is related to a higher proportion of conditions that may be confused with PAH and which use screening tests that fail to distinguish these conditions (e.g., PCWP >15 mmHg can be easily found at RHC but is difficult to ascertain by echocardiography; BNP can be similarly elevated in CHF and PAH).

Second, the diagnosis of PAH is based on multiple components that include not only pulmonary artery pressure but also the absence of elevated PCWP and elevated PVR. However, nearly all studies of echocardiographic screening relied on the measurement of a single parameter—TRV—as the sole basis for calculation of TG. TG is the principal component for estimation of sPAP and is a key part of estimation of PVR as  $TRV/VTI_{RVOT}$ . In theory, the use of ancillary data of a different sort, such as NT-proBNP, is potentially valuable as a diagnostic strategy.

One study that used serial application of echocardiography and biomarker testing (NT-proBNP) suggests that a combination of echocardiography and biomarker testing can work. With a goal of identifying patients with elevated echocardiography sPAP who could safely refrain from RHC, this study applied a low (highly sensitive) threshold for NT-proBNP and also used ECG evidence of RVH. However, this study was small and, like all of the other studies we identified, suffers from inadequate verification of disease status of at least some screening of test-negative patients.

Given the invasive nature of the RHC reference standard test, it is not surprising that many studies, especially those in lower risk screening populations, would shun widespread verification of test-negative patients. However, the selection of test-negative patients for verification when based on other clinical characteristics (such as DLCO measures or symptoms of dyspnea) was often inadequately reported to quantify the bias due to inadequate verification. None of the studies used an alternate reference standard for test-negative patients; however, two studies that sought to prospectively identify predictors of incident PAH provide valuable insight into this problem—suggesting that approximately 10 percent of echocardiography-screened negative SSc patients would meet PAH diagnostic criteria within 6 to 36 months.

The value of a screening test for early diagnosis depends not only on the diagnostic accuracy of the test for diagnosing the target condition but also the consequences of the different outcomes of testing. These consequences include (1) adverse effects of followup testing or treatment of patients with a false-positive screen and (2) outcomes for patients who go undiagnosed or untreated after a false-negative screen balanced against the benefits that accrue to patients with the target condition who may begin treatment earlier as a result of a true-positive screen. In the case of PAH, although we found no indication of harms related to the screening tests themselves, neither did we find information about the harms of subsequent diagnostic evaluation (such as RHC). Also, there are no clear data on benefits of early treatment or harms from delaying treatment. Thus the considerations are limited to the diagnostic accuracy of testing rather than a broader examination of a policy of screening for early identification.

The main focus of KQ 2 was to determine the comparative effectiveness of biomarkers, echocardiographic parameters, or the combination of both to manage PAH and affect diagnostic thinking efficacy, therapeutic efficacy, and patient outcome efficacy. None of the included studies addressed diagnostic thinking efficacy or therapeutic efficacy. Several studies evaluated changes in levels of biomarkers or echocardiographic parameters in response to therapy, but there were too few studies for any particular marker, as well as significant heterogeneity among studies, leading to insufficient evidence to assess patient outcome efficacy. In addition, no studies evaluated the combination of biomarkers and echocardiography in regard to management of PAH. While there were several studies included in the review that evaluated biomarkers, only BNP had a sufficient number of studies to allow meta-analysis. We limited the evaluation of biomarkers and echocardiographic parameters to those most widely studied; however, the literature review did reveal a wide range of other biomarkers and echocardiographic parameters

in a limited number of studies that may be promising in the management of PAH. Further, while studies evaluating echocardiography or using RHC as a comparator reported results for multiple different parameters, it was unclear in the literature which parameters were most clinically relevant.

Assessing the prognostic value of biomarkers or echocardiographic parameters for such outcomes as the need for transplantation may be biased since all these studies were observational and lacked blinding, and the predictors may have influenced clinical decisions about management or referral for transplantation. Additional research is needed to more fully address the questions posed by KQ 2. Future studies need to evaluate how biomarkers or echocardiography affect diagnostic thinking efficacy and therapeutic efficacy. It has been proposed that a measure that combines a biomarker or biomarkers and echocardiography may be a more effective tool in managing PAH, but research is needed to support this theory. More research needs to be done focusing on response to therapy with increased standardization of duration of followup and medication regimens. A greater body of evidence is needed for novel biomarkers and echocardiographic parameters to effectively assess their usefulness in managing PAH. Future studies should focus on echocardiographic parameters and RHC parameters that are most clinically important.

The evidence for KQ 3 had several limitations. First, we found only a small number of RCTs to analyze. This greatly limited our ability to perform the wide range of meta-analyses on which we had planned, and as such there are gaps in the data. We did not identify any eligible studies that evaluated the comparative effectiveness of calcium channel blockers on intermediate-term and long-term patient outcomes, or that randomized treatment-naïve patients to monotherapy versus combination therapy, or that directly compared two drug classes.

Study populations also were not comparable from study to study, in part because sicker patients are more likely to be receiving prostanoid therapy, so the data on the efficacy of oral therapies may appear to be more favorable because they were studied in patients who were less sick. There is also a paucity of evidence in the published literature to help interpret the clinical significance of the magnitude of effects observed for most outcomes. Recent data on 6MWD, the most commonly assessed outcome measure in the studies analyzed for KQ 3 illustrate this issue. Mathai et al.<sup>211</sup> recently estimated the minimal important difference of the 6MWD for patients with PAH to be approximately 33 meters, which is very close to the effect observed for each of the three drug classes we evaluated, as well as the apparent benefit conferred by combination therapy relative to continuation of monotherapy in patients already on monotherapy. Another recent study suggested a threshold of 41.8 m for change in 6MWD to result in a reduction in clinical events.<sup>216</sup> These recent findings suggest that there may be some question as to the extent to which the statistically significant improvements in 6MWD associated with treatment in clinical trials is clinically meaningful. The paucity of evidence about minimal important differences applies especially to the intermediate outcomes assessed by right heart catheterization. The evidence base for KQ 3 was also limited by nonstandardized and nonsystematic reporting of adverse events.

Although we did not find evidence for publication bias in a funnel plot of 6MWD outcomes, this does not ensure the absence of selective reporting. Modest but statistically significant effects seen in extant studies might nevertheless result from biases in study design or selective reporting of results. The extent to which the funding source may be related to this is unclear from our data; a majority of treatment trials (68%) were industry funded.

## Research Gaps

The available evidence leaves numerous gaps and areas for potential future research. We used the framework recommended by Robinson et al.<sup>217</sup> to identify gaps in evidence and describe why these gaps exist. Results are as follows:

### KQ 1: Screening for PAH

- Patients at elevated risk for PAH, other than systemic sclerosis, have been seldom studied in screening test studies.
  - Consider cohort studies of testing for PH among high-risk populations other than those with systemic sclerosis, including patients with HIV, sickle cell anemia or trait portal hypertension, family history of PAH, or catecholaminergic drug use.
  - Different populations may have different risks of PAH and different benefits from screening; in studies where heterogeneous populations are included, the effectiveness of screening should be examined according to risk factor.
- Relatively few data exist on screening of asymptomatic patients with a combination of echocardiography and biomarker testing.
  - Consider cohort studies that apply echocardiography and biomarker screening in a coordinated or algorithmic way, and studies that verify diagnosis in at least a sample of test-negative patients by RHC or lengthy followup.
  - Future tests of the added value of biomarkers should use well-validated echocardiography parameters as a screening test, including estimates of pulmonary artery pressures (sPAP, TG, and TRV) and pulmonary vascular resistance ( $TRV/VTI_{RVOT}$ ).
- Studies of echocardiography for diagnosis of PH have focused on the association of single measures or parameters at a time rather than an integrated diagnostic assessment based on an entire exam and multiple echocardiographic measures or parameters.
  - Consider studies that evaluate a global echocardiographic assessment based not only on sPAP but also on right heart chamber size wall thickness and function, estimated PVR, and left heart measures.
  - Consider further development of data on the use of echocardiography to measure exercise response to sPAP.
  - Consider further development of echocardiographic estimation of mPAP, which would better align with the diagnostic criteria for PAH.
  - Consider studies of additional promising measures such as end diastolic pulmonary regurgitation gradient, mean tricuspid regurgitation gradient, and Doppler tissue imaging of the tricuspid annulus.

### KQ 2: Management of PAH

- Echocardiographic- and BNP-guided treatment strategies have not been explicitly tested.
  - Consider cohort studies evaluating prognosis as well as treatment trials examining association of baseline echocardiographic parameters and BNP levels to response to treatment.
- Other imaging modalities, such as magnetic resonance imaging, have been little studied as an alternative noninvasive test to assess RV function.

- Cardiopulmonary exercise testing and exercise echocardiography have relatively few data, uncertain clinical utility, and relationship to PH diagnostic criteria.
  - Consider validation studies to demonstrate prognostic value particularly for patients with normal resting echocardiography but abnormal exercise echocardiography.

### **KQ 3: Pharmacotherapy for PAH**

- Relatively few data exist on the efficacy of treating PAH early in the disease course (WHO functional class I-II).
  - Improved data on efficacy of early PAH would strengthen linkage to efficacy of screening testing.
  - Consider treatment trials in early stage PAH, particularly among patients identified by case finding or screening interventions.
- Relatively few data exist on children with persistent PH or congenital heart disease.
  - Consider controlled trials in children.
- Few treatment trials address direct comparison of alternative drug treatment, particularly for PAH patients early in the disease course.
  - Consider trials designed to compare clinical alternative treatments to permit more evidence-based treatment selection such as head-to-head treatment comparisons rather than placebo-control or combination versus monotherapy trials.
- The majority of RCTs thus far have not collected adequate surrogate data and have failed to demonstrate therapeutic gain in terms of definitive endpoints.
  - Consider including biomarker and imaging techniques with conventional clinical outcomes to improve data on validity and responsiveness of surrogate outcomes.
- Few data are available about differences in response to treatment based on patient characteristics from trials.
  - Consider subgroup analysis of treatment efficacy by WHO functional class, underlying etiology, and other patient-level factors.
- Data on the efficacy of combination treatments are limited.
  - Consider more combination treatment trials, in particular trials with clear criteria for starting combination therapy and trials in patients who have not failed monotherapy.
- The duration of controlled trial efficacy data are limited.
  - Consider, particularly for clinically relevant comparisons (e.g., head-to-head treatment or combo versus monotherapy trials), longer term followup studies that retain randomized group comparisons while assessing long-term efficacy.

### **Conclusions**

Further research is needed to confirm the single good-quality study suggesting that echocardiography and the biomarker NT-proBNP in combination may be sufficiently accurate to rule out PAH when testing symptomatic patients. In asymptomatic populations, more research is needed to draw conclusions regarding the effectiveness for screening. BNP, RA size, the presence of pericardial effusion and uric acid had prognostic value in patients with PAH, but other echocardiographic parameters and biomarkers either were not predictive or had insufficient data. Although no treatments demonstrate a strong and consistent mortality reduction, many are

associated with improved 6MWD and reduced hospitalization rates. Comparisons of different drug combinations are inconclusive regarding a mortality reduction but suggest an improvement in 6MWD compared with continuation of monotherapy.



## References

1. Galie N, Torbicki A, Barst R, et al. Guidelines on diagnosis and treatment of pulmonary arterial hypertension. The Task Force on Diagnosis and Treatment of Pulmonary Arterial Hypertension of the European Society of Cardiology. *Eur Heart J*. 2004;25(24):2243-78. PMID: 15589643.
2. Badesch DB, Abman SH, Simonneau G, et al. Medical therapy for pulmonary arterial hypertension: updated ACCP evidence-based clinical practice guidelines. *Chest*. 2007;131(6):1917-28. PMID: 17565025.
3. Simonneau G, Robbins IM, Beghetti M, et al. Updated clinical classification of pulmonary hypertension. *J Am Coll Cardiol*. 2009;54(1 Suppl):S43-54. PMID: 19555858.
4. D'Alonzo GE, Barst RJ, Ayres SM, et al. Survival in patients with primary pulmonary hypertension. Results from a national prospective registry. *Ann Intern Med*. 1991;115(5):343-9. PMID: 1863023.
5. Hoeper MM, Lee SH, Voswinckel R, et al. Complications of right heart catheterization procedures in patients with pulmonary hypertension in experienced centers. *J Am Coll Cardiol*. 2006;48(12):2546-52. PMID: 17174196.
6. Benza RL, Miller DP, Gomberg-Maitland M, et al. Predicting survival in pulmonary arterial hypertension: insights from the Registry to Evaluate Early and Long-Term Pulmonary Arterial Hypertension Disease Management (REVEAL). *Circulation*. 2010;122(2):164-72. PMID: 20585012.
7. Cacciapuoti F. Echocardiographic evaluation of right heart function and pulmonary vascular bed. *Int J Cardiovasc Imaging*. 2009;25(7):689-97. PMID: 19634000.
8. Barst RJ, McGoon M, Torbicki A, et al. Diagnosis and differential assessment of pulmonary arterial hypertension. *J Am Coll Cardiol*. 2004;43(12 Suppl S):40S-47S. PMID: 15194177.
9. Farber HW, Foreman AJ, Miller DP, et al. REVEAL Registry: correlation of right heart catheterization and echocardiography in patients with pulmonary arterial hypertension. *Congest Heart Fail*. 2011;17(2):56-64. PMID: 21449993.
10. Kiatchoosakun S, Wongvipaporn C, Nanagara R, et al. Right ventricular systolic pressure assessed by echocardiography: a predictive factor of mortality in patients with scleroderma. *Clin Cardiol*. 2011;34(8):488-93. PMID: 21717471.
11. Sachdev A, Villarraga HR, Frantz RP, et al. Right ventricular strain for prediction of survival in patients with pulmonary arterial hypertension. *Chest*. 2011;139(6):1299-309. PMID: 21148241.
12. Galie N, Hoeper MM, Humbert M, et al. Guidelines for the diagnosis and treatment of pulmonary hypertension: the Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS), endorsed by the International Society of Heart and Lung Transplantation (ISHLT). *Eur Heart J*. 2009;30(20):2493-537. PMID: 19713419.
13. Bernal V, Pascual I, Esquivias P, et al. N-terminal brain natriuretic peptide as a diagnostic test in cirrhotic patients with pulmonary arterial hypertension. *Transplant Proc*. 2009;41(3):987-8. PMID: 19376405.
14. Cavagna L, Caporali R, Klersy C, et al. Comparison of brain natriuretic peptide (BNP) and NT-proBNP in screening for pulmonary arterial hypertension in patients with systemic sclerosis. *J Rheumatol*. 2010;37(10):2064-70. PMID: 20634241.
15. Aubert JD. Biochemical markers in the management of pulmonary hypertension. *Swiss Med Wkly*. 2005;135(3-4):43-9. PMID: 15729606.
16. Soon E, Holmes AM, Treacy CM, et al. Elevated levels of inflammatory cytokines predict survival in idiopathic and familial pulmonary arterial hypertension. *Circulation*. 2010;122(9):920-7. PMID: 20713898.

17. Macchia A, Marchioli R, Tognoni G, et al. Systematic review of trials using vasodilators in pulmonary arterial hypertension: why a new approach is needed. *Am Heart J*. 2010;159(2):245-57. PMID: 20152223.
18. Sitbon O, Humbert M, Jais X, et al. Long-term response to calcium channel blockers in idiopathic pulmonary arterial hypertension. *Circulation*. 2005;111(23):3105-11. PMID: 15939821.
19. McLaughlin VV, Archer SL, Badesch DB, et al. ACCF/AHA 2009 expert consensus document on pulmonary hypertension a report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents and the American Heart Association developed in collaboration with the American College of Chest Physicians; American Thoracic Society, Inc.; and the Pulmonary Hypertension Association. *J Am Coll Cardiol*. 2009;53(17):1573-619. PMID: 19389575.
20. Agency for Healthcare Research and Quality. Methods Guide for Effectiveness and Comparative Effectiveness Reviews. Rockville, MD: Agency for Healthcare Research and Quality. [www.effectivehealthcare.ahrq.gov/index.cfm/search-for-guides-reviews-and-reports/?pageaction=displayproduct&productid=318](http://www.effectivehealthcare.ahrq.gov/index.cfm/search-for-guides-reviews-and-reports/?pageaction=displayproduct&productid=318). Accessed March 19, 2012.
21. Moher D, Liberati A, Tetzlaff J, et al. Preferred Reporting Items for Systematic Reviews and Meta-analyses: The PRISMA Statement. *PLoS Med*. 2009;6(7):e1000097. PMID: 19621072.
22. Anonymous. Evidence-based Practice Center Systematic Review Protocol. Project Title: Pulmonary Arterial Hypertension: Screening, Management, and Treatment. January 18, 2012. [www.effectivehealthcare.ahrq.gov/index.cfm/search-for-guides-reviews-and-reports/?pageaction=displayproduct&productid=934](http://www.effectivehealthcare.ahrq.gov/index.cfm/search-for-guides-reviews-and-reports/?pageaction=displayproduct&productid=934). Accessed November 19, 2012.
23. Whiting PF, Rutjes AW, Westwood ME, et al. QUADAS-2: A Revised Tool for the Quality Assessment of Diagnostic Accuracy Studies. *Ann Intern Med*. 2011;155(8):529-36. PMID: 22007046.
24. Owens DK, Lohr KN, Atkins D, et al. AHRQ series paper 5: Grading the strength of a body of evidence when comparing medical interventions--Agency for Healthcare Research and Quality and the Effective Health-Care Program. *J Clin Epidemiol*. 2010;63(5):513-23. PMID: 19595577.
25. Atkins D, Chang SM, Gartlehner G, et al. Assessing applicability when comparing medical interventions: AHRQ and the Effective Health Care Program. *J Clin Epidemiol*. 2011;64(11):1198-207. PMID: 21463926.
26. Bonderman D, Wexberg P, Martischniig AM, et al. A noninvasive algorithm to exclude pre-capillary pulmonary hypertension. *Eur Respir J*. 2011;37(5):1096-103. PMID: 20693249.
27. Allanore Y, Borderie D, Avouac J, et al. High N-terminal pro-brain natriuretic peptide levels and low diffusing capacity for carbon monoxide as independent predictors of the occurrence of precapillary pulmonary arterial hypertension in patients with systemic sclerosis. *Arthritis Rheum*. 2008;58(1):284-91. PMID: 18163505.
28. Bogdan M, Humbert M, Francoual J, et al. Urinary cGMP concentrations in severe primary pulmonary hypertension. *Thorax*. 1998;53(12):1059-62. PMID: 10195079.
29. Colle IO, Moreau R, Godinho E, et al. Diagnosis of portopulmonary hypertension in candidates for liver transplantation: a prospective study. *Hepatology*. 2003;37(2):401-9. PMID: 12540791.
30. Condliffe R, Radon M, Hurdman J, et al. CT pulmonary angiography combined with echocardiography in suspected systemic sclerosis-associated pulmonary arterial hypertension. *Rheumatology (Oxford)*. 2011;50(8):1480-6. PMID: 21447566.
31. Dahiya A, Vollbon W, Jellis C, et al. Echocardiographic assessment of raised pulmonary vascular resistance: application to diagnosis and follow-up of pulmonary hypertension. *Heart*. 2010;96(24):2005-9. PMID: 21088122.

32. Denton CP, Cailes JB, Phillips GD, et al. Comparison of Doppler echocardiography and right heart catheterization to assess pulmonary hypertension in systemic sclerosis. *Br J Rheumatol*. 1997;36(2):239-43. PMID: 9133938.
33. Fisher MR, Forfia PR, Chamera E, et al. Accuracy of Doppler echocardiography in the hemodynamic assessment of pulmonary hypertension. *Am J Respir Crit Care Med*. 2009;179(7):615-21. PMID: 19164700.
34. Fonseca GH, Souza R, Salemi VM, et al. Pulmonary hypertension diagnosed by right heart catheterization in sickle cell disease. *Eur Respir J*. 2012; 39(1):112-8. PMID: 21778170.
35. Frea S, Capriolo M, Marra WG, et al. Echo Doppler predictors of pulmonary artery hypertension in patients with systemic sclerosis. *Echocardiography*. 2011;28(8):860-9. PMID: 21906161.
36. Hachulla E, Gressin V, Guillemin L, et al. Early detection of pulmonary arterial hypertension in systemic sclerosis: a French nationwide prospective multicenter study. *Arthritis Rheum*. 2005;52(12):3792-800. PMID: 16320330.
37. Hsu VM, Moreyra AE, Wilson AC, et al. Assessment of pulmonary arterial hypertension in patients with systemic sclerosis: comparison of noninvasive tests with results of right-heart catheterization. *J Rheumatol*. 2008;35(3):458-65. PMID: 18203320.
38. Hua R, Sun YW, Wu ZY, et al. Role of 2-dimensional Doppler echo-cardiography in screening portopulmonary hypertension in portal hypertension patients. *Hepatobiliary Pancreat Dis Int*. 2009;8(2):157-61. PMID: 19357029.
39. Jansa P, Becvar R, Ambroz D, et al. Pulmonary arterial hypertension associated with systemic sclerosis in the Czech Republic. *Clin Rheumatol*. 2012;31(3):557-61. PMID: 22105781.
40. Kovacs G, Maier R, Aberer E, et al. Assessment of pulmonary arterial pressure during exercise in collagen vascular disease: echocardiography vs right-sided heart catheterization. *Chest*. 2010;138(2):270-8. PMID: 20418368.
41. Lindqvist P, Soderberg S, Gonzalez MC, et al. Echocardiography based estimation of pulmonary vascular resistance in patients with pulmonary hypertension: a simultaneous Doppler echocardiography and cardiac catheterization study. *Eur J Echocardiogr*. 2011;12(12):961-6. PMID: 22011836.
42. Low AJ, Fowler D, Manghani MK, et al. Screening and Treating Pulmonary Arterial Hypertension in a Tertiary Hospital -based Multidisciplinary Clinic - The First 200 Patients. *Intern Med J*. 2013;43(1):32-7. PMID: 22032309.
43. Machado RF, Anthi A, Steinberg MH, et al. N-terminal pro-brain natriuretic peptide levels and risk of death in sickle cell disease. *JAMA*. 2006;296(3):310-8. PMID: 16849664.
44. McLean AS, Ting I, Huang SJ, et al. The use of the right ventricular diameter and tricuspid annular tissue Doppler velocity parameter to predict the presence of pulmonary hypertension. *Eur J Echocardiogr*. 2007;8(2):128-36. PMID: 16672193.
45. Mourani PM, Sontag MK, Younoszai A, et al. Clinical utility of echocardiography for the diagnosis and management of pulmonary vascular disease in young children with chronic lung disease. *Pediatrics*. 2008;121(2):317-25. PMID: 18245423.
46. Mukerjee D, St George D, Knight C, et al. Echocardiography and pulmonary function as screening tests for pulmonary arterial hypertension in systemic sclerosis. *Rheumatology (Oxford)*. 2004;43(4):461-6. PMID: 15024134.
47. Murata I, Takenaka K, Yoshinoya S, et al. Clinical evaluation of pulmonary hypertension in systemic sclerosis and related disorders. A Doppler echocardiographic study of 135 Japanese patients. *Chest*. 1997;111(1):36-43. PMID: 8995990.
48. Nakayama Y, Sugimachi M, Nakanishi N, et al. Noninvasive differential diagnosis between chronic pulmonary thromboembolism and primary pulmonary hypertension by means of Doppler ultrasound measurement. *J Am Coll Cardiol*. 1998;31(6):1367-71. PMID: 9581735.

49. Nogami M, Ohno Y, Koyama H, et al. Utility of phase contrast MR imaging for assessment of pulmonary flow and pressure estimation in patients with pulmonary hypertension: comparison with right heart catheterization and echocardiography. *J Magn Reson Imaging*. 2009;30(5):973-80. PMID: 19856412.
50. Phung S, Strange G, Chung LP, et al. Prevalence of pulmonary arterial hypertension in an Australian scleroderma population: screening allows for earlier diagnosis. *Intern Med J*. 2009;39(10):682-91. PMID: 19220532.
51. Pilatis ND, Jacobs LE, Rerkpattanapipat P, et al. Clinical predictors of pulmonary hypertension in patients undergoing liver transplant evaluation. *Liver Transpl*. 2000;6(1):85-91. PMID: 10648583.
52. Rajagopalan N, Simon MA, Suffoletto MS, et al. Noninvasive estimation of pulmonary vascular resistance in pulmonary hypertension. *Echocardiography*. 2009;26(5):489-94. PMID: 19054039.
53. Rich JD, Shah SJ, Swamy RS, et al. Inaccuracy of Doppler echocardiographic estimates of pulmonary artery pressures in patients with pulmonary hypertension: implications for clinical practice. *Chest*. 2011;139(5):988-93. PMID: 20864617.
54. Roeleveld RJ, Marcus JT, Boonstra A, et al. A comparison of noninvasive MRI-based methods of estimating pulmonary artery pressure in pulmonary hypertension. *J Magn Reson Imaging*. 2005;22(1):67-72. PMID: 15971176.
55. Roule V, Labombarda F, Pellissier A, et al. Echocardiographic assessment of pulmonary vascular resistance in pulmonary arterial hypertension. *Cardiovasc Ultrasound*. 2010;8:21. PMID: 20529278.
56. Ruan Q, Nagueh SF. Clinical application of tissue Doppler imaging in patients with idiopathic pulmonary hypertension. *Chest*. 2007;131(2):395-401. PMID: 17296639.
57. Selimovic N, Rundqvist B, Bergh CH, et al. Assessment of pulmonary vascular resistance by Doppler echocardiography in patients with pulmonary arterial hypertension. *J Heart Lung Transplant*. 2007;26(9):927-34. PMID: 17845932.
58. Simeoni S, Lippi G, Puccetti A, et al. N-terminal pro-BNP in scleroderma patients on bosentan therapy for PAH. *Rheumatol Int*. 2008;28(7):657-60. PMID: 18092166.
59. Steen V, Chou M, Shanmugam V, et al. Exercise-induced pulmonary arterial hypertension in patients with systemic sclerosis. *Chest*. 2008;134(1):146-51. PMID: 18403670.
60. Torregrosa M, Genesca J, Gonzalez A, et al. Role of Doppler echocardiography in the assessment of portopulmonary hypertension in liver transplantation candidates. *Transplantation*. 2001;71(4):572-4. PMID: 11258439.
61. Tei C, Dujardin KS, Hodge DO, et al. Doppler echocardiographic index for assessment of global right ventricular function. *J Am Soc Echocardiogr*. 1996;9(6):838-47. PMID: 8943444.
62. Tian Z, Liu YT, Fang Q, et al. Hemodynamic parameters obtained by transthoracic echocardiography and right heart catheterization: a comparative study in patients with pulmonary hypertension. *Chin Med J (Engl)*. 2011;124(12):1796-801. PMID: 21740835.
63. Toyono M, Harada K, Tamura M, et al. Paradoxical relationship between B-type natriuretic peptide and pulmonary vascular resistance in patients with ventricular septal defect and concomitant severe pulmonary hypertension. *Pediatr Cardiol*. 2008;29(1):65-9. PMID: 17786380.
64. Tutar HE, Imamoglu A, Atalay S, et al. Plasma endothelin-1 levels in patients with left-to-right shunt with or without pulmonary hypertension. *Int J Cardiol*. 1999;70(1):57-62. PMID: 10402046.
65. Vlahos AP, Feinstein JA, Schiller NB, et al. Extension of Doppler-derived echocardiographic measures of pulmonary vascular resistance to patients with moderate or severe pulmonary vascular disease. *J Am Soc Echocardiogr*. 2008;21(6):711-4. PMID: 18187297.

66. Vonk MC, Sander MH, van den Hoogen FH, et al. Right ventricle Tei-index: a tool to increase the accuracy of non-invasive detection of pulmonary arterial hypertension in connective tissue diseases. *Eur J Echocardiogr.* 2007;8(5):317-21. PMID: 16846757.
67. Willens HJ, Chirinos JA, Gomez-Marin O, et al. Noninvasive differentiation of pulmonary arterial and venous hypertension using conventional and Doppler tissue imaging echocardiography. *J Am Soc Echocardiogr.* 2008;21(6):715-9. PMID: 18325734.
68. Williams MH, Handler CE, Akram R, et al. Role of N-terminal brain natriuretic peptide (N-TproBNP) in scleroderma-associated pulmonary arterial hypertension. *Eur Heart J.* 2006;27(12):1485-94. PMID: 16682379.
69. Ajami GH, Cheriki S, Amoozgar H, et al. Accuracy of doppler-derived estimation of pulmonary vascular resistance in congenital heart disease: An index of operability. *Pediatr Cardiol.* 2011;32(8):1168-74. PMID: 21779967.
70. Ciurzynski M, Bienias P, Irzyk K, et al. Usefulness of echocardiography in the identification of an excessive increase in pulmonary arterial pressure in patients with systemic sclerosis. *Kardiol Pol.* 2011;69(1):9-15. PMID: 21267956.
71. Gialafos EJ, Moyssakis I, Psaltopoulou T, et al. Circulating tissue inhibitor of matrix metalloproteinase-4 (TIMP-4) in systemic sclerosis patients with elevated pulmonary arterial pressure. *Mediators Inflamm.* 2008;2008:164134. PMID: PMC2630404.
72. Fukuda Y, Tanaka H, Sugiyama D, et al. Utility of right ventricular free wall speckle-tracking strain for evaluation of right ventricular performance in patients with pulmonary hypertension. *J Am Soc Echocardiogr.* 2011;24(10):1101-08. PMID: 21775102.
73. Ghio S, Matteo AD, Scelsi L, et al. Plasma brain natriuretic peptide is a marker of right ventricular overload in pulmonary hypertension associated to HIV infection. *Eur Heart J Suppl.* 2004;6(6):F35-F39.
74. Cevik A, Kula S, Olgunturk R, et al. Quantitative Evaluation of Right Ventricle Function by Transthoracic Echocardiography in Childhood Congenital Heart Disease Patients with Pulmonary Hypertension. *Echocardiography.* 2012;29(7):840-8. PMID: 22494051.
75. Fitzgerald M, Fagan K, Herbert DE, et al. Misclassification of pulmonary hypertension in adults with sickle hemoglobinopathies using doppler echocardiography. *South Med J.* 2012;105(6):300-5. PMID: 22665152.
76. Hammerstingl C, Schueler R, Bors L, et al. Diagnostic value of echocardiography in the diagnosis of pulmonary hypertension. *PLoS ONE.* 2012;7(6):e38519. PMID: 22685577.
77. Rajaram S, Swift AJ, Capener D, et al. Comparison of the diagnostic utility of cardiac magnetic resonance imaging, computed tomography, and echocardiography in assessment of suspected pulmonary arterial hypertension in patients with connective tissue disease. *J Rheumatol.* 2012;39(6):1265-74. PMID: 22589263.
78. Ruiz-Irastorza G, Garmendia M, Villar I, et al. Pulmonary hypertension in systemic lupus erythematosus: prevalence, predictors and diagnostic strategy. *Autoimmunity Reviews.* 2013; 12(3):410-5. PMID: 22841984.
79. Sanli C, Oguz D, Olgunturk R, et al. Elevated Homocysteine and Asymmetric Dimethyl Arginine Levels in Pulmonary Hypertension Associated With Congenital Heart Disease. *Pediatr Cardiol.* 2012:1-9. PMID: 22526220.
80. Selby VN, Scherzer R, Barnett CF, et al. Doppler echocardiography does not accurately estimate pulmonary artery systolic pressure in HIV-infected patients. *AIDS.* 2012;26(15):1967-9. PMID: 22781217.
81. Thakkar V, Stevens WM, Prior D, et al. N-terminal pro-brain natriuretic peptide in a novel screening algorithm for pulmonary arterial hypertension in systemic sclerosis: A case-control study. *Arthritis Research and Therapy.* 2012;14(3). PMID: 22691291.

82. Takatsuki S, Nakayama T, Jone PN, et al. Tissue Doppler Imaging Predicts Adverse Outcome in Children with Idiopathic Pulmonary Arterial Hypertension. *J Pediatr*. 2012;161(6):1126-31. PMID: 22748515.
83. Arcasoy SM, Christie JD, Ferrari VA, et al. Echocardiographic assessment of pulmonary hypertension in patients with advanced lung disease. *Am J Respir Crit Care Med*. 2003;167(5):735-40. PMID: 12480614.
84. Andreassen AK, Wergeland R, Simonsen S, et al. N-terminal pro-B-type natriuretic peptide as an indicator of disease severity in a heterogeneous group of patients with chronic precapillary pulmonary hypertension. *Am J Cardiol*. 2006;98(4):525-9. PMID: 16893710.
85. Barst RJ, Rubin LJ, Long WA, et al. A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension. The Primary Pulmonary Hypertension Study Group. *N Engl J Med*. 1996;334(5):296-302. PMID: 8532025.
86. Bendayan D, Shitrit D, Ygla M, et al. Hyperuricemia as a prognostic factor in pulmonary arterial hypertension. *Respir Med*. 2003;97(2):130-3. PMID: 12587962.
87. Bernus A, Wagner BD, Accurso F, et al. Brain natriuretic peptide levels in managing pediatric patients with pulmonary arterial hypertension. *Chest*. 2009;135(3):745-51. PMID: 18849405.
88. Bharani A, Patel A, Saraf J, et al. Efficacy and safety of PDE-5 inhibitor tadalafil in pulmonary arterial hypertension. *Indian Heart J*. 2007;59(4):323-8. PMID: 19126937.
89. Borges AC, Knebel F, Eddicks S, et al. Right ventricular function assessed by two-dimensional strain and tissue Doppler echocardiography in patients with pulmonary arterial hypertension and effect of vasodilator therapy. *Am J Cardiol*. 2006;98(4):530-4. PMID: 16893711.
90. Brierre G, Blot-Souletie N, Degano B, et al. New echocardiographic prognostic factors for mortality in pulmonary arterial hypertension. *Eur J Echocardiogr*. 2010;11(6):516-22. PMID: 20185528.
91. Bustamante-Labarta M, Perrone S, De La Fuente RL, et al. Right atrial size and tricuspid regurgitation severity predict mortality or transplantation in primary pulmonary hypertension. *J Am Soc Echocardiogr*. 2002;15(10 Pt 2):1160-4. PMID: 12411899.
92. Cella G, Vianello F, Cozzi F, et al. Effect of bosentan on plasma markers of endothelial cell activity in patients with secondary pulmonary hypertension related to connective tissue diseases. *J Rheumatol*. 2009;36(4):760-7. PMID: 19208592.
93. Campana C, Pasotti M, Monti L, et al. The evaluation of right ventricular performance in different clinical models of heart failure. *Eur Heart J Suppl*. 2004;6(6):F61-F67.
94. Channick RN, Simonneau G, Sitbon O, et al. Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: a randomised placebo-controlled study. *Lancet*. 2001;358(9288):1119-23. PMID: 11597664.
95. Chin KM, Channick RN, Kim NH, et al. Central venous blood oxygen saturation monitoring in patients with chronic pulmonary arterial hypertension treated with continuous IV epoprostenol: correlation with measurements of hemodynamics and plasma brain natriuretic peptide levels. *Chest*. 2007;132(3):786-92. PMID: 17646224.
96. D'Alto M, Romeo E, Argiento P, et al. Bosentan-sildenafil association in patients with congenital heart disease-related pulmonary arterial hypertension and Eisenmenger physiology. *Int J Cardiol*. 2012;155(3):378-82. PMID: 21081251.
97. Dimitroulas T, Giannakoulas G, Karvounis H, et al. N-terminal probrain natriuretic peptide as a biochemical marker in the evaluation of bosentan treatment in systemic-sclerosis-related pulmonary arterial hypertension. *Clin Rheumatol*. 2008;27(5):655-8. PMID: 18204995.
98. Dyer KL, Pauliks LB, Das B, et al. Use of myocardial performance index in pediatric patients with idiopathic pulmonary arterial hypertension. *J Am Soc Echocardiogr*. 2006;19(1):21-7. PMID: 16423665.

99. Elstein D, Nir A, Klutstein M, et al. N-brain natriuretic peptide: correlation with tricuspid insufficiency in Gaucher disease. *Pulm Pharmacol Ther.* 2004;17(5):319-23. PMID: 15477128.
100. Fahmy Elnoamany M, Abdelraouf Dawood A. Right ventricular myocardial isovolumic relaxation time as novel method for evaluation of pulmonary hypertension: correlation with endothelin-1 levels. *J Am Soc Echocardiogr.* 2007;20(5):462-9. PMID: 17484984.
101. Feliciano J, Cacela D, Agapito A, et al. Selective pulmonary vasodilators for severe pulmonary hypertension: comparison between endpoints. *Rev Port Cardiol.* 2005;24(3):399-404. PMID: 15929623.
102. Fijalkowska A, Kurzyna M, Torbicki A, et al. Serum N-terminal brain natriuretic peptide as a prognostic parameter in patients with pulmonary hypertension. *Chest.* 2006;129(5):1313-21. PMID: 16685024.
103. Filusch A, Giannitsis E, Katus HA, et al. High-sensitive troponin T: a novel biomarker for prognosis and disease severity in patients with pulmonary arterial hypertension. *Clin Sci (Lond).* 2010;119(5):207-13. PMID: 20412051.
104. Forfia PR, Fisher MR, Mathai SC, et al. Tricuspid annular displacement predicts survival in pulmonary hypertension. *Am J Respir Crit Care Med.* 2006;174(9):1034-41. PMID: 16888289.
105. Friedberg MK, Feinstein JA, Rosenthal DN. A novel echocardiographic Doppler method for estimation of pulmonary arterial pressures. *J Am Soc Echocardiogr.* 2006;19(5):559-62. PMID: 16644441.
106. Galie N, Olschewski H, Oudiz RJ, et al. Ambrisentan for the treatment of pulmonary arterial hypertension: results of the ambrisentan in pulmonary arterial hypertension, randomized, double-blind, placebo-controlled, multicenter, efficacy (ARIES) study 1 and 2. *Circulation.* 2008;117(23):3010-9. PMID: 18506008.
107. Gan CT, McCann GP, Marcus JT, et al. NT-proBNP reflects right ventricular structure and function in pulmonary hypertension. *Eur Respir J.* 2006;28(6):1190-4. PMID: 16971413.
108. Ghio S, Klersy C, Magrini G, et al. Prognostic relevance of the echocardiographic assessment of right ventricular function in patients with idiopathic pulmonary arterial hypertension. *Int J Cardiol.* 2010;140(3):272-8. PMID: 19070379.
109. Ghofrani HA, Wiedemann R, Rose F, et al. Lung cGMP release subsequent to NO inhalation in pulmonary hypertension: responders versus nonresponders. *Eur Respir J.* 2002;19(4):664-71. PMID: 11998996.
110. Goto K, Arai M, Watanabe A, et al. Utility of echocardiography versus BNP level for the prediction of pulmonary arterial pressure in patients with pulmonary arterial hypertension. *Int Heart J.* 2010;51(5):343-7. PMID: 20966607.
111. Grapsa I, Pavlopoulos H, Dawson D, et al. Retrospective study of pulmonary hypertensive patients: is right ventricular myocardial performance index a vital prognostic factor? *Hellenic J Cardiol.* 2007;48(3):152-60. PMID: 17629178.
112. Grubstein A, Benjaminov O, Dayan DB, et al. Computed tomography angiography in pulmonary hypertension. *Isr Med Assoc J.* 2008;10(2):117-20. PMID: 18432023.
113. Haddad F, Zamanian R, Beraud AS, et al. A novel non-invasive method of estimating pulmonary vascular resistance in patients with pulmonary arterial hypertension. *J Am Soc Echocardiogr.* 2009;22(5):523-9. PMID: 19307098.
114. Hampole CV, Mehrotra AK, Thenappan T, et al. Usefulness of red cell distribution width as a prognostic marker in pulmonary hypertension. *Am J Cardiol.* 2009;104(6):868-72. PMID: 19733726.
115. Heresi GA, Aytakin M, Newman J, et al. CXC-chemokine ligand 10 in idiopathic pulmonary arterial hypertension: marker of improved survival. *Lung.* 2010;188(3):191-7. PMID: 20186422.

116. Hinderliter AL, Willis PWt, Barst RJ, et al. Effects of long-term infusion of prostacyclin (epoprostenol) on echocardiographic measures of right ventricular structure and function in primary pulmonary hypertension. Primary Pulmonary Hypertension Study Group. *Circulation*. 1997;95(6):1479-86. PMID: 9118516.
117. Hiramoto Y, Shioyama W, Higuchi K, et al. Clinical significance of plasma endothelin-1 level after bosentan administration in pulmonary arterial hypertension. *J Cardiol*. 2009;53(3):374-80. PMID: 19477379.
118. Homma A, Anzueto A, Peters JJ, et al. Pulmonary artery systolic pressures estimated by echocardiogram vs cardiac catheterization in patients awaiting lung transplantation. *J Heart Lung Transplant*. 2001;20(8):833-9. PMID: 11502405.
119. Jacobs W, Boonstra A, Marcus JT, et al. Addition of prostanoids in pulmonary hypertension deteriorating on oral therapy. *J Heart Lung Transplant*. 2009;28(3):280-4. PMID: 19285621.
120. Ho WJ, Hsu TS, Tsay PK, et al. Serial plasma brain natriuretic peptide testing in clinical management of pulmonary arterial hypertension. *Acta Cardiol Sin*. 2009;25(3):147-53.
121. Keogh A, Strange G, Kotlyar E, et al. Survival after the initiation of combination therapy in patients with pulmonary arterial hypertension: an Australian collaborative report. *Intern Med J*. 2011;41(3):235-44. PMID: 21118410.
122. Lammers AE, Hislop AA, Haworth SG. Prognostic value of B-type natriuretic peptide in children with pulmonary hypertension. *Int J Cardiol*. 2009;135(1):21-6. PMID: 18599134.
123. Langleben D, Barst RJ, Badesch D, et al. Continuous infusion of epoprostenol improves the net balance between pulmonary endothelin-1 clearance and release in primary pulmonary hypertension. *Circulation*. 1999;99(25):3266-71. PMID: 10385501.
124. Leuchte HH, Holzappel M, Baumgartner RA, et al. Characterization of brain natriuretic peptide in long-term follow-up of pulmonary arterial hypertension. *Chest*. 2005;128(4):2368-74. PMID: 16236896.
125. Lorenzen JM, Nickel N, Kramer R, et al. Osteopontin in patients with idiopathic pulmonary hypertension. *Chest*. 2011;139(5):1010-7. PMID: 20947652.
126. Machado RF, Londhe Nerkar MV, Dweik RA, et al. Nitric oxide and pulmonary arterial pressures in pulmonary hypertension. *Free Radic Biol Med*. 2004;37(7):1010-7. PMID: 15336317.
127. Mahapatra S, Nishimura RA, Oh JK, et al. The prognostic value of pulmonary vascular capacitance determined by Doppler echocardiography in patients with pulmonary arterial hypertension. *J Am Soc Echocardiogr*. 2006;19(8):1045-50. PMID: 16880101.
128. Mathai SC, Sibley CT, Forfia PR, et al. Tricuspid annular plane systolic excursion is a robust outcome measure in systemic sclerosis-associated pulmonary arterial hypertension. *J Rheumatol*. 2011;38(11):2410-8. PMID: 21965638.
129. Knirsch W, Hausermann E, Fasnacht M, et al. Plasma B-type natriuretic peptide levels in children with heart disease. *Acta Paediatr Int J Paediatr*. 2011;100(9):1213-1216.
130. Mauritz GJ, Rizopoulos D, Groepenhoff H, et al. Usefulness of serial N-terminal ProB-type natriuretic peptide measurements for determining prognosis in patients with pulmonary arterial hypertension. *Am J Cardiol*. 2011;108(11):1645-50. PMID: 21890089.
131. McLaughlin VV, Benza RL, Rubin LJ, et al. Addition of inhaled treprostinil to oral therapy for pulmonary arterial hypertension: a randomized controlled clinical trial. *J Am Coll Cardiol*. 2010;55(18):1915-22. PMID: 20430262.
132. Michelakis E, Tymchak W, Lien D, et al. Oral sildenafil is an effective and specific pulmonary vasodilator in patients with pulmonary arterial hypertension: comparison with inhaled nitric oxide. *Circulation*. 2002;105(20):2398-403. PMID: 12021227.
133. Minniti CP, Machado RF, Coles WA, et al. Endothelin receptor antagonists for pulmonary hypertension in adult patients with sickle cell disease. *Br J Haematol*. 2009;147(5):737-43. PMID: 19775299.



134. Montani D, Souza R, Binkert C, et al. Endothelin-1/endothelin-3 ratio: a potential prognostic factor of pulmonary arterial hypertension. *Chest*. 2007;131(1):101-8. PMID: 17218562.
135. Nagaya N, Nishikimi T, Uematsu M, et al. Plasma brain natriuretic peptide as a prognostic indicator in patients with primary pulmonary hypertension. *Circulation*. 2000;102(8):865-70. PMID: 10952954.
136. Nakayama T, Shimada H, Takatsuki S, et al. Efficacy and limitations of continuous intravenous epoprostenol therapy for idiopathic pulmonary arterial hypertension in Japanese children. *Circ J*. 2007;71(11):1785-90. PMID: 17965503.
137. Nath J, Demarco T, Hourigan L, et al. Correlation between right ventricular indices and clinical improvement in epoprostenol treated pulmonary hypertension patients. *Echocardiography*. 2005;22(5):374-9. PMID: 15901287.
138. Morishita T, Miyaji K, Akao I, et al. The ratio of the atrial areas reflects the clinical status of patients with pulmonary arterial hypertension. *J Med Ultrason*. 2009;36(4):201-6.
139. Mukerjee D, Yap LB, Holmes AM, et al. Significance of plasma N-terminal pro-brain natriuretic peptide in patients with systemic sclerosis-related pulmonary arterial hypertension. *Respir Med*. 2003;97(11):1230-6. PMID: 14635979.
140. Nickel N, Kempf T, Tapken H, et al. Growth differentiation factor-15 in idiopathic pulmonary arterial hypertension. *Am J Respir Crit Care Med*. 2008;178(5):534-41. PMID: 18565955.
141. Njaman W, Iesaki T, Iwama Y, et al. Serum uric Acid as a prognostic predictor in pulmonary arterial hypertension with connective tissue disease. *Int Heart J*. 2007;48(4):523-32. PMID: 17827824.
142. Park MH, Scott RL, Uber PA, et al. Usefulness of B-type natriuretic peptide as a predictor of treatment outcome in pulmonary arterial hypertension. *Congest Heart Fail*. 2004;10(5):221-5. PMID: 15470298.
143. Raymond RJ, Hinderliter AL, Willis PW, et al. Echocardiographic predictors of adverse outcomes in primary pulmonary hypertension. *J Am Coll Cardiol*. 2002;39(7):1214-9. PMID: 11923049.
144. Rhodes CJ, Wharton J, Howard LS, et al. Red cell distribution width outperforms other potential circulating biomarkers in predicting survival in idiopathic pulmonary arterial hypertension. *Heart*. 2011;97(13):1054-60. PMID: 21558476.
145. Schumann C, Lepper PM, Frank H, et al. Circulating biomarkers of tissue remodelling in pulmonary hypertension. *Biomarkers*. 2010;15(6):523-32. PMID: 20528622.
146. Sebbag I, Rudski LG, Therrien J, et al. Effect of chronic infusion of epoprostenol on echocardiographic right ventricular myocardial performance index and its relation to clinical outcome in patients with primary pulmonary hypertension. *Am J Cardiol*. 2001;88(9):1060-3. PMID: 11704014.
147. Soon E, Doughty NJ, Treacy CM, et al. Log-transformation improves the prognostic value of serial NT-proBNP levels in apparently stable pulmonary arterial hypertension. *Pulm Circ*. 2011;1(2):244-9. PMID: 22034610.
148. Souza R, Jardim C, Julio Cesar Fernandes C, et al. NT-proBNP as a tool to stratify disease severity in pulmonary arterial hypertension. *Respir Med*. 2007;101(1):69-75. PMID: 16781131.
149. Takeda Y, Tomimoto S, Tani T, et al. Bilirubin as a prognostic marker in patients with pulmonary arterial hypertension. *BMC Pulm Med*. 2010;10:22. PMID: 20412580.
150. Torbicki A, Kurzyna M, Kuca P, et al. Detectable serum cardiac troponin T as a marker of poor prognosis among patients with chronic precapillary pulmonary hypertension. *Circulation*. 2003;108(7):844-8. PMID: 12900346.
151. Utsunomiya H, Nakatani S, Okada T, et al. A simple method to predict impaired right ventricular performance and disease severity in chronic pulmonary hypertension using strain rate imaging. *Int J Cardiol*. 2011;147(1):88-94. PMID: 19747741.

152. Utsunomiya H, Nakatani S, Nishihira M, et al. Value of estimated right ventricular filling pressure in predicting cardiac events in chronic pulmonary arterial hypertension. *J Am Soc Echocardiogr.* 2009;22(12):1368-74. PMID: 19944957.
153. Van Albada ME, Loot FG, Fokkema R, et al. Biological serum markers in the management of pediatric pulmonary arterial hypertension. *Pediatr Res.* 2008;63(3):321-7. PMID: 18287971.
154. Vizza CD, Letizia C, Petramala L, et al. Venous endotelin-1 (ET-1) and brain natriuretic peptide (BNP) plasma levels during 6-month bosentan treatment for pulmonary arterial hypertension. *Regul Pept.* 2008;151(1-3):48-53. PMID: 18796317.
155. Voelkel MA, Wynne KM, Badesch DB, et al. Hyperuricemia in severe pulmonary hypertension. *Chest.* 2000;117(1):19-24. PMID: 10631193.
156. Wilkins MR, Paul GA, Strange JW, et al. Sildenafil versus Endothelin Receptor Antagonist for Pulmonary Hypertension (SERAPH) study. *Am J Respir Crit Care Med.* 2005;171(11):1292-7. PMID: 15750042.
157. Zafir N, Zingerman B, Solodky A, et al. Use of noninvasive tools in primary pulmonary hypertension to assess the correlation of right ventricular function with functional capacity and to predict outcome. *Int J Cardiovasc Imaging.* 2007;23(2):209-15. PMID: 16972146.
158. Zeng WJ, Sun YJ, Xiong CM, et al. Prognostic value of echocardiographic right/left ventricular end-diastolic diameter ratio in idiopathic pulmonary arterial hypertension. *Chin Med J (Engl).* 2011;124(11):1672-7. PMID: 21740775.
159. Yanagisawa R, Kataoka M, Taguchi H, et al. Impact of First-Line Sildenafil Monotreatment for Pulmonary Arterial Hypertension. *Circ J.* 2012;76(5):1245-52. PMID: 22333215.
160. Sadushi-Kolici R, Skoro-Sajer N, Zimmer D, et al. Long-term treatment, tolerability, and survival with sub-cutaneous treprostinil for severe pulmonary hypertension. *J Heart Lung Transplant.* 2012;31(7):735-43. PMID: 22480725.
161. Yamada Y, Okuda S, Kataoka M, et al. Prognostic value of cardiac magnetic resonance imaging for idiopathic pulmonary arterial hypertension before initiating intravenous prostacyclin therapy. *Circulation Journal.* 2012;76(7):1737-43. PMID: 22498565.
162. Nickel N, Golpon H, Greer M, et al. The prognostic impact of follow-up assessments in patients with idiopathic pulmonary arterial hypertension. *Eur Respir J.* 2012;39(3):589-96. PMID: 21885392.
163. Zhao QH, Peng FH, Wei H, et al. Serum high-density lipoprotein cholesterol levels as a prognostic indicator in patients with idiopathic pulmonary arterial hypertension. *Am J Cardiol.* 2012;110(3):433-9. PMID: 22560769.
164. Halank M, Knudsen L, Seyfarth HJ, et al. Ambrisentan improves exercise capacity and symptoms in patients with portopulmonary hypertension. *Z Gastroenterol.* 2011;49(9):1258-62. PMID: 21887662.
165. Kaya MG, Lam YY, Erer B, et al. Long-term effect of bosentan therapy on cardiac function and symptomatic benefits in adult patients with eisenmenger syndrome. *J Card Fail.* 2012;18(5):379-84. PMID: 22555267.
166. Kopec G, Tyrka A, Misalski-Jamka T, et al. Changes in Exercise Capacity and Cardiac Performance in a Series of Patients with Eisenmenger's Syndrome Transitioned from Selective to Dual Endothelin Receptor Antagonist. *Heart Lung and Circulation.* 2012;21(11):671-8. PMID: 22819097.
167. Ogawa A, Miyaji K, Yamadori I, et al. Safety and efficacy of epoprostenol therapy in pulmonary veno-occlusive disease and pulmonary capillary hemangiomatosis. *Circulation Journal.* 2012;76(7):1729-36. PMID: 22481098.
168. Taguchi H, Kataoka M, Yanagisawa R, et al. Platelet level as a new prognostic factor for idiopathic pulmonary arterial hypertension in the era of combination therapy. *Circulation Journal.* 2012;76(6):1494-1500. PMID: 22447010.
169. Yang SI, Chung WJ, Jung SH, et al. Effects of inhaled iloprost on congenital heart disease with eisenmenger syndrome. *Pediatr Cardiol.* 2012;33(5):744-8. PMID: 22349672.

170. Shimony A, Fox BD, Langleben D, et al. Incidence and Significance of Pericardial Effusion in Patients With Pulmonary Arterial Hypertension. *Can J Cardiol*. 2012. PMID: 22717247.
171. Badesch DB, Feldman J, Keogh A, et al. ARIES-3: ambrisentan therapy in a diverse population of patients with pulmonary hypertension. *Cardiovasc Ther*. 2012;30(2):93-9. PMID: 21884013.
172. Takatsuki S, Calderbank M, Ivy DD. Initial experience with tadalafil in pediatric pulmonary arterial hypertension. *Pediatr Cardiol*. 2012;33(5):683-688. PMID: 22402804.
173. Takatsuki S, Rosenzweig EB, Zuckerman W, et al. Clinical safety, pharmacokinetics, and efficacy of ambrisentan therapy in children with pulmonary arterial hypertension. *Pediatr Pulmonol*. 2013;48(1):27-34. PMID: 22511577.
174. Yoshida S, Shirato K, Shimamura R, et al. Long-term safety and efficacy of ambrisentan in Japanese adults with pulmonary arterial hypertension. *Curr Med Res Opin*. 2012;28(6):1069-1076. PMID: 22506623.
175. Heresi GA, Tang WH, Aytekin M, et al. Sensitive cardiac troponin I predicts poor outcomes in pulmonary arterial hypertension. *Eur Respir J*. 2012;39(4):939-44. PMID: 21885398.
176. Pyxaras SA, Pinamonti B, Barbati G, et al. Echocardiographic evaluation of systolic and mean pulmonary artery pressure in the follow-up of patients with pulmonary hypertension. *Eur J Echocardiogr*. 2011;12(9):696-701. PMID: 21821609.
177. Takatsuki S, Wagner BD, Ivy DD. B-type Natriuretic Peptide and Amino-terminal Pro-B-type Natriuretic Peptide in Pediatric Patients with Pulmonary Arterial Hypertension. *Congenital Heart Disease*. 2012;7(3):259-67. PMID: 22325151.
178. Vizza CD, Letizia C, Badagliacca R, et al. Relationship between baseline ET-1 plasma levels and outcome in patients with idiopathic pulmonary hypertension treated with bosentan. *Int J Cardiol*. 2012. PMID: 22265324.
179. Benza RL, Gomberg-Maitland M, Miller DP, et al. The REVEAL Registry risk score calculator in patients newly diagnosed with pulmonary arterial hypertension. *Chest*. 2012;141(2):354-62. PMID: 21680644.
180. Benza RL, Seeger W, McLaughlin VV, et al. Long-term effects of inhaled treprostinil in patients with pulmonary arterial hypertension: The TReprostinil sodium Inhalation Used in the Management of Pulmonary arterial Hypertension (TRIUMPH) study open-label extension. *J Heart Lung Transplant*. 2011;30(12):1327-33.
181. Rubin LJ, Mendoza J, Hood M, et al. Treatment of primary pulmonary hypertension with continuous intravenous prostacyclin (epoprostenol). Results of a randomized trial. *Ann Intern Med*. 1990;112(7):485-91. PMID: 2107780.
182. Rubin LJ, Badesch DB, Barst RJ, et al. Bosentan therapy for pulmonary arterial hypertension. *N Engl J Med*. 2002;346(12):896-903. PMID: 11907289.
183. Galie N, Beghetti M, Gatzoulis MA, et al. Bosentan therapy in patients with Eisenmenger syndrome: A multicenter, double-blind, randomized, placebo-controlled study. *Circulation*. 2006;114(1):48-54. PMID: 16801459.
184. Galie N, Rubin L, Hoeper M, et al. Treatment of patients with mildly symptomatic pulmonary arterial hypertension with bosentan (EARLY study): a double-blind, randomised controlled trial. *Lancet*. 2008;371(9630):2093-100. PMID: 18572079.
185. Barst RJ, Mubarak KK, Machado RF, et al. Exercise capacity and haemodynamics in patients with sickle cell disease with pulmonary hypertension treated with bosentan: results of the ASSET studies. *Br J Haematol*. 2010;149(3):426-35. PMID: 20175775.
186. Humbert M, Barst RJ, Robbins IM, et al. Combination of bosentan with epoprostenol in pulmonary arterial hypertension: BREATHE-2. *Eur Respir J*. 2004;24(3):353-9. PMID: 15358690.

187. Galie N, Ghofrani HA, Torbicki A, et al. Sildenafil citrate therapy for pulmonary arterial hypertension. *N Engl J Med*. 2005;353(20):2148-57. PMID: 16291984.
188. Barst RJ, Ivy DD, Gaitan G, et al. A randomized, double-blind, placebo-controlled, dose-ranging study of oral sildenafil citrate in treatment-naïve children with pulmonary arterial hypertension. *Circulation*. 2012;125(2):324-34. PMID: 22128226.
189. Simonneau G, Rubin LJ, Galie N, et al. Addition of sildenafil to long-term intravenous epoprostenol therapy in patients with pulmonary arterial hypertension: a randomized trial. *Ann Intern Med*. 2008;149(8):521-30. PMID: 18936500.
190. Olschewski H, Simonneau G, Galie N, et al. Inhaled iloprost for severe pulmonary hypertension. *N Engl J Med*. 2002;347(5):322-9. PMID: 12151469.
191. Olschewski H, Hoeper MM, Behr J, et al. Long-term therapy with inhaled iloprost in patients with pulmonary hypertension. *Respir Med*. 2010;104(5):731-40. PMID: 20153158.
192. Hoeper MM, Leuchte H, Halank M, et al. Combining inhaled iloprost with bosentan in patients with idiopathic pulmonary arterial hypertension. *Eur Respir J*. 2006;28(4):691-4. PMID: 17012628.
193. McLaughlin VV, Oudiz RJ, Frost A, et al. Randomized study of adding inhaled iloprost to existing bosentan in pulmonary arterial hypertension. *Am J Respir Crit Care Med*. 2006;174(11):1257-63. PMID: 16946127.
194. Badesch DB, Tapon VF, McGoon MD, et al. Continuous intravenous epoprostenol for pulmonary hypertension due to the scleroderma spectrum of disease. A randomized, controlled trial. *Ann Intern Med*. 2000;132(6):425-34. PMID: 10733441.
195. Mukhopadhyay S, Nathani S, Yusuf J, et al. Clinical efficacy of phosphodiesterase-5 inhibitor tadalafil in Eisenmenger Syndrome-A randomized, placebo-controlled, double-blind crossover study. *Congenit Heart Dis*. 2011;6(5):424-31. PMID: 21914136.
196. Galie N, Brundage BH, Ghofrani HA, et al. Tadalafil therapy for pulmonary arterial hypertension. *Circulation*. 2009;119(22):2894-903. PMID: 19470885.
197. Simonneau G, Barst RJ, Galie N, et al. Continuous subcutaneous infusion of treprostinil, a prostacyclin analogue, in patients with pulmonary arterial hypertension: a double-blind, randomized, placebo-controlled trial. *Am J Respir Crit Care Med*. 2002;165(6):800-4. PMID: 11897647.
198. McLaughlin VV, Gaine SP, Barst RJ, et al. Efficacy and safety of treprostinil: an epoprostenol analog for primary pulmonary hypertension. *J Cardiovasc Pharmacol*. 2003;41(2):293-9. PMID: 12548091.
199. Hiremath J, Thanikachalam S, Parikh K, et al. Exercise improvement and plasma biomarker changes with intravenous treprostinil therapy for pulmonary arterial hypertension: a placebo-controlled trial. *J Heart Lung Transplant*. 2010;29(2):137-49. PMID: 20022264.
200. Jing ZC, Yu ZX, Shen JY, et al. Vardenafil in pulmonary arterial hypertension: a randomized, double-blind, placebo-controlled study. *Am J Respir Crit Care Med*. 2011;183(12):1723-9. PMID: 21471085.
201. Fix OK, Bass NM, De Marco T, et al. Long-term follow-up of portopulmonary hypertension: effect of treatment with epoprostenol. *Liver Transpl*. 2007;13(6):875-85. PMID: 17539008.
202. Hoeper MM, Seyfarth HJ, Hoeffken G, et al. Experience with inhaled iloprost and bosentan in portopulmonary hypertension. *Eur Respir J*. 2007;30(6):1096-102. PMID: 17652314.
203. Reichenberger F, Mainwood A, Morrell NW, et al. Intravenous epoprostenol versus high dose inhaled iloprost for long-term treatment of pulmonary hypertension. *Pulm Pharmacol Ther*. 2011;24(1):169-73. PMID: 20601049.
204. Sastry BK, Raju BS, Narasimhan C, et al. Sildenafil improves survival in idiopathic pulmonary arterial hypertension. *Indian Heart J*. 2007;59(4):336-41. PMID: 19126939.

205. Zeng WJ, Sun YJ, Gu Q, et al. Impact of Sildenafil on Survival of Patients With Idiopathic Pulmonary Arterial Hypertension. *J Clin Pharmacol*. 2012;52(9):1357-64. PMID: 21956607.
206. Kemp K, Savale L, O'Callaghan DS, et al. Usefulness of first-line combination therapy with epoprostenol and bosentan in pulmonary arterial hypertension: an observational study. *J Heart Lung Transplant*. 2012;31(2):150-8. PMID: 22138355.
207. Rich JD, Glassner C, Wade M, et al. The effect of diluent pH on bloodstream infection rates in patients receiving IV treprostinil for pulmonary arterial hypertension. *Chest*. 2012;141(1):36-42. PMID: 21659437.
208. Higenbottam TW, Spiegelhalter D, Scott JP, et al. Prostacyclin (epoprostenol) and heart-lung transplantation as treatments for severe pulmonary hypertension. *Br Heart J*. 1993;70(4):366-70. PMID: 8217447.
209. Barst RJ, Oudiz RJ, Beardsworth A, et al. Tadalafil monotherapy and as add-on to background bosentan in patients with pulmonary arterial hypertension. *J Heart Lung Transplant*. 2011;30(6):632-43. PMID: 21256048.
210. Fox BD, Shimony A, Langleben D. Meta-analysis of monotherapy versus combination therapy for pulmonary arterial hypertension. *Am J Cardiol*. 2011;108(8):1177-82.
211. Mathai SC, Puhan MA, Lam D, et al. The minimal important difference in the 6-minute walk test for patients with pulmonary arterial hypertension. *Am J Respir Crit Care Med*. 2012;186(5):428-33. PMID: 22723290.
212. Zhang RF, Zhou L, Ma GF, et al. Diagnostic value of transthoracic Doppler echocardiography in pulmonary hypertension: a meta-analysis. *Am J Hypertens*. 2010;23(12):1261-4. PMID: 20940713.
213. Janda S, Shahidi N, Gin K, et al. Diagnostic accuracy of echocardiography for pulmonary hypertension: a systematic review and meta-analysis. *Heart*. 2011;97(8):612-22. PMID: 21357375.
214. Ryerson CJ, Nayar S, Swiston JR, et al. Pharmacotherapy in pulmonary arterial hypertension: a systematic review and meta-analysis. *Respir Res*. 2010;11:12. PMID: 20113497.
215. Galie N, Hoeper MM, Humbert M, et al. Guidelines for the diagnosis and treatment of pulmonary hypertension. *Eur Respir J*. 2009;34(6):1219-63. PMID: 19749199.
216. Gabler NB, French B, Strom BL, et al. Validation of 6-minute walk distance as a surrogate end point in pulmonary arterial hypertension trials. *Circulation*. 2012;126(3):349-56.
217. Robinson KA, Saldanha IJ, Mckoy NA. Frameworks for Determining Research Gaps During Systematic Reviews. Methods Future Research Needs Report No. 2. (Prepared by the Johns Hopkins University Evidence-based Practice Center under Contract No. HHS 290-2007-10061-I.) AHRQ Publication No. 11-EHC043-EF. Rockville, MD: Agency for Healthcare Research and Quality. June 2011. [www.effectivehealthcare.ahrq.gov/reports/final.cfm](http://www.effectivehealthcare.ahrq.gov/reports/final.cfm). Accessed May 22, 2012.

## Abbreviations

6MWD	6-minute walk distance
AHRQ	Agency for Healthcare Research and Quality
BID	two times per day
BNP	B-type natriuretic peptide
CI	confidence interval
CHF	congestive heart failure
COPD	chronic obstructive pulmonary disease
CTEPH	chronic thromboembolic pulmonary hypertension
CVD	collagen vascular disease
DLCO	diffusion capacity of the lung for carbon monoxide
FAC	fractional area change
FC	functional class
HR	hazard ratio
HRQOL	health-related quality of life
IQR	interquartile range
KQ	Key Question
MI	myocardial infarction
MIF	migration inhibitory factor
mo	month/months
mPAP	mean pulmonary artery pressure
MPI	myocardial performance index
NA	not applicable
NR	not reported
NT-proBNP	N-terminal pro-B-type natriuretic peptide
NYHA	New York Heart Association
OR	odds ratio
PAH	pulmonary arterial hypertension
PADP	pulmonary artery diastolic pressure
PASP	pulmonary artery systolic pressure
PCWP	pulmonary capillary wedge pressure
PH	pulmonary hypertension
PPH	primary pulmonary hypertension
PVR	pulmonary vascular resistance
QOL	quality of life
RA	right atrium
RAP	right atrial pressure
RHC	right heart catheterization
RIMP	right index of myocardial performance
RR	risk ratio
RV	right ventricle
RVEF	right ventricle ejection fraction
S'	tricuspid lateral annular systolic velocity
SD	standard deviation
SEM	standard error of the mean

SOE	strength of evidence
sPAP	systolic pulmonary artery pressure
SSc	systemic sclerosis
TAPSE	tricuspid annular plane systolic excursion
TDI	tissue Doppler imaging
TID	three times per day
TEP	Technical Expert Panel
TG	tricuspid gradient
TRV	tricuspid regurgitant jet velocity
VSD	ventricular septal defect
VTI <sub>RVOT</sub>	velocity-time integral of right ventricular outflow tract
yr	year/years

# Appendix A. Exact Search Strings

## PubMed® search strategy (August 14, 2012)

Table A-1. PubMed search terms for KQ 1: Screening for PAH

Set #	Terms
#1	("Hypertension, Pulmonary"[Mesh] OR "Idiopathic pulmonary hypertension "[Supplementary Concept]) OR ("pulmonary hypertension"[ti] OR "pulmonary arterial hypertension"[ti] OR "pulmonary artery hypertension"[ti]) OR (("hypertension, pulmonary"[MeSH Terms] OR "pulmonary hypertension"[tiab] OR ("pulmonary"[tiab] AND "hypertension"[tiab])) AND (pah[ti] OR ipah[ti] OR pph[ti]))
#2	"Echocardiography"[Mesh] OR echocardiogram[tiab] OR echocardiography[tiab] OR TTE[tiab] OR TEE[tiab] OR echo[tiab]
#3	(sensitive[tiab] OR sensitivity[tiab] OR specificity[tiab] OR "sensitivity and specificity"[MeSH Terms] OR diagnosis[tiab] OR diagnostic[tiab] OR diagnosed[tiab] OR "diagnosis"[MeSH Terms] OR "diagnosis"[Subheading] OR screening[tiab] OR screen[tiab] OR "mass screening"[MeSH Terms] OR "cross-sectional studies"[MeSH Terms] OR cross-sectional[tiab]) NOT (Editorial[ptyp] OR Letter[ptyp] OR Case Reports[ptyp] OR Comment[ptyp]) NOT ("animals"[MeSH Terms] NOT "humans"[MeSH Terms])
#4	#1 AND #2 AND #3 English, Publication Date from 1995 to 2011
#5	"Natriuretic Peptides"[Mesh] OR "Uric Acid"[Mesh] OR "Troponin"[Mesh] OR "Nitric Oxide"[Mesh] OR "dimethylarginine"[Supplementary Concept] OR "fibrin fragment D"[Supplementary Concept] OR "Serotonin"[Mesh] OR "von Willebrand Factor"[Mesh] OR "Thrombomodulin"[Mesh] OR "Selectins"[Mesh] OR "C-Reactive Protein"[Mesh] OR "Isoprostanes"[Mesh] OR "Interleukins"[Mesh] OR "Endothelin-1"[Mesh] OR "Cyclic GMP"[Mesh] OR (Natriuretic[tiab] AND Peptides[tiab]) OR (Natriuretic[tiab] AND Peptide[tiab]) OR "Uric Acid"[tiab] OR "Troponin"[tiab] OR "Nitric Oxide"[tiab] OR "dimethylarginine"[tiab] OR "d-dimer"[tiab] OR "Serotonin"[tiab] OR "Willebrand Factor"[tiab] OR "Thrombomodulin"[tiab] OR "Selectins"[tiab] OR "Selectin"[tiab] AND R[All Fields] AND "C-Reactive Protein"[tiab] OR "Isoprostanes"[tiab] OR Isoprostane[tiab] OR "Interleukins"[tiab] OR "Interleukin"[tiab] OR "Endothelin-1"[tiab] OR "Cyclic GMP"[tiab] OR cgmp[tiab] OR (soluble[tiab] AND ligand[tiab]) OR (endothelial[tiab] AND dysfunction[tiab]) OR "Biological Markers"[Mesh] OR (biological[tiab] AND (marker[tiab] OR markers[tiab])) OR biomarker[tiab] OR biomarkers[tiab]
#6	#1 AND #5 AND #3 English, Publication Date from 1995 to 2011
#7	#1 AND #2 AND #5 English, Publication Date from 1995 to 2011

Table A-2. PubMed search terms for KQ 2: Management of PAH

Set #	Terms
#1	("Hypertension, Pulmonary"[Mesh] OR "Idiopathic pulmonary hypertension "[Supplementary Concept]) OR ("pulmonary hypertension"[ti] OR "pulmonary arterial hypertension"[ti] OR "pulmonary artery hypertension"[ti]) OR (("hypertension, pulmonary"[MeSH Terms] OR "pulmonary hypertension"[tiab] OR ("pulmonary"[tiab] AND "hypertension"[tiab])) AND (pah[ti] OR ipah[ti] OR pph[ti]))
#2	"Echocardiography"[Mesh] OR echocardiogram[tiab] OR echocardiography[tiab] OR TTE[tiab] OR TEE[tiab] OR echo[tiab]
#3	#1 AND #2 English, Publication Date from 1995 to 2011
#4	(clinical[tiab] AND decision[tiab]) OR (clinical[tiab] AND decisions[tiab]) OR (decision[tiab] AND making[tiab]) OR screening[tiab] OR screen[tiab] OR "mass screening"[MeSH Terms] OR management[tiab] OR "treatment outcome"[MeSH Terms] OR outcome[tiab] OR outcomes[tiab] OR "Patient Care Management"[Mesh] OR treatment[tiab] OR therapy[tiab]
#5	#3 AND #4 English, Publication Date from 1995 to 2011



Set #	Terms
#6	"Natriuretic Peptides"[Mesh] OR "Uric Acid"[Mesh] OR "Troponin"[Mesh] OR "Nitric Oxide"[Mesh] OR "dimethylarginine"[Supplementary Concept] OR "fibrin fragment D"[Supplementary Concept] OR "Serotonin"[Mesh] OR "von Willebrand Factor"[Mesh] OR "Thrombomodulin"[Mesh] OR "Selectins"[Mesh] OR "C-Reactive Protein"[Mesh] OR "Isoprostanes"[Mesh] OR "Interleukins"[Mesh] OR "Endothelin-1"[Mesh] OR "Cyclic GMP"[Mesh] OR (Natriuretic[tiab] AND Peptides[tiab]) OR (Natriuretic[tiab] AND Peptide[tiab]) OR "Uric Acid"[tiab] OR "Troponin"[tiab] OR "Nitric Oxide"[tiab] OR "dimethylarginine"[tiab] OR "d-dimer"[tiab] OR "Serotonin"[tiab] OR "Willebrand Factor"[tiab] OR "Thrombomodulin"[tiab] OR "Selectins"[tiab] OR "Selectin"[tiab] AND R[All Fields] AND "C-Reactive Protein"[tiab] OR "Isoprostanes"[tiab] OR Isoprostane[tiab] OR "Interleukins"[tiab] OR "Interleukin"[tiab] OR "Endothelin-1"[tiab] OR "Cyclic GMP"[tiab] OR cgmp[tiab] OR (soluble[tiab] AND ligand[tiab]) OR (endothelial[tiab] AND dysfunction[tiab]) OR "Biological Markers"[Mesh] OR (biological[tiab] AND (marker[tiab] OR markers[tiab])) OR biomarker[tiab] OR biomarkers[tiab]
#7	#1 AND #6 English, Publication Date from 1995 to 2011
#8	#7 AND #4 English, Publication Date from 1995 to 2011
#9	#1 AND #2 AND #6 English, Publication Date from 1995 to 2011
#10	#1 AND (#2 OR #6) English, Publication Date from 1995 to 2011
#11	(sensitive[tiab] OR sensitivity[tiab] OR specificity[tiab] OR "sensitivity and specificity"[MeSH Terms] OR diagnosis[tiab] OR diagnostic[tiab] OR diagnosed[tiab] OR "diagnosis"[MeSH Terms] OR "diagnosis"[Subheading] OR screening[tiab] OR screen[tiab] OR "mass screening"[MeSH Terms] OR "cross-sectional studies"[MeSH Terms] OR cross-sectional[tiab]) NOT (Editorial[ptyp] OR Letter[ptyp] OR Case Reports[ptyp] OR Comment[ptyp]) NOT ("animals"[MeSH Terms] NOT "humans"[MeSH Terms])
#12	#1 AND (#2 OR #6) AND (#3 OR #11) English, Publication Date from 1995 to 2011

**Table A-3. PubMed search terms for KQ 3: Monotherapy vs. Combination Therapy for PAH**

Set #	Terms
#1	("Hypertension, Pulmonary"[Mesh] OR "Idiopathic pulmonary hypertension "[Supplementary Concept]) OR ("pulmonary hypertension"[ti] OR "pulmonary arterial hypertension"[ti] OR "pulmonary artery hypertension"[ti] OR ("hypertension, pulmonary"[MeSH Terms] OR "pulmonary hypertension"[tiab] OR ("pulmonary"[tiab] AND "hypertension"[tiab])) AND (pah[ti] OR ipah[ti] OR pph[ti]))
#2	("Calcium Channel Blockers"[Mesh] OR "Calcium Channel Blockers"[Pharmacological Action] OR calcium channel blockers[tiab] OR calcium channel blocker[tiab] OR nifedipine[tiab] OR diltiazem[tiab] OR amlodipine[tiab] OR ("prostaglandins"[MeSH Terms] OR "prostaglandins"[tiab] OR "prostaglandins"[tiab] OR "prostanoid"[tiab] OR "prostanoids"[tiab] OR "epoprostenol"[MeSH Terms] OR "epoprostenol"[tiab] OR "prostacyclin"[tiab] OR "treprostinil"[Supplementary Concept] OR "treprostinil"[tiab] OR "iloprost"[MeSH Terms] OR "iloprost"[tiab] OR "Receptors, Endothelin/antagonists and inhibitors"[Mesh] OR ("endothelins"[MeSH Terms] OR "endothelins"[tiab] OR "endothelin"[tiab]) AND (antagonist[tiab] OR "antagonists"[tiab] OR "inhibitors"[tiab])) OR "bosentan"[Supplementary Concept] OR "bosentan"[tiab] OR "ambrisentan"[Supplementary Concept] OR "ambrisentan"[tiab] OR "phosphodiesterase inhibitors"[MeSH Terms] OR ("phosphodiesterase"[tiab] AND "inhibitors"[tiab]) OR "phosphodiesterase inhibitors"[tiab] OR "phosphodiesterase inhibitors"[Pharmacological Action] OR "phosphodiesterase 5 inhibitors"[tiab] OR "phosphoric diester hydrolases"[MeSH Terms] OR ("phosphoric"[tiab] AND "diester"[tiab] AND "hydrolases"[tiab]) OR ("phosphodiesterase"[tiab] OR "phosphodiesterases"[tiab] AND (inhibitor[tiab] OR "antagonists and inhibitors"[Subheading] OR "antagonists"[tiab] OR "inhibitors"[tiab] OR antagonist[tiab])) OR (pde5[tiab] AND (inhibitor[tiab] OR "antagonists and inhibitors"[Subheading] OR "antagonists"[tiab] OR "antagonist"[tiab] OR "inhibitors"[tiab] OR "inhibitors"[tiab])) OR pde5i[tiab] OR "sildenafil"[Supplementary Concept] OR "sildenafil"[tiab] OR "tadalafil"[Supplementary Concept] OR "tadalafil"[tiab] OR "Vasodilator Agents"[Mesh:noexp] OR "Vasodilator Agents"[Pharmacological Action])

Set #	Terms
#3	(randomized controlled trial[pt] OR controlled clinical trial[pt] OR randomized[tiab] OR randomised[tiab] OR randomization[tiab] OR randomisation[tiab] OR placebo[tiab] OR "drug therapy"[Subheading] OR randomly[tiab] OR trial[tiab] OR groups[tiab] OR Clinical trial[pt] OR "clinical trial"[tw] OR "clinical trials"[tw] OR "evaluation studies"[Publication Type] OR "evaluation studies as topic"[MeSH Terms] OR "evaluation study"[tw] OR evaluation studies[tw] OR "intervention studies"[MeSH Terms] OR "intervention study"[tw] OR "intervention studies"[tw] OR "case-control studies"[MeSH Terms] OR "case-control"[tw] OR "cohort studies"[MeSH Terms] OR cohort[tw] OR "longitudinal studies"[MeSH Terms] OR "longitudinal"[tw] OR longitudinally[tw] OR "prospective"[tw] OR prospectively[tw] OR "retrospective studies"[MeSH Terms] OR "retrospective"[tw] OR "follow up"[tw] OR "comparative study"[Publication Type] OR "comparative study"[tw] OR systematic[subset] OR "meta-analysis"[Publication Type] OR "meta-analysis as topic"[MeSH Terms] OR "meta-analysis"[tw] OR "meta-analyses"[tw] NOT (Editorial[ptyp] OR Letter[ptyp] OR Case Reports[ptyp] OR Comment[ptyp]) NOT ("animals"[MeSH Terms] NOT "humans"[MeSH Terms])
#4	#1 AND #2 AND #3 English, Publication Date from 1995 to 2011

## Embase® search strategy (August 14, 2012)

Platform: Embase.com

**Table A-4. Embase search terms for KQ 1: Screening for PAH**

Set #	Terms
#1	'pulmonary hypertension'/exp OR "idiopathic pulmonary hypertension":ab,ti OR "pulmonary arterial hypertension":ab,ti OR "pulmonary artery hypertension":ab,ti OR "pulmonary hypertension":ab,ti OR pah:ab,ti OR ipah:ab,ti OR pph:ab,ti
#2	'echocardiography'/exp OR echocardiography:ab,ti OR echocardiogram:ab,ti OR echo:ab,ti OR TEE:ab,ti OR TEE:ab,ti
#3	('sensitivity and specificity'/exp OR diagnosis:de OR diagnostic:de OR 'screening'/exp OR 'cross-sectional study'/exp OR sensitive:ab,ti OR sensitive:ab,ti OR sensitivity:ab,ti OR specificity:ab,ti OR diagnosis:ab,ti OR diagnostic:ab,ti OR diagnosed:ab,ti OR screening:ab,ti OR screen:ab,ti OR cross-sectional:ab,ti OR likelihood:ab,ti ) NOT 'editorial'/exp OR 'letter'/exp OR 'case report'/exp
#4	#1 AND #2 AND #3
#5	#1 AND #2 AND #3 AND [embase]/lim NOT [medline]/lim AND [humans]/lim AND [1995-2012]/py
#6	'natriuretic factor'/exp OR 'uric acid'/exp OR 'troponin'/exp OR 'nitric oxide'/exp OR '6 n,n` dimethylarginine'/exp OR 'serotonin'/exp OR 'von Willebrand factor'/exp OR 'C reactive protein'/exp OR 'isoprostane derivative'/exp OR 'interleukin derivative'/exp OR 'endothelin 1'/exp OR 'cyclic GMP'/exp OR 'thrombomodulin'/exp OR 'selectin'/exp OR 'biological marker'/exp OR "Natriuretic Peptides":ab,ti OR "Natriuretic Peptide":ab,ti OR "Uric Acid":ab,ti OR Troponin:ab,ti OR "Nitric Oxide":ab,ti OR dimethylarginine:ab,ti OR d-dimer:ab,ti OR Serotonin:ab,ti OR "Willebrand Factor":ab,ti OR Thrombomodulin:ab,ti OR Selectins:ab,ti OR Selectin:ab,ti OR "C-Reactive Protein":ab,ti OR Isoprostanes:ab,ti OR Isoprostane:ab,ti OR Interleukins:ab,ti OR Interleukin:ab,ti OR Endothelin-1:ab,ti OR "Cyclic GMP":ab,ti OR cgmp:ab,ti OR "soluble ligand":ab,ti OR "biological marker":ab,ti OR "biological markers":ab,ti OR biomarker:ab,ti OR biomarkers:ab,ti OR "endothelial dysfunction":ab,ti OR fibrin fragment:de
#7	#1 AND #6 AND #3
#8	#7 AND [embase]/lim NOT [medline]/lim AND [humans]/lim AND [1995-2012]/py
#9	#1 AND #2 AND #3 AND #6 AND [embase]/lim NOT [medline]/lim AND [humans]/lim AND [1995-2012]/py

**Table A-5. Embase search terms for KQ 2: Management of PAH**

Set #	Terms
#1	'pulmonary hypertension'/exp OR "idiopathic pulmonary hypertension":ab,ti OR "pulmonary arterial hypertension":ab,ti OR "pulmonary artery hypertension":ab,ti OR "pulmonary hypertension":ab,ti OR pah:ab,ti OR ipah:ab,ti OR pph:ab,ti
#2	'echocardiography'/exp OR echocardiography:ab,ti OR echocardiogram:ab,ti OR echo:ab,ti OR TEE:ab,ti OR TEE:ab,ti

Set #	Terms
#3	'treatment outcome'/exp OR 'clinical decision making'/exp OR 'decision making'/exp OR 'patient care'/de OR (clinical:ab,ti AND decision:ab,ti) OR (clinical:ab,ti AND decisions:ab,ti) OR (decision:ab,ti AND making:ab,ti) OR management:ab,ti OR 'treatment outcome':ab,ti OR outcome:ab,ti OR outcomes:ab,ti OR treatment:ab,ti OR therapy:ab,ti OR 'controlled clinical trial'/exp OR 'clinical trial'/exp OR 'evidence based medicine'/exp
#4	#3 NOT ('editorial'/exp OR 'letter'/exp OR 'case report'/exp)
#5	#1 AND #2 AND #4
#6	#5 AND [embase]/lim NOT [medline]/lim AND [humans]/lim AND [1995-2012]/py
#7	'natriuretic factor'/exp OR 'uric acid'/exp OR 'troponin'/exp OR 'nitric oxide'/exp OR '6 n,n' dimethylarginine'/exp OR 'serotonin'/exp OR 'von Willebrand factor'/exp OR 'C reactive protein'/exp OR 'isoprostane derivative'/exp OR 'interleukin derivative'/exp OR 'endothelin 1'/exp OR 'cyclic GMP'/exp OR 'thrombomodulin'/exp OR 'selectin'/exp OR 'biological marker'/exp OR "Natriuretic Peptides":ab,ti OR "Natriuretic Peptide":ab,ti OR "Uric Acid":ab,ti OR Troponin:ab,ti OR "Nitric Oxide":ab,ti OR dimethylarginine:ab,ti OR d-dimer:ab,ti OR Serotonin:ab,ti OR "Willebrand Factor":ab,ti OR Thrombomodulin:ab,ti OR Selectins:ab,ti OR Selectin:ab,ti OR "C-Reactive Protein":ab,ti OR Isoprostanes:ab,ti OR Isoprostane:ab,ti OR Interleukins:ab,ti OR Interleukin:ab,ti OR Endothelin-1:ab,ti OR "Cyclic GMP":ab,ti OR cgmp:ab,ti OR "soluble ligand":ab,ti OR "biological marker":ab,ti OR "biological markers":ab,ti OR biomarker:ab,ti OR biomarkers:ab,ti OR "endothelial dysfunction":ab,ti OR fibrin fragment:de
#8	#1 AND #7 AND #4
#9	#8 AND [embase]/lim NOT [medline]/lim AND [humans]/lim AND [1995-2012]/py
#10	#1 AND #2 AND #7 AND [english]/lim AND [1995-2012]/py AND [embase]/lim NOT [medline]/lim AND [humans]/lim

**Table A-6. Embase search terms for KQ 3: Monotherapy vs. Combination Therapy for PAH**

Set #	Terms
#1	'pulmonary hypertension'/exp OR "idiopathic pulmonary hypertension":ab,ti OR "pulmonary arterial hypertension":ab,ti OR "pulmonary artery hypertension":ab,ti OR "pulmonary hypertension":ab,ti OR pah:ab,ti OR ipah:ab,ti
#2	'prostaglandin'/exp OR 'iloprost'/exp OR 'endothelin receptor'/exp OR 'bosentan'/exp OR 'ambrisentan'/exp OR 'phosphodiesterase inhibitor'/exp OR 'phosphodiesterase'/exp OR 'sildenafil'/exp OR 'tadalafil'/exp OR 'vasodilator agent'/exp OR "prostaglandin":ab,ti OR "prostaglandins":ab,ti OR "prostanoid":ab,ti OR "prostanoids":ab,ti OR "epoprostenol":ab,ti OR "prostacyclin":ab,ti OR "treprostinil":ab,ti OR "iloprost":ab,ti OR "bosentan":ab,ti OR "ambrisentan":ab,ti OR ("phosphodiesterase":ab,ti AND "inhibitors":ab,ti) OR "phosphodiesterase inhibitors":ab,ti OR "phosphodiesterase 5 inhibitors":ab,ti OR ("phosphoric":ab,ti AND "diester":ab,ti AND "hydrolases":ab,ti) OR "sildenafil":ab,ti OR "tadalafil":ab,ti OR ("phosphodiesterase":ab,ti OR "phosphodiesterases":ab,ti OR "endothelins":ab,ti OR "endothelin":ab,ti OR pde5:ab,ti) AND (inhibitor:ab,ti OR "antagonists":ab,ti OR "inhibitors":ab,ti OR antagonist:ab,ti)
#3	'calcium channel blocking agent'/exp OR 'calcium channel blocker':ab,ti OR 'calcium channel blockers':ab,ti OR Amlodipine:ab,ti OR Amrinone:ab,ti OR anandamide:ab,ti OR anipamil:ab,ti OR azimilide:ab,ti OR Bencyclane:ab,ti OR benidipine:ab,ti OR Bepridil:ab,ti OR berbamine:ab,ti OR canadine:ab,ti OR 'carboxyamido-triazole':ab,ti OR caroverine:ab,ti OR cilnidipine:ab,ti OR Cinnarizine:ab,ti OR clentiazem:ab,ti OR Conotoxins:ab,ti OR darodipine:ab,ti OR dauricine:ab,ti OR devapamil:ab,ti OR Diltiazem:ab,ti OR dimeditapramine:ab,ti OR dotarizine:ab,ti OR efonidipine:ab,ti OR emopamil:ab,ti OR enpiperate:ab,ti OR eperisone:ab,ti OR falipamil:ab,ti OR fantofarone:ab,ti OR fasudil:ab,ti OR Felodipine:ab,ti OR 'fenamic acid':ab,ti OR Fendiline:ab,ti OR Flunarizine:ab,ti OR fosfedil:ab,ti OR gabapentin:ab,ti OR Gallopamil:ab,ti OR Isradipine:ab,ti OR lacidipine:ab,ti OR lamotrigine:ab,ti OR lercanidipine:ab,ti OR Lidoflazine:ab,ti OR 'Magnesium Sulfate':ab,ti OR manidipine:ab,ti OR manoalide:ab,ti OR mepirodipine:ab,ti OR Mibefradil:ab,ti OR monatepil:ab,ti OR naftopidil:ab,ti OR Nicardipine:ab,ti OR Nifedipine:ab,ti OR niguldipine:ab,ti OR niludipin:ab,ti OR nilvadipine:ab,ti OR Nimodipine:ab,ti OR Nisoldipine:ab,ti OR Nitrendipine:ab,ti OR norverapamil:ab,ti OR ochratoxin:ab,ti OR octylonium:ab,ti OR 'omega-Agatoxin':ab,ti OR 'omega-Conotoxin':ab,ti OR 'omega-Conotoxins':ab,ti OR osthol:ab,ti OR oxodipine:ab,ti OR Perhexiline:ab,ti OR pinaverium:ab,ti OR piperidine:ab,ti OR pranidipine:ab,ti OR Prenylamine:ab,ti OR 'risedronic acid':ab,ti OR ryodipine:ab,ti OR sesamodil:ab,ti OR stepholidine:ab,ti OR terodiline:ab,ti OR tetrahydropalmatine:ab,ti OR tetrandrine:ab,ti OR 'tolfenamic acid':ab,ti OR tranilast:ab,ti OR Verapamil:ab,ti OR ziconotide:ab,ti

Set #	Terms
#4	('randomized controlled trial'/exp OR 'crossover procedure'/exp OR 'double blind procedure'/exp OR 'single blind procedure'/exp OR random*:ab,ti OR factorial*:ab,ti OR crossover*:ab,ti OR (cross NEAR/1 over*):ab,ti OR placebo*:ab,ti OR (doubl* NEAR/1 blind*):ab,ti OR (singl* NEAR/1 blind*):ab,ti OR assign*:ab,ti OR allocat*:ab,ti OR volunteer*:ab,ti OR 'clinical study'/exp OR "clinical trial":ti,ab OR "clinical trials":ti,ab OR 'controlled study'/exp OR 'evaluation'/exp OR "evaluation study":ab,ti OR "evaluation studies":ab,ti OR "intervention study":ab,ti OR "intervention studies":ab,ti OR "case control":ab,ti OR 'cohort analysis'/exp OR cohort:ab,ti OR longitudinal*:ab,ti OR prospective:ab,ti OR prospectively:ab,ti OR retrospective:ab,ti OR 'follow up'/exp OR "follow up":ab,ti OR 'comparative effectiveness'/exp OR 'comparative study'/exp OR "comparative study":ab,ti OR "comparative studies":ab,ti OR 'evidence based medicine'/exp OR "systematic review":ab,ti OR "meta-analysis":ab,ti OR "meta-analyses":ab,ti) NOT ('case report'/exp OR 'case study'/exp OR 'editorial'/exp OR 'letter'/exp OR 'note'/exp)
#5	#1 AND (#2 OR #3) AND #4
#6	#5 AND [embase]/lim NOT [medline]/lim AND [humans]/lim AND [1995-2012]/py

## Cochrane Database of Systematic Reviews (August 14, 2012)

Platform: Wiley

**Table A-7. Cochrane search terms for KQs 1 and 2: Screening and Management of PAH**

Set #	Terms
#1	MeSH descriptor Hypertension, Pulmonary explode all trees OR (pulmonary hypertension):ti,ab,kw OR (idiopathic pulmonary hypertension):ti,ab,kw OR (pulmonary arterial hypertension):ti,ab,kw OR (pulmonary artery hypertension):ti,ab,kw OR pah:ti,ab,kw OR ipah:ti,ab,kw
#2	MeSH descriptor echocardiography explode all trees OR echocardiography:ti,ab,kw OR echocardiogram:ti,ab,kw OR echo:ti,ab,kw OR TEE:ti,ab,kw OR TEE:ti,ab,kw
#3	#1 AND #2 AND (Cochrane Reviews, other reviews) AND 1995-2012
#4	MeSH descriptor Natriuretic Peptides explode all trees OR MeSH descriptor Uric Acid explode all trees OR MeSH descriptor Troponin explode all trees OR MeSH descriptor Nitric Oxide explode all trees OR MeSH descriptor Serotonin explode all trees OR MeSH descriptor von Willebrand Factor explode all trees OR MeSH descriptor C-Reactive Protein explode all trees OR MeSH descriptor Isoprostanes explode all trees OR MeSH descriptor Interleukins explode all trees OR MeSH descriptor Endothelins explode all trees OR MeSH descriptor Cyclic GMP explode all trees OR MeSH descriptor Thrombomodulin explode all trees OR MeSH descriptor Selectins explode all trees OR MeSH descriptor Biological Markers explode all trees OR (Natriuretic Peptides):ti,ab,kw OR (Natriuretic Peptide):ti,ab,kw OR (Uric Acid):ti,ab,kw OR Troponin:ti,ab,kw OR (Nitric Oxide):ti,ab,kw OR dimethylarginine:ti,ab,kw OR (d-dimer):ti,ab,kw OR Serotonin:ti,ab,kw OR (Willebrand Factor):ti,ab,kw OR Thrombomodulin:ti,ab,kw OR Selectins:ti,ab,kw OR Selectin:ti,ab,kw OR (C-Reactive Protein):ti,ab,kw OR Isoprostanes:ti,ab,kw OR Isoprostane:ti,ab,kw OR Interleukins:ti,ab,kw OR Interleukin:ti,ab,kw OR (Endothelin-1):ti,ab,kw OR (Cyclic GMP):ti,ab,kw OR cgmp:ti,ab,kw OR (soluble ligand):ti,ab,kw OR (biological marker):ti,ab,kw OR (biological markers):ti,ab,kw OR biomarker:ti,ab,kw OR biomarkers:ti,ab,kw OR (endothelial dysfunction):ti,ab,kw OR (fibrin fragment):ti,ab,kw
#5	#1 AND #4 AND (Cochrane Reviews, other reviews) AND 1995-2012
#6	#1 AND #2 AND #4 AND (Cochrane Reviews, other reviews) AND 1995-2012

**Table A-8. Cochrane search terms for KQ 3: Monotherapy vs. Combination Therapy for PAH**

Set #	Terms
#1	MeSH descriptor Hypertension, Pulmonary explode all trees OR (pulmonary hypertension):ti,ab,kw OR (idiopathic pulmonary hypertension):ti,ab,kw OR (pulmonary arterial hypertension):ti,ab,kw OR (pulmonary artery hypertension):ti,ab,kw OR pah:ti,ab,kw OR ipah:ti,ab,kw
#2	bosentan:ti,ab,kw OR ambrisentan:ti,ab,kw OR phosphodiesterase:ti,ab,kw OR sildenafil:ti,ab,kw OR tadalafil:ti,ab,kw OR (vasodilator agent):ti,ab,kw OR prostaglandin:ti,ab,kw OR prostaglandins:ti,ab,kw OR prostanoid:ti,ab,kw OR prostanoids:ti,ab,kw OR epoprostenol:ti,ab,kw OR prostacyclin:ti,ab,kw OR treprostinil:ti,ab,kw OR iloprost:ti,ab,kw OR bosentan:ti,ab,kw OR ambrisentan:ti,ab,kw OR sildenafil:ti,ab,kw OR tadalafil:ti,ab,kw OR endothelins:ti,ab,kw OR endothelin:ti,ab,kw OR pde5:ti,ab,kw OR MeSH descriptor Vasodilator Agents explode all trees OR MeSH descriptor Endothelins explode all trees OR MeSH descriptor Prostaglandins explode all trees OR MeSH descriptor Hydrolases explode all trees OR MeSH descriptor Phosphodiesterase Inhibitors explode all trees
#3	Amlodipine:ti,ab,kw OR Amrinone:ti,ab,kw OR anandamide:ti,ab,kw OR anipamil:ti,ab,kw OR azimilide:ti,ab,kw OR Bencyclane:ti,ab,kw OR benidipine:ti,ab,kw OR Bepridil:ti,ab,kw OR berbamine:ti,ab,kw OR canadine:ti,ab,kw OR (carboxyamido-triazole):ti,ab,kw OR caroverine:ti,ab,kw OR cilnidipine:ti,ab,kw OR Cinnarizine:ti,ab,kw OR clentiazem:ti,ab,kw OR Conotoxins:ti,ab,kw OR darodipine:ti,ab,kw OR dauricine:ti,ab,kw OR devapamil:ti,ab,kw OR Diltiazem:ti,ab,kw OR dimeditiapramine:ti,ab,kw OR dotarizine:ti,ab,kw OR efonidipine:ti,ab,kw OR emopamil:ti,ab,kw OR enpiperate:ti,ab,kw OR eperisone:ti,ab,kw OR falipamil:ti,ab,kw OR fantofarone:ti,ab,kw OR fasudil:ti,ab,kw OR Felodipine:ti,ab,kw OR (fenamic acid):ti,ab,kw OR Fendiline:ti,ab,kw OR Flunarizine:ti,ab,kw OR fosfedil:ti,ab,kw OR gabapentin:ti,ab,kw OR Gallopamil:ti,ab,kw OR Isradipine:ti,ab,kw OR lacidipine:ti,ab,kw OR lamotrigine:ti,ab,kw OR lercanidipine:ti,ab,kw OR Lidoflazine:ti,ab,kw OR (Magnesium Sulfate):ti,ab,kw OR manidipine:ti,ab,kw OR manoalide:ti,ab,kw OR mepirodipine:ti,ab,kw OR Mibefradil:ti,ab,kw OR monatepil:ti,ab,kw OR naftopidil:ti,ab,kw OR Nicardipine:ti,ab,kw OR Nifedipine:ti,ab,kw OR niguldipine:ti,ab,kw OR niludipin:ti,ab,kw OR nilvadipine:ti,ab,kw OR Nimodipine:ti,ab,kw OR Nisoldipine:ti,ab,kw OR Nitrendipine:ti,ab,kw OR norverapamil:ti,ab,kw OR ochratoxin:ti,ab,kw OR octylonium:ti,ab,kw OR (omega-Agatoxin):ti,ab,kw OR (omega-Conotoxin):ti,ab,kw OR (omega-Conotoxins):ti,ab,kw OR osthol:ti,ab,kw OR oxodipine:ti,ab,kw OR Perhexiline:ti,ab,kw OR pinaverium:ti,ab,kw OR piperidine:ti,ab,kw OR pranidipine:ti,ab,kw OR Prenylamine:ti,ab,kw OR (risedronic acid):ti,ab,kw OR ryodipine:ti,ab,kw OR sesamolil:ti,ab,kw OR stepholidine:ti,ab,kw OR terodiline:ti,ab,kw OR tetrahydropalmatine:ti,ab,kw OR tetrandrone:ti,ab,kw OR (tolfenamic acid):ti,ab,kw OR tranilast:ti,ab,kw OR Verapamil:ti,ab,kw OR ziconotide:ti,ab,kw OR MeSH descriptor Calcium Channel Blockers explode all trees
#4	#1 AND (#2 OR #3) AND (Cochrane Reviews, other reviews) AND 1995-2012

# Appendix B. Data Abstraction Elements

## I. Study Characteristics

- First Author (Last Name) and Year of Publication
- Additional Articles Used in This Abstraction
- Study Sites
  - Single Center; Multicenter; Not reported/Unclear
- Number of Sites
- Geographical Location (Select all applicable geographic regions)
  - US; Canada; UK; Europe; South America; Central America; Asia; Africa; Australia/New Zealand; Not reported/Unclear; Other (Specify)
- Funding Source (Check all that apply)
  - Government; Private Foundation; Industry; Not reported; Other (Specify)
- Enrollment Approach (Check all that apply)
  - Consecutive patients; Convenience sample (not explicitly consecutive); Other (Specify); Not reported/Unclear
- Study Inclusion and Exclusion Criteria
  - Copy/paste inclusion/exclusion criteria as reported in the article
- Study Design
  - RCT; Cohort; Other (describe)
- Study Enrollment/Study Completion
  - Total, Treatment Arm 1, 2, 3, 4
    - Assessed for eligibility (N)
    - Eligible (N)
    - Enrolled/Randomized (N)
    - Completed follow-up (N)
- Subgroup Analysis (Yes/No)
  - If Yes: Describe the subgroups reported
- Key Question Applicability
  - KQ1; KQ2; KQ3
    - KQ 1. For patients with suspected pulmonary arterial hypertension (PAH) and asymptomatic patients at high risk for PAH, what is the comparative effectiveness and safety of echocardiography versus echocardiography plus biomarkers as screening modalities before right heart catheterization to establish the diagnosis of PAH (diagnostic accuracy efficacy)?
    - KQ 2. For patients with PAH, what is the comparative effectiveness and safety of (a) echocardiography plus clinical assessment (e.g., functional class, dyspnea, 6-minute walk test) versus biomarkers plus clinical assessment and (b) echocardiography plus clinical assessment versus echocardiography plus biomarkers and clinical assessment in managing PAH (diagnostic thinking efficacy and therapeutic efficacy) and on intermediate-term ( $\leq 90$  days) and long-term ( $>90$  days) patient outcomes (patient outcome efficacy)?
    - KQ 3. For patients with PAH, what is the comparative effectiveness and safety of monotherapy or combination therapy for PAH using calcium-channel blockers, prostanoids, endothelin receptor antagonists, or phosphodiesterase inhibitors on intermediate-term and long-term patient outcomes?
- Comments

## II. Baseline Characteristics

- Total, Study Arm 1, Study Arm 2, Study Arm 3, Study Arm 4

- Patient Population

Describe the population for each study arm

- Number of Subjects

N

- Total
- Female
- Male
- Adults
- Children
- Mixed

%

- Female
- Male
- Adults
- Children
- Mixed

- Age

Mean

- SD
- SE

Median

- IQR

- Ethnicity

Hispanic or Latino

- N
- %

No Hispanic or Latino

- N
- %

- Race

Black/African American

- N
- %

American Indian or Alaska Native

- N
- %

Asian

- N
- %

Native Hawaiian or other Pacific Islander

- N
- %

White

- N
- %

Multiracial

- N

- %
- Other (Specify)
  - N
  - %
- Baseline Characteristics
  - BMI
    - Mean
      - SD
      - SE
    - Median
      - IQR
  - WHO Functional Class (N)
    - Class I
    - Class II
    - Class III
    - Class IV
  - NYHA Functional Classification (N)
    - Class I
    - Class II
    - Class III
    - Class IV
  - PAH Etiology (N)
    - Idiopathic (1.1)
    - Familial (1.2)
    - Collagen vascular disease (1.3.1)
    - Congenital shunts (1.3.2)
    - Portal HTN (1.3.3)
    - HIV (1.3.4)
    - Drugs/toxins (1.3.5)
    - Venous or capillary disease (1.4.x)
    - Pulmonary HTN of newborn (1.5)
    - Thromboembolic (4.x)
    - Other
  - Disease Duration
    - Mean
      - SD
      - SE
    - Median
      - IQR
  - Obesity (e.g. N with BMI>30)
    - Mean
      - SD
      - SE
    - Median
      - IQR
    - N
  - Prior Treatments (N)
    - Calcium channel blockers
    - Diuretics



- Digoxin
- Prostanoids
- Endothelin antagonists
- Phosphodiesterase inhibitors
- Anticoagulants
- Other

Left ventricular ejection fraction (LVEF)

- Mean
  - SD
  - SE
- Median
  - IQR

Other (Specify)

- Mean
  - SD
  - SE
- Median
  - IQR
- N

- Comments

### III. Intervention Characteristics

- Study Arm 1, Study Arm 2, Study Arm 3, Study Arm 4
  - Medical Therapy Intervention
    - Amlodipine; Diltiazem; Nifedipine; Verapamil; Epoprostenol; Treprostinil; Iloprost; Bosentan; Ambrisentan; Sildenafil; Tadalafil; Other (Specify); NR/NA
    - Dosage
    - Frequency
    - Duration
      - Administration (oral, inhaled, intravenous, subcutaneous)
  - Describe tests administered
  - Describe biomarkers
  - Describe echocardiographic tests
  - Describe co-treatments
  - Did the study use echocardiography and/or biomarkers?
    - Echocardiography
    - Biomarker(s)
    - Echo + biomarkers
    - NR/NA

### IV. Outcomes Definitions

- Time points
  - Time 1
  - Time 2
  - Time 3
  - Time 4
  - Time 5
- Echocardiographic parameters (Check all that apply)
  - Right ventricle (RV) size (any RV linear dimension or area by 2D echo)
  - Right atrium (RA) size (any RA linear dimension or area by 2D echo)

- Fractional area change (FAC)
- Tricuspid Annular Plane Systolic Excursion (TAPSE)
- Systolic excursion velocity (S-prime)
- RIMP/MPI/Tei Index
- Systolic pulmonary artery pressure (sPAP)
- Mean pulmonary artery pressure (mPAP)
- Tricuspid regurgitant (TR) jet velocity
- Peak TR velocity
- Right ventricular outflow tract (RVOT) velocity-time integral
- Right ventricular ejection fraction (RVEF)
- Pericardial effusion
- Other (specify; don't need to include measures of LV function)
- Right-heart catheterization measures (Check all that apply)
  - Mean pulmonary artery pressure (mPAP)
  - Systolic pulmonary artery pressure (sPAP)
  - Diastolic pulmonary artery pressure (dPAP)
  - Pulmonary vascular resistance (PVR)
  - Cardiac output (CO)
  - Other right-heart catheterization measure (specify)
- Biomarkers (Check all that apply)
  - Natriuretic peptides (e.g., atrial natriuretic peptide, brain natriuretic peptide)
  - Endothelin-1
  - Uric acid
  - Troponin T
  - Nitric oxide
  - Asymmetric dimethylarginine
  - Cyclic guanosine monophosphate
  - D-dimer
  - Serotonin
  - Other biomarker (specify)
- Clinical outcomes (Check all that apply)
  - Diagnostic thinking efficacy
  - Therapeutic efficacy (e.g. clinician judgment about diagnosis/prognosis, choice of treatment)
  - Dyspnea
  - 6-minute walk change
  - 6-minute walk absolute score
  - Hospitalization
  - Functional class
  - Quality of life (e.g. SF-36, Minnesota Living With Heart Failure [MLWHF], Cambridge Pulmonary Hypertension Outcome Review [CAMPHOR])
  - Right ventricular dysfunction
  - Right heart failure
  - Mortality
  - Progression to right heart failure
  - Other clinical outcomes (specify)
  - Adverse effect – bleeding
  - Adverse effect – bruising
  - Adverse effect – infection
  - Adverse effect – transient ischemic attack from bubble/contrast echocardiogram
  - Adverse effect – liver function abnormalities

- Adverse effect – headache
- Adverse effect – flushing
- Adverse effect – cough
- Adverse effect – epistaxis
- Adverse effect – dyspepsia
- Adverse effect – diarrhea
- Adverse effect – peripheral edema
- Adverse effect – nausea
- Adverse effect – nasal congestion
- Adverse effect – dizziness
- Adverse effect – syncope
- Adverse effect – hypoxia
- Adverse effect – increased international normalized ratio
- Adverse effect – increased prothrombin time
- Adverse effect – line infection
- Adverse effect – site pain
- Adverse effect – abrupt catheter occlusion
- Adverse effect – other (specify)
- Comments

## V. KQ 1 Outcomes

- Did the study present other clinical outcomes that will need to be extracted (i.e. bleeding, bruising, etc.)?
- Echo Parameter
  - RV size
  - RA size
  - Fractional area change
  - TAPSE
  - RIMP/MPI/Tei Index
  - sPAP (systolic pulmonary artery pressure)
  - mPAP (mean pulmonary artery pressure)
  - Tricuspid regurgitant jet velocity
  - Peak tricuspid regurgitant velocity
  - RVOT velocity-time integral
  - RVEF
  - Pericardial effusion
  - Echo Parameter Threshold
  - How was this measure calculated?
  - For how many patients was there no test result for this measure?
- Reference standard
  - mPAP (mean pulmonary artery pressure)-RH Cath
  - sPAP (systolic pulmonary artery pressure)-RH Cath
  - dPAP (diastolic pulmonary artery pressure)-RH Cath
  - PVR (pulmonary vascular resistance)-RH Cath
  - CO (cardiac output)-RH Cath
  - CI (cardiac Index)
  - RAP (right atrial pressure)
  - PCWP (pulmonary capillary wedge pressure)
  - Reference Standard Threshold
- Biomarker

Natriuretic peptides/BNP  
 Endothelin-1  
 Uric acid  
 Troponin T  
 Nitric oxide  
 Asymmetric dimethylarginine  
 Cyclic guanosine monophosphate  
 D-dimer

- How was this measure calculated?
- Biomarker Threshold
- For how many patients was there no test result for this measure?
- Data presentation
  - Dichotomous/ Continuous/ Both
  - If Dichotomous or Both selected:
    - Echo Alone; Echo + Biomarkers; Biomarkers Alone
      - Test positive
        - Disease Positive – True positive N
        - Disease Negative – False positive N
        - Unclear – N unclear
        - Total – Total N
      - Test negative
        - Disease Positive – False negative
        - Disease Negative – True negative
        - Unclear – N unclear
        - Total – Total N
      - Test uncertain
        - Disease Positive – N positive
        - Disease Negative – N negative
        - Unclear – N unclear
        - Total – Total N
      - Total
        - Disease Positive – N positive
        - Disease Negative – N negative
        - Unclear – N unclear
        - Total – Total N
    - If Continuous or Both selected:
      - Echo Alone; Echo + Biomarkers; Biomarkers Alone
        - Table 1
          - N for Analysis
          - Pearson product-moment correlation (r)
          - $r^2$
          - Bland-Altman analysis
          - Variability
            - Standard Error(SE)/ Standard Deviation(SD)/
            - Other(Specify)
          - p-value between test and reference standard
          - Time interval between test and reference standard
        - Table 2
          - Disease Positive
          - N Positive

- Mean
    - SD
    - SE
  - Median
    - IQR
- Disease Negative
  - N Negative
  - Mean
    - SD
    - SE
  - Median
    - IQR
- Diagnosis Unclear
  - N Unclear
  - Mean
    - SD
    - SE
  - Median
    - IQR
- Other
  - N
  - Mean
    - SD
    - SE
  - Median
    - IQR
- p-value between Test and Reference Standard

## VI. KQ 2 Outcomes

- Did the study report other clinical outcomes that will need to be abstracted?(Yes/No)
- Table 1, Table2, Table 3, Table 4, Table 5
  - Timing
    - Baseline
    - Intermediate term >30 days and  $\leq$  1 year
      - 1 month/ 2 months/ 3 months/ 4 months/ 6 months/ 1 year/ Other (Specify)
    - Long-term > 1 year
      - 2 years/ 3 years/ 4 years/ 5 years/ Other (Specify)
  - Intervention
    - Intervention 1
      - RV size
      - RA size
      - Fractional area change
      - TAPSE
      - RIMP/MPI/Tei Index
      - sPAP (systolic pulmonary artery pressure)
      - mPAP (mean pulmonary artery pressure)
      - Tricuspid regurgitant jet velocity
      - Peak tricuspid regurgitant velocity

- RVOT velocity-time integral
- RVEF
- Pericardial effusion
- RVSP
- Natriuretic peptides/BNP
- Endothelin-1
- Uric acid
- Troponin T
- Nitric oxide
- Asymmetric dimethylarginine
- Cyclic guanosine monophosphate
- D-dimer

Describe Intervention 1

Intervention 2

- RV size
- RA size
- Fractional area change
- TAPSE
- RIMP/MPI/Tei Index
- sPAP (systolic pulmonary artery pressure)
- mPAP (mean pulmonary artery pressure)
- Tricuspid regurgitant jet velocity
- Peak tricuspid regurgitant velocity
- RVOT velocity-time integral
- RVEF
- Pericardial effusion
- RVSP
- Natriuretic peptides/BNP
- Endothelin-1
- Uric acid
- Troponin T
- Nitric oxide
- Asymmetric dimethylarginine
- Cyclic guanosine monophosphate
- D-dimer
- NA

Describe Intervention 2

○ Comparator

Comparator 1

- RV size
- RA size
- Fractional area change
- TAPSE
- RIMP/MPI/Tei Index
- sPAP (systolic pulmonary artery pressure)
- mPAP (mean pulmonary artery pressure)
- Tricuspid regurgitant jet velocity
- Peak tricuspid regurgitant velocity

- RVOT velocity-time integral
- RVEF
- Pericardial effusion
- RVSP
- Natriuretic peptides/BNP
- Endothelin-1
- Uric acid
- Troponin T
- Nitric oxide
- Asymmetric dimethylarginine
- Cyclic guanosine monophosphate
- D-dimer
- RH cath-mPAP
- RH cath-sPAP
- RH cath-dPAP
- RH cath-PVR
- RH cath-CO
- Cardiac index (CI)
- Right atrial pressure (RAP)
- Pulmonary capillary wedge pressure (PCWP)
- Dyspnea
- 6 minute walk change
- 6 minute walk (absolute)
- Hospitalization
- Functional class
- Quality of life
- Right ventricular dysfunction
- Right heart failure/progression to right heart failure
- Mortality
- Transplant
- Adverse effect – bleeding
- Adverse effect – bruising
- Adverse effect – infection
- Adverse effect – transient ischemic attack
- Adverse effect – liver function
- Adverse effect – headache
- Adverse effect – flushing
- Adverse effect – cough
- Adverse effect – epistaxis
- Adverse effect – dyspepsia
- Adverse effect – diarrhea
- Adverse effect – peripheral edema
- Adverse effect – nausea
- Adverse effect – nasal congestion
- Adverse effect – dizziness
- Adverse effect – syncope
- Adverse effect – hypoxia
- Adverse effect – increased INR

- Adverse effect – line infection
- Adverse effect – site pain
- Adverse effect – abrupt catheter occlusion
- Adverse effect – rash
- Adverse effect – jaw pain
- Composite outcome (Specify)

Describe Comparator 1

Comparator 2

- RV size
- RA size
- Fractional area change
- TAPSE
- RIMP/MPI/Tei Index
- sPAP (systolic pulmonary artery pressure)
- mPAP (mean pulmonary artery pressure)
- Tricuspid regurgitant jet velocity
- Peak tricuspid regurgitant velocity
- RVOT velocity-time integral
- RVEF
- Pericardial effusion
- RVSP
- Natriuretic peptides/BNP
- Endothelin-1
- Uric acid
- Troponin T
- Nitric oxide
- Asymmetric dimethylarginine
- Cyclic guanosine monophosphate
- D-dimer
- RH cath-mPAP
- RH cath-sPAP
- RH cath-dPAP
- RH cath-PVR
- RH cath-CO
- Cardiac index (CI)
- Right atrial pressure (RAP)
- Pulmonary capillary wedge pressure (PCWP)
- Dyspnea
- 6 minute walk change
- 6 minute walk (absolute)
- Hospitalization
- Functional class
- Quality of life
- Right ventricular dysfunction
- Right heart failure/progression to right heart failure
- Mortality
- Transplant
- Adverse effect – bleeding



- Adverse effect – bruising
  - Adverse effect – infection
  - Adverse effect – transient ischemic attack
  - Adverse effect – liver function
  - Adverse effect – headache
  - Adverse effect – flushing
  - Adverse effect – cough
  - Adverse effect – epistaxis
  - Adverse effect – dyspepsia
  - Adverse effect – diarrhea
  - Adverse effect – peripheral edema
  - Adverse effect – nausea
  - Adverse effect – nasal congestion
  - Adverse effect – dizziness
  - Adverse effect – syncope
  - Adverse effect – hypoxia
  - Adverse effect – increased INR
  - Adverse effect – line infection
  - Adverse effect – site pain
  - Adverse effect – abrupt catheter occlusion
  - Adverse effect – rash
  - Adverse effect – jaw pain
  - Composite outcome (Specify)
- Describe Comparator 2
- Population and N for Analysis
    - Intervention
      - Population
      - N for Analysis
    - Comparator
      - Population
      - N for Analysis
  - Result
    - Mean
    - Median
    - Number Patients with Outcome
    - % Patients with Outcome
    - Relative Risk (RR)
    - Relative Hazard (HR)
    - Odds Ratio (OR)
    - Risk difference
    - Correlation
    - Other (Specify)
  - Variability
    - Standard Error (SE)
    - Standard Deviation (SD)
    - Other (Specify)
  - Confidence interval (CI) or Interquartile Range (IQR)
    - 95% CI/ Other % CI (Specify)/ IQR
      - LL (25% if IQR)

- UL (75% if IQR)
  - p-value between treatment groups
- Describe the diagnostic thinking efficacy
- Describe the therapeutic efficacy
- Comments

## VII. Clinical Outcomes

- Outcome reported on this form
  - Dyspnea
  - Six minute walk change
  - Six minute walk (absolute)
  - Hospitalization
  - Functional class
  - Quality of life (SF-36, MLWH, CAMPHOR)
  - Right ventricular dysfunction
  - Right heart failure/progression to right heart failure
  - Mortality
  - Transplant/progression to transplant
  - Adverse effect – bleeding
  - Adverse effect – bruising
  - Adverse effect – infection
  - Adverse effect – transient ischemic attack
  - Adverse effect – liver function abnormalities
  - Adverse effect – headache
  - Adverse effect – flushing
  - Adverse effect – cough
  - Adverse effect – epistaxis
  - Adverse effect – dyspepsia
  - Adverse effect – diarrhea
  - Adverse effect – peripheral edema
  - Adverse effect – nausea
  - Adverse effect – nasal congestion
  - Adverse effect – dizziness
  - Adverse effect – syncope
  - Adverse effect – hypoxia
  - Adverse effect – increased international normalized ratio
  - Adverse effect – line infection
  - Adverse effect – site pain
  - Adverse effect – abrupt catheter occlusion
  - Adverse effect – jaw pain
  - Adverse effect – rash
  - Composite outcome
    - Composite outcome consisted of
    - RV size
    - RA size
    - Fractional area change
    - TAPSE
    - RIMP/MPI/Tei Index
    - sPAP
    - mPAP

- TR jet velocity
- Peak TR velocity/RVOT velocity-time interval
- RVEF
- Pericardial Effusion
- RVSP
- Natriuretic peptides/BNP
- Endothelin-1
- Uric acid
- Troponin T
- Nitric oxide
- Asymmetric dimethylarginine
- c-GMP
- D-dimer
- RH cath – sPAP
- RH cath – mPAP
- RH cath – dPAP
- RH cath –PVR
- RH cath – CO
- Cardiac Index (CI)
- Right atrial pressure (RAP)
- Pulmonary capillary wedge pressure (PCWP)
- Additional/alternate outcome name (if applicable)
- Authors' definition of outcome (if applicable)
- Table 1, 2, 3, 4, 5
  - Timing
    - Baseline
    - Intermediate term > 30 days and  $\leq$  1 year
      - 1 month/ 2 months/ 3 months/ 4 months/ 6 months/ 1 year/ Other (Specify)
    - Long-term > 1 year
      - 2 years/ 3 years/ 4 years/ 5 years/ Other (Specify)
  - Adjustments
    - Results are not adjusted
    - Age
    - Sex
    - Race/ethnicity
    - Comorbidity(ies) (Specify)
    - Body weight/ BMI
    - Risk factors
    - PAH classification
    - Other (specify all)
  - Group
    - Study Arm 1, 2, 3, 4
  - N for Analysis
  - Result
    - Mean
    - Median
    - Number Patients with Outcome
    - % Patients with Outcome
    - Relative Risk (RR)

- Relative Hazard (HR)
  - Odds Ratio (OR)
  - Risk difference
  - Other (Specify)
- Variability
  - Standard Error (SE)
  - Standard Deviation (SD)
  - Other (Specify)
- Confidence Interval (CI) or Interquartile Range (IQR)
  - 95% CI/ Other % CI (Specify)/ IQR
    - LL (25% if IQR)
    - UL (75% if IQR)
- p-value between treatment groups
- Reference group (for comparisons between treatment groups)
- Comments

### VIII. Quality

- Was this an accuracy study? (Yes/No)
  - If Yes:
    - Population (P)
      - Was a consecutive or random sample of patients unrolled? (Yes/No/Unclear)
      - Was a case-control design avoided? (Yes/No/Unclear)
      - Did the study avoid inappropriate exclusions? (Yes/No/Unclear)
      - Could the selection of patients have introduced bias? (Yes/No/Unclear)
    - Interventions (I)
      - Were the index test results interpreted without knowledge of the results of the reference standard? (Yes/No/Unclear)
      - If a threshold was used, was it pre-specified? (Yes/No/Unclear)
      - Could the conduct or interpretation of the index test have introduced bias? (Yes/No/Unclear)
    - Comparators (C)
      - Is the reference standard likely to correctly classify the target condition? (Yes/No/Unclear)
      - Were the reference standard results interpreted without knowledge of the results of the index test? (Yes/No/Unclear)
      - Could the reference standard, its conduct, or its interpretation have introduced bias? (Yes/No/Unclear)
    - Timing (T)
      - Was there an appropriate interval between index test(s) and reference standard? (Yes/No/Unclear)
      - Did all patients receive a reference standard? (Yes/No/Unclear)
      - Did all patients receive the same reference standard? (Yes/No/Unclear)
      - Were all patients included in the analysis? (Yes/No/Unclear)
      - Could the patient flow have introduced bias? (Yes/No/Unclear)
    - Overall study rating (Good/Fair/Poor)
      - If Fair: Describe why the study was given a 'Fair' rating
      - If Poor: Describe why the study was given a 'Poor' rating
  - If No:

Was this study randomized? (Yes/No)

- If Yes:
  - Were study subjects randomized? (Yes/No/Unclear)
  - Was the randomization process described? (Yes/No/Unclear)
  - Was the outcome assessor blinded to study assignment? (Yes/No/Unclear)
  - Were patients blinded to study intervention? (Yes/No/Unclear)
  - Were results adjusted for clustering? (Yes/No/Unclear)
  - Were measures of outcomes based on validated procedures or instruments? (Yes/No/Unclear)
  - Conducted an intent-to-treat analysis? (Yes/No/Unclear)
  - Were all outcomes reported (i.e. was there evidence of selective outcome reporting)? (Yes/No/Unclear)
  - Were incomplete data adequately addressed? (Yes/No/Unclear)
  - Was there adequate power (either based on pre-study or post-hoc power calculations [80% power for primary outcome])? (Yes/No/Unclear)
  - Were systematic differences observed in baseline characteristics and prognostic factors across the groups compared? (Yes/No/Unclear)
  - Were comparable groups maintained? (Yes/No/Unclear)
  - Was there absence of potential important conflict-of-interest? (Yes/No/Unclear)
- If No:
  - Basic Design
    - Is the study design prospective, retrospective, or mixed? (Prospective/Mixed/Retrospective/Cannot determine)
  - Selection Bias
    - Inclusion/Exclusion Criteria
      - Are the inclusion/exclusion criteria clearly stated (does not require the reader to infer)? (Yes/Partially/No)
      - Did the study apply inclusion/exclusion criteria uniformly to all comparison groups? (Yes/Partially/No/NA)
    - Recruitment
      - Did the strategy for recruiting participants into the study differ across study groups? (Yes/No/Cannot determine/NA)
    - Baseline characteristics similar or appropriate adjusted analysis
      - Are key characteristics of study participants similar between intervention and control groups? If not similar, did the analysis appropriately adjust for important differences? (Yes/Partially/No/Insufficient reporting to be able to determine/NA)
    - Comparison Group
      - Is the selection of the comparison group appropriate? (Yes/No/Cannot determine/NA)

○ Performance Bias

Intervention implementation

- What is the level of detail in describing the intervention or exposure?
  - High; very clear, all PI-required details provided
  - Medium; somewhat clear, majority of PI-required details provided
  - Low; unclear, many PI-required details missing

Concurrent/concomitant interventions

- Did researchers isolate the impact from a concurrent intervention or unintended exposure that might bias the results, e.g., through multivariate analysis, stratification, or subgroup analysis? (Yes/Partially/Not described/NA)

○ Attrition Bias

Equality of length of follow-up for participants

- In cohort studies, is the length of follow-up different between the groups? (Yes/No or cannot determine/NA)

Completeness of follow-up

- Was there a high rate of differential or overall attrition? (Yes/No/Cannot determine)

Attrition affecting participant composition

- Did attrition result in a difference in group characteristics between baseline and follow-up? (Yes/No/Cannot determine)

Any attempt to balance

- Any attempt to balance the allocation between the groups? (Yes/No/Cannot determine/NA)

Intention-to-treat analysis

- Is the analysis conducted on an intention-to-treat (ITT) basis, that is, the intervention allocation status rather than the actual intervention received? (Yes/No/Cannot determine/NA)

○ Detection Bias

Source of information re: outcomes

- Are clinical outcomes (e.g. hemodynamic parameters, right heart failure or right ventricular dysfunction, and mortality) assessed using valid and reliable measures and implemented consistently across all study participants? (Yes/No/Cannot determine/NA)
- Are patient-reported outcomes (e.g., symptom scores, quality of life) assessed using valid and reliable measures and implemented consistently across all study participants? (Yes/No/Cannot determine/NA)

- Are functional capacity outcomes (e.g. 6-minute walk test, functional class) assessed using valid and reliable measures, implemented consistently across all study participants? (Yes/No/Cannot determine/NA)
- Reporting Bias
  - Are any important primary outcomes missing from the results? (Yes/No/Cannot determine/Primary outcomes not pre-specified)
- Other risk of bias issues
  - Are the statistical methods used to assess the primary outcomes appropriate to the data? (Yes/Partially/No/Cannot determine)
- Power and sample size
  - Did the authors report conducting a power analysis or some other basis for determining the adequacy of study group sizes for the primary outcome(s) being abstracted? (Yes/No/NA)
- Overall rating of the study (Good/Fair/Poor)
  - If Fair: Describe why the study was given a 'Fair' rating
  - If Poor: Describe why the study was given a 'Poor' rating

## IX. Applicability

- Population (P)
  - Is there concern that the study population is inadequately described to assess the applicability of this study? (Yes/No)
  - Is there concern that participants are at widely differing points in natural history of disease? (Yes/No)
  - Is there concern that participants have widely differing degrees of disease severity? (Yes/No)
  - Is there concern that the included patients do not match the review question? (Yes/No)
  - Did the study exclude participants with other conditions that might be easily confused with PAH such as PH due to heart failure, thrombotic disease, COPD? (KQ1 only) (Yes/No)
  - Did the study include patients with a wide variety of conditions in addition to the target population? (Yes/No)
  - Did the study selectively recruit participants who demonstrated a history of favorable or unfavorable response to drug or other interventions for the condition? (KQ2 and KQ3 only) (Yes/No)
- Intervention (I)
  - Is there concern that the index test, its conduct, or interpretation differ from the review question? (KQ1,2) (Yes/No)
  - Is there concern that equipment or operator level of training/proficiency is not widely available? (KQ1, KQ2) (Yes/No)
  - Is there concern that the intervention (active arm) is not similar to that used in routine clinical practice? (Yes/No)
- Comparator (C)
  - Is there concern that the target condition as defined by the reference standard does not match the review question? (Yes/No)

- Outcomes (O)
  - Is there concern that cointerventions/treatments do not adequately reflect routine clinical practice? (Yes/No)
  - If surrogate outcomes were used, is there concern that they are not sufficiently clinically relevant? (Yes/No)
  - Is there concern that outcomes are not measured for sufficiently long duration of treatment? (KQ2, KQ3) (Yes/No)
  - Is there concern that potential adverse events associated with testing (KQ1,2) or treatment (KQ2,3) were not measured or reported? (Yes/No)
- Setting (S)
  - Is there concern that the care delivery setting is widely divergent from the current typical US setting? (Yes/No)
- Did the study have significant issues with applicability? (Yes/No)
- Comments



## Appendix C. List of Included Studies

Ajami GH, Cheriki S, Amoozgar H, et al. Accuracy of doppler-derived estimation of pulmonary vascular resistance in congenital heart disease: An index of operability. *Pediatr Cardiol.* 2011;32(8):1168-1174. PMID: 21779967.

Allanore Y, Borderie D, Avouac J, et al. High N-terminal pro-brain natriuretic peptide levels and low diffusing capacity for carbon monoxide as independent predictors of the occurrence of precapillary pulmonary arterial hypertension in patients with systemic sclerosis. *Arthritis Rheum.* 2008;58(1):284-91. PMID: 18163505.

Andreassen AK, Wergeland R, Simonsen S, et al. N-terminal pro-B-type natriuretic peptide as an indicator of disease severity in a heterogeneous group of patients with chronic precapillary pulmonary hypertension. *Am J Cardiol.* 2006;98(4):525-9. PMID: 16893710.

Arcasoy SM, Christie JD, Ferrari VA, et al. Echocardiographic assessment of pulmonary hypertension in patients with advanced lung disease. *Am J Respir Crit Care Med.* 2003;167(5):735-40. PMID: 12480614.

Badesch DB, Bodin F, Channick RN, et al. Complete results of the first randomized, placebo-controlled study of bosentan, a dual endothelin receptor antagonist, in pulmonary arterial hypertension. *Curr Ther Res Clin Exp.* 2002;63(4):227-246.

Badesch DB, Feldman J, Keogh A, et al. ARIES-3: Ambrisentan Therapy in a Diverse Population of Patients with Pulmonary Hypertension. *Cardiovasc Ther.* 2011. PMID: 21884013.

Badesch DB, Feldman J, Keogh A, et al. ARIES-3: ambrisentan therapy in a diverse population of patients with pulmonary hypertension. *Cardiovasc Ther.* 2012;30(2):93-9. PMID: 21884013.

Badesch DB, Hill NS, Burgess G, et al. Sildenafil for pulmonary arterial hypertension associated with connective tissue disease. *J Rheumatol.* 2007;34(12):2417-22. PMID: 17985403.

Badesch DB, Tapson VF, McGoon MD, et al. Continuous intravenous epoprostenol for pulmonary hypertension due to the scleroderma spectrum of disease. A randomized, controlled trial. *Ann Intern Med.* 2000;132(6):425-34. PMID: 10733441.

Barst RJ, Ivy DD, Gaitan G, et al. A Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study of Oral Sildenafil Citrate in Treatment-Naive Children with Pulmonary Arterial Hypertension. *Circulation.* 2011. PMID: 22128226.

Barst RJ, Mubarak KK, Machado RF, et al. Exercise capacity and haemodynamics in patients with sickle cell disease with pulmonary hypertension treated with bosentan: results of the ASSET studies. *Br J Haematol.* 2010;149(3):426-35. PMID: 20175775.

Barst RJ, Oudiz RJ, Beardsworth A, et al. Tadalafil monotherapy and as add-on to background bosentan in patients with pulmonary arterial hypertension. *J Heart Lung Transplant.* 2011;30(6):632-43. PMID: 21256048.

Barst RJ, Rubin LJ, Long WA, et al. A comparison of continuous intravenous epoprostenol (prostaglandin) with conventional therapy for primary pulmonary hypertension. The Primary Pulmonary Hypertension Study Group. *N Engl J Med.* 1996;334(5):296-302. PMID: 8532025.

Barst RJ, Rubin LJ, McGoon MD, et al. Survival in primary pulmonary hypertension with long-term continuous intravenous prostacyclin. *Ann Intern Med.* 1994;121(6):409-15. PMID: 8053614.

Bendayan D, Shitrit D, Ygla M, et al. Hyperuricemia as a prognostic factor in pulmonary arterial hypertension. *Respir Med.* 2003;97(2):130-3. PMID: 12587962.

Benza RL, Miller DP, Gomberg-Maitland M, et al. Predicting survival in pulmonary arterial hypertension: insights from the Registry to Evaluate Early and Long-Term Pulmonary Arterial Hypertension Disease Management (REVEAL). *Circulation.* 2010;122(2):164-72. PMID: 20585012.

Bernus A, Wagner BD, Accurso F, et al. Brain natriuretic peptide levels in managing pediatric patients with pulmonary arterial hypertension. *Chest.* 2009;135(3):745-51. PMID: 18849405.

Bharani A, Patel A, Saraf J, et al. Efficacy and safety of PDE-5 inhibitor tadalafil in pulmonary arterial hypertension. *Indian Heart J.* 2007;59(4):323-8. PMID: 19126937.

Bogdan M, Humbert M, Francoual J, et al. Urinary cGMP concentrations in severe primary pulmonary hypertension. *Thorax.* 1998;53(12):1059-62. PMID: 10195079.

- Bonderman D, Wexberg P, Martischnig AM, et al. A noninvasive algorithm to exclude pre-capillary pulmonary hypertension. *Eur Respir J*. 2011;37(5):1096-103. PMID: 20693249.
- Borges AC, Knebel F, Eddicks S, et al. Right ventricular function assessed by two-dimensional strain and tissue Doppler echocardiography in patients with pulmonary arterial hypertension and effect of vasodilator therapy. *Am J Cardiol*. 2006;98(4):530-4. PMID: 16893711.
- Brierre G, Blot-Souletie N, Degano B, et al. New echocardiographic prognostic factors for mortality in pulmonary arterial hypertension. *Eur J Echocardiogr*. 2010;11(6):516-22. PMID: 20185528.
- Bustamante-Labarta M, Perrone S, De La Fuente RL, et al. Right atrial size and tricuspid regurgitation severity predict mortality or transplantation in primary pulmonary hypertension. *J Am Soc Echocardiogr*. 2002;15(10 Pt 2):1160-4. PMID: 12411899.
- Campana C, Pasotti M, Monti L, et al. The evaluation of right ventricular performance in different clinical models of heart failure. *Eur Heart J Suppl*. 2004;6(6):F61-F67.
- Cavagna L, Caporali R, Klersy C, et al. Comparison of brain natriuretic peptide (BNP) and NT-proBNP in screening for pulmonary arterial hypertension in patients with systemic sclerosis. *J Rheumatol*. 2010;37(10):2064-70. PMID: 20634241.
- Cella G, Vianello F, Cozzi F, et al. Effect of bosentan on plasma markers of endothelial cell activity in patients with secondary pulmonary hypertension related to connective tissue diseases. *J Rheumatol*. 2009;36(4):760-7. PMID: 19208592.
- Cevik A, Kula S, Olgunturk R, et al. Quantitative Evaluation of Right Ventricle Function by Transthoracic Echocardiography in Childhood Congenital Heart Disease Patients with Pulmonary Hypertension. *Echocardiography*. 2012. PMID: 22494051.
- Channick RN, Simonneau G, Sitbon O, et al. Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: a randomised placebo-controlled study. *Lancet*. 2001;358(9288):1119-23. PMID: 11597664.
- Chin KM, Channick RN, Kim NH, et al. Central venous blood oxygen saturation monitoring in patients with chronic pulmonary arterial hypertension treated with continuous IV epoprostenol: correlation with measurements of hemodynamics and plasma brain natriuretic peptide levels. *Chest*. 2007;132(3):786-92. PMID: 17646224.
- Ciurzynski M, Bienias P, Irzyk K, et al. Usefulness of echocardiography in the identification of an excessive increase in pulmonary arterial pressure in patients with systemic sclerosis. *Kardiologia Pol*. 2011;69(1):9-15. PMID: 21267956.
- Colle IO, Moreau R, Godinho E, et al. Diagnosis of portopulmonary hypertension in candidates for liver transplantation: a prospective study. *Hepatology*. 2003;37(2):401-9. PMID: 12540791.
- Condliffe R, Radon M, Hurdman J, et al. CT pulmonary angiography combined with echocardiography in suspected systemic sclerosis-associated pulmonary arterial hypertension. *Rheumatology (Oxford)*. 2011;50(8):1480-6. PMID: 21447566.
- Dahiya A, Vollbon W, Jellis C, et al. Echocardiographic assessment of raised pulmonary vascular resistance: application to diagnosis and follow-up of pulmonary hypertension. *Heart*. 2010;96(24):2005-9. PMID: 21088122.
- D'Alto M, Romeo E, Argiento P, et al. Bosentan-sildenafil association in patients with congenital heart disease-related pulmonary arterial hypertension and Eisenmenger physiology. *Int J Cardiol*. 2010. PMID: 21081251.
- Denton CP, Cailes JB, Phillips GD, et al. Comparison of Doppler echocardiography and right heart catheterization to assess pulmonary hypertension in systemic sclerosis. *Br J Rheumatol*. 1997;36(2):239-43. PMID: 9133938.
- Denton CP, Humbert M, Rubin L, et al. Bosentan treatment for pulmonary arterial hypertension related to connective tissue disease: a subgroup analysis of the pivotal clinical trials and their open-label extensions. *Ann Rheum Dis*. 2006;65(10):1336-40. PMID: 16793845.
- Dimitroulas T, Giannakoulas G, Karvounis H, et al. N-terminal probrain natriuretic peptide as a biochemical marker in the evaluation of bosentan treatment in systemic-sclerosis-related pulmonary arterial hypertension. *Clin Rheumatol*. 2008;27(5):655-8. PMID: 18204995.

- Dyer KL, Pauliks LB, Das B, et al. Use of myocardial performance index in pediatric patients with idiopathic pulmonary arterial hypertension. *J Am Soc Echocardiogr.* 2006;19(1):21-7. PMID: 16423665.
- Elstein D, Nir A, Klutstein M, et al. N-brain natriuretic peptide: correlation with tricuspid insufficiency in Gaucher disease. *Pulm Pharmacol Ther.* 2004;17(5):319-23. PMID: 15477128.
- Fahmy Elnoamany M, Abdelraouf Dawood A. Right ventricular myocardial isovolumic relaxation time as novel method for evaluation of pulmonary hypertension: correlation with endothelin-1 levels. *J Am Soc Echocardiogr.* 2007;20(5):462-9. PMID: 17484984.
- Farber HW, Foreman AJ, Miller DP, et al. REVEAL Registry: correlation of right heart catheterization and echocardiography in patients with pulmonary arterial hypertension. *Congest Heart Fail.* 2011;17(2):56-64. PMID: 21449993.
- Feliciano J, Cacela D, Agapito A, et al. Selective pulmonary vasodilators for severe pulmonary hypertension: comparison between endpoints. *Rev Port Cardiol.* 2005;24(3):399-404. PMID: 15929623.
- Fijalkowska A, Kurzyna M, Torbicki A, et al. Serum N-terminal brain natriuretic peptide as a prognostic parameter in patients with pulmonary hypertension. *Chest.* 2006;129(5):1313-21. PMID: 16685024.
- Filusch A, Giannitsis E, Katus HA, et al. High-sensitive troponin T: a novel biomarker for prognosis and disease severity in patients with pulmonary arterial hypertension. *Clin Sci (Lond).* 2010;119(5):207-13. PMID: 20412051.
- Fisher MR, Forfia PR, Chamera E, et al. Accuracy of Doppler echocardiography in the hemodynamic assessment of pulmonary hypertension. *Am J Respir Crit Care Med.* 2009;179(7):615-21. PMID: 19164700.
- Fitzgerald M, Fagan K, Herbert DE, et al. Misclassification of pulmonary hypertension in adults with sickle hemoglobinopathies using doppler echocardiography. *South Med J.* 2012;105(6):300-305. PMID: 22665152.
- Fix OK, Bass NM, De Marco T, et al. Long-term follow-up of portopulmonary hypertension: effect of treatment with epoprostenol. *Liver Transpl.* 2007;13(6):875-85. PMID: 17539008.
- Fonseca GH, Souza R, Salemi VM, et al. Pulmonary hypertension diagnosed by right heart catheterisation in sickle cell disease. *Eur Respir J.* 2012;39(1):112-8. PMID: 21778170.
- Forfia PR, Fisher MR, Mathai SC, et al. Tricuspid annular displacement predicts survival in pulmonary hypertension. *Am J Respir Crit Care Med.* 2006;174(9):1034-41. PMID: 16888289.
- Frantz RP, McDevitt S, Walker S. Baseline NT-proBNP correlates with change in 6-minute walk distance in patients with pulmonary arterial hypertension in the pivotal inhaled treprostinil study TRIUMPH-1. *J Heart Lung Transplant.* 2012;31(8):811-816. PMID: 22759797.
- Frea S, Capriolo M, Marra WG, et al. Echo Doppler predictors of pulmonary artery hypertension in patients with systemic sclerosis. *Echocardiography.* 2011;28(8):860-9. PMID: 21906161.
- Friedberg MK, Feinstein JA, Rosenthal DN. A novel echocardiographic Doppler method for estimation of pulmonary arterial pressures. *J Am Soc Echocardiogr.* 2006;19(5):559-62. PMID: 16644441.
- Fukuda Y, Tanaka H, Sugiyama D, et al. Utility of right ventricular free wall speckle-tracking strain for evaluation of right ventricular performance in patients with pulmonary hypertension. *J Am Soc Echocardiogr.* 2011;24(10):1101-1108. PMID: 21775102.
- Galie N, Beghetti M, Gatzoulis MA, et al. Bosentan therapy in patients with Eisenmenger syndrome: A multicenter, double-blind, randomized, placebo-controlled study. *Circulation.* 2006;114(1):48-54. PMID: 16801459.
- Galie N, Brundage BH, Ghofrani HA, et al. Tadalafil therapy for pulmonary arterial hypertension. *Circulation.* 2009;119(22):2894-903. PMID: 19470885.
- Galie N, Ghofrani HA, Torbicki A, et al. Sildenafil citrate therapy for pulmonary arterial hypertension. *N Engl J Med.* 2005;353(20):2148-57. PMID: 16291984.
- Galie N, Hinderliter AL, Torbicki A, et al. Effects of the oral endothelin-receptor antagonist bosentan on echocardiographic and doppler measures in patients with pulmonary arterial hypertension. *J Am Coll Cardiol.* 2003;41(8):1380-6. PMID: 12706935.
- Galie N, Olschewski H, Oudiz RJ, et al. Ambrisentan for the treatment of pulmonary arterial hypertension: results of the ambrisentan in pulmonary arterial hypertension, randomized, double-blind, placebo-controlled, multicenter, efficacy (ARIES) study 1 and 2. *Circulation.* 2008;117(23):3010-9. PMID: 18506008.

- Galie N, Rubin L, Hoeper M, et al. Treatment of patients with mildly symptomatic pulmonary arterial hypertension with bosentan (EARLY study): a double-blind, randomised controlled trial. *Lancet*. 2008;371(9630):2093-100. PMID: 18572079.
- Gan CT, McCann GP, Marcus JT, et al. NT-proBNP reflects right ventricular structure and function in pulmonary hypertension. *Eur Respir J*. 2006;28(6):1190-4. PMID: 16971413.
- Ghio S, Klersy C, Magrini G, et al. Prognostic relevance of the echocardiographic assessment of right ventricular function in patients with idiopathic pulmonary arterial hypertension. *Int J Cardiol*. 2010;140(3):272-8. PMID: 19070379.
- Ghio S, Matteo AD, Scelsi L, et al. Plasma brain natriuretic peptide is a marker of right ventricular overload in pulmonary hypertension associated to HIV infection. *Eur Heart J Suppl*. 2004;6(6):F35-F39.
- Ghofrani HA, Wiedemann R, Rose F, et al. Lung cGMP release subsequent to NO inhalation in pulmonary hypertension: responders versus nonresponders. *Eur Respir J*. 2002;19(4):664-71. PMID: 11998996.
- Gialafos EJ, Moyssakis I, Psaltopoulou T, et al. Circulating tissue inhibitor of matrix metalloproteinase-4 (TIMP-4) in systemic sclerosis patients with elevated pulmonary arterial pressure. *Mediators Inflamm*. 2008;2008.
- Goto K, Arai M, Watanabe A, et al. Utility of echocardiography versus BNP level for the prediction of pulmonary arterial pressure in patients with pulmonary arterial hypertension. *Int Heart J*. 2010;51(5):343-7. PMID: 20966607.
- Grapsa I, Pavlopoulos H, Dawson D, et al. Retrospective study of pulmonary hypertensive patients: is right ventricular myocardial performance index a vital prognostic factor? *Hellenic J Cardiol*. 2007;48(3):152-60. PMID: 17629178.
- Grubstein A, Benjaminov O, Dayan DB, et al. Computed tomography angiography in pulmonary hypertension. *Isr Med Assoc J*. 2008;10(2):117-20. PMID: 18432023.
- Hachulla E, Gressin V, Guillemin L, et al. Early detection of pulmonary arterial hypertension in systemic sclerosis: a French nationwide prospective multicenter study. *Arthritis Rheum*. 2005;52(12):3792-800. PMID: 16320330.
- Haddad F, Zamanian R, Beraud AS, et al. A novel non-invasive method of estimating pulmonary vascular resistance in patients with pulmonary arterial hypertension. *J Am Soc Echocardiogr*. 2009;22(5):523-9. PMID: 19307098.
- Halank M, Knudsen L, Seyfarth HJ, et al. Ambrisentan improves exercise capacity and symptoms in patients with portopulmonary hypertension. *Z Gastroenterol*. 2011;49(9):1258-62. PMID: 21887662.
- Hammerstingl C, Schueler R, Bors L, et al. Diagnostic value of echocardiography in the diagnosis of pulmonary hypertension. *PLoS ONE*. 2012;7(6). PMID: 22685577.
- Hampole CV, Mehrotra AK, Thenappan T, et al. Usefulness of red cell distribution width as a prognostic marker in pulmonary hypertension. *Am J Cardiol*. 2009;104(6):868-72. PMID: 19733726.
- Heresi GA, Aytekin M, Newman J, et al. CXC-chemokine ligand 10 in idiopathic pulmonary arterial hypertension: marker of improved survival. *Lung*. 2010;188(3):191-7. PMID: 20186422.
- Heresi GA, Tang WH, Aytekin M, et al. Sensitive cardiac troponin I predicts poor outcomes in pulmonary arterial hypertension. *Eur Respir J*. 2012;39(4):939-44. PMID: 21885398.
- Higenbottam TW, Spiegelhalter D, Scott JP, et al. Prostacyclin (epoprostenol) and heart-lung transplantation as treatments for severe pulmonary hypertension. *Br Heart J* 1993;70(4):366-70. PMID: 8217447.
- Hinderliter AL, Willis PWt, Barst RJ, et al. Effects of long-term infusion of prostacyclin (epoprostenol) on echocardiographic measures of right ventricular structure and function in primary pulmonary hypertension. Primary Pulmonary Hypertension Study Group. *Circulation*. 1997;95(6):1479-86. PMID: 9118516.
- Hiramoto Y, Shioyama W, Higuchi K, et al. Clinical significance of plasma endothelin-1 level after bosentan administration in pulmonary arterial hypertension. *J Cardiol*. 2009;53(3):374-80. PMID: 19477379.
- Hiremath J, Thanikachalam S, Parikh K, et al. Exercise improvement and plasma biomarker changes with intravenous treprostinil therapy for pulmonary arterial hypertension: a placebo-controlled trial. *J Heart Lung Transplant*. 2010;29(2):137-49. PMID: 20022264.

- Ho WJ, Hsu TS, Tsay PK, et al. Serial plasma brain natriuretic peptide testing in clinical management of pulmonary arterial hypertension. *Acta Cardiol Sin.* 2009;25(3):147-153.
- Hoepfer MM, Leuchte H, Halank M, et al. Combining inhaled iloprost with bosentan in patients with idiopathic pulmonary arterial hypertension. *Eur Respir J.* 2006;28(4):691-4. PMID: 17012628.
- Hoepfer MM, Seyfarth HJ, Hoeffken G, et al. Experience with inhaled iloprost and bosentan in portopulmonary hypertension. *Eur Respir J.* 2007;30(6):1096-102. PMID: 17652314.
- Homma A, Anzueto A, Peters JI, et al. Pulmonary artery systolic pressures estimated by echocardiogram vs cardiac catheterization in patients awaiting lung transplantation. *J Heart Lung Transplant.* 2001;20(8):833-9. PMID: 11502405.
- Hsu VM, Moreyra AE, Wilson AC, et al. Assessment of pulmonary arterial hypertension in patients with systemic sclerosis: comparison of noninvasive tests with results of right-heart catheterization. *J Rheumatol.* 2008;35(3):458-65. PMID: 18203320.
- Hua R, Sun YW, Wu ZY, et al. Role of 2-dimensional Doppler echo-cardiography in screening portopulmonary hypertension in portal hypertension patients. *Hepatobiliary Pancreat Dis Int.* 2009;8(2):157-61. PMID: 19357029.
- Humbert M, Barst RJ, Robbins IM, et al. Combination of bosentan with epoprostenol in pulmonary arterial hypertension: BREATHE-2. *Eur Respir J.* 2004;24(3):353-9. PMID: 15358690.
- Jacobs W, Boonstra A, Marcus JT, et al. Addition of prostanoids in pulmonary hypertension deteriorating on oral therapy. *J Heart Lung Transplant.* 2009;28(3):280-4. PMID: 19285621.
- Jansa P, Becvar R, Ambroz D, et al. Pulmonary arterial hypertension associated with systemic sclerosis in the Czech Republic. *Clin Rheumatol.* 2012;31(3):557-61. PMID: 22105781.
- Jing ZC, Yu ZX, Shen JY, et al. Vardenafil in pulmonary arterial hypertension: a randomized, double-blind, placebo-controlled study. *Am J Respir Crit Care Med.* 2011;183(12):1723-9. PMID: 21471085.
- Kaya MG, Lam YY, Erer B, et al. Long-term effect of bosentan therapy on cardiac function and symptomatic benefits in adult patients with eisenmenger syndrome. *J Card Fail.* 2012;18(5):379-384. PMID: 22555267.
- Kemp K, Savale L, O'Callaghan DS, et al. Usefulness of first-line combination therapy with epoprostenol and bosentan in pulmonary arterial hypertension: an observational study. *J Heart Lung Transplant.* 2012;31(2):150-8. PMID: 22138355.
- Keogh A, Strange G, Kotlyar E, et al. Survival after the initiation of combination therapy in patients with pulmonary arterial hypertension: an Australian collaborative report. *Intern Med J.* 2011;41(3):235-44. PMID: 21118410.
- Knirsch W, Hausermann E, Fasnacht M, et al. Plasma B-type natriuretic peptide levels in children with heart disease. *Acta Paediatr Int J Paediatr.* 2011;100(9):1213-1216.
- Kopec G, Tyrka A, Miszalski-Jamka T, et al. Changes in Exercise Capacity and Cardiac Performance in a Series of Patients with Eisenmenger's Syndrome Transitioned from Selective to Dual Endothelin Receptor Antagonist. *Heart Lung and Circulation.* 2012. PMID: 22819097.
- Kovacs G, Maier R, Aberer E, et al. Assessment of pulmonary arterial pressure during exercise in collagen vascular disease: echocardiography vs right-sided heart catheterization. *Chest.* 2010;138(2):270-8. PMID: 20418368.
- Lammers AE, Hislop AA, Haworth SG. Prognostic value of B-type natriuretic peptide in children with pulmonary hypertension. *Int J Cardiol.* 2009;135(1):21-6. PMID: 18599134.
- Langleben D, Barst RJ, Badesch D, et al. Continuous infusion of epoprostenol improves the net balance between pulmonary endothelin-1 clearance and release in primary pulmonary hypertension. *Circulation.* 1999;99(25):3266-71. PMID: 10385501.
- Leuchte HH, Holzapfel M, Baumgartner RA, et al. Characterization of brain natriuretic peptide in long-term follow-up of pulmonary arterial hypertension. *Chest.* 2005;128(4):2368-74. PMID: 16236896.
- Lindqvist P, Soderberg S, Gonzalez MC, et al. Echocardiography based estimation of pulmonary vascular resistance in patients with pulmonary hypertension: a simultaneous Doppler echocardiography and cardiac catheterization study. *Eur J Echocardiogr.* 2011;12(12):961-6. PMID: 22011836.
- Lorenzen JM, Nickel N, Kramer R, et al. Osteopontin in patients with idiopathic pulmonary hypertension. *Chest.* 2011;139(5):1010-7. PMID: 20947652.

- Low AJ, Fowler D, Manghani MK, et al. Screening and Treating Pulmonary Arterial Hypertension in a Tertiary Hospital -based Multidisciplinary Clinic - The First 200 Patients. *Intern Med J*. 2011. PMID: 22032309.
- Machado RF, Anthi A, Steinberg MH, et al. N-terminal pro-brain natriuretic peptide levels and risk of death in sickle cell disease. *JAMA*. 2006;296(3):310-8. PMID: 16849664.
- Machado RF, Londhe Nerkar MV, Dweik RA, et al. Nitric oxide and pulmonary arterial pressures in pulmonary hypertension. *Free Radic Biol Med*. 2004;37(7):1010-7. PMID: 15336317.
- Mahapatra S, Nishimura RA, Oh JK, et al. The prognostic value of pulmonary vascular capacitance determined by Doppler echocardiography in patients with pulmonary arterial hypertension. *J Am Soc Echocardiogr*. 2006;19(8):1045-50. PMID: 16880101.
- Mathai SC, Sibley CT, Forfia PR, et al. Tricuspid annular plane systolic excursion is a robust outcome measure in systemic sclerosis-associated pulmonary arterial hypertension. *J Rheumatol*. 2011;38(11):2410-8. PMID: 21965638.
- Mauritz GJ, Rizopoulos D, Groepenhoff H, et al. Usefulness of serial N-terminal ProB-type natriuretic peptide measurements for determining prognosis in patients with pulmonary arterial hypertension. *Am J Cardiol*. 2011;108(11):1645-1650. PMID: 21890089.
- McLaughlin VV, Benza RL, Rubin LJ, et al. Addition of inhaled treprostinil to oral therapy for pulmonary arterial hypertension: a randomized controlled clinical trial. *J Am Coll Cardiol*. 2010;55(18):1915-22. PMID: 20430262.
- McLaughlin VV, Gaine SP, Barst RJ, et al. Efficacy and safety of treprostinil: an epoprostenol analog for primary pulmonary hypertension. *J Cardiovasc Pharmacol*. 2003;41(2):293-9. PMID: 12548091.
- McLaughlin VV, Oudiz RJ, Frost A, et al. Randomized study of adding inhaled iloprost to existing bosentan in pulmonary arterial hypertension. *Am J Respir Crit Care Med*. 2006;174(11):1257-63. PMID: 16946127.
- McLean AS, Ting I, Huang SJ, et al. The use of the right ventricular diameter and tricuspid annular tissue Doppler velocity parameter to predict the presence of pulmonary hypertension. *Eur J Echocardiogr*. 2007;8(2):128-36. PMID: 16672193.
- Michelakis E, Tymchak W, Lien D, et al. Oral sildenafil is an effective and specific pulmonary vasodilator in patients with pulmonary arterial hypertension: comparison with inhaled nitric oxide. *Circulation*. 2002;105(20):2398-403. PMID: 12021227.
- Minniti CP, Machado RF, Coles WA, et al. Endothelin receptor antagonists for pulmonary hypertension in adult patients with sickle cell disease. *Br J Haematol*. 2009;147(5):737-43. PMID: 19775299.
- Montani D, Souza R, Binkert C, et al. Endothelin-1/endothelin-3 ratio: a potential prognostic factor of pulmonary arterial hypertension. *Chest*. 2007;131(1):101-8. PMID: 17218562.
- Morishita T, Miyaji K, Akao I, et al. The ratio of the atrial areas reflects the clinical status of patients with pulmonary arterial hypertension. *J Med Ultrason*. 2009;36(4):201-206.
- Mourani PM, Sontag MK, Younoszai A, et al. Clinical utility of echocardiography for the diagnosis and management of pulmonary vascular disease in young children with chronic lung disease. *Pediatrics*. 2008;121(2):317-25. PMID: 18245423.
- Mukerjee D, St George D, Knight C, et al. Echocardiography and pulmonary function as screening tests for pulmonary arterial hypertension in systemic sclerosis. *Rheumatology (Oxford)*. 2004;43(4):461-6. PMID: 15024134.
- Mukerjee D, Yap LB, Holmes AM, et al. Significance of plasma N-terminal pro-brain natriuretic peptide in patients with systemic sclerosis-related pulmonary arterial hypertension. *Respir Med*. 2003;97(11):1230-6. PMID: 14635979.
- Mukhopadhyay S, Nathani S, Yusuf J, et al. Clinical efficacy of phosphodiesterase-5 inhibitor tadalafil in Eisenmenger Syndrome-A randomized, placebo-controlled, double-blind crossover study. *Congenit Heart Dis*. 2011;6(5):424-431. PMID: 21914136.
- Murata I, Takenaka K, Yoshinoya S, et al. Clinical evaluation of pulmonary hypertension in systemic sclerosis and related disorders. A Doppler echocardiographic study of 135 Japanese patients. *Chest*. 1997;111(1):36-43. PMID: 8995990.
- Nagaya N, Nishikimi T, Uematsu M, et al. Plasma brain natriuretic peptide as a prognostic indicator in patients with primary pulmonary hypertension. *Circulation*. 2000;102(8):865-70. PMID: 10952954.

- Nakayama T, Shimada H, Takatsuki S, et al. Efficacy and limitations of continuous intravenous epoprostenol therapy for idiopathic pulmonary arterial hypertension in Japanese children. *Circ J*. 2007;71(11):1785-90. PMID: 17965503.
- Nakayama Y, Sugimachi M, Nakanishi N, et al. Noninvasive differential diagnosis between chronic pulmonary thromboembolism and primary pulmonary hypertension by means of Doppler ultrasound measurement. *J Am Coll Cardiol*. 1998;31(6):1367-71. PMID: 9581735.
- Nath J, Demarco T, Hourigan L, et al. Correlation between right ventricular indices and clinical improvement in epoprostenol treated pulmonary hypertension patients. *Echocardiography*. 2005;22(5):374-9. PMID: 15901287.
- Nickel N, Golpon H, Greer M, et al. The prognostic impact of follow-up assessments in patients with idiopathic pulmonary arterial hypertension. *Eur Respir J*. 2012;39(3):589-96. PMID: 21885392.
- Nickel N, Kempf T, Tapken H, et al. Growth differentiation factor-15 in idiopathic pulmonary arterial hypertension. *Am J Respir Crit Care Med*. 2008;178(5):534-41. PMID: 18565955.
- Njman W, Iesaki T, Iwama Y, et al. Serum uric Acid as a prognostic predictor in pulmonary arterial hypertension with connective tissue disease. *Int Heart J*. 2007;48(4):523-32. PMID: 17827824.
- Nogami M, Ohno Y, Koyama H, et al. Utility of phase contrast MR imaging for assessment of pulmonary flow and pressure estimation in patients with pulmonary hypertension: comparison with right heart catheterization and echocardiography. *J Magn Reson Imaging*. 2009;30(5):973-80. PMID: 19856412.
- Ogawa A, Miyaji K, Yamadori I, et al. Safety and efficacy of epoprostenol therapy in pulmonary veno-occlusive disease and pulmonary capillary hemangiomatosis. *Circulation Journal*. 2012;76(7):1729-1736. PMID: 22481098.
- Olschewski H, Hoeper MM, Behr J, et al. Long-term therapy with inhaled iloprost in patients with pulmonary hypertension. *Respir Med*. 2010;104(5):731-40. PMID: 20153158.
- Olschewski H, Simonneau G, Galie N, et al. Inhaled iloprost for severe pulmonary hypertension. *N Engl J Med*. 2002;347(5):322-9. PMID: 12151469.
- Oudiz RJ, Brundage BH, Galie N, et al. Tadalafil for the Treatment of Pulmonary Arterial Hypertension. A Double-Blind 52-Week Uncontrolled Extension Study. *J Am Coll Cardiol*. 2012. PMID: 22818063.
- Oudiz RJ, Galie N, Olschewski H, et al. Long-term ambrisentan therapy for the treatment of pulmonary arterial hypertension. *J Am Coll Cardiol*. 2009;54(21):1971-81. PMID: 19909879.
- Park MH, Scott RL, Uber PA, et al. Usefulness of B-type natriuretic peptide as a predictor of treatment outcome in pulmonary arterial hypertension. *Congest Heart Fail*. 2004;10(5):221-5. PMID: 15470298.
- Phung S, Strange G, Chung LP, et al. Prevalence of pulmonary arterial hypertension in an Australian scleroderma population: screening allows for earlier diagnosis. *Intern Med J*. 2009;39(10):682-91. PMID: 19220532.
- Pilatis ND, Jacobs LE, Rerkpattanapipat P, et al. Clinical predictors of pulmonary hypertension in patients undergoing liver transplant evaluation. *Liver Transpl*. 2000;6(1):85-91. PMID: 10648583.
- Pyxaras SA, Pinamonti B, Barbat G, et al. Echocardiographic evaluation of systolic and mean pulmonary artery pressure in the follow-up of patients with pulmonary hypertension. *Eur J Echocardiogr*. 2011;12(9):696-701. PMID: 21821609.
- Rajagopalan N, Saxena N, Simon MA, et al. Correlation of tricuspid annular velocities with invasive hemodynamics in pulmonary hypertension. *Congest Heart Fail*. 2007;13(4):200-4. PMID: 17673871.
- Rajagopalan N, Simon MA, Suffoletto MS, et al. Noninvasive estimation of pulmonary vascular resistance in pulmonary hypertension. *Echocardiography*. 2009;26(5):489-94. PMID: 19054039.
- Rajaram S, Swift AJ, Capener D, et al. Comparison of the diagnostic utility of cardiac magnetic resonance imaging, computed tomography, and echocardiography in assessment of suspected pulmonary arterial hypertension in patients with connective tissue disease. *J Rheumatol*. 2012;39(6):1265-1274. PMID: 22589263.
- Raymond RJ, Hinderliter AL, Willis PW, et al. Echocardiographic predictors of adverse outcomes in primary pulmonary hypertension. *J Am Coll Cardiol*. 2002;39(7):1214-9. PMID: 11923049.
- Reichenberger F, Mainwood A, Morrell NW, et al. Intravenous epoprostenol versus high dose inhaled iloprost for long-term treatment of pulmonary hypertension. *Pulm Pharmacol Ther*. 2011;24(1):169-73. PMID: 20601049.

- Rhodes CJ, Wharton J, Howard LS, et al. Red cell distribution width outperforms other potential circulating biomarkers in predicting survival in idiopathic pulmonary arterial hypertension. *Heart*. 2011;97(13):1054-60. PMID: 21558476.
- Rich JD, Glassner C, Wade M, et al. The effect of diluent pH on bloodstream infection rates in patients receiving IV treprostinil for pulmonary arterial hypertension. *Chest*. 2012;141(1):36-42. PMID: 21659437.
- Rich JD, Shah SJ, Swamy RS, et al. Inaccuracy of Doppler echocardiographic estimates of pulmonary artery pressures in patients with pulmonary hypertension: implications for clinical practice. *Chest*. 2011;139(5):988-93. PMID: 20864617.
- Roeleveld RJ, Marcus JT, Boonstra A, et al. A comparison of noninvasive MRI-based methods of estimating pulmonary artery pressure in pulmonary hypertension. *J Magn Reson Imaging*. 2005;22(1):67-72. PMID: 15971176.
- Roule V, Labombarda F, Pellissier A, et al. Echocardiographic assessment of pulmonary vascular resistance in pulmonary arterial hypertension. *Cardiovasc Ultrasound*. 2010;8:21. PMID: 20529278.
- Ruan Q, Nagueh SF. Clinical application of tissue Doppler imaging in patients with idiopathic pulmonary hypertension. *Chest*. 2007;131(2):395-401. PMID: 17296639.
- Rubin LJ, Badesch DB, Barst RJ, et al. Bosentan therapy for pulmonary arterial hypertension. *N Engl J Med*. 2002;346(12):896-903. PMID: 11907289.
- Rubin LJ, Badesch DB, Fleming TR, et al. Long-term treatment with sildenafil citrate in pulmonary arterial hypertension: the SUPER-2 study. *Chest*. 2011;140(5):1274-83. PMID: 21546436.
- Rubin LJ, Mendoza J, Hood M, et al. Treatment of primary pulmonary hypertension with continuous intravenous prostacyclin (epoprostenol). Results of a randomized trial. *Ann Intern Med*. 1990;112(7):485-91. PMID: 2107780.
- Ruiz-Irastorza G, Garmendia M, Villar I, et al. Pulmonary hypertension in systemic lupus erythematosus: prevalence, predictors and diagnostic strategy. *Autoimmunity Reviews*. 2012. PMID: 22841984.
- Sadushi-Kolici R, Skoro-Sajer N, Zimmer D, et al. Long-term treatment, tolerability, and survival with sub-cutaneous treprostinil for severe pulmonary hypertension. *J Heart Lung Transplant*. 2012;31(7):735-743. PMID: 22480725.
- Sanli C, Oguz D, Olgunturk R, et al. Elevated Homocysteine and Asymmetric Dimethyl Arginine Levels in Pulmonary Hypertension Associated With Congenital Heart Disease. *Pediatr Cardiol*. 2012;1-9. PMID: 22526220.
- Sastry BK, Raju BS, Narasimhan C, et al. Sildenafil improves survival in idiopathic pulmonary arterial hypertension. *Indian Heart J*. 2007;59(4):336-41. PMID: 19126939.
- Schumann C, Lepper PM, Frank H, et al. Circulating biomarkers of tissue remodelling in pulmonary hypertension. *Biomarkers*. 2010;15(6):523-32. PMID: 20528622.
- Sebbag I, Rudski LG, Therrien J, et al. Effect of chronic infusion of epoprostenol on echocardiographic right ventricular myocardial performance index and its relation to clinical outcome in patients with primary pulmonary hypertension. *Am J Cardiol*. 2001;88(9):1060-3. PMID: 11704014.
- Selby VN, Scherzer R, Barnett CF, et al. Doppler echocardiography does not accurately estimate pulmonary artery systolic pressure in HIV-infected patients. *AIDS*. 2012. PMID: 22781217.
- Selimovic N, Rundqvist B, Bergh CH, et al. Assessment of pulmonary vascular resistance by Doppler echocardiography in patients with pulmonary arterial hypertension. *J Heart Lung Transplant*. 2007;26(9):927-34. PMID: 17845932.
- Shapiro S, Pollock DM, Gillies H, et al. Frequency of Edema in Patients With Pulmonary Arterial Hypertension Receiving Ambrisentan. *Am J Cardiol*. 2012. PMID: 22858181.
- Shimony A, Fox BD, Langleben D, et al. Incidence and Significance of Pericardial Effusion in Patients With Pulmonary Arterial Hypertension. *Can J Cardiol*. 2012. PMID: 22717247.
- Simeoni S, Lippi G, Puccetti A, et al. N-terminal pro-BNP in sclerodermic patients on bosentan therapy for PAH. *Rheumatol Int*. 2008;28(7):657-60. PMID: 18092166.
- Simonneau G, Barst RJ, Galie N, et al. Continuous subcutaneous infusion of treprostinil, a prostacyclin analogue, in patients with pulmonary arterial hypertension: a double-blind, randomized, placebo-controlled trial. *Am J Respir Crit Care Med*. 2002;165(6):800-4. PMID: 11897647.



- Simonneau G, Rubin LJ, Galie N, et al. Addition of sildenafil to long-term intravenous epoprostenol therapy in patients with pulmonary arterial hypertension: a randomized trial. *Ann Intern Med*. 2008;149(8):521-30. PMID: 18936500.
- Soon E, Doughty NJ, Treacy CM, et al. Log-transformation improves the prognostic value of serial NT-proBNP levels in apparently stable pulmonary arterial hypertension. *Pulm Circ*. 2011;1(2):244-9. PMID: 22034610.
- Souza R, Jardim C, Julio Cesar Fernandes C, et al. NT-proBNP as a tool to stratify disease severity in pulmonary arterial hypertension. *Respir Med*. 2007;101(1):69-75. PMID: 16781131.
- Steen V, Chou M, Shanmugam V, et al. Exercise-induced pulmonary arterial hypertension in patients with systemic sclerosis. *Chest*. 2008;134(1):146-51. PMID: 18403670.
- Taguchi H, Kataoka M, Yanagisawa R, et al. Platelet level as a new prognostic factor for idiopathic pulmonary arterial hypertension in the era of combination therapy. *Circulation Journal*. 2012;76(6):1494-1500. PMID: 22447010.
- Takatsuki S, Calderbank M, Ivy DD. Initial experience with tadalafil in pediatric pulmonary arterial hypertension. *Pediatr Cardiol*. 2012;33(5):683-688. PMID: 22402804.
- Takatsuki S, Nakayama T, Jone PN, et al. Tissue Doppler Imaging Predicts Adverse Outcome in Children with Idiopathic Pulmonary Arterial Hypertension. *J Pediatr*. 2012. PMID: 33748515.
- Takatsuki S, Rosenzweig EB, Zuckerman W, et al. Clinical safety, pharmacokinetics, and efficacy of ambrisentan therapy in children with pulmonary arterial hypertension. *Pediatr Pulmonol*. 2012. PMID: 22511577.
- Takatsuki S, Wagner BD, Ivy DD. B-type Natriuretic Peptide and Amino-terminal Pro-B-type Natriuretic Peptide in Pediatric Patients with Pulmonary Arterial Hypertension. *Congenital Heart Disease*. 2012;7(3):259-267. PMID: 22325151.
- Takeda Y, Tomimoto S, Tani T, et al. Bilirubin as a prognostic marker in patients with pulmonary arterial hypertension. *BMC Pulm Med*. 2010;10:22. PMID: 20412580.
- Tei C, Dujardin KS, Hodge DO, et al. Doppler echocardiographic index for assessment of global right ventricular function. *J Am Soc Echocardiogr*. 1996;9(6):838-47. PMID: 8943444.
- Thakkar V, Stevens WM, Prior D, et al. N-terminal pro-brain natriuretic peptide in a novel screening algorithm for pulmonary arterial hypertension in systemic sclerosis: A case-control study. *Arthritis Research and Therapy*. 2012;14(3). PMID: 22691291.
- Tian Z, Liu YT, Fang Q, et al. Hemodynamic parameters obtained by transthoracic echocardiography and right heart catheterization: a comparative study in patients with pulmonary hypertension. *Chin Med J (Engl)*. 2011;124(12):1796-801. PMID: 21740835.
- Torbicki A, Kurzyna M, Kuca P, et al. Detectable serum cardiac troponin T as a marker of poor prognosis among patients with chronic precapillary pulmonary hypertension. *Circulation*. 2003;108(7):844-8. PMID: 12900346.
- Torregrosa M, Genesca J, Gonzalez A, et al. Role of Doppler echocardiography in the assessment of portopulmonary hypertension in liver transplantation candidates. *Transplantation*. 2001;71(4):572-4. PMID: 11258439.
- Toyono M, Harada K, Tamura M, et al. Paradoxical relationship between B-type natriuretic peptide and pulmonary vascular resistance in patients with ventricular septal defect and concomitant severe pulmonary hypertension. *Pediatr Cardiol*. 2008;29(1):65-9. PMID: 17786380.
- Tutar HE, Imamoglu A, Atalay S, et al. Plasma endothelin-1 levels in patients with left-to-right shunt with or without pulmonary hypertension. *Int J Cardiol*. 1999;70(1):57-62. PMID: 10402046.
- Utsunomiya H, Nakatani S, Nishihira M, et al. Value of estimated right ventricular filling pressure in predicting cardiac events in chronic pulmonary arterial hypertension. *J Am Soc Echocardiogr*. 2009;22(12):1368-74. PMID: 19944957.
- Utsunomiya H, Nakatani S, Okada T, et al. A simple method to predict impaired right ventricular performance and disease severity in chronic pulmonary hypertension using strain rate imaging. *Int J Cardiol*. 2011;147(1):88-94. PMID: 19747741.
- Van Albada ME, Loot FG, Fokkema R, et al. Biological serum markers in the management of pediatric pulmonary arterial hypertension. *Pediatr Res*. 2008;63(3):321-7. PMID: 18287971.
- Vizza CD, Letizia C, Badagliacca R, et al. Relationship between baseline ET-1 plasma levels and outcome in patients with idiopathic pulmonary hypertension treated with bosentan. *Int J Cardiol*. 2012. PMID: 22265324.

Vizza CD, Letizia C, Petramala L, et al. Venous endothelin-1 (ET-1) and brain natriuretic peptide (BNP) plasma levels during 6-month bosentan treatment for pulmonary arterial hypertension. *Regul Pept.* 2008;151(1-3):48-53. PMID: 18796317.

Vlahos AP, Feinstein JA, Schiller NB, et al. Extension of Doppler-derived echocardiographic measures of pulmonary vascular resistance to patients with moderate or severe pulmonary vascular disease. *J Am Soc Echocardiogr.* 2008;21(6):711-4. PMID: 18187297.

Voelkel MA, Wynne KM, Badesch DB, et al. Hyperuricemia in severe pulmonary hypertension. *Chest.* 2000;117(1):19-24. PMID: 10631193.

Vonk MC, Sander MH, van den Hoogen FH, et al. Right ventricle Tei-index: a tool to increase the accuracy of non-invasive detection of pulmonary arterial hypertension in connective tissue diseases. *Eur J Echocardiogr.* 2007;8(5):317-21. PMID: 16846757.

Wilkins MR, Paul GA, Strange JW, et al. Sildenafil versus Endothelin Receptor Antagonist for Pulmonary Hypertension (SERAPH) study. *Am J Respir Crit Care Med.* 2005;171(11):1292-7. PMID: 15750042.

Willens HJ, Chirinos JA, Gomez-Marin O, et al. Noninvasive differentiation of pulmonary arterial and venous hypertension using conventional and Doppler tissue imaging echocardiography. *J Am Soc Echocardiogr.* 2008;21(6):715-9. PMID: 18325734.

Williams MH, Handler CE, Akram R, et al. Role of N-terminal brain natriuretic peptide (N-TproBNP) in scleroderma-associated pulmonary arterial hypertension. *Eur Heart J.* 2006;27(12):1485-94. PMID: 16682379.

Yamada Y, Okuda S, Kataoka M, et al. Prognostic value of cardiac magnetic resonance imaging for idiopathic pulmonary arterial hypertension before initiating intravenous prostacyclin therapy. *Circulation Journal.* 2012;76(7):1737-1743. PMID: 22498565.

Yanagisawa R, Kataoka M, Taguchi H, et al. Impact of First-Line Sildenafil Monotreatment for Pulmonary Arterial Hypertension. *Circ J.* 2012;76(5):1245-1252. PMID: 22333215.

Yang SI, Chung WJ, Jung SH, et al. Effects of inhaled iloprost on congenital heart disease with eisenmenger syndrome. *Pediatr Cardiol.* 2012;33(5):744-748. PMID: 22349672.

Yoshida S, Shirato K, Shimamura R, et al. Long-term safety and efficacy of ambrisentan in Japanese adults with pulmonary arterial hypertension. *Curr Med Res Opin.* 2012;28(6):1069-1076. PMID: 22506623.

Zafir N, Zingerman B, Solodky A, et al. Use of noninvasive tools in primary pulmonary hypertension to assess the correlation of right ventricular function with functional capacity and to predict outcome. *Int J Cardiovasc Imaging.* 2007;23(2):209-15. PMID: 16972146.

Zeng WJ, Sun YJ, Gu Q, et al. Impact of Sildenafil on Survival of Patients With Idiopathic Pulmonary Arterial Hypertension. *J Clin Pharmacol.* 2011. PMID: 21956607.

Zeng WJ, Sun YJ, Xiong CM, et al. Prognostic value of echocardiographic right/left ventricular end-diastolic diameter ratio in idiopathic pulmonary arterial hypertension. *Chin Med J (Engl).* 2011;124(11):1672-7. PMID: 21740775.

Zhao QH, Peng FH, Wei H, et al. Serum high-density lipoprotein cholesterol levels as a prognostic indicator in patients with idiopathic pulmonary arterial hypertension. *Am J Cardiol.* 2012;110(3):433-439. PMID: 22560769.

## Study Groupings

Table C-1 presents a key to the primary and companion articles included in this report, organized alphabetically by study designation (if applicable). A full reference list follows the table.

**Table C-1. Primary articles and companion articles**

Study Designation	Primary Article	Companion Article(s)
AIR (Aerosolized Iloprost Randomized Study)	Olschewski, 2010 <sup>1</sup>	None
ARIES-1 ARIES-2	Galie, 2008 <sup>2</sup>	Oudiz 2009 <sup>3</sup> Shapiro 2012 <sup>4</sup>
ARIES-3	Badesch, 2012 <sup>5</sup>	Badesch 2011 <sup>6</sup>
ASSET-1 ASSET-2	Barst, 2010 <sup>7</sup>	None
BREATH-1 (Bosentan Randomized Trial of Endothelin Antagonist Therapy)	Rubin, 2002 <sup>8</sup>	Denton 2006 <sup>9</sup> Galie 2003 <sup>10</sup>
BREATHE-2 (Bosentan Randomized Trial of Endothelin Antagonist Therapy for PAH)	Humbert, 2004 <sup>11</sup>	None
BREATHE-5 (Bosentan Randomized Trial of Endothelin Antagonist Therapy-5)	Galie, 2006 <sup>12</sup>	None
COMBI (Combination Therapy of Bosentan and aerosolized Iloprost in Idiopathic Pulmonary Arterial Hypertension trial)	Hoeper, 2006 <sup>13</sup>	None
EARLY (Endothelin Antagonist Trial in Mildly Symptomatic Pulmonary Arterial Hypertension Patients)	Galie, 2008 <sup>14</sup>	None
EVALUATION (Efficacy and Safety of Vardenafil in the Treatment of Pulmonary Arterial Hypertension Study)	Jing, 2011 <sup>15</sup>	None
MSH (Multicenter Study of Hydroxyurea in Sickle Cell Anemia Patients)	Machado, 2006 <sup>16</sup>	None
PACES (Pulmonary Arterial Hypertension Combination Study of Epoprostenol and Sildenafil)	Simonneau, 2008 <sup>17</sup>	None
PHC (Pulmonary Hypertension Connection Registry)	Hampole, 2009 <sup>18</sup>	None
PHIRST (Pulmonary Arterial Hypertension and Response to Tadalafil)	Galie, 2009 <sup>19</sup>	Barst 2011 <sup>20</sup> Oudiz 2012 <sup>21</sup>
Primary Pulmonary Hypertension Study	Barst, 1996 <sup>22</sup>	None
Prospective Evaluation of Adolescents and Children with Pulmonary Arterial Hypertension	Bernus, 2009 <sup>23</sup>	None
REVEAL (Registry to Evaluate Early and Long-Term Pulmonary Arterial Hypertension Disease Management)	Benza, 2010 <sup>24</sup> Farber, 2011 <sup>25</sup>	None
SERAPH (Sildenafil versus Endothelin Receptor Antagonist for Pulmonary Hypertension Study)	Wilkins, 2005 <sup>26</sup>	None
STARTS-1 (Sildenafil in Treatment-Naïve Children, Aged 1-17 Years, With Pulmonary Arterial Hypertension)	Barst, 2011 <sup>27</sup>	None
SUPER (Sildenafil Use in Pulmonary Arterial Hypertension)	Galie, 2005 <sup>28</sup>	Badesch 2007 <sup>29</sup> Rubin 2011 <sup>30</sup>
Treprostinil Study Group	McLaughlin, 2003 <sup>31</sup> Simonneau, 2002 <sup>32</sup>	None
TRIUMPH (TREprostinil Sodium Inhalation Used in the Management of Pulmonary Arterial Hypertension)	McLaughlin, 2010 <sup>33</sup>	Frantz 2012 <sup>34</sup>

Study Designation	Primary Article	Companion Article(s)
TRUST	Hiremath, 2010 <sup>35</sup>	None
None indicated	Ajami, 2011 <sup>36</sup>	None
None indicated	Allanore, 2008 <sup>37</sup>	None
None indicated	Andreassen, 2006 <sup>38</sup>	None
None indicated	Arcasoy, 2003 <sup>39</sup>	None
None indicated	Badesch, 2000 <sup>40</sup>	None
None indicated	Bendayan, 2003 <sup>41</sup>	None
None indicated	Bharani, 2007 <sup>42</sup>	None
None indicated	Bogdan, 1998 <sup>43</sup>	None
None indicated	Bonderman, 2011 <sup>44</sup>	None
None indicated	Borges, 2006 <sup>45</sup>	None
None indicated	Brierre, 2010 <sup>46</sup>	None
None indicated	Bustamante-Labarta, 2002 <sup>47</sup>	None
None indicated	Campana, 2004 <sup>48</sup>	None
None indicated	Cavagna, 2010 <sup>49</sup>	None
None indicated	Cella, 2009 <sup>50</sup>	None
None indicated	Cevik, 2012 <sup>51</sup>	None
None indicated	Channick, 2001 <sup>52</sup>	Badesch 2002 <sup>53</sup>
None indicated	Chin, 2007 <sup>54</sup>	None
None indicated	Ciurzynski, 2011 <sup>55</sup>	None
None indicated	Colle, 2003 <sup>56</sup>	None
None indicated	Condliffe, 2011 <sup>57</sup>	None
None indicated	Dahiya, 2010 <sup>58</sup>	None
None indicated	D'Alto, 2010 <sup>59</sup>	None
None indicated	Denton, 1997 <sup>60</sup>	None
None indicated	Dimitroulas, 2008 <sup>61</sup>	None
None indicated	Dyer, 2006 <sup>62</sup>	None
None indicated	Elstein, 2004 <sup>63</sup>	None
None indicated	Fahmy Elnoamany, 2007 <sup>64</sup>	None
None indicated	Feliciano, 2005 <sup>65</sup>	None
None indicated	Fijalkowska, 2006 <sup>66</sup>	None
None indicated	Filusch, 2010 <sup>67</sup>	None
None indicated	Fisher, 2009 <sup>68</sup>	None
None indicated	Fitzgerald, 2012 <sup>69</sup>	None
None indicated	Fix, 2007 <sup>70</sup>	None
None indicated	Fonseca, 2012 <sup>71</sup>	None
None indicated	Forfia, 2006 <sup>72</sup>	None
None indicated	Frea, 2011 <sup>73</sup>	None
None indicated	Friedberg, 2006 <sup>74</sup>	None
None indicated	Fukuda, 2011 <sup>75</sup>	None
None indicated	Gan, 2006 <sup>76</sup>	None
None indicated	Ghio, 2010 <sup>77</sup>	None
None indicated	Ghio, 2004 <sup>78</sup>	None
None indicated	Ghofrani, 2002 <sup>79</sup>	None
None indicated	Gialafos, 2008 <sup>80</sup>	None
None indicated	Goto, 2010 <sup>81</sup>	None
None indicated	Grapsa, 2007 <sup>82</sup>	None
None indicated	Grubstein, 2008 <sup>83</sup>	None
None indicated	Hachulla, 2005 <sup>84</sup>	None
None indicated	Haddad, 2009 <sup>85</sup>	None
None indicated	Halank, 2011 <sup>86</sup>	None
None indicated	Hammerstingl, 2012 <sup>87</sup>	None
None indicated	Heresi, 2010 <sup>88</sup>	None
None indicated	Heresi, 2012 <sup>89</sup>	None
None indicated	Higenbottam, 1993 <sup>90</sup>	None
None indicated	Hinderliter, 1997 <sup>91</sup>	None
None indicated	Hiramoto, 2009 <sup>92</sup>	None

Study Designation	Primary Article	Companion Article(s)
None indicated	Ho, 2009 <sup>93</sup>	None
None indicated	Hoeper, 2007 <sup>94</sup>	None
None indicated	Homma, 2001 <sup>95</sup>	None
None indicated	Hsu, 2008 <sup>96</sup>	None
None indicated	Hua, 2009 <sup>97</sup>	None
None indicated	Jacobs, 2009 <sup>98</sup>	None
None indicated	Jansa, 2012 <sup>99</sup>	None
None indicated	Kaya, 2012 <sup>100</sup>	None
None indicated	Kemp, 2012 <sup>101</sup>	None
None indicated	Keogh, 2011 <sup>102</sup>	None
None indicated	Knirsch, 2011 <sup>103</sup>	None
None indicated	Kopec, 2012 <sup>104</sup>	None
None indicated	Kovacs, 2010 <sup>105</sup>	None
None indicated	Lammers, 2009 <sup>106</sup>	None
None indicated	Langleben, 1999 <sup>107</sup>	None
None indicated	Leuchte, 2005 <sup>108</sup>	None
None indicated	Lindqvist, 2011 <sup>109</sup>	None
None indicated	Lorenzen, 2011 <sup>110</sup>	None
None indicated	Low, 2011 <sup>111</sup>	None
None indicated	Machado, 2004 <sup>112</sup>	None
None indicated	Mahapatra, 2006 <sup>113</sup>	None
None indicated	Mathai, 2011 <sup>114</sup>	None
None indicated	Mauritz, 2011 <sup>115</sup>	None
None indicated	McLaughlin, 2006 <sup>116</sup>	None
None indicated	McLean, 2007 <sup>117</sup>	None
None indicated	Michelakis, 2002 <sup>118</sup>	None
None indicated	Minniti, 2009 <sup>119</sup>	None
None indicated	Montani, 2007 <sup>120</sup>	None
None indicated	Morishita, 2009 <sup>121</sup>	None
None indicated	Mourani, 2008 <sup>122</sup>	None
None indicated	Mukherjee, 2004 <sup>123</sup>	None
None indicated	Mukherjee, 2003 <sup>124</sup>	None
None indicated	Mukhopadhyay, 2011 <sup>125</sup>	None
None indicated	Murata, 1997 <sup>126</sup>	None
None indicated	Nagaya, 2000 <sup>127</sup>	None
None indicated	Nakayama, 2007 <sup>128</sup>	None
None indicated	Nakayama, 1998 <sup>129</sup>	None
None indicated	Nath, 2005 <sup>130</sup>	None
None indicated	Nickel, 2012 <sup>131</sup>	None
None indicated	Nickel, 2008 <sup>132</sup>	None
None indicated	Njama, 2007 <sup>133</sup>	None
None indicated	Nogami, 2009 <sup>134</sup>	None
None indicated	Ogawa, 2012 <sup>135</sup>	None
None indicated	Olschewski, 2002 <sup>136</sup>	None
None indicated	Park, 2004 <sup>137</sup>	None
None indicated	Phung, 2009 <sup>138</sup>	None
None indicated	Pilatis, 2000 <sup>139</sup>	None
None indicated	Pyxaras, 2011 <sup>140</sup>	None
None indicated	Rajagopalan, 2009 <sup>141</sup>	Rajagopalan 2007 <sup>142</sup>
None indicated	Rajaram, 2012 <sup>143</sup>	None
None indicated	Raymond, 2002 <sup>144</sup>	None
None indicated	Reichenberger, 2011 <sup>145</sup>	None
None indicated	Rhodes, 2011 <sup>146</sup>	None
None indicated	Rich, 2012 <sup>147</sup>	None
None indicated	Rich, 2011 <sup>148</sup>	None
None indicated	Roeleveld, 2005 <sup>149</sup>	None
None indicated	Roule, 2010 <sup>150</sup>	None

Study Designation	Primary Article	Companion Article(s)
None indicated	Ruan, 2007 <sup>151</sup>	None
None indicated	Rubin, 1990 <sup>152</sup>	Barst, 1994 <sup>153</sup>
None indicated	Ruiz-Irastorza, 2012 <sup>154</sup>	None
None indicated	Sadushi-Kolici, 2012 <sup>155</sup>	None
None indicated	Sanli, 2012 <sup>156</sup>	None
None indicated	Sastry, 2007 <sup>157</sup>	None
None indicated	Schumann, 2010 <sup>158</sup>	None
None indicated	Sebbag, 2001 <sup>159</sup>	None
None indicated	Selby, 2012 <sup>160</sup>	None
None indicated	Selimovic, 2007 <sup>161</sup>	None
None indicated	Shimony, 2012 <sup>162</sup>	None
None indicated	Simeoni, 2008 <sup>163</sup>	None
None indicated	Soon, 2011 <sup>164</sup>	None
None indicated	Souza, 2007 <sup>165</sup>	None
None indicated	Steen, 2008 <sup>166</sup>	None
None indicated	Taguchi, 2012 <sup>167</sup>	None
None indicated	Takatsuki, 2012 <sup>168</sup>	None
None indicated	Takatsuki, 2012 <sup>169</sup>	None
None indicated	Takatsuki, 2012 <sup>170</sup>	None
None indicated	Takatsuki, 2012 <sup>171</sup>	None
None indicated	Takeda, 2010 <sup>172</sup>	None
None indicated	Tei, 1996 <sup>173</sup>	None
None indicated	Thakkar, 2012 <sup>174</sup>	None
None indicated	Tian, 2011 <sup>175</sup>	None
None indicated	Torbicki, 2003 <sup>176</sup>	None
None indicated	Torregrosa, 2001 <sup>177</sup>	None
None indicated	Toyono, 2008 <sup>178</sup>	None
None indicated	Tutar, 1999 <sup>179</sup>	None
None indicated	Utsunomiya, 2009 <sup>180</sup>	None
None indicated	Utsunomiya, 2011 <sup>181</sup>	None
None indicated	van Albada, 2008 <sup>182</sup>	None
None indicated	Vizza, 2012 <sup>183</sup>	None
None indicated	Vizza, 2008 <sup>184</sup>	None
None indicated	Vlahos, 2008 <sup>185</sup>	None
None indicate	Voelkel, 2000 <sup>186</sup>	None
None indicated	Vonk, 2007 <sup>187</sup>	None
None indicated	Willens, 2008 <sup>188</sup>	None
None indicated	Williams, 2006 <sup>189</sup>	None
None indicated	Yamada, 2012 <sup>190</sup>	None
None indicated	Yanagisawa, 2012 <sup>191</sup>	None
None indicated	Yang, 2012 <sup>192</sup>	None
None indicated	Yoshida, 2012 <sup>193</sup>	None
None indicated	Zafir, 2007 <sup>194</sup>	None
None indicated	Zeng, 2011 <sup>195</sup>	None
None indicated	Zeng, 2011 <sup>196</sup>	None
None indicated	Zhao, 2012 <sup>197</sup>	None

## References for Study Groupings

1. Olschewski H, Hoeper MM, Behr J, et al. Long-term therapy with inhaled iloprost in patients with pulmonary hypertension. *Respir Med.* 2010;104(5):731-40. PMID: 20153158.
2. Galie N, Olschewski H, Oudiz RJ, et al. Ambrisentan for the treatment of pulmonary arterial hypertension: results of the ambrisentan in pulmonary arterial hypertension, randomized, double-blind, placebo-controlled, multicenter, efficacy (ARIES) study 1 and 2. *Circulation.* 2008;117(23):3010-9. PMID: 18506008.
3. Oudiz RJ, Galie N, Olschewski H, et al. Long-term ambrisentan therapy for the treatment of pulmonary arterial hypertension. *J Am Coll Cardiol.* 2009;54(21):1971-81. PMID: 19909879.
4. Shapiro S, Pollock DM, Gillies H, et al. Frequency of Edema in Patients With Pulmonary Arterial Hypertension Receiving Ambrisentan. *Am J Cardiol.* 2012. PMID: 22858181.
5. Badesch DB, Feldman J, Keogh A, et al. ARIES-3: ambrisentan therapy in a diverse population of patients with pulmonary hypertension. *Cardiovasc Ther.* 2012;30(2):93-9. PMID: 21884013.
6. Badesch DB, Feldman J, Keogh A, et al. ARIES-3: Ambrisentan Therapy in a Diverse Population of Patients with Pulmonary Hypertension. *Cardiovasc Ther.* 2011. PMID: 21884013.
7. Barst RJ, Mubarak KK, Machado RF, et al. Exercise capacity and haemodynamics in patients with sickle cell disease with pulmonary hypertension treated with bosentan: results of the ASSET studies. *Br J Haematol.* 2010;149(3):426-35. PMID: 20175775.
8. Rubin LJ, Badesch DB, Barst RJ, et al. Bosentan therapy for pulmonary arterial hypertension. *N Engl J Med.* 2002;346(12):896-903. PMID: 11907289.
9. Denton CP, Humbert M, Rubin L, et al. Bosentan treatment for pulmonary arterial hypertension related to connective tissue disease: a subgroup analysis of the pivotal clinical trials and their open-label extensions. *Ann Rheum Dis.* 2006;65(10):1336-40. PMID: 16793845.
10. Galie N, Hinderliter AL, Torbicki A, et al. Effects of the oral endothelin-receptor antagonist bosentan on echocardiographic and doppler measures in patients with pulmonary arterial hypertension. *J Am Coll Cardiol.* 2003;41(8):1380-6. PMID: 12706935.
11. Humbert M, Barst RJ, Robbins IM, et al. Combination of bosentan with epoprostenol in pulmonary arterial hypertension: BREATHE-2. *Eur Respir J.* 2004;24(3):353-9. PMID: 15358690.
12. Galie N, Beghetti M, Gatzoulis MA, et al. Bosentan therapy in patients with Eisenmenger syndrome: A multicenter, double-blind, randomized, placebo-controlled study. *Circulation.* 2006;114(1):48-54. PMID: 16801459.
13. Hoeper MM, Leuchte H, Halank M, et al. Combining inhaled iloprost with bosentan in patients with idiopathic pulmonary arterial hypertension. *Eur Respir J.* 2006;28(4):691-4. PMID: 17012628.
14. Galie N, Rubin L, Hoeper M, et al. Treatment of patients with mildly symptomatic pulmonary arterial hypertension with bosentan (EARLY study): a double-blind, randomised controlled trial. *Lancet.* 2008;371(9630):2093-100. PMID: 18572079.
15. Jing ZC, Yu ZX, Shen JY, et al. Vardenafil in pulmonary arterial hypertension: a randomized, double-blind, placebo-controlled study. *Am J Respir Crit Care Med.* 2011;183(12):1723-9. PMID: 21471085.

16. Machado RF, Anthi A, Steinberg MH, et al. N-terminal pro-brain natriuretic peptide levels and risk of death in sickle cell disease. *JAMA*. 2006;296(3):310-8. PMID: 16849664.
17. Simonneau G, Rubin LJ, Galie N, et al. Addition of sildenafil to long-term intravenous epoprostenol therapy in patients with pulmonary arterial hypertension: a randomized trial. *Ann Intern Med*. 2008;149(8):521-30. PMID: 18936500.
18. Hampole CV, Mehrotra AK, Thenappan T, et al. Usefulness of red cell distribution width as a prognostic marker in pulmonary hypertension. *Am J Cardiol*. 2009;104(6):868-72. PMID: 19733726.
19. Galie N, Brundage BH, Ghofrani HA, et al. Tadalafil therapy for pulmonary arterial hypertension. *Circulation*. 2009;119(22):2894-903. PMID: 19470885.
20. Barst RJ, Oudiz RJ, Beardsworth A, et al. Tadalafil monotherapy and as add-on to background bosentan in patients with pulmonary arterial hypertension. *J Heart Lung Transplant*. 2011;30(6):632-43. PMID: 21256048.
21. Oudiz RJ, Brundage BH, Galie N, et al. Tadalafil for the Treatment of Pulmonary Arterial Hypertension. A Double-Blind 52-Week Uncontrolled Extension Study. *J Am Coll Cardiol*. 2012. PMID: 22818063.
22. Barst RJ, Rubin LJ, Long WA, et al. A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension. The Primary Pulmonary Hypertension Study Group. *N Engl J Med*. 1996;334(5):296-302. PMID: 8532025.
23. Bernus A, Wagner BD, Accurso F, et al. Brain natriuretic peptide levels in managing pediatric patients with pulmonary arterial hypertension. *Chest*. 2009;135(3):745-51. PMID: 18849405.
24. Benza RL, Miller DP, Gomberg-Maitland M, et al. Predicting survival in pulmonary arterial hypertension: insights from the Registry to Evaluate Early and Long-Term Pulmonary Arterial Hypertension Disease Management (REVEAL). *Circulation*. 2010;122(2):164-72. PMID: 20585012.
25. Farber HW, Foreman AJ, Miller DP, et al. REVEAL Registry: correlation of right heart catheterization and echocardiography in patients with pulmonary arterial hypertension. *Congest Heart Fail*. 2011;17(2):56-64. PMID: 21449993.
26. Wilkins MR, Paul GA, Strange JW, et al. Sildenafil versus Endothelin Receptor Antagonist for Pulmonary Hypertension (SERAPH) study. *Am J Respir Crit Care Med*. 2005;171(11):1292-7. PMID: 15750042.
27. Barst RJ, Ivy DD, Gaitan G, et al. A Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study of Oral Sildenafil Citrate in Treatment-Naive Children with Pulmonary Arterial Hypertension. *Circulation*. 2011. PMID: 22128226.
28. Galie N, Ghofrani HA, Torbicki A, et al. Sildenafil citrate therapy for pulmonary arterial hypertension. *N Engl J Med*. 2005;353(20):2148-57. PMID: 16291984.
29. Badesch DB, Hill NS, Burgess G, et al. Sildenafil for pulmonary arterial hypertension associated with connective tissue disease. *J Rheumatol*. 2007;34(12):2417-22. PMID: 17985403.
30. Rubin LJ, Badesch DB, Fleming TR, et al. Long-term treatment with sildenafil citrate in pulmonary arterial hypertension: the SUPER-2 study. *Chest*. 2011;140(5):1274-83. PMID: 21546436.
31. McLaughlin VV, Gaine SP, Barst RJ, et al. Efficacy and safety of treprostinil: an epoprostenol analog for primary pulmonary hypertension. *J Cardiovasc Pharmacol*. 2003;41(2):293-9. PMID: 12548091.
32. Simonneau G, Barst RJ, Galie N, et al. Continuous subcutaneous infusion of treprostinil, a prostacyclin analogue, in patients with pulmonary arterial hypertension: a double-blind, randomized, placebo-controlled trial. *Am J Respir Crit Care Med*. 2002;165(6):800-4. PMID: 11897647.
33. McLaughlin VV, Benza RL, Rubin LJ, et al. Addition of inhaled treprostinil to oral therapy for pulmonary arterial hypertension: a randomized controlled clinical trial. *J Am Coll Cardiol*. 2010;55(18):1915-22. PMID: 20430262.



34. Frantz RP, McDevitt S, Walker S. Baseline NT-proBNP correlates with change in 6-minute walk distance in patients with pulmonary arterial hypertension in the pivotal inhaled treprostinil study TRIUMPH-1. *J Heart Lung Transplant*. 2012;31(8):811-816. PMID: 22759797.
35. Hiremath J, Thanikachalam S, Parikh K, et al. Exercise improvement and plasma biomarker changes with intravenous treprostinil therapy for pulmonary arterial hypertension: a placebo-controlled trial. *J Heart Lung Transplant*. 2010;29(2):137-49. PMID: 20022264.
36. Ajami GH, Cheriki S, Amoozgar H, et al. Accuracy of doppler-derived estimation of pulmonary vascular resistance in congenital heart disease: An index of operability. *Pediatr Cardiol*. 2011;32(8):1168-1174. PMID: 21779967.
37. Allanore Y, Borderie D, Avouac J, et al. High N-terminal pro-brain natriuretic peptide levels and low diffusing capacity for carbon monoxide as independent predictors of the occurrence of precapillary pulmonary arterial hypertension in patients with systemic sclerosis. *Arthritis Rheum*. 2008;58(1):284-91. PMID: 18163505.
38. Andreassen AK, Wergeland R, Simonsen S, et al. N-terminal pro-B-type natriuretic peptide as an indicator of disease severity in a heterogeneous group of patients with chronic precapillary pulmonary hypertension. *Am J Cardiol*. 2006;98(4):525-9. PMID: 16893710.
39. Arcasoy SM, Christie JD, Ferrari VA, et al. Echocardiographic assessment of pulmonary hypertension in patients with advanced lung disease. *Am J Respir Crit Care Med*. 2003;167(5):735-40. PMID: 12480614.
40. Badesch DB, Tapson VF, McGoon MD, et al. Continuous intravenous epoprostenol for pulmonary hypertension due to the scleroderma spectrum of disease. A randomized, controlled trial. *Ann Intern Med*. 2000;132(6):425-34. PMID: 10733441.
41. Bendayan D, Shitrit D, Ygla M, et al. Hyperuricemia as a prognostic factor in pulmonary arterial hypertension. *Respir Med*. 2003;97(2):130-3. PMID: 12587962.
42. Bharani A, Patel A, Saraf J, et al. Efficacy and safety of PDE-5 inhibitor tadalafil in pulmonary arterial hypertension. *Indian Heart J*. 2007;59(4):323-8. PMID: 19126937.
43. Bogdan M, Humbert M, Francoual J, et al. Urinary cGMP concentrations in severe primary pulmonary hypertension. *Thorax*. 1998;53(12):1059-62. PMID: 10195079.
44. Bonderman D, Wexberg P, Martischniig AM, et al. A noninvasive algorithm to exclude pre-capillary pulmonary hypertension. *Eur Respir J*. 2011;37(5):1096-103. PMID: 20693249.
45. Borges AC, Knebel F, Eddicks S, et al. Right ventricular function assessed by two-dimensional strain and tissue Doppler echocardiography in patients with pulmonary arterial hypertension and effect of vasodilator therapy. *Am J Cardiol*. 2006;98(4):530-4. PMID: 16893711.
46. Brierre G, Blot-Souletie N, Degano B, et al. New echocardiographic prognostic factors for mortality in pulmonary arterial hypertension. *Eur J Echocardiogr*. 2010;11(6):516-22. PMID: 20185528.
47. Bustamante-Labarta M, Perrone S, De La Fuente RL, et al. Right atrial size and tricuspid regurgitation severity predict mortality or transplantation in primary pulmonary hypertension. *J Am Soc Echocardiogr*. 2002;15(10 Pt 2):1160-4. PMID: 12411899.
48. Campana C, Pasotti M, Monti L, et al. The evaluation of right ventricular performance in different clinical models of heart failure. *Eur Heart J Suppl*. 2004;6(6):F61-F67.
49. Cavagna L, Caporali R, Klersy C, et al. Comparison of brain natriuretic peptide (BNP) and NT-proBNP in screening for pulmonary arterial hypertension in patients with systemic sclerosis. *J Rheumatol*. 2010;37(10):2064-70. PMID: 20634241.
50. Cella G, Vianello F, Cozzi F, et al. Effect of bosentan on plasma markers of endothelial cell activity in patients with secondary pulmonary hypertension related to connective tissue diseases. *J Rheumatol*. 2009;36(4):760-7. PMID: 19208592.

51. Cevik A, Kula S, Olgunturk R, et al. Quantitative Evaluation of Right Ventricle Function by Transthoracic Echocardiography in Childhood Congenital Heart Disease Patients with Pulmonary Hypertension. *Echocardiography*. 2012. PMID: 22494051.
52. Channick RN, Simonneau G, Sitbon O, et al. Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: a randomised placebo-controlled study. *Lancet*. 2001;358(9288):1119-23. PMID: 11597664.
53. Badesch DB, Bodin F, Channick RN, et al. Complete results of the first randomized, placebo-controlled study of bosentan, a dual endothelin receptor antagonist, in pulmonary arterial hypertension. *Curr Ther Res Clin Exp*. 2002;63(4):227-246.
54. Chin KM, Channick RN, Kim NH, et al. Central venous blood oxygen saturation monitoring in patients with chronic pulmonary arterial hypertension treated with continuous IV epoprostenol: correlation with measurements of hemodynamics and plasma brain natriuretic peptide levels. *Chest*. 2007;132(3):786-92. PMID: 17646224.
55. Ciurzynski M, Bienias P, Irzyk K, et al. Usefulness of echocardiography in the identification of an excessive increase in pulmonary arterial pressure in patients with systemic sclerosis. *Kardiologia Pol*. 2011;69(1):9-15. PMID: 21267956.
56. Colle IO, Moreau R, Godinho E, et al. Diagnosis of portopulmonary hypertension in candidates for liver transplantation: a prospective study. *Hepatology*. 2003;37(2):401-9. PMID: 12540791.
57. Condliffe R, Radon M, Hurdman J, et al. CT pulmonary angiography combined with echocardiography in suspected systemic sclerosis-associated pulmonary arterial hypertension. *Rheumatology (Oxford)*. 2011;50(8):1480-6. PMID: 21447566.
58. Dahiya A, Vollbon W, Jellis C, et al. Echocardiographic assessment of raised pulmonary vascular resistance: application to diagnosis and follow-up of pulmonary hypertension. *Heart*. 2010;96(24):2005-9. PMID: 21088122.
59. D'Alto M, Romeo E, Argiento P, et al. Bosentan-sildenafil association in patients with congenital heart disease-related pulmonary arterial hypertension and Eisenmenger physiology. *Int J Cardiol*. 2010. PMID: 21081251.
60. Denton CP, Cailes JB, Phillips GD, et al. Comparison of Doppler echocardiography and right heart catheterization to assess pulmonary hypertension in systemic sclerosis. *Br J Rheumatol*. 1997;36(2):239-43. PMID: 9133938.
61. Dimitroulas T, Giannakoulas G, Karvounis H, et al. N-terminal probrain natriuretic peptide as a biochemical marker in the evaluation of bosentan treatment in systemic-sclerosis-related pulmonary arterial hypertension. *Clin Rheumatol*. 2008;27(5):655-8. PMID: 18204995.
62. Dyer KL, Pauliks LB, Das B, et al. Use of myocardial performance index in pediatric patients with idiopathic pulmonary arterial hypertension. *J Am Soc Echocardiogr*. 2006;19(1):21-7. PMID: 16423665.
63. Elstein D, Nir A, Klutstein M, et al. N-brain natriuretic peptide: correlation with tricuspid insufficiency in Gaucher disease. *Pulm Pharmacol Ther*. 2004;17(5):319-23. PMID: 15477128.
64. Fahmy Elnoamany M, Abdelraouf Dawood A. Right ventricular myocardial isovolumic relaxation time as novel method for evaluation of pulmonary hypertension: correlation with endothelin-1 levels. *J Am Soc Echocardiogr*. 2007;20(5):462-9. PMID: 17484984.
65. Feliciano J, Cacela D, Agapito A, et al. Selective pulmonary vasodilators for severe pulmonary hypertension: comparison between endpoints. *Rev Port Cardiol*. 2005;24(3):399-404. PMID: 15929623.
66. Fijalkowska A, Kurzyna M, Torbicki A, et al. Serum N-terminal brain natriuretic peptide as a prognostic parameter in patients with pulmonary hypertension. *Chest*. 2006;129(5):1313-21. PMID: 16685024.
67. Filusch A, Giannitsis E, Katus HA, et al. High-sensitive troponin T: a novel biomarker for prognosis and disease severity in patients with pulmonary arterial hypertension. *Clin Sci (Lond)*. 2010;119(5):207-13. PMID: 20412051.

68. Fisher MR, Forfia PR, Chamera E, et al. Accuracy of Doppler echocardiography in the hemodynamic assessment of pulmonary hypertension. *Am J Respir Crit Care Med*. 2009;179(7):615-21. PMID: 19164700.
69. Fitzgerald M, Fagan K, Herbert DE, et al. Misclassification of pulmonary hypertension in adults with sickle hemoglobinopathies using doppler echocardiography. *South Med J*. 2012;105(6):300-305. PMID: 22665152.
70. Fix OK, Bass NM, De Marco T, et al. Long-term follow-up of portopulmonary hypertension: effect of treatment with epoprostenol. *Liver Transpl*. 2007;13(6):875-85. PMID: 17539008.
71. Fonseca GH, Souza R, Salemi VM, et al. Pulmonary hypertension diagnosed by right heart catheterisation in sickle cell disease. *Eur Respir J*. 2012;39(1):112-8. PMID: 21778170.
72. Forfia PR, Fisher MR, Mathai SC, et al. Tricuspid annular displacement predicts survival in pulmonary hypertension. *Am J Respir Crit Care Med*. 2006;174(9):1034-41. PMID: 16888289.
73. Frea S, Capriolo M, Marra WG, et al. Echo Doppler predictors of pulmonary artery hypertension in patients with systemic sclerosis. *Echocardiography*. 2011;28(8):860-9. PMID: 21906161.
74. Friedberg MK, Feinstein JA, Rosenthal DN. A novel echocardiographic Doppler method for estimation of pulmonary arterial pressures. *J Am Soc Echocardiogr*. 2006;19(5):559-62. PMID: 16644441.
75. Fukuda Y, Tanaka H, Sugiyama D, et al. Utility of right ventricular free wall speckle-tracking strain for evaluation of right ventricular performance in patients with pulmonary hypertension. *J Am Soc Echocardiogr*. 2011;24(10):1101-1108. PMID: 21775102.
76. Gan CT, McCann GP, Marcus JT, et al. NT-proBNP reflects right ventricular structure and function in pulmonary hypertension. *Eur Respir J*. 2006;28(6):1190-4. PMID: 16971413.
77. Ghio S, Klersy C, Magrini G, et al. Prognostic relevance of the echocardiographic assessment of right ventricular function in patients with idiopathic pulmonary arterial hypertension. *Int J Cardiol*. 2010;140(3):272-8. PMID: 19070379.
78. Ghio S, Matteo AD, Scelsi L, et al. Plasma brain natriuretic peptide is a marker of right ventricular overload in pulmonary hypertension associated to HIV infection. *Eur Heart J Suppl*. 2004;6(6):F35-F39.
79. Ghofrani HA, Wiedemann R, Rose F, et al. Lung cGMP release subsequent to NO inhalation in pulmonary hypertension: responders versus nonresponders. *Eur Respir J*. 2002;19(4):664-71. PMID: 11998996.
80. Gialafos EJ, Moyssakis I, Psaltopoulou T, et al. Circulating tissue inhibitor of matrix metalloproteinase-4 (TIMP-4) in systemic sclerosis patients with elevated pulmonary arterial pressure. *Mediators Inflamm*. 2008;2008.
81. Goto K, Arai M, Watanabe A, et al. Utility of echocardiography versus BNP level for the prediction of pulmonary arterial pressure in patients with pulmonary arterial hypertension. *Int Heart J*. 2010;51(5):343-7. PMID: 20966607.
82. Grapsa I, Pavlopoulos H, Dawson D, et al. Retrospective study of pulmonary hypertensive patients: is right ventricular myocardial performance index a vital prognostic factor? *Hellenic J Cardiol*. 2007;48(3):152-60. PMID: 17629178.
83. Grubstein A, Benjaminov O, Dayan DB, et al. Computed tomography angiography in pulmonary hypertension. *Isr Med Assoc J*. 2008;10(2):117-20. PMID: 18432023.
84. Hachulla E, Gressin V, Guillemin L, et al. Early detection of pulmonary arterial hypertension in systemic sclerosis: a French nationwide prospective multicenter study. *Arthritis Rheum*. 2005;52(12):3792-800. PMID: 16320330.
85. Haddad F, Zamanian R, Beraud AS, et al. A novel non-invasive method of estimating pulmonary vascular resistance in patients with pulmonary arterial hypertension. *J Am Soc Echocardiogr*. 2009;22(5):523-9. PMID: 19307098.

86. Halank M, Knudsen L, Seyfarth HJ, et al. Ambrisentan improves exercise capacity and symptoms in patients with portopulmonary hypertension. *Z Gastroenterol*. 2011;49(9):1258-62. PMID: 21887662.
87. Hammerstingl C, Schueler R, Bors L, et al. Diagnostic value of echocardiography in the diagnosis of pulmonary hypertension. *PLoS ONE*. 2012;7(6). PMID: 22685577.
88. Heresi GA, Aytekin M, Newman J, et al. CXC-chemokine ligand 10 in idiopathic pulmonary arterial hypertension: marker of improved survival. *Lung*. 2010;188(3):191-7. PMID: 20186422.
89. Heresi GA, Tang WH, Aytekin M, et al. Sensitive cardiac troponin I predicts poor outcomes in pulmonary arterial hypertension. *Eur Respir J*. 2012;39(4):939-44. PMID: 21885398.
90. Higenbottam TW, Spiegelhalter D, Scott JP, et al. Prostacyclin (epoprostenol) and heart-lung transplantation as treatments for severe pulmonary hypertension. *Br Heart J*. 1993;70(4):366-70. PMID: 8217447.
91. Hinderliter AL, Willis PWt, Barst RJ, et al. Effects of long-term infusion of prostacyclin (epoprostenol) on echocardiographic measures of right ventricular structure and function in primary pulmonary hypertension. Primary Pulmonary Hypertension Study Group. *Circulation*. 1997;95(6):1479-86. PMID: 9118516.
92. Hiramoto Y, Shioyama W, Higuchi K, et al. Clinical significance of plasma endothelin-1 level after bosentan administration in pulmonary arterial hypertension. *J Cardiol*. 2009;53(3):374-80. PMID: 19477379.
93. Ho WJ, Hsu TS, Tsay PK, et al. Serial plasma brain natriuretic peptide testing in clinical management of pulmonary arterial hypertension. *Acta Cardiol Sin*. 2009;25(3):147-153.
94. Hoeper MM, Seyfarth HJ, Hoeffken G, et al. Experience with inhaled iloprost and bosentan in portopulmonary hypertension. *Eur Respir J*. 2007;30(6):1096-102. PMID: 17652314.
95. Homma A, Anzueto A, Peters JJ, et al. Pulmonary artery systolic pressures estimated by echocardiogram vs cardiac catheterization in patients awaiting lung transplantation. *J Heart Lung Transplant*. 2001;20(8):833-9. PMID: 11502405.
96. Hsu VM, Moreyra AE, Wilson AC, et al. Assessment of pulmonary arterial hypertension in patients with systemic sclerosis: comparison of noninvasive tests with results of right-heart catheterization. *J Rheumatol*. 2008;35(3):458-65. PMID: 18203320.
97. Hua R, Sun YW, Wu ZY, et al. Role of 2-dimensional Doppler echo-cardiography in screening portopulmonary hypertension in portal hypertension patients. *Hepatobiliary Pancreat Dis Int*. 2009;8(2):157-61. PMID: 19357029.
98. Jacobs W, Boonstra A, Marcus JT, et al. Addition of prostanoids in pulmonary hypertension deteriorating on oral therapy. *J Heart Lung Transplant*. 2009;28(3):280-4. PMID: 19285621.
99. Jansa P, Becvar R, Ambroz D, et al. Pulmonary arterial hypertension associated with systemic sclerosis in the Czech Republic. *Clin Rheumatol*. 2012;31(3):557-61. PMID: 22105781.
100. Kaya MG, Lam YY, Erer B, et al. Long-term effect of bosentan therapy on cardiac function and symptomatic benefits in adult patients with eisenmenger syndrome. *J Card Fail*. 2012;18(5):379-384. PMID: 22555267.
101. Kemp K, Savale L, O'Callaghan DS, et al. Usefulness of first-line combination therapy with epoprostenol and bosentan in pulmonary arterial hypertension: an observational study. *J Heart Lung Transplant*. 2012;31(2):150-8. PMID: 22138355.
102. Keogh A, Strange G, Kotlyar E, et al. Survival after the initiation of combination therapy in patients with pulmonary arterial hypertension: an Australian collaborative report. *Intern Med J*. 2011;41(3):235-44. PMID: 21118410.
103. Knirsch W, Hausermann E, Fasnacht M, et al. Plasma B-type natriuretic peptide levels in children with heart disease. *Acta Paediatr Int J Paediatr*. 2011;100(9):1213-1216.

104. Kopec G, Tyrka A, Miszalski-Jamka T, et al. Changes in Exercise Capacity and Cardiac Performance in a Series of Patients with Eisenmenger's Syndrome Transitioned from Selective to Dual Endothelin Receptor Antagonist. *Heart Lung and Circulation*. 2012. PMID: 22819097.
105. Kovacs G, Maier R, Aberer E, et al. Assessment of pulmonary arterial pressure during exercise in collagen vascular disease: echocardiography vs right-sided heart catheterization. *Chest*. 2010;138(2):270-8. PMID: 20418368.
106. Lammers AE, Hislop AA, Haworth SG. Prognostic value of B-type natriuretic peptide in children with pulmonary hypertension. *Int J Cardiol*. 2009;135(1):21-6. PMID: 18599134.
107. Langleben D, Barst RJ, Badesch D, et al. Continuous infusion of epoprostenol improves the net balance between pulmonary endothelin-1 clearance and release in primary pulmonary hypertension. *Circulation*. 1999;99(25):3266-71. PMID: 10385501.
108. Leuchte HH, Holzapfel M, Baumgartner RA, et al. Characterization of brain natriuretic peptide in long-term follow-up of pulmonary arterial hypertension. *Chest*. 2005;128(4):2368-74. PMID: 16236896.
109. Lindqvist P, Soderberg S, Gonzalez MC, et al. Echocardiography based estimation of pulmonary vascular resistance in patients with pulmonary hypertension: a simultaneous Doppler echocardiography and cardiac catheterization study. *Eur J Echocardiogr*. 2011;12(12):961-6. PMID: 22011836.
110. Lorenzen JM, Nickel N, Kramer R, et al. Osteopontin in patients with idiopathic pulmonary hypertension. *Chest*. 2011;139(5):1010-7. PMID: 20947652.
111. Low AJ, Fowler D, Manghani MK, et al. Screening and Treating Pulmonary Arterial Hypertension in a Tertiary Hospital -based Multidisciplinary Clinic - The First 200 Patients. *Intern Med J*. 2011. PMID: 22032309.
112. Machado RF, Londhe Nerkar MV, Dweik RA, et al. Nitric oxide and pulmonary arterial pressures in pulmonary hypertension. *Free Radic Biol Med*. 2004;37(7):1010-7. PMID: 15336317.
113. Mahapatra S, Nishimura RA, Oh JK, et al. The prognostic value of pulmonary vascular capacitance determined by Doppler echocardiography in patients with pulmonary arterial hypertension. *J Am Soc Echocardiogr*. 2006;19(8):1045-50. PMID: 16880101.
114. Mathai SC, Sibley CT, Forfia PR, et al. Tricuspid annular plane systolic excursion is a robust outcome measure in systemic sclerosis-associated pulmonary arterial hypertension. *J Rheumatol*. 2011;38(11):2410-8. PMID: 21965638.
115. Mauritz GJ, Rizopoulos D, Groepenhoff H, et al. Usefulness of serial N-terminal ProB-type natriuretic peptide measurements for determining prognosis in patients with pulmonary arterial hypertension. *Am J Cardiol*. 2011;108(11):1645-1650. PMID: 21890089.
116. McLaughlin VV, Oudiz RJ, Frost A, et al. Randomized study of adding inhaled iloprost to existing bosentan in pulmonary arterial hypertension. *Am J Respir Crit Care Med*. 2006;174(11):1257-63. PMID: 16946127.
117. McLean AS, Ting I, Huang SJ, et al. The use of the right ventricular diameter and tricuspid annular tissue Doppler velocity parameter to predict the presence of pulmonary hypertension. *Eur J Echocardiogr*. 2007;8(2):128-36. PMID: 16672193.
118. Michelakis E, Tymchak W, Lien D, et al. Oral sildenafil is an effective and specific pulmonary vasodilator in patients with pulmonary arterial hypertension: comparison with inhaled nitric oxide. *Circulation*. 2002;105(20):2398-403. PMID: 12021227.
119. Minniti CP, Machado RF, Coles WA, et al. Endothelin receptor antagonists for pulmonary hypertension in adult patients with sickle cell disease. *Br J Haematol*. 2009;147(5):737-43. PMID: 19775299.

120. Montani D, Souza R, Binkert C, et al. Endothelin-1/endothelin-3 ratio: a potential prognostic factor of pulmonary arterial hypertension. *Chest*. 2007;131(1):101-8. PMID: 17218562.
121. Morishita T, Miyaji K, Akao I, et al. The ratio of the atrial areas reflects the clinical status of patients with pulmonary arterial hypertension. *J Med Ultrason*. 2009;36(4):201-206.
122. Mourani PM, Sontag MK, Younoszai A, et al. Clinical utility of echocardiography for the diagnosis and management of pulmonary vascular disease in young children with chronic lung disease. *Pediatrics*. 2008;121(2):317-25. PMID: 18245423.
123. Mukerjee D, St George D, Knight C, et al. Echocardiography and pulmonary function as screening tests for pulmonary arterial hypertension in systemic sclerosis. *Rheumatology (Oxford)*. 2004;43(4):461-6. PMID: 15024134.
124. Mukerjee D, Yap LB, Holmes AM, et al. Significance of plasma N-terminal pro-brain natriuretic peptide in patients with systemic sclerosis-related pulmonary arterial hypertension. *Respir Med*. 2003;97(11):1230-6. PMID: 14635979.
125. Mukhopadhyay S, Nathani S, Yusuf J, et al. Clinical efficacy of phosphodiesterase-5 inhibitor tadalafil in Eisenmenger Syndrome-A randomized, placebo-controlled, double-blind crossover study. *Congenit Heart Dis*. 2011;6(5):424-431. PMID: 21914136.
126. Murata I, Takenaka K, Yoshinoya S, et al. Clinical evaluation of pulmonary hypertension in systemic sclerosis and related disorders. A Doppler echocardiographic study of 135 Japanese patients. *Chest*. 1997;111(1):36-43. PMID: 8995990.
127. Nagaya N, Nishikimi T, Uematsu M, et al. Plasma brain natriuretic peptide as a prognostic indicator in patients with primary pulmonary hypertension. *Circulation*. 2000;102(8):865-70. PMID: 10952954.
128. Nakayama T, Shimada H, Takatsuki S, et al. Efficacy and limitations of continuous intravenous epoprostenol therapy for idiopathic pulmonary arterial hypertension in Japanese children. *Circ J*. 2007;71(11):1785-90. PMID: 17965503.
129. Nakayama Y, Sugimachi M, Nakanishi N, et al. Noninvasive differential diagnosis between chronic pulmonary thromboembolism and primary pulmonary hypertension by means of Doppler ultrasound measurement. *J Am Coll Cardiol*. 1998;31(6):1367-71. PMID: 9581735.
130. Nath J, Demarco T, Hourigan L, et al. Correlation between right ventricular indices and clinical improvement in epoprostenol treated pulmonary hypertension patients. *Echocardiography*. 2005;22(5):374-9. PMID: 15901287.
131. Nickel N, Golpon H, Greer M, et al. The prognostic impact of follow-up assessments in patients with idiopathic pulmonary arterial hypertension. *Eur Respir J*. 2012;39(3):589-96. PMID: 21885392.
132. Nickel N, Kempf T, Tapken H, et al. Growth differentiation factor-15 in idiopathic pulmonary arterial hypertension. *Am J Respir Crit Care Med*. 2008;178(5):534-41. PMID: 18565955.
133. Njaman W, Iesaki T, Iwama Y, et al. Serum uric Acid as a prognostic predictor in pulmonary arterial hypertension with connective tissue disease. *Int Heart J*. 2007;48(4):523-32. PMID: 17827824.
134. Nogami M, Ohno Y, Koyama H, et al. Utility of phase contrast MR imaging for assessment of pulmonary flow and pressure estimation in patients with pulmonary hypertension: comparison with right heart catheterization and echocardiography. *J Magn Reson Imaging*. 2009;30(5):973-80. PMID: 19856412.
135. Ogawa A, Miyaji K, Yamadori I, et al. Safety and efficacy of epoprostenol therapy in pulmonary veno-occlusive disease and pulmonary capillary hemangiomatosis. *Circulation Journal*. 2012;76(7):1729-1736. PMID: 22481098.
136. Olschewski H, Simonneau G, Galie N, et al. Inhaled iloprost for severe pulmonary hypertension. *N Engl J Med*. 2002;347(5):322-9. PMID: 12151469.

137. Park MH, Scott RL, Uber PA, et al. Usefulness of B-type natriuretic peptide as a predictor of treatment outcome in pulmonary arterial hypertension. *Congest Heart Fail.* 2004;10(5):221-5. PMID: 15470298.
138. Phung S, Strange G, Chung LP, et al. Prevalence of pulmonary arterial hypertension in an Australian scleroderma population: screening allows for earlier diagnosis. *Intern Med J.* 2009;39(10):682-91. PMID: 19220532.
139. Pilatis ND, Jacobs LE, Rerkpattanapipat P, et al. Clinical predictors of pulmonary hypertension in patients undergoing liver transplant evaluation. *Liver Transpl.* 2000;6(1):85-91. PMID: 10648583.
140. Pyxaras SA, Pinamonti B, Barbati G, et al. Echocardiographic evaluation of systolic and mean pulmonary artery pressure in the follow-up of patients with pulmonary hypertension. *Eur J Echocardiogr.* 2011;12(9):696-701. PMID: 21821609.
141. Rajagopalan N, Simon MA, Suffoletto MS, et al. Noninvasive estimation of pulmonary vascular resistance in pulmonary hypertension. *Echocardiography.* 2009;26(5):489-94. PMID: 19054039.
142. Rajagopalan N, Saxena N, Simon MA, et al. Correlation of tricuspid annular velocities with invasive hemodynamics in pulmonary hypertension. *Congest Heart Fail.* 2007;13(4):200-4. PMID: 17673871.
143. Rajaram S, Swift AJ, Capener D, et al. Comparison of the diagnostic utility of cardiac magnetic resonance imaging, computed tomography, and echocardiography in assessment of suspected pulmonary arterial hypertension in patients with connective tissue disease. *J Rheumatol.* 2012;39(6):1265-1274. PMID: 22589263.
144. Raymond RJ, Hinderliter AL, Willis PW, et al. Echocardiographic predictors of adverse outcomes in primary pulmonary hypertension. *J Am Coll Cardiol.* 2002;39(7):1214-9. PMID: 11923049.
145. Reichenberger F, Mainwood A, Morrell NW, et al. Intravenous epoprostenol versus high dose inhaled iloprost for long-term treatment of pulmonary hypertension. *Pulm Pharmacol Ther.* 2011;24(1):169-73. PMID: 20601049.
146. Rhodes CJ, Wharton J, Howard LS, et al. Red cell distribution width outperforms other potential circulating biomarkers in predicting survival in idiopathic pulmonary arterial hypertension. *Heart.* 2011;97(13):1054-60. PMID: 21558476.
147. Rich JD, Glassner C, Wade M, et al. The effect of diluent pH on bloodstream infection rates in patients receiving IV treprostinil for pulmonary arterial hypertension. *Chest.* 2012;141(1):36-42. PMID: 21659437.
148. Rich JD, Shah SJ, Swamy RS, et al. Inaccuracy of Doppler echocardiographic estimates of pulmonary artery pressures in patients with pulmonary hypertension: implications for clinical practice. *Chest.* 2011;139(5):988-93. PMID: 20864617.
149. Roeleveld RJ, Marcus JT, Boonstra A, et al. A comparison of noninvasive MRI-based methods of estimating pulmonary artery pressure in pulmonary hypertension. *J Magn Reson Imaging.* 2005;22(1):67-72. PMID: 15971176.
150. Roule V, Labombarda F, Pellissier A, et al. Echocardiographic assessment of pulmonary vascular resistance in pulmonary arterial hypertension. *Cardiovasc Ultrasound.* 2010;8:21. PMID: 20529278.
151. Ruan Q, Nagueh SF. Clinical application of tissue Doppler imaging in patients with idiopathic pulmonary hypertension. *Chest.* 2007;131(2):395-401. PMID: 17296639.
152. Rubin LJ, Mendoza J, Hood M, et al. Treatment of primary pulmonary hypertension with continuous intravenous prostacyclin (epoprostenol). Results of a randomized trial. *Ann Intern Med.* 1990;112(7):485-91. PMID: 2107780.
153. Barst RJ, Rubin LJ, McGoon MD, et al. Survival in primary pulmonary hypertension with long-term continuous intravenous prostacyclin. *Ann Intern Med.* 1994;121(6):409-15. PMID: 8053614.

154. Ruiz-Irastorza G, Garmendia M, Villar I, et al. Pulmonary hypertension in systemic lupus erythematosus: prevalence, predictors and diagnostic strategy. *Autoimmunity Reviews*. 2012. PMID: 22841984.
155. Sadushi-Kolici R, Skoro-Sajer N, Zimmer D, et al. Long-term treatment, tolerability, and survival with sub-cutaneous treprostinil for severe pulmonary hypertension. *J Heart Lung Transplant*. 2012;31(7):735-743. PMID: 22480725.
156. Sanli C, Oguz D, Olgunturk R, et al. Elevated Homocysteine and Asymmetric Dimethyl Arginine Levels in Pulmonary Hypertension Associated With Congenital Heart Disease. *Pediatr Cardiol*. 2012;1-9. PMID: 22526220.
157. Sastry BK, Raju BS, Narasimhan C, et al. Sildenafil improves survival in idiopathic pulmonary arterial hypertension. *Indian Heart J*. 2007;59(4):336-41. PMID: 19126939.
158. Schumann C, Lepper PM, Frank H, et al. Circulating biomarkers of tissue remodelling in pulmonary hypertension. *Biomarkers*. 2010;15(6):523-32. PMID: 20528622.
159. Sebbag I, Rudski LG, Therrien J, et al. Effect of chronic infusion of epoprostenol on echocardiographic right ventricular myocardial performance index and its relation to clinical outcome in patients with primary pulmonary hypertension. *Am J Cardiol*. 2001;88(9):1060-3. PMID: 11704014.
160. Selby VN, Scherzer R, Barnett CF, et al. Doppler echocardiography does not accurately estimate pulmonary artery systolic pressure in HIV-infected patients. *AIDS*. 2012. PMID: 22781217.
161. Selimovic N, Rundqvist B, Bergh CH, et al. Assessment of pulmonary vascular resistance by Doppler echocardiography in patients with pulmonary arterial hypertension. *J Heart Lung Transplant*. 2007;26(9):927-34. PMID: 17845932.
162. Shimony A, Fox BD, Langleben D, et al. Incidence and Significance of Pericardial Effusion in Patients With Pulmonary Arterial Hypertension. *Can J Cardiol*. 2012. PMID: 22717247.
163. Simeoni S, Lippi G, Puccetti A, et al. N-terminal pro-BNP in sclerodermic patients on bosentan therapy for PAH. *Rheumatol Int*. 2008;28(7):657-60. PMID: 18092166.
164. Soon E, Doughty NJ, Treacy CM, et al. Log-transformation improves the prognostic value of serial NT-proBNP levels in apparently stable pulmonary arterial hypertension. *Pulm Circ*. 2011;1(2):244-9. PMID: 22034610.
165. Souza R, Jardim C, Julio Cesar Fernandes C, et al. NT-proBNP as a tool to stratify disease severity in pulmonary arterial hypertension. *Respir Med*. 2007;101(1):69-75. PMID: 16781131.
166. Steen V, Chou M, Shanmugam V, et al. Exercise-induced pulmonary arterial hypertension in patients with systemic sclerosis. *Chest*. 2008;134(1):146-51. PMID: 18403670.
167. Taguchi H, Kataoka M, Yanagisawa R, et al. Platelet level as a new prognostic factor for idiopathic pulmonary arterial hypertension in the era of combination therapy. *Circulation Journal*. 2012;76(6):1494-1500. PMID: 22447010.
168. Takatsuki S, Calderbank M, Ivy DD. Initial experience with tadalafil in pediatric pulmonary arterial hypertension. *Pediatr Cardiol*. 2012;33(5):683-688. PMID: 22402804.
169. Takatsuki S, Nakayama T, Jone PN, et al. Tissue Doppler Imaging Predicts Adverse Outcome in Children with Idiopathic Pulmonary Arterial Hypertension. *J Pediatr*. 2012. PMID: 33748515.
170. Takatsuki S, Rosenzweig EB, Zuckerman W, et al. Clinical safety, pharmacokinetics, and efficacy of ambrisentan therapy in children with pulmonary arterial hypertension. *Pediatr Pulmonol*. 2012. PMID: 22511577.
171. Takatsuki S, Wagner BD, Ivy DD. B-type Natriuretic Peptide and Amino-terminal Pro-B-type Natriuretic Peptide in Pediatric Patients with Pulmonary Arterial Hypertension. *Congenital Heart Disease*. 2012;7(3):259-267. PMID: 22325151.



172. Takeda Y, Tomimoto S, Tani T, et al. Bilirubin as a prognostic marker in patients with pulmonary arterial hypertension. *BMC Pulm Med*. 2010;10:22. PMID: 20412580.
173. Tei C, Dujardin KS, Hodge DO, et al. Doppler echocardiographic index for assessment of global right ventricular function. *J Am Soc Echocardiogr*. 1996;9(6):838-47. PMID: 8943444.
174. Thakkar V, Stevens WM, Prior D, et al. N-terminal pro-brain natriuretic peptide in a novel screening algorithm for pulmonary arterial hypertension in systemic sclerosis: A case-control study. *Arthritis Research and Therapy*. 2012;14(3). PMID: 22691291.
175. Tian Z, Liu YT, Fang Q, et al. Hemodynamic parameters obtained by transthoracic echocardiography and right heart catheterization: a comparative study in patients with pulmonary hypertension. *Chin Med J (Engl)*. 2011;124(12):1796-801. PMID: 21740835.
176. Torbicki A, Kurzyna M, Kuca P, et al. Detectable serum cardiac troponin T as a marker of poor prognosis among patients with chronic precapillary pulmonary hypertension. *Circulation*. 2003;108(7):844-8. PMID: 12900346.
177. Torregrosa M, Genesca J, Gonzalez A, et al. Role of Doppler echocardiography in the assessment of portopulmonary hypertension in liver transplantation candidates. *Transplantation*. 2001;71(4):572-4. PMID: 11258439.
178. Toyono M, Harada K, Tamura M, et al. Paradoxical relationship between B-type natriuretic peptide and pulmonary vascular resistance in patients with ventricular septal defect and concomitant severe pulmonary hypertension. *Pediatr Cardiol*. 2008;29(1):65-9. PMID: 17786380.
179. Tutar HE, Imamoglu A, Atalay S, et al. Plasma endothelin-1 levels in patients with left-to-right shunt with or without pulmonary hypertension. *Int J Cardiol*. 1999;70(1):57-62. PMID: 10402046.
180. Utsunomiya H, Nakatani S, Nishihira M, et al. Value of estimated right ventricular filling pressure in predicting cardiac events in chronic pulmonary arterial hypertension. *J Am Soc Echocardiogr*. 2009;22(12):1368-74. PMID: 19944957.
181. Utsunomiya H, Nakatani S, Okada T, et al. A simple method to predict impaired right ventricular performance and disease severity in chronic pulmonary hypertension using strain rate imaging. *Int J Cardiol*. 2011;147(1):88-94. PMID: 19747741.
182. Van Albada ME, Loot FG, Fokkema R, et al. Biological serum markers in the management of pediatric pulmonary arterial hypertension. *Pediatr Res*. 2008;63(3):321-7. PMID: 18287971.
183. Vizza CD, Letizia C, Badagliacca R, et al. Relationship between baseline ET-1 plasma levels and outcome in patients with idiopathic pulmonary hypertension treated with bosentan. *Int J Cardiol*. 2012. PMID: 22265324.
184. Vizza CD, Letizia C, Petramala L, et al. Venous endothelin-1 (ET-1) and brain natriuretic peptide (BNP) plasma levels during 6-month bosentan treatment for pulmonary arterial hypertension. *Regul Pept*. 2008;151(1-3):48-53. PMID: 18796317.
185. Vlahos AP, Feinstein JA, Schiller NB, et al. Extension of Doppler-derived echocardiographic measures of pulmonary vascular resistance to patients with moderate or severe pulmonary vascular disease. *J Am Soc Echocardiogr*. 2008;21(6):711-4. PMID: 18187297.
186. Voelkel MA, Wynne KM, Badesch DB, et al. Hyperuricemia in severe pulmonary hypertension. *Chest*. 2000;117(1):19-24. PMID: 10631193.
187. Vonk MC, Sander MH, van den Hoogen FH, et al. Right ventricle Tei-index: a tool to increase the accuracy of non-invasive detection of pulmonary arterial hypertension in connective tissue diseases. *Eur J Echocardiogr*. 2007;8(5):317-21. PMID: 16846757.
188. Willens HJ, Chirinos JA, Gomez-Marin O, et al. Noninvasive differentiation of pulmonary arterial and venous hypertension using conventional and Doppler tissue imaging echocardiography. *J Am Soc Echocardiogr*. 2008;21(6):715-9. PMID: 18325734.

189. Williams MH, Handler CE, Akram R, et al. Role of N-terminal brain natriuretic peptide (N-TproBNP) in scleroderma-associated pulmonary arterial hypertension. *Eur Heart J*. 2006;27(12):1485-94. PMID: 16682379.
190. Yamada Y, Okuda S, Kataoka M, et al. Prognostic value of cardiac magnetic resonance imaging for idiopathic pulmonary arterial hypertension before initiating intravenous prostacyclin therapy. *Circulation Journal*. 2012;76(7):1737-1743. PMID: 22498565.
191. Yanagisawa R, Kataoka M, Taguchi H, et al. Impact of First-Line Sildenafil Monotreatment for Pulmonary Arterial Hypertension. *Circ J*. 2012;76(5):1245-1252. PMID: 22333215.
192. Yang SI, Chung WJ, Jung SH, et al. Effects of inhaled iloprost on congenital heart disease with Eisenmenger syndrome. *Pediatr Cardiol*. 2012;33(5):744-748. PMID: 22349672.
193. Yoshida S, Shirato K, Shimamura R, et al. Long-term safety and efficacy of ambrisentan in Japanese adults with pulmonary arterial hypertension. *Curr Med Res Opin*. 2012;28(6):1069-1076. PMID: 22506623.
194. Zafir N, Zingerman B, Solodky A, et al. Use of noninvasive tools in primary pulmonary hypertension to assess the correlation of right ventricular function with functional capacity and to predict outcome. *Int J Cardiovasc Imaging*. 2007;23(2):209-15. PMID: 16972146.
195. Zeng WJ, Sun YJ, Gu Q, et al. Impact of Sildenafil on Survival of Patients With Idiopathic Pulmonary Arterial Hypertension. *J Clin Pharmacol*. 2011. PMID: 21956607.
196. Zeng WJ, Sun YJ, Xiong CM, et al. Prognostic value of echocardiographic right/left ventricular end-diastolic diameter ratio in idiopathic pulmonary arterial hypertension. *Chin Med J (Engl)*. 2011;124(11):1672-7. PMID: 21740775.
197. Zhao QH, Peng FH, Wei H, et al. Serum high-density lipoprotein cholesterol levels as a prognostic indicator in patients with idiopathic pulmonary arterial hypertension. *Am J Cardiol*. 2012;110(3):433-439. PMID: 22560769.

## Appendix D. Quality and Applicability of Included Studies

**Table D-1. Quality and applicability for KQ 1 studies**

Study	Test Measures	Quality	Limitations to Applicability
Ajami, 2011 <sup>1</sup>	<ul style="list-style-type: none"> <li>• TRV/VTIRVOT</li> </ul>	Good	<ul style="list-style-type: none"> <li>• Participants had widely differing degrees of disease severity</li> <li>• Included patients did not match the review question</li> <li>• Study excluded participants with other conditions that might be easily confused with PAH such as PH due to heart failure, thrombotic disease, COPD</li> </ul>
Allanore, 2008 <sup>2</sup>	<ul style="list-style-type: none"> <li>• NT-proBNP, plasma</li> <li>• sPAP</li> </ul>	Good	<ul style="list-style-type: none"> <li>• Included patients did not match the review question</li> <li>• Study excluded participants with other conditions that might be easily confused with PAH such as PH due to heart failure, thrombotic disease, COPD</li> <li>• Index test, its conduct, or interpretation differed from the review question</li> </ul>
Arcasoy 2003 <sup>3</sup>	<ul style="list-style-type: none"> <li>• sPAP</li> <li>• RAP</li> </ul>	Good	<ul style="list-style-type: none"> <li>• Study population is inadequately described</li> <li>• Included patients did not match the review question</li> <li>• Study included patients with a wide variety of conditions in addition to the target population</li> </ul>
Bogdan, 1998 <sup>4</sup>	<ul style="list-style-type: none"> <li>• cGMP, urine</li> </ul>	Poor	<ul style="list-style-type: none"> <li>• Participants were at widely differing points in natural history of disease</li> <li>• Participants had widely differing degrees of disease severity</li> <li>• Included patients did not match the review question</li> <li>• Study excluded participants with other conditions that might be easily confused with PAH such as PH due to heart failure, thrombotic disease, COPD</li> <li>• Study included patients with a wide variety of conditions in addition to the target population</li> </ul>
Bonderman, 2011 <sup>5</sup>	<ul style="list-style-type: none"> <li>• NT-proBNP</li> <li>• sPAP</li> <li>• RA size</li> <li>• RV size</li> <li>• TAPSE</li> </ul>	Good	<ul style="list-style-type: none"> <li>• Included patients did not match the review question</li> </ul>
Cavagna, 2010 <sup>6</sup>	<ul style="list-style-type: none"> <li>• BNP</li> <li>• NT-proBNP</li> </ul>	Good	<ul style="list-style-type: none"> <li>• Study excluded participants with other conditions that might be easily confused with PAH such as PH due to heart failure, thrombotic disease, COPD</li> <li>• None</li> </ul>

Study	Test Measures	Quality	Limitations to Applicability
Cevik, 2012 <sup>7</sup>	<ul style="list-style-type: none"> <li>• RIMP/MPI/Tei index</li> <li>• mPAP</li> <li>• S'</li> <li>• TAPSE</li> <li>• TRV/VTI<sub>RVOT</sub></li> </ul>	Fair	<ul style="list-style-type: none"> <li>• Study population is inadequately described</li> <li>• Study excluded participants with other conditions that might be easily confused with PAH such as PH due to heart failure, thrombotic disease, COPD</li> <li>• Care delivery setting is widely divergent from typical U.S. setting</li> </ul>
Ciurzynski, 2011 <sup>8</sup>	<ul style="list-style-type: none"> <li>• Transtricuspid gradient rest/exercise</li> </ul>	Good	<ul style="list-style-type: none"> <li>• None</li> </ul>
Colle, 2003 <sup>9</sup>	<ul style="list-style-type: none"> <li>• sPAP</li> </ul>	Good	<ul style="list-style-type: none"> <li>• None</li> </ul>
Condliffe, 2011 <sup>10</sup>	<ul style="list-style-type: none"> <li>• Tricuspid gradient</li> </ul>	Fair	<ul style="list-style-type: none"> <li>• None</li> </ul>
Dahiya, 2010 <sup>11</sup>	<ul style="list-style-type: none"> <li>• TRV/VTIRVOT</li> </ul>	Good	<ul style="list-style-type: none"> <li>• Participants were at widely differing points in natural history of disease</li> <li>• Participants had widely differing degrees of disease severity</li> </ul>
Denton, 1997 <sup>12</sup>	<ul style="list-style-type: none"> <li>• RV size</li> <li>• sPAP</li> </ul>	Fair	<ul style="list-style-type: none"> <li>• None</li> </ul>
Farber, 2011 <sup>13</sup>	<ul style="list-style-type: none"> <li>• sPAP</li> <li>• RAP</li> </ul>	Fair	<ul style="list-style-type: none"> <li>• None</li> </ul>
Fisher, 2009 <sup>14</sup>	<ul style="list-style-type: none"> <li>• sPAP</li> <li>• Transtricuspid gradient</li> </ul>	Good	<ul style="list-style-type: none"> <li>• Study excluded participants with other conditions that might be easily confused with PAH such as PH due to heart failure, thrombotic disease, COPD</li> </ul>
Fitzgerald, 2012 <sup>15</sup>	<ul style="list-style-type: none"> <li>• TRV</li> <li>• mPAP</li> </ul>	Poor	<ul style="list-style-type: none"> <li>• Study population is inadequately described</li> <li>• Participants were at widely differing points in natural history of disease</li> <li>• Participants had widely differing degrees of disease severity</li> <li>• Included patients did not match the review question</li> <li>• Index test, its conduct, or interpretation differed from the review question</li> <li>• Cointerventions/treatments did not adequately reflect routine clinical practice</li> </ul>
Fonseca, 2011 <sup>16</sup>	<ul style="list-style-type: none"> <li>• TRV</li> <li>• Uric acid</li> </ul>	Fair	<ul style="list-style-type: none"> <li>• None</li> </ul>
Frea, 2011 <sup>17</sup>	<ul style="list-style-type: none"> <li>• NT-proBNP</li> <li>• FAC</li> <li>• RIMP/MPI/Tei index</li> <li>• RV size</li> <li>• TRV/VTIRVOT</li> <li>• TAPSE</li> </ul>	Fair	<ul style="list-style-type: none"> <li>• Index test, its conduct, or interpretation differed from the review question</li> </ul>
Fukuda, 2011 <sup>18</sup>	<ul style="list-style-type: none"> <li>• FAC</li> <li>• TAPSE</li> <li>• RIMP/MPI/Tei index</li> <li>• sPAP</li> </ul>	Fair	<ul style="list-style-type: none"> <li>• Participants had widely differing degrees of disease severity</li> <li>• Included patients did not match the review question</li> <li>• Study excluded participants with other conditions that might be easily confused with PAH such as PH due to heart failure, thrombotic disease, COPD</li> </ul>
Ghio, 2004 <sup>19</sup>	<ul style="list-style-type: none"> <li>• NT-proBNP</li> </ul>	Fair	<ul style="list-style-type: none"> <li>• Target condition as defined by the reference standard did not match the review question</li> </ul>
Gialafos, 2008 <sup>20</sup>	<ul style="list-style-type: none"> <li>• NT-proBNP</li> <li>• RIMP/MPI/Tei index</li> </ul>	Fair	<ul style="list-style-type: none"> <li>• None</li> </ul>

Study	Test Measures	Quality	Limitations to Applicability
Hachulla, 2005 <sup>21</sup>	<ul style="list-style-type: none"> <li>• TRV</li> </ul>	Poor	<ul style="list-style-type: none"> <li>• None</li> </ul>
Hammerstingl, 2012 <sup>22</sup>	<ul style="list-style-type: none"> <li>• sPAP</li> <li>• mPAP</li> </ul>	Fair	<ul style="list-style-type: none"> <li>• Participants were at widely differing points in natural history of disease</li> <li>• Participants had widely differing degrees of disease severity</li> <li>• Included patients did not match the review question</li> <li>• Study included patients with a wide variety of conditions in addition to the target population</li> <li>• Index test, its conduct, or interpretation differed from the review question</li> <li>• Equipment or operator level of training/proficiency is not widely available</li> <li>• Intervention (active arm) was not similar to that used in routine clinical practice</li> </ul>
Hsu, 2008 <sup>23</sup>	<ul style="list-style-type: none"> <li>• sPAP</li> </ul>	Good	<ul style="list-style-type: none"> <li>• None</li> </ul>
Hua, 2009 <sup>24</sup>	<ul style="list-style-type: none"> <li>• sPAP</li> </ul>	Good	<ul style="list-style-type: none"> <li>• None</li> </ul>
Jansa, 2012 <sup>25</sup>	<ul style="list-style-type: none"> <li>• TRV</li> </ul>	Fair	<ul style="list-style-type: none"> <li>• Participants were at widely differing points in natural history of disease</li> <li>• Participants had widely differing degrees of disease severity</li> </ul>
Kovacs, 2010 <sup>26</sup>	<ul style="list-style-type: none"> <li>• sPAP rest and exercise</li> </ul>	Good	<ul style="list-style-type: none"> <li>• None</li> </ul>
Lindqvist, 2011 <sup>27</sup>	<ul style="list-style-type: none"> <li>• TRV/VTIRVOT</li> </ul>	Fair	<ul style="list-style-type: none"> <li>• Participants had widely differing degrees of disease severity</li> <li>• Included patients did not match the review question</li> </ul>
Low, 2011 <sup>28</sup>	<ul style="list-style-type: none"> <li>• Transtricuspid gradient</li> </ul>	Poor	<ul style="list-style-type: none"> <li>• Participants were at widely differing points in natural history of disease</li> <li>• Participants had widely differing degrees of disease severity</li> <li>• Included patients did not match the review question</li> </ul>
Machado, 2006 <sup>29</sup>	<ul style="list-style-type: none"> <li>• NT-proBNP</li> </ul>	Poor	<ul style="list-style-type: none"> <li>• None</li> </ul>
McLean, 2007 <sup>30</sup>	<ul style="list-style-type: none"> <li>• RV end-diastolic diameter (RVD)</li> <li>• Tpeak (RV tricuspid annular motion by TDI, time from beginning of IC to first Sm peak)</li> </ul>	Poor	<ul style="list-style-type: none"> <li>• Participants were at widely differing points in natural history of disease</li> <li>• Participants had widely differing degrees of disease severity</li> <li>• Included patients did not match the review question</li> <li>• Study included patients with a wide variety of conditions in addition to the target population</li> <li>• Index test, its conduct, or interpretation differed from the review question</li> <li>• Intervention (active arm) was not similar to that used in routine clinical practice</li> <li>• Cointerventions/treatments did not adequately reflect routine clinical practice</li> </ul>
Mourani, 2008 <sup>31</sup>	<ul style="list-style-type: none"> <li>• RA size</li> <li>• RV size</li> <li>• Transtricuspid gradient</li> </ul>	Fair	<ul style="list-style-type: none"> <li>• Participants were at widely differing points in natural history of disease</li> <li>• Participants had widely differing degrees of disease severity</li> <li>• Included patients did not match the review question</li> <li>• Study excluded participants with other conditions that might be easily confused with PAH such as PH due to heart failure, thrombotic disease, COPD</li> <li>• Study included patients with a wide variety of conditions in addition to the target population</li> </ul>

Study	Test Measures	Quality	Limitations to Applicability
Mukerjee, 2004 <sup>32</sup>	<ul style="list-style-type: none"> <li>sPAP</li> </ul>	Fair	<ul style="list-style-type: none"> <li>Index test, its conduct, or interpretation differed from the review question</li> <li>Potential adverse events associated with testing or treatment were not measured or reported</li> </ul>
Murata, 1997 <sup>33</sup>	<ul style="list-style-type: none"> <li>sPAP</li> </ul>	Fair	<ul style="list-style-type: none"> <li>Included patients did not match the review question</li> <li>Study excluded participants with other conditions that might be easily confused with PAH such as PH due to heart failure, thrombotic disease, COPD</li> </ul>
Nakayama, 1998 <sup>34</sup>	<ul style="list-style-type: none"> <li>sPAP</li> <li>mPAP</li> </ul>	Fair	<ul style="list-style-type: none"> <li>Included patients did not match the review question</li> <li>Study excluded participants with other conditions that might be easily confused with PAH such as PH due to heart failure, thrombotic disease, COPD</li> <li>Potential adverse events associated with testing or treatment were not measured or reported</li> </ul>
Nogami, 2009 <sup>35</sup>	<ul style="list-style-type: none"> <li>sPAP</li> </ul>	Good	<ul style="list-style-type: none"> <li>Participants had widely differing degrees of disease severity</li> <li>Included patients did not match the review question</li> <li>Study included patients with a wide variety of conditions in addition to the target population</li> </ul>
Phung, 2009 <sup>36</sup>	<ul style="list-style-type: none"> <li>sPAP</li> </ul>	Good	<ul style="list-style-type: none"> <li>Study included patients with a wide variety of conditions in addition to the target population</li> </ul>
Pilatis, 2000 <sup>37</sup>	<ul style="list-style-type: none"> <li>RV size</li> <li>sPAP</li> </ul>	Fair	<ul style="list-style-type: none"> <li>Target condition as defined by the reference standard did not match the review question</li> <li>Potential adverse events associated with testing or treatment were not measured or reported</li> </ul>
Rajagopalan, 2009 <sup>38</sup> Rajagopalan, 2007 <sup>39</sup>	<ul style="list-style-type: none"> <li>TRV/VTIRVOT</li> <li>sPAP</li> <li>S'</li> </ul>	Fair	<ul style="list-style-type: none"> <li>Participants were at widely differing points in natural history of disease</li> <li>Participants had widely differing degrees of disease severity</li> <li>Included patients did not match the review question</li> <li>Study excluded participants with other conditions that might be easily confused with PAH such as PH due to heart failure, thrombotic disease, COPD</li> <li>Study included patients with a wide variety of conditions in addition to the target population</li> </ul>
Rajaram, 2012 <sup>40</sup>	<ul style="list-style-type: none"> <li>sPAP</li> <li>mPAP</li> <li>Pericardial effusion</li> </ul>	Fair	<ul style="list-style-type: none"> <li>None</li> </ul>
Rich, 2011 <sup>41</sup>	<ul style="list-style-type: none"> <li>sPAP</li> </ul>	Good	<ul style="list-style-type: none"> <li>Included patients did not match the review question</li> <li>Study excluded participants with other conditions that might be easily confused with PAH such as PH due to heart failure, thrombotic disease, COPD</li> <li>Index test, its conduct, or interpretation differed from the review question</li> </ul>

Study	Test Measures	Quality	Limitations to Applicability
Roeleveld, 2005 <sup>42</sup>	<ul style="list-style-type: none"> <li>sPAP</li> </ul>	Fair	<ul style="list-style-type: none"> <li>Included patients did not match the review question</li> <li>Study excluded participants with other conditions that might be easily confused with PAH such as PH due to heart failure, thrombotic disease, COPD</li> </ul>
Roule, 2010 <sup>43</sup>	<ul style="list-style-type: none"> <li>TRV</li> <li>TRV/VTIRVOT</li> </ul>	Good	<ul style="list-style-type: none"> <li>Study excluded participants with other conditions that might be easily confused with PAH such as PH due to heart failure, thrombotic disease, COPD</li> </ul>
Ruan, 2007 <sup>44</sup>	<ul style="list-style-type: none"> <li>FAC</li> <li>RV size</li> <li>sPAP</li> </ul>	Fair	<ul style="list-style-type: none"> <li>Participants were at widely differing points in natural history of disease</li> <li>Participants had widely differing degrees of disease severity</li> <li>Included patients did not match the review question</li> <li>Study excluded participants with other conditions that might be easily confused with PAH such as PH due to heart failure, thrombotic disease, COPD</li> </ul>
Ruiz-Irastorza, 2012 <sup>45</sup>	<ul style="list-style-type: none"> <li>sPAP</li> <li>mPAP</li> </ul>	Fair	<ul style="list-style-type: none"> <li>Participants were at widely differing points in natural history of disease</li> <li>Participants had widely differing degrees of disease severity</li> <li>Study included patients with a wide variety of conditions in addition to the target population</li> </ul>
Sanli, 2012 <sup>46</sup>	<ul style="list-style-type: none"> <li>RV size</li> <li>mPAP</li> <li>Nitric oxide</li> <li>RIMP/MPI/Tei index</li> <li>TAPSE</li> </ul>	Fair	<ul style="list-style-type: none"> <li>Study population is inadequately described</li> <li>Participants were at widely differing points in natural history of disease</li> <li>Participants had widely differing degrees of disease severity</li> <li>Study included patients with a wide variety of conditions in addition to the target population</li> </ul>
Selby, 2012 <sup>47</sup>	<ul style="list-style-type: none"> <li>sPAP</li> </ul>	Fair	<ul style="list-style-type: none"> <li>Study population is inadequately described</li> </ul>
Selimovic, 2007 <sup>48</sup>	<ul style="list-style-type: none"> <li>sPAP</li> <li>mPAP</li> </ul>	Good	<ul style="list-style-type: none"> <li>Included patients did not match the review question</li> <li>Study excluded participants with other conditions that might be easily confused with PAH such as PH due to heart failure, thrombotic disease, COPD</li> </ul>
Simeoni, 2008 <sup>49</sup>	<ul style="list-style-type: none"> <li>NT-proBNP</li> </ul>	Poor	<ul style="list-style-type: none"> <li>Participants were at widely differing points in natural history of disease</li> <li>Participants had widely differing degrees of disease severity</li> <li>Included patients did not match the review question</li> <li>Study excluded participants with other conditions that might be easily confused with PAH such as PH due to heart failure, thrombotic disease, COPD</li> <li>Study included patients with a wide variety of conditions in addition to the target population</li> </ul>
Steen, 2008 <sup>50</sup>	<ul style="list-style-type: none"> <li>sPAP rest/exercise</li> </ul>	Fair	<ul style="list-style-type: none"> <li>Target condition as defined by the reference standard did not match the review question</li> <li>Surrogate outcomes were not sufficiently clinically relevant</li> </ul>

Study	Test Measures	Quality	Limitations to Applicability
Takatsuki, 2012 <sup>51</sup>	<ul style="list-style-type: none"> <li>• S'</li> <li>• mPAP</li> </ul>	Fair	<ul style="list-style-type: none"> <li>• Study population is inadequately described</li> <li>• Participants were at widely differing points in natural history of disease</li> <li>• Participants had widely differing degrees of disease severity</li> <li>• Study excluded participants with other conditions that might be easily confused with PAH such as PH due to heart failure, thrombotic disease, COPD</li> </ul>
Tei, 1996 <sup>52</sup>	<ul style="list-style-type: none"> <li>• RIMP/MPI/Tei index</li> </ul>	Poor	<ul style="list-style-type: none"> <li>• Participants were at widely differing points in natural history of disease</li> <li>• Participants had widely differing degrees of disease severity</li> <li>• Included patients did not match the review question</li> <li>• Study excluded participants with other conditions that might be easily confused with PAH such as PH due to heart failure, thrombotic disease, COPD</li> </ul>
Tian, 2011 <sup>53</sup>	<ul style="list-style-type: none"> <li>• sPAP</li> <li>• mPAP</li> </ul>	Fair	<ul style="list-style-type: none"> <li>• Included patients did not match the review question</li> <li>• Study excluded participants with other conditions that might be easily confused with PAH such as PH due to heart failure, thrombotic disease, COPD</li> </ul>
Thakkar, 2012 <sup>54</sup>	<ul style="list-style-type: none"> <li>• sPAP</li> <li>• NT-proBNP</li> </ul>	Fair	<ul style="list-style-type: none"> <li>• Participants were at widely differing points in natural history of disease</li> <li>• Participants had widely differing degrees of disease severity</li> <li>• Included patients did not match the review question</li> <li>• Study excluded participants with other conditions that might be easily confused with PAH such as PH due to heart failure, thrombotic disease, COPD</li> <li>• Study included patients with a wide variety of conditions in addition to the target population</li> </ul>
Torregrosa, 2001 <sup>55</sup>	<ul style="list-style-type: none"> <li>• sPAP</li> </ul>	Fair	<ul style="list-style-type: none"> <li>• None</li> </ul>
Toyono, 2008 <sup>56</sup>	<ul style="list-style-type: none"> <li>• BNP</li> </ul>	Good	<ul style="list-style-type: none"> <li>• Participants were at widely differing points in natural history of disease</li> <li>• Participants had widely differing degrees of disease severity</li> </ul>
Tutar, 1999 <sup>57</sup>	<ul style="list-style-type: none"> <li>• Endothelin-1, plasma</li> </ul>	Fair	<ul style="list-style-type: none"> <li>• Participants had widely differing degrees of disease severity</li> </ul>
Vlahos, 2007 <sup>58</sup>	<ul style="list-style-type: none"> <li>• TRV/VTIRVOT</li> </ul>	Poor	<ul style="list-style-type: none"> <li>• Included patients did not match the review question</li> <li>• Study excluded participants with other conditions that might be easily confused with PAH such as PH due to heart failure, thrombotic disease, COPD</li> </ul>
Vonk, 2007 <sup>59</sup>	<ul style="list-style-type: none"> <li>• RIMP/MPI/Tei index</li> <li>• sPAP</li> </ul>	Fair	<ul style="list-style-type: none"> <li>• None</li> </ul>
Willens, 2008 <sup>60</sup>	<ul style="list-style-type: none"> <li>• sPAP</li> </ul>	Fair	<ul style="list-style-type: none"> <li>• Included patients did not match the review question</li> </ul>
Williams, 2006 <sup>61</sup>	<ul style="list-style-type: none"> <li>• NT-proBNP</li> </ul>	Fair	<ul style="list-style-type: none"> <li>• None</li> </ul>

Abbreviations: BNP=brain natriuretic peptide; cGMP= cyclic guanosine monophosphate; CHF=congestive heart failure; COPD=chronic obstructive pulmonary disease; CTEPH=chronic thromboembolic pulmonary hypertension; CVD=collagen vascular disease; DLCO=diffusion capacity of the lung for carbon monoxide; FAC=fractional area change; mPAP=mean pulmonary artery pressure; MPI=myocardial performance index; NT-proBNP=N-terminal pro-B-type natriuretic peptide; NYHA=New York Heart Association; PAH=pulmonary arterial hypertension; PH=pulmonary hypertension; PPH=primary pulmonary hypertension; PVR=pulmonary vascular resistance; RA=right atrium; RHC=right heart catheterization; RIMP=right index of myocardial performance; RV=right ventricle; S'=tricuspid lateral annular systolic velocity; sPAP=systolic pulmonary artery



pressure; SSc=systemic sclerosis; TAPSE=tricuspid annular plane systolic excursion; TDI=tissue Doppler imaging; TRV=tricuspid regurgitant jet velocity; VSD=ventricular septal defect; VTI<sub>RVOT</sub>=velocity-time integral of right ventricular outflow tract

**Table D-2. Quality and applicability for KQ 2 studies**

Study	Index Tests/Comparators	Quality	Limitations to Applicability
Andreassen, 2006 <sup>62</sup>	<ul style="list-style-type: none"> <li>• BNP</li> <li>• Cardiac index</li> <li>• Functional class</li> <li>• RHC-mPAP</li> <li>• RHC-PVR</li> <li>• RHC-sPAP</li> <li>• RAP</li> <li>• Mortality</li> </ul>	Good	<ul style="list-style-type: none"> <li>• None</li> </ul>
Badesch, 2012 <sup>63</sup> Badesch 2011 <sup>64</sup>	<ul style="list-style-type: none"> <li>• BNP</li> </ul>	Good	<ul style="list-style-type: none"> <li>• Included patients did not match the review question</li> </ul>
Barst, 1996 <sup>65</sup>	<ul style="list-style-type: none"> <li>• mPAP</li> </ul>	Good	<ul style="list-style-type: none"> <li>• None</li> </ul>
Bendayan, 2002 <sup>66</sup>	<ul style="list-style-type: none"> <li>• Uric acid</li> <li>• 6MWD (absolute)</li> <li>• Functional class</li> <li>• Mortality</li> <li>• RHC-CO</li> <li>• RHC-mPAP</li> </ul>	Good	<ul style="list-style-type: none"> <li>• None</li> </ul>
Benza, 2010 <sup>67</sup>	<ul style="list-style-type: none"> <li>• BNP &gt;180</li> <li>• BNP &lt;50</li> <li>• Pericardial effusion</li> <li>• Mortality</li> </ul>	Good	<ul style="list-style-type: none"> <li>• None</li> </ul>
Bernus, 2009 <sup>68</sup>	<ul style="list-style-type: none"> <li>• BNP</li> <li>• Cardiac index</li> <li>• Peak TRV</li> <li>• PCWP</li> <li>• RHC-mPAP</li> <li>• RHC-PVR</li> <li>• Right atrial pressure</li> <li>• RV size</li> <li>• TRV</li> </ul>	Good	<ul style="list-style-type: none"> <li>• None</li> </ul>
Bharani, 2007 <sup>69</sup>	<ul style="list-style-type: none"> <li>• sPAP</li> </ul>	Fair	<ul style="list-style-type: none"> <li>• Intervention (active arm) was not similar to that used in routine clinical practice</li> </ul>

Study	Index Tests/Comparators	Quality	Limitations to Applicability
Borges, 2006 <sup>70</sup>	<ul style="list-style-type: none"> <li>• RIMP/MPI/Tei index</li> <li>• RV size</li> <li>• 6MWD (absolute)</li> <li>• RHC-PVR</li> </ul>	Good	<ul style="list-style-type: none"> <li>• None</li> </ul>
Brierre, 2010 <sup>71</sup>	<ul style="list-style-type: none"> <li>• mPAP</li> <li>• mPAP <math>\geq 49</math></li> <li>• Pericardial effusion</li> <li>• RIMP/MPI/Tei index</li> <li>• RIMP/MPI/Tei index <math>\geq 0.98</math></li> <li>• TAPSE</li> <li>• Mortality</li> </ul>	Good	<ul style="list-style-type: none"> <li>• Outcomes were not measured for sufficiently long duration of treatment</li> </ul>
Bustamante-Labarta, 2002 <sup>72</sup>	<ul style="list-style-type: none"> <li>• RA size</li> <li>• Survival free from lung transplant</li> </ul>	Good	<ul style="list-style-type: none"> <li>• None</li> </ul>
Campana, 2004 <sup>73</sup>	<ul style="list-style-type: none"> <li>• BNP</li> <li>• Cardiac index</li> <li>• FAC</li> <li>• RV size</li> <li>• TAPSE</li> <li>• mPAP</li> <li>• Right atrial pressure</li> <li>• RVEF</li> </ul>	Good	<ul style="list-style-type: none"> <li>• None</li> </ul>
Cella, 2009 <sup>74</sup>	<ul style="list-style-type: none"> <li>• RVSP</li> <li>• Nitric oxide</li> <li>• 6MWD (change)</li> </ul>	Good	<ul style="list-style-type: none"> <li>• None</li> </ul>
Channick, 2001 <sup>75</sup> Badesch 2002 <sup>76</sup>	<ul style="list-style-type: none"> <li>• mPAP</li> </ul>	Good	<ul style="list-style-type: none"> <li>• Potential adverse events associated with testing or treatment were not measured or reported</li> </ul>
Chin, 2007 <sup>77</sup>	<ul style="list-style-type: none"> <li>• BNP</li> <li>• 6MWD (absolute)</li> <li>• PCWP</li> <li>• RHC-CO</li> <li>• RHC-mPAP</li> <li>• RHC-PVR</li> <li>• Right atrial pressure</li> </ul>	Good	<ul style="list-style-type: none"> <li>• None</li> </ul>
Dimitroulas, 2007 <sup>78</sup>	<ul style="list-style-type: none"> <li>• BNP</li> </ul>	Good	<ul style="list-style-type: none"> <li>• None</li> </ul>
D'Alto, 2010 <sup>79</sup>	<ul style="list-style-type: none"> <li>• BNP</li> </ul>	Fair	<ul style="list-style-type: none"> <li>• None</li> </ul>
Dyer, 2006 <sup>80</sup>	<ul style="list-style-type: none"> <li>• RIMP/MPI/Tei index</li> <li>• RHC-mPAP</li> </ul>	Fair	<ul style="list-style-type: none"> <li>• None</li> </ul>
Elstein, 2004 <sup>81</sup>	<ul style="list-style-type: none"> <li>• BNP</li> <li>• Tricuspid insufficiency</li> </ul>	Good	<ul style="list-style-type: none"> <li>• None</li> </ul>

Study	Index Tests/Comparators	Quality	Limitations to Applicability
Fahmy Elnamany, 2007 <sup>82</sup>	<ul style="list-style-type: none"> <li>• Endothelin-1</li> <li>• sPAP</li> <li>• RHC-sPAP</li> <li>• RIMP/MPI/Tei Index</li> <li>• RVEF</li> </ul>	Fair	<ul style="list-style-type: none"> <li>• None</li> </ul>
Feliciano, 2005 <sup>83</sup>	<ul style="list-style-type: none"> <li>• RIMP/MPI/Tei index</li> </ul>	Good	<ul style="list-style-type: none"> <li>• None</li> </ul>
Fijalkowska, 2006 <sup>84</sup>	<ul style="list-style-type: none"> <li>• BNP</li> <li>• FAC</li> <li>• Pericardial effusion</li> <li>• RA size</li> <li>• RIMP/MPI/Tei index</li> <li>• RV size</li> <li>• Troponin T</li> <li>• 6MWD (absolute)</li> <li>• Cardiac index</li> <li>• Functional class</li> <li>• Peak TRV</li> <li>• RHC-mPAP</li> <li>• RHC-PVR</li> <li>• Right atrial pressure</li> <li>• Mortality</li> </ul>	Good	<ul style="list-style-type: none"> <li>• None</li> </ul>
Filusch, 2010 <sup>85</sup>	<ul style="list-style-type: none"> <li>• cTroponin T</li> <li>• hsTroponin T</li> <li>• BNP</li> <li>• Mortality</li> <li>• WHO class</li> </ul>	Good	<ul style="list-style-type: none"> <li>• Surrogate outcomes were not sufficiently clinically relevant</li> </ul>
Forfia, 2006 <sup>86</sup>	<ul style="list-style-type: none"> <li>• TAPSE</li> <li>• RHC-PVR</li> <li>• Mortality</li> </ul>	Good	<ul style="list-style-type: none"> <li>• None</li> </ul>
Friedberg, 2006 <sup>87</sup>	<ul style="list-style-type: none"> <li>• mPAP</li> <li>• BNP</li> <li>• sPAP</li> <li>• RHC-mPAP</li> <li>• RHC-sPAP</li> </ul>	Good	<ul style="list-style-type: none"> <li>• Included patients did not match the review question</li> <li>• Study included patients with a wide variety of conditions in addition to the target population</li> </ul>
Galie, 2008 <sup>88</sup> Oudiz 2009 <sup>89</sup> Shapiro 2012 <sup>90</sup>	<ul style="list-style-type: none"> <li>• BNP</li> </ul>	Good	<ul style="list-style-type: none"> <li>• None</li> </ul>

Study	Index Tests/Comparators	Quality	Limitations to Applicability
Gan, 2006 <sup>91</sup>	<ul style="list-style-type: none"> <li>• BNP</li> <li>• 6MWD (absolute)</li> <li>• Cardiac index</li> <li>• RHC-mPAP</li> <li>• RHC-PVR</li> <li>• Right atrial pressure</li> <li>• RVEF</li> </ul>	Good	<ul style="list-style-type: none"> <li>• None</li> </ul>
Ghio, 2010 <sup>92</sup>	<ul style="list-style-type: none"> <li>• FAC</li> <li>• Pericardial effusion</li> <li>• RIMP/MPI/Tei index</li> <li>• sPAP</li> <li>• TAPSE</li> <li>• Mortality</li> </ul>	Good	<ul style="list-style-type: none"> <li>• Study population was inadequately described to assess the applicability of this study</li> <li>• Target condition as defined by the reference standard did not match the review question</li> </ul>
Ghofrani, 2002 <sup>93</sup>	<ul style="list-style-type: none"> <li>• BNP</li> <li>• cGMP</li> <li>• RHC-PVR</li> </ul>	Fair	<ul style="list-style-type: none"> <li>• Surrogate outcomes were not sufficiently clinically relevant</li> <li>•</li> </ul>
Goto, 2010 <sup>94</sup>	<ul style="list-style-type: none"> <li>• BNP</li> <li>• sPAP</li> <li>• RHC-mPAP</li> <li>• RHC-sPAP</li> </ul>	Good	<ul style="list-style-type: none"> <li>• Study population was inadequately described to assess the applicability of this study</li> <li>• Participants had widely differing degrees of disease severity</li> <li>• Included patients did not match the review question</li> </ul>
Grapsa, 2007 <sup>95</sup>	<ul style="list-style-type: none"> <li>• RIMP/MPI/Tei index</li> <li>• Pericardial effusion</li> <li>• RA size</li> <li>• TRV</li> </ul>	Good	<ul style="list-style-type: none"> <li>• None</li> </ul>
Grubstein, 2008 <sup>96</sup>	<ul style="list-style-type: none"> <li>• sPAP</li> <li>• RHC-sPAP</li> </ul>	Fair	<ul style="list-style-type: none"> <li>• None</li> </ul>
Haddad, 2009 <sup>97</sup>	<ul style="list-style-type: none"> <li>• mPAP</li> <li>• sPAP</li> <li>• RHC-mPAP</li> <li>• RHC-sPAP</li> </ul>	Good	<ul style="list-style-type: none"> <li>• None</li> </ul>
Halank, 2011 <sup>98</sup>	<ul style="list-style-type: none"> <li>• BNP</li> <li>• Median</li> </ul>	Fair	<ul style="list-style-type: none"> <li>• None</li> </ul>
Hampole, 2009 <sup>99</sup>	<ul style="list-style-type: none"> <li>• BNP</li> <li>• Mortality</li> </ul>	Good	<ul style="list-style-type: none"> <li>• None</li> </ul>
Heresi, 2012 <sup>100</sup>	<ul style="list-style-type: none"> <li>• cTnI (detectable vs. nondetectable)</li> <li>• BNP</li> <li>• NYHA class</li> <li>• RA size</li> <li>• 6MWD</li> </ul>	Good	<ul style="list-style-type: none"> <li>• None</li> </ul>

Study	Index Tests/Comparators	Quality	Limitations to Applicability
Heresi, 2010 <sup>101</sup>	<ul style="list-style-type: none"> <li>• BNP</li> <li>• 6MWD (absolute)</li> <li>• Cardiac index</li> <li>• RHC-mPAP</li> <li>• RHC-PVR</li> <li>• Right atrial pressure</li> <li>• Mortality</li> </ul>	Good	<ul style="list-style-type: none"> <li>• None</li> </ul>
Hinderliter, 1997 <sup>102</sup>	<ul style="list-style-type: none"> <li>• FAC</li> <li>• Pericardial effusion</li> <li>• RV size</li> <li>• sPAP</li> <li>• TRV</li> <li>• 6MWD (absolute)</li> <li>• Cardiac index</li> <li>• RHC-mPAP</li> <li>• Right atrial pressure</li> <li>• RHC-sPAP</li> </ul>	Fair	<ul style="list-style-type: none"> <li>• Outcomes were not measured for sufficiently long duration of treatment</li> <li>• Potential adverse events associated with testing or treatment were not measured or reported</li> </ul>
Hiramoto, 2009 <sup>103</sup>	<ul style="list-style-type: none"> <li>• BNP</li> <li>• Endothelin-1</li> </ul>	Fair	<ul style="list-style-type: none"> <li>• None</li> </ul>
Ho, 2009 <sup>104</sup>	<ul style="list-style-type: none"> <li>• RIMP/MPI/Tei Index</li> <li>• FAC</li> <li>• BNP</li> <li>• sPAP</li> <li>• RVEF</li> </ul>	Good	<ul style="list-style-type: none"> <li>• None</li> </ul>
Homma, 2001 <sup>105</sup>	<ul style="list-style-type: none"> <li>• sPAP</li> <li>• RHC-sPAP</li> </ul>	Good	<ul style="list-style-type: none"> <li>• None</li> </ul>
Jacobs, 2009 <sup>106</sup>	<ul style="list-style-type: none"> <li>• BNP</li> </ul>	Fair	<ul style="list-style-type: none"> <li>• None</li> </ul>
Kaya, 2012 <sup>107</sup>	<ul style="list-style-type: none"> <li>• RV size</li> <li>• RA size</li> <li>• sPAP</li> <li>• S'</li> </ul>	Good	<ul style="list-style-type: none"> <li>• None</li> </ul>
Keogh, 2011 <sup>108</sup>	<ul style="list-style-type: none"> <li>• sPAP</li> </ul>	Fair	<ul style="list-style-type: none"> <li>• None</li> </ul>
Knirsch, 2011 <sup>109</sup>	<ul style="list-style-type: none"> <li>• BNP</li> </ul>	Good	<ul style="list-style-type: none"> <li>• Study population was inadequately described to assess the applicability of this study</li> <li>• Study included patients with a wide variety of conditions in addition to the target population</li> <li>• Cointerventions/treatments did not adequately reflect routine clinical practice</li> <li>• Outcomes were not measured for sufficiently long duration of treatment</li> </ul>
Kopec, 2012 <sup>110</sup>	<ul style="list-style-type: none"> <li>• BNP</li> <li>• ET-1</li> </ul>	Fair	<ul style="list-style-type: none"> <li>• Index test, its conduct, or interpretation differed from the review question</li> </ul>

Study	Index Tests/Comparators	Quality	Limitations to Applicability
Lammers, 2009 <sup>111</sup>	<ul style="list-style-type: none"> <li>• BNP</li> <li>• 6MWD (absolute)</li> <li>• Functional class</li> </ul>	Good	<ul style="list-style-type: none"> <li>• None</li> </ul>
Langleben, 1999 <sup>112</sup>	<ul style="list-style-type: none"> <li>• Endothelin-1</li> </ul>	Good	<ul style="list-style-type: none"> <li>• None</li> </ul>
Leuchte, 2005 <sup>113</sup>	<ul style="list-style-type: none"> <li>• Change in BNP</li> <li>• BNP</li> <li>• Change in :</li> <li>• 6MWD (absolute)</li> <li>• Cardiac index</li> <li>• RHC-CO</li> <li>• RHC-mPAP</li> <li>• RHC-PVR</li> <li>• Right atrial pressure</li> </ul>	Good	<ul style="list-style-type: none"> <li>• None</li> </ul>
Lorenzen, 2011 <sup>114</sup>	<ul style="list-style-type: none"> <li>• BNP</li> <li>• Uric acid</li> <li>• Mortality</li> </ul>	Good	<ul style="list-style-type: none"> <li>• None</li> </ul>
Machado, 2006 <sup>29</sup>	<ul style="list-style-type: none"> <li>• BNP</li> <li>• BNP <math>\geq 160</math>, unadjusted <math>\geq 160</math>, adjusted log10, adjusted log10, unadjusted</li> <li>• 6MWD (absolute)</li> <li>• mPAP</li> <li>• PCWP</li> <li>• RA size</li> <li>• RHC-CO</li> <li>• RHC-dPAP</li> <li>• RHC-PVR</li> <li>• RHC-sPAP</li> <li>• RV size</li> <li>• TRV</li> <li>• Mortality</li> </ul>	Poor	<ul style="list-style-type: none"> <li>• None</li> </ul>
Machado, 2004 <sup>115</sup>	<ul style="list-style-type: none"> <li>• Nitric oxide</li> <li>• sPAP</li> <li>• mPAP</li> <li>• RHC-sPAP</li> </ul>	Fair	<ul style="list-style-type: none"> <li>• None</li> </ul>
Mahapatra, 2006 <sup>116</sup>	<ul style="list-style-type: none"> <li>• RIMP/MPI/Tei Index</li> <li>• RVSP</li> <li>• Mortality</li> </ul>	Fair	<ul style="list-style-type: none"> <li>• None</li> </ul>

Study	Index Tests/Comparators	Quality	Limitations to Applicability
Mathai, 2011 <sup>117</sup>	<ul style="list-style-type: none"> <li>• FAC</li> <li>• Peak TRV</li> <li>• Pericardial effusion</li> <li>• RA size</li> <li>• TAPSE</li> <li>• Mortality</li> </ul>	Fair	<ul style="list-style-type: none"> <li>• None</li> </ul>
Mauritz, 2011 <sup>118</sup>	<ul style="list-style-type: none"> <li>• BNP</li> </ul>	Good	<ul style="list-style-type: none"> <li>• None</li> </ul>
McLaughlin, 2010 <sup>119</sup> Frantz, 2012 <sup>120</sup>	<ul style="list-style-type: none"> <li>• BNP</li> </ul>	Good	<ul style="list-style-type: none"> <li>• None</li> </ul>
Michelakis, 2002 <sup>121</sup>	<ul style="list-style-type: none"> <li>• cGMP</li> </ul>	Fair	<ul style="list-style-type: none"> <li>• Surrogate outcomes were not sufficiently clinically relevant</li> <li>• Outcomes were not measured for sufficiently long duration of treatment</li> <li>• Potential adverse events associated with testing or treatment were not measured or reported</li> </ul>
Minniti, 2009 <sup>122</sup>	<ul style="list-style-type: none"> <li>• BNP</li> <li>• TRV</li> </ul>	Poor	<ul style="list-style-type: none"> <li>• None</li> </ul>
Montani, 2007 <sup>123</sup>	<ul style="list-style-type: none"> <li>• Endothelin-1</li> <li>• Cardiac index</li> <li>• RHC-PVR</li> <li>• Right atrial pressure</li> </ul>	Fair	<ul style="list-style-type: none"> <li>• Participants were at widely differing points in natural history of disease</li> <li>• Intervention (active arm) was not similar to that used in routine clinical practice</li> </ul>
Morishita, 2009 <sup>124</sup>	<ul style="list-style-type: none"> <li>• Pericardial effusion</li> <li>• RA size</li> <li>• RA size</li> <li>• BNP</li> <li>• Functional class</li> </ul>	Good	<ul style="list-style-type: none"> <li>• None</li> </ul>
Mukerjee, 2003 <sup>125</sup>	<ul style="list-style-type: none"> <li>• BNP</li> <li>• RHC-mPAP</li> <li>• RHC-PVR</li> </ul>	Good	<ul style="list-style-type: none"> <li>• None</li> </ul>
Nagaya, 2000 <sup>126</sup>	<ul style="list-style-type: none"> <li>• ANP</li> <li>• BNP</li> <li>• PCWP</li> <li>• RHC-CO</li> <li>• RHC-mPAP</li> <li>• Right atrial pressure</li> <li>• Mortality</li> <li>• RHC-PVR</li> <li>• Right atrial pressure</li> <li>• RV size</li> </ul>	Good	<ul style="list-style-type: none"> <li>• None</li> </ul>
Nakayama, 2007 <sup>127</sup>	<ul style="list-style-type: none"> <li>• BNP</li> </ul>	Fair	<ul style="list-style-type: none"> <li>• None</li> </ul>

Study	Index Tests/Comparators	Quality	Limitations to Applicability
Nath, 2005 <sup>128</sup>	<ul style="list-style-type: none"> <li>• Peak TRV</li> <li>• RIMP/MPI/Tei Index</li> <li>• RV size</li> <li>• sPAP</li> <li>• TRV</li> <li>• Functional class</li> </ul>	Good	<ul style="list-style-type: none"> <li>• Participants were at widely differing points in natural history of disease</li> <li>• Participants had widely differing degrees of disease severity</li> </ul>
Nickel, 2012 <sup>129</sup>	<ul style="list-style-type: none"> <li>• BNP</li> <li>• Uric acid</li> <li>• Mortality</li> </ul>	Fair	<ul style="list-style-type: none"> <li>• None</li> </ul>
Nickel, 2008 <sup>130</sup>	<ul style="list-style-type: none"> <li>• BNP</li> <li>• Uric acid</li> <li>• Composite outcome (death or lung transplantation)</li> </ul>	Fair	<ul style="list-style-type: none"> <li>• Participants were at widely differing points in natural history of disease</li> <li>• Participants had widely differing degrees of disease severity</li> </ul>
Njaman, 2007 <sup>131</sup>	<ul style="list-style-type: none"> <li>• Uric acid</li> <li>• Mortality</li> </ul>	Good	<ul style="list-style-type: none"> <li>• None</li> </ul>
Ogawa, 2012 <sup>132</sup>	<ul style="list-style-type: none"> <li>• BNP</li> </ul>	Fair	<ul style="list-style-type: none"> <li>• None</li> </ul>
Park, 2004 <sup>133</sup>	<ul style="list-style-type: none"> <li>• sPAP</li> <li>• BNP</li> <li>• Clinical event</li> </ul>	Fair	<ul style="list-style-type: none"> <li>• None</li> </ul>
Pyxaras, 2011 <sup>134</sup>	<ul style="list-style-type: none"> <li>• sPAP</li> <li>• mPAP</li> <li>• RHC-sPAP</li> <li>• RHC-mPAP</li> </ul>	Good	<ul style="list-style-type: none"> <li>• None</li> </ul>
Raymond, 2002 <sup>135</sup>	<ul style="list-style-type: none"> <li>• FAC</li> <li>• Peak TRV</li> <li>• Pericardial effusion</li> <li>• RA size</li> <li>• Mortality</li> <li>• Composite outcome (death or transplantation)</li> </ul>	Fair	<ul style="list-style-type: none"> <li>• None</li> </ul>
Rhodes, 2011 <sup>136</sup>	<ul style="list-style-type: none"> <li>• BNP</li> <li>• 6MWD (absolute)</li> <li>• Cardiac index</li> <li>• PCWP</li> <li>• RHC-PVR</li> <li>• Right atrial pressure</li> <li>• Mortality</li> </ul>	Good	<ul style="list-style-type: none"> <li>• Participants were at widely differing points in natural history of disease</li> <li>• Participants had widely differing degrees of disease severity</li> </ul>
Sadushi-Kolici, 2012 <sup>137</sup>	<ul style="list-style-type: none"> <li>• Pericardial effusion</li> <li>• Mortality</li> </ul>	Fair	<ul style="list-style-type: none"> <li>• None</li> </ul>
Schumann, 2010 <sup>138</sup>	<ul style="list-style-type: none"> <li>• BNP</li> <li>• sPAP</li> </ul>	Good	<ul style="list-style-type: none"> <li>• Participants were at widely differing points in natural history of disease</li> <li>• Participants had widely differing degrees of disease severity</li> </ul>



Study	Index Tests/Comparators	Quality	Limitations to Applicability
Sebbag, 2001 <sup>139</sup>	<ul style="list-style-type: none"> <li>• RIMP/MPI/Tei Index</li> <li>• SPAP</li> </ul>	Good	<ul style="list-style-type: none"> <li>• Participants were at widely differing points in natural history of disease</li> <li>• Participants had widely differing degrees of disease severity</li> <li>• Potential adverse events associated with testing or treatment were not measured or reported</li> </ul>
Shimony, 2012 <sup>140</sup>	<ul style="list-style-type: none"> <li>• Pericardial effusion (prevalent v incident)</li> <li>• Mortality</li> </ul>	Fair	<ul style="list-style-type: none"> <li>• None</li> </ul>
Simeoni, 2008 <sup>49</sup>	<ul style="list-style-type: none"> <li>• BNP</li> </ul>	Good	<ul style="list-style-type: none"> <li>• Participants were at widely differing points in natural history of disease</li> <li>• Participants had widely differing degrees of disease severity</li> <li>• Included patients did not match the review question</li> <li>• Study excluded participants with other conditions that might be easily confused with PAH such as PH due to heart failure, thrombotic disease, COPD</li> <li>• Study included patients with a wide variety of conditions in addition to the target population</li> </ul>
Soon, 2011 <sup>141</sup>	<ul style="list-style-type: none"> <li>• BNP</li> </ul>	Good	<ul style="list-style-type: none"> <li>• Participants were at widely differing points in natural history of disease</li> <li>• Participants had widely differing degrees of disease severity</li> </ul>
Souza, 2007 <sup>142</sup>	<ul style="list-style-type: none"> <li>• BNP</li> <li>• 6MWD (absolute)</li> <li>• Cardiac index</li> <li>• Functional class</li> <li>• RHC-mPAP</li> <li>• RHC-PVR</li> <li>• Right atrial pressure</li> </ul>	Good	<ul style="list-style-type: none"> <li>• None</li> </ul>
Taguchi, 2012 <sup>143</sup>	<ul style="list-style-type: none"> <li>• BNP</li> </ul>	Good	<ul style="list-style-type: none"> <li>• None</li> </ul>
Takatsuki, 2012 <sup>144</sup>	<ul style="list-style-type: none"> <li>• TRJv</li> <li>• RV size</li> <li>• BNP</li> </ul>	Good	<ul style="list-style-type: none"> <li>• None</li> </ul>
Takatsuki, 2012 <sup>145</sup>	<ul style="list-style-type: none"> <li>• BNP</li> </ul>	Good	<ul style="list-style-type: none"> <li>• None</li> </ul>
Takatsuki, 2012 <sup>146</sup>	<ul style="list-style-type: none"> <li>• BNP (BNP and NT-proBNP)</li> <li>• 6MWD</li> <li>• RHC-mPAP</li> <li>• RHC-RAP</li> <li>• RHC-PVRi</li> <li>• RHC-CI</li> <li>• TRJv</li> </ul>	Good	<ul style="list-style-type: none"> <li>• None</li> </ul>
Takeda, 2010 <sup>147</sup>	<ul style="list-style-type: none"> <li>• BNP</li> <li>• Mortality</li> </ul>	Good	<ul style="list-style-type: none"> <li>• None</li> </ul>

Study	Index Tests/Comparators	Quality	Limitations to Applicability
Torbicki, 2003 <sup>148</sup>	<ul style="list-style-type: none"> <li>• FAC</li> <li>• BNP</li> <li>• Pericardial effusion</li> <li>• RA size</li> <li>• Troponin T</li> <li>• Mortality</li> </ul>	Good	<ul style="list-style-type: none"> <li>• None</li> </ul>
Utsunomiya, 2011 <sup>149</sup>	<ul style="list-style-type: none"> <li>• BNP</li> <li>• RA size</li> <li>• RIMP/MPI/Tei Index</li> <li>• Mortality</li> </ul>	Fair	<ul style="list-style-type: none"> <li>• None</li> </ul>
Utsunomiya, 2009 <sup>150</sup>	<ul style="list-style-type: none"> <li>• RA size</li> <li>• Right atrial pressure</li> <li>• RIMP/MPI/Tei Index</li> </ul>	Good	<ul style="list-style-type: none"> <li>• None</li> </ul>
Van Albada, 2008 <sup>151</sup>	<ul style="list-style-type: none"> <li>• Uric acid</li> <li>• Cardiac index</li> <li>• Mortality</li> <li>• RHC-mPAP</li> <li>• RHC-PVR</li> </ul>	Good	<ul style="list-style-type: none"> <li>• Potential adverse events associated with testing or treatment were not measured or reported</li> </ul>
Vizza, 2012 <sup>152</sup>	<ul style="list-style-type: none"> <li>• ET-1</li> <li>• BNP</li> <li>• WHO FC</li> <li>• RHC-mPAP</li> <li>• RHC-CI</li> <li>• RHC-PVR</li> <li>• Clinical worsening</li> </ul>	Good	<ul style="list-style-type: none"> <li>• None</li> </ul>
Vizza, 2008 <sup>153</sup>	<ul style="list-style-type: none"> <li>• Endothelin-1</li> <li>• BNP</li> </ul>	Good	<ul style="list-style-type: none"> <li>• None</li> </ul>
Voelkel, 2000 <sup>154</sup>	<ul style="list-style-type: none"> <li>• Uric acid</li> <li>• RHC-mPAP</li> <li>• Right atrial pressure</li> </ul>	Good	<ul style="list-style-type: none"> <li>• None</li> </ul>
Williams, 2006 <sup>61</sup>	<ul style="list-style-type: none"> <li>• BNP</li> <li>• 10-fold increase from baseline levels</li> </ul>	Fair	<ul style="list-style-type: none"> <li>• None</li> </ul>
Wilkins, 2005 <sup>155</sup>	<ul style="list-style-type: none"> <li>• RV size</li> <li>• Cardiac index</li> <li>• RIMP/MPI/Tei Index</li> <li>• RA size</li> <li>• BNP</li> </ul>	Good	<ul style="list-style-type: none"> <li>• None</li> </ul>
Yamada, 2012 <sup>156</sup>	<ul style="list-style-type: none"> <li>• BNP</li> <li>• Uric acid</li> <li>• Mortality</li> <li>• Hospitalization</li> </ul>	Good	<ul style="list-style-type: none"> <li>• None</li> </ul>

Study	Index Tests/Comparators	Quality	Limitations to Applicability
Yanagisawa, 2012 <sup>157</sup>	• BNP	Good	• None
Yang, 2012 <sup>158</sup>	• RV size • mPAP	Fair	• None
Yoshida, 2012 <sup>159</sup>	• BNP • mPAP	Fair	• None
Zafirir, 2007 <sup>160</sup>	• RA size • RIMP/MPI/Tei Index • RVEF	Good	• None
Zeng, 2011 <sup>161</sup>	• BNP	Good	• None
Zhao, 2012 <sup>162</sup>	• Uric acid • Mortality	Good	• None

Abbreviations: 6MWD=6-minute walk distance; BNP=brain natriuretic peptide; CHF=congestive heart failure; CTEPH=chronic thromboembolic pulmonary hypertension; CVD=collagen vascular disease; DLCO=diffusion capacity of the lung for carbon monoxide; FAC=fractional area change; mPAP=mean pulmonary artery pressure; MPI=myocardial performance index; NT-proBNP=N-terminal pro-B-type natriuretic peptide; NYHA=New York Heart Association; PAH=pulmonary arterial hypertension; PH=pulmonary hypertension; PPH=primary pulmonary hypertension; PVR=pulmonary vascular resistance; RA=right atrium; RHC=right heart catheterization; RIMP=right index of myocardial performance; RV=right ventricle; RVEF=right ventricular ejection fraction; S'=tricuspid lateral annular systolic velocity; sPAP=systolic pulmonary artery pressure; SSs=systemic sclerosis; TAPSE=tricuspid annular plane systolic excursion; TDI=tissue Doppler imaging; TRV=tricuspid regurgitant jet velocity; VSD=ventricular septal defect; VTI<sub>RVOT</sub>=velocity-time integral of right ventricular outflow tract

**Table D-3. Quality and applicability for KQ 3 studies**

Study	Intervention/Comparator	Quality	Limitations to Applicability
Badesch, 2000 <sup>163</sup>	• Epoprostenol $\leq 2$ ng/kg, then adjusted • Conventional therapy only	Fair	• None
Barst, 1996 <sup>65</sup> Primary Pulmonary Hypertension Study	• Epoprostenol $\leq 4$ ng/kg, then adjusted • Conventional therapy only	Good	• None
Barst, 2010 <sup>164</sup> ASSET-1	• Bosentan 62.5 mg BID, then 125 mg BID • Placebo	Fair	• None
Barst, 2010 <sup>164</sup> ASSET-2	• Bosentan 62.5 mg BID, then 125 mg BID • Placebo	Fair	• None
Barst, 2011 <sup>165</sup> STARTS-1	• Low dose sildenafil • Medium dose sildenafil • High dose sildenafil • Placebo	Fair	• None
Bharani, 2007 <sup>69</sup>	• Tadalafil 20 mg daily • Placebo 20 mg daily	Fair	• Intervention (active arm) was not similar to that used in routine clinical practice

Study	Intervention/Comparator	Quality	Limitations to Applicability
Channick, 2001 <sup>75</sup> Badesch, 2002 <sup>76</sup>	<ul style="list-style-type: none"> <li>• Bosentan 62.5 mg BID, then 125 mg BID</li> <li>• Placebo</li> </ul>	Good	<ul style="list-style-type: none"> <li>• Potential adverse events associated with testing or treatment were not measured or reported</li> </ul>
Fix, 2007 <sup>166</sup>	<ul style="list-style-type: none"> <li>• Epoprostenol 1 ng/kg/min, then titrated to mean dose of 29 ng/kg/min</li> <li>• Non-epoprostenol group</li> </ul>	Fair	<ul style="list-style-type: none"> <li>• None</li> </ul>
Galie, 2005 <sup>167</sup> Badesch, 2007 <sup>168</sup> Rubin, 2011 <sup>169</sup>  SUPER	<ul style="list-style-type: none"> <li>• Sildenafil 20 mg TID</li> <li>• Sildenafil 40 mg TID</li> <li>• Sildenafil 80 mg TID</li> <li>• Placebo</li> </ul>	Good	<ul style="list-style-type: none"> <li>• None</li> </ul>
Galie, 2006 <sup>170</sup>  BREATHE-5	<ul style="list-style-type: none"> <li>• Bosentan 62.5 mg BID, then 125 mg BID</li> <li>• Placebo</li> </ul>	Good	<ul style="list-style-type: none"> <li>• None</li> </ul>
Galie, 2008 <sup>171</sup>  EARLY	<ul style="list-style-type: none"> <li>• Bosentan 62.5 mg BID, then 125 mg BID</li> <li>• Placebo</li> </ul>	Good	<ul style="list-style-type: none"> <li>• None</li> </ul>
Galie, 2008 <sup>88</sup> Shapiro, 2012 <sup>90</sup>  ARIES-1	<ul style="list-style-type: none"> <li>• Ambrisentan 5 mg daily</li> <li>• Ambrisentan 10 mg daily</li> <li>• Placebo</li> </ul>	Good	<ul style="list-style-type: none"> <li>• None</li> </ul>
Galie, 2008 <sup>88</sup> Shapiro, 2012 <sup>90</sup>  ARIES-2	<ul style="list-style-type: none"> <li>• Ambrisentan 2.5 mg daily</li> <li>• Ambrisentan 5 mg daily</li> <li>• Placebo</li> </ul>	Good	<ul style="list-style-type: none"> <li>• None</li> </ul>
Galie, 2009 <sup>172</sup> Barst, 2011 <sup>173</sup> Oudiz, 2012 <sup>174</sup>  PHIRST	<ul style="list-style-type: none"> <li>• Tadalafil 2.5 mg daily</li> <li>• Tadalafil 10 mg daily</li> <li>• Tadalafil 20 mg daily</li> <li>• Tadalafil 40 mg daily</li> <li>• Placebo</li> </ul>	Good	<ul style="list-style-type: none"> <li>• None</li> </ul>
Higenbottam, 1993 <sup>175</sup>	<ul style="list-style-type: none"> <li>• Epoprostenol, initial mean dose 5.2 (0.5) ng/kg/min then titrated up to mean 18.7 (4.5) ng/kg/min</li> <li>• No epoprostenol</li> </ul>	Fair	<ul style="list-style-type: none"> <li>• Study population was inadequately described to assess the applicability of this study</li> <li>• Study selectively recruited participants who demonstrated a history of favorable or unfavorable response to the drug/intervention of interest</li> <li>• Included patients did not match the review question</li> <li>• Potential adverse events associated with testing or treatment were not measured or reported</li> </ul>

Study	Intervention/Comparator	Quality	Limitations to Applicability
Hiremath, 2010 <sup>176</sup> TRUST	<ul style="list-style-type: none"> <li>Treprostinil 4 ng/kg/min, then adjusted</li> <li>Placebo</li> </ul>	Fair	<ul style="list-style-type: none"> <li>Study population was inadequately described to assess the applicability of this study</li> <li>Cointerventions/treatments did not adequately reflect routine clinical practice</li> <li>Care delivery setting was widely divergent from the current typical US setting</li> </ul>
Hoeper, 2006 <sup>177</sup> COMBI	<ul style="list-style-type: none"> <li>Bosentan 125 mg BID + iloprost (aerosolized)</li> <li>Bosentan 125 mg</li> </ul>	Fair	<ul style="list-style-type: none"> <li>None</li> </ul>
Hoeper, 2007 <sup>178</sup>	<ul style="list-style-type: none"> <li>Bosentan 62.5 mg BID x 4 weeks, then 125 mg thereafter</li> <li>Iloprost (aerosolized) 5 mcg 6x daily</li> </ul>	Fair	<ul style="list-style-type: none"> <li>None</li> </ul>
Humbert, 2004 <sup>179</sup> BREATHE-2	<ul style="list-style-type: none"> <li>Epoprostenol + bosentan 62.5 mg BID, then 125 mg BID</li> <li>Epoprostenol + placebo</li> </ul>	Good	<ul style="list-style-type: none"> <li>None</li> </ul>
Jacobs, 2009 <sup>106</sup>	<ul style="list-style-type: none"> <li>Epoprostenol titrated to 6-8 ng/kg/min after 1 week (N=6)</li> <li>Treprostinil gradually increased to 10 ng/kg/min after 1 week, then 20 ng/kg/min after 6 weeks (N=10)</li> </ul>	Fair	<ul style="list-style-type: none"> <li>None</li> </ul>
Jing, 2011 <sup>180</sup> EVALUATION	<ul style="list-style-type: none"> <li>Vardenafil 5 mg qD, then 5 mg BID</li> <li>Placebo</li> </ul>	Good	<ul style="list-style-type: none"> <li>None</li> </ul>
Kemp, 2012 <sup>181</sup>	<ul style="list-style-type: none"> <li>Epoprostenol/bosentan combined</li> <li>Epoprostenol monotherapy</li> </ul>	Fair	<ul style="list-style-type: none"> <li>None</li> </ul>
McLaughlin, 2003 <sup>182</sup>	<ul style="list-style-type: none"> <li>Treprostinil 2.5-5.0 ng/kg/min, then adjusted</li> <li>Placebo</li> </ul>	Poor	<ul style="list-style-type: none"> <li>None</li> </ul>
McLaughlin, 2006 <sup>183</sup>	<ul style="list-style-type: none"> <li>Bosentan + iloprost (aerosolized)</li> <li>Bosentan + placebo</li> </ul>	Good	<ul style="list-style-type: none"> <li>None</li> </ul>
McLaughlin, 2010 <sup>119</sup> Frantz, 2012 <sup>120</sup> TRIUMPH 1	<ul style="list-style-type: none"> <li>Treprostinil (aerosolized)</li> <li>Placebo</li> </ul>	Good	<ul style="list-style-type: none"> <li>None</li> </ul>
Mukhopadhyay, 2011 <sup>184</sup>	<ul style="list-style-type: none"> <li>Tadalafil 40 mg daily</li> <li>Placebo</li> </ul>	Fair	<ul style="list-style-type: none"> <li>Care delivery setting was widely divergent from the current typical US setting</li> </ul>
Olschewski, 2002 <sup>185</sup>	<ul style="list-style-type: none"> <li>Iloprost (aerosolized)</li> <li>Placebo</li> </ul>	Good	<ul style="list-style-type: none"> <li>None</li> </ul>
Olschewski, 2010 <sup>186</sup> AIR	<ul style="list-style-type: none"> <li>Iloprost (aerosolized)</li> <li>Standard therapy only</li> </ul>	Fair	<ul style="list-style-type: none"> <li>None</li> </ul>

Study	Intervention/Comparator	Quality	Limitations to Applicability
Reichenberger, 2011 <sup>187</sup>	<ul style="list-style-type: none"> <li>• Epoprostenol</li> <li>• Iloprost up to 20 mcg per breath, max 120 mcg total daily dose</li> </ul>	Fair	<ul style="list-style-type: none"> <li>• None</li> </ul>
Rich, 2012 <sup>188</sup>	<ul style="list-style-type: none"> <li>• IV treprostinil in epoprostenol diluent</li> <li>• IV epoprostenol in epoprostenol diluent</li> <li>• IV treprostinil in native diluent</li> </ul>	Fair	<ul style="list-style-type: none"> <li>• Participants had widely differing degrees of disease severity</li> <li>• Study selectively recruited participants who demonstrated a history of favorable or unfavorable response to the drug/intervention of interest</li> </ul>
Rubin, 2002 <sup>189</sup> Galie, 2003 <sup>190</sup> Denton, 2006 <sup>191</sup>  BREATHE	<ul style="list-style-type: none"> <li>• Bosentan 62.5 mg BID, then 125 mg BID</li> <li>• Bosentan 62.5 mg BID, then 250 mg BID</li> <li>• Placebo</li> </ul>	Good	<ul style="list-style-type: none"> <li>• None</li> </ul>
Rubin, 1990 <sup>192</sup> Barst, 1994 <sup>193</sup>	<ul style="list-style-type: none"> <li>• Intravenous epoprostenol 1–2 ng/kg per minute initially, then increased as tolerated</li> <li>• Conventional therapy</li> </ul>	Good	<ul style="list-style-type: none"> <li>• Study selectively recruited participants who demonstrated a history of favorable or unfavorable response to the drug/intervention of interest</li> <li>• Current methods for treatment of the disease have changed since the study took place</li> </ul>
Sastry, 2007 <sup>194</sup>	<ul style="list-style-type: none"> <li>• Sildenafil 25-50 mg TID</li> <li>• Conventional therapy</li> </ul>	Fair	<ul style="list-style-type: none"> <li>• None</li> </ul>
Simonneau, 2002 <sup>195</sup>  Treprostinil Study	<ul style="list-style-type: none"> <li>• Treprostinil 1.25 ng/kg/min, then adjusted</li> <li>• Placebo</li> </ul>	Good	<ul style="list-style-type: none"> <li>• None</li> </ul>
Simonneau, 2008 <sup>196</sup>  PACES	<ul style="list-style-type: none"> <li>• Sildenafil 20 mg TID, then up to 80 mg TID</li> <li>• Placebo</li> </ul>	Good	<ul style="list-style-type: none"> <li>• None</li> </ul>
Wilkins, 2005 <sup>155</sup>  SERAPH	<ul style="list-style-type: none"> <li>• Bosentan 62.5 mg BID, then 125 mg BID</li> <li>• Sildenafil 50 mg BID, then 50 mg TID</li> </ul>	Good	<ul style="list-style-type: none"> <li>• None</li> </ul>
Zeng, 2011 <sup>197</sup>	<ul style="list-style-type: none"> <li>• Sildenafil</li> <li>• Conventional therapy</li> </ul>	Fair	<ul style="list-style-type: none"> <li>• None</li> </ul>

Abbreviations: BID=twice daily; kg=kilogram; mcg=microgram; mg=milligram; ng=nanogram; TID=three times daily

## References Cited in Appendix D

1. Ajami GH, Cheriki S, Amoozgar H, et al. Accuracy of doppler-derived estimation of pulmonary vascular resistance in congenital heart disease: An index of operability. *Pediatr Cardiol.* 2011;32(8):1168-1174. PMID: 21779967.
2. Allanore Y, Borderie D, Avouac J, et al. High N-terminal pro-brain natriuretic peptide levels and low diffusing capacity for carbon monoxide as independent predictors of the occurrence of precapillary pulmonary arterial hypertension in patients with systemic sclerosis. *Arthritis Rheum.* 2008;58(1):284-91. PMID: 18163505.
3. Arcasoy SM, Christie JD, Ferrari VA, et al. Echocardiographic assessment of pulmonary hypertension in patients with advanced lung disease. *Am J Respir Crit Care Med.* 2003;167(5):735-40. PMID: 12480614.
4. Bogdan M, Humbert M, Francoual J, et al. Urinary cGMP concentrations in severe primary pulmonary hypertension. *Thorax.* 1998;53(12):1059-62. PMID: 10195079.
5. Bonderman D, Wexberg P, Martischniq AM, et al. A noninvasive algorithm to exclude pre-capillary pulmonary hypertension. *Eur Respir J.* 2011;37(5):1096-103. PMID: 20693249.
6. Cavagna L, Caporali R, Klersy C, et al. Comparison of brain natriuretic peptide (BNP) and NT-proBNP in screening for pulmonary arterial hypertension in patients with systemic sclerosis. *J Rheumatol.* 2010;37(10):2064-70. PMID: 20634241.
7. Cevik A, Kula S, Olgunturk R, et al. Quantitative Evaluation of Right Ventricle Function by Transthoracic Echocardiography in Childhood Congenital Heart Disease Patients with Pulmonary Hypertension. *Echocardiography.* 2012. PMID: 22494051.
8. Ciurzynski M, Bienias P, Irzyk K, et al. Usefulness of echocardiography in the identification of an excessive increase in pulmonary arterial pressure in patients with systemic sclerosis. *Kardiol Pol.* 2011;69(1):9-15. PMID: 21267956.
9. Colle IO, Moreau R, Godinho E, et al. Diagnosis of portopulmonary hypertension in candidates for liver transplantation: a prospective study. *Hepatology.* 2003;37(2):401-9. PMID: 12540791.
10. Condliffe R, Radon M, Hurdman J, et al. CT pulmonary angiography combined with echocardiography in suspected systemic sclerosis-associated pulmonary arterial hypertension. *Rheumatology (Oxford).* 2011;50(8):1480-6. PMID: 21447566.
11. Dahiya A, Vollbon W, Jellis C, et al. Echocardiographic assessment of raised pulmonary vascular resistance: application to diagnosis and follow-up of pulmonary hypertension. *Heart.* 2010;96(24):2005-9. PMID: 21088122.
12. Denton CP, Cailes JB, Phillips GD, et al. Comparison of Doppler echocardiography and right heart catheterization to assess pulmonary hypertension in systemic sclerosis. *Br J Rheumatol.* 1997;36(2):239-43. PMID: 9133938.
13. Farber HW, Foreman AJ, Miller DP, et al. REVEAL Registry: correlation of right heart catheterization and echocardiography in patients with pulmonary arterial hypertension. *Congest Heart Fail.* 2011;17(2):56-64. PMID: 21449993.
14. Fisher MR, Forfia PR, Chamera E, et al. Accuracy of Doppler echocardiography in the hemodynamic assessment of pulmonary hypertension. *Am J Respir Crit Care Med.* 2009;179(7):615-21. PMID: 19164700.
15. Fitzgerald M, Fagan K, Herbert DE, et al. Misclassification of pulmonary hypertension in adults with sickle hemoglobinopathies using doppler echocardiography. *South Med J.* 2012;105(6):300-305. PMID: 22665152.
16. Fonseca GH, Souza R, Salemi VM, et al. Pulmonary hypertension diagnosed by right heart catheterization in sickle cell disease. *Eur Respir J.* 2011. PMID: 21778170.
17. Frea S, Capriolo M, Marra WG, et al. Echo Doppler predictors of pulmonary artery hypertension in patients with systemic sclerosis. *Echocardiography.* 2011;28(8):860-9. PMID: 21906161.

18. Fukuda Y, Tanaka H, Sugiyama D, et al. Utility of right ventricular free wall speckle-tracking strain for evaluation of right ventricular performance in patients with pulmonary hypertension. *J Am Soc Echocardiogr.* 2011;24(10):1101-1108. PMID: 21775102.
19. Ghio S, Matteo AD, Scelsi L, et al. Plasma brain natriuretic peptide is a marker of right ventricular overload in pulmonary hypertension associated to HIV infection. *Eur Heart J Suppl.* 2004;6(6):F35-F39.
20. Gialafos EJ, Moyssakis I, Psaltopoulou T, et al. Circulating tissue inhibitor of matrix metalloproteinase-4 (TIMP-4) in systemic sclerosis patients with elevated pulmonary arterial pressure. *Mediators Inflamm.* 2008;2008.
21. Hachulla E, Gressin V, Guillemin L, et al. Early detection of pulmonary arterial hypertension in systemic sclerosis: a French nationwide prospective multicenter study. *Arthritis Rheum.* 2005;52(12):3792-800. PMID: 16320330.
22. Hammerstingl C, Schueler R, Bors L, et al. Diagnostic value of echocardiography in the diagnosis of pulmonary hypertension. *PLoS ONE.* 2012;7(6). PMID: 22685577.
23. Hsu VM, Moreyra AE, Wilson AC, et al. Assessment of pulmonary arterial hypertension in patients with systemic sclerosis: comparison of noninvasive tests with results of right-heart catheterization. *J Rheumatol.* 2008;35(3):458-65. PMID: 18203320.
24. Hua R, Sun YW, Wu ZY, et al. Role of 2-dimensional Doppler echo-cardiography in screening portopulmonary hypertension in portal hypertension patients. *Hepatobiliary Pancreat Dis Int.* 2009;8(2):157-61. PMID: 19357029.
25. Jansa P, Becvar R, Ambroz D, et al. Pulmonary arterial hypertension associated with systemic sclerosis in the Czech Republic. *Clin Rheumatol.* 2012;31(3):557-61. PMID: 22105781.
26. Kovacs G, Maier R, Aberer E, et al. Assessment of pulmonary arterial pressure during exercise in collagen vascular disease: echocardiography vs right-sided heart catheterization. *Chest.* 2010;138(2):270-8. PMID: 20418368.
27. Lindqvist P, Soderberg S, Gonzalez MC, et al. Echocardiography based estimation of pulmonary vascular resistance in patients with pulmonary hypertension: a simultaneous Doppler echocardiography and cardiac catheterization study. *Eur J Echocardiogr.* 2011;12(12):961-6. PMID: 22011836.
28. Low AJ, Fowler D, Manghani MK, et al. Screening and Treating Pulmonary Arterial Hypertension in a Tertiary Hospital -based Multidisciplinary Clinic - The First 200 Patients. *Intern Med J.* 2011. PMID: 22032309.
29. Machado RF, Anthi A, Steinberg MH, et al. N-terminal pro-brain natriuretic peptide levels and risk of death in sickle cell disease. *JAMA.* 2006;296(3):310-8. PMID: 16849664.
30. McLean AS, Ting I, Huang SJ, et al. The use of the right ventricular diameter and tricuspid annular tissue Doppler velocity parameter to predict the presence of pulmonary hypertension. *Eur J Echocardiogr.* 2007;8(2):128-36. PMID: 16672193.
31. Mourani PM, Sontag MK, Younoszai A, et al. Clinical utility of echocardiography for the diagnosis and management of pulmonary vascular disease in young children with chronic lung disease. *Pediatrics.* 2008;121(2):317-25. PMID: 18245423.
32. Mukerjee D, St George D, Knight C, et al. Echocardiography and pulmonary function as screening tests for pulmonary arterial hypertension in systemic sclerosis. *Rheumatology (Oxford).* 2004;43(4):461-6. PMID: 15024134.
33. Murata I, Takenaka K, Yoshinoya S, et al. Clinical evaluation of pulmonary hypertension in systemic sclerosis and related disorders. A Doppler echocardiographic study of 135 Japanese patients. *Chest.* 1997;111(1):36-43. PMID: 8995990.
34. Nakayama Y, Sugimachi M, Nakanishi N, et al. Noninvasive differential diagnosis between chronic pulmonary thromboembolism and primary pulmonary hypertension by means of Doppler ultrasound measurement. *J Am Coll Cardiol.* 1998;31(6):1367-71. PMID: 9581735.



35. Nogami M, Ohno Y, Koyama H, et al. Utility of phase contrast MR imaging for assessment of pulmonary flow and pressure estimation in patients with pulmonary hypertension: comparison with right heart catheterization and echocardiography. *J Magn Reson Imaging*. 2009;30(5):973-80. PMID: 19856412.
36. Phung S, Strange G, Chung LP, et al. Prevalence of pulmonary arterial hypertension in an Australian scleroderma population: screening allows for earlier diagnosis. *Intern Med J*. 2009;39(10):682-91. PMID: 19220532.
37. Pilatis ND, Jacobs LE, Rerkpattanapipat P, et al. Clinical predictors of pulmonary hypertension in patients undergoing liver transplant evaluation. *Liver Transpl*. 2000;6(1):85-91. PMID: 10648583.
38. Rajagopalan N, Simon MA, Suffoletto MS, et al. Noninvasive estimation of pulmonary vascular resistance in pulmonary hypertension. *Echocardiography*. 2009;26(5):489-94. PMID: 19054039.
39. Rajagopalan N, Saxena N, Simon MA, et al. Correlation of tricuspid annular velocities with invasive hemodynamics in pulmonary hypertension. *Congest Heart Fail*. 2007;13(4):200-4. PMID: 17673871.
40. Rajaram S, Swift AJ, Capener D, et al. Comparison of the diagnostic utility of cardiac magnetic resonance imaging, computed tomography, and echocardiography in assessment of suspected pulmonary arterial hypertension in patients with connective tissue disease. *J Rheumatol*. 2012;39(6):1265-1274. PMID: 22589263.
41. Rich JD, Shah SJ, Swamy RS, et al. Inaccuracy of Doppler echocardiographic estimates of pulmonary artery pressures in patients with pulmonary hypertension: implications for clinical practice. *Chest*. 2011;139(5):988-93. PMID: 20864617.
42. Roeleveld RJ, Marcus JT, Boonstra A, et al. A comparison of noninvasive MRI-based methods of estimating pulmonary artery pressure in pulmonary hypertension. *J Magn Reson Imaging*. 2005;22(1):67-72. PMID: 15971176.
43. Roule V, Labombarda F, Pellissier A, et al. Echocardiographic assessment of pulmonary vascular resistance in pulmonary arterial hypertension. *Cardiovasc Ultrasound*. 2010;8:21. PMID: 20529278.
44. Ruan Q, Nagueh SF. Clinical application of tissue Doppler imaging in patients with idiopathic pulmonary hypertension. *Chest*. 2007;131(2):395-401. PMID: 17296639.
45. Ruiz-Irastorza G, Garmendia M, Villar I, et al. Pulmonary hypertension in systemic lupus erythematosus: prevalence, predictors and diagnostic strategy. *Autoimmunity Reviews*. 2012. PMID: 22841984.
46. Sanli C, Oguz D, Olgunturk R, et al. Elevated Homocysteine and Asymmetric Dimethyl Arginine Levels in Pulmonary Hypertension Associated With Congenital Heart Disease. *Pediatr Cardiol*. 2012;1-9. PMID: 22526220.
47. Selby VN, Scherzer R, Barnett CF, et al. Doppler echocardiography does not accurately estimate pulmonary artery systolic pressure in HIV-infected patients. *AIDS*. 2012. PMID: 22781217.
48. Selimovic N, Rundqvist B, Bergh CH, et al. Assessment of pulmonary vascular resistance by Doppler echocardiography in patients with pulmonary arterial hypertension. *J Heart Lung Transplant*. 2007;26(9):927-34. PMID: 17845932.
49. Simeoni S, Lippi G, Puccetti A, et al. N-terminal pro-BNP in sclerodermic patients on bosentan therapy for PAH. *Rheumatol Int*. 2008;28(7):657-60. PMID: 18092166.
50. Steen V, Chou M, Shanmugam V, et al. Exercise-induced pulmonary arterial hypertension in patients with systemic sclerosis. *Chest*. 2008;134(1):146-51. PMID: 18403670.
51. Takatsuki S, Nakayama T, Jone PN, et al. Tissue Doppler Imaging Predicts Adverse Outcome in Children with Idiopathic Pulmonary Arterial Hypertension. *J Pediatr*. 2012. PMID: 33748515.
52. Tei C, Dujardin KS, Hodge DO, et al. Doppler echocardiographic index for assessment of global right ventricular function. *J Am Soc Echocardiogr*. 1996;9(6):838-47. PMID: 8943444.

53. Tian Z, Liu YT, Fang Q, et al. Hemodynamic parameters obtained by transthoracic echocardiography and right heart catheterization: a comparative study in patients with pulmonary hypertension. *Chin Med J (Engl)*. 2011;124(12):1796-801. PMID: 21740835.
54. Thakkar V, Stevens WM, Prior D, et al. N-terminal pro-brain natriuretic peptide in a novel screening algorithm for pulmonary arterial hypertension in systemic sclerosis: A case-control study. *Arthritis Research and Therapy*. 2012;14(3). PMID: 22691291.
55. Torregrosa M, Genesca J, Gonzalez A, et al. Role of Doppler echocardiography in the assessment of portopulmonary hypertension in liver transplantation candidates. *Transplantation*. 2001;71(4):572-4. PMID: 11258439.
56. Toyono M, Harada K, Tamura M, et al. Paradoxical relationship between B-type natriuretic peptide and pulmonary vascular resistance in patients with ventricular septal defect and concomitant severe pulmonary hypertension. *Pediatr Cardiol*. 2008;29(1):65-9. PMID: 17786380.
57. Tutar HE, Imamoglu A, Atalay S, et al. Plasma endothelin-1 levels in patients with left-to-right shunt with or without pulmonary hypertension. *Int J Cardiol*. 1999;70(1):57-62. PMID: 10402046.
58. Vlahos AP, Feinstein JA, Schiller NB, et al. Extension of Doppler-derived echocardiographic measures of pulmonary vascular resistance to patients with moderate or severe pulmonary vascular disease. *J Am Soc Echocardiogr*. 2008;21(6):711-4. PMID: 18187297.
59. Vonk MC, Sander MH, van den Hoogen FH, et al. Right ventricle Tei-index: a tool to increase the accuracy of non-invasive detection of pulmonary arterial hypertension in connective tissue diseases. *Eur J Echocardiogr*. 2007;8(5):317-21. PMID: 16846757.
60. Willens HJ, Chirinos JA, Gomez-Marin O, et al. Noninvasive differentiation of pulmonary arterial and venous hypertension using conventional and Doppler tissue imaging echocardiography. *J Am Soc Echocardiogr*. 2008;21(6):715-9. PMID: 18325734.
61. Williams MH, Handler CE, Akram R, et al. Role of N-terminal brain natriuretic peptide (N-TproBNP) in scleroderma-associated pulmonary arterial hypertension. *Eur Heart J*. 2006;27(12):1485-94. PMID: 16682379.
62. Andreassen AK, Wergeland R, Simonsen S, et al. N-terminal pro-B-type natriuretic peptide as an indicator of disease severity in a heterogeneous group of patients with chronic precapillary pulmonary hypertension. *Am J Cardiol*. 2006;98(4):525-9. PMID: 16893710.
63. Badesch DB, Feldman J, Keogh A, et al. ARIES-3: ambrisentan therapy in a diverse population of patients with pulmonary hypertension. *Cardiovasc Ther*. 2012;30(2):93-9. PMID: 21884013.
64. Badesch DB, Feldman J, Keogh A, et al. ARIES-3: Ambrisentan Therapy in a Diverse Population of Patients with Pulmonary Hypertension. *Cardiovasc Ther*. 2011. PMID: 21884013.
65. Barst RJ, Rubin LJ, Long WA, et al. A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension. The Primary Pulmonary Hypertension Study Group. *N Engl J Med*. 1996;334(5):296-302. PMID: 8532025.
66. Bendayan D, Shitrit D, Ygla M, et al. Hyperuricemia as a prognostic factor in pulmonary arterial hypertension. *Respir Med*. 2003;97(2):130-3. PMID: 12587962.
67. Benza RL, Miller DP, Gomberg-Maitland M, et al. Predicting survival in pulmonary arterial hypertension: insights from the Registry to Evaluate Early and Long-Term Pulmonary Arterial Hypertension Disease Management (REVEAL). *Circulation*. 2010;122(2):164-72. PMID: 20585012.
68. Bernus A, Wagner BD, Accurso F, et al. Brain natriuretic peptide levels in managing pediatric patients with pulmonary arterial hypertension. *Chest*. 2009;135(3):745-51. PMID: 18849405.
69. Bharani A, Patel A, Saraf J, et al. Efficacy and safety of PDE-5 inhibitor tadalafil in pulmonary arterial hypertension. *Indian Heart J*. 2007;59(4):323-8. PMID: 19126937.

70. Borges AC, Knebel F, Eddicks S, et al. Right ventricular function assessed by two-dimensional strain and tissue Doppler echocardiography in patients with pulmonary arterial hypertension and effect of vasodilator therapy. *Am J Cardiol.* 2006;98(4):530-4. PMID: 16893711.
71. Brierre G, Blot-Souletie N, Degano B, et al. New echocardiographic prognostic factors for mortality in pulmonary arterial hypertension. *Eur J Echocardiogr.* 2010;11(6):516-22. PMID: 20185528.
72. Bustamante-Labarta M, Perrone S, De La Fuente RL, et al. Right atrial size and tricuspid regurgitation severity predict mortality or transplantation in primary pulmonary hypertension. *J Am Soc Echocardiogr.* 2002;15(10 Pt 2):1160-4. PMID: 12411899.
73. Campana C, Pasotti M, Monti L, et al. The evaluation of right ventricular performance in different clinical models of heart failure. *Eur Heart J Suppl.* 2004;6(6):F61-F67.
74. Cella G, Vianello F, Cozzi F, et al. Effect of bosentan on plasma markers of endothelial cell activity in patients with secondary pulmonary hypertension related to connective tissue diseases. *J Rheumatol.* 2009;36(4):760-7. PMID: 19208592.
75. Channick RN, Simonneau G, Sitbon O, et al. Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: a randomised placebo-controlled study. *Lancet.* 2001;358(9288):1119-23. PMID: 11597664.
76. Badesch DB, Bodin F, Channick RN, et al. Complete results of the first randomized, placebo-controlled study of bosentan, a dual endothelin receptor antagonist, in pulmonary arterial hypertension. *Curr Ther Res Clin Exp.* 2002;63(4):227-246.
77. Chin KM, Channick RN, Kim NH, et al. Central venous blood oxygen saturation monitoring in patients with chronic pulmonary arterial hypertension treated with continuous IV epoprostenol: correlation with measurements of hemodynamics and plasma brain natriuretic peptide levels. *Chest.* 2007;132(3):786-92. PMID: 17646224.
78. Dimitroulas T, Giannakoulas G, Karvounis H, et al. N-terminal probrain natriuretic peptide as a biochemical marker in the evaluation of bosentan treatment in systemic-sclerosis-related pulmonary arterial hypertension. *Clin Rheumatol.* 2008;27(5):655-8. PMID: 18204995.
79. D'Alto M, Romeo E, Argiento P, et al. Bosentan-sildenafil association in patients with congenital heart disease-related pulmonary arterial hypertension and Eisenmenger physiology. *Int J Cardiol.* 2010. PMID: 21081251.
80. Dyer KL, Pauliks LB, Das B, et al. Use of myocardial performance index in pediatric patients with idiopathic pulmonary arterial hypertension. *J Am Soc Echocardiogr.* 2006;19(1):21-7. PMID: 16423665.
81. Elstein D, Nir A, Klutstein M, et al. N-brain natriuretic peptide: correlation with tricuspid insufficiency in Gaucher disease. *Pulm Pharmacol Ther.* 2004;17(5):319-23. PMID: 15477128.
82. Fahmy Elnoamany M, Abdelraouf Dawood A. Right ventricular myocardial isovolumic relaxation time as novel method for evaluation of pulmonary hypertension: correlation with endothelin-1 levels. *J Am Soc Echocardiogr.* 2007;20(5):462-9. PMID: 17484984.
83. Feliciano J, Cacula D, Agapito A, et al. Selective pulmonary vasodilators for severe pulmonary hypertension: comparison between endpoints. *Rev Port Cardiol.* 2005;24(3):399-404. PMID: 15929623.
84. Fijalkowska A, Kurzyna M, Torbicki A, et al. Serum N-terminal brain natriuretic peptide as a prognostic parameter in patients with pulmonary hypertension. *Chest.* 2006;129(5):1313-21. PMID: 16685024.
85. Filusch A, Giannitsis E, Katus HA, et al. High-sensitive troponin T: a novel biomarker for prognosis and disease severity in patients with pulmonary arterial hypertension. *Clin Sci (Lond).* 2010;119(5):207-13. PMID: 20412051.
86. Forfia PR, Fisher MR, Mathai SC, et al. Tricuspid annular displacement predicts survival in pulmonary hypertension. *Am J Respir Crit Care Med.* 2006;174(9):1034-41. PMID: 16888289.

87. Friedberg MK, Feinstein JA, Rosenthal DN. A novel echocardiographic Doppler method for estimation of pulmonary arterial pressures. *J Am Soc Echocardiogr*. 2006;19(5):559-62. PMID: 16644441.
88. Galie N, Olschewski H, Oudiz RJ, et al. Ambrisentan for the treatment of pulmonary arterial hypertension: results of the ambrisentan in pulmonary arterial hypertension, randomized, double-blind, placebo-controlled, multicenter, efficacy (ARIES) study 1 and 2. *Circulation*. 2008;117(23):3010-9. PMID: 18506008.
89. Oudiz RJ, Galie N, Olschewski H, et al. Long-term ambrisentan therapy for the treatment of pulmonary arterial hypertension. *J Am Coll Cardiol*. 2009;54(21):1971-81. PMID: 19909879.
90. Shapiro S, Pollock DM, Gillies H, et al. Frequency of Edema in Patients With Pulmonary Arterial Hypertension Receiving Ambrisentan. *Am J Cardiol*. 2012. PMID: 22858181.
91. Gan CT, McCann GP, Marcus JT, et al. NT-proBNP reflects right ventricular structure and function in pulmonary hypertension. *Eur Respir J*. 2006;28(6):1190-4. PMID: 16971413.
92. Ghio S, Klersy C, Magrini G, et al. Prognostic relevance of the echocardiographic assessment of right ventricular function in patients with idiopathic pulmonary arterial hypertension. *Int J Cardiol*. 2010;140(3):272-8. PMID: 19070379.
93. Ghofrani HA, Wiedemann R, Rose F, et al. Lung cGMP release subsequent to NO inhalation in pulmonary hypertension: responders versus nonresponders. *Eur Respir J*. 2002;19(4):664-71. PMID: 11998996.
94. Goto K, Arai M, Watanabe A, et al. Utility of echocardiography versus BNP level for the prediction of pulmonary arterial pressure in patients with pulmonary arterial hypertension. *Int Heart J*. 2010;51(5):343-7. PMID: 20966607.
95. Grapsa I, Pavlopoulos H, Dawson D, et al. Retrospective study of pulmonary hypertensive patients: is right ventricular myocardial performance index a vital prognostic factor? *Hellenic J Cardiol*. 2007;48(3):152-60. PMID: 17629178.
96. Grubstein A, Benjaminov O, Dayan DB, et al. Computed tomography angiography in pulmonary hypertension. *Isr Med Assoc J*. 2008;10(2):117-20. PMID: 18432023.
97. Haddad F, Zamanian R, Beraud AS, et al. A novel non-invasive method of estimating pulmonary vascular resistance in patients with pulmonary arterial hypertension. *J Am Soc Echocardiogr*. 2009;22(5):523-9. PMID: 19307098.
98. Halank M, Knudsen L, Seyfarth HJ, et al. Ambrisentan improves exercise capacity and symptoms in patients with portopulmonary hypertension. *Z Gastroenterol*. 2011;49(9):1258-62. PMID: 21887662.
99. Hampole CV, Mehrotra AK, Thenappan T, et al. Usefulness of red cell distribution width as a prognostic marker in pulmonary hypertension. *Am J Cardiol*. 2009;104(6):868-72. PMID: 19733726.
100. Heresi GA, Tang WH, Aytekin M, et al. Sensitive cardiac troponin I predicts poor outcomes in pulmonary arterial hypertension. *Eur Respir J*. 2012;39(4):939-44. PMID: 21885398.
101. Heresi GA, Aytekin M, Newman J, et al. CXC-chemokine ligand 10 in idiopathic pulmonary arterial hypertension: marker of improved survival. *Lung*. 2010;188(3):191-7. PMID: 20186422.
102. Hinderliter AL, Willis PWt, Barst RJ, et al. Effects of long-term infusion of prostacyclin (epoprostenol) on echocardiographic measures of right ventricular structure and function in primary pulmonary hypertension. Primary Pulmonary Hypertension Study Group. *Circulation*. 1997;95(6):1479-86. PMID: 9118516.
103. Hiramoto Y, Shioyama W, Higuchi K, et al. Clinical significance of plasma endothelin-1 level after bosentan administration in pulmonary arterial hypertension. *J Cardiol*. 2009;53(3):374-80. PMID: 19477379.

104. Ho WJ, Hsu TS, Tsay PK, et al. Serial plasma brain natriuretic peptide testing in clinical management of pulmonary arterial hypertension. *Acta Cardiol Sin.* 2009;25(3):147-153.
105. Homma A, Anzueto A, Peters JJ, et al. Pulmonary artery systolic pressures estimated by echocardiogram vs cardiac catheterization in patients awaiting lung transplantation. *J Heart Lung Transplant.* 2001;20(8):833-9. PMID: 11502405.
106. Jacobs W, Boonstra A, Marcus JT, et al. Addition of prostanoids in pulmonary hypertension deteriorating on oral therapy. *J Heart Lung Transplant.* 2009;28(3):280-4. PMID: 19285621.
107. Kaya MG, Lam YY, Erer B, et al. Long-term effect of bosentan therapy on cardiac function and symptomatic benefits in adult patients with Eisenmenger syndrome. *J Card Fail.* 2012;18(5):379-384. PMID: 22555267.
108. Keogh A, Strange G, Kotlyar E, et al. Survival after the initiation of combination therapy in patients with pulmonary arterial hypertension: an Australian collaborative report. *Intern Med J.* 2011;41(3):235-44. PMID: 21118410.
109. Knirsch W, Hausermann E, Fasnacht M, et al. Plasma B-type natriuretic peptide levels in children with heart disease. *Acta Paediatr Int J Paediatr.* 2011;100(9):1213-1216.
110. Kopeck G, Tyrka A, Miszalski-Jamka T, et al. Changes in Exercise Capacity and Cardiac Performance in a Series of Patients with Eisenmenger's Syndrome Transitioned from Selective to Dual Endothelin Receptor Antagonist. *Heart Lung and Circulation.* 2012. PMID: 22819097.
111. Lammers AE, Hislop AA, Haworth SG. Prognostic value of B-type natriuretic peptide in children with pulmonary hypertension. *Int J Cardiol.* 2009;135(1):21-6. PMID: 18599134.
112. Langleben D, Barst RJ, Badesch D, et al. Continuous infusion of epoprostenol improves the net balance between pulmonary endothelin-1 clearance and release in primary pulmonary hypertension. *Circulation.* 1999;99(25):3266-71. PMID: 10385501.
113. Leuchte HH, Holzapfel M, Baumgartner RA, et al. Characterization of brain natriuretic peptide in long-term follow-up of pulmonary arterial hypertension. *Chest.* 2005;128(4):2368-74. PMID: 16236896.
114. Lorenzen JM, Nickel N, Kramer R, et al. Osteopontin in patients with idiopathic pulmonary hypertension. *Chest.* 2011;139(5):1010-7. PMID: 20947652.
115. Machado RF, Londhe Nerkar MV, Dweik RA, et al. Nitric oxide and pulmonary arterial pressures in pulmonary hypertension. *Free Radic Biol Med.* 2004;37(7):1010-7. PMID: 15336317.
116. Mahapatra S, Nishimura RA, Oh JK, et al. The prognostic value of pulmonary vascular capacitance determined by Doppler echocardiography in patients with pulmonary arterial hypertension. *J Am Soc Echocardiogr.* 2006;19(8):1045-50. PMID: 16880101.
117. Mathai SC, Sibley CT, Forfia PR, et al. Tricuspid annular plane systolic excursion is a robust outcome measure in systemic sclerosis-associated pulmonary arterial hypertension. *J Rheumatol.* 2011;38(11):2410-8. PMID: 21965638.
118. Mauritz GJ, Rizopoulos D, Groepenhoff H, et al. Usefulness of serial N-terminal ProB-type natriuretic peptide measurements for determining prognosis in patients with pulmonary arterial hypertension. *Am J Cardiol.* 2011;108(11):1645-1650. PMID: 21890089.
119. McLaughlin VV, Benza RL, Rubin LJ, et al. Addition of inhaled treprostinil to oral therapy for pulmonary arterial hypertension: a randomized controlled clinical trial. *J Am Coll Cardiol.* 2010;55(18):1915-22. PMID: 20430262.
120. Frantz RP, McDevitt S, Walker S. Baseline NT-proBNP correlates with change in 6-minute walk distance in patients with pulmonary arterial hypertension in the pivotal inhaled treprostinil study TRIUMPH-1. *J Heart Lung Transplant.* 2012;31(8):811-816. PMID: 22759797.

121. Michelakis E, Tymchak W, Lien D, et al. Oral sildenafil is an effective and specific pulmonary vasodilator in patients with pulmonary arterial hypertension: comparison with inhaled nitric oxide. *Circulation*. 2002;105(20):2398-403. PMID: 12021227.
122. Minniti CP, Machado RF, Coles WA, et al. Endothelin receptor antagonists for pulmonary hypertension in adult patients with sickle cell disease. *Br J Haematol*. 2009;147(5):737-43. PMID: 19775299.
123. Montani D, Souza R, Binkert C, et al. Endothelin-1/endothelin-3 ratio: a potential prognostic factor of pulmonary arterial hypertension. *Chest*. 2007;131(1):101-8. PMID: 17218562.
124. Morishita T, Miyaji K, Akao I, et al. The ratio of the atrial areas reflects the clinical status of patients with pulmonary arterial hypertension. *J Med Ultrason*. 2009;36(4):201-206.
125. Mukerjee D, Yap LB, Holmes AM, et al. Significance of plasma N-terminal pro-brain natriuretic peptide in patients with systemic sclerosis-related pulmonary arterial hypertension. *Respir Med*. 2003;97(11):1230-6. PMID: 14635979.
126. Nagaya N, Nishikimi T, Uematsu M, et al. Plasma brain natriuretic peptide as a prognostic indicator in patients with primary pulmonary hypertension. *Circulation*. 2000;102(8):865-70. PMID: 10952954.
127. Nakayama T, Shimada H, Takatsuki S, et al. Efficacy and limitations of continuous intravenous epoprostenol therapy for idiopathic pulmonary arterial hypertension in Japanese children. *Circ J*. 2007;71(11):1785-90. PMID: 17965503.
128. Nath J, Demarco T, Hourigan L, et al. Correlation between right ventricular indices and clinical improvement in epoprostenol treated pulmonary hypertension patients. *Echocardiography*. 2005;22(5):374-9. PMID: 15901287.
129. Nickel N, Golpon H, Greer M, et al. The prognostic impact of follow-up assessments in patients with idiopathic pulmonary arterial hypertension. *Eur Respir J*. 2012;39(3):589-96. PMID: 21885392.
130. Nickel N, Kempf T, Tapken H, et al. Growth differentiation factor-15 in idiopathic pulmonary arterial hypertension. *Am J Respir Crit Care Med*. 2008;178(5):534-41. PMID: 18565955.
131. Njaman W, Iesaki T, Iwama Y, et al. Serum uric Acid as a prognostic predictor in pulmonary arterial hypertension with connective tissue disease. *Int Heart J*. 2007;48(4):523-32. PMID: 17827824.
132. Ogawa A, Miyaji K, Yamadori I, et al. Safety and efficacy of epoprostenol therapy in pulmonary veno-occlusive disease and pulmonary capillary hemangiomatosis. *Circulation Journal*. 2012;76(7):1729-1736. PMID: 22481098.
133. Park MH, Scott RL, Uber PA, et al. Usefulness of B-type natriuretic peptide as a predictor of treatment outcome in pulmonary arterial hypertension. *Congest Heart Fail*. 2004;10(5):221-5. PMID: 15470298.
134. Pyxaras SA, Pinamonti B, Barbati G, et al. Echocardiographic evaluation of systolic and mean pulmonary artery pressure in the follow-up of patients with pulmonary hypertension. *Eur J Echocardiogr*. 2011;12(9):696-701. PMID: 21821609.
135. Raymond RJ, Hinderliter AL, Willis PW, et al. Echocardiographic predictors of adverse outcomes in primary pulmonary hypertension. *J Am Coll Cardiol*. 2002;39(7):1214-9. PMID: 11923049.
136. Rhodes CJ, Wharton J, Howard LS, et al. Red cell distribution width outperforms other potential circulating biomarkers in predicting survival in idiopathic pulmonary arterial hypertension. *Heart*. 2011;97(13):1054-60. PMID: 21558476.
137. Sadushi-Kolici R, Skoro-Sajer N, Zimmer D, et al. Long-term treatment, tolerability, and survival with sub-cutaneous treprostinil for severe pulmonary hypertension. *J Heart Lung Transplant*. 2012;31(7):735-743. PMID: 22480725.
138. Schumann C, Lepper PM, Frank H, et al. Circulating biomarkers of tissue remodelling in pulmonary hypertension. *Biomarkers*. 2010;15(6):523-32. PMID: 20528622.

139. Sebbag I, Rudski LG, Therrien J, et al. Effect of chronic infusion of epoprostenol on echocardiographic right ventricular myocardial performance index and its relation to clinical outcome in patients with primary pulmonary hypertension. *Am J Cardiol*. 2001;88(9):1060-3. PMID: 11704014.
140. Shimony A, Fox BD, Langleben D, et al. Incidence and Significance of Pericardial Effusion in Patients With Pulmonary Arterial Hypertension. *Can J Cardiol*. 2012. PMID: 22717247.
141. Soon E, Doughty NJ, Treacy CM, et al. Log-transformation improves the prognostic value of serial NT-proBNP levels in apparently stable pulmonary arterial hypertension. *Pulm Circ*. 2011;1(2):244-9. PMID: 22034610.
142. Souza R, Jardim C, Julio Cesar Fernandes C, et al. NT-proBNP as a tool to stratify disease severity in pulmonary arterial hypertension. *Respir Med*. 2007;101(1):69-75. PMID: 16781131.
143. Taguchi H, Kataoka M, Yanagisawa R, et al. Platelet level as a new prognostic factor for idiopathic pulmonary arterial hypertension in the era of combination therapy. *Circulation Journal*. 2012;76(6):1494-1500. PMID: 22447010.
144. Takatsuki S, Calderbank M, Ivy DD. Initial experience with tadalafil in pediatric pulmonary arterial hypertension. *Pediatr Cardiol*. 2012;33(5):683-688. PMID: 22402804.
145. Takatsuki S, Rosenzweig EB, Zuckerman W, et al. Clinical safety, pharmacokinetics, and efficacy of ambrisentan therapy in children with pulmonary arterial hypertension. *Pediatr Pulmonol*. 2012. PMID: 22511577.
146. Takatsuki S, Wagner BD, Ivy DD. B-type Natriuretic Peptide and Amino-terminal Pro-B-type Natriuretic Peptide in Pediatric Patients with Pulmonary Arterial Hypertension. *Congenital Heart Disease*. 2012;7(3):259-267. PMID: 22325151.
147. Takeda Y, Tomimoto S, Tani T, et al. Bilirubin as a prognostic marker in patients with pulmonary arterial hypertension. *BMC Pulm Med*. 2010;10:22. PMID: 20412580.
148. Torbicki A, Kurzyna M, Kuca P, et al. Detectable serum cardiac troponin T as a marker of poor prognosis among patients with chronic precapillary pulmonary hypertension. *Circulation*. 2003;108(7):844-8. PMID: 12900346.
149. Utsunomiya H, Nakatani S, Okada T, et al. A simple method to predict impaired right ventricular performance and disease severity in chronic pulmonary hypertension using strain rate imaging. *Int J Cardiol*. 2011;147(1):88-94. PMID: 19747741.
150. Utsunomiya H, Nakatani S, Nishihira M, et al. Value of estimated right ventricular filling pressure in predicting cardiac events in chronic pulmonary arterial hypertension. *J Am Soc Echocardiogr*. 2009;22(12):1368-74. PMID: 19944957.
151. Van Albada ME, Loot FG, Fokkema R, et al. Biological serum markers in the management of pediatric pulmonary arterial hypertension. *Pediatr Res*. 2008;63(3):321-7. PMID: 18287971.
152. Vizza CD, Letizia C, Badagliacca R, et al. Relationship between baseline ET-1 plasma levels and outcome in patients with idiopathic pulmonary hypertension treated with bosentan. *Int J Cardiol*. 2012. PMID: 22265324.
153. Vizza CD, Letizia C, Petramala L, et al. Venous endotelin-1 (ET-1) and brain natriuretic peptide (BNP) plasma levels during 6-month bosentan treatment for pulmonary arterial hypertension. *Regul Pept*. 2008;151(1-3):48-53. PMID: 18796317.
154. Voelkel MA, Wynne KM, Badesch DB, et al. Hyperuricemia in severe pulmonary hypertension. *Chest*. 2000;117(1):19-24. PMID: 10631193.
155. Wilkins MR, Paul GA, Strange JW, et al. Sildenafil versus Endothelin Receptor Antagonist for Pulmonary Hypertension (SERAPH) study. *Am J Respir Crit Care Med*. 2005;171(11):1292-7. PMID: 15750042.
156. Yamada Y, Okuda S, Kataoka M, et al. Prognostic value of cardiac magnetic resonance imaging for idiopathic pulmonary arterial hypertension before initiating intravenous prostacyclin therapy. *Circulation Journal*. 2012;76(7):1737-1743. PMID: 22498565.

157. Yanagisawa R, Kataoka M, Taguchi H, et al. Impact of First-Line Sildenafil Monotreatment for Pulmonary Arterial Hypertension. *Circ J*. 2012;76(5):1245-1252. PMID: 22333215.
158. Yang SI, Chung WJ, Jung SH, et al. Effects of inhaled iloprost on congenital heart disease with eisenmenger syndrome. *Pediatr Cardiol*. 2012;33(5):744-748. PMID: 22349672.
159. Yoshida S, Shirato K, Shimamura R, et al. Long-term safety and efficacy of ambrisentan in Japanese adults with pulmonary arterial hypertension. *Curr Med Res Opin*. 2012;28(6):1069-1076. PMID: 22506623.
160. Zafir N, Zingerman B, Solodky A, et al. Use of noninvasive tools in primary pulmonary hypertension to assess the correlation of right ventricular function with functional capacity and to predict outcome. *Int J Cardiovasc Imaging*. 2007;23(2):209-15. PMID: 16972146.
161. Zeng WJ, Sun YJ, Xiong CM, et al. Prognostic value of echocardiographic right/left ventricular end-diastolic diameter ratio in idiopathic pulmonary arterial hypertension. *Chin Med J (Engl)*. 2011;124(11):1672-7. PMID: 21740775.
162. Zhao QH, Peng FH, Wei H, et al. Serum high-density lipoprotein cholesterol levels as a prognostic indicator in patients with idiopathic pulmonary arterial hypertension. *Am J Cardiol*. 2012;110(3):433-439. PMID: 22560769.
163. Badesch DB, Tapson VF, McGoon MD, et al. Continuous intravenous epoprostenol for pulmonary hypertension due to the scleroderma spectrum of disease. A randomized, controlled trial. *Ann Intern Med*. 2000;132(6):425-34. PMID: 10733441.
164. Barst RJ, Mubarak KK, Machado RF, et al. Exercise capacity and haemodynamics in patients with sickle cell disease with pulmonary hypertension treated with bosentan: results of the ASSET studies. *Br J Haematol*. 2010;149(3):426-35. PMID: 20175775.
165. Barst RJ, Ivy DD, Gaitan G, et al. A Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study of Oral Sildenafil Citrate in Treatment-Naive Children with Pulmonary Arterial Hypertension. *Circulation*. 2011. PMID: 22128226.
166. Fix OK, Bass NM, De Marco T, et al. Long-term follow-up of portopulmonary hypertension: effect of treatment with epoprostenol. *Liver Transpl*. 2007;13(6):875-85. PMID: 17539008.
167. Galie N, Ghofrani HA, Torbicki A, et al. Sildenafil citrate therapy for pulmonary arterial hypertension. *N Engl J Med*. 2005;353(20):2148-57. PMID: 16291984.
168. Badesch DB, Hill NS, Burgess G, et al. Sildenafil for pulmonary arterial hypertension associated with connective tissue disease. *J Rheumatol*. 2007;34(12):2417-22. PMID: 17985403.
169. Rubin LJ, Badesch DB, Fleming TR, et al. Long-term treatment with sildenafil citrate in pulmonary arterial hypertension: the SUPER-2 study. *Chest*. 2011;140(5):1274-83. PMID: 21546436.
170. Galie N, Beghetti M, Gatzoulis MA, et al. Bosentan therapy in patients with Eisenmenger syndrome: A multicenter, double-blind, randomized, placebo-controlled study. *Circulation*. 2006;114(1):48-54. PMID: 16801459.
171. Galie N, Rubin L, Hoeper M, et al. Treatment of patients with mildly symptomatic pulmonary arterial hypertension with bosentan (EARLY study): a double-blind, randomised controlled trial. *Lancet*. 2008;371(9630):2093-100. PMID: 18572079.
172. Galie N, Brundage BH, Ghofrani HA, et al. Tadalafil therapy for pulmonary arterial hypertension. *Circulation*. 2009;119(22):2894-903. PMID: 19470885.
173. Barst RJ, Oudiz RJ, Beardsworth A, et al. Tadalafil monotherapy and as add-on to background bosentan in patients with pulmonary arterial hypertension. *J Heart Lung Transplant*. 2011;30(6):632-43. PMID: 21256048.



174. Oudiz RJ, Brundage BH, Galie N, et al. Tadalafil for the Treatment of Pulmonary Arterial Hypertension. A Double-Blind 52-Week Uncontrolled Extension Study. *J Am Coll Cardiol*. 2012. PMID: 22818063.
175. Higenbottam TW, Spiegelhalter D, Scott JP, et al. Prostacyclin (epoprostenol) and heart-lung transplantation as treatments for severe pulmonary hypertension. *Br Heart J*. 1993;70(4):366-70. PMID: 8217447.
176. Hiremath J, Thanikachalam S, Parikh K, et al. Exercise improvement and plasma biomarker changes with intravenous treprostinil therapy for pulmonary arterial hypertension: a placebo-controlled trial. *J Heart Lung Transplant*. 2010;29(2):137-49. PMID: 20022264.
177. Hoeper MM, Leuchte H, Halank M, et al. Combining inhaled iloprost with bosentan in patients with idiopathic pulmonary arterial hypertension. *Eur Respir J*. 2006;28(4):691-4. PMID: 17012628.
178. Hoeper MM, Seyfarth HJ, Hoeffken G, et al. Experience with inhaled iloprost and bosentan in portopulmonary hypertension. *Eur Respir J*. 2007;30(6):1096-102. PMID: 17652314.
179. Humbert M, Barst RJ, Robbins IM, et al. Combination of bosentan with epoprostenol in pulmonary arterial hypertension: BREATHE-2. *Eur Respir J*. 2004;24(3):353-9. PMID: 15358690.
180. Jing ZC, Yu ZX, Shen JY, et al. Vardenafil in pulmonary arterial hypertension: a randomized, double-blind, placebo-controlled study. *Am J Respir Crit Care Med*. 2011;183(12):1723-9. PMID: 21471085.
181. Kemp K, Savale L, O'Callaghan DS, et al. Usefulness of first-line combination therapy with epoprostenol and bosentan in pulmonary arterial hypertension: an observational study. *J Heart Lung Transplant*. 2012;31(2):150-8. PMID: 22138355.
182. McLaughlin VV, Gaine SP, Barst RJ, et al. Efficacy and safety of treprostinil: an epoprostenol analog for primary pulmonary hypertension. *J Cardiovasc Pharmacol*. 2003;41(2):293-9. PMID: 12548091.
183. McLaughlin VV, Oudiz RJ, Frost A, et al. Randomized study of adding inhaled iloprost to existing bosentan in pulmonary arterial hypertension. *Am J Respir Crit Care Med*. 2006;174(11):1257-63. PMID: 16946127.
184. Mukhopadhyay S, Nathani S, Yusuf J, et al. Clinical efficacy of phosphodiesterase-5 inhibitor tadalafil in Eisenmenger Syndrome-A randomized, placebo-controlled, double-blind crossover study. *Congenit Heart Dis*. 2011;6(5):424-431. PMID: 21914136.
185. Olschewski H, Simonneau G, Galie N, et al. Inhaled iloprost for severe pulmonary hypertension. *N Engl J Med*. 2002;347(5):322-9. PMID: 12151469.
186. Olschewski H, Hoeper MM, Behr J, et al. Long-term therapy with inhaled iloprost in patients with pulmonary hypertension. *Respir Med*. 2010;104(5):731-40. PMID: 20153158.
187. Reichenberger F, Mainwood A, Morrell NW, et al. Intravenous epoprostenol versus high dose inhaled iloprost for long-term treatment of pulmonary hypertension. *Pulm Pharmacol Ther*. 2011;24(1):169-73. PMID: 20601049.
188. Rich JD, Glassner C, Wade M, et al. The effect of diluent pH on bloodstream infection rates in patients receiving IV treprostinil for pulmonary arterial hypertension. *Chest*. 2012;141(1):36-42. PMID: 21659437.
189. Rubin LJ, Badesch DB, Barst RJ, et al. Bosentan therapy for pulmonary arterial hypertension. *N Engl J Med*. 2002;346(12):896-903. PMID: 11907289.
190. Galie N, Hinderliter AL, Torbicki A, et al. Effects of the oral endothelin-receptor antagonist bosentan on echocardiographic and doppler measures in patients with pulmonary arterial hypertension. *J Am Coll Cardiol*. 2003;41(8):1380-6. PMID: 12706935.
191. Denton CP, Humbert M, Rubin L, et al. Bosentan treatment for pulmonary arterial hypertension related to connective tissue disease: a subgroup analysis of the pivotal clinical trials and their open-label extensions. *Ann Rheum Dis*. 2006;65(10):1336-40. PMID: 16793845.

192. Rubin LJ, Mendoza J, Hood M, et al. Treatment of primary pulmonary hypertension with continuous intravenous prostacyclin (epoprostenol). Results of a randomized trial. *Ann Intern Med*. 1990;112(7):485-91. PMID: 2107780.
193. Barst RJ, Rubin LJ, McGoon MD, et al. Survival in primary pulmonary hypertension with long-term continuous intravenous prostacyclin. *Ann Intern Med*. 1994;121(6):409-15. PMID: 8053614.
194. Sastry BK, Raju BS, Narasimhan C, et al. Sildenafil improves survival in idiopathic pulmonary arterial hypertension. *Indian Heart J*. 2007;59(4):336-41. PMID: 19126939.
195. Simonneau G, Barst RJ, Galie N, et al. Continuous subcutaneous infusion of treprostinil, a prostacyclin analogue, in patients with pulmonary arterial hypertension: a double-blind, randomized, placebo-controlled trial. *Am J Respir Crit Care Med*. 2002;165(6):800-4. PMID: 11897647.
196. Simonneau G, Rubin LJ, Galie N, et al. Addition of sildenafil to long-term intravenous epoprostenol therapy in patients with pulmonary arterial hypertension: a randomized trial. *Ann Intern Med*. 2008;149(8):521-30. PMID: 18936500.
197. Zeng WJ, Sun YJ, Gu Q, et al. Impact of Sildenafil on Survival of Patients With Idiopathic Pulmonary Arterial Hypertension. *J Clin Pharmacol*. 2011. PMID: 21956607.

## Appendix E. List of Excluded Studies

All studies listed below were reviewed in their full-text version and excluded for the reason shown in *italics*. Reasons for exclusion signify only the usefulness of the articles for this study and are not intended as criticisms of the articles.

Abbas AE, Fortuin FD, Schiller NB, et al. Echocardiographic determination of mean pulmonary artery pressure. *Am J Cardiol.* 2003;92(11):1373-6. PMID: 14636929. *Exclude - No comparisons of interest*

Abdelwahed A, Klada E, Vaghasia P, et al. Cardiac-MRI derived index to diagnose pulmonary Hypertension. *Chest.* 2011;140(4). *Exclude - Not a full publication*

Abdul-Salam VB, Paul GA, Ali JO, et al. Identification of plasma protein biomarkers associated with idiopathic pulmonary arterial hypertension. *Proteomics.* 2006;6(7):2286-94. PMID: 16493708. *Exclude - No comparisons of interest*

Abman SH. Pulmonary hypertension in older children: new approaches and therapies. *Paediatr Respir Rev.* 2006;7 Suppl 1:S177-9. PMID: 16798555. *Exclude - Background Other*

Acikel M, Yilmaz M, Gurlertop Y, et al. Evaluation of left ventricular diastolic function by doppler echocardiography and tissue doppler imaging in chronic cor pulmonale. *Turk Kardiyoloji Dernegi Arsivi.* 2003;31(7):384-391. *Exclude - not available in English.*

Acosta Colman MI, Avila Pedretti G, Acosta ME, et al. Can we predict the severity of pulmonary hypertension in patients with scleroderma? *Reumatologia Clinica.* 2012. *Exclude - Not a full publication*

Adatia I, Beghetti M. Early postoperative care of patients with pulmonary hypertension associated with congenital cardiac disease. *Cardiol Young.* 2009;19(4):315-9. PMID: 19493364. *Exclude - Not a full publication*

Adnot S, Raffestin B, Eddahibi S. Nitric oxide in the pulmonary circulation. *Monaldi Arch Chest Dis.* 1996;51(6):519-27. PMID: 9046167. *Exclude - Does not include intervention of interest*

Adriaenssens T, Delcroix M, Van Deyk K, et al. Advanced therapy may delay the need for transplantation in patients with the Eisenmenger syndrome. *Eur Heart J.* 2006;27(12):1472-7. PMID: 16707548. *Exclude - No comparisons of interest*

Aduen JF, Castello R, Daniels JT, et al. Accuracy and precision of three echocardiographic methods for estimating mean pulmonary artery pressure. *Chest.* 2011;139(2):347-52. PMID: 20651021. *Exclude - Does not include intervention of interest*

Aessopos A, Farmakis D, Deftereos S, et al. Cardiovascular effects of splenomegaly and splenectomy in beta-thalassemia. *Ann Hematol.* 2005;84(6):353-7. PMID: 15711802. *Exclude - Does not include intervention of interest*

Aessopos A, Farmakis D, Deftereos S, et al. Thalassemia heart disease: a comparative evaluation of thalassemia major and thalassemia intermedia. *Chest.* 2005;127(5):1523-30. PMID: 15888823. *Exclude - Does not include intervention of interest*

Aessopos A, Farmakis D, Hatziliami A, et al. Cardiac status in well-treated patients with thalassemia major. *Eur J Haematol.* 2004;73(5):359-66. PMID: 15458515. *Exclude - Does not include intervention of interest*

Aessopos A, Farmakis D, Karagiorga M, et al. Cardiac involvement in thalassemia intermedia: a multicenter study. *Blood.* 2001;97(11):3411-6. PMID: 11369631. *Exclude - Does not include intervention of interest*

Aessopos A, Stamatelos G, Skoumas V, et al. Pulmonary hypertension and right heart failure in patients with beta-thalassemia intermedia. *Chest.* 1995;107(1):50-3. PMID: 7813310. *Exclude - Does not include intervention of interest*

Afifi S, Shayan S, Al-Qamari A. Pulmonary hypertension and right ventricular function: interdependence in pathophysiology and management. *Int Anesthesiol Clin.* 2009;47(1):97-120. PMID: 19131755. *Exclude - Not a full publication*

Agapito AF, Sousa L, Oliveira JA, et al. Eisenmenger syndrome in the adult--experience with new drugs for the treatment of pulmonary hypertension. *Rev Port Cardiol.* 2005;24(3):421-31. PMID: 15929625.

*Exclude - No comparisons of interest*

Aggarwal P, Patial RK, Negi PC, et al. Oral tadalafil in pulmonary artery hypertension: a prospective study. *Indian Heart J.* 2007;59(4):329-35. PMID: 19126938. *Exclude - No study population of interest*

Aggarwal SK, Mishra J, Sai V, et al. Aortopulmonary window in adults: diagnosis and treatment of late-presenting patients. *Congenit Heart Dis.* 2008;3(5):341-6. PMID: 18837813. *Exclude - Does not include intervention of interest*

Aguilar RV, Farber HW. Epoprostenol (prostacyclin) therapy in HIV-associated pulmonary hypertension. *Am J Respir Crit Care Med.* 2000;162(5):1846-50. PMID: 11069824. *Exclude - No comparisons of interest*

Ahearn GS, Tapson VF, Rebeiz A, et al. Electrocardiography to define clinical status in primary pulmonary hypertension and pulmonary arterial hypertension secondary to collagen vascular disease. *Chest.* 2002;122(2):524-7. PMID: 12171826. *Exclude - No comparisons of interest*

Ahmadi-Simab K, Hellmich B, Gross WL. Bosentan for severe pulmonary arterial hypertension related to systemic sclerosis with interstitial lung disease. *Eur J Clin Invest.* 2006;36 Suppl 3:44-8. PMID: 16919010. *Exclude - No comparisons of interest*

Ahmed AE, Ibrahim AS, Elshafie SM. Pulmonary hypertension in patients with treated pulmonary tuberculosis: analysis of 14 consecutive cases. *Clin Med Insights Circ Respir Pulm Med.* 2011;5:1-5. PMID: 21339885. *Exclude - No study population of interest*

Ahmed AM, El-Shamaa MF. Asymptomatic cardiac involvement in children with Systemic Lupus Erythematosus. *J Med Sci (Pakistan).* 2006;6(6):944-949. *Exclude - no primary or secondary outcomes of interest*

Ahmed S, Siddiqui AK, Sadiq A, et al. Echocardiographic abnormalities in sickle cell disease. *Am J Hematol.* 2004;76(3):195-8. PMID: 15224351. *Exclude - Does not include intervention of interest*

Airo P, Rossi M, Scarsi M, et al. Disease-modifying effects of long-term cyclic iloprost therapy in systemic sclerosis. A retrospective analysis and comparison with a control group. *Clin Exp Rheumatol.* 2007;25(5):722-7. PMID: 18078620.

*Exclude - No comparisons of interest*

Ajami GH, Borzoe M, Radvar M, et al. Comparison of the effectiveness of oral sildenafil versus oxygen administration as a test for feasibility of operation for patients with secondary pulmonary arterial hypertension. *Pediatr Cardiol.* 2008;29(3):552-5. PMID: 18058160. *Exclude - No comparisons of interest*

Akagi S, Matsubara H, Miyaji K, et al. Additional effects of bosentan in patients with idiopathic pulmonary arterial hypertension already treated with high-dose epoprostenol. *Circ J.* 2008;72(7):1142-6. PMID: 18577825. *Exclude - No comparisons of interest*

Akagi S, Matsubara H, Ogawa A, et al. Prevention of catheter-related infections using a closed hub system in patients with pulmonary arterial hypertension. *Circ J.* 2007;71(4):559-64. PMID: 17384460. *Exclude - Does not include intervention of interest*

Akagi S, Nakamura K, Miyaji K, et al. Marked hemodynamic improvements by high-dose epoprostenol therapy in patients with idiopathic pulmonary arterial hypertension. *Circ J.* 2010;74(10):2200-5. PMID: 20697180. *Exclude - No comparisons of interest*

Akdogan A, Kilic L, Dogan I, et al. Pulmonary hypertension in systemic lupus erythematosus: Pulmonary thromboembolism is the leading cause. *Int J Cardiol.* 2012;155:S29. *Exclude - Not a full publication*

Akdogan A, Okutucu S, Kilic L, et al. Is early diagnosis of pulmonary arterial hypertension possible inflammatory rheumatic diseases? *Int J Cardiol.* 2012;155:S29-S30. *Exclude - Not a full publication*

Akgul F, Seyfeli E, Melek I, et al. Increased QT dispersion in sickle cell disease: effect of pulmonary hypertension. *Acta Haematol.* 2007;118(1):1-6. PMID: 17374947. *Exclude - Does not include intervention of interest*

Akgul F, Yalcin F, Babayigit C, et al. Right ventricular and pulmonary function in sickle cell disease patients with pulmonary hypertension. *Pediatr Cardiol.* 2006;27(4):440-6. PMID: 16835804. *Exclude - No comparisons of interest*

Albert NM, Hague K. Managing patients with primary pulmonary hypertension: prostacyclin therapy. *Am J Crit Care*. 1997;6(4):274-80. PMID: 9215424. *Exclude - Not a full publication*

Aleem A, Jehangir A, Owais M, et al. Echocardiographic abnormalities in adolescent and adult Saudi patients with sickle cell disease. *Saudi Med J*. 2007;28(7):1072-5. PMID: 17603714. *Exclude - Does not include intervention of interest*

Alehan D, Yildirim I, Sahin M, et al. Long-term inhaled iloprost use in children with pulmonary arterial hypertension. *Cardiol Young*. 2011:1-8. PMID: 22067137. *Exclude - No comparisons of interest.*

Alehan D, Yildirim I, Sahin M, et al. Long-term inhaled iloprost use in children with pulmonary arterial hypertension. *Cardiol Young*. 2012;22(4):396-403. *Exclude - No comparisons of interest*

Alkassab F, Steen V. Estimated systolic pulmonary artery pressure versus tricuspid regurgitant jet velocity as screening tools for pulmonary hypertension in systemic sclerosis: The pharos experience. *Clin Exp Rheumatol*. 2010;28(2):S130. *Exclude - not a full publication.*

Alkon J, Humpl T, Manhiot C, et al. Usefulness of the right ventricular systolic to diastolic duration ratio to predict functional capacity and survival in children with pulmonary arterial hypertension. *Am J Cardiol*. 2010;106(3):430-6. PMID: 20643259. *Exclude - Does not include intervention of interest*

Alkotob ML, Soltani P, Sheatt MA, et al. Reduced exercise capacity and stress-induced pulmonary hypertension in patients with scleroderma. *Chest*. 2006;130(1):176-81. PMID: 16840399. *Exclude - Does not include intervention of interest*

Allanore Y, Borderie D, Meune C, et al. N-terminal pro-brain natriuretic peptide as a diagnostic marker of early pulmonary artery hypertension in patients with systemic sclerosis and effects of calcium-channel blockers. *Arthritis Rheum*. 2003;48(12):3503-8. PMID: 14674001. *Exclude - Does not include intervention of interest*

Allanore Y, Borderie D, Meune C, et al. Increased plasma soluble CD40 ligand concentrations in systemic sclerosis and association with pulmonary arterial hypertension and digital ulcers. *Ann Rheum Dis*. 2005;64(3):481-3. PMID: 15708899. *Exclude - Does not include intervention of interest*

Allanore Y, Wahbi K, Borderie D, et al. N-terminal pro-brain natriuretic peptide in systemic sclerosis: a new cornerstone of cardiovascular assessment? *Ann Rheum Dis*. 2009;68(12):1885-9. PMID: 19054819. *Exclude - no primary or secondary outcomes of interest*

Al-Otair H. Inhaled iloprost for pulmonary hypertension: Clinical effects of adding inhaled iloprost to existing sildenafil therapy. *Ann Thorac Med*. 2011;6(3):164-165. *Exclude - Not a full publication*

Alpert MA, Pressly TA, Mukerji V, et al. Acute and long-term effects of nifedipine on pulmonary and systemic hemodynamics in patients with pulmonary hypertension associated with diffuse systemic sclerosis, the CREST syndrome and mixed connective tissue disease. *Am J Cardiol*. 1991;68(17):1687-91. PMID: 1746473. *Exclude – no primary or secondary outcomes of interest*

Altintas A, Karahan Z, Pasa S, et al. Pulmonary hypertension in patients with essential thrombocythemia and reactive thrombocytosis. *Leuk Lymphoma*. 2007;48(10):1981-7. PMID: 17852711. *Exclude - Does not include intervention of interest*

Amabile N, Heiss C, Chang V, et al. Increased CD62e(+) endothelial microparticle levels predict poor outcome in pulmonary hypertension patients. *J Heart Lung Transplant*. 2009;28(10):1081-6. PMID: 19782291. *Exclude - Does not include intervention of interest*

Amabile N, Heiss C, Real WM, et al. Circulating endothelial microparticle levels predict hemodynamic severity of pulmonary hypertension. *Am J Respir Crit Care Med*. 2008;177(11):1268-75. PMID: 18310479. *Exclude - Does not include intervention of interest*

Amaki M, Nakatani S, Kanzaki H, et al. Usefulness of three-dimensional echocardiography in assessing right ventricular function in patients with primary pulmonary hypertension. *Hypertens Res*. 2009;32(5):419-22. PMID: 19325565. *Exclude - No comparisons of interest*

Ambroz D, Jansa P, Maresova J, et al. Infectious complications of long-term intravenous epoprostenol therapy in patients with pulmonary arterial hypertension. *Cor Vasa*. 2009;51(7-8):488-490. *Exclude - Not available in English.*

Ambrusko SJ, Gunawardena S, Sakara A, et al. Elevation of tricuspid regurgitant jet velocity, a marker for pulmonary hypertension in children with sickle cell disease. *Pediatr Blood Cancer*. 2006;47(7):907-13. PMID: 16496290. *Exclude - Does not include intervention of interest*

Ameling A, Joosten KF, Berger RM. The semi-elective use of the pulmonary artery flotation catheter in children with progressive pulmonary hypertension or left ventricular dysfunction. *Pediatr Crit Care Med*. 2001;2(3):211-6. PMID: 12793943. *Exclude - Does not include intervention of interest*

Amoozgar H, Farhani N, Karimi M. Early echocardiographic findings in beta-thalassemia intermedia patients using standard and tissue Doppler methods. *Pediatr Cardiol*. 2011;32(2):154-9. PMID: 21082174. *Exclude - Does not include intervention of interest*

Andrade A, Vargas-Barron J, Rijlaarsdam M, et al. Utility of transesophageal echocardiography in the examination of adult patients with patent ductus arteriosus. *Am Heart J*. 1995;130(3 Pt 1):543-6. PMID: 7661073. *Exclude - Does not include intervention of interest*

Andreassen AK, Geiran O, Madsen S, et al. Treatment with prostacyclin or calcium channel blockers in pulmonary arterial hypertension. *Tidsskr Nor Laegeforen*. 2003;123(23):3393-3396. *Exclude - Not available in English*.

Angalakuditi M, Edgell E, Beardsworth A, et al. Treatment patterns and resource utilization and costs among patients with pulmonary arterial hypertension in the United States. *J Med Econ*. 2010;13(3):393-402. PMID: 20608882. *Exclude - no primary or secondary outcomes of interest*

Anonymous. Sildenafil shows some promise for the treatment of pulmonary hypertension. *Pharm J*. 2001;267(7158):112. *Exclude - not a full publication*.

Anonymous. New developments in the treatment of scleroderma. *Drugs Ther Perspect*. 2002;18(2):19-21. *Exclude - Not a full publication*

Anonymous. Calcium-channel-blocker response in idiopathic pulmonary arterial hypertension. *Nat Clin Pract Cardiovasc Med*. 2005;2(8):381. *Exclude - Not a full publication*

Anonymous. New agents may permit tailored therapy in PAH. *Cardiol Rev*. 2005;22(12):6-7. *Exclude - Not a full publication*

Anonymous. Treprostinil. Pulmonary artery hypertension: Just another (disappointing) prostacycline analogue. *Prescrire Int*. 2006;15(85):177-179. *Exclude - Not a full publication*

Anonymous. Bosentan: Also too risky in mildly symptomatic pulmonary arterial hypertension. *Prescrire Int*. 2009;18(100):55. *Exclude - Not a full publication*

Anonymous. Tadalafil (Adcirca) for pulmonary arterial hypertension. *Med Lett Drugs Ther*. 2009;51(1324):87-8. PMID: 19890245. *Exclude - Not a full publication*

Ansari S, Usman M, Dalal B, et al. Echocardiographic evaluation of patients with sickle cell disease. *Chest*. 2011;140(4). *Exclude - Not a full publication*

Antoniou SA. Bosentan for treatment of pulmonary arterial hypertension (I). *Therapy*. 2005;2(6):843-847. *Exclude - Not a full publication*

Antoniou SA. Non-prostanoid prostacyclin agonists for the treatment of pulmonary arterial hypertension. *Expert Opin Investig Drugs*. 2006;15(3):327-30. PMID: 16503768. *Exclude - No study population of interest*

Antoniou SA. Sildenafil citrate for the treatment of pulmonary arterial hypertension. *Expert Opin Pharmacother*. 2006;7(6):825-8. PMID: 16556096. *Exclude - Not a full publication*

Apfel HD, Shen Z, Gopal AS, et al. Quantitative three dimensional echocardiography in patients with pulmonary hypertension and compressed left ventricles: comparison with cross sectional echocardiography and magnetic resonance imaging. *Heart*. 1996;76(4):350-4. PMID: 8983683. *Exclude - Does not include intervention of interest*

Apitz C, Reyes JT, Holtby H, et al. Pharmacokinetic and hemodynamic responses to oral sildenafil during invasive testing in children with pulmonary hypertension. *J Am Coll Cardiol*. 2010;55(14):1456-62. PMID: 20359596. *Exclude - No comparisons of interest*

Apitz C, Zimmermann R, Kreuder J, et al. Assessment of pulmonary endothelial function during invasive testing in children and adolescents with idiopathic pulmonary arterial hypertension. *J Am Coll Cardiol*. 2012;60(2):157-164. *Exclude - Does not include intervention of interest*

Apostolopoulou SC, Kantzis M, Tsoutsinos A, et al. 15 year experience in pulmonary hypertension due to congenital heart disease before and after targeted therapies: the durability of the right ventricle in this disease. *Eur Heart J*. 2011;32:174. *Exclude - Not a full publication*

Apostolopoulou SC, Kourgiannidis G, Manginas A, et al. Differential vasoactive response to endothelin receptor antagonists and prostacyclin in patients with severe pulmonary hypertension. *Clin Sci (Lond)*. 2002;103 Suppl 48:298S-301S. PMID: 12193108. *Exclude - Does not include intervention of interest*

Apostolopoulou SC, Manginas A, Cokkinos DV, et al. Effect of the oral endothelin antagonist bosentan on the clinical, exercise, and haemodynamic status of patients with pulmonary arterial hypertension related to congenital heart disease. *Heart*. 2005;91(11):1447-52. PMID: 15761050. *Exclude - no comparisons of interest.*

Apostolopoulou SC, Manginas A, Cokkinos DV, et al. Long-term oral bosentan treatment in patients with pulmonary arterial hypertension related to congenital heart disease: a 2-year study. *Heart*. 2007;93(3):350-4. PMID: 16980516. *Exclude - no comparisons of interest.*

Archer SL, Michelakis ED. Phosphodiesterase type 5 inhibitors for pulmonary arterial hypertension. *N Engl J Med*. 2009;361(19):1864-71. PMID: 19890129. *Exclude - Not a full publication*

Archer SL, Raizner AE. Management of pulmonary hypertension. *ACC Cardiosource Rev J*. 2007;16(6):35-37. *Exclude - Not a full publication*

Argiento P, Chesler N, Mule M, et al. Exercise stress echocardiography for the study of the pulmonary circulation. *Eur Respir J*. 2010;35(6):1273-8. PMID: 19926746. *Exclude - No study population of interest*

Arkles JS, Opatowsky AR, Ojeda J, et al. Shape of the right ventricular Doppler envelope predicts hemodynamics and right heart function in pulmonary hypertension. *Am J Respir Crit Care Med*. 2011;183(2):268-76. PMID: 20709819. *Exclude - No comparisons of interest*

Armigliato M, Paolini R, Aggio S, et al. Hyperthyroidism as a cause of pulmonary arterial hypertension: a prospective study. *Angiology*. 2006;57(5):600-6. PMID: 17067983. *Exclude - No comparisons of interest*

Armstrong DW, Tsimiklis G, Matangi MF. Factors influencing the echocardiographic estimate of right ventricular systolic pressure in normal patients and clinically relevant ranges according to age. *Can J Cardiol*. 2010;26(2):e35-9. PMID: 20151056. *Exclude - No comparisons of interest*

Arshad MS, Shaikh S. The pattern of ventricular septal defects and the severity of associated pulmonary hypertension in our set-up. *Med Forum Monthly*. 2011;22(8):55-58. *Exclude - unable to obtain full-text*

Arya B, Kerstein D, Leu CS, et al. Echocardiographic assessment of right atrial pressure in a pediatric and young adult population. *J Am Soc Echocardiogr*. 2012;25(6):B35. *Exclude - Not a full publication*

Aschner JL. New therapies for pulmonary hypertension in neonates and children. *Pediatr Pulmonol Suppl*. 2004;26:132-5. PMID: 15029628. *Exclude - Not a full publication*

Ashfaq M, Chinnakotla S, Rogers L, et al. The impact of treatment of portopulmonary hypertension on survival following liver transplantation. *Am J Transplant*. 2007;7(5):1258-64. PMID: 17286619. *Exclude - No comparisons of interest*

Asosingh K, Aldred MA, Vasanji A, et al. Circulating angiogenic precursors in idiopathic pulmonary arterial hypertension. *Am J Pathol*. 2008;172(3):615-27. PMID: 18258847. *Exclude - No comparisons of interest*

Ataga KI, Moore CG, Hillery CA, et al. Coagulation activation and inflammation in sickle cell disease-associated pulmonary hypertension. *Haematologica*. 2008;93(1):20-6. PMID: 18166781. *Exclude - No comparisons of interest*

Ataga KI, Moore CG, Jones S, et al. Pulmonary hypertension in patients with sickle cell disease: a longitudinal study. *Br J Haematol*. 2006;134(1):109-15. PMID: 16803576. *Exclude - No comparisons of interest*

Atichartakarn V, Likittanasombat K, Chuncharunee S, et al. Pulmonary arterial hypertension in previously splenectomized patients with beta-thalassemic disorders. *Int J Hematol*. 2003;78(2):139-45. PMID: 12953808. *Exclude - No comparisons of interest*

Atiq M, Tasneem H, Aziz K. Estimation of pulmonary vascular resistance with Doppler diastolic gradients. *Asian Cardiovasc Thorac Ann*. 2008;16(3):221-5. PMID: 18515672. *Exclude - No comparisons of interest*

Attaran RR, Ramaraj R, Sorrell VL, et al. Poor correlation of estimated pulmonary artery systolic pressure between echocardiography and right heart catheterization in patients awaiting cardiac transplantation: results from the clinical arena. *Transplant Proc*. 2009;41(9):3827-30. PMID: 19917395. *Exclude - No study population of interest*

Augoustides JG, Ochroch EA. Inhaled selective pulmonary vasodilators. *Int Anesthesiol Clin*. 2005;43(2):101-14. PMID: 15795566. *Exclude - Not a full publication*

Auletta M, Oliviero U, Iasiuolo L, et al. Pulmonary hypertension associated with liver cirrhosis: an echocardiographic study. *Angiology*. 2000;51(12):1013-20. PMID: 11132993. *Exclude - No comparisons of interest*

Avellana P, Segovia J, Sufrate E, et al. Long-term (5 years) effects of bosentan in patients with pulmonary arterial hypertension. *Rev Esp Cardiol*. 2011;64(8):667-73. PMID: 21719181. *Exclude - No comparisons of interest*

Avouac J, Airo P, Meune C, et al. Point prevalence of pulmonary hypertension in systemic sclerosis: Results from two large cohorts (of European caucasian patients) and meta-analysis. *Clin Exp Rheumatol*. 2010;28(2):S129. *Exclude - Not a full publication*

Avouac J, Airo P, Meune C, et al. Prevalence of pulmonary hypertension in systemic sclerosis in European Caucasians and metaanalysis of 5 studies. *J Rheumatol*. 2010;37(11):2290-8. PMID: 20810505. *Exclude - Does not include intervention of interest*

Awadallah S, Halaweish I, Kutayli F. Tele-echocardiography in neonates: utility and benefits in South Dakota primary care hospitals. *S D Med*. 2006;59(3):97-100. PMID: 16566300. *Exclude - No comparisons of interest*

Azzouni F, Abu samra K. Are phosphodiesterase type 5 inhibitors associated with vision-threatening adverse events? a critical analysis and review of the literature. *J Sex Med*. 2011;8(10):2894-2903. *Exclude - Not a full publication*

Bacal F, de Freitas AF, Jr., Moreira LF, et al. Validation of a cutoff value on echo Doppler analysis to replace right heart catheterization during pulmonary hypertension evaluation in heart transplant candidates. *Transplant Proc*. 2010;42(2):535-8. PMID: 20304186. *Exclude - No comparisons of interest*

Badesch D, Hwang LJ, Teal S, et al. Posthoc subgroup analysis: Sildenafil (SIL) added to long-term epoprostenol therapy in patients with idiopathic and connective tissue disease (CTD)-associated pulmonary arterial hypertension (PAH). *Eur Heart J*. 2011;32:173. *Exclude - Not a full publication*

Badesch DB, McGoon MD, Barst RJ, et al. Longterm survival among patients with scleroderma-associated pulmonary arterial hypertension treated with intravenous epoprostenol. *J Rheumatol*. 2009;36(10):2244-9. PMID: 19723905. *Exclude - no comparisons of interest.*

Badesch DB, Peschel T, Pizzuti D, et al. Post-marketing hepatic safety profile of ambrisentan in patients with pulmonary arterial hypertension-4 year update. *J Heart Lung Transplant*. 2012;31(4):S60. *Exclude - Not a full publication*

Bagga H, Chia KS, Freeman D, et al. The initial 18 months of the first multi-disciplinary regional Pulmonary Arterial Hypertension Clinic in Australia. *Aust J Rural Health*. 2011;19(2):89-94. PMID: 21438951. *Exclude - No comparisons of interest*

Bakouboula B, Morel O, Faure A, et al. Procoagulant membrane microparticles correlate with the severity of pulmonary arterial hypertension. *Am J Respir Crit Care Med*. 2008;177(5):536-43. PMID: 18006886. *Exclude - No comparisons of interest*

Baldovinos A, Kalangos A, Sierra J, et al. Is partially reversible pulmonary hypertension a contraindication for heart transplantation? *Transplant Proc*. 2000;32(2):468-9. PMID: 10715482. *Exclude - No comparisons of interest*

Bando K, Vijayaraghavan P, Turrentine MW, et al. Dynamic changes of endothelin-1, nitric oxide, and cyclic GMP in patients with congenital heart disease. *Circulation*. 1997;96(9 Suppl):II-346-51. PMID: 9386122. *Exclude - Does not include intervention of interest*

Baptista MJ, Correia-Pinto J, Rocha G, et al. Brain-type natriuretic peptide in the diagnosis and management of persistent pulmonary hypertension of the newborn. *Pediatrics*. 2005;115(4):1111; author reply 1112. PMID: 15805406. *Exclude - Not a full publication*

Baptista MJ, Rocha G, Clemente F, et al. N-terminal-pro-B type natriuretic peptide as a useful tool to evaluate pulmonary hypertension and cardiac function in CDH infants. *Neonatology*. 2008;94(1):22-30. PMID: 18160811. *Exclude - No study population of interest*

Baquero H, Soliz A, Neira F, et al. Oral sildenafil in infants with persistent pulmonary hypertension of the newborn: a pilot randomized blinded study. *Pediatrics*. 2006;117(4):1077-83. PMID: 16585301. *Exclude - no primary or secondary outcomes of interest*

Barbosa MM, Lamounier JA, Oliveira EC, et al. Pulmonary hypertension in schistosomiasis mansoni. *Trans R Soc Trop Med Hyg*. 1996;90(6):663-5. PMID: 9015509. *Exclude - no primary or secondary outcomes of interest*

Barreto AC, Franchi SM, Castro CR, et al. One-year follow-up of the effects of sildenafil on pulmonary arterial hypertension and veno-occlusive disease. *Braz J Med Biol Res*. 2005;38(2):185-95. PMID: 15785829. *Exclude - No comparisons of interest*



- Barreto AC, Maeda NY, Soares RP, et al. Rosuvastatin and vascular dysfunction markers in pulmonary arterial hypertension: a placebo-controlled study. *Braz J Med Biol Res.* 2008;41(8):657-63. PMID: 18797697. *Exclude - No comparisons of interest*
- Barst R, Russell S, Oudiz R, et al. Effects of oral sildenafil treatment on exercise capacity in pediatric pulmonary arterial hypertension (PAH). *Chest.* 2011;140(4). *Exclude - Not a full publication*
- Barst RJ. Long-term prostacyclin reduces pulmonary vascular resistance in severe primary pulmonary hypertension. *Clin Exp Rheumatol.* 1998;16(3):253-4. PMID: 9631745. *Exclude - Not a full publication*
- Barst RJ, Galie N, Naeije R, et al. Long-term outcome in pulmonary arterial hypertension patients treated with subcutaneous treprostinil. *Eur Respir J.* 2006;28(6):1195-203. PMID: 16899485. *Exclude - no comparisons of interest.*
- Barst RJ, Ivy D, Dingemans J, et al. Pharmacokinetics, safety, and efficacy of bosentan in pediatric patients with pulmonary arterial hypertension. *Clin Pharmacol Ther.* 2003;73(4):372-82. PMID: 12709727. *Exclude - No comparisons of interest*
- Barst RJ, Kato GJ, Sachdev V, et al. Predictors of six-minute walk distance in adults with sickle cell anemia in the walk-PHaSST study. *Blood.* 2010;116(21). *Exclude - Not a full publication*
- Barst RJ, Maislin G, Fishman AP. Vasodilator therapy for primary pulmonary hypertension in children. *Circulation.* 1999;99(9):1197-208. PMID: 10069788. *Exclude - no comparisons of interest.*
- Bartosik I, Eskilsson J, Ekman R, et al. Correlation between plasma concentrations of calcitonin gene related peptide and pulmonary pressure in patients with systemic sclerosis. *Ann Rheum Dis.* 2002;61(3):261-3. PMID: 11830435. *Exclude - No comparisons of interest*
- Baskar Karthekeyan R, Saldanha R, Sahadevan MR, et al. Scimitar syndrome: experience with 6 patients. *Asian Cardiovasc Thorac Ann.* 2009;17(3):266-71. PMID: 19643850. *Exclude - Not a full publication*
- Bassyouni IH, Gheita TA, Talaat RM. Clinical significance of serum levels of sCD36 in patients with systemic sclerosis: preliminary data. *Rheumatology (Oxford).* 2011;50(11):2108-12. PMID: 21890620. *Exclude - No comparisons of interest*
- Batal O, Buchanan K, Elliott A, et al. Does obesity affect brain natriuretic peptide levels in patients with pulmonary arterial hypertension? *J Am Coll Cardiol.* 2012;59(13):E1591. *Exclude - Not a full publication*
- Battle RW, Davitt MA, Cooper SM, et al. Prevalence of pulmonary hypertension in limited and diffuse scleroderma. *Chest.* 1996;110(6):1515-9. PMID: 8989070. *Exclude - No comparisons of interest*
- Baughman RP, Judson MA, Lower EE, et al. Inhaled iloprost for sarcoidosis associated pulmonary hypertension. *Sarcoidosis Vasc Diffuse Lung Dis.* 2009;26(2):110-20. PMID: 20560291. *Exclude - No comparisons of interest*
- Baysal A, Yildirim A, Sasmazel A, et al. The prognostic value of plasma B-type natriuretic peptide in children with pulmonary hypertension undergoing congenital heart disease surgery. *Appl Cardiopulm Pathophysiol.* 2012;16:200-201. *Exclude - Not a full publication*
- Bech-Hanssen O, Lindgren F, Selimovic N, et al. Echocardiography can identify patients with increased pulmonary vascular resistance by assessing pressure reflection in the pulmonary circulation. *Circ Cardiovasc Imaging.* 2010;3(4):424-32. PMID: 20448141. *Exclude - no primary or secondary outcomes of interest*
- Bech-Hanssen O, Selimovic N, Rundqvist B, et al. Doppler echocardiography can provide a comprehensive assessment of right ventricular afterload. *J Am Soc Echocardiogr.* 2009;22(12):1360-7. PMID: 19880275. *Exclude - no primary or secondary outcomes of interest*
- Becvar R, Jansa P, Stork J, et al. Epidemiological study of pulmonary arterial hypertension related to systemic sclerosis in the Czech Republic. *Clin Exp Rheumatol.* 2010;28(2):S129. *Exclude - Not a full publication*
- Beghetti M, Haworth SG, Bonnet D, et al. Pharmacokinetic and clinical profile of a novel formulation of bosentan in children with pulmonary arterial hypertension: the FUTURE-1 study. *Br J Clin Pharmacol.* 2009;68(6):948-55. PMID: 20002090. *Exclude - No comparisons of interest*
- Beghetti M, Hoepfer MM, Kiely DG, et al. Safety experience with bosentan in 146 children 2-11 years old with pulmonary arterial hypertension: results from the European Postmarketing Surveillance program. *Pediatr Res.* 2008;64(2):200-4. PMID: 18414142. *Exclude - No comparisons of interest*

Behzadnia N, Najafizadeh K, Sharif-Kashani B, et al. Noninvasive assessment of acute cardiopulmonary effects of an oral single dose of sildenafil in patients with idiopathic pulmonary hypertension. *Heart Vessels*. 2010;25(4):313-8. PMID: 20676840.

*Exclude - No comparisons of interest*

Belden H. New PAH drug improves exercise capacity. *Drug Topics*. 2007;151(14). *Exclude - Not a full publication*

Belenkov Yu N, Chazova IE, Samko AN, et al. Use of a calcium antagonist isradipine in patients with primary pulmonary hypertension. *Kardiologiya*. 1995;35(7):9-13. *Exclude - Not available in English*.

Benatar A, Clarke J, Silverman M. Pulmonary hypertension in infants with chronic lung disease: non-invasive evaluation and short term effect of oxygen treatment. *Arch Dis Child Fetal Neonatal Ed*. 1995;72(1):F14-9. PMID: 7743277. *Exclude - No comparisons of interest*

Bendayan D, Fink G, Aravot D, et al. Continuous intravenous epoprostenol in pulmonary hypertension: the Israel experience. *Isr Med Assoc J*. 2002;4(4):255-8. PMID: 12001697. *Exclude - No comparisons of interest*

Ben-Dor I, Kramer MR, Raccach A, et al. Echocardiography versus right-sided heart catheterization among lung transplantation candidates. *Ann Thorac Surg*. 2006;81(3):1056-60. PMID: 16488722. *Exclude - No study population of interest*

Benjaminov FS, Prentice M, Sniderman KW, et al. Portopulmonary hypertension in decompensated cirrhosis with refractory ascites. *Gut*. 2003;52(9):1355-62. PMID: 12912870. *Exclude - No comparisons of interest*

Benza R, Gotzkowsky K, Jenkins A, et al. Effect of earlier initiation of inhaled treprostinil (ITRE) on long term outcomes in patients with pulmonary arterial hypertension (PAH). *Chest*. 2011;140(4). *Exclude - Not a full publication*

Benza RL, Gomberg-Maitland M, Miller DP, et al. The REVEAL Registry risk score calculator in patients newly diagnosed with pulmonary arterial hypertension. *Chest*. 2012;141(2):354-62. PMID: 21680644. *Exclude - no primary or secondary outcomes of interest*

Benza RL, Gomberg-Maitland M, Naeije R, et al. Prognostic factors associated with increased survival in patients with pulmonary arterial hypertension treated with subcutaneous treprostinil in randomized, placebo-controlled trials. *J Heart Lung Transplant*. 2011;30(9):982-9. PMID: 21531577. *Exclude - Does not include intervention of interest*

Benza RL, Rayburn BK, Tallaj JA, et al. Efficacy of bosentan in a small cohort of adult patients with pulmonary arterial hypertension related to congenital heart disease. *Chest*. 2006;129(4):1009-15. PMID: 16608951. *Exclude - No comparisons of interest*

Benza RL, Rayburn BK, Tallaj JA, et al. Treprostinil-based therapy in the treatment of moderate-to-severe pulmonary arterial hypertension: long-term efficacy and combination with bosentan. *Chest*. 2008;134(1):139-45. PMID: 18403673. *Exclude - no comparisons of interest*.

Benza RL, Seeger W, McLaughlin VV, et al. Long-term effects of inhaled treprostinil in patients with pulmonary arterial hypertension: The TREprostinil sodium Inhalation Used in the Management of Pulmonary arterial Hypertension (TRIUMPH) study open-label extension. *J Heart Lung Transplant*. 2011;30(12):1327-1333. *Exclude - no comparisons of interest*.

Beretta L, Caronni M, Origgi L, et al. Hormone replacement therapy may prevent the development of isolated pulmonary hypertension in patients with systemic sclerosis and limited cutaneous involvement. *Scand J Rheumatol*. 2006;35(6):468-71. PMID: 17343256. *Exclude - Does not include intervention of interest*

Berger RM, Beghetti M, Galie N, et al. Atrial septal defects versus ventricular septal defects in BREATHE-5, a placebo-controlled study of pulmonary arterial hypertension related to Eisenmenger's syndrome: a subgroup analysis. *Int J Cardiol*. 2010;144(3):373-8. PMID: 19464064. *Exclude - No study population of interest*

Bergot E, Sitbon O, Cottin V, et al. Current epoprostenol use in patients with severe pulmonary hypertension (PH): Data from the French PH registry. *Eur Heart J*. 2011;32:172-173. *Exclude - Not a full publication*

Bernal V, Pascual I, Esquivias P, et al. N-terminal brain natriuretic peptide as a diagnostic test in cirrhotic patients with pulmonary arterial hypertension. *Transplant Proc*. 2009;41(3):987-8. PMID: 19376405. *Exclude - no primary or secondary outcomes of interest*

Beyer J, Kolditz M, Ewert R, et al. L-arginine plasma levels and severity of idiopathic pulmonary arterial hypertension. *Vasa*. 2008;37(1):61-7. PMID: 18512543. *Exclude - Does not include intervention of interest*

Beyer S, Speich R, Fischler M, et al. Long-term experience with oral or inhaled vasodilator combination therapy in patients with pulmonary hypertension. *Swiss Med Wkly*. 2006;136(7-8):114-8. PMID: 16633955. *Exclude - Does not include intervention of interest.*

Bharani A, Mathew V, Sahu A, et al. The efficacy and tolerability of sildenafil in patients with moderate-to-severe pulmonary hypertension. *Indian Heart J*. 2003;55(1):55-9. PMID: 12760589. *Exclude - No comparisons of interest*

Bhatia S, Frantz RP, Severson CJ, et al. Immediate and long-term hemodynamic and clinical effects of sildenafil in patients with pulmonary arterial hypertension receiving vasodilator therapy. *Mayo Clin Proc*. 2003;78(10):1207-13. PMID: 14531479. *Exclude - No comparisons of interest*

Billy-Brissac R, Blanchet-Deverly A, Etienne-Julan M, et al. Pulmonary hypertension in an adult sickle cell population in Guadeloupe. *Int J Cardiol*. 2009;135(1):122-3. PMID: 18466988. *Exclude - No comparisons of interest*

Blagnjevic J, Pallini F, Peruzzi F, et al. Detection of nulllatentnull pulmonary arterial hypertension (PAH) in systemic sclerosis (SSC): The usefulness of non invasive echocardiography. *Clin Exp Rheumatol*. 2010;28(2):S131. *Exclude - Not a full publication*

Blagnjevic J, Pallini F, Peruzzi F, et al. Bosentan for exercise induced pulmonary arterial hypertension in systemic sclerosis: Results from an open study. *Clin Exp Rheumatol*. 2010;28(2):S131. *Exclude - Not a full publication*

Blalock SE, Matulevicius S, Mitchell LC, et al. Long-term outcomes with ambrisentan monotherapy in pulmonary arterial hypertension. *J Card Fail*. 2010;16(2):121-7. PMID: 20142023. *Exclude - no comparisons of interest.*

Blumberg FC, Riegger GA, Pfeifer M. Hemodynamic effects of aerosolized iloprost in pulmonary hypertension at rest and during exercise. *Chest*. 2002;121(5):1566-71. PMID: 12006445. *Exclude - No comparisons of interest*

Bombardini T, Sicari R, Bianchini E, et al. Abnormal shortened diastolic time length at increasing heart rates in patients with abnormal exercise-induced increase in pulmonary artery pressure. *Cardiovasc Ultrasound*. 2011;9:36. PMID: 22104611. *Exclude - No study population of interest*

Bonino C, Cavagna L, Caporali R, et al. Head to head comparison of brain natriuretic peptide and NT-proBNP in the screening of pulmonary arterial hypertension in systemic sclerosis patients. *Clin Exp Rheumatol*. 2010;28(2):S129. *Exclude - Not a full publication*

Bonnet D, Jas X, Rottat L, et al. Characteristics of PAH associated with pretricuspid shunts in the registry of the French PAH network. *Cardiol Young*. 2012;22:S29-S30. *Exclude - Not a full publication*

Bonnet D, Levy M, Mauge L, et al. Circulating endothelial cell levels decrease after vasodilator therapy and are a biomarker of deterioration in pediatric pulmonary hypertension. *Cardiol Young*. 2012;22:S40. *Exclude - Not a full publication*

Bossone E, Duong-Wagner TH, Paciocco G, et al. Echocardiographic features of primary pulmonary hypertension. *J Am Soc Echocardiogr*. 1999;12(8):655-62. PMID: 10441222. *Exclude - No comparisons of interest*

Bouchard JL, Aurigemma GP, Hill JC, et al. Usefulness of the pulmonary arterial systolic pressure to predict pulmonary arterial wedge pressure in patients with normal left ventricular systolic function. *Am J Cardiol*. 2008;101(11):1673-6. PMID: 18489950. *Exclude - No study population of interest*

Bozbas SS, Bozbas H, Atar A, et al. Comparative effects of losartan and nifedipine therapy on exercise capacity, Doppler echocardiographic parameters and endothelin levels in patients with secondary pulmonary hypertension. *Anadolu Kardiyol Derg*. 2010;10(1):43-9. PMID: 20150004. *Exclude - No study population of interest*

Bozbas SS, Yilmaz EB, Dogrul I, et al. Preoperative pulmonary evaluation of liver transplant candidates: Results from 341 adult patients. *Ann Transplant*. 2011;16(3):88-96. *Exclude - no primary or secondary outcomes of interest*

Brady CJ. Improving access to pulmonary care for children with sickle cell disease. *Am J Hematol*. 2011;86(10):E32-E33. *Exclude - Not a full publication*

- Bratel T, Lagerstrand L, Brodin LA, et al. Ventilation/perfusion ratios in pulmonary arterial hypertension: effects of IV and inhaled prostacyclin derivatives. *Chest*. 2005;128(6 Suppl):615S-616S. PMID: 16373868. *Exclude - Not a full publication*
- Bratel T, Lagerstrand L, Brodin LA, et al. Ventilation-perfusion relationships in pulmonary arterial hypertension: effect of intravenous and inhaled prostacyclin treatment. *Respir Physiol Neurobiol*. 2007;158(1):59-69. PMID: 17452130. *Exclude - Does not include intervention of interest*
- Bream-Rouwenhorst HR, Hobbs RA. Pulmonary hypertension: An update. *US Pharm*. 2008;33(8). *Exclude - Not a full publication*
- Brechot N, Gambotti L, Lafitte S, et al. Usefulness of right ventricular isovolumic relaxation time in predicting systolic pulmonary artery pressure. *Eur J Echocardiogr*. 2008;9(4):547-54. PMID: 18490309. *Exclude - No comparisons of interest*
- Brenot F, Herve P, Petitpretz P, et al. Primary pulmonary hypertension and fenfluramine use. *Br Heart J*. 1993;70(6):537-41. PMID: 8280518. *Exclude – does not include intervention of interest*
- Bright J, Shumoogam J, Tear S. Deal highlights. *IDrugs*. 2007;10(10):732-735. *Exclude - Not a full publication*
- Brili SSV, Stamatopoulos H, Misailidou M, et al. Longitudinal strain curves of the RV free wall differ in morphology in patients with pulmonary hypertension compared with controls. *Eur Heart J*. 2011;32:117. *Exclude - Not a full publication*
- Brittain JE, Hulkower B, Jones SK, et al. Placenta growth factor in sickle cell disease: association with hemolysis and inflammation. *Blood*. 2010;115(10):2014-20. PMID: 20040765. *Exclude - No comparisons of interest*
- Brown SB, Raina A, Katz D, et al. Longitudinal shortening accounts for the majority of right ventricular contraction and improves after pulmonary vasodilator therapy in normal subjects and patients with pulmonary arterial hypertension. *Chest*. 2011;140(1):27-33. PMID: 21106653. *Exclude - No comparisons of interest*
- Brun H, Holmstrom H, Thaulow E, et al. Patients with pulmonary hypertension related to congenital systemic-to-pulmonary shunts are characterized by inflammation involving endothelial cell activation and platelet-mediated inflammation. *Congenit Heart Dis*. 2009;4(3):153-9. PMID: 19489942. *Exclude - No comparisons of interest*
- Brun H, Moller T, Fredriksen PM, et al. Mechanisms of exercise-induced pulmonary hypertension in patients with cardiac septal defects. *Pediatr Cardiol*. 2012;33(5):782-790. *Exclude - no primary or secondary outcomes of interest*
- Bull TM, Golpon H, Hebbel RP, et al. Circulating endothelial cells in pulmonary hypertension. *Thromb Haemost*. 2003;90(4):698-703. PMID: 14515191. *Exclude - No comparisons of interest*
- Bushuev VI, Miasnikova GY, Sergueeva AI, et al. Endothelin-1, vascular endothelial growth factor and systolic pulmonary artery pressure in patients with Chuvash polycythemia. *Haematologica*. 2006;91(6):744-9. PMID: 16769575. *Exclude - No comparisons of interest*
- Busteed S, Moots RJ, Thompson RN. Screening for pulmonary arterial hypertension in systemic sclerosis. *Rheumatology (Oxford)*. 2004;43(10):1315-6; author reply 1316. PMID: 15448224. *Exclude - Not a full publication*
- Butt AY, Higenbottam T. New therapies for primary pulmonary hypertension. *Chest*. 1994;105(2 Suppl):21S-25S. PMID: 8110298. *Exclude – not a full publication*
- Cacoub P, Dorent R, Nataf P, et al. Endothelin-1 in the lungs of patients with pulmonary hypertension. *Cardiovasc Res*. 1997;33(1):196-200. PMID: 9059544. *Exclude - Does not include intervention of interest*
- Cada DJ, Levien T, Baker DE. Treprostinil sodium injection. *Hosp Pharm*. 2002;37(11):1196-1204. *Exclude - Not a full publication*
- Cada DJ, Levien T, Baker DE. Ambrisentan. *Hosp Pharm*. 2007;42(12):1145-1154. *Exclude - Not a full publication*
- Cadeddu Dessalvi C, Caeddu F, Lilliu M, et al. Usefulness of exercise echocardiography in the evaluation of left ventricular impairment in systemic sclerosis patients. *Eur Heart J*. 2011;32:601. *Exclude - Not a full publication*
- Callejas-Rubio JL, Moreno-Escobar E, de la Fuente PM, et al. Prevalence of exercise pulmonary arterial hypertension in scleroderma. *J Rheumatol*. 2008;35(9):1812-6. PMID: 18634147. *Exclude - No comparisons of interest*
- Can MM, Kaymaz C, Tanboga IH, et al. Increased right ventricular glucose metabolism in patients with pulmonary arterial hypertension. *Clin Nucl Med*. 2011;36(9):743-8. PMID: 21825840. *Exclude - No comparisons of interest*

Can MM, Tanboga IH, Demircan HC, et al. Enhanced hemostatic indices in patients with pulmonary arterial hypertension: an observational study. *Thromb Res.* 2010;126(4):280-2. PMID: 20673969. *Exclude - No comparisons of interest*

Can MM, Tanboga IH, Tokgoz HC, et al. The prognostic value of FDG PET/CT uptake of bone marrow in patients with idiopathic pulmonary arterial hypertension. *Eur Heart J.* 2011;32:434. *Exclude - Not a full publication*

Cappelleri JC, Hwang LJ, Mardekian J, et al. Measurement properties of peak VO<sub>2</sub> in children with pulmonary arterial hypertension. *Value Health.* 2010;13(7):A367. *Exclude - Not a full publication*

Cappelleri JC, Hwang LJ, Mardekian J, et al. Response profiles of sildenafil citrate on exercise capacity, hemodynamic function, and health-related quality of life in children with pulmonary arterial hypertension. *Value Health.* 2010;13(7):A343. *Exclude - Not a full publication*

Caramaschi P, Volpe A, Tinazzi I, et al. Does cyclically iloprost infusion prevent severe isolated pulmonary hypertension in systemic sclerosis? Preliminary results. *Rheumatol Int.* 2006;27(2):203-5. PMID: 17006704. *Exclude - No comparisons of interest*

Caravita S, Wu SC, Secchi MB, et al. Long-term effects of intermittent iloprost infusion on pulmonary arterial pressure in connective tissue disease. *Eur J Intern Med.* 2011;22(5):518-521. *Exclude - no primary or secondary outcomes of interest*

Carroll CL, Backer CL, Mavroudis C, et al. Inhaled prostacyclin following surgical repair of congenital heart disease--a pilot study. *J Card Surg.* 2005;20(5):436-9. PMID: 16153274. *Exclude - No comparisons of interest*

Cartin-Ceba R, Swanson K, Iyer V, et al. Safety and efficacy of ambrisentan for the treatment of portopulmonary hypertension. *Chest.* 2011;139(1):109-14. PMID: 20705798. *Exclude - No comparisons of interest*

Carulli MT, Handler C, Coghlan JG, et al. Can CCL2 serum levels be used in risk stratification or to monitor treatment response in systemic sclerosis? *Ann Rheum Dis.* 2008;67(1):105-9. PMID: 17604287. *Exclude - No comparisons of interest*

Castelain V, Chemla D, Humbert M, et al. Pulmonary artery pressure-flow relations after prostacyclin in primary pulmonary hypertension. *Am J Respir Crit Care Med.* 2002;165(3):338-40. PMID: 11818317. *Exclude - No comparisons of interest*

Castillo-Palma MJ, Garcia-Hernandez FJ, Gonzalez-Leon R, et al. Pulmonary hypertension in a series of patients with SSc. Prevalence of different variants. *Rheumatology (Oxford).* 2012;51:ii91-ii92. *Exclude - Not a full publication*

Castro PF, Greig D, Verdejo HE, et al. Intrapulmonary shunting associated with sildenafil treatment in a patient with idiopathic pulmonary arterial hypertension. *Thorax.* 2011;66(12):1097-8. PMID: 21289023. *Exclude - Not a full publication*

Cefle A, Inanc M, Sayarlioglu M, et al. Pulmonary hypertension in systemic lupus erythematosus: relationship with antiphospholipid antibodies and severe disease outcome. *Rheumatol Int.* 2011;31(2):183-9. PMID: 20012052. *Exclude - No comparisons of interest*

Cella G, Bellotto F, Tona F, et al. Plasma markers of endothelial dysfunction in pulmonary hypertension. *Chest.* 2001;120(4):1226-30. PMID: 11591565. *Exclude - No comparisons of interest*

Chadha C, Pritzker M, Mariash CN. Effect of epoprostenol on the thyroid gland: enlargement and secretion of thyroid hormone. *Endocr Pract.* 2009;15(2):116-21. PMID: 19289321. *Exclude - No study population of interest*

Chang B, Wigley FM, White B, et al. Scleroderma patients with combined pulmonary hypertension and interstitial lung disease. *J Rheumatol.* 2003;30(11):2398-405. PMID: 14677184. *Exclude - No comparisons of interest*

Channick R, Badesch DB, Tapson VF, et al. Effects of the dual endothelin receptor antagonist bosentan in patients with pulmonary hypertension: a placebo-controlled study. *J Heart Lung Transplant.* 2001;20(2):262-263. PMID: 11250530. *Exclude - Not a full publication*

Channick RN, Olschewski H, Seeger W, et al. Safety and efficacy of inhaled treprostinil as add-on therapy to bosentan in pulmonary arterial hypertension. *J Am Coll Cardiol.* 2006;48(7):1433-7. PMID: 17010807. *Exclude - No comparisons of interest*

Chapman PJ, Bateman ED, Benatar SR. Prognostic and therapeutic considerations in clinical primary pulmonary hypertension. *Respir Med.* 1990;84(6):489-94. PMID: 2274688. *Exclude - no primary or secondary outcomes of interest*

- Charloux A, Chaouat A, Piquard F, et al. Renal hyporesponsiveness to brain natriuretic peptide: both generation and renal activity of cGMP are decreased in patients with pulmonary hypertension. *Peptides*. 2006;27(11):2993-9. PMID: 16822585. *Exclude - Does not include intervention of interest*
- Chau EM, Fan KY, Chow WH. Effects of chronic sildenafil in patients with Eisenmenger syndrome versus idiopathic pulmonary arterial hypertension. *Int J Cardiol*. 2007;120(3):301-5. PMID: 17174418. *Exclude - No comparisons of interest*
- Chaudhry TA, Younas M, Baig A. Ventricular Septal defect and associated complications. *J Pak Med Assoc*. 2011;61(10):1001-1004. *Exclude - no primary or secondary outcomes of interest*
- Chaudry RA, Cikes M, Karu T, et al. Paediatric sickle cell disease: pulmonary hypertension but normal vascular resistance. *Arch Dis Child*. 2011;96(2):131-6. PMID: 21030373. *Exclude - No comparisons of interest*
- Chen JM, Levin HR, Michler RE, et al. Reevaluating the significance of pulmonary hypertension before cardiac transplantation: determination of optimal thresholds and quantification of the effect of reversibility on perioperative mortality. *J Thorac Cardiovasc Surg*. 1997;114(4):627-34. PMID: 9338649. *Exclude - No comparisons of interest*
- Chen L, Zhong W, Xin Z, et al. Summerization of adverse drug reaction of Vardenafil in treatment of 2062 patients. *Chin J Androl*. 2009;23(1):35-38. *Exclude - not available in English*.
- Chin KM, Badesch DB, Robbins IM, et al. Veletri(registered trademark) and Flolan(registered trademark) (epoprostenol sodium) in the treatment of pulmonary arterial hypertension. *J Heart Lung Transplant*. 2012;31(4):S28. *Exclude - Not a full publication*
- Chin KM, Channick RN, de Lemos JA, et al. Hemodynamics and epoprostenol use are associated with thrombocytopenia in pulmonary arterial hypertension. *Chest*. 2009;135(1):130-6. PMID: 18719056. *Exclude - No comparisons of interest*
- Chin KM, Kingman M, de Lemos JA, et al. Changes in right ventricular structure and function assessed using cardiac magnetic resonance imaging in bosentan-treated patients with pulmonary arterial hypertension. *Am J Cardiol*. 2008;101(11):1669-72. PMID: 18489949. *Exclude - No comparisons of interest*
- Chockalingam A, Gnanavelu G, Venkatesan S, et al. Efficacy and optimal dose of sildenafil in primary pulmonary hypertension. *Int J Cardiol*. 2005;99(1):91-5. PMID: 15721505. *Exclude - No comparisons of interest*
- Chua R, Keogh AM, Byth K, et al. Comparison and validation of three measures of quality of life in patients with pulmonary hypertension. *Intern Med J*. 2006;36(11):705-10. PMID: 17040356. *Exclude - Does not include intervention of interest*
- Chung L, Liu J, Parsons L, et al. Characterization of connective tissue disease-associated pulmonary arterial hypertension from REVEAL: Identifying systemic sclerosis as a unique phenotype. *Chest*. 2010;138(6):1383-1394. *Exclude - no primary or secondary outcomes of interest*
- Chung L, Parsons LS, Hassoun PM, et al. Functional class change in patients with connective tissue disease-associated pulmonary arterial hypertension: Associations with survival and exercise capacity. *Arthritis Rheum*. 2011;63(10). *Exclude - Not a full publication*
- Chung SM, Lee CK, Lee EY, et al. Clinical aspects of pulmonary hypertension in patients with systemic lupus erythematosus and in patients with idiopathic pulmonary arterial hypertension. *Clin Rheumatol*. 2006;25(6):866-72. PMID: 16496078. *Exclude - No comparisons of interest*
- Cioffi G, de Simone G, Mureddu G, et al. Right atrial size and function in patients with pulmonary hypertension associated with disorders of respiratory system or hypoxemia. *Eur J Echocardiogr*. 2007;8(5):322-31. PMID: 16876482. *Exclude - No study population of interest*
- Ciurzynski M, Bienias P, Irzyk K, et al. Endothelin and N-terminal pro-B type natriuretic peptide reflect impaired right ventricular function and decreased exercise capacity in patients with systemic sclerosis. *Eur Heart J*. 2011;32:823. *Exclude - Not a full publication*
- Ciurzynski M, Bienias P, Lichodziejewska B, et al. Non-invasive diagnostic and functional evaluation of cardiac involvement in patients with systemic sclerosis. *Clin Rheumatol*. 2008;27(8):991-7. PMID: 18256871. *Exclude - No comparisons of interest*
- Ciurzynski M, Bienias P, Pruszczyk P. Should patients with connective tissue disease undergo exercise Doppler echocardiography? *Chest*. 2010;138(6):1523-4; author reply 1524. PMID: 21138893. *Exclude - Not a full publication*

Clements PJ, Tan M, McLaughlin VV, et al. The pulmonary arterial hypertension quality enhancement research initiative: comparison of patients with idiopathic PAH to patients with systemic sclerosis-associated PAH. *Ann Rheum Dis*. 2011. PMID: 21998119. *Exclude - No comparisons of interest*

Clements PJ, Tan M, McLaughlin VV, et al. The pulmonary arterial hypertension quality enhancement research initiative: comparison of patients with idiopathic PAH to patients with systemic sclerosis-associated PAH. *Ann Rheum Dis*. 2012;71(2):249-52. PMID: 21998119. *Exclude - no primary or secondary outcomes of interest*

Cockrill BA, Kacmarek RM, Fifer MA, et al. Comparison of the effects of nitric oxide, nitroprusside, and nifedipine on hemodynamics and right ventricular contractility in patients with chronic pulmonary hypertension. *Chest*. 2001;119(1):128-36. PMID: 11157594. *Exclude - No comparisons of interest*

Codullo V, Cuomo G, Fusetti C, et al. Exercise echocardiography in SSC: Predictive role in the development of pulmonary hypertension. *Rheumatology (Oxford)*. 2012;51:ii11-ii12. *Exclude - Not a full publication*

Codullo V, Cuomo G, Fusetti C, et al. Features of SSC patients with inappropriate exercise-induced increase in pulmonary artery pressure estimated by echocardiography. *Rheumatology (Oxford)*. 2012;51:ii12. *Exclude - Not a full publication*

Cohen AJ, Cool C, Gorg S, et al. Low or absent peptidase expression in plexiform lesions of primary pulmonary hypertension. *Chest*. 1998;114(1 Suppl):30S-31S. PMID: 9676613. *Exclude - Not a full publication*

Collados MT, Sandoval J, Lopez S, et al. Characterization of von Willebrand factor in primary pulmonary hypertension. *Heart Vessels*. 1999;14(5):246-52. PMID: 10830921. *Exclude - No comparisons of interest*

Collados MT, Velazquez B, Borbolla JR, et al. Endothelin-1 and functional tissue factor: a possible relationship with severity in primary pulmonary hypertension. *Heart Vessels*. 2003;18(1):12-7. PMID: 12644876. *Exclude - No comparisons of interest*

Colli AM, Ciarmoli E, Gangi S, et al. Predictors of medium-term treatment of pulmonary hypertension in a population of very and extremely low birthweight (VLBW, ELBW) preterm infants. *G Ital Cardiol*. 2011;12(10):14S-15S. *Exclude - Not a full publication*

Collins N, Bastian B, Quikere L, et al. Abnormal pulmonary vascular responses in patients registered with a systemic autoimmunity database: Pulmonary Hypertension Assessment and Screening Evaluation using stress echocardiography (PHASE-I). *Eur J Echocardiogr*. 2006;7(6):439-46. PMID: 16431161. *Exclude - No comparisons of interest*

Colombatti R, Maschietto N, Varotto E, et al. Pulmonary hypertension in sickle cell disease children under 10 years of age. *Br J Haematol*. 2010;150(5):601-9. PMID: 20553267. *Exclude - No comparisons of interest*

Condino AA, Ivy DD, O'Connor JA, et al. Portopulmonary hypertension in pediatric patients. *J Pediatr*. 2005;147(1):20-6. PMID: 16027687. *Exclude - No comparisons of interest*

Condliffe R, Pickworth J, Hopkinson K, et al. Serum osteoprotegerin predicts mortality in a prospective study on incident cases of pulmonary arterial hypertension. *Thorax*. 2011;66:A34. *Exclude - Not a full publication*

Condo M, Evans N, Bellu R, et al. Echocardiographic assessment of ductal significance: Retrospective comparison of two methods. *Arch Dis Child Fetal Neonatal Ed*. 2012;97(1):F35-F38. *Exclude - No comparisons of interest*

Conficoni E, Leci E, Palazzini M, et al. Effects of s.c. treprostinil on top of double oral combination therapy in patients with pulmonary arterial hypertension (PAH) and inoperable chronic thromboembolic pulmonary hypertension (CTEPH). *Eur Heart J*. 2011;32:173. *Exclude - Not a full publication*

Conte JV, Gaine SP, Orens JB, et al. The influence of continuous intravenous prostacyclin therapy for primary pulmonary hypertension on the timing and outcome of transplantation. *J Heart Lung Transplant*. 1998;17(7):679-85. PMID: 9703232. *Exclude - No comparisons of interest*

Coral-Alvarado P, Quintana G, Garces MF, et al. Potential biomarkers for detecting pulmonary arterial hypertension in patients with systemic sclerosis. *Rheumatol Int*. 2009;29(9):1017-24. PMID: 19116719. *Exclude - No comparisons of interest*

Coral-Alvarado PX, Garces MF, Caminos JE, et al. Serum endoglin levels in patients suffering from systemic sclerosis and elevated systolic pulmonary arterial pressure. *Intl J Rheumatol*. 2010;2010. *Exclude - no primary or secondary outcomes of interest*

Cornwell WK, McLaughlin VV, Krishnan SM, et al. Does the outcome justify an oral-first treatment strategy for management of pulmonary arterial hypertension? *Chest*. 2011;140(3):697-705. PMID: 21622545. *Exclude - No comparisons of interest.*

Costard-Jackle A, Fowler MB, Influence of preoperative pulmonary artery pressure on mortality after heart transplantation: testing of potential reversibility of pulmonary hypertension with nitroprusside is useful in defining a high risk group. *J Am Coll Cardiol*. 1992;19(1):48-54. PMID: 1729345. *Exclude – does not include intervention of interest*

Cotrim C, Simoes O, Loureiro MJ, et al. Stress echocardiography in the evaluation of exercise physiology in patients with severe arterial pulmonary hypertension. New methodology. *Rev Port Cardiol*. 2005;24(12):1451-60. PMID: 16566404. *Exclude - No comparisons of interest*

Cotton CL, Gandhi S, Vaitkus PT, et al. Role of echocardiography in detecting portopulmonary hypertension in liver transplant candidates. *Liver Transpl*. 2002;8(11):1051-4. PMID: 12424719. *Exclude - No comparisons of interest*

Cozzi F, Montisci R, Marotta H, et al. Bosentan therapy of pulmonary arterial hypertension in connective tissue diseases. *Eur J Clin Invest*. 2006;36 Suppl 3:49-53. PMID: 16919011. *Exclude - No comparisons of interest*

Cracowski JL, Cracowski C, Bessard G, et al. Increased lipid peroxidation in patients with pulmonary hypertension. *Am J Respir Crit Care Med*. 2001;164(6):1038-42. PMID: 11587993. *Exclude - No comparisons of interest*

Croxtall JD, Lyseng-Williamson KA. Tadalafil: in pulmonary arterial hypertension. *Drugs*. 2010;70(4):479-88. PMID: 20205489. *Exclude - Not a full publication*

Dadfarmay S, Alhaj E, Manchikalapudi RB, et al. Left ventricular diastolic dysfunction in patients with pulmonary arterial hypertension (PAH). *J Card Fail*. 2010;16(8):S19. *Exclude - Not a full publication*

Dahoui HA, Hayek MN, Nietert PJ, et al. Pulmonary hypertension in children and young adults with sickle cell disease: evidence for familial clustering. *Pediatr Blood Cancer*. 2010;54(3):398-402. PMID: 19827138. *Exclude - No comparisons of interest*

D'Alto M, Romeo E, Argiento P, et al. Oral bosentan in patients with congenital heart disease related pulmonary hypertension and PWP >15 mm HG: Safety, tolerability, clinical, and haemodynamic impact. *Chest*. 2011;140(4). *Exclude - Not a full publication*

D'Alto M, Romeo E, Argiento P, et al. Survival and predictors of death in Eisenmenger syndrome. *Chest*. 2011;140(4). *Exclude - Not a full publication*

D'Alto M, Romeo E, Argiento P, et al. Therapy for pulmonary arterial hypertension due to congenital heart disease and Down's syndrome. *Int J Cardiol*. 2011. PMID: 21802156. *Exclude - No comparisons of interest*

D'Alto M, Romeo E, Argiento P, et al. Pulmonary vasoreactivity predicts long-term outcome in patients with Eisenmenger syndrome receiving bosentan therapy. *Heart*. 2010;96(18):1475-9. PMID: 20668108. *Exclude - Does not include intervention of interest*

D'Alto M, Romeo E, Argiento P, et al. Safety, tolerability, clinical and haemodynamic impact of oral bosentan in patients with congenital heart disease related pulmonary hypertension or Eisenmenger syndrome and PWP >15 mmHg. *Eur Heart J*. 2011;32:113. *Exclude - Not a full publication*

D'Alto M, Vizza CD, Romeo E, et al. Long term effects of bosentan treatment in adult patients with pulmonary arterial hypertension related to congenital heart disease (Eisenmenger physiology): safety, tolerability, clinical, and haemodynamic effect. *Heart*. 2007;93(5):621-5. PMID: 17135220. *Exclude - No comparisons of interest*

Damas JK, Otterdal K, Yndestad A, et al. Soluble CD40 ligand in pulmonary arterial hypertension: possible pathogenic role of the interaction between platelets and endothelial cells. *Circulation*. 2004;110(8):999-1005. PMID: 15302794. *Exclude - No comparisons of interest*

Dambrauskaite V, Delcroix M, Claus P, et al. Regional right ventricular dysfunction in chronic pulmonary hypertension. *J Am Soc Echocardiogr*. 2007;20(10):1172-80. PMID: 17570637. *Exclude - No comparisons of interest*

Dambrauskaite V, Delcroix M, Claus P, et al. The evaluation of pulmonary hypertension using right ventricular myocardial isovolumic relaxation time. *J Am Soc Echocardiogr*. 2005;18(11):1113-20. PMID: 16275518. *Exclude - No comparisons of interest*



- Dandekar PG, Verma Y. Efficacy and safety profile of phosphodiesterase 5 inhibitor sildenafil in pulmonary hypertension. *European Heart Journal, Supplement*. 2012;14:A7. *Exclude - Not a full publication*
- Dandel M, Kemper D, Weng Y, et al. Primary pulmonary hypertension: survival benefits of therapy with prostacyclin analogs and transplantation. *Transplant Proc*. 2003;35(6):2117-20. PMID: 14529860. *Exclude - No comparisons of interest*.
- Dandel M, Lehmkühl HB, Mulahasanovic S, et al. Survival of patients with idiopathic pulmonary arterial hypertension after listing for transplantation: impact of iloprost and bosentan treatment. *J Heart Lung Transplant*. 2007;26(9):898-906. PMID: 17845928. *Exclude - No comparisons of interest*.
- Date H, Kusano KF, Matsubara H, et al. Living-donor lobar lung transplantation for pulmonary arterial hypertension after failure of epoprostenol therapy. *J Am Coll Cardiol*. 2007;50(6):523-7. PMID: 17678735. *Exclude - No comparisons of interest*
- Davarpanah AH, Hodnett PA, Farrelly CT, et al. MDCT bolus tracking data as an adjunct for predicting the diagnosis of pulmonary hypertension and concomitant right-heart failure. *AJR Am J Roentgenol*. 2011;197(5):1064-72. PMID: 22021497. *Exclude - Does not include intervention of interest*
- Dawson JK, Goodson NG, Graham DR, et al. Raised pulmonary artery pressures measured with Doppler echocardiography in rheumatoid arthritis patients. *Rheumatology (Oxford)*. 2000;39(12):1320-5. PMID: 11136873. *Exclude - No comparisons of interest*
- de Azevedo AB, Sampaio-Barros PD, Torres RM, et al. Prevalence of pulmonary hypertension in systemic sclerosis. *Clin Exp Rheumatol*. 2005;23(4):447-54. PMID: 16095111. *Exclude - No comparisons of interest*
- De Castro LM, Jonassaint JC, Graham FL, et al. Pulmonary hypertension associated with sickle cell disease: clinical and laboratory endpoints and disease outcomes. *Am J Hematol*. 2008;83(1):19-25. PMID: 17724699. *Exclude - Does not include intervention of interest*
- De Castro S, Cavarretta E, Milan A, et al. Usefulness of tricuspid annular velocity in identifying global RV dysfunction in patients with primary pulmonary hypertension: a comparison with 3D echo-derived right ventricular ejection fraction. *Echocardiography*. 2008;25(3):289-93. PMID: 18307442. *Exclude - No comparisons of interest*
- De Chiara B, Moreo A, Musca F, et al. Assessment of pulmonary arterial pressure during exercise-Doppler echocardiography in systemic sclerosis. *Eur Heart J*. 2011;32:439. *Exclude - Not a full publication*
- de Groote P, Gressin V, Hachulla E, et al. Evaluation of cardiac abnormalities by Doppler echocardiography in a large nationwide multicentric cohort of patients with systemic sclerosis. *Ann Rheum Dis*. 2008;67(1):31-6. PMID: 17267515. *Exclude - No comparisons of interest*
- De Jaegere AP, van den Anker JN. Endotracheal instillation of prostacyclin in preterm infants with persistent pulmonary hypertension. *Eur Respir J*. 1998;12(4):932-4. PMID: 9817171. *Exclude - No comparisons of interest*
- De Macedo TB, Braz AS, Anti SMA, et al. Echocardiographic evaluation in systemic lupus erythematosus: A cross-sectional study of 35 patients. *Rev Bras Reumatol*. 2000;40(3):97-104. *Exclude - Not available in English*.
- De Pietri L, Montalti R, Begliomini B, et al. Pulmonary hypertension as a predictor of postoperative complications and mortality after liver transplantation. *Transplant Proc*. 2010;42(4):1188-90. PMID: 20534257. *Exclude - No comparisons of interest*
- De Santo LS, Mastroianni C, Romano G, et al. Role of sildenafil in acute posttransplant right ventricular dysfunction: successful experience in 13 consecutive patients. *Transplant Proc*. 2008;40(6):2015-8. PMID: 18675118. *Exclude - No study population of interest*
- De Wet CJ, Affleck DG, Jacobsohn E, et al. Inhaled prostacyclin is safe, effective, and affordable in patients with pulmonary hypertension, right heart dysfunction, and refractory hypoxemia after cardiothoracic surgery. *J Thorac Cardiovasc Surg*. 2004;127(4):1058-67. PMID: 15052203. *Exclude - No study population of interest*
- Degano B, Yaici A, Le Pavée J, et al. Long-term effects of bosentan in patients with HIV-associated pulmonary arterial hypertension. *Eur Respir J*. 2009;33(1):92-8. PMID: 18799506. *Exclude - No comparisons of interest*
- Della Rossa A, Casigliani S, D'Ascanio A, et al. Is NT-probnp a marker of vascular burden in SSc? *Rheumatology (Oxford)*. 2012;51:ii101. *Exclude - Not a full publication*

Demoncheaux EA, Higenbottam TW, Kiely DG, et al. Decreased whole body endogenous nitric oxide production in patients with primary pulmonary hypertension. *J Vasc Res.* 2005;42(2):133-6. PMID: 15665548. *Exclude - No comparisons of interest*

Denton CP, Pope JE, Peter HH, et al. Long-term effects of bosentan on quality of life, survival, safety and tolerability in pulmonary arterial hypertension related to connective tissue diseases. *Ann Rheum Dis.* 2008;67(9):1222-8. PMID: 18055477. *Exclude - No comparisons of interest*

Derchi G, Forni GL, Formisano F, et al. Efficacy and safety of sildenafil in the treatment of severe pulmonary hypertension in patients with hemoglobinopathies. *Haematologica.* 2005;90(4):452-8. PMID: 15820939. *Exclude - No comparisons of interest*

Desai PC, May R, Jones S, et al. Longitudinal study of echocardiographically-derived tricuspid regurgitant jet velocity in sickle cell disease. *Blood.* 2011;118(21). *Exclude - Not a full publication*

Desai PC, May R, Jones SK, et al. Longitudinal study of echocardiographically-derived tricuspid regurgitant jet velocity in sickle cell disease. *Am J Hematol.* 2011;86(10):E11-E12. *Exclude - Not a full publication*

Detterich J, Noetzli L, Carson S, et al. Pulmonary hypertension is uncommon in well-transfused thalassemia major patients. *Blood.* 2010;116(21). *Exclude - Not a full publication*

Devaraj A, Wells AU, Meister MG, et al. Detection of pulmonary hypertension with multidetector CT and echocardiography alone and in combination. *Radiology.* 2010;254(2):609-16. PMID: 20093532. *Exclude - No comparisons of interest*

Dham N, Ensing G, Minniti C, et al. Prospective echocardiography assessment of pulmonary hypertension and its potential etiologies in children with sickle cell disease. *Am J Cardiol.* 2009;104(5):713-20. PMID: 19699350. *Exclude - No comparisons of interest*

Diaz-Guzman E, Heresi GA, Dweik RA, et al. Long-term experience after transition from parenteral prostanoids to oral agents in patients with pulmonary hypertension. *Respir Med.* 2008;102(5):681-9. PMID: 18280130. *Exclude - No comparisons of interest*

Dickinson MG, Scholvinck EH, Boonstra A, et al. Low complication rates with totally implantable access port use in epoprostenol treatment of pulmonary hypertension. *J Heart Lung Transplant.* 2009;28(3):273-9. PMID: 19285620. *Exclude - No comparisons of interest*

Diller GP, Dimopoulos K, Kaya MG, et al. Long-term safety, tolerability and efficacy of bosentan in adults with pulmonary arterial hypertension associated with congenital heart disease. *Heart.* 2007;93(8):974-6. PMID: 17639112. *Exclude - No comparisons of interest*

Diller GP, van Eijl S, Okonko DO, et al. Circulating endothelial progenitor cells in patients with Eisenmenger syndrome and idiopathic pulmonary arterial hypertension. *Circulation.* 2008;117(23):3020-30. PMID: 18519847. *Exclude - No comparisons of interest*

Dimitroulas T, Giannakoulas G, Dimitroula H, et al. Significance of serum uric acid in pulmonary hypertension due to systemic sclerosis: a pilot study. *Rheumatol Int.* 2011;31(2):263-7. PMID: 20658290. *Exclude - No comparisons of interest*

Dimitroulas T, Giannakoulas G, Karvounis H, et al. Neurohormonal activation in patients with systemic sclerosis-related pulmonary arterial hypertension. *Int J Cardiol.* 2007;121(1):135-7. PMID: 17088004. *Exclude - Not a full publication*

Dimitroulas T, Giannakoulas G, Papadopoulou K, et al. Left atrial volume and N-terminal pro-B type natriuretic peptide are associated with elevated pulmonary artery pressure in patients with systemic sclerosis. *Clin Rheumatol.* 2010;29(9):957-64. PMID: 20526641. *Exclude - No comparisons of interest*

Dimitroulas T, Giannakoulas G, Sfetsios T, et al. Asymmetrical dimethylarginine in systemic sclerosis-related pulmonary arterial hypertension. *Rheumatology (Oxford).* 2008;47(11):1682-5. PMID: 18753191. *Exclude - No comparisons of interest*

Dimopoulos K, Inuzuka R, Goletto S, et al. Improved survival among patients with Eisenmenger syndrome receiving advanced therapy for pulmonary arterial hypertension. *Circulation.* 2010;121(1):20-5. PMID: 20026774. *Exclude - No comparisons of interest.*

Ding J, Ma G, Huang Y, et al. Atrial natriuretic peptide and three-dimensional echocardiography after transcatheter closure of atrial septal defect. *Cardiovasc Ultrasound.* 2008;6. *Exclude - no primary or secondary outcomes of interest*

Dinh Xuan AT, Higenbottam TW, Scott JP, et al. Comparative effects of long-term treatment with prostacyclin and its analogue, iloprost, on exercise tolerance of patients with primary pulmonary hypertension. *Eur J Pharmacol.* 1990;183(2):527-528. *Exclude – not a full publication*

Do e Z, Fukumoto Y, Takaki A, et al. Evidence for Rho-kinase activation in patients with pulmonary arterial hypertension. *Circ J.* 2009;73(9):1731-9. PMID: 19590140. *Exclude - No comparisons of interest*

Dogan Y, Soylu A, Kilickesmez O, et al. The value of hepatic diffusion-weighted MR imaging in demonstrating hepatic congestion secondary to pulmonary hypertension. *Cardiovasc Ultrasound.* 2010;8:28. PMID: 20663149. *Exclude - Does not include intervention of interest*

Dollberg S, Warner BW, Myatt L. Urinary nitrite and nitrate concentrations in patients with idiopathic persistent pulmonary hypertension of the newborn and effect of extracorporeal membrane oxygenation. *Pediatr Res.* 1995;37(1):31-4. PMID: 7700731. *Exclude - No comparisons of interest*

Dong MF, Ma ZS, Ma SJ, et al. Effect of Prostaglandin E1 on Pulmonary Arterial Hypertension Following Corrective Surgery for Congenital Heart Disease. *J Cardiovasc Pharmacol Ther.* 2011. PMID: 22203134. *Exclude - Does not include intervention of interest.*

Douwes JM, van Loon RL, Hoendermis ES, et al. Acute pulmonary vasodilator response in paediatric and adult pulmonary arterial hypertension: occurrence and prognostic value when comparing three response criteria. *Eur Heart J.* 2011;32(24):3137-46. PMID: 21893489. *Exclude - Does not include intervention of interest*

Droste AS, Rohde D, Voelkers M, et al. Endothelin receptor antagonist and airway dysfunction in pulmonary arterial hypertension. *Respir Res.* 2009;10:129. PMID: 20042085. *Exclude - No comparisons of interest*

Du ZD, Roguin N, Milgram E, et al. Pulmonary hypertension in patients with thalassemia major. *Am Heart J.* 1997;134(3):532-7. PMID: 9327712. *Exclude - No comparisons of interest*

Duffels M, van Loon L, Berger R, et al. Pulmonary arterial hypertension associated with a congenital heart defect: advanced medium-term medical treatment stabilizes clinical condition. *Congenit Heart Dis.* 2007;2(4):242-9. PMID: 18377475. *Exclude - No comparisons of interest*

Duffels MG, Hardziyenka M, Surie S, et al. Duration of right ventricular contraction predicts the efficacy of bosentan treatment in patients with pulmonary hypertension. *Eur J Echocardiogr.* 2009;10(3):433-8. PMID: 19042941. *Exclude - Does not include intervention of interest*

Duffels MG, van der Plas MN, Surie S, et al. Bosentan in pulmonary arterial hypertension: a comparison between congenital heart disease and chronic pulmonary embolism. *Neth Heart J.* 2009;17(9):334-8. PMID: 19949475. *Exclude - No comparisons of interest*

Duffels MG, Vis JC, van Loon RL, et al. Effect of bosentan on exercise capacity and quality of life in adults with pulmonary arterial hypertension associated with congenital heart disease with and without Down's syndrome. *Am J Cardiol.* 2009;103(9):1309-15. PMID: 19406277. *Exclude - No comparisons of interest*

Duffels MGJ, Berger RMF, Bresser P, et al. Applicability of bosentan in Dutch patients with Eisenmenger syndrome: Preliminary results on safety and exercise capacity. *Neth Heart J.* 2006;14(5):165-170. *Exclude - No comparisons of interest*

Dulac Y, Acar P. Pharmacokinetic and clinical profile of a novel formulation of bosentan in children with pulmonary arterial hypertension: The FUTURE-1 study. *Arch Cardiovasc Dis.* 2010;2(2):146-152. *Exclude - Not available in English.*

Dumitrescu A, Walsh KP. Eisenmenger syndrome - Conventional management and new therapeutic prospects. *Br J Cardiol.* 2006;13(6):419-424. *Exclude - Not a full publication*

Dumitrescu D, Seck C, Moinezhadeh P, et al. Relevance of exercise gas exchange in different stages of scleroderma-associated pulmonary arterial hypertension - Comparison with resting echocardiography. *Eur Heart J.* 2011;32:439. *Exclude - Not a full publication*

Dupuis J, Cernacek P, Tardif JC, et al. Reduced pulmonary clearance of endothelin-1 in pulmonary hypertension. *Am Heart J.* 1998;135(4):614-20. PMID: 9539476. *Exclude - Does not include intervention of interest*

Durongpisitkul K, Jakrapanichakul D, Laohaprasitiporn D, et al. Combination therapy of prostacyclin for pulmonary hypertension in congenital heart disease. *J Med Assoc Thai.* 2005;88 Suppl 8:S60-5. PMID: 16856428. *Exclude - No comparisons of interest*

- Durongpisitkul K, Jakrapanichakul D, Sompradikul S. A retrospective study of bosentan in pulmonary arterial hypertension associated with congenital heart disease. *J Med Assoc Thai*. 2008;91(2):196-202. PMID: 18389984. *Exclude - No comparisons of interest*
- Durongpisitkul K, Pornrattanarungsi S, Panjasamanvong P, et al. Efficacy and safety of high dose generic sildenafil in Thai patients with pulmonary arterial hypertension. *J Med Assoc Thai*. 2011;94(4):421-6. PMID: 21591526. *Exclude - No comparisons of interest*
- Dyer K, Lanning C, Das B, et al. Noninvasive Doppler tissue measurement of pulmonary artery compliance in children with pulmonary hypertension. *J Am Soc Echocardiogr*. 2006;19(4):403-12. PMID: 16581479. *Exclude - Does not include intervention of interest*
- Eddahibi S, Humbert M, Sediame S, et al. Imbalance between platelet vascular endothelial growth factor and platelet-derived growth factor in pulmonary hypertension. Effect of prostacyclin therapy. *Am J Respir Crit Care Med*. 2000;162(4 Pt 1):1493-9. PMID: 11029367. *Exclude - no primary or secondary outcomes of interest*
- Eifinger F, Sreeram N, Mehler K, et al. Aerosolized iloprost in the treatment of pulmonary hypertension in extremely preterm infants: a pilot study. *Klin Padiatr*. 2008;220(2):66-9. PMID: 17710738. *Exclude - No comparisons of interest*
- Einarson TR, Granton JT, Vicente C, et al. Cost-effectiveness of treprostinil versus epoprostenol in patients with pulmonary arterial hypertension: a Canadian analysis. *Can Respir J*. 2005;12(8):419-25. PMID: 16331313. *Exclude - no primary or secondary outcomes of interest*
- El-Beshlawy A, Youssry I, El-Saidi S, et al. Pulmonary hypertension in beta-thalassemia major and the role of L-carnitine therapy. *Pediatr Hematol Oncol*. 2008;25(8):734-43. PMID: 19065439. *Exclude - No comparisons of interest*
- Elnoamany MF, Dawood A, Khalil T, et al. Reliability of right ventricular myocardial isovolumic relaxation time as a predictor of pulmonary hypertension. *Eur Heart J*. 2011;32:1019. *Exclude - Not a full publication*
- Elstein D, Klutstein MW, Lahad A, et al. Echocardiographic assessment of pulmonary hypertension in Gaucher's disease. *Lancet*. 1998;351(9115):1544-6. PMID: 10326537. *Exclude - No comparisons of interest*
- Elstein D, Nir A, Klutstein M, et al. C-reactive protein and NT-proBNP as surrogate markers for pulmonary hypertension in Gaucher disease. *Blood Cells Mol Dis*. 2005;34(3):201-5. PMID: 15885602. *Exclude - No comparisons of interest*
- Er F, Ederer S, Nia AM, et al. Accuracy of Doppler-echocardiographic mean pulmonary artery pressure for diagnosis of pulmonary hypertension. *PLoS One*. 2010;5(12):e15670. PMID: 21179417. *Exclude - No study population of interest*
- Eronen M, Pohjavuori M, Andersson S, et al. Prostacyclin treatment for persistent pulmonary hypertension of the newborn. *Pediatr Cardiol*. 1997;18(1):3-7. PMID: 8960484. *Exclude - No comparisons of interest*
- Espinola-Zavaleta N, Vargas-Barron J, Tazar JI, et al. Echocardiographic Evaluation of Patients with Primary Pulmonary Hypertension Before and After Atrial Septostomy. *Echocardiography*. 1999;16(7, Pt 1):625-634. PMID: 11175203. *Exclude - no primary or secondary outcomes of interest*
- Espinosa Martinez E, Garcia Caraballosa MB, Espinosa Estrada EE, et al. Pulmonary hypertension in adults with sickle cell anemia. Preliminary results. *Rev Cuba Hematol Immunol Hemoterapia*. 2010;26(3):206-215. *Exclude - Not available in English*
- Evans N, Kluckow M, Currie A. Range of echocardiographic findings in term neonates with high oxygen requirements. *Arch Dis Child Fetal Neonatal Ed*. 1998;78(2):F105-11. PMID: 9577279. *Exclude - No study population of interest*
- Ewert R, Opitz C, Wensel R, et al. Iloprost as inhalative or intravenous long-term treatment of patients with primary pulmonary hypertension. Register of the Berlin Study Group for Pulmonary Hypertension. *Z Kardiol*. 2000;89(11):987-999. *Exclude - Not available in English*
- Ewert R, Opitz CF, Wensel R, et al. Continuous intravenous iloprost to revert treatment failure of first-line inhaled iloprost therapy in patients with idiopathic pulmonary arterial hypertension. *Clin Res Cardiol*. 2007;96(4):211-7. PMID: 17294349. *Exclude - No comparisons of interest*
- Eysmann SB, Palevsky HI, Reichel N, et al. Echo/Doppler and hemodynamic correlates of vasodilator responsiveness in primary pulmonary hypertension. *Chest*. 1991;99(5):1066-71. PMID: 2019158. *Exclude - no primary or secondary outcomes of interest*

- Fasnacht MS, Tolsa JF, Beghetti M. The Swiss registry for pulmonary arterial hypertension: the paediatric experience. *Swiss Med Wkly.* 2007;137(35-36):510-3. PMID: 17990138. *Exclude - Not a full publication*
- Ferlinz J. Right ventricular diastolic performance: compliance characteristics with focus on pulmonary hypertension, right ventricular hypertrophy, and calcium channel blockade. *Cathet Cardiovasc Diagn.* 1998;43(2):206-43. PMID: 9488559. *Exclude - Not a full publication*
- Fernandes CJ, Dias BA, Jardim CV, et al. The role of target therapies in schistosomiasis-associated pulmonary arterial hypertension. *Chest.* 2012;141(4):923-8. PMID: 22030800. *Exclude - No comparisons of interest*
- Fernandez A, Simeon CP, Fonollosa V, et al. Clinical, epidemiological and haemodynamic differences between idiopathic and scleroderma-related pulmonary arterial hypertension. *Rheumatology (Oxford).* 2012;51:ii97-ii98. *Exclude - Not a full publication*
- Fields A, Roberts J, Forfia P. Pulmonary hypertension specific therapy improves cardiac structure and function without detectable changes in doppler pa systolic pressure in patients with pulmonary arterial hypertension. *Chest.* 2011;140(4). *Exclude - Not a full publication*
- Fields A, Roberts J, Forfia P. Serial tapse at 1 year, not baseline tapse, predicts survival differences in patients with an incident diagnosis of pulmonary arterial hypertension. *Chest.* 2011;140(4). *Exclude - Not a full publication*
- Fields AV, Sinha SS, Saggar R, et al. Simple echo-Doppler tool powerfully predicts response to pulmonary hypertension specific therapy in WHO Group 3 pulmonary hypertension. *J Heart Lung Transplant.* 2012;31(4):S212. *Exclude - Not a full publication*
- Filusch A, Mereles D, Gruenig E, et al. Strain and strain rate echocardiography for evaluation of right ventricular dysfunction in patients with idiopathic pulmonary arterial hypertension. *Clin Res Cardiol.* 2010;99(8):491-8. PMID: 20352437. *Exclude - Does not include intervention of interest*
- Filusch A, Zelniker T, Baumgartner C, et al. Soluble TWEAK predicts hemodynamic impairment and functional capacity in patients with pulmonary arterial hypertension. *Clin Res Cardiol.* 2011;100(10):879-85. PMID: 21479966. *Exclude - Does not include intervention of interest*
- Finazzi S, Vicenzi E, Faggioli P, et al. NT-proBNP in systemic sclerosis-related pulmonary arterial hypertension. *Riv Ital Med Labor.* 2006;2(3):224-228. *Exclude - Not available in English.*
- Fisher EA, Ruden R. Pulmonary artery pressures and valvular lesions in patients taking diet suppressants. *Cardiovasc Rev Rep.* 1998;19(4):13-16. *Exclude - No comparisons of interest*
- Flattery MP, Pinson JM, Savage L, et al. Living with pulmonary artery hypertension: patients' experiences. *Heart Lung.* 2005;34(2):99-107. PMID: 15761454. *Exclude - Does not include intervention of interest*
- Flox-Camacho A, Escribano-Subias P, Jimenez-Lopez Guarch C, et al. Factors affecting the response to exercise in patients with severe pulmonary arterial hypertension. *Arch Bronconeumol.* 2011;47(1):10-6. PMID: 20889250. *Exclude - no primary or secondary outcomes of interest*
- Fois E, Le Guern V, Dupuy A, et al. Noninvasive assessment of systolic pulmonary artery pressure in systemic lupus erythematosus: retrospective analysis of 93 patients. *Clin Exp Rheumatol.* 2010;28(6):836-41. PMID: 21205461. *Exclude - No comparisons of interest*
- Foley RJ, Wilcox D, Walsh SJ, et al. Survival of geriatric idiopathic pulmonary arterial hypertension patients. *Conn Med.* 2011;75(1):11-5. PMID: 21329286. *Exclude - Does not include intervention of interest*
- Ford HJ, Aris RM, Andreoni K. Screening for portopulmonary hypertension with transthoracic echocardiography: implications for early mortality associated with liver transplantation. *Am J Respir Crit Care Med.* 2009;180(4):378; author reply 378-9. PMID: 19661254. *Exclude - Not a full publication*
- Forrest IA, Small T, Corris PA. Effect of nebulized epoprostenol (prostacyclin) on exhaled nitric oxide in patients with pulmonary hypertension due to congenital heart disease and in normal controls. *Clin Sci (Lond).* 1999;97(1):99-102. PMID: 10369800. *Exclude - no primary or secondary outcomes of interest*
- Forrest S, Kim A, Carbonella J, et al. Proteinuria is associated with elevated tricuspid regurgitant jet velocity in children with sickle cell disease. *Pediatr Blood Cancer.* 2012;58(6):937-40. PMID: 21990235. *Exclude - Does not include intervention of interest*
- Forrest SJ, Pashankar FD. Pulmonary hypertension and proteinuria in children with sickle cell disease. *Am J Hematol.* 2011;86(10):E21. *Exclude - Not a full publication*

Fox BD, Kassirer M, Weiss I, et al. Ambulatory rehabilitation improves exercise capacity in patients with pulmonary hypertension. *J Card Fail*. 2011;17(3):196-200. PMID: 21362526. *Exclude - Does not include intervention of interest*

Fraisse A, Butrous G, Taylor MB, et al. Intravenous sildenafil for postoperative pulmonary hypertension in children with congenital heart disease. *Intensive Care Med*. 2011;37(3):502-9. PMID: 21069290. *Exclude - no primary or secondary outcomes of interest*

Fraisse A, Geva T, Gaudart J, et al. Doppler echocardiographic predictors of outcome in newborns with persistent pulmonary hypertension. *Cardiol Young*. 2004;14(3):277-83. PMID: 15680021. *Exclude - Does not include intervention of interest*

Fraisse A, Jais X, Schleich JM, et al. Characteristics and prospective two-year follow-up of children with pulmonary arterial hypertension in France. *Arch Cardiovasc Dis*. 2010;2(2):137-145. *Exclude - Not available in English.*

Frantz RP, Benza RL, Kjellstrom B, et al. Continuous hemodynamic monitoring in patients with pulmonary arterial hypertension. *J Heart Lung Transplant*. 2008;27(7):780-8. PMID: 18582809. *Exclude - Does not include intervention of interest*

Friedberg MK, Feinstein JA, Rosenthal DN. Noninvasive assessment of pulmonary arterial capacitance by echocardiography. *J Am Soc Echocardiogr*. 2007;20(2):186-90. PMID: 17275705. *Exclude - Does not include intervention of interest*

Friedman D, Szmuszkowicz J, Rabai M, et al. Systemic endothelial dysfunction in children with idiopathic pulmonary arterial hypertension correlates with disease severity. *J Heart Lung Transplant*. 2012;31(6):642-647. *Exclude - Does not include intervention of interest*

Friedman R, Mears JG, Barst RJ. Continuous infusion of prostacyclin normalizes plasma markers of endothelial cell injury and platelet aggregation in primary pulmonary hypertension. *Circulation*. 1997;96(9):2782-4. PMID: 9386137. *Exclude - no primary or secondary outcomes of interest*

Fruchter O, Yigla M. Underlying aetiology of pulmonary hypertension in 191 patients: a single centre experience. *Respirology*. 2008;13(6):825-31. PMID: 18811881. *Exclude - no primary or secondary outcomes of interest*

Fruhwald FM, Kjellstrom B, Perthold W, et al. Continuous hemodynamic monitoring in pulmonary hypertensive patients treated with inhaled iloprost. *Chest*. 2003;124(1):351-9. PMID: 12853544. *Exclude - No comparisons of interest*

Funauchi M, Kishimoto K, Shimazu H, et al. Effects of bosentan on the skin lesions: an observational study from a single center in Japan. *Rheumatol Int*. 2009;29(7):769-75. PMID: 19037604. *Exclude - No comparisons of interest*

Furuya Y, Kuwana M. Effect of bosentan on systemic sclerosis-associated interstitial lung disease ineligible for cyclophosphamide therapy: A prospective open-label study. *J Rheumatol*. 2011;38(10):2186-2192. *Exclude - No study population of interest*

Gabler NB, French B, Strom BL, et al. Race and sex differences in response to endothelin receptor antagonists for pulmonary arterial hypertension. *Chest*. 2012;141(1):20-6. PMID: 21940766. *Exclude - Background SR/MA*

Gabrielli LA, Castro PF, Godoy I, et al. Systemic oxidative stress and endothelial dysfunction is associated with an attenuated acute vascular response to inhaled prostanoid in pulmonary artery hypertension patients. *J Card Fail*. 2011;17(12):1012-7. PMID: 22123364. *Exclude - no primary or secondary outcomes of interest.*

Galie N, Badesch D, Oudiz R, et al. Ambrisentan therapy for pulmonary arterial hypertension. *J Am Coll Cardiol*. 2005;46(3):529-35. PMID: 16053970. *Exclude - No comparisons of interest*

Galie N, Barst R, Brundage B, et al. Long-term outcomes of patients with pulmonary arterial hypertension associated with connective tissue disease as compared with idiopathic or heritable pulmonary arterial hypertension treated with tadalafil. *Chest*. 2011;140(4). *Exclude - Not a full publication*

Galie N, Humbert M, Vachiery JL, et al. Effects of beraprost sodium, an oral prostacyclin analogue, in patients with pulmonary arterial hypertension: a randomized, double-blind, placebo-controlled trial. *J Am Coll Cardiol*. 2002;39(9):1496-502. PMID: 11985913. *Exclude - Does not include intervention of interest*

Gan CT, Holverda S, Marcus JT, et al. Right ventricular diastolic dysfunction and the acute effects of sildenafil in pulmonary hypertension patients. *Chest*. 2007;132(1):11-7. PMID: 17625080. *Exclude - No comparisons of interest*

Garg N, Sharma MK, Sinha N. Role of oral sildenafil in severe pulmonary arterial hypertension: clinical efficacy and dose response relationship. *Int J Cardiol.* 2007;120(3):306-13. PMID: 17174417. *Exclude - No comparisons of interest*

Garg N, Tripathy N, Sinha N. Comparative efficacy of sildenafil in Eisenmenger's syndrome secondary to atrial septal defect versus ventricular septal defect: A cardiac catheterisation follow-up study. *Cardiol Young.* 2011;21(6):637-638. *Exclude - No comparisons of interest*

Garin MC, Clark L, Chumney EC, et al. Cost-utility of treatments for pulmonary arterial hypertension: a Markov state-transition decision analysis model. *Clin Drug Investig.* 2009;29(10):635-46. PMID: 19715380. *Exclude - no primary or secondary outcomes of interest*

Garypidou V, Vakalopoulou S, Dimitriadis D, et al. Incidence of pulmonary hypertension in patients with chronic myeloproliferative disorders. *Haematologica.* 2004;89(2):245-6. PMID: 15003906. *Exclude - Not a full publication*

Generali J, Cada DJ. Tadalafil: Pulmonary hypertension (adults). *Hosp Pharm.* 2005;40(3):225-232. *Exclude - Not a full publication*

Gessler T, Schmehl T, Hoeper MM, et al. Ultrasonic versus jet nebulization of iloprost in severe pulmonary hypertension. *Eur Respir J.* 2001;17(1):14-9. PMID: 11307743. *Exclude - No comparisons of interest*

Ghayumi SMA, Mehrabi S, Zamirian M, et al. Pulmonary complications in cirrhotic candidates for liver transplantation. *Hepatitis Mon.* 2010;10(2):105-109. *Exclude - No comparisons of interest*

Ghio S, Pazzano AS, Klersy C, et al. Clinical and prognostic relevance of echocardiographic evaluation of right ventricular geometry in patients with idiopathic pulmonary arterial hypertension. *Am J Cardiol.* 2011;107(4):628-32. PMID: 21184990. *Exclude - Does not include intervention of interest*

Ghofrani HA, Friese G, Discher T, et al. Inhaled iloprost is a potent acute pulmonary vasodilator in HIV-related severe pulmonary hypertension. *Eur Respir J.* 2004;23(2):321-6. PMID: 14979511. *Exclude - No comparisons of interest*

Ghofrani HA, Grimminger F. Modulating cGMP to treat lung diseases. *Handb Exp Pharmacol.* 2009;191:469-483. *Exclude - Background Other*

Ghofrani HA, Rose F, Schermuly RT, et al. Oral sildenafil as long-term adjunct therapy to inhaled iloprost in severe pulmonary arterial hypertension. *J Am Coll Cardiol.* 2003;42(1):158-64. PMID: 12849677. *Exclude - No comparisons of interest*

Ghofrani HA, Rose F, Schermuly RT, et al. Amplification of the pulmonary vasodilatory response to inhaled iloprost by subthreshold phosphodiesterase types 3 and 4 inhibition in severe pulmonary hypertension. *Crit Care Med.* 2002;30(11):2489-92. PMID: 12441759. *Exclude - No comparisons of interest*

Ghofrani HA, Schermuly RT, Rose F, et al. Sildenafil for long-term treatment of nonoperable chronic thromboembolic pulmonary hypertension. *Am J Respir Crit Care Med.* 2003;167(8):1139-41. PMID: 12684251. *Exclude - No study population of interest*

Ghofrani HA, Voswinckel R, Reichenberger F, et al. Differences in hemodynamic and oxygenation responses to three different phosphodiesterase-5 inhibitors in patients with pulmonary arterial hypertension: a randomized prospective study. *J Am Coll Cardiol.* 2004;44(7):1488-96. PMID: 15464333. *Exclude - no primary or secondary outcomes of interest*

Ghofrani HA, Wiedemann R, Rose F, et al. Combination therapy with oral sildenafil and inhaled iloprost for severe pulmonary hypertension. *Ann Intern Med.* 2002;136(7):515-22. PMID: 11926786. *Exclude - no primary or secondary outcomes of interest*

Ghosh K, Meera V, Jijina F. Pulmonary hypertension in patients with hematological disorders following splenectomy. *Indian J Hematol Blood Transfus.* 2009;25(2):45-48. *Exclude - no primary or secondary outcomes of interest*

Giannelli G, Iannone F, Marinosci F, et al. The effect of bosentan on matrix metalloproteinase-9 levels in patients with systemic sclerosis-induced pulmonary hypertension. *Curr Med Res Opin.* 2005;21(3):327-32. PMID: 15811199. *Exclude - No comparisons of interest*

Giannelli G, Iannone F, Marinosci F, et al. Clinical outcomes of bosentan in pulmonary arterial hypertension do not correlate with levels of TIMPs. *Eur J Clin Invest.* 2006;36 Suppl 3:73-7. PMID: 16919016. *Exclude - Does not include intervention of interest*

- Gilbert C, Brown MC, Cappelleri JC, et al. Estimating a minimally important difference in pulmonary arterial hypertension following treatment with sildenafil. *Chest*. 2009;135(1):137-42. PMID: 18812447. *Exclude - no primary or secondary outcomes of interest*
- Gilbert N, Luther YC, Miera O, et al. Initial experience with bosentan (Tracleer) as treatment for pulmonary arterial hypertension (PAH) due to congenital heart disease in infants and young children. *Z Kardiol*. 2005;94(9):570-4. PMID: 16142516. *Exclude - No comparisons of interest*
- Gildein HP, Wildberg A, Mocellin R. Comparison of the effect of prostacyclin and nifedipine on the hemodynamics in patients with Eisenmenger syndrome. *Z Kardiol*. 1995;84(1):55-63. *Exclude - Not available in English.*
- Gindzienska-Sieskiewicz E, Kowal-Bielecka O, Kita J, et al. The occurrence of pulmonary hypertension in patients with systemic sclerosis hospitalized in the Department of Rheumatology and Internal Diseases Medical University of Bialystok in years 2003-2004. *Rocz Akad Med Bialymst*. 2005;50 Suppl 1:297-300. PMID: 16119691. *Exclude - No comparisons of interest*
- Girgis RE, Champion HC, Diette GB, et al. Decreased exhaled nitric oxide in pulmonary arterial hypertension: response to bosentan therapy. *Am J Respir Crit Care Med*. 2005;172(3):352-7. PMID: 15879413. *Exclude - no primary or secondary outcomes of interest*
- Girgis RE, Mathai SC, Krishnan JA, et al. Long-term outcome of bosentan treatment in idiopathic pulmonary arterial hypertension and pulmonary arterial hypertension associated with the scleroderma spectrum of diseases. *J Heart Lung Transplant*. 2005;24(10):1626-31. PMID: 16210140. *Exclude - No comparisons of interest*
- Giunta A, Tirri E, Maione S, et al. Right ventricular diastolic abnormalities in systemic sclerosis. Relation to left ventricular involvement and pulmonary hypertension. *Ann Rheum Dis*. 2000;59(2):94-8. PMID: 10666162. *Exclude - No comparisons of interest*
- Gladwin MT. Prevalence, risk factors and mortality of pulmonary hypertension defined by right heart catheterization in patients with sickle cell disease. *Expert Rev Hematol*. 2011;4(6):593-6. PMID: 22077523. *Exclude - Not a full publication*
- Gladwin MT, Barst RJ, Castro OL, et al. Pulmonary hypertension and NO in sickle cell. *Blood*. 2010;116(5):852-4. PMID: 20688967. *Exclude - Not a full publication*
- Gladwin MT, Sachdev V, Jison ML, et al. Pulmonary hypertension as a risk factor for death in patients with sickle cell disease. *N Engl J Med*. 2004;350(9):886-95. PMID: 14985486. *Exclude - No comparisons of interest*
- Gnaneswaran N, Pang B, Gerche AL, et al. Comparison of doppler-derived methods to predict invasive mean pulmonary artery pressure at rest and after exercise in patients with scleroderma. *Heart Lung Circul*. 2011;20:S164. *Exclude - Not a full publication*
- Gomberg-Maitland M, McLaughlin V, Gulati M, et al. Efficacy and safety of sildenafil added to treprostinil in pulmonary hypertension. *Am J Cardiol*. 2005;96(9):1334-6. PMID: 16253609. *Exclude - No comparisons of interest*
- Gomberg-Maitland M, Tapson VF, Benza RL, et al. Transition from intravenous epoprostenol to intravenous treprostinil in pulmonary hypertension. *Am J Respir Crit Care Med*. 2005;172(12):1586-9. PMID: 16151039. *Exclude - No comparisons of interest*
- Gomez A, Bialostozky D, Zajarias A, et al. Right ventricular ischemia in patients with primary pulmonary hypertension. *J Am Coll Cardiol*. 2001;38(4):1137-42. PMID: 11583894. *Exclude - No comparisons of interest*
- Goncalvesova E, Luknar M, Lesny P. ECG signs of right ventricular hypertrophy may help distinguish pulmonary arterial hypertension and pulmonary hypertension due to left ventricular diastolic dysfunction. *Bratisl Lek Listy*. 2011;112(11):614-8. PMID: 22180986. *Exclude - Does not include intervention of interest*
- Gonzalez-Juanatey C, Amigo-Diaz E, Miranda-Filloo JA, et al. Lack of echocardiographic and Doppler abnormalities in psoriatic arthritis patients without clinically evident cardiovascular disease or classic atherosclerosis risk factors. *Semin Arthritis Rheum*. 2006;35(5):333-9. PMID: 16616156. *Exclude - No comparisons of interest*
- Gonzalez-Juanatey C, Testa A, Garcia-Castelo A, et al. Echocardiographic and Doppler findings in long-term treated rheumatoid arthritis patients without clinically evident cardiovascular disease. *Semin Arthritis Rheum*. 2004;33(4):231-8. PMID: 14978661. *Exclude - Does not include intervention of interest*



Gorcsan J, 3rd, Edwards TD, Ziady GM, et al. Transesophageal echocardiography to evaluate patients with severe pulmonary hypertension for lung transplantation. *Ann Thorac Surg.* 1995;59(3):717-22. PMID: 7887718. *Exclude - Does not include intervention of interest*

Gorenflo M, Bettendorf M, Brockmeier K, et al. Pulmonary vasoreactivity and vasoactive mediators in children with pulmonary hypertension. *Z Kardiol.* 2000;89(11):1000-8. PMID: 11149265. *Exclude - no primary or secondary outcomes of interest*

Gorenflo M, Gu H, Xu Z. Peri-operative pulmonary hypertension in paediatric patients: current strategies in children with congenital heart disease. *Cardiology.* 2010;116(1):10-7. PMID: 20424447. *Exclude - Not a full publication*

Gorenflo M, Zheng C, Poge A, et al. Metabolites of the L-arginine-NO pathway in patients with left-to-right shunt. *Clin Lab.* 2001;47(9-10):441-7. PMID: 11596905. *Exclude - Does not include intervention of interest*

Gough MS, White RJ. Sildenafil therapy is associated with improved hemodynamics in liver transplantation candidates with pulmonary arterial hypertension. *Liver Transpl.* 2009;15(1):30-6. PMID: 19109844. *Exclude - No comparisons of interest*

Graf S, Hakendorf P, Lester S, et al. South Australian scleroderma register: Autoantibodies as predictive biomarkers of phenotype and outcome. *Internal Medicine Journal.* 2011;41:1. *Exclude - Not a full publication*

Grapsa J, Gibbs JS, Dawson D, et al. Morphologic and functional remodeling of the right ventricle in pulmonary hypertension by real time three dimensional echocardiography. *Am J Cardiol.* 2012;109(6):906-13. PMID: 22196780. *Exclude - no primary or secondary outcomes of interest*

Grapsa J, Gibbs JSR, Cabrita IZ, et al. Clinical outcome and right atrial remodeling in patients with pulmonary arterial hypertension: Study with real time 3D Echocardiography. *Eur Heart J.* 2011;32:437-438. *Exclude - Not a full publication*

Grapsa J, O'Regan DP, Pavlopoulos H, et al. Right ventricular remodelling in pulmonary arterial hypertension with three-dimensional echocardiography: comparison with cardiac magnetic resonance imaging. *Eur J Echocardiogr.* 2010;11(1):64-73. PMID: 19939819. *Exclude - no primary or secondary outcomes of interest*

Graul A, Leeson PA, Castaner J. Sitaxsentan sodium. Endothelin ET(A) antagonist treatment of heart failure treatment of pulmonary hypertension. *Drugs Future.* 2000;25(2):159-164. *Exclude - Not a full publication*

Grimminger F, Olschewski H, Rose F, et al. Severe pulmonary hypertension - Vasodilatory treatment of pulmonary flow. *Pneumologie.* 2000;54(4):160-169. *Exclude - Not available in English.*

Gruenig E, Michelakis E, Vachiery JL, et al. Acute hemodynamic effects of single-dose sildenafil when added to established bosentan therapy in patients with pulmonary arterial hypertension: results of the COMPASS-1 study. *J Clin Pharmacol.* 2009;49(11):1343-52. PMID: 19755415. *Exclude - No comparisons of interest*

Grunig E, Janssen B, Mereles D, et al. Abnormal pulmonary artery pressure response in asymptomatic carriers of primary pulmonary hypertension gene. *Circulation.* 2000;102(10):1145-50. PMID: 10973844. *Exclude - Does not include intervention of interest*

Grunig E, Koehler R, Miltenberger-Miltenyi G, et al. Primary pulmonary hypertension in children may have a different genetic background than in adults. *Pediatr Res.* 2004;56(4):571-8. PMID: 15295086. *Exclude - Does not include intervention of interest*

Grunig E, Mereles D, Arnold K, et al. Primary pulmonary hypertension is predominantly a hereditary disease. *Chest.* 2002;121(3 Suppl):81S-82S. PMID: 11893705. *Exclude - Not a full publication*

Grunig E, Weissmann S, Ehlken N, et al. Stress Doppler echocardiography in relatives of patients with idiopathic and familial pulmonary arterial hypertension: results of a multicenter European analysis of pulmonary artery pressure response to exercise and hypoxia. *Circulation.* 2009;119(13):1747-57. PMID: 19307479. *Exclude - No comparisons of interest*

Guazzi M, Vicenzi M, Arena R, et al. A long term follow-up study of patients with mild to moderate group 2 pulmonary hypertension treated with Pde5-inhibition: A comparison between heart failure with reduced and preserved ejection fraction. *Circulation.* 2011;124(21). *Exclude - Not a full publication*

Gueffet JP, Piriou N, Trochu JN. Valvular heart disease associated with benfluorex. *Arch Cardiovasc Dis.* 2010;103(5):342-3. PMID: 20619246. *Exclude - Not a full publication*

Gunes Y, Guntekin U, Tuncer M, et al. Association of coronary sinus diameter with pulmonary hypertension. *Echocardiography*. 2008;25(9):935-40. PMID: 18771553. *Exclude - No study population of interest*

Guntekin U, Gunes Y, Tuncer M, et al. QTc dispersion in hyperthyroidism and its association with pulmonary hypertension. *Pacing Clin Electrophysiol*. 2009;32(4):494-9. PMID: 19335859. *Exclude - No comparisons of interest*

Guogan W, Baiping C, Hanying L, et al. The alteration of the pulmonary artery flow spectrum with pulmonary hypertension. *Chin Med Sci J*. 1999;14(4):220-3. PMID: 12894895. *Exclude - no primary or secondary outcomes of interest*

Gupta A, Kerkar P. Sildenafil for pulmonary hypertension secondary to congenital heart diseases. *Indian Heart J*. 2007;59(4):342-5. PMID: 19126940. *Exclude - No comparisons of interest*

Gupta R, Perumandla S, Patsiornik Y, et al. Incidence of pulmonary hypertension in patients with chronic myeloproliferative disorders. *J Natl Med Assoc*. 2006;98(11):1779-82. PMID: 17128687. *Exclude - No comparisons of interest*

Gupta U, Abdulla RI, Bokowski J. Benign outcome of pulmonary hypertension in neonates with a restrictive patent foramen ovale versus result for neonates with an unrestrictive patent foramen ovale. *Pediatr Cardiol*. 2011;32(7):972-6. PMID: 21710183. *Exclude - Does not include intervention of interest*

Gustafsson J, Simard JF, Gunnarsson I, et al. Risk factors for cardiovascular mortality in patients with systemic lupus erythematosus, a prospective cohort study. *Arthritis Research & Therapy*. 2012;R46. *Exclude - Does not include intervention of interest*

Ha JW, Choi D, Park S, et al. Determinants of exercise-induced pulmonary hypertension in patients with normal left ventricular ejection fraction. *Heart*. 2009;95(6):490-4. PMID: 18653569. *Exclude - Does not include intervention of interest*

Hache M, Denault A, Belisle S, et al. Inhaled epoprostenol (prostacyclin) and pulmonary hypertension before cardiac surgery. *J Thorac Cardiovasc Surg*. 2003;125(3):642-9. PMID: 12658208. *Exclude - no primary or secondary outcomes of interest*

Hache M, Denault AY, Belisle S, et al. Inhaled prostacyclin (PGI<sub>2</sub>) is an effective addition to the treatment of pulmonary hypertension and hypoxia in the operating room and intensive care unit. *Can J Anaesth*. 2001;48(9):924-9. PMID: 11606352. *Exclude - No study population of interest*

Hachulla E, de Groote P, Gressin V, et al. The three-year incidence of pulmonary arterial hypertension associated with systemic sclerosis in a multicenter nationwide longitudinal study in France. *Arthritis Rheum*. 2009;60(6):1831-9. PMID: 19479881. *Exclude - Does not include intervention of interest*

Haddad F, Doyle R, Denault AY, et al. Echocardiographic and clinical predictors of outcome in patients with pulmonary arterial hypertension. *J Heart Lung Transplant*. 2012;31(4):S284. *Exclude - Not a full publication*

Haeck ML, Scherp tong RW, Marsan NA, et al. Prognostic implications of right ventricular longitudinal peak systolic strain on long-term outcome in patients with pulmonary hypertension. *Circulation*. 2011;124(21). *Exclude - Not a full publication*

Hagan G, Southwood M, Treacy C, et al. Are inflammatory cytokine levels altered by treatment of pulmonary arterial hypertension? *Thorax*. 2011;66:A67-A68. *Exclude - Not a full publication*

Hagar RW, Michlitsch JG, Gardner J, et al. Clinical differences between children and adults with pulmonary hypertension and sickle cell disease. *Br J Haematol*. 2008;140(1):104-12. PMID: 17916102. *Exclude - Does not include intervention of interest*

Hahn CH, Kang SM, Moon JW, et al. The Utility of Measurement of Plasma N-terminal Pro-brain Natriuretic Peptide in Diagnosis of Pulmonary Hypertension. *Tuberc Respir Dis*. 2004;56(1):67-76. *Exclude - Not available in English*

Hahn KL. Old drugs are new again. *Pharm Times*. 2011;77(6). *Exclude - Not a full publication*

Hall SM, Davie N, Klein N, et al. Endothelin receptor expression in idiopathic pulmonary arterial hypertension: Effect of bosentan and epoprostenol treatment. *Eur Respir J*. 2011;38(4):851-860. *Exclude - Does not include intervention of interest*

Hallioglu O, Dilber E, Celiker A. Comparison of acute hemodynamic effects of aerosolized and intravenous iloprost in secondary pulmonary hypertension in children with congenital heart disease. *Am J Cardiol*. 2003;92(8):1007-9. PMID: 14556887. *Exclude - Not a full publication*

Handa T, Nagai S, Miki S, et al. Incidence of pulmonary hypertension and its clinical relevance in patients with interstitial pneumonias: comparison between idiopathic and collagen vascular disease associated interstitial pneumonias. *Intern Med*. 2007;46(12):831-7. PMID: 17575374. *Exclude - no primary or secondary outcomes of interest*

Hanna MG, Shaltout FF, El-Fikky MA, et al. Assessment of the role of inhaled nitric oxide and high frequency oscillatory ventilation in persistent pulmonary hypertension of the newborn. *Egypt J Anaesth*. 2004;20(1):47-52. *Exclude - unable to obtain full-text*

Hansmann G, Plouffe BD, Hatch A, et al. Design and validation of an endothelial progenitor cell capture chip and its application in patients with pulmonary arterial hypertension. *J Mol Med (Berl)*. 2011;89(10):971-83. PMID: 21735044. *Exclude - Does not include intervention of interest*

Haque AK, Gokhale S, Rampy BA, et al. Pulmonary hypertension in sickle cell hemoglobinopathy: a clinicopathologic study of 20 cases. *Hum Pathol*. 2002;33(10):1037-43. PMID: 12395378. *Exclude - No comparisons of interest*

Hardegree E, Sachdev A, Villarraga H, et al. Prognostic significance of ventricular interdependence in right ventricular pressure overload: Reduction in left ventricular systolic strain predicts early mortality in pulmonary arterial hypertension. *Chest*. 2011;140(4). *Exclude - Not a full publication*

Haroon N, Nisha RS, Chandran V, et al. Pulmonary hypertension not a major feature of early mixed connective tissue disease: a prospective clinicoserological study. *J Postgrad Med*. 2005;51(2):104-7, discussion 107-8. PMID: 16006700. *Exclude - No study population of interest*

Harrison RE, Berger R, Haworth SG, et al. Transforming growth factor-beta receptor mutations and pulmonary arterial hypertension in childhood. *Circulation*. 2005;111(4):435-41. PMID: 15687131. *Exclude - Does not include intervention of interest*

Hatano M, Yao A, Kinugawa K, et al. Acute effect of sildenafil is maintained in pulmonary arterial hypertension patients chronically treated with bosentan. *Int Heart J*. 2011;52(4):233-9. PMID: 21828950. *Exclude - no primary or secondary outcomes of interest*

Hatano M, Yao A, Shiga T, et al. Imatinib mesylate has the potential to exert its efficacy by down-regulating the plasma concentration of platelet-derived growth factor in patients with pulmonary arterial hypertension. *Int Heart J*. 2010;51(4):272-6. PMID: 20716845. *Exclude - Does not include intervention of interest*

Haworth SG, Hislop AA. Treatment and survival in children with pulmonary arterial hypertension: the UK Pulmonary Hypertension Service for Children 2001-2006. *Heart*. 2009;95(4):312-7. PMID: 18952635. *Exclude - No study population of interest*

He B, Zhang F, Li X, et al. Meta-analysis of randomized controlled trials on treatment of pulmonary arterial hypertension. *Circ J*. 2010;74(7):1458-64. PMID: 20519876. *Exclude - Background SR/MA*

Hemnes AR, Pugh ME, Newman AL, et al. End tidal CO(2) tension: pulmonary arterial hypertension vs pulmonary venous hypertension and response to treatment. *Chest*. 2011;140(5):1267-73. PMID: 21622547. *Exclude - Does not include intervention of interest*

Hemnes AR, Robbins IM. Sildenafil monotherapy in portopulmonary hypertension can facilitate liver transplantation. *Liver Transpl*. 2009;15(1):15-9. PMID: 19109843. *Exclude - No comparisons of interest*

Heper G, Polat M, Yetkin E, et al. Cardiac findings in Behcet's patients. *Int J Dermatol*. 2010;49(5):574-8. PMID: 20534096. *Exclude - No study population of interest*

Heresi GA, Minai OA. Lupus-associated pulmonary hypertension: long-term response to vasoactive therapy. *Respir Med*. 2007;101(10):2099-107. PMID: 17618103. *Exclude - No comparisons of interest.*

Hermon M, Golej J, Burda G, et al. Intravenous prostacyclin mitigates inhaled nitric oxide rebound effect: A case control study. *Artif Organs*. 1999;23(11):975-8. PMID: 10564300. *Exclude - Does not include intervention of interest*

Hesselstrand R, Ekman R, Eskilsson J, et al. Screening for pulmonary hypertension in systemic sclerosis: the longitudinal development of tricuspid gradient in 227 consecutive patients, 1992-2001. *Rheumatology (Oxford)*. 2005;44(3):366-71. PMID: 15561735. *Exclude - no primary or secondary outcomes of interest*

Hesselstrand R, Wildt M, Ekmehag B, et al. Survival in patients with pulmonary arterial hypertension associated with systemic sclerosis from a Swedish single centre: prognosis still poor and prediction difficult. *Scand J Rheumatol*. 2011;40(2):127-32. PMID: 20858146. *Exclude - No comparisons of interest*

Higenbottam T, Butt AY, McMahon A, et al. Long-term intravenous prostaglandin (epoprostenol or iloprost) for treatment of severe pulmonary hypertension. *Heart*. 1998;80(2):151-5. PMID: 9813561. *Exclude - No comparisons of interest*

Higenbottam TW, Butt AY, Dinh-Xaun AT, et al. Treatment of pulmonary hypertension with the continuous infusion of a prostacyclin analogue, iloprost. *Heart*. 1998;79(2):175-9. PMID: 9538312. *Exclude - No comparisons of interest*

Higham MA, Dawson D, Joshi J, et al. Utility of echocardiography in assessment of pulmonary hypertension secondary to COPD. *Eur Respir J*. 2001;17(3):350-5. PMID: 11405510. *Exclude - No study population of interest*

Highland KB, Strange C, Mazur J, et al. Treatment of pulmonary arterial hypertension: a preliminary decision analysis. *Chest*. 2003;124(6):2087-92. PMID: 14665484. *Exclude - Does not include intervention of interest*

Hill KD, Lim DS, Everett AD, et al. Assessment of pulmonary hypertension in the pediatric catheterization laboratory: current insights from the Magic registry. *Catheter Cardiovasc Interv*. 2010;76(6):865-73. PMID: 20549685. *Exclude - Does not include intervention of interest*

Hill LL, Pearl RG. Combined inhaled nitric oxide and inhaled prostacyclin during experimental chronic pulmonary hypertension. *J Appl Physiol*. 1999;86(4):1160-4. PMID: 10194197. *Exclude - No study population of interest*

Hinchcliff M, Fischer A, Schioppa E, et al. Pulmonary Hypertension Assessment and Recognition of Outcomes in Scleroderma (PHAROS): baseline characteristics and description of study population. *J Rheumatol*. 2011;38(10):2172-9. PMID: 21844142. *Exclude - Background Other*

Hinderliter AL, Willis PWt, Long W, et al. Frequency and prognostic significance of pericardial effusion in primary pulmonary hypertension. PPH Study Group. Primary pulmonary hypertension. *Am J Cardiol*. 1999;84(4):481-4, A10. PMID: 10468096. *Exclude - No study population of interest*

Hinderliter AL, Willis PWt, Long WA, et al. Frequency and severity of tricuspid regurgitation determined by Doppler echocardiography in primary pulmonary hypertension. *Am J Cardiol*. 2003;91(8):1033-7, A9. PMID: 12686360. *Exclude - No comparisons of interest*

Hiramoto Y, Shioyama W, Kuroda T, et al. Effect of bosentan on plasma endothelin-1 concentration in patients with pulmonary arterial hypertension. *Circ J*. 2007;71(3):367-9. PMID: 17322637. *Exclude - No comparisons of interest*

Hirani N, Helmersen D, Brazil A, et al. First-line oral combination therapy with bosentan and sildenafil in pulmonary arterial hypertension: Preliminary results. *Chest*. 2011;140(4). *Exclude - Not a full publication*

Hirata Y, Sata M, Makiuchi Y, et al. Comparative analysis of *Micrococcus luteus* isolates from blood cultures of patients with pulmonary hypertension receiving epoprostenol continuous infusion. *J Infect Chemother*. 2009;15(6):424-5. PMID: 20012737. *Exclude - No comparisons of interest*

Hirono K, Yoshimura N, Taguchi M, et al. Bosentan induces clinical and hemodynamic improvement in candidates for right-sided heart bypass surgery. *J Thorac Cardiovasc Surg*. 2010;140(2):346-51. PMID: 20434177. *Exclude - No study population of interest*

Hislop AA, Moledina S, Foster H, et al. Long-term efficacy of bosentan in treatment of pulmonary arterial hypertension in children. *Eur Respir J*. 2011;38(1):70-7. PMID: 21177841. *Exclude - No comparisons of interest*

Hoeper M. Is sitaxsentan a safe and efficacious treatment for pulmonary arterial hypertension? *Nat Clin Pract Cardiovasc Med*. 2006;3(10):536-537. *Exclude - Not a full publication*

Hoeper M, Barst R, Bourge R, et al. Imatinib improves exercise capacity and hemodynamics at 24 weeks as add-on therapy in symptomatic pulmonary arterial hypertension patients: The impres study. *Chest*. 2011;140(4). *Exclude - Not a full publication*

Hoeper MM. Increasing complexities in PAH management. *Br J Cardiol*. 2009;16(SUPPL. 1):S7-S9. *Exclude - Not a full publication*

Hoeper MM, Faulenbach C, Golpon H, et al. Combination therapy with bosentan and sildenafil in idiopathic pulmonary arterial hypertension. *Eur Respir J*. 2004;24(6):1007-10. PMID: 15572546. *Exclude - No comparisons of interest*

Hoepfer MM, Gall H, Seyfarth HJ, et al. Long-term outcome with intravenous iloprost in pulmonary arterial hypertension. *Eur Respir J*. 2009;34(1):132-7. PMID: 19251782. *Exclude - No comparisons of interest*

Hoepfer MM, Halank M, Marx C, et al. Bosentan therapy for portopulmonary hypertension. *Eur Respir J*. 2005;25(3):502-8. PMID: 15738295. *Exclude - No comparisons of interest*

Hoepfer MM, Markevych I, Spiekerkoetter E, et al. Goal-oriented treatment and combination therapy for pulmonary arterial hypertension. *Eur Respir J*. 2005;26(5):858-63. PMID: 16264047. *Exclude - No comparisons of interest*

Hoepfer MM, Olschewski H, Ghofrani HA, et al. A comparison of the acute hemodynamic effects of inhaled nitric oxide and aerosolized iloprost in primary pulmonary hypertension. German PPH study group. *J Am Coll Cardiol*. 2000;35(1):176-82. PMID: 10636277. *Exclude - No comparisons of interest*

Hoepfer MM, Schwarze M, Ehlerding S, et al. Long-term treatment of primary pulmonary hypertension with aerosolized iloprost, a prostacyclin analogue. *N Engl J Med*. 2000;342(25):1866-70. PMID: 10861321. *Exclude - No comparisons of interest*

Hoepfer MM, Spiekerkoetter E, Westerkamp V, et al. Intravenous iloprost for treatment failure of aerosolized iloprost in pulmonary arterial hypertension. *Eur Respir J*. 2002;20(2):339-43. PMID: 12212965. *Exclude - No comparisons of interest*

Hoepfer MM, Taha N, Bekjarova A, et al. Bosentan treatment in patients with primary pulmonary hypertension receiving nonparenteral prostanoids. *Eur Respir J*. 2003;22(2):330-4. PMID: 12952269. *Exclude - No comparisons of interest*

Hoepfer MM, Tongers J, Leppert A, et al. Evaluation of right ventricular performance with a right ventricular ejection fraction thermodilution catheter and MRI in patients with pulmonary hypertension. *Chest*. 2001;120(2):502-7. PMID: 11502650. *Exclude - No comparisons of interest*

Holcomb BW, Loyd JE, Byrd BF, 3rd, et al. Iatrogenic paradoxical air embolism in pulmonary hypertension. *Chest*. 2001;119(5):1602-5. PMID: 11348976. *Exclude - Does not include intervention of interest*

Hopkins WE, Feinberg MS, Barzilai B. Automated determination of pulmonary artery pulsatility during transesophageal echocardiography. *Am J Cardiol*. 1995;76(5):411-4. PMID: 7639174. *Exclude - No study population of interest*

Hopkins WE, Waggoner AD. Severe pulmonary hypertension without right ventricular failure: the unique hearts of patients with Eisenmenger syndrome. *Am J Cardiol*. 2002;89(1):34-8. PMID: 11779519. *Exclude - Does not include intervention of interest*

Hotchi J, Yamada H, Nishio S, et al. Efficacy of six-minute walk stress echocardiography for detection of pulmonary arterial hypertension in patients with connective tissue disease. *J Am Soc Echocardiogr*. 2012;25(6):B24. *Exclude - Not a full publication*

Hsiao SH, Chang SM, Lee CY, et al. Usefulness of tissue Doppler parameters for identifying pulmonary embolism in patients with signs of pulmonary hypertension. *Am J Cardiol*. 2006;98(5):685-90. PMID: 16923462. *Exclude - No study population of interest*

Hsiao SH, Lee CY, Chang SM, et al. Right heart function in scleroderma: insights from myocardial Doppler tissue imaging. *J Am Soc Echocardiogr*. 2006;19(5):507-14. PMID: 16644433. *Exclude - no primary or secondary outcomes of interest*

Hsiao SH, Lee CY, Chang SM, et al. Usefulness of pulmonary arterial flow discordance to identify pulmonary embolism. *Am J Cardiol*. 2007;99(4):579-83. PMID: 17293207. *Exclude - Does not include intervention of interest*

Hsiao SH, Lee CY, Chang SM, et al. Pulmonary embolism and right heart function: insights from myocardial Doppler tissue imaging. *J Am Soc Echocardiogr*. 2006;19(6):822-8. PMID: 16762763. *Exclude - No study population of interest*

Hsiao SH, Wang WC, Yang SH, et al. Myocardial tissue Doppler-based indexes to distinguish right ventricular volume overload from right ventricular pressure overload. *Am J Cardiol*. 2008;101(4):536-41. PMID: 18312773. *Exclude - Does not include intervention of interest*

Hsiao SH, Yang SH, Wang WC, et al. Usefulness of regional myocardial performance index to diagnose pulmonary embolism in patients with echocardiographic signs of pulmonary hypertension. *Am J Cardiol*. 2006;98(12):1652-5. PMID: 17145228. *Exclude - No study population of interest*

Hsu HH, Chen JS, Chen RJ, et al. Long-term outcome and effects of oral bosentan therapy in Taiwanese patients with advanced idiopathic pulmonary arterial hypertension. *Respir Med*. 2007;101(7):1556-62. PMID: 17223329. *Exclude - No comparisons of interest*

Hsu HH, Chen JS, Kuo SH, et al. Effects of continuous intravenous epoprostenol therapy on advanced primary pulmonary hypertension in Taiwanese patients. *J Formos Med Assoc*. 2005;104(1):60-3. PMID: 15660181. *Exclude - No comparisons of interest*

Hsu V, Cheng Q, Steen V. Pulmonary hypertension assessment and recognition of outcomes in scleroderma (Pharos): Predictive factors in the development of pulmonary hypertension in a high-risk population with SSc. *Rheumatology (Oxford)*. 2012;51:ii9-ii10. *Exclude - Not a full publication*

Hsue PY, Deeks SG, Farah HH, et al. Role of HIV and human herpesvirus-8 infection in pulmonary arterial hypertension. *AIDS*. 2008;22(7):825-33. PMID: 18427200. *Exclude - No study population of interest*

Huez S, Brimiouille S, Naeije R, et al. Feasibility of routine pulmonary arterial impedance measurements in pulmonary hypertension. *Chest*. 2004;125(6):2121-8. PMID: 15189931. *Exclude - no primary or secondary outcomes of interest*

Huez S, Roufousse F, Vachieri JL, et al. Isolated right ventricular dysfunction in systemic sclerosis: latent pulmonary hypertension? *Eur Respir J*. 2007;30(5):928-36. PMID: 17690126. *Exclude - No comparisons of interest*

Huez S, Vachieri JL, Unger P, et al. Tissue Doppler imaging evaluation of cardiac adaptation to severe pulmonary hypertension. *Am J Cardiol*. 2007;100(9):1473-8. PMID: 17950811. *Exclude - Does not include intervention of interest*

Hughes R, Tong J, Oates C, et al. Evidence for systemic endothelial dysfunction in patients and first-order relatives with pulmonary arterial hypertension. *Chest*. 2005;128(6 Suppl):617S. PMID: 16373872. *Exclude - No comparisons of interest*

Huizinga T, Nigrovic P, Ruderman E, et al. Randomized, prospective, placebo-controlled trial of bosentan in interstitial lung disease secondary to systemic sclerosis: Commentary. *International Journal of Advances in Rheumatology*. 2010;8(4):146-147. *Exclude - Not a full publication*

Humbert M, Sanchez O, Fartoukh M, et al. Short-term and long-term epoprostenol (prostacyclin) therapy in pulmonary hypertension secondary to connective tissue diseases: results of a pilot study. *Eur Respir J*. 1999;13(6):1351-6. PMID: 10445611. *Exclude - No comparisons of interest*

Humbert M, Segal ES, Kiely DG, et al. Results of European post-marketing surveillance of bosentan in pulmonary hypertension. *Eur Respir J*. 2007;30(2):338-44. PMID: 17504794. *Exclude - No comparisons of interest*

Hummers LK, Hall A, Wigley FM, et al. Abnormalities in the regulators of angiogenesis in patients with scleroderma. *J Rheumatol*. 2009;36(3):576-82. PMID: 19228661. *Exclude - No study population of interest*

Humpl T, Barst RJ, Kronmal R, et al. Current medical treatment in Pediatric Pulmonary Hypertension (PH)-Insights from the Global Registry Tracking Outcomes and Practice in Pediatric Pulmonary Hypertension (TOPP). *Cardiol Young*. 2012;22:S29. *Exclude - Not a full publication*

Humpl T, Reyes JT, Erickson S, et al. Sildenafil therapy for neonatal and childhood pulmonary hypertensive vascular disease. *Cardiol Young*. 2011;21(2):187-93. PMID: 21138617. *Exclude - No comparisons of interest*

Humpl T, Reyes JT, Holtby H, et al. Beneficial effect of oral sildenafil therapy on childhood pulmonary arterial hypertension: twelve-month clinical trial of a single-drug, open-label, pilot study. *Circulation*. 2005;111(24):3274-80. PMID: 15956137. *Exclude - No comparisons of interest*

Hwang YI, Geun MP, Sung YK, et al. Correlation between NT-proBNP and pulmonary arterial pressure in COPD patients. *Tuberc Respir Dis*. 2007;63(4):346-352. *Exclude - Not available in English*

Iannone F, Riccardi MT, Guiducci S, et al. Bosentan regulates the expression of adhesion molecules on circulating T cells and serum soluble adhesion molecules in systemic sclerosis-associated pulmonary arterial hypertension. *Ann Rheum Dis*. 2008;67(8):1121-6. PMID: 18029384. *Exclude - No comparisons of interest*

Ibrahim ES, Bajwa A. Relationship between pulmonary artery hemodynamics and right ventricle function in pulmonary arterial hypertension using cardiovascular magnetic resonance. *Journal of Cardiovascular Magnetic Resonance*. 2012;14. *Exclude - Not a full publication*

- Ibrahim R, Granton JT, Mehta S. An open-label, multicentre pilot study of bosentan in pulmonary arterial hypertension related to congenital heart disease. *Can Respir J*. 2006;13(8):415-20. PMID: 17149459. *Exclude - No comparisons of interest*
- Ichida F, Uese K, Hamamichi Y, et al. Chronic effects of oral prostacyclin analogue on thromboxane A2 and prostacyclin metabolites in pulmonary hypertension. *Acta Paediatr Jpn*. 1998;40(1):14-9. PMID: 9583194. *Exclude - Does not include intervention of interest*
- Ichida F, Uese K, Hashimoto I, et al. Acute effect of oral prostacyclin and inhaled nitric oxide on pulmonary hypertension in children. *J Cardiol*. 1997;29(4):217-24. PMID: 9127838. *Exclude - No study population of interest*
- Ichida F, Uese K, Tsubata S, et al. Additive effect of beraprost on pulmonary vasodilation by inhaled nitric oxide in children with pulmonary hypertension. *Am J Cardiol*. 1997;80(5):662-4. PMID: 9295007. *Exclude - No comparisons of interest*
- Ikeda D, Tsujino I, Ohira H, et al. Addition of oral sildenafil to beraprost is a safe and effective therapeutic option for patients with pulmonary hypertension. *J Cardiovasc Pharmacol*. 2005;45(4):286-9. PMID: 15772514. *Exclude - no primary or secondary outcomes of interest*
- Ikeda D, Tsujino I, Sakaue S, et al. Pilot study of short-term effects of a novel long-acting oral beraprost in patients with pulmonary arterial hypertension. *Circ J*. 2007;71(11):1829-31. PMID: 17965512. *Exclude - No comparisons of interest*
- Ilsar R, Levitt J, Adams MR, et al. Bosentan improves pulmonary microvascular endothelial function in adults with pulmonary arterial hypertension. *Eur Heart J*. 2009;30:110. *Exclude - Not a full publication*
- Ishii J. Clinical Utility of a New Marker for Cardiac Function and Heart Failure "NT-proBNP". *Jpn J Clin Chem*. 2008;37(3):283-291. *Exclude - Not available in English*
- Islam S, Masiakos P, Schnitzer JJ, et al. Diltiazem reduces pulmonary arterial pressures in recurrent pulmonary hypertension associated with pulmonary hypoplasia. *J Pediatr Surg*. 1999;34(5):712-4. PMID: 10359169. *Exclude - No study population of interest*
- Ito T, Harada K, Tamura M, et al. Changes in patterns of left ventricular diastolic filling revealed by Doppler echocardiography in infants with ventricular septal defect. *Cardiol Young*. 1998;8(1):94-9. PMID: 9680278. *Exclude - No study population of interest*
- Ittrow D, Schweikert B, Hoepfer M, et al. Treatment patterns and outcomes in patients with pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension: Results of a retrospective chart review in six european countries. *Value in Health*. 2012;15(4):A115. *Exclude - Not a full publication*
- Ivy DD, Calderbank M, Wagner BD, et al. Closed-hub systems with protected connections and the reduction of risk of catheter-related bloodstream infection in pediatric patients receiving intravenous prostanoïd therapy for pulmonary hypertension. *Infect Control Hosp Epidemiol*. 2009;30(9):823-9. PMID: 19637961. *Exclude - No comparisons of interest*
- Ivy DD, Claussen L, Doran A. Transition of stable pediatric patients with pulmonary arterial hypertension from intravenous epoprostenol to intravenous treprostinil. *Am J Cardiol*. 2007;99(5):696-8. PMID: 17317374. *Exclude - No comparisons of interest*
- Ivy DD, Doran A, Claussen L, et al. Weaning and discontinuation of epoprostenol in children with idiopathic pulmonary arterial hypertension receiving concomitant bosentan. *Am J Cardiol*. 2004;93(7):943-6. PMID: 15050507. *Exclude - No comparisons of interest*
- Ivy DD, Doran AK, Smith KJ, et al. Short- and long-term effects of inhaled iloprost therapy in children with pulmonary arterial hypertension. *J Am Coll Cardiol*. 2008;51(2):161-9. PMID: 18191742. *Exclude - No comparisons of interest*
- Ivy DD, Rosenzweig EB, Lemarie JC, et al. Long-term outcomes in children with pulmonary arterial hypertension treated with bosentan in real-world clinical settings. *Am J Cardiol*. 2010;106(9):1332-8. PMID: 21029834. *Exclude - No comparisons of interest*
- Jacobs W, Boonstra A, Brand M, et al. Long-term outcomes in pulmonary arterial hypertension in the first-line epoprostenol or first-line bosentan era. *J Heart Lung Transplant*. 2010;29(10):1150-8. PMID: 20580264. *Exclude - no comparisons of interest*

- Jais X, Launay D, Yaici A, et al. Immunosuppressive therapy in lupus- and mixed connective tissue disease-associated pulmonary arterial hypertension: a retrospective analysis of twenty-three cases. *Arthritis Rheum.* 2008;58(2):521-31. PMID: 18240255. *Exclude - No comparisons of interest*
- Jardin F, Dubourg O, Bourdarias JP. Echocardiographic pattern of acute cor pulmonale. *Chest.* 1997;111(1):209-17. PMID: 8996019. *Exclude - Does not include intervention of interest*
- Jensen-Urstad K, Svenungsson E, de Faire U, et al. Cardiac valvular abnormalities are frequent in systemic lupus erythematosus patients with manifest arterial disease. *Lupus.* 2002;11(11):744-52. PMID: 12475005. *Exclude - Does not include intervention of interest*
- Jia B, Zhang S, Chen Z, et al. Plasma endothelin 1 concentrations in children with congenital heart defects. *Minerva Pediatr.* 1998;50(4):99-103. PMID: 9808961. *Exclude - No study population of interest*
- Jiang L, Wang K, Su D, et al. Study of right ventricular contraction synchrony and function in patients with pulmonary arterial hypertension. *Int J Cardiol.* 2011;152:S51-S52. *Exclude - Not a full publication*
- Jing ZC, Jiang X, Han ZY, et al. Iloprost for pulmonary vasodilator testing in idiopathic pulmonary arterial hypertension. *Eur Respir J.* 2009;33(6):1354-60. PMID: 19213781. *Exclude - No comparisons of interest*
- Jing ZC, Jiang X, Wu BX, et al. Vardenafil treatment for patients with pulmonary arterial hypertension: a multicentre, open-label study. *Heart.* 2009;95(18):1531-6. PMID: 19549620. *Exclude - No comparisons of interest*
- Jing ZC, Strange G, Zhu XY, et al. Efficacy, safety and tolerability of bosentan in Chinese patients with pulmonary arterial hypertension. *J Heart Lung Transplant.* 2010;29(2):150-6. PMID: 20113907. *Exclude - No comparisons of interest*
- Jing ZC, Xu XQ, Han ZY, et al. Registry and survival study in chinese patients with idiopathic and familial pulmonary arterial hypertension. *Chest.* 2007;132(2):373-9. PMID: 17400671. *Exclude - Does not include intervention of interest*
- Jobard M, Vignand C, Parinaud AS, et al. Ambrisentan in pulmonary hypertension: Experience from the french reference center. *Int J Clin Pharm.* 2011;33(2):326-327. *Exclude - Not a full publication*
- Joglekar A, Tsai FS, McCloskey DA, et al. Bosentan in pulmonary arterial hypertension secondary to scleroderma. *J Rheumatol.* 2006;33(1):61-8. PMID: 16395751. *Exclude - No comparisons of interest*
- John A, Fagondes S, Schwartz I, et al. Sleep abnormalities in untreated patients with mucopolysaccharidosis type VI. *Am J Med Genet A.* 2011;155A(7):1546-51. PMID: 21638759. *Exclude - No study population of interest*
- Johnson MC, Kirkham FJ, Redline S, et al. Left ventricular hypertrophy and diastolic dysfunction in children with sickle cell disease are related to asleep and waking oxygen desaturation. *Blood.* 2010;116(1):16-21. PMID: 20378754. *Exclude - No study population of interest*
- Johnson RF, Loyd JE, Mullican AL, et al. Long-term follow-up after conversion from intravenous epoprostenol to oral therapy with bosentan or sildenafil in 13 patients with pulmonary arterial hypertension. *J Heart Lung Transplant.* 2007;26(4):363-9. PMID: 17403478. *Exclude - No comparisons of interest*
- Johnson SR, Gladman DD, Urowitz MB, et al. Pulmonary hypertension in systemic lupus. *Lupus.* 2004;13(7):506-9. PMID: 15352421. *Exclude - No comparisons of interest*
- Jone PN, Hinzman J, Ivy D, et al. Right ventricular to left ventricular ratio in systole predicts severity of pulmonary hypertension in children. *J Am Coll Cardiol.* 2012;59(13):E1606. *Exclude - Not a full publication*
- Kadikoylu G, Onbasili A, Tekten T, et al. Functional and morphological cardiac changes in myeloproliferative disorders (clinical study). *Int J Cardiol.* 2004;97(2):213-20. PMID: 15458686. *Exclude - No study population of interest*
- Kahler CM, Graziadei I, Wiedermann CJ, et al. Successful use of continuous intravenous prostacyclin in a patient with severe portopulmonary hypertension. *Wien Klin Wochenschr.* 2000;112(14):637-40. PMID: 11008327. *Exclude - Not a full publication*
- Kaiser R, Lensch C, Bals R, et al. Cardiac bioimpedance for noninvasive assessment of hemodynamics in patients with pulmonary hypertension. *Chest.* 2011;140(4). *Exclude - Not a full publication*



Kakishita M, Nishikimi T, Okano Y, et al. Increased plasma levels of adrenomedullin in patients with pulmonary hypertension. Clin Sci (Lond). 1999;96(1):33-9. PMID: 9857104. *Exclude - Does not include intervention of interest*

Kallen AJ, Lederman E, Balaji A, et al. Bloodstream infections in patients given treatment with intravenous prostanoids. Infect Control Hosp Epidemiol. 2008;29(4):342-9. PMID: 18462147. *Exclude - No comparisons of interest*

Kalogeropoulos AP, Georgiopoulou VV, Howell S, et al. Evaluation of right intraventricular dyssynchrony by two-dimensional strain echocardiography in patients with pulmonary arterial hypertension. J Am Soc Echocardiogr. 2008;21(9):1028-34. PMID: 18558476. *Exclude - Does not include intervention of interest*

Kamata S, Kamiyama M, Usui N, et al. Is adrenomedullin involved in the pathophysiology of persistent pulmonary hypertension of the newborn? Pediatr Surg Int. 2004;20(1):24-6. PMID: 14691636. *Exclude - Does not include intervention of interest*

Kamel SR, Omar GM, Darwish AF, et al. Asymptomatic pulmonary hypertension in systemic lupus erythematosus. Clin Med Insights Arthritis Musculoskelet Disord. 2011;4:77-86. PMID: 22084605. *Exclude - No comparisons of interest*

Kampolis C, Plastiras S, Vlachoyiannopoulos P, et al. The presence of anti-centromere antibodies may predict progression of estimated pulmonary arterial systolic pressure in systemic sclerosis. Scand J Rheumatol. 2008;37(4):278-83. PMID: 18612928. *Exclude - no primary or secondary outcomes of interest*

Kaneko FT, Arroliga AC, Dweik RA, et al. Biochemical reaction products of nitric oxide as quantitative markers of primary pulmonary hypertension. Am J Respir Crit Care Med. 1998;158(3):917-23. PMID: 9731026. *Exclude - Does not include intervention of interest*

Karatza AA, Bush A, Magee AG. Safety and efficacy of Sildenafil therapy in children with pulmonary hypertension. Int J Cardiol. 2005;100(2):267-73. PMID: 15823634. *Exclude - No comparisons of interest*

Karavolias GK, Georgiadou P, Gkouziouta A, et al. Short and long term anti-inflammatory effects of bosentan therapy in patients with pulmonary arterial hypertension: relation to clinical and hemodynamic responses. Expert Opin Ther Targets. 2010;14(12):1283-9. PMID: 20958219. *Exclude - No comparisons of interest*

Karimi M, Borzouee M, Mehrabani A, et al. Echocardiographic finding in beta-thalassemia intermedia and major: absence of pulmonary hypertension following hydroxyurea treatment in beta-thalassemia intermedia. Eur J Haematol. 2009;82(3):213-8. PMID: 19077048. *Exclude - No study population of interest*

Kasparian A, Floros A, Gialafos E, et al. Raynaud's phenomenon is correlated with elevated systolic pulmonary arterial pressure in patients with systemic lupus erythematosus. Lupus. 2007;16(7):505-8. PMID: 17670849. *Exclude - Does not include intervention of interest*

Kassem EA, Friedberg MK. Clinical significance of 2-dimensional, m-mode and doppler echo indices of rightventricular function in children with idiopathic pulmonary arterial hypertension. J Am Soc Echocardiogr. 2012;25(6):B33-B34. *Exclude - Not a full publication*

Kataoka M, Satoh T, Manabe T, et al. Oral sildenafil improves primary pulmonary hypertension refractory to epoprostenol. Circ J. 2005;69(4):461-5. PMID: 15791043. *Exclude - No comparisons of interest*

Kato GJ. Risk factors for echocardiography-determined cardiopulmonary abnormalities in sickle cell anemia in the walk-PHaSST study. Blood. 2010;116(21). *Exclude - Not a full publication*

Kato GJ, McGowan V, Machado RF, et al. Lactate dehydrogenase as a biomarker of hemolysis-associated nitric oxide resistance, priapism, leg ulceration, pulmonary hypertension, and death in patients with sickle cell disease. Blood. 2006;107(6):2279-85. PMID: 16291595. *Exclude - No study population of interest*

Kato GJ, Sable C, Ensing G, et al. Plasma level of NT-Pro-BNP in children with sickle cell disease is associated with degree of anemia and left ventricular measures: The PUSH study. Blood. 2010;116(21). *Exclude - Not a full publication*

Katsushi H, Kazufumi N, Hideki F, et al. Epoprostenol therapy decreases elevated circulating levels of monocyte chemoattractant protein-1 in patients with primary pulmonary hypertension. Circ J. 2004;68(3):227-31. PMID: 14993777. *Exclude - No comparisons of interest*

Kavvadia V, Greenough A, Lilley J, et al. Plasma arginine levels and the response to inhaled nitric oxide in neonates. Biol Neonate. 1999;76(6):340-7. PMID: 10567762. *Exclude - Does not include intervention of interest*

Kawaguchi Y, Tochimoto A, Hara M, et al. NOS2 polymorphisms associated with the susceptibility to pulmonary arterial hypertension with systemic sclerosis: contribution to the transcriptional activity. *Arthritis Res Ther*. 2006;8(4):R104. PMID: 16813666. *Exclude - Does not include intervention of interest*

Kawut S. Sitaxentan in pulmonary arterial hypertension: A viewpoint by Steven Kawut. *Drugs*. 2007;67(5):771. *Exclude - Not a full publication*

Kawut SM, Al-Naamani N, Agerstrand C, et al. Determinants of right ventricular ejection fraction in pulmonary arterial hypertension. *Chest*. 2009;135(3):752-9. PMID: 18849396. *Exclude - No comparisons of interest*

Kawut SM, Horn EM, Berekashvili KK, et al. von Willebrand factor independently predicts long-term survival in patients with pulmonary arterial hypertension. *Chest*. 2005;128(4):2355-62. PMID: 16236894. *Exclude - Does not include intervention of interest*

Kayser SR. Use of epoprostenol (Flolan) in the management of primary pulmonary hypertension. *Prog Cardiovasc Nurs*. 1998;13(3):39-41, 45. PMID: 9950022. *Exclude - Not a full publication*

Kayser SR. Combination drug therapy in the management of pulmonary arterial hypertension. *Prog Cardiovasc Nurs*. 2005;20(4):177-82. PMID: 16276142. *Exclude - Not a full publication*

Kehat R, Bonsall DJ, North R, et al. Ocular findings of oral sildenafil use in term and near-term neonates. *J AAPOS*. 2010;14(2):159-62. PMID: 20199882. *Exclude - no primary or secondary outcomes of interest*

Keller RL, Tacy TA, Hendricks-Munoz K, et al. Congenital diaphragmatic hernia: endothelin-1, pulmonary hypertension, and disease severity. *Am J Respir Crit Care Med*. 2010;182(4):555-61. PMID: 20413632. *Exclude - No study population of interest*

Kelly LK, Porta NF, Goodman DM, et al. Inhaled prostacyclin for term infants with persistent pulmonary hypertension refractory to inhaled nitric oxide. *J Pediatr*. 2002;141(6):830-2. PMID: 12461501. *Exclude - No comparisons of interest*

Keogh A, Strange G, McNeil K, et al. The bosentan patient registry: long-term survival in pulmonary arterial hypertension. *Intern Med J*. 2011;41(3):227-34. PMID: 20002851. *Exclude - No comparisons of interest*

Keogh AM, Jabbour A, Hayward CS, et al. Clinical deterioration after sildenafil cessation in patients with pulmonary hypertension. *Vasc Health Risk Manag*. 2008;4(5):1111-3. PMID: 19183760. *Exclude - No comparisons of interest*

Keogh AM, Jabbour A, Weintraub R, et al. Safety and efficacy of transition from subcutaneous treprostinil to oral sildenafil in patients with pulmonary arterial hypertension. *J Heart Lung Transplant*. 2007;26(11):1079-83. PMID: 18022071. *Exclude - No comparisons of interest*

Keogh AM, McNeil KD, Wlodarczyk J, et al. Quality of life in pulmonary arterial hypertension: improvement and maintenance with bosentan. *J Heart Lung Transplant*. 2007;26(2):181-7. PMID: 17258153. *Exclude - No comparisons of interest*

Kereveur A, Callebort J, Humbert M, et al. High plasma serotonin levels in primary pulmonary hypertension. Effect of long-term epoprostenol (prostacyclin) therapy. *Arterioscler Thromb Vasc Biol*. 2000;20(10):2233-9. PMID: 11031209. *Exclude - No comparisons of interest*

Kermeeen FD, Franks C, O'Brien K, et al. Endothelin receptor antagonists are an effective long term treatment option in pulmonary arterial hypertension associated with congenital heart disease with or without trisomy 21. *Heart Lung Circ*. 2010;19(10):595-600. PMID: 20728407. *Exclude - No comparisons of interest*

Keser G, Capar I, Aksu K, et al. Pulmonary hypertension in rheumatoid arthritis. *Scand J Rheumatol*. 2004;33(4):244-5. PMID: 15370720. *Exclude - No comparisons of interest*

Kharitonov SA, Cailes JB, Black CM, et al. Decreased nitric oxide in the exhaled air of patients with systemic sclerosis with pulmonary hypertension. *Thorax*. 1997;52(12):1051-5. PMID: 9516898. *Exclude - No comparisons of interest*

Khorana M, Yookaseam T, Layangool T, et al. Outcome of oral sildenafil therapy on persistent pulmonary hypertension of the newborn at Queen Sirikit National Institute of Child Health. *J Med Assoc Thai*. 2011;94 Suppl 3:S64-73. PMID: 22043756. *Exclude - No comparisons of interest*

Kiatchoosakun S, Ungkasekvina W, Wonvipaporn C, et al. D-dimer and pulmonary arterial hypertension in systemic sclerosis. *J Med Assoc Thai*. 2007;90(10):2024-9. PMID: 18041419. *Exclude - No comparisons of interest*

Kiatchoosakun S, Wongvipaporn C, Nanagara R, et al. Right ventricular systolic pressure assessed by echocardiography: a predictive factor of mortality in patients with scleroderma. *Clin Cardiol*. 2011;34(8):488-93. PMID: 21717471. *Exclude - No comparisons of interest*

Kielstein JT, Bode-Boger SM, Hesse G, et al. Asymmetrical dimethylarginine in idiopathic pulmonary arterial hypertension. *Arterioscler Thromb Vasc Biol*. 2005;25(7):1414-8. PMID: 15860741. *Exclude - No comparisons of interest*

Kiettisanpipop P, Lertsapcharorn P, Chotivittayatarakorn P, et al. Plasma levels of nitric oxide in children with congenital heart disease and increased pulmonary blood flow. *J Med Assoc Thai*. 2007;90(10):2053-7. PMID: 18041423. *Exclude - No comparisons of interest*

Kim HW, Kim GB, Je HG, et al. Pulmonary arterial hypertension in children: A single center experience. *Korean Circ J*. 2008;38(12):644-650. *Exclude - No comparisons of interest*

Kim KJ, Kim JY, Park SJ, et al. Prevalence and associated factors for asymptomatic pulmonary arterial hypertension in patients with systemic lupus erythematosus. *Arthritis Rheum*. 2011;63(10). *Exclude - Not a full publication*

Kim KJ, Yoon HS, Yoon CH, et al. Prevalence and associated factors for asymptomatic pulmonary arterial hypertension in patients with systemic lupus erythematosus. *Inflamm Res*. 2011;60:S217-S218. *Exclude - Not a full publication*

Kim LH, Korn JH. Update in systemic sclerosis. *Arthritis Care Res*. 2003;49(4):605-613. *Exclude - Background Other*

Kim MA, Kim DK, Lee CH, et al. The correlation of brain natriuretic peptide (BNP), pulmonary arterial pressure, and St. George Respiratory Questionnaire (SGRQ) and their changes with a trial of an angiotensin converting enzyme inhibitor. *Tuberc Respir Dis*. 2010;68(5):273-279. *Exclude - Not available in English*

Kim WH, Otsuji Y, Seward JB, et al. Estimation of left ventricular function in right ventricular volume and pressure overload. Detection of early left ventricular dysfunction by Tei index. *Jpn Heart J*. 1999;40(2):145-54. PMID: 10420876. *Exclude - no primary or secondary outcomes of interest*

Kim WR, Krowka MJ, Plevak DJ, et al. Accuracy of Doppler echocardiography in the assessment of pulmonary hypertension in liver transplant candidates. *Liver Transpl*. 2000;6(4):453-8. PMID: 10915168. *Exclude - No comparisons of interest*

Kincaid L. Promise in the PAH pipeline. *Good Clin Pract J*. 2006;13(5):26-27. *Exclude - Not a full publication*

King P, Tulloh R. Management of pulmonary hypertension and Down syndrome. *Int J Clin Pract*. 2011;65(SUPPL. 174):8-13. *Exclude - Background Other*

Kingman MS, Tankersley MA, Lombardi S, et al. Prostacyclin administration errors in pulmonary arterial hypertension patients admitted to hospitals in the United States: a national survey. *J Heart Lung Transplant*. 2010;29(8):841-6. PMID: 20430649. *Exclude - No comparisons of interest*

Kittipovanonth M, Bellavia D, Chandrasekaran K, et al. Doppler myocardial imaging for early detection of right ventricular dysfunction in patients with pulmonary hypertension. *J Am Soc Echocardiogr*. 2008;21(9):1035-41. PMID: 18765178. *Exclude - Does not include intervention of interest*

Klinger JR, Oudiz RJ, Spence R, et al. Long-term pulmonary hemodynamic effects of ambrisentan in pulmonary arterial hypertension. *Am J Cardiol*. 2011;108(2):302-7. PMID: 21545989. *Exclude - No comparisons of interest*

Klinger JR, Thaker S, Houtchens J, et al. Pulmonary hemodynamic responses to brain natriuretic peptide and sildenafil in patients with pulmonary arterial hypertension. *Chest*. 2006;129(2):417-25. PMID: 16478861. *Exclude - no primary or secondary outcomes of interest*

Klings ES, Anton Bland D, Rosenman D, et al. Pulmonary arterial hypertension and left-sided heart disease in sickle cell disease: clinical characteristics and association with soluble adhesion molecule expression. *Am J Hematol*. 2008;83(7):547-53. PMID: 18383329. *Exclude - No comparisons of interest*

Klings ES, Hill NS, Jeong MH, et al. Systemic sclerosis-associated pulmonary hypertension: short- and long-term effects of epoprostenol (prostacyclin). *Arthritis Rheum*. 1999;42(12):2638-45. PMID: 10616012. *Exclude - No comparisons of interest*

Knight-Perry JE, de Las Fuentes L, Waggoner AD, et al. Abnormalities in cardiac structure and function in adults with sickle cell disease are not associated with pulmonary hypertension. *J Am Soc Echocardiogr*. 2011;24(11):1285-90. PMID: 21873028. *Exclude - no primary or secondary outcomes of interest*

Knirsch W, Hausermann E, Fasnacht M, et al. Effect of medical treatment on plasma B-type natriuretic peptide levels and 6 min walking test in children with pulmonary hypertension. *Clin Res Cardiol*. 2011;100(9):858-859. *Exclude - Not a full publication*

Knudsen L, Schurawlew A, Nickel N, et al. Long-term effects of intravenous iloprost in patients with idiopathic pulmonary arterial hypertension deteriorating on non-parenteral therapy. *BMC Pulm Med*. 2011;11(1):56. PMID: 22133492. *Exclude - No comparisons of interest*

Koca F, Tanboga IH, Can MM, et al. Neutrophil gelatinase-associated lipocalin levels in right and left heart failure: An observational study. *Anadolu Kardiyol Derg*. 2011;11(6):498-503. *Exclude - no primary or secondary outcomes of interest*

Kojonazarov BK, Imanov BZ, Amatov TA, et al. Noninvasive and invasive evaluation of pulmonary arterial pressure in highlanders. *Eur Respir J*. 2007;29(2):352-6. PMID: 17079253. *Exclude - No study population of interest*

Kong D, Shu X, Pan C, et al. Evaluation of right ventricular regional volume and systolic function in patients with pulmonary arterial hypertension using three-dimensional echocardiography. *J Am Soc Echocardiogr*. 2012;25(6):B74-B75. *Exclude - Not a full publication*

Kong D, Shu X, Pan C, et al. Rightventricular regional systolic function and dyssynchrony in patients with pulmonary hypertension evaluated by three-dimensional echocardiography. *J Am Soc Echocardiogr*. 2012;25(6):B106. *Exclude - Not a full publication*

Kong KO, Badsha H, Thumboo J, et al. Intermittent epoprostenol infusions in systemic lupus erythematosus associated pulmonary hypertension--a series of three cases. *Ann Acad Med Singapore*. 2003;32(1):118-21. PMID: 12625109. *Exclude - No comparisons of interest*

Kotake F, Kobayashi J, Sonoda M, et al. Nitric oxide-related compounds in patients with congenital heart defects and pulmonary hypertension. *Pediatr Int*. 2000;42(3):249-54. PMID: 10881580. *Exclude - No comparisons of interest*

Kothari SS, Duggal B. Chronic oral sildenafil therapy in severe pulmonary artery hypertension. *Indian Heart J*. 2002;54(4):404-9. PMID: 12462669. *Exclude - No comparisons of interest*

Kotlyar E, Sy R, Keogh AM, et al. Bosentan for the treatment of pulmonary arterial hypertension associated with congenital cardiac disease. *Cardiol Young*. 2006;16(3):268-74. PMID: 16725066. *Exclude - No comparisons of interest*

Kourouklis S, Christopoulos A, Liagkas K, et al. Bosentan in Eisenmenger syndrome and chronic thromboembolic pulmonary hypertension. *Eur J Clin Invest*. 2006;36 Suppl 3:39-43. PMID: 16919009. *Exclude - Not a full publication*

Kouzu H, Nakatani S, Kyotani S, et al. Noninvasive estimation of pulmonary vascular resistance by Doppler echocardiography in patients with pulmonary arterial hypertension. *Am J Cardiol*. 2009;103(6):872-6. PMID: 19268748. *Exclude - No comparisons of interest*

Kovacs G, Kqiku X, Maier R, et al. Early therapy with bosentan may reverse pulmonary vasculopathy in scleroderma patients. *Pneumologie*. 2010;64. *Exclude - Not a full publication*

Kovacs G, Maier R, Aberer E, et al. Pulmonary arterial hypertension therapy may be safe and effective in patients with systemic sclerosis and borderline pulmonary pressures. *Arthritis Rheum*. 2011. PMID: 22127844. *Exclude - No comparisons of interest*

Kowal-Bielecka O, Avouac J, Pittrow D, et al. Analysis of the validation status of Quality of Life and Functional Disability Measures in Pulmonary Arterial Hypertension related to systemic sclerosis: results of a systematic literature Analysis by the Expert Panel on Outcomes Measures in Pulmonary Arterial Hypertension related to systemic sclerosis (EPOSS). *J Rheumatol*. 2011;38(11):2419-27. PMID: 21965635. *Exclude - Not a full publication*

Krasuski RA, Warner JJ, Wang A, et al. Inhaled nitric oxide selectively dilates pulmonary vasculature in adult patients with pulmonary hypertension, irrespective of etiology. *J Am Coll Cardiol*. 2000;36(7):2204-11. PMID: 11127462. *Exclude - no primary or secondary outcomes of interest*

Krowka MJ, Frantz RP, McGoon MD, et al. Improvement in pulmonary hemodynamics during intravenous epoprostenol (prostacyclin): A study of 15 patients with moderate to severe portopulmonary hypertension. *Hepatology*. 1999;30(3):641-8. PMID: 10462369. *Exclude - No comparisons of interest*

Krowka MJ, Swanson KL, Frantz RP, et al. Portopulmonary hypertension: Results from a 10-year screening algorithm. *Hepatology*. 2006;44(6):1502-10. PMID: 17133488. *Exclude - No comparisons of interest*

Kubaneck M, Malek I, Kautzner J, et al. The value of B-type natriuretic peptide and big endothelin-1 for detection of severe pulmonary hypertension in heart transplant candidates. *Eur J Heart Fail*. 2005;7(7):1149-55. PMID: 15916922. *Exclude - No comparisons of interest*

Kuhn KP, Byrne DW, Arbogast PG, et al. Outcome in 91 consecutive patients with pulmonary arterial hypertension receiving epoprostenol. *Am J Respir Crit Care Med*. 2003;167(4):580-6. PMID: 12446266. *Exclude - No comparisons of interest*

Kuhn KP, Wickersham NE, Robbins IM, et al. Acute effects of sildenafil in patients with primary pulmonary hypertension receiving epoprostenol. *Exp Lung Res*. 2004;30(2):135-45. PMID: 14972773. *Exclude - no primary or secondary outcomes of interest*

Kulkarni A. Changing trends in neonatal pharmacotherapy. *Perinatology*. 2004;6(5):231-236. *Exclude - Not a full publication*

Kulkarni H, Srinivas A, Vora A, et al. Acute hemodynamic response to vasodilators in primary pulmonary hypertension. *J Postgrad Med*. 1996;42(1):7-11. PMID: 9715289. *Exclude - no primary or secondary outcomes of interest*

Kumar P, Kazzi NJ, Shankaran S. Plasma immunoreactive endothelin-1 concentrations in infants with persistent pulmonary hypertension of the newborn. *Am J Perinatol*. 1996;13(6):335-41. PMID: 8865978. *Exclude - No study population of interest*

Kumar U, Gokhle SS, Sreenivas V, et al. Prospective, open-label, uncontrolled pilot study to study safety and efficacy of sildenafil in systemic sclerosis-related pulmonary artery hypertension and cutaneous vascular complications. *Rheumatol Int*. 2012;1-6. *Exclude - No study population of interest*

Kumar U, Ramteke R, Yadav R, et al. Prevalence and predictors of pulmonary artery hypertension in systemic sclerosis. *J Assoc Physicians India*. 2008;56:413-7. PMID: 18822619. *Exclude - No comparisons of interest*

Kumbhani DJ, Bhatt DL. Ambrisentan in pulmonary arterial hypertension efficacy study 1 and 2 (Aries 1 and 2). *ACC Cardiosource Rev J*. 2008;17(7):41. *Exclude - Not a full publication*

Kumpers P, Nickel N, Lukasz A, et al. Circulating angiopoietins in idiopathic pulmonary arterial hypertension. *Eur Heart J*. 2010;31(18):2291-300. PMID: 20601390. *Exclude - No comparisons of interest*

Kunieda T, Nakanishi N, Matsubara H, et al. Effects of long-acting beraprost sodium (TRK-100STP) in Japanese patients with pulmonary arterial hypertension. *Int Heart J*. 2009;50(4):513-29. PMID: 19609055. *Exclude - Does not include intervention of interest*

Kuntzen C, Gulberg V, Gerbes AL. Use of a mixed endothelin receptor antagonist in portopulmonary hypertension: a safe and effective therapy? *Gastroenterology*. 2005;128(1):164-8. PMID: 15633133. *Exclude - Not a full publication*

Kuo PC, Alfrey EJ, Li K, et al. Magnetic resonance imaging-derived parameter of portal flow predicts volume-mediated pulmonary hypertension in liver transplantation candidates. *Surgery*. 1995;118(4):685-91; discussion 691-2. PMID: 7570323. *Exclude - Does not include intervention of interest*

Kuo PC, Plotkin JS, Johnson LB, et al. Distinctive clinical features of portopulmonary hypertension. *Chest*. 1997;112(4):980-6. PMID: 9377962. *Exclude - No comparisons of interest*

Kuo PC, Schroeder RA, Vagelos RH, et al. Volume-mediated pulmonary responses in liver transplant candidates. *Clin Transplant*. 1996;10(6 Pt 1):521-7. PMID: 8996773. *Exclude - Does not include intervention of interest*

Kupecz D, Berardinelli C. Ease symptoms of pulmonary hypertension with bosentan. *Nurse Pract*. 2002;27(6):51-3. PMID: 12094086. *Exclude - Not a full publication*

Kurzyna M, Zylkowska J, Fijalkowska A, et al. Characteristics and prognosis of patients with decompensated right ventricular failure during the course of pulmonary hypertension. *Kardiol Pol*. 2008;66(10):1033-9; discussion 1040-1. PMID: 19006024. *Exclude - Does not include intervention of interest*

Kylhammar D, Kornhall B, Persson L, et al. Haemodynamic effects of first-line single- or combination therapy in patients with idiopathic or familial pulmonary arterial hypertension from the Lund cohort of the Swedish Pulmonary Arterial Hypertension Registry. *Scand Cardiovasc J*. 2012;46:15. *Exclude - Not a full publication*

- Kyriazis J, Papagiannis N, Kavouria E, et al. The role of tissue doppler imaging (TDI) in the evaluation of pulmonary hypertension (PH) in hemodialysis (HD) patients. *NDT Plus*. 2010;3:iii178. *Exclude - Not a full publication*
- Lakshmanan RV, Sharma A, Khanduja K, et al. Preoperative transthoracic echocardiography does not predict intraoperative systolic pulmonary artery pressure in liver transplant candidates. *Liver Transplantation*. 2012;18:S127. *Exclude - Not a full publication*
- Lal MK, Field DJ. Clinical management of persistent pulmonary hypertension of the newborn. *Perinatology*. 2001;3(5):249-261. *Exclude - unable to obtain full-text*
- Lammers AE, Hislop AA, Flynn Y, et al. Epoprostenol treatment in children with severe pulmonary hypertension. *Heart*. 2007;93(6):739-43. PMID: 17065181. *Exclude - No comparisons of interest*
- Landburg PP, Teerlink T, Biemond BJ, et al. Plasma asymmetric dimethylarginine concentrations in sickle cell disease are related to the hemolytic phenotype. *Blood Cells Mol Dis*. 2010;44(4):229-32. PMID: 20185345. *Exclude - no primary or secondary outcomes of interest*
- Lang I, Gomez-Sanchez M, Kneussl M, et al. Efficacy of long-term subcutaneous treprostinil sodium therapy in pulmonary hypertension. *Chest*. 2006;129(6):1636-43. PMID: 16778286. *Exclude - No comparisons of interest*
- Langer F, Wilhelm W, Tscholl D, et al. Intraoperative inhalation of the long-acting prostacyclin analog iloprost for pulmonary hypertension. *J Thorac Cardiovasc Surg*. 2003;126(3):874-5. PMID: 14502175. *Exclude - No study population of interest*
- Langleben D, Brock T, Dixon R, et al. STRIDE 1: effects of the selective ET(A) receptor antagonist, sitaxsentan sodium, in a patient population with pulmonary arterial hypertension that meets traditional inclusion criteria of previous pulmonary arterial hypertension trials. *J Cardiovasc Pharmacol*. 2004;44 Suppl 1:S80-4. PMID: 15838366. *Exclude - Does not include intervention of interest*
- Langleben D, Cacoub P. A review of STRIDE-2 and STRIDE-2X: the case for selective endothelin receptor blockade. *Eur J Clin Invest*. 2009;39 Suppl 2:27-31. PMID: 19335744. *Exclude - Not a full publication*
- Langleben D, Hirsch AM, Shalit E, et al. Sustained symptomatic, functional, and hemodynamic benefit with the selective endothelin-A receptor antagonist, sitaxsentan, in patients with pulmonary arterial hypertension: a 1-year follow-up study. *Chest*. 2004;126(4):1377-81. PMID: 15486408. *Exclude - Does not include intervention of interest*
- Lanzarini L, Fontana A, Campana C, et al. Two simple echo-Doppler measurements can accurately identify pulmonary hypertension in the large majority of patients with chronic heart failure. *J Heart Lung Transplant*. 2005;24(6):745-54. PMID: 15949736. *Exclude - No study population of interest*
- Lapa M, Dias B, Jardim C, et al. Cardiopulmonary manifestations of hepatosplenic schistosomiasis. *Circulation*. 2009;119(11):1518-23. PMID: 19273723. *Exclude - Does not include intervention of interest*
- Larsen KO, Yndestad A, Sjaastad I, et al. Lack of CCR7 induces pulmonary hypertension involving perivascular leukocyte infiltration and inflammation. *Am J Physiol Lung Cell Mol Physiol*. 2011;301(1):L50-9. PMID: 21498626. *Exclude - Not a full publication*
- Launay D. Pulmonary hypertension, the "bete noire" of systemic diseases: from systemic sclerosis to hereditary hemorrhagic telangiectasia. *Rev Med Interne*. 2006;27(11):899-902. *Exclude - Not available in English*
- Launay D, Hachulla E, Hatron PY, et al. Aerosolized iloprost in CREST syndrome related pulmonary hypertension. *J Rheumatol*. 2001;28(10):2252-6. PMID: 11669165. *Exclude - No comparisons of interest*
- Launay D, Hachulla E, Hatron PY, et al. Pulmonary arterial hypertension: a rare complication of primary Sjogren syndrome: report of 9 new cases and review of the literature. *Medicine (Baltimore)*. 2007;86(5):299-315. PMID: 17873760. *Exclude - Not a full publication*
- Launay D, Mouthon L, Hachulla E, et al. Prevalence and characteristics of moderate to severe pulmonary hypertension in systemic sclerosis with and without interstitial lung disease. *J Rheumatol*. 2007;34(5):1005-11. PMID: 17444586. *Exclude - No comparisons of interest*
- Launay D, Sitbon O, Cordier JF, et al. Survival and prognostic factors in patients with incident systemic sclerosis-associated pulmonary arterial hypertension from the French registry. *Eur Heart J*. 2011;32:174. *Exclude - Not a full publication*

Launay D, Sitbon O, Le Pavec J, et al. Long-term outcome of systemic sclerosis-associated pulmonary arterial hypertension treated with bosentan as first-line monotherapy followed or not by the addition of prostanooids or sildenafil. *Rheumatology (Oxford)*. 2010;49(3):490-500. PMID: 20015974. *Exclude - no comparisons of interest.*

Lawrie A, Waterman E, Southwood M, et al. Evidence of a role for osteoprotegerin in the pathogenesis of pulmonary arterial hypertension. *Am J Pathol*. 2008;172(1):256-64. PMID: 18156213. *Exclude - No comparisons of interest*

Le Ven F, Tribouilloy C, Habib G, et al. Valvular heart disease associated with benfluorex therapy: results from the French multicentre registry. *Eur J Echocardiogr*. 2011;12(4):265-71. PMID: 21193484. *Exclude - No comparisons of interest*

Leal GN, de Paula AC, Leone C, et al. Echocardiographic study of paediatric patients with mucopolysaccharidosis. *Cardiol Young*. 2010;20(3):254-61. PMID: 20416133. *Exclude - Does not include intervention of interest*

Lee AJ, Chiao TB, Tsang MP. Sildenafil for pulmonary hypertention. *Ann Pharmacother*. 2005;39(5):869-884. *Exclude - Background SR/MA*

Lee H, Kim SY, Lee SJ, et al. Potential of right to left ventricular volume ratio measured on chest CT for the prediction of pulmonary hypertension: correlation with pulmonary arterial systolic pressure estimated by echocardiography. *Eur Radiol*. 2012;1-8. *Exclude - Does not include intervention of interest*

Lee MT, Small T, Khan MA, et al. Doppler-defined pulmonary hypertension and the risk of death in children with sickle cell disease followed for a mean of three years. *Br J Haematol*. 2009;146(4):437-41. PMID: 19563512. *Exclude - no primary or secondary outcomes of interest*

Lee S, Chung W. Interplay between body mass index and brain natriuretic peptide in screening for pulmonary arterial hypertension in SSc. *Rheumatology (Oxford)*. 2012;51:ii81. *Exclude - Not a full publication*

Lei MH, Chen JJ, Ko YL, et al. Reappraisal of quantitative evaluation of pulmonary regurgitation and estimation of pulmonary artery pressure by continuous wave Doppler echocardiography. *Cardiology*. 1995;86(3):249-56. PMID: 7614499. *Exclude - No comparisons of interest*

Lepore JJ, Maroo A, Pereira NL, et al. Effect of sildenafil on the acute pulmonary vasodilator response to inhaled nitric oxide in adults with primary pulmonary hypertension. *Am J Cardiol*. 2002;90(6):677-80. PMID: 12231108. *Exclude - no primary or secondary outcomes of interest*

Leuchte HH, El Nounou M, Tuerpe JC, et al. N-terminal pro-brain natriuretic peptide and renal insufficiency as predictors of mortality in pulmonary hypertension. *Chest*. 2007;131(2):402-9. PMID: 17296640. *Exclude - No comparisons of interest*

Leuchte HH, Schwaiblmair M, Baumgartner RA, et al. Hemodynamic response to sildenafil, nitric oxide, and iloprost in primary pulmonary hypertension. *Chest*. 2004;125(2):580-6. PMID: 14769741. *Exclude - no primary or secondary outcomes of interest*

Ley S, Mereles D, Puderbach M, et al. Value of MR phase-contrast flow measurements for functional assessment of pulmonary arterial hypertension. *Eur Radiol*. 2007;17(7):1892-7. PMID: 17225131. *Exclude - Does not include intervention of interest*

Li EK, Tam LS. Pulmonary hypertension in systemic lupus erythematosus: clinical association and survival in 18 patients. *J Rheumatol*. 1999;26(9):1923-9. PMID: 10493670. *Exclude - Does not include intervention of interest*

Li YD, Wu YF, Ma ZH, et al. Correlation of hemodynamic parameters measured with echocardiography and those obtained with right heart catheterization in patients of pulmonary hypertension. *Chinese Journal of Medical Imaging Technology*. 2011;27(7):1405-1408. *Exclude - Not a full publication*

Liem RI, Nevin MA, Prestridge A, et al. Tricuspid regurgitant jet velocity elevation and its relationship to lung function in pediatric sickle cell disease. *Pediatr Pulmonol*. 2009;44(3):281-9. PMID: 19205056. *Exclude - Does not include intervention of interest*

Liem RI, Young LT, Lay AS, et al. Reproducibility of tricuspid regurgitant jet velocity measurements in children and young adults with sickle cell disease undergoing screening for pulmonary hypertension. *Am J Hematol*. 2010;85(10):741-5. PMID: 20652966. *Exclude - Does not include intervention of interest*

Limsuwan A, Khosithseth A, Wanichkul S, et al. Aerosolized iloprost for pulmonary vasoreactivity testing in children with long-standing pulmonary hypertension related to congenital heart disease. *Catheter Cardiovasc Interv.* 2009;73(1):98-104. PMID: 19089967. *Exclude - No comparisons of interest*

Limsuwan A, Wanitkul S, Khosithseth A, et al. Aerosolized iloprost for postoperative pulmonary hypertensive crisis in children with congenital heart disease. *Int J Cardiol.* 2008;129(3):333-8. PMID: 18096256. *Exclude - No comparisons of interest*

Lin SC, Chen RJC, Lee JH. The correlation between right descending pulmonary artery diameter and echocardiography-estimated systolic pulmonary artery pressure. *Acta Cardiol Sin.* 2009;25(4):213-217. *Exclude - Does not include intervention of interest*

Lise MC, Sparsa A, Marie I, et al. Serum neurotrophin profile in systemic sclerosis. *PLoS One.* 2010;5(11). *Exclude - no primary or secondary outcomes of interest*

Liu J, Feng ZC. Changes in pulmonary arterial pressure in term-infants with hypoxic-ischemic encephalopathy. *Pediatr Int.* 2009;51(6):786-9. PMID: 19419507. *Exclude - No study population of interest*

Liu YT, Li MT, Fang Q, et al. Right-heart function related to the results of acute pulmonary vasodilator testing in patients with pulmonary arterial hypertension caused by connective tissue disease. *J Am Soc Echocardiogr.* 2012;25(3):274-9. PMID: 22137255. *Exclude - no primary or secondary outcomes of interest*

Liu YT, Li MT, Tian Z, et al. Right-Heart Function Related to the Results of Acute Pulmonary Vasodilator Testing in Patients with Pulmonary Arterial Hypertension Caused by Connective Tissue Disease. *J Am Soc Echocardiogr.* 2011. PMID: 22137255. *Exclude - Does not include intervention of interest*

LoBuono C. Pulmonary hypertension guidelines include latest drugs. *Drug Topics.* 2004;148(16):29. *Exclude - Not a full publication Exclude - Not a full publication*

LoBuono C. First inhaled prostacyclin for pulmonary hypertension. *Drug Topics.* 2005;149(4). *Exclude - Not a full publication*

Lopes AA, Barreto AC, Maeda NY, et al. Plasma von Willebrand factor as a predictor of survival in pulmonary arterial hypertension associated with congenital heart disease. *Braz J Med Biol Res.* 2011;44(12):1269-1275. *Exclude - Does not include intervention of interest*

Lopes AA, Maeda NY, Bydlowski SP. Abnormalities in circulating von Willebrand factor and survival in pulmonary hypertension. *Am J Med.* 1998;105(1):21-6. PMID: 9688017. *Exclude - Does not include intervention of interest*

Lopes AA, Maeda NY, Goncalves RC, et al. Endothelial cell dysfunction correlates differentially with survival in primary and secondary pulmonary hypertension. *Am Heart J.* 2000;139(4):618-23. PMID: 10740142. *Exclude - Does not include intervention of interest*

Lopes LR, Loureiro MJ, Miranda R, et al. The usefulness of contrast during exercise echocardiography for the assessment of systolic pulmonary pressure. *Cardiovasc Ultrasound.* 2008;6:51. PMID: 18851729. *Exclude - Does not include intervention of interest*

Lopez-Candales A, Bazaz R, Edelman K, et al. Apical systolic eccentricity index: a better marker of right ventricular compromise in pulmonary hypertension. *Echocardiography.* 2010;27(5):534-8. PMID: 20345450. *Exclude - no primary or secondary outcomes of interest*

Lopez-Candales A, Dohi K, Bazaz R, et al. Relation of right ventricular free wall mechanical delay to right ventricular dysfunction as determined by tissue Doppler imaging. *Am J Cardiol.* 2005;96(4):602-6. PMID: 16098321. *Exclude - no primary or secondary outcomes of interest*

Lopez-Candales A, Dohi K, Iliescu A, et al. An abnormal right ventricular apical angle is indicative of global right ventricular impairment. *Echocardiography.* 2006;23(5):361-8. PMID: 16686617. *Exclude - no primary or secondary outcomes of interest*

Lopez-Candales A, Dohi K, Rajagopalan N, et al. Defining normal variables of right ventricular size and function in pulmonary hypertension: an echocardiographic study. *Postgrad Med J.* 2008;84(987):40-5. PMID: 18230750. *Exclude - Does not include intervention of interest*



Lopez-Candales A, Dohi K, Rajagopalan N, et al. Right ventricular dyssynchrony in patients with pulmonary hypertension is associated with disease severity and functional class. *Cardiovasc Ultrasound*. 2005;3:23. PMID: 16129028. *Exclude - Does not include intervention of interest*

Lopez-Candales A, Edelman K. Ratio of right to left ventricular ejection: a pilot study using Doppler to detect interventricular dyssynchrony. *Clin Cardiol*. 2011;34(6):366-71. PMID: 21538384. *Exclude - no primary or secondary outcomes of interest*

Lopez-Candales A, Edelman K, Gulyasy B. The effect of chronic pulmonary hypertension on diastolic annular tissue velocities: a pilot study. *Am J Med Sci*. 2011;341(5):344-9. PMID: 21478731. *Exclude - no primary or secondary outcomes of interest*

Lopez-Candales A, Edelman K, Gulyasy B, et al. New annular tissue Doppler markers of pulmonary hypertension. *Echocardiography*. 2010;27(8):969-76. PMID: 20849485. *Exclude - no primary or secondary outcomes of interest*

Lopez-Candales A, Eleswarapu A, Shaver J, et al. Right ventricular outflow tract spectral signal: a useful marker of right ventricular systolic performance and pulmonary hypertension severity. *Eur J Echocardiogr*. 2010;11(6):509-15. PMID: 20207723. *Exclude - no primary or secondary outcomes of interest*

Lopez-Candales A, Rajagopalan N, Dohi K, et al. Normal range of mechanical variables in pulmonary hypertension: a tissue Doppler imaging study. *Echocardiography*. 2008;25(8):864-72. PMID: 18986414. *Exclude - no primary or secondary outcomes of interest*

Lopez-Candales A, Rajagopalan N, Dohi K, et al. Abnormal right ventricular myocardial strain generation in mild pulmonary hypertension. *Echocardiography*. 2007;24(6):615-22. PMID: 17584201. *Exclude - No comparisons of interest*

Lopez-Candales A, Rajagopalan N, Gulyasy B, et al. A delayed time of the peak tricuspid regurgitation signal: marker of right ventricular dysfunction. *Am J Med Sci*. 2008;336(3):224-9. PMID: 18794616. *Exclude - no primary or secondary outcomes of interest*

Lopez-Candales A, Rajagopalan N, Gulyasy B, et al. Differential strain and velocity generation along the right ventricular free wall in pulmonary hypertension. *Can J Cardiol*. 2009;25(3):e73-7. PMID: 19279990. *Exclude - no primary or secondary outcomes of interest*

Lopez-Medrano F, Fernandez-Ruiz M, Ruiz-Cano MJ, et al. High Incidence of Bloodstream Infection Due to Gram-negative Bacilli in Patients With Pulmonary Hypertension Receiving Intravenous Treprostinil. *Arch Bronconeumol*. 2012. *Exclude - Not a full publication*

Loukanov T, Arnold R, Gross J, et al. Endothelin-1 and asymmetric dimethylarginine in children with left-to-right shunt after intracardiac repair. *Clin Res Cardiol*. 2008;97(6):383-8. PMID: 18297323. *Exclude - no primary or secondary outcomes of interest*

Low A, Teng GG, Law WG, et al. Association of pulmonary hypertension by echocardiography with clinical parameters in Asian patients with SSc. *Rheumatology (Oxford)*. 2012;51:ii80-ii81. *Exclude - Not a full publication*

Low AHL, Tan YS, Yoong J, et al. Relationship between quantitative nail-fold capillaroscopic measurements and echocardiographic pulmonary arterial systolic pressure in SSc. *Rheumatology (Oxford)*. 2012;51:ii80. *Exclude - Not a full publication*

Lu H, Chen S, Wang H, et al. Role of adrenomedullin in congenital heart disease associated with pulmonary hypertension. *J Huazhong Univ Sci Technolog Med Sci*. 2003;23(3):275-7. PMID: 14526432. *Exclude - No study population of interest*

Lu XL, Xiong CM, Shan GL, et al. Impact of sildenafil therapy on pulmonary arterial hypertension in adults with congenital heart disease. *Cardiovasc Ther*. 2010;28(6):350-5. PMID: 20637015. *Exclude - No comparisons of interest*

Lunardini A, Spadoni I, De Lucia V, et al. Advanced therapies in adult and pediatric patients with pulmonary arterial hypertension associated with congenital heart disease: Mid-term follow-up results. *G Ital Cardiol*. 2011;12(10):37S. *Exclude - Not a full publication*

Lunze K, Gilbert N, Mebus S, et al. First experience with an oral combination therapy using bosentan and sildenafil for pulmonary arterial hypertension. *Eur J Clin Invest*. 2006;36 Suppl 3:32-8. PMID: 16919008. *Exclude - No comparisons of interest*

Lupi-Herrera E, Sandoval J, Figueroa J, et al. Left and right ventricular power: outputs are the strongest hemodynamic correlates to allow identification of acute responders to vasodilator treatment in idiopathic pulmonary arterial hypertension. *Arch Cardiol Mex*. 2011;81(2):100-107. PMID: 21775243. *Exclude - No comparisons of interest*

MacGregor AJ, Canavan R, Knight C, et al. Pulmonary hypertension in systemic sclerosis: risk factors for progression and consequences for survival. *Rheumatology (Oxford)*. 2001;40(4):453-9. PMID: 11312386. *Exclude - No study population of interest*

Machado C, Brito I, Souza D, et al. Etiological frequency of pulmonary hypertension in a reference outpatient clinic in Bahia, Brazil. *Arq Bras Cardiol*. 2009;93(6):629-36, 679-86. PMID: 20379644. *Exclude - Does not include intervention of interest*

Machado RF, Barst RJ, Yovetich NA, et al. Hospitalization for pain in patients with sickle cell disease treated with sildenafil for elevated TRV and low exercise capacity. *Blood*. 2011;118(4):855-64. PMID: 21527519. *Exclude - No study population of interest*

Machado RF, Hildesheim M, Mendelsohn L, et al. NT-pro brain natriuretic peptide levels and the risk of death in the cooperative study of sickle cell disease. *Br J Haematol*. 2011;154(4):512-20. PMID: 21689089. *Exclude - no primary or secondary outcomes of interest*

Machado RF, Mack AK, Martyr S, et al. Severity of pulmonary hypertension during vaso-occlusive pain crisis and exercise in patients with sickle cell disease. *Br J Haematol*. 2007;136(2):319-25. PMID: 17156401. *Exclude - Does not include intervention of interest*

Machado RF, Martyr S, Kato GJ, et al. Sildenafil therapy in patients with sickle cell disease and pulmonary hypertension. *Br J Haematol*. 2005;130(3):445-53. PMID: 16042696. *Exclude - No comparisons of interest*

Machherndl S, Kneussl M, Baumgartner H, et al. Long-term treatment of pulmonary hypertension with aerosolized iloprost. *Eur Respir J*. 2001;17(1):8-13. PMID: 11307761. *Exclude - No comparisons of interest*

Maeda NY, Carvalho JH, Otake AH, et al. Platelet protease-activated receptor 1 and membrane expression of P-selectin in pulmonary arterial hypertension. *Thromb Res*. 2010;125(1):38-43. PMID: 19447475. *Exclude - Does not include intervention of interest*

Magne J, Lancellotti P, Pierard LA. Exercise pulmonary hypertension in asymptomatic degenerative mitral regurgitation. *Circulation*. 2010;122(1):33-41. PMID: 20566950. *Exclude - No study population of interest*

Mahmud E, Raisinghani A, Keramati S, et al. Dilation of the coronary sinus on echocardiogram: prevalence and significance in patients with chronic pulmonary hypertension. *J Am Soc Echocardiogr*. 2001;14(1):44-9. PMID: 11174433. *Exclude - no primary or secondary outcomes of interest*

Mainguy V, Maltais F, Saey D, et al. Effects of a rehabilitation program on skeletal muscle function in idiopathic pulmonary arterial hypertension. *J Cardiopulm Rehabil Prev*. 2010;30(5):319-23. PMID: 20410828. *Exclude - Does not include intervention of interest*

Maisel AS, Nakao K, Ponikowski P, et al. Japanese-Western consensus meeting on biomarkers. *Int Heart J*. 2011;52(5):253-65. PMID: 22008432. *Exclude - Not a full publication*

Maiya S, Hislop AA, Flynn Y, et al. Response to bosentan in children with pulmonary hypertension. *Heart*. 2006;92(5):664-70. PMID: 16216850. *Exclude - No comparisons of interest*

Malerba M, Radaeli A, Ragnoli B, et al. Exhaled nitric oxide levels in systemic sclerosis with and without pulmonary involvement. *Chest*. 2007;132(2):575-80. PMID: 17550935. *Exclude - No study population of interest*

Malhotra R, Hess D, Lewis GD, et al. Vasoreactivity to inhaled nitric oxide with oxygen predicts long-term survival in pulmonary arterial hypertension. *Pulm Circ*. 2011;1(2):250-258. PMID: 22020367. *Exclude - Does not include intervention of interest*

Malik AS, Warshafsky S, Lehrman S. Long-term nifedipine treatment for pulmonary hypertension: A meta- analysis. *Cardiol Rev*. 1998;15(1):35-40. *Exclude - Background SR/MA*

Malinowski A, Henrohn D, Eriksson A, et al. Increased plasma and salivary nitrite and decreased bronchial contribution to exhaled NO in pulmonary arterial hypertension. *Eur J Clin Invest*. 2011;41(8):889-97. PMID: 21554268. *Exclude - no primary or secondary outcomes of interest*

Mancano MA. New drugs of 2007. *Pharm Times*. 2008;74(3):75-82. *Exclude - Not a full publication*

Manno RL, Wigley FM, Gelber AC, et al. Late-age onset systemic sclerosis. *J Rheumatol*. 2011;38(7):1317-25. PMID: 21685299. *Exclude - no primary or secondary outcomes of interest*

Martischneg AM, Tichy A, Nikfardjam M, et al. Inhaled iloprost for patients with precapillary pulmonary hypertension and right-side heart failure. *J Card Fail*. 2011;17(10):813-818. *Exclude - No comparisons of interest*

- Marvisi M, Brianti M, Marani G, et al. Hyperthyroidism and pulmonary hypertension. *Respir Med.* 2002;96(4):215-20. PMID: 11999999. *Exclude - No comparisons of interest*
- Masri FA, Comhair SA, Dostanic-Larson I, et al. Deficiency of lung antioxidants in idiopathic pulmonary arterial hypertension. *Clin Transl Sci.* 2008;1(2):99-106. PMID: 20443830. *Exclude - Does not include intervention of interest*
- Mathai SC, Girgis RE, Fisher MR, et al. Addition of sildenafil to bosentan monotherapy in pulmonary arterial hypertension. *Eur Respir J.* 2007;29(3):469-75. PMID: 17079256. *Exclude - No comparisons of interest*
- Mathai SC, Girgis RE, Fisher MR, et al. Addition of sildenafil to bosentan monotherapy in pulmonary arterial hypertension. *Eur Respir J.* 2007;29(3):469-475. *Exclude - No comparisons of interest*
- Mathai SC, Hummers LK, Champion HC, et al. Survival in pulmonary hypertension associated with the scleroderma spectrum of diseases: impact of interstitial lung disease. *Arthritis Rheum.* 2009;60(2):569-77. PMID: 19180517. *Exclude - Does not include intervention of interest*
- Mathewson HS. Selective drug therapy for pulmonary hypertension. *Respir Care.* 1995;40(8):871-875. *Exclude - Not a full publication*
- Mattuzzi S, Barbi S, Carletto A, et al. Association of polymorphisms in the IL1B and IL2 genes with susceptibility and severity of systemic sclerosis. *J Rheumatol.* 2007;34(5):997-1004. PMID: 17444587. *Exclude - Does not include intervention of interest*
- Mazhar J, Pera V, Liang M, et al. How good is tricuspid regurgitation velocity in excluding pulmonary hypertension in patients with left heart disease. *Heart Lung Circul.* 2011;20:S176. *Exclude - Not a full publication*
- Mazurek JA, Salamon J, Zolty R. Endothelin-1 levels in pulmonary hypertension: A comparison between pulmonary arterial hypertension and diastolic heart failure-induced pulmonary hypertension. *J Am Coll Cardiol.* 2012;59(13):E1617. *Exclude - Not a full publication*
- Mazurek JA, Salamon JN, Kelesidis I, et al. Endothelin-1 levels in pulmonary hypertension: A comparison between pulmonary arterial hypertension and diastolic heart failure-induced pulmonary hypertension. *J Heart Lung Transplant.* 2012;31(4):S214-S215. *Exclude - Not a full publication*
- McCann GP, Gan CT, Beek AM, et al. Extent of MRI delayed enhancement of myocardial mass is related to right ventricular dysfunction in pulmonary artery hypertension. *AJR Am J Roentgenol.* 2007;188(2):349-55. PMID: 17242241. *Exclude - no primary or secondary outcomes of interest*
- McConnell J, Nathan S, Hobbs K, et al. A multicenter, retrospective study of patients with pulmonary arterial hypertension who received inhaled iloprost for more than one year. *Chest.* 2011;140(4). *Exclude - Not a full publication*
- McConnell MV, Solomon SD, Rayan ME, et al. Regional right ventricular dysfunction detected by echocardiography in acute pulmonary embolism. *Am J Cardiol.* 1996;78(4):469-73. PMID: 8752195. *Exclude - No study population of interest*
- McGoldrick S. Pivotal protocols. *Good Clin Pract J.* 2007;14(12):18-21. *Exclude - Not a full publication*
- McGoon MD, Frost AE, Oudiz RJ, et al. Ambrisentan therapy in patients with pulmonary arterial hypertension who discontinued bosentan or sitaxsentan due to liver function test abnormalities. *Chest.* 2009;135(1):122-9. PMID: 18812445. *Exclude - No comparisons of interest*
- McLaughlin VV. Survival in patients with pulmonary arterial hypertension treated with first-line bosentan. *Eur J Clin Invest.* 2006;36 Suppl 3:10-5. PMID: 16919005. *Exclude - No comparisons of interest*
- McLaughlin VV, Archer SL, Badesch DB, et al. A report of the american college of cardiology foundation task force on expert consensus documents and the american heart association. *Circulation.* 2009;119(16):2250-2294. *Exclude - Background SR/MA*
- McLaughlin VV, Genthner DE, Panella MM, et al. Reduction in pulmonary vascular resistance with long-term epoprostenol (prostacyclin) therapy in primary pulmonary hypertension. *N Engl J Med.* 1998;338(5):273-7. PMID: 9445406. *Exclude - no comparisons of interest.*
- McLaughlin VV, Shillington A, Rich S. Survival in primary pulmonary hypertension: the impact of epoprostenol therapy. *Circulation.* 2002;106(12):1477-82. PMID: 12234951. *Exclude - No comparisons of interest*
- McLaughlin VV, Sitbon O, Badesch DB, et al. Survival with first-line bosentan in patients with primary pulmonary hypertension. *Eur Respir J.* 2005;25(2):244-9. PMID: 15684287. *Exclude - no comparisons of interest.*

- McLure LE, Brown A, Lee WN, et al. Non-invasive stroke volume measurement by cardiac magnetic resonance imaging and inert gas rebreathing in pulmonary hypertension. *Clin Physiol Funct Imaging*. 2011;31(3):221-6. PMID: 21470362. *Exclude - Does not include intervention of interest*
- Meadows CA, Risbano MG, Zhang L, et al. Increased expression of growth differentiation factor-15 in systemic sclerosis-associated pulmonary arterial hypertension. *Chest*. 2011;139(5):994-1002. PMID: 20829333. *Exclude - Does not include intervention of interest*
- Mealy NE, Bayes M, Del Fresno M. Bosentan: Treatment of pulmonary hypertension, treatment of heart failure, antihypertensive, endothelin ETA/ETB antagonist. *Drugs Future*. 2001;26(12):1149-1154. *Exclude - Not a full publication*
- Mehari A, Tian X, Alam S, et al. Hemodynamic parameters predict mortality in sickle cell disease-related pulmonary hypertension. *Blood*. 2010;116(21). *Exclude - Not a full publication*
- Mehta NJ, Khan IA, Mehta RN, et al. HIV-Related pulmonary hypertension: analytic review of 131 cases. *Chest*. 2000;118(4):1133-41. PMID: 11035689. *Exclude - Not a full publication*
- Mekontso Dessap A, Leon R, Habibi A, et al. Pulmonary hypertension and cor pulmonale during severe acute chest syndrome in sickle cell disease. *Am J Respir Crit Care Med*. 2008;177(6):646-53. PMID: 18174543. *Exclude - no primary or secondary outcomes of interest*
- Melenovsky V, Al-Hiti H, Kazdova L, et al. Transpulmonary B-type natriuretic peptide uptake and cyclic guanosine monophosphate release in heart failure and pulmonary hypertension: the effects of sildenafil. *J Am Coll Cardiol*. 2009;54(7):595-600. PMID: 19660688. *Exclude - No study population of interest*
- Melgosa MT, Ricci GL, Garcia-Pagan JC, et al. Acute and long-term effects of inhaled iloprost in portopulmonary hypertension. *Liver Transpl*. 2010;16(3):348-56. PMID: 20209595. *Exclude - No comparisons of interest*
- Melnick L, Barst RJ, Rowan CA, et al. Effectiveness of transition from intravenous epoprostenol to oral/inhaled targeted pulmonary arterial hypertension therapy in pediatric idiopathic and familial pulmonary arterial hypertension. *Am J Cardiol*. 2010;105(10):1485-9. PMID: 20451700. *Exclude - No comparisons of interest*
- Meng J, Li ZX, Jiang W, et al. Relationship of serum ADMA with pulmonary hypertension in patients on hemodialysis. *Dial Transplant*. 2010;39(6):242-246. *Exclude - No study population of interest*
- Menon N, McAlpine L, Peacock AJ, et al. The acute effects of prostacyclin on pulmonary hemodynamics in patients with pulmonary hypertension secondary to systemic sclerosis. *Arthritis Rheum*. 1998;41(3):466-9. PMID: 9506575. *Exclude - No comparisons of interest*
- Menzel T, Kramm T, Bruckner A, et al. Quantitative assessment of right ventricular volumes in severe chronic thromboembolic pulmonary hypertension using transthoracic three-dimensional echocardiography: changes due to pulmonary thromboendarterectomy. *Eur J Echocardiogr*. 2002;3(1):67-72. PMID: 12067537. *Exclude - No study population of interest*
- Menzel T, Kramm T, Mohr-Kahaly S, et al. Assessment of cardiac performance using Tei indices in patients undergoing pulmonary thromboendarterectomy. *Ann Thorac Surg*. 2002;73(3):762-6. PMID: 11899179. *Exclude - No study population of interest*
- Menzel T, Kramm T, Wagner S, et al. Improvement of tricuspid regurgitation after pulmonary thromboendarterectomy. *Ann Thorac Surg*. 2002;73(3):756-61. PMID: 11899178. *Exclude - No study population of interest*
- Menzel T, Wagner S, Kramm T, et al. Pathophysiology of impaired right and left ventricular function in chronic embolic pulmonary hypertension: changes after pulmonary thromboendarterectomy. *Chest*. 2000;118(4):897-903. PMID: 11035654. *Exclude - No study population of interest*
- Merce J, Ferras S, Oltra C, et al. Cardiovascular abnormalities in hyperthyroidism: a prospective Doppler echocardiographic study. *Am J Med*. 2005;118(2):126-31. PMID: 15694895. *Exclude - No comparisons of interest*
- Meune C, Avouac J, Gobeaux C, et al. Ultra sensitive troponin in systemic sclerosis. *Arthritis Rheum*. 2011;63(10). *Exclude - Not a full publication*
- Meune C, Avouac J, Gobeaux C, et al. Ultra sensitive troponin in SSc. *Rheumatology (Oxford)*. 2012;51:ii111. *Exclude - Not a full publication*

- Michelakis ED, Tymchak W, Noga M, et al. Long-term treatment with oral sildenafil is safe and improves functional capacity and hemodynamics in patients with pulmonary arterial hypertension. *Circulation*. 2003;108(17):2066-9. PMID: 14568893. *Exclude - No comparisons of interest*
- Mikhail G, Gibbs J, Richardson M, et al. An evaluation of nebulized prostacyclin in patients with primary and secondary pulmonary hypertension. *Eur Heart J*. 1997;18(9):1499-504. PMID: 9458458. *Exclude - No study population of interest*
- Mikhail GW, Prasad SK, Li W, et al. Clinical and haemodynamic effects of sildenafil in pulmonary hypertension: acute and mid-term effects. *Eur Heart J*. 2004;25(5):431-6. PMID: 15033256. *Exclude - No comparisons of interest*
- Miller SK. Pulsed Doppler echocardiographic measurement of pulmonary acceleration time in diagnosing patients with pulmonary hypertension. *J Diagn Med Sonogr*. 1995;11(5):241-245. *Exclude - No comparisons of interest*
- Milman N, Burton CM, Iversen M, et al. Pulmonary hypertension in end-stage pulmonary sarcoidosis: therapeutic effect of sildenafil? *J Heart Lung Transplant*. 2008;27(3):329-34. PMID: 18342757. *Exclude - No study population of interest*
- Mingo S, Garcia Lunar I, Monivas V, et al. Right ventricular 2D strain: A new echocardiographic prognostic factor for mortality in pulmonary hypertension. *Eur Heart J*. 2011;32:437. *Exclude - Not a full publication*
- Mininni S, Vono R, Diricatti G, et al. Exercise doppler echocardiography: A new approach in the evaluation of pulmonary artery disease. *Cardiovasc Imaging*. 1996;8(2):323-326. *Exclude - no primary or secondary outcomes of interest*
- Minniti CP, Sable C, Campbell A, et al. Elevated tricuspid regurgitant jet velocity in children and adolescents with sickle cell disease: association with hemolysis and hemoglobin oxygen desaturation. *Haematologica*. 2009;94(3):340-7. PMID: 19211639. *Exclude - Does not include intervention of interest*
- Mistry PK, Sirrs S, Chan A, et al. Pulmonary hypertension in type 1 Gaucher's disease: genetic and epigenetic determinants of phenotype and response to therapy. *Mol Genet Metab*. 2002;77(1-2):91-8. PMID: 12359135. *Exclude - no primary or secondary outcomes of interest*
- Mitoff PR, Burwash I, De Kemp RJ, et al. Right ventricle glucose metabolism and pressure overload in patients with pulmonary arterial hypertension. *J Card Fail*. 2011;17(8):S16. *Exclude - Not a full publication*
- Moazami N, Oz MC. Natriuretic peptides in the perioperative management of cardiac surgery patients. *Heart Surg Forum*. 2005;8(3):141-147. *Exclude - Not a full publication*
- Moceri P, Dimopoulos K, Lioudakis E, et al. Echocardiographic predictors of outcome in Eisenmenger syndrome. *J Am Coll Cardiol*. 2012;59(13):E795. *Exclude - Not a full publication*
- Modrykamien AM, Gudavalli R, McCarthy K, et al. Echocardiography, 6-minute walk distance, and distance-saturation product as predictors of pulmonary arterial hypertension in idiopathic pulmonary fibrosis. *Respir Care*. 2010;55(5):584-8. PMID: 20420729. *Exclude - No study population of interest*
- Mogollon Jimenez MV, Escoresca Ortega AM, Cabeza Letran ML, et al. Correlation of echocardiographic and hemodynamic parameters in pulmonary hypertension assessment prior to heart transplantation. *Transplant Proc*. 2008;40(9):3023-4. PMID: 19010179. *Exclude - No study population of interest*
- Mogollon Jimenez MV, Escoresca Ortega AM, Hinojosa Perez R, et al. Comparison between two drugs on the hemodynamic evaluation of pulmonary hypertension prior to heart transplantation. *Transplant Proc*. 2008;40(9):3009-11. PMID: 19010174. *Exclude - No study population of interest*
- Mohamed WA, Ismail M. A randomized, double-blind, placebo-controlled, prospective study of bosentan for the treatment of persistent pulmonary hypertension of the newborn. *J Perinatol*. 2011. PMID: 22076415. *Exclude - no study population of interest.*
- Mohan N. Importance of screening and early detection of pulmonary hypertension and current treatment options. *J Postgrad Med*. 2005;51(2):107. *Exclude - Not a full publication*
- Mok MY, Cheung BM, Lo Y, et al. Elevated plasma adrenomedullin and vascular manifestations in patients with systemic sclerosis. *J Rheumatol*. 2007;34(11):2224-9. PMID: 17937467. *Exclude - Does not include intervention of interest*

Mok MY, Tsang PL, Lam YM, et al. Bosentan use in systemic lupus erythematosus patients with pulmonary arterial hypertension. *Lupus*. 2007;16(4):279-85. PMID: 17439935. *Exclude - No comparisons of interest*

Molaei A, Aarabi Mogaddam MY, Davari PN, et al. Validity of sildenafil test in patients with pulmonary arterial hypertension associated with congenital heart disease according to clinical and echocardiographic parameters. *J Tehran Uni Heart Cent*. 2009;4(2):103-108. *Exclude - No comparisons of interest*

Moledina S, Hislop AA, Foster H, et al. Childhood idiopathic pulmonary arterial hypertension: a national cohort study. *Heart*. 2010;96(17):1401-6. PMID: 20406768. *Exclude - no comparisons of interest*.

Monahan K, Hickson D, Butler K, et al. Distribution and determinants of pulmonary artery systolic pressure in african-americans: The jackson heart study. *Circulation*. 2011;124(21). *Exclude - Not a full publication*

Monfredi O, Griffiths L, Clarke B, et al. Efficacy and safety of Bosentan for pulmonary arterial hypertension in adults with congenital heart disease. *Am J Cardiol*. 2011;108(10):1483-8. PMID: 21943933. *Exclude - No comparisons of interest*

Montani D, Savale L, Natali D, et al. Long-term response to calcium-channel blockers in non-idiopathic pulmonary arterial hypertension. *Eur Heart J*. 2010;31(15):1898-907. PMID: 20543192. *Exclude - Background Other*

Morales-Blanhir J, Santos S, de Jover L, et al. Clinical value of vasodilator test with inhaled nitric oxide for predicting long-term response to oral vasodilators in pulmonary hypertension. *Respir Med*. 2004;98(3):225-34. PMID: 15002758. *Exclude - no primary or secondary outcomes of interest*

Morelli S, Ferri C, Poletti E, et al. Plasma endothelin-1 levels, pulmonary hypertension, and lung fibrosis in patients with systemic sclerosis. *Am J Med*. 1995;99(3):255-60. PMID: 7653485. *Exclude - no primary or secondary outcomes of interest*

Mori S, Nakatani S, Kanzaki H, et al. Patterns of the interventricular septal motion can predict conditions of patients with pulmonary hypertension. *J Am Soc Echocardiogr*. 2008;21(4):386-93. PMID: 17681728. *Exclude - no primary or secondary outcomes of interest*

Morikawa T, Murata M, Okuda S, et al. Quantitative analysis of right ventricular function in patients with pulmonary hypertension using three-dimensional echocardiography and a two-dimensional summation method compared to magnetic resonance imaging. *Am J Cardiol*. 2011;107(3):484-9. PMID: 21257019. *Exclude - No comparisons of interest*

Morris CR, Kato GJ, Poljakovic M, et al. Dysregulated arginine metabolism, hemolysis-associated pulmonary hypertension, and mortality in sickle cell disease. *JAMA*. 2005;294(1):81-90. PMID: 15998894. *Exclude - Does not include intervention of interest*

Morsy MF, Alnajjar AA, Almuzainy IS, et al. Splenectomized versus non-splenectomized patients with thalassemia major. Echocardiographic comparison. *Saudi Med J*. 2008;29(9):1310-4. PMID: 18813418. *Exclude - no primary or secondary outcomes of interest*

Motiwala A, Fatimi SH, Akhtar N, et al. Patients with congenital atrial septal defects: effect of age at repair and defect size on pulmonary artery pressures prior to repair. *Thorac Cardiovasc Surg*. 2011;59(5):281-6. PMID: 21412709. *Exclude - no primary or secondary outcomes of interest*

Motoji Y, Tanaka H, Fukuda Y, et al. Utility of rightventricular free wall longitudinal speckle tracking strain for evaluation of outcome in patients with pulmonary hypertension. *J Am Soc Echocardiogr*. 2012;25(6):B102. *Exclude - Not a full publication*

Mourani PM, Sontag MK, Ivy DD, et al. Effects of long-term sildenafil treatment for pulmonary hypertension in infants with chronic lung disease. *J Pediatr*. 2009;154(3):379-84, 384 e1-2. PMID: 18950791. *Exclude - No comparisons of interest*

Moustapha A, Kaushik V, Diaz S, et al. Echocardiographic evaluation of left-ventricular diastolic function in patients with chronic pulmonary hypertension. *Cardiology*. 2001;95(2):96-100. PMID: 11423714. *Exclude - no primary or secondary outcomes of interest*

Moustapha A, Lim M, Saikia S, et al. Interrogation of the tricuspid annulus by Doppler tissue imaging in patients with chronic pulmonary hypertension: implications for the assessment of right-ventricular systolic and diastolic function. *Cardiology*. 2001;95(2):101-4. PMID: 11423715. *Exclude - no primary or secondary outcomes of interest*

- Mukerjee D, St George D, Coleiro B, et al. Prevalence and outcome in systemic sclerosis associated pulmonary arterial hypertension: application of a registry approach. *Ann Rheum Dis*. 2003;62(11):1088-93. PMID: 14583573. *Exclude - no primary or secondary outcomes of interest*
- Mulligan C, Beghetti M. Inhaled iloprost for the control of acute pulmonary hypertension in children: A systematic review. *Pediatr Crit Care Med*. 2011. PMID: 21926655. *Exclude - Background SR/MA*
- Muneer A, Ralph DJ, Minhas S. Sildenafil citrate (Viagra(trademark)). *J Drug Eval*. 2003;1(7):225-246. *Exclude - Not a full publication*
- Murase M, Ishida A. Serial pulsed Doppler assessment of pulmonary artery pressure in very low birth-weight infants. *Pediatr Cardiol*. 2000;21(5):452-7. PMID: 10982705. *Exclude - No study population of interest*
- Murata I, Sonoda M, Morita T, et al. The clinical significance of reversed flow in the main pulmonary artery detected by doppler color flow imaging. *Chest*. 2000;118(2):336-41. PMID: 10936121. *Exclude - no primary or secondary outcomes of interest*
- Mussivand T. Multidisciplinary congress in cardio-thoracic healthcare. August 17-20, 2006, 16th World Congress of the World Society of Cardio-Thoracic surgeons, Ottawa, Canada. *Future Cardiol*. 2006;2(6):647-650. *Exclude - Not a full publication*
- Mychaskiw MA, Berger A, Mardekian J, et al. Methods for estimating health-state utilities in pulmonary arterial hypertension. *Value Health*. 2010;13(7):A361. *Exclude - Not a full publication*
- Mychaskiw MA, Berger A, Mardekian J, et al. Patterns of therapy, health care utilization, and health care costs in patients with pulmonary arterial hypertension (PAH) initiating therapy with sildenafil: Findings from retrospective analyses of administrative health care claims data. *Value Health*. 2010;13(7):A351. *Exclude - Not a full publication*
- Myers SA, Ahearn GS, Angelica Selim M, et al. Cutaneous findings in patients with pulmonary arterial hypertension receiving long-term epoprostenol therapy. *J Am Acad Dermatol*. 2004;51(1):98-102. PMID: 15243533. *Exclude - No comparisons of interest*
- Myers SN, Nouraie M, Minniti C, et al. Clinical manifestations of high and low degrees of hemolysis in children with SCD. *Am J Hematol*. 2010;85(8):E29-E30. *Exclude - Not a full publication*
- Naderi N, Ojaghi Haghighi SZ, Amin A, et al. Utility of right ventricular strain imaging in predicting pulmonary vascular resistance in patients with pulmonary hypertension. *J Am Coll Cardiol*. 2012;59(13):E1608. *Exclude - Not a full publication*
- Nadrous HF, Pellikka PA, Krowka MJ, et al. Pulmonary hypertension in patients with idiopathic pulmonary fibrosis. *Chest*. 2005;128(4):2393-9. PMID: 16236900. *Exclude - No study population of interest*
- Nagaya N, Satoh T, Uematsu M, et al. Shortening of Doppler-derived deceleration time of early diastolic transmitral flow in the presence of pulmonary hypertension through ventricular interaction. *Am J Cardiol*. 1997;79(11):1502-6. PMID: 9185641. *Exclude - Does not include intervention of interest*
- Nagaya N, Shimizu Y, Satoh T, et al. Oral beraprost sodium improves exercise capacity and ventilatory efficiency in patients with primary or thromboembolic pulmonary hypertension. *Heart*. 2002;87(4):340-5. PMID: 11907007. *Exclude - No comparisons of interest*
- Nagaya N, Uematsu M, Okano Y, et al. Effect of orally active prostacyclin analogue on survival of outpatients with primary pulmonary hypertension. *J Am Coll Cardiol*. 1999;34(4):1188-92. PMID: 10520811. *Exclude - Does not include intervention of interest*
- Nakahata Y, Hiraishi S, Oowada N, et al. Quantitative assessment of pulmonary vascular resistance and reactivity in children with pulmonary hypertension due to congenital heart disease using a noninvasive method: new Doppler-derived indexes. *Pediatr Cardiol*. 2009;30(3):232-9. PMID: 18956135. *Exclude - Does not include intervention of interest*
- Nakamura K, Miyahara Y, Ikeda S, et al. Assessment of right ventricular diastolic function by pulsed Doppler echocardiography in chronic pulmonary disease and pulmonary thromboembolism. *Respiration*. 1995;62(5):237-43. PMID: 8560088. *Exclude - No study population of interest*
- Nakhoul F, Yigla M, Gilman R, et al. The pathogenesis of pulmonary hypertension in haemodialysis patients via arterio-venous access. *Nephrol Dial Transplant*. 2005;20(8):1686-92. PMID: 15840664. *Exclude - No study population of interest*
- Nakwan N, Wannaro J. Persistent pulmonary hypertension of the newborn successfully treated with beraprost sodium: a retrospective chart review. *Neonatology*. 2011;99(1):32-7. PMID: 20588068. *Exclude - No comparisons of interest*

- Namachivayam P, Theilen U, Butt WW, et al. Sildenafil prevents rebound pulmonary hypertension after withdrawal of nitric oxide in children. *Am J Respir Crit Care Med*. 2006;174(9):1042-7. PMID: 16917115. *Exclude - No study population of interest*
- Narvaez David R, Dorantes G J, Hernandez R P, et al. Preliminary report of acute pharmacological effect of sildenafil in pulmonary hypertension of several causes. *Med Interna Mex*. 2006;22(4):292-296. *Exclude - Not available in English.*
- Nathan SD, Shlobin OA, Barnett SD, et al. Right ventricular systolic pressure by echocardiography as a predictor of pulmonary hypertension in idiopathic pulmonary fibrosis. *Respir Med*. 2008;102(9):1305-10. PMID: 18619825. *Exclude - No study population of interest*
- Nef HM, Tiede H, Moellmann H, et al. Diagnostic value of plasma soluble FMS-like tyrosine kinase-1 (SFLT) and placental growth factor (PLGF) in patients with dyspnea: Results from the Biosphere-II study. *Eur Heart J*. 2011;32:434-435. *Exclude - Not a full publication*
- Neil E, Ruth A, Rod H. Neonatal outcomes following the introduction of a time-metered nitric oxide delivery system. *J Paediatr Child Health*. 2012;48:33. *Exclude - Not a full publication*
- Nelson SC, Adade BB, McDonough EA, et al. High prevalence of pulmonary hypertension in children with sickle cell disease. *J Pediatr Hematol Oncol*. 2007;29(5):334-7. PMID: 17483714. *Exclude - No comparisons of interest*
- Nemoto S, Sasaki T, Ozawa H, et al. Oral sildenafil for persistent pulmonary hypertension early after congenital cardiac surgery in children. *Eur J Cardiothorac Surg*. 2010;38(1):71-7. PMID: 20206543. *Exclude - No comparisons of interest*
- Neuhof W. Method for diagnosis of a disease involving an anti-endothelin receptor antibody. *Expert Opin Med Diagn*. 2008;2(7):875-878. *Exclude - Not a full publication*
- Neuman Y, Kotliroff A, Bental T, et al. Pulmonary artery pressure and diastolic dysfunction in normal left ventricular systolic function. *Int J Cardiol*. 2008;127(2):174-8. PMID: 17643534. *Exclude - No study population of interest*
- Newman JH, Kar S, Kirkpatrick P. Ambrisentan. *Nat Rev Drug Discov*. 2007;6(9):697-8. PMID: 17907344. *Exclude - Not a full publication*
- Ng C, Franklin O, Vaidya M, et al. Adenosine infusion for the management of persistent pulmonary hypertension of the newborn. *Pediatr Crit Care Med*. 2004;5(1):10-3. PMID: 14697102. *Exclude - Does not include intervention of interest*
- Ngian G, Nikpour M, Byron J, et al. Survival in Australian patients with connective tissue disease-associated pulmonary arterial hypertension. *Intern Med J*. 2011;41:12. *Exclude - Not a full publication*
- Ngian GS, Stevens W, Byron J, et al. Survival and predictors of mortality in Australian patients with connective tissue disease-associated pulmonary arterial hypertension. *Arthritis Rheum*. 2011;63(10). *Exclude - Not a full publication*
- Nicholl R. Nitric oxide in preterm babies. *Arch Dis Child*. 2002;86(1):59-60. PMID: 11806888. *Exclude - Not a full publication*
- Nishimura E, Ikeda S, Naito T, et al. Evaluation of right-ventricular function by Doppler echocardiography in patients with chronic respiratory failure. *J Int Med Res*. 1999;27(2):65-73. PMID: 10446692. *Exclude - No study population of interest*
- Noori S, Friedlich P, Wong P, et al. Cardiovascular effects of sildenafil in neonates and infants with congenital diaphragmatic hernia and pulmonary hypertension. *Neonatology*. 2007;91(2):92-100. PMID: 17344658. *Exclude - No study population of interest*
- Nootens M, Kaufmann E, Rich S. Short-term effectiveness of nifedipine in secondary pulmonary hypertension. *Am J Cardiol*. 1993;71(16):1475-6. PMID: 8517404. *Exclude - does not include intervention of interest*
- Nootens M, Schrader B, Kaufmann E, et al. Comparative acute effects of adenosine and prostacyclin in primary pulmonary hypertension. *Chest*. 1995;107(1):54-7. PMID: 7813311. *Exclude - Does not include intervention of interest*
- Nouraie M, Barst RJ, Rosenzweig EB, et al. NT-proBNP as a marker of cardiopulmonary compromise and exercise limitation in adults with sickle cell anemia in the walk-phasst study. *Blood*. 2010;116(21). *Exclude - Not a full publication*
- Nunes H, Humbert M, Sitbon O, et al. Prognostic factors for survival in human immunodeficiency virus-associated pulmonary arterial hypertension. *Am J Respir Crit Care Med*. 2003;167(10):1433-9. PMID: 12615632. *Exclude - No comparisons of interest*



- Nyp M, Sandritter T, Poppinga N, et al. Sildenafil citrate, bronchopulmonary dysplasia and disordered pulmonary gas exchange: any benefits? *J Perinatol*. 2011. *Exclude - No comparisons of interest*
- O'Callaghan DS, Rich J, Thenappan T. From NT-proBNP as a survival parameter to left-sided heart failure, and more: 6 Months in pulmonary hypertension. *Int J Clin Pract*. 2007;61(SUPPL. 156):32-43. *Exclude - Not a full publication*
- Ochikubo CG, Waffarn F, Turbow R, et al. Echocardiographic evidence of improved hemodynamics during inhaled nitric oxide therapy for persistent pulmonary hypertension of the newborn. *Pediatr Cardiol*. 1997;18(4):282-7. PMID: 9175525. *Exclude - Does not include intervention of interest*
- Oelberg DA, Marcotte F, Kreisman H, et al. Evaluation of right ventricular systolic pressure during incremental exercise by Doppler echocardiography in adults with atrial septal defect. *Chest*. 1998;113(6):1459-65. PMID: 9631778. *Exclude - Does not include intervention of interest*
- Ogawa A, Matsubara H, Fujio H, et al. Risk of alveolar hemorrhage in patients with primary pulmonary hypertension--anticoagulation and epoprostenol therapy. *Circ J*. 2005;69(2):216-20. PMID: 15671616. *Exclude - No comparisons of interest*
- Ohashi M, Sato K, Suzuki S, et al. Doppler echocardiographic evaluation of latent pulmonary hypertension by passive leg raising. *Coron Artery Dis*. 1997;8(10):651-5. PMID: 9457447. *Exclude - No study population of interest*
- Ohno Y, Koyama H, Nogami M, et al. Dynamic perfusion MRI: capability for evaluation of disease severity and progression of pulmonary arterial hypertension in patients with connective tissue disease. *J Magn Reson Imaging*. 2008;28(4):887-99. PMID: 18821609. *Exclude - Does not include intervention of interest*
- Okano Y, Yoshioka T, Shimouchi A, et al. Short-term effect of continuous intravenous prostacyclin (Epoprostenol) in patients with primary pulmonary hypertension. *Respir Circ*. 1997;45(1):73-79. *Exclude - not available in English*
- Olschewski H, Ghofrani HA, Schmehl T, et al. Inhaled iloprost to treat severe pulmonary hypertension. An uncontrolled trial. German PPH Study Group. *Ann Intern Med*. 2000;132(6):435-43. PMID: 10733442. *Exclude - No comparisons of interest*
- Olschewski H, Walrath D, Schermuly R, et al. Aerosolized prostacyclin and iloprost in severe pulmonary hypertension. *Ann Intern Med*. 1996;124(9):820-4. PMID: 8610951. *Exclude - Does not include intervention of interest*
- Olson TP, Snyder EM, Frantz RP, et al. Repeat length polymorphism of the serotonin transporter gene influences pulmonary artery pressure in heart failure. *Am Heart J*. 2007;153(3):426-32. PMID: 17307423. *Exclude - No study population of interest*
- Omar HA, Gong F, Sun MY, et al. Nebulized nitroglycerin in children with pulmonary hypertension secondary to congenital heart disease. *W V Med J*. 1999;95(2):74-5. PMID: 10214095. *Exclude - Does not include intervention of interest*
- Omelyanovsky V, Avxentyeva M, Krysanov I, et al. Cost-effectiveness analysis of bosentan and sildenafil compared with standard therapy in treatment of primary pulmonary arterial hypertension in Russian Federation. *Value Health*. 2011;14(7):A367. *Exclude - Not a full publication*
- Ono F, Nagaya N, Kyotani S, et al. Hemodynamic and hormonal effects of beraprost sodium, an orally active prostacyclin analogue, in patients with secondary precapillary pulmonary hypertension. *Circ J*. 2003;67(5):375-8. PMID: 12736472. *Exclude - no comparisons of interest*
- Opitz CF, Wensel R, Bettmann M, et al. Assessment of the vasodilator response in primary pulmonary hypertension. Comparing prostacyclin and iloprost administered by either infusion or inhalation. *Eur Heart J*. 2003;24(4):356-65. PMID: 12581683. *Exclude - no primary or secondary outcomes of interest*
- Opitz CF, Wensel R, Winkler J, et al. Clinical efficacy and survival with first-line inhaled iloprost therapy in patients with idiopathic pulmonary arterial hypertension. *Eur Heart J*. 2005;26(18):1895-902. PMID: 15888496. *Exclude - No comparisons of interest*
- Orfanos SE, Psevdi E, Stratigis N, et al. Pulmonary capillary endothelial dysfunction in early systemic sclerosis. *Arthritis Rheum*. 2001;44(4):902-11. PMID: 11315930. *Exclude - no primary or secondary outcomes of interest*
- Otterdal K, Andreassen AK, Yndestad A, et al. Raised LIGHT levels in pulmonary arterial hypertension: potential role in thrombus formation. *Am J Respir Crit Care Med*. 2008;177(2):202-7. PMID: 17962639. *Exclude - Does not include intervention of interest*

- Oudiz R, Allard M, Blair C, et al. Ambrisentan therapy in patients with pulmonary arterial hypertension: 3-year outcome. *Chest*. 2011;140(4). *Exclude - Not a full publication*
- Oudiz R, Shapiro S, Torres F, et al. Athena-1: Hemodynamic improvements following the addition of ambrisentan to background pde5I therapy in patients with pulmonary arterial hypertension. *Chest*. 2011;140(4). *Exclude - Not a full publication*
- Oudiz RJ, Roveran G, Hansen JE, et al. Effect of sildenafil on ventilatory efficiency and exercise tolerance in pulmonary hypertension. *Eur J Heart Fail*. 2007;9(9):917-21. PMID: 17707133. *Exclude - No comparisons of interest*
- Oudiz RJ, Schilz RJ, Barst RJ, et al. Treprostinil, a prostacyclin analogue, in pulmonary arterial hypertension associated with connective tissue disease. *Chest*. 2004;126(2):420-7. PMID: 15302727. *Exclude - No comparisons of interest*
- Oudiz RJ, Widlitz A, Beckmann XJ, et al. Micrococcus-associated central venous catheter infection in patients with pulmonary arterial hypertension. *Chest*. 2004;126(1):90-4. PMID: 15249447. *Exclude - No comparisons of interest*
- Owens AT, Jessup M. The year in heart failure. *J Am Coll Cardiol*. 2011;57(15):1573-83. PMID: 21474036. *Exclude - Not a full publication*
- Ozawa T, Ninomiya Y, Honma T, et al. Increased serum angiotensin I-converting enzyme activity in patients with mixed connective tissue disease and pulmonary hypertension. *Scand J Rheumatol*. 1995;24(1):38-43. PMID: 7863277. *Exclude - no primary or secondary outcomes of interest*
- Ozkan M, Dweik RA, Laskowski D, et al. High levels of nitric oxide in individuals with pulmonary hypertension receiving epoprostenol therapy. *Lung*. 2001;179(4):233-43. PMID: 11891614. *Exclude - no primary or secondary outcomes of interest*
- Pabst S, Hammerstingl C, Schwarze-Zander C, et al. Prevalence of pulmonary arterial hypertension in the HIV cohort of the University Bonn: Results of the PAHIBO study. *Eur Heart J*. 2011;32:116. *Exclude - Not a full publication*
- Palii I, Vataman E, Maniuc L, et al. Clinical and haemodynamic effects of sildenafil in pulmonary hypertension secondary congenital systemic-to-pulmonary shunts and RV dysfunction. *Eur Heart J*. 2011;32:113. *Exclude - Not a full publication*
- Parikh R, Scherzer R, Nitta E, et al. Asymmetric dimethylarginine levels are associated with pulmonary arterial hypertension in HIV-infected individuals. *J Am Coll Cardiol*. 2012;59(13):E1614. *Exclude - Not a full publication*
- Park MM, Lundgrin EL, Sharp J, et al. Right ventricular global longitudinal strain by two-dimensional speckle tracking echocardiography correlates with conventional echocardiographic determinants of severity in pulmonary hypertension. *J Am Soc Echocardiogr*. 2012;25(6):B104. *Exclude - Not a full publication*
- Park MM, Park JH, Sharp J, et al. Compatibility of strain with speckle tracking echocardiography and velocityvector imaging in detection of adverse clinical outcomes in patients with pulmonary arterial hypertension. *J Am Soc Echocardiogr*. 2012;25(6):B11. *Exclude - Not a full publication*
- Pashankar F, Manwani D, Lee M, et al. Effect of hydroxyurea on elevated pulmonary artery pressures in children with sickle cell disease. *Blood*. 2011;118(21). *Exclude - Not a full publication*
- Patel N, Mills JF, Cheung MM. Assessment of right ventricular function using tissue Doppler imaging in infants with pulmonary hypertension. *Neonatology*. 2009;96(3):193-9; discussion 200-2. PMID: 19407463. *Exclude - Does not include intervention of interest*
- Payvandi LA, Burri MV, Gupta D, et al. Can 2-dimensional echocardiography provide accurate assessments of right ventricular volume and systolic function in patients with pulmonary hypertension? *Circulation*. 2011;124(21). *Exclude - Not a full publication*
- Pendergrass SA, Hayes E, Farina G, et al. Limited systemic sclerosis patients with pulmonary arterial hypertension show biomarkers of inflammation and vascular injury. *PLoS One*. 2010;5(8):e12106. PMID: 20808962. *Exclude - no primary or secondary outcomes of interest*
- Peoples C, Domsic RT, Medsger TA, et al. Pulmonary hypertension assessment and recognition of outcomes in scleroderma: Racial differences in systemic sclerosis-related pulmonary hypertension. *Arthritis Rheum*. 2011;63(10). *Exclude - Not a full publication*
- Perez VAdJ, Rosenzweig E, Rubin LJ, et al. Safety and Efficacy of Transition from Systemic Prostanoids to Inhaled Treprostinil in Pulmonary Arterial Hypertension. *Am J Cardiol*. 2012. *Exclude - No comparisons of interest*

- Perez-Penate GM, Julia-Serda G, Ojeda-Betancort N, et al. Long-term inhaled nitric oxide plus phosphodiesterase 5 inhibitors for severe pulmonary hypertension. *J Heart Lung Transplant*. 2008;27(12):1326-32. PMID: 19059113. *Exclude - No comparisons of interest*
- Perkins JD. Diagnosing hepatopulmonary syndrome. *Liver Transplant*. 2007;13(10):1464-1465. *Exclude - Background Other*
- Perkins JD. Screening for portopulmonary hypertension: Comments. *Liver Transplant*. 2007;13(3):463-464. *Exclude - Background Other*
- Peterson AL, Deatsman S, Frommelt MA, et al. Correlation of echocardiographic markers and therapy in persistent pulmonary hypertension of the newborn. *Pediatr Cardiol*. 2009;30(2):160-5. PMID: 18779989. *Exclude - Does not include intervention of interest*
- Petkov V, Ziesche R, Mosgoeller W, et al. Aerosolised iloprost improves pulmonary haemodynamics in patients with primary pulmonary hypertension receiving continuous epoprostenol treatment. *Thorax*. 2001;56(9):734-6. PMID: 11514696. *Exclude - no primary or secondary outcomes of interest*
- Pignone A, Mori F, Pieri F, et al. Exercise Doppler echocardiography identifies preclinic asymptomatic pulmonary hypertension in systemic sclerosis. *Ann N Y Acad Sci*. 2007;1108:291-304. PMID: 17893993. *Exclude - No study population of interest*
- Piranfar MA, Karvandi M, Tofigh AM. Intracardiac shunts and role of tissue Doppler imaging in diagnosis and discrimination. *J Tehran Uni Heart Cent*. 2008;3(2):95-100. *Exclude - no primary or secondary outcomes of interest*
- Plastiras SC, Karadimitrakakis SP, Kampolis C, et al. Determinants of pulmonary arterial hypertension in scleroderma. *Semin Arthritis Rheum*. 2007;36(6):392-6. PMID: 17204309. *Exclude - no primary or secondary outcomes of interest*
- Pope JE, Lee P, Baron M, et al. Prevalence of elevated pulmonary arterial pressures measured by echocardiography in a multicenter study of patients with systemic sclerosis. *J Rheumatol*. 2005;32(7):1273-8. PMID: 15996064. *Exclude - No comparisons of interest*
- Popovtzer B, Salamon JN, Mazurek J, et al. Mortality in primary pulmonary arterial hypertension stratified by hemoglobin levels. *J Card Fail*. 2011;17(8):S96. *Exclude - Not a full publication*
- Porhownik NR, Al-Sharif H, Bshouty Z. Addition of sildenafil in patients with pulmonary arterial hypertension with inadequate response to bosentan monotherapy. *Can Respir J*. 2008;15(8):427-30. PMID: 19107243. *Exclude - no comparisons of interest*
- Preston I, Ishizawar D, Burger C, et al. Transition from inhaled to parenteral treprostinil in selected patients with pulmonary arterial hypertension. *Chest*. 2011;140(4). *Exclude - Not a full publication*
- Preston IR, Klinger JR, Houtches J, et al. Acute and chronic effects of sildenafil in patients with pulmonary arterial hypertension. *Respir Med*. 2005;99(12):1501-10. PMID: 15890512. *Exclude - no primary or secondary outcomes of interest*
- Preston IR, Klinger JR, Landzberg MJ, et al. Vasoresponsiveness of sarcoidosis-associated pulmonary hypertension. *Chest*. 2001;120(3):866-72. PMID: 11555522. *Exclude - No study population of interest*
- Provencher S, Herve P, Sitbon O, et al. Changes in exercise haemodynamics during treatment in pulmonary arterial hypertension. *Eur Respir J*. 2008;32(2):393-8. PMID: 18417516. *Exclude - No comparisons of interest*
- Puchalski MD, Lozier JS, Bradley DJ, et al. Electrocardiography in the diagnosis of right ventricular hypertrophy in children. *Pediatrics*. 2006;118(3):1052-5. PMID: 16950997. *Exclude - Does not include intervention of interest*
- Pulido T, Sandoval J, Roquet I, et al. Interaction of acenocoumarol and sitaxentan in pulmonary arterial hypertension. *Eur J Clin Invest*. 2009;39 Suppl 2:14-8. PMID: 19335742. *Exclude - No comparisons of interest*
- Pyxaras S, Valentincic M, Perkan A, et al. Echocardiographic evaluation of systolic and mean pulmonary artery pressure in the follow-up of patients with pulmonary hypertension. *G Ital Cardiol*. 2011;12(5):75S. *Exclude - Not a full publication*
- Quarck R, Durand H, Ninio E, et al. Platelet-activating factor acetylhydrolase (PAF-AH): A predictor of adverse event in medically treated CTEPH patients? *J Heart Lung Transplant*. 2012;31(4):S61. *Exclude - Not a full publication*
- Quarck R, Nawrot T, Meyns B, et al. C-reactive protein: a new predictor of adverse outcome in pulmonary arterial hypertension. *J Am Coll Cardiol*. 2009;53(14):1211-8. PMID: 19341863. *Exclude - Does not include intervention of interest*

Qureshi N, Joyce JJ, Qi N, et al. Right ventricular abnormalities in sickle cell anemia: evidence of a progressive increase in pulmonary vascular resistance. *J Pediatr*. 2006;149(1):23-7. PMID: 16860121. *Exclude - no primary or secondary outcomes of interest*

Rabasseda X. Therapies for heart failure: a report from the Heart Failure Congress 2007. *Timely Top Med Cardiovasc Dis*. 2007;11:E16. PMID: 18297144. *Exclude - unable to obtain full-text*

Raffy O, Azarian R, Brenot F, et al. Clinical significance of the pulmonary vasodilator response during short-term infusion of prostacyclin in primary pulmonary hypertension. *Circulation*. 1996;93(3):484-8. PMID: 8565165. *Exclude - no primary or secondary outcomes of interest*

Raimondi F, Migliaro F, Capasso L, et al. Intravenous magnesium sulphate vs. inhaled nitric oxide for moderate, persistent pulmonary hypertension of the newborn. A Multicentre, retrospective study. *J Trop Pediatr*. 2008;54(3):196-9. PMID: 18048460. *Exclude - Does not include intervention of interest*

Raja SG, Danton MD, MacArthur KJ, et al. Treatment of pulmonary arterial hypertension with sildenafil: from pathophysiology to clinical evidence. *J Cardiothorac Vasc Anesth*. 2006;20(5):722-35. PMID: 17023298. *Exclude - Background SR/MA*

Raja SG, Danton MD, MacArthur KJ, et al. Effects of escalating doses of sildenafil on hemodynamics and gas exchange in children with pulmonary hypertension and congenital cardiac defects. *J Cardiothorac Vasc Anesth*. 2007;21(2):203-7. PMID: 17418732. *Exclude - no primary or secondary outcomes of interest*

Rajagopalan N, Simon MA, Mathier MA, et al. Identifying right ventricular dysfunction with tissue Doppler imaging in pulmonary hypertension. *Int J Cardiol*. 2008;128(3):359-63. PMID: 17714807. *Exclude - no primary or secondary outcomes of interest*

Ranjan S, Hall T, Huynh L, et al. Echocardiographic indices of right ventricular function as predictors of severity of pulmonary arterial hypertension. *Heart Lung Circul*. 2011;20:S172. *Exclude - Not a full publication*

Ranu H, Connell E, Hunt C, et al. Elevated tricuspid regurgitation jet velocity on echocardiogram in patients with sickle cell disease is associated with worse steady state functional class, poor lung function and low haemoglobin but not other markers of haemolysis or endothelin-1. *Blood*. 2010;116(21). *Exclude - Not a full publication*

Reichenberger F, Mainwood A, Doughty N, et al. Effects of nebulised iloprost on pulmonary function and gas exchange in severe pulmonary hypertension. *Respir Med*. 2007;101(2):217-22. PMID: 16831539. *Exclude - No comparisons of interest*

Reichenberger F, Voswinckel R, Schulz R, et al. Noninvasive detection of early pulmonary vascular dysfunction in scleroderma. *Respir Med*. 2009;103(11):1713-8. PMID: 19497725. *Exclude - No study population of interest*

Reichenberger F, Voswinckel R, Steveling E, et al. Sildenafil treatment for portopulmonary hypertension. *Eur Respir J*. 2006;28(3):563-7. PMID: 16807265. *Exclude - No comparisons of interest*

Reynolds EW, Ellington JG, Vranicar M, et al. Brain-type natriuretic peptide in the diagnosis and management of persistent pulmonary hypertension of the newborn. *Pediatrics*. 2004;114(5):1297-304. PMID: 15520111. *Exclude - no primary or secondary outcomes of interest*

Rich S. The effects of vasodilators in pulmonary hypertension: pulmonary vascular or peripheral vascular? *Circ Heart Fail*. 2009;2(2):145-50. PMID: 19808330. *Exclude - Not a full publication*

Riedel B, Lim J, Brauer K, et al. Diagnosis and management of persistent pulmonary thromboembolism. *J Cardiothorac Vasc Anesth*. 2006;20(4):616-9. PMID: 16885000. *Exclude - Not a full publication*

Rimensberger PC, Spahr-Schopfer I, Berner M, et al. Inhaled nitric oxide versus aerosolized iloprost in secondary pulmonary hypertension in children with congenital heart disease: vasodilator capacity and cellular mechanisms. *Circulation*. 2001;103(4):544-8. PMID: 11157720. *Exclude - no primary or secondary outcomes of interest*

Robbins IM, Barst RJ, Rubin LJ, et al. Increased levels of prostaglandin D(2) suggest macrophage activation in patients with primary pulmonary hypertension. *Chest*. 2001;120(5):1639-44. PMID: 11713147. *Exclude - no primary or secondary outcomes of interest*

- Roberts JD, Jr., Fineman JR, Morin FC, 3rd, et al. Inhaled nitric oxide and persistent pulmonary hypertension of the newborn. The Inhaled Nitric Oxide Study Group. *N Engl J Med.* 1997;336(9):605-10. PMID: 9032045. *Exclude - Does not include intervention of interest*
- Roberts KE, Fallon MB, Krowka MJ, et al. Serotonin transporter polymorphisms in patients with portopulmonary hypertension. *Chest.* 2009;135(6):1470-5. PMID: 19141529. *Exclude - Does not include intervention of interest*
- Roca GQ, Campbell P, Barst R, et al. Right ventricular longitudinal strain correlates with cardiopulmonary hemodynamics and nt-probnp in pulmonary arterial hypertension. *J Am Coll Cardiol.* 2012;59(13):E1285. *Exclude - Not a full publication*
- Rocha G, Baptista MJ, Guimaraes H. Persistent pulmonary hypertension of non cardiac cause in a neonatal intensive care unit. *Pulmonary Medicine.* 2012. *Exclude - No study population of interest*
- Roeleveld RJ, Vonk-Noordegraaf A, Marcus JT, et al. Effects of epoprostenol on right ventricular hypertrophy and dilatation in pulmonary hypertension. *Chest.* 2004;125(2):572-9. PMID: 14769740. *Exclude - no primary or secondary outcomes of interest*
- Rolla G, Colagrande P, Scappaticci E, et al. Exhaled nitric oxide in systemic sclerosis: relationships with lung involvement and pulmonary hypertension. *J Rheumatol.* 2000;27(7):1693-8. PMID: 10914853. *Exclude - no primary or secondary outcomes of interest*
- Roman A, Rodes-Cabau J, Lara B, et al. Clinic-hemodynamic study and treatment of 44 patients with primary pulmonary hypertension. *Med Clin.* 2002;118(20):761-766. *Exclude - Not available in English.*
- Rondelet B, Dewachter L, Kerbaul F, et al. Sildenafil added to sitaxsentan in overcirculation-induced pulmonary arterial hypertension. *Am J Physiol Heart Circ Physiol.* 2010;299(4):H1118-23. PMID: 20693396. *Exclude - Not a full publication*
- Rosenzweig EB, Ivy DD, Widlitz A, et al. Effects of long-term bosentan in children with pulmonary arterial hypertension. *J Am Coll Cardiol.* 2005;46(4):697-704. PMID: 16098438. *Exclude - No comparisons of interest.*
- Rosenzweig EB, Kerstein D, Barst RJ. Long-term prostacyclin for pulmonary hypertension with associated congenital heart defects. *Circulation.* 1999;99(14):1858-65. PMID: 10199883. *Exclude - No comparisons of interest*
- Roushdy A, Ragab I, Raout WA. Noninvasive assessment of elevated pulmonary vascular resistance in children with pulmonary hypertension secondary to congenital heart disease. Comparative study between 5 different doppler indices. *J Am Soc Echocardiogr.* 2012;25(6):B98. *Exclude - Not a full publication*
- Rubens C, Ewert R, Halank M, et al. Big endothelin-1 and endothelin-1 plasma levels are correlated with the severity of primary pulmonary hypertension. *Chest.* 2001;120(5):1562-9. PMID: 11713135. *Exclude - no primary or secondary outcomes of interest*
- Rubin L, Parikh K, Pulido T, et al. Freedom-M: Efficacy and safety of oral treprostinil diethanolamine as monotherapy in patients with pulmonary arterial hypertension. *Chest.* 2011;140(4). *Exclude - Not a full publication*
- Ruiz MJ, Escribano P, Delgado JF, et al. Efficacy of sildenafil as a rescue therapy for patients with severe pulmonary arterial hypertension and given long-term treatment with prostanoids: 2-year experience. *J Heart Lung Transplant.* 2006;25(11):1353-7. PMID: 17097500. *Exclude - No comparisons of interest*
- Rutter N. Echocardiography for the neonatologist. *Curr Paediatr.* 1999;9(2):128-131. *Exclude - Background Other*
- Saadjan AY, Paganelli F, Gaubert ML, et al. Adenosine plasma concentration in pulmonary hypertension. *Cardiovasc Res.* 1999;43(1):228-36. PMID: 10536708. *Exclude - no primary or secondary outcomes of interest*
- Sablotzki A, Czeslick E, Gruenig E, et al. First experiences with the stable prostacyclin analog iloprost in the evaluation of heart transplant candidates with increased pulmonary vascular resistance. *J Thorac Cardiovasc Surg.* 2003;125(4):960-2. PMID: 12698166. *Exclude - No study population of interest*
- Sachdev A, Villarraga HR, Frantz RP, et al. Right ventricular strain for prediction of survival in patients with pulmonary arterial hypertension. *Chest.* 2011;139(6):1299-309. PMID: 21148241. *Exclude - Does not include intervention of interest*

- Sachdev V, Kato GJ, Gibbs JS, et al. Echocardiographic markers of elevated pulmonary pressure and left ventricular diastolic dysfunction are associated with exercise intolerance in adults and adolescents with homozygous sickle cell anemia in the United States and United Kingdom. *Circulation*. 2011;124(13):1452-60. PMID: 21900080. *Exclude - no primary or secondary outcomes of interest*
- Sadushi-Kolici R, Jakowitsch J, Skoro-Sajer N, et al. Plasma levels of soluble P-selectin predict survival in chronic thromboembolic pulmonary hypertension. *Journal fur Kardiologie*. 2011;18(5-6):196. *Exclude - Not a full publication*
- Sadushi-Kolici R, Skoro-Sajer N, Zimmer D, et al. Long-term treatment, tolerability and survival with subcutaneous treprostinil for severe pulmonary hypertension. *Journal fur Kardiologie*. 2011;18(5-6):196. *Exclude - Not a full publication*
- Safdar Z. Treatment of pulmonary arterial hypertension: the role of prostacyclin and prostaglandin analogs. *Respir Med*. 2011;105(6):818-27. PMID: 21273054. *Exclude - Not a full publication*
- Saggar R, Derhovanessian A, Fields AV, et al. 'Notching' of the right ventricular outflow tract Doppler profile (DopplerRVOT) is a highly sensitive and specific predictor of pulmonary vascular disease among patients with systemic sclerosis. *J Heart Lung Transplant*. 2012;31(4):S68. *Exclude - Not a full publication*
- Sahni J. Revatio (sildenafil citrate) for the treatment of pulmonary arterial hypertension. *Conn Med*. 2006;70(6):381-3. PMID: 16869470. *Exclude - Not a full publication*
- Saji T, Ozawa Y, Ishikita T, et al. Short-term hemodynamic effect of a new oral PGI2 analogue, beraprost, in primary and secondary pulmonary hypertension. *Am J Cardiol*. 1996;78(2):244-7. PMID: 8712155. *Exclude - Does not include intervention of interest*
- Salgado M, Madeira L, Theilacker L, et al. Prevalence of pulmonary hypertension in SSc: Correlation with clinical form. *Rheumatology (Oxford)*. 2012;51:ii65. *Exclude - Not a full publication*
- Sanchez O, Marcos E, Perros F, et al. Role of endothelium-derived CC chemokine ligand 2 in idiopathic pulmonary arterial hypertension. *Am J Respir Crit Care Med*. 2007;176(10):1041-7. PMID: 17823354. *Exclude - Does not include intervention of interest*
- Sandoval J, Bauerie O, Palomar A, et al. Survival in primary pulmonary hypertension. Validation of a prognostic equation. *Circulation*. 1994;89(4):1733-44. PMID: 8149539. *Exclude - does not include intervention of interest*
- Sandoval J, Gaspar J, Pena H, et al. Effect of atrial septostomy on the survival of patients with severe pulmonary arterial hypertension. *Eur Respir J*. 2011;38(6):1343-1348. *Exclude - Does not include intervention of interest*
- Sasayama S. Treatment of pulmonary hypertension with Bosentan. *Respir Circ*. 2003;51(9):901-907. *Exclude - Not available in English*
- Saxena N, Rajagopalan N, Edelman K, et al. Tricuspid annular systolic velocity: a useful measurement in determining right ventricular systolic function regardless of pulmonary artery pressures. *Echocardiography*. 2006;23(9):750-5. PMID: 16999693. *Exclude - no primary or secondary outcomes of interest*
- Sbarouni E, Georgiadou P, Manginas A, et al. Ischaemia-modified albumin in pulmonary hypertension. *Biomarkers*. 2010;15(3):238-42. PMID: 19995310. *Exclude - Does not include intervention of interest*
- Schattke S, Knebel F, Grohmann A, et al. Early right ventricular systolic dysfunction in patients with systemic sclerosis without pulmonary hypertension: a Doppler Tissue and Speckle Tracking echocardiography study. *Cardiovasc Ultrasound*. 2010;8:3. PMID: 20096122. *Exclude - No study population of interest*
- Schenk P, Madl C, Kramer L, et al. Acute vasodilator testing in primary and secondary pulmonary hypertension. *Wien Klin Wochenschr*. 2001;113(13-14):496-503. *Exclude - no primary or secondary outcomes of interest*
- Scholzel BE, Post MC, Thijs Plokker HW, et al. Clinical worsening during long-term follow-up in inoperable chronic thromboembolic pulmonary hypertension. *Lung*. 2012;190(2):161-7. PMID: 22160210. *Exclude - No study population of interest*
- Schulze-Neick I, Uhlemann F, Nurnberg JH, et al. Aerolized prostacyclin for preoperative evaluation and postoperative treatment of patients with pulmonary hypertension. *Z Kardiol*. 1997;86(2):71-80. *Exclude - Not available in English*

Schwaiblmair M, Faul C, von Scheidt W, et al. Influence of specific drug therapy on cardiopulmonary exercise testing parameters in patients with pulmonary hypertension. *Appl Cardiopulm Pathophysiol*. 2011;15(2):71-80. *Exclude - Does not include intervention of interest*

Schwartz BG, Kloner RA. Drug interactions with phosphodiesterase-5 inhibitors used for the treatment of erectile dysfunction or pulmonary hypertension. *Circulation*. 2010;122(1):88-95. PMID: 20606131. *Exclude - Not a full publication*

Scott JP, Higenbottam T, Wallwork J. The acute effect of the synthetic prostacyclin analogue iloprost in primary pulmonary hypertension. *Br J Clin Pract*. 1990;44(6):231-4. PMID: 1698429. *Exclude - does not include intervention of interest*

Sehgal A. Ultrasound features of pulmonary hypertension: Audit and review of literature. *J Paediatr Child Health*. 2012;48:156. *Exclude - Not a full publication*

Selimovic N, Bergh CH, Andersson B, et al. Growth factors and interleukin-6 across the lung circulation in pulmonary hypertension. *Eur Respir J*. 2009;34(3):662-8. PMID: 19324949. *Exclude - Does not include intervention of interest*

Serra W, Chetta A, Santilli D, et al. Echocardiography may help detect pulmonary vasculopathy in the early stages of pulmonary artery hypertension associated with systemic sclerosis. *Cardiovasc Ultrasound*. 2010;8:25. PMID: 20598164. *Exclude - No study population of interest*

Seyfarth HJ, Pankau H, Hammerschmidt S, et al. Bosentan improves exercise tolerance and Tei index in patients with pulmonary hypertension and prostanoid therapy. *Chest*. 2005;128(2):709-13. PMID: 16100158. *Exclude - No comparisons of interest*

Shah AA, Chung SE, Wigley FM, et al. The value of periodic echocardiography screening to detect pulmonary hypertension and predict mortality in scleroderma. *Arthritis Rheum*. 2011;63(10). *Exclude - Not a full publication*

Shah AA, Mayer S, Girgis R, et al. Correlation between exercise echocardiography and right heart catheterization in scleroderma patients at risk for pulmonary hypertension. *Arthritis Rheum*. 2011;63(10). *Exclude - Not a full publication*

Sharma S, Kadali R, Daggubati R, et al. Pulmonary artery occlusion pressure may overdiagnose pulmonary artery hypertension in sickle cell disease. *Chest*. 2011;140(4). *Exclude - Not a full publication*

Shen J, He B, Wang B. Effects of lipo-prostaglandin E1 on pulmonary hemodynamics and clinical outcomes in patients with pulmonary arterial hypertension. *Chest*. 2005;128(2):714-9. PMID: 16100159. *Exclude - Does not include intervention of interest*

Shen JY, Yao TB, Liu H, et al. Diagnosis and differentiation of pulmonary arterial hypertension through an algorithm based on right heart catheterisation. *Heart*. 2011;97:A228. *Exclude - Not a full publication*

Shen Y, Wen F. Inaccuracy of doppler echocardiography diagnoses mild congenital heart disease related pulmonary hypertension. *Heart*. 2011;97:A156-A157. *Exclude - Not a full publication*

Shiina Y, Funabashi N, Lee K, et al. Right atrium contractility and right ventricular diastolic function assessed by pulsed tissue Doppler imaging can predict brain natriuretic peptide in adults with acquired pulmonary hypertension. *Int J Cardiol*. 2009;135(1):53-9. PMID: 18793807. *Exclude - No study population of interest*

Shirai Y, Yasuoka H, Takeuchi T, et al. Long-term outcomes of patients with pulmonary arterial hypertension and connective tissue disease treated with intravenous epoprostenol. *Rheumatology (Oxford)*. 2012;51:ii60-ii61. *Exclude - Not a full publication*

Shuster J. Various adverse effects and behaviors associated with sildenafil; Another case of glycemic control problems associated with fluoroquinolone therapy; The first case of pure white cell aplasia in a patient treated with imipenem-cilastatin; High-output heart failure associated with anagrelide; Renal dysfunction attributed to oral acyclovir therapy. *Hosp Pharm*. 2005;40(10):848-852. *Exclude - Not a full publication*

Simon MA, Deible C, Mathier MA, et al. Phenotyping the right ventricle in patients with pulmonary hypertension. *Clin Transl Sci*. 2009;2(4):294-9. PMID: 20443908. *Exclude - no primary or secondary outcomes of interest*

Simon MA, Rajagopalan N, Mathier MA, et al. Tissue Doppler imaging of right ventricular decompensation in pulmonary hypertension. *Congest Heart Fail*. 2009;15(6):271-6. PMID: 19925505. *Exclude - no primary or secondary outcomes of interest*

Singh R, Choudhury M, Saxena A, et al. Inhaled nitroglycerin versus inhaled milrinone in children with congenital heart disease suffering from pulmonary artery hypertension. *J Cardiothorac Vasc Anesth.* 2010;24(5):797-801. PMID: 20056439. *Exclude - Does not include intervention of interest*

Sirithanakul K, Mubarak KK. Pulmonary arterial hypertension: new treatments are improving outcomes. *J Fam Pract.* 2004;53(12):959-69. PMID: 15581438. *Exclude - Not a full publication*

Sitbon O, Humbert M, Nunes H, et al. Long-term intravenous epoprostenol infusion in primary pulmonary hypertension: prognostic factors and survival. *J Am Coll Cardiol.* 2002;40(4):780-8. PMID: 12204511. *Exclude - No comparisons of interest*

Sitbon O, McLaughlin VV, Badesch DB, et al. Survival in patients with class III idiopathic pulmonary arterial hypertension treated with first line oral bosentan compared with an historical cohort of patients started on intravenous epoprostenol. *Thorax.* 2005;60(12):1025-30. PMID: 16055621. *Exclude - no comparisons of interest.*

Sivasli E, Yurdakok M, Karagoz T, et al. Inhaled iloprost to treat neonatal pulmonary hypertension. *Cocuk Sagligi Hast Derg.* 2005;48(2):142-146. *Exclude - Not available in English.*

Skrok J, Shehata ML, Mathai S, et al. Pulmonary arterial hypertension: MR imaging-derived first-pass bolus kinetic parameters are biomarkers for pulmonary hemodynamics, cardiac function, and ventricular remodeling. *Radiology.* 2012;263(3):678-687. *Exclude - Does not include intervention of interest*

Smadja DM, Gaussem P, Mauge L, et al. Circulating endothelial cells: a new candidate biomarker of irreversible pulmonary hypertension secondary to congenital heart disease. *Circulation.* 2009;119(3):374-81. PMID: 19139384. *Exclude - no primary or secondary outcomes of interest*

Smadja DM, Mauge L, Sanchez O, et al. Distinct patterns of circulating endothelial cells in pulmonary hypertension. *Eur Respir J.* 2010;36(6):1284-93. PMID: 20413531. *Exclude - Does not include intervention of interest*

Smrzova A, Horak P, Skacelova M, et al. Pulmonary hypertension in patients with systemic scleroderma, mixed ctd, localized scleroderma and primary RP. *Rheumatology (Oxford).* 2012;51:ii121. *Exclude - Not a full publication*

Song JW, Song JK, Kim DS. Echocardiography and brain natriuretic peptide as prognostic indicators in idiopathic pulmonary fibrosis. *Respir Med.* 2009;103(2):180-6. PMID: 19097877. *Exclude - No study population of interest*

Song ZZ, Ma J. Right ventricular function evaluated by quantitative tissue velocity imaging and cardiac catheterization in pulmonary artery hypertension patients. *Chin J Med Imaging Technol.* 2007;23(5):686-688. *Exclude - Not available in English.*

Sood BG, Delaney-Black V, Glibetic M, et al. PGE2/TXB2 imbalance in neonatal hypoxemic respiratory failure. *Acta Paediatr Int J Paediatr.* 2007;96(5):669-673. *Exclude - No study population of interest*

Sood BG, Wykes S, Landa M, et al. Expression of eNOS in the lungs of neonates with pulmonary hypertension. *Exp Mol Pathol.* 2011;90(1):9-12. PMID: 21111729. *Exclude - Does not include intervention of interest*

Soon E, Holmes AM, Treacy CM, et al. Elevated levels of inflammatory cytokines predict survival in idiopathic and familial pulmonary arterial hypertension. *Circulation.* 2010;122(9):920-7. PMID: 20713898. *Exclude - Does not include intervention of interest*

SoRelle R. Report From the 93rd Cardiovascular and Renal Drugs Advisory Committee Meeting, August 9-10, 2001. *Circulation.* 2001;104(9):E9017-8. PMID: 11526948. *Exclude - Not a full publication*

Souza R, Bogossian HB, Humbert M, et al. N-terminal-pro-brain natriuretic peptide as a haemodynamic marker in idiopathic pulmonary arterial hypertension. *Eur Respir J.* 2005;25(3):509-13. PMID: 15738296. *Exclude - no primary or secondary outcomes of interest*

Souza R, Jardim C, Martins B, et al. Effect of bosentan treatment on surrogate markers in pulmonary arterial hypertension. *Curr Med Res Opin.* 2005;21(6):907-11. PMID: 15969891. *Exclude - No comparisons of interest*

Stackhouse KA, Devendra G, Hart S, et al. Right ventricular size and function and its change over time independently predict survival in pulmonary hypertension. *J Heart Lung Transplant.* 2012;31(4):S80. *Exclude - Not a full publication*



Stasch JP, Pacher P, Evgenov OV. Soluble guanylate cyclase as an emerging therapeutic target in cardiopulmonary disease. *Circulation*. 2011;123(20):2263-73. PMID: 21606405. *Exclude - Not a full publication*

Steen V, Medsger TA, Jr. Predictors of isolated pulmonary hypertension in patients with systemic sclerosis and limited cutaneous involvement. *Arthritis Rheum*. 2003;48(2):516-22. PMID: 12571862. *Exclude - Does not include intervention of interest*

Stefanantoni K, Sciarra I, Iannace N, et al. SSc with and without pulmonary arterial hypertension compared to idiopathic pulmonary arterial hypertension. different behaviour of some angiogenetic biomarkers. *Rheumatology (Oxford)*. 2012;51:ii116. *Exclude - Not a full publication*

Stefanidis A, Koutroulis G, Kollias G, et al. Role of Echocardiography in the Diagnosis and Follow-up of Patients with Pulmonary Arterial and Chronic Thromboembolic Pulmonary Hypertension. *Hell J Cardiol*. 2004;45(1):48-56. *Exclude - Background Other*

Steringer-Mascherbauer R, Eder V, Huber C, et al. Transitioning from subcutaneous to intravenous treprostinil administered by the implantable infusion pump Lenuspro(registered trademark): A single-center pilot study. *Journal fur Kardiologie*. 2012;19(5-6):153. *Exclude - Not a full publication*

Stocker C, Penny DJ, Brizard CP, et al. Intravenous sildenafil and inhaled nitric oxide: a randomised trial in infants after cardiac surgery. *Intensive Care Med*. 2003;29(11):1996-2003. PMID: 14530859. *Exclude - Does not include intervention of interest*

Stricker H, Domenighetti G, Popov W, et al. Severe pulmonary hypertension: data from the Swiss Registry. *Swiss Med Wkly*. 2001;131(23-24):346-50. PMID: 11486567. *Exclude - Does not include intervention of interest*

Strumpher J, Jacobsohn E. Pulmonary hypertension and right ventricular dysfunction: Physiology and perioperative management. *J Cardiothorac Vasc Anesth*. 2011;25(4):687-704. *Exclude - Not a full publication*

Suleman N, Frost AE. Transition from epoprostenol and treprostinil to the oral endothelin receptor antagonist bosentan in patients with pulmonary hypertension. *Chest*. 2004;126(3):808-15. PMID: 15364760. *Exclude - no primary or secondary outcomes of interest*

Sulica R, Dinh HV, Dunskey K, et al. The acute hemodynamic effect of IV nitroglycerin and dipyridamole in patients with pulmonary arterial hypertension: comparison with IV epoprostenol. *Congest Heart Fail*. 2005;11(3):139-44; quiz 145-6. PMID: 15947535. *Exclude - Does not include intervention of interest*

Sulica R, Teirstein AS, Kakarla S, et al. Distinctive clinical, radiographic, and functional characteristics of patients with sarcoidosis-related pulmonary hypertension. *Chest*. 2005;128(3):1483-9. PMID: 16162747. *Exclude - No study population of interest*

Sun YJ, Xiong CM, Shan GL, et al. Inhaled low-dose iloprost for pulmonary hypertension: A prospective, multicenter, open-label study. *Clin Cardiol*. 2012;35(6):365-370. *Exclude - No comparisons of interest*

Suntharalingam J, Hodgkins D, Cafferty FH, et al. Does rapid dose titration affect the hepatic safety profile of Bosentan? *Vascul Pharmacol*. 2006;44(6):508-12. PMID: 16713365. *Exclude - No comparisons of interest*

Suntharalingam J, Hughes RJ, Goldsmith K, et al. Acute haemodynamic responses to inhaled nitric oxide and intravenous sildenafil in distal chronic thromboembolic pulmonary hypertension (CTEPH). *Vascul Pharmacol*. 2007;46(6):449-55. PMID: 17368113. *Exclude - No study population of interest*

Suntharalingam J, Treacy CM, Doughty NJ, et al. Long-term use of sildenafil in inoperable chronic thromboembolic pulmonary hypertension. *Chest*. 2008;134(2):229-36. PMID: 18263674. *Exclude - No study population of interest*

Swanson KL, Utz JP, Krowka MJ. Doppler echocardiography-right heart catheterization relationships in patients with idiopathic pulmonary fibrosis and suspected pulmonary hypertension. *Med Sci Monit*. 2008;14(4):CR177-82. PMID: 18376344. *Exclude - No study population of interest*

Sztajzel J, Ricou F, Jeanpretre M, et al. Right heart involvement in asymptomatic HIV patients: An outpatient study combining Doppler-echocardiography and radionuclide angiograph. *J Noninvasive Cardiol*. 1998;2(5):20-27. *Exclude - No comparisons of interest*

Takahashi K, Mori Y, Yamamura H, et al. Effect of beraprost sodium on pulmonary vascular resistance in candidates for a Fontan procedure: a preliminary study. *Pediatr Int*. 2003;45(6):671-5. PMID: 14651539. *Exclude - No comparisons of interest*

Takahashi T, Sakuma M, Ikeda J, et al. Effects and problems of continuous infusion of epoprostenol for patients with primary pulmonary hypertension. *Intern Med.* 2002;41(10):784-8. PMID: 12412996. *Exclude - No comparisons of interest*

Talosi G, Katona M, Racz K, et al. Prostaglandin E1 treatment in patent ductus arteriosus dependent congenital heart defects. *J Perinat Med.* 2004;32(4):368-374. *Exclude - No comparisons of interest*

Talwalkar JA, Swanson KL, Krowka MJ, et al. Prevalence of spontaneous portosystemic shunts in patients with portopulmonary hypertension and effect on treatment. *Gastroenterology.* 2011;141(5):1673-1679. *Exclude - no primary or secondary outcomes of interest*

Tam NL, He XS. Clinical management of portopulmonary hypertension. *Hepatobiliary Pancreat Dis Int.* 2007;6(5):464-9. PMID: 17897906. *Exclude - Not a full publication*

Tanaka S, Hoshi K, Tanaka J, et al. Serum brain natriuretic peptide is a reliable marker for survival of pulmonary arterial hypertension associated with connective tissue diseases, including systemic sclerosis, mixed connective tissue disease and systemic lupus erythematosus. *Arthritis Rheum.* 2011;63(10). *Exclude - Not a full publication*

Tanaseanu C, Tudor S, Tamsulea I, et al. Vascular endothelial growth factor, lipoprotein-associated phospholipase A2, sP-selectin and antiphospholipid antibodies, biological markers with prognostic value in pulmonary hypertension associated with chronic obstructive pulmonary disease and systemic lupus erythematosus. *Eur J Med Res.* 2007;12(4):145-51. PMID: 17509958. *Exclude - no primary or secondary outcomes of interest*

Tapson VF, Gomberg-Maitland M, McLaughlin VV, et al. Safety and efficacy of IV treprostinil for pulmonary arterial hypertension: a prospective, multicenter, open-label, 12-week trial. *Chest.* 2006;129(3):683-8. PMID: 16537868. *Exclude - No comparisons of interest*

Tapson VF, McLaughlin VV, Gomberg-Maitland M, et al. Delivery of intravenous treprostinil at low infusion rates using a miniaturized infusion pump in patients with pulmonary arterial hypertension. *J Vasc Access.* 2006;7(3):112-7. PMID: 17019662. *Exclude - No comparisons of interest*

Tarras F, Benjelloun M, Medkouri G, et al. Doppler echocardiograph evaluation of pulmonary hypertension in patients undergoing hemodialysis. *Hemodial Int.* 2006;10(4):356-9. PMID: 17014511. *Exclude - no primary or secondary outcomes of interest*

Taveira-DaSilva AM, Hathaway OM, Sachdev V, et al. Pulmonary artery pressure in lymphangiomyomatosis: an echocardiographic study. *Chest.* 2007;132(5):1573-8. PMID: 17890459. *Exclude - No study population of interest*

Tavli T, Sekuri C, Goktalay T, et al. The acute effects of cilazapril on pulmonary function tests and arterial blood gas changes in patients with pulmonary hypertension. *Int J Clin Pharmacol Res.* 2003;23(2-3):53-9. PMID: 15018019. *Exclude - No study population of interest*

Tedford RJ, Hemnes AR, Russell SD, et al. PDE5A inhibitor treatment of persistent pulmonary hypertension after mechanical circulatory support. *Circ Heart Fail.* 2008;1(4):213-9. PMID: 19808294. *Exclude - No study population of interest*

Tegzova D, Ambroz D, Jansa P, et al. Possibilities of early detection of severe cardiovascular manifestations of SLE. *Ceska Revmatol.* 2007;15(3):131-141. *Exclude - Not available in English.*

Tegzova D, Kamenik L, Musilova L, et al. The incidence and course of pulmonary hypertension in systemic lupus erythematosus patients. Three years follow up outcome. *Ceska Revmatol.* 2003;11(3):117-127. *Exclude - Not available in English.*

Thai A, Addetia K, Langleben D, et al. Clinical utility of right ventricular end-diastolic wall stress in patients with pulmonary hypertension. *J Am Soc Echocardiogr.* 2012;25(6):B7. *Exclude - Not a full publication*

Thakkar V, Patterson K, Stevens W, et al. Novel biomarkers of dysregulated angiogenesis are not specific to pulmonary arterial hypertension in SSc. *Rheumatology (Oxford).* 2012;51:ii28. *Exclude - Not a full publication*

Thakkar V, Stevens W, Prior D, et al. N-terminal pro-brain natriuretic peptide levels predict incident pulmonary arterial hypertension in SSc. *Rheumatology (Oxford).* 2012;51:ii8. *Exclude - Not a full publication*

- Thenappan T, Palevsky HI. Long-term outcomes in pulmonary arterial hypertension. *Int J Clin Pract*. 2009;63(SUPPL. 162):42-44. *Exclude - Not a full publication*
- Thurnheer R, Jenni R, Russi EW, et al. Hyperthyroidism and pulmonary hypertension. *J Intern Med*. 1997;242(2):185-188. *Exclude - Not a full publication*
- Tillman O, Speich R. Primary pulmonary hypertension. *Schweiz Med Wochenschr*. 1997;127(22):923-934. *Exclude - Not available in English*
- Ting H, Sun XG, Chuang ML, et al. A noninvasive assessment of pulmonary perfusion abnormality in patients with primary pulmonary hypertension. *Chest*. 2001;119(3):824-32. PMID: 11243964. *Exclude - Does not include intervention of interest*
- Tits G, Van den Brande P, Van Mieghem W, et al. Clinical and haemodynamic spectrum of primary pulmonary hypertension. *Eur J Intern Med*. 1998;9(3):165-170. *Exclude - No comparisons of interest*
- Tolsa JF, Cotting J, Sekarski N, et al. Magnesium sulphate as an alternative and safe treatment for severe persistent pulmonary hypertension of the newborn. *Arch Dis Child Fetal Neonatal Ed*. 1995;72(3):F184-7. PMID: 7796235. *Exclude - Does not include intervention of interest*
- Tonelli AR, Plana JC, Heresi GA, et al. Prevalence and prognostic value of left ventricular diastolic dysfunction in idiopathic and heritable pulmonary arterial hypertension. *Chest*. 2012;141(6):1457-65. PMID: 22207680. *Exclude - no primary or secondary outcomes of interest*
- Torielli F, Fashaw LM, Knudson O, et al. Echocardiographic outcome of infants treated as newborns with inhaled nitric oxide for severe hypoxemic respiratory failure. *J Pediatr*. 2001;138(3):349-54. PMID: 11241041. *Exclude - Does not include intervention of interest*
- Torres Macho J, Delgado Jimenez JF, Sanz Salvo J, et al. Effect of different pharmacologic agents to reverse severe pulmonary hypertension among end-stage heart failure patients. *Transplant Proc*. 2009;41(6):2477-9. PMID: 19715956. *Exclude - No study population of interest*
- Toshner MR, Gopalan D, Suntharalingam J, et al. Pulmonary arterial size and response to sildenafil in chronic thromboembolic pulmonary hypertension. *J Heart Lung Transplant*. 2010;29(6):610-5. PMID: 20227301. *Exclude - No study population of interest*
- Trachte AL, Lobato EB, Urdaneta F, et al. Oral sildenafil reduces pulmonary hypertension after cardiac surgery. *Ann Thorac Surg*. 2005;79(1):194-7; discussion 194-7. PMID: 15620942. *Exclude - No study population of interest*
- Tsiakalos A, Hatzis G, Moyssakis I, et al. Portopulmonary hypertension and serum endothelin levels in hospitalized patients with cirrhosis. *Hepatobiliary Pancreat Dis Int*. 2011;10(4):393-8. PMID: 21813388. *Exclude - Does not include intervention of interest*
- Tsutsui JM, Maciel RR, Costa JM, et al. Hand-carried ultrasound performed at bedside in cardiology inpatient setting - A comparative study with comprehensive echocardiography. *Cardiovasc Ultrasound*. 2004;2. *Exclude - No study population of interest*
- Tuomi L. Drug therapy in primary pulmonary hypertension. *J Cardpulm Rehabil*. 1994;14(4):224-227. *Exclude - not a full publication*
- Turanlahti M, Pesonen E, Pohjavuori M, et al. Plasma cyclic guanosine monophosphate reflecting the severity of persistent pulmonary hypertension of the newborn. *Biol Neonate*. 2001;80(2):107-12. PMID: 11509809. *Exclude - no primary or secondary outcomes of interest*
- Turanlahti MI, Laitinen PO, Sarna SJ, et al. Nitric oxide, oxygen, and prostacyclin in children with pulmonary hypertension. *Heart*. 1998;79(2):169-74. PMID: 9538311. *Exclude - Does not include intervention of interest*
- Ulett KB, Marwick TH. Incorporation of pulmonary vascular resistance measurement into standard echocardiography: implications for assessment of pulmonary hypertension. *Echocardiography*. 2007;24(10):1020-2. PMID: 18001353. *Exclude - no primary or secondary outcomes of interest*
- Ulrich S, Fischler M, Speich R, et al. Chronic thromboembolic and pulmonary arterial hypertension share acute vasoreactivity properties. *Chest*. 2006;130(3):841-6. PMID: 16963684. *Exclude - Does not include intervention of interest*
- Ulrich S, Huber LC, Fischler M, et al. Platelet serotonin content and transpulmonary platelet serotonin gradient in patients with pulmonary hypertension. *Respiration*. 2011;81(3):211-216. *Exclude - Does not include intervention of interest*

Ulrich S, Speich R, Domenighetti G, et al. Bosentan therapy for chronic thromboembolic pulmonary hypertension. A national open label study assessing the effect of Bosentan on haemodynamics, exercise capacity, quality of life, safety and tolerability in patients with chronic thromboembolic pulmonary hypertension (BOCTEPH-Study). *Swiss Med Wkly.* 2007;137(41-42):573-80. PMID: 17990150. *Exclude - No study population of interest*

Uner A, Dogan M, Demirtas M, et al. Comparison of nifedipine and captopril in children with pulmonary hypertension due to bronchopneumonia. *J Trop Pediatr.* 2008;54(5):294-9. PMID: 18304952. *Exclude - No study population of interest*

Upadhyaya B, Ntim W, Little W, et al. Identification of high risk patient with sickle cell disease using echocardiography. *J Am Soc Echocardiogr.* 2012;25(6):B6. *Exclude - Not a full publication*

Uslu S, Kumtepe S, Bulbul A, et al. A comparison of magnesium sulphate and sildenafil in the treatment of the newborns with persistent pulmonary hypertension: a randomized controlled trial. *J Trop Pediatr.* 2011;57(4):245-50. PMID: 20923790. *Exclude - no primary or secondary outcomes of interest*

Vachieri JL, Delcroix M, Huez S, et al. Sildenafil use in pulmonary hypertension: The Belgian experience. *Acta Cardiol.* 2011;66(1):130-131. *Exclude - Not a full publication*

Vachieri JL, Hill N, Zwicke D, et al. Transitioning from i.v. epoprostenol to subcutaneous treprostinil in pulmonary arterial hypertension. *Chest.* 2002;121(5):1561-5. PMID: 12006444. *Exclude - no primary or secondary outcomes of interest*

Vadapalli S, Rani HS, Sastry B, et al. Endothelin-1 and endothelial nitric oxide polymorphisms in idiopathic pulmonary arterial hypertension. *Int J Mol Epidemiol Genet.* 2010;1(3):208-13. PMID: 21537392. *Exclude - Does not include intervention of interest*

Valdivia-Arenas MA, Sood N. Micrococcus bloodstream infection in patients with pulmonary hypertension on epoprostenol. *Infect Dis Clin Pract.* 2008;16(5):285-287. *Exclude - No comparisons of interest*

Valerio CJ, Handler CE, Kabunga P, et al. Clinical experience with bosentan and sitaxentan in connective tissue disease-associated pulmonary arterial hypertension. *Rheumatology (Oxford).* 2010;49(11):2147-53. PMID: 20675359. *Exclude - No comparisons of interest*

Valerio G, Bracciale P, Grazia D'Agostino A. Effect of bosentan upon pulmonary hypertension in chronic obstructive pulmonary disease. *Ther Adv Respir Dis.* 2009;3(1):15-21. PMID: 19293199. *Exclude - No study population of interest*

van Beers EJ, Nur E, Schaefer-Prokop CM, et al. Cardiopulmonary imaging, functional and laboratory studies in sickle cell disease associated pulmonary hypertension. *Am J Hematol.* 2008;83(11):850-4. PMID: 18819095. *Exclude - Does not include intervention of interest*

Van De Bruaene A, De Meester P, Voigt JU, et al. Right ventricular function in patients with Eisenmenger syndrome. *Acta Cardiol.* 2012;67(1):144-145. *Exclude - Not a full publication*

van Loon RL, Hoendermis ES, Duffels MG, et al. Long-term effect of bosentan in adults versus children with pulmonary arterial hypertension associated with systemic-to-pulmonary shunt: does the beneficial effect persist? *Am Heart J.* 2007;154(4):776-82. PMID: 17893008. *Exclude - No comparisons of interest*

van Loon RL, Roofthoof MT, Delhaas T, et al. Outcome of pediatric patients with pulmonary arterial hypertension in the era of new medical therapies. *Am J Cardiol.* 2010;106(1):117-24. PMID: 20609658. *Exclude - Does not include intervention of interest.*

Van Riel ACMJ, Schuurin M, Vis J, et al. Determinants of mortality in adults with pulmonary arterial hypertension due to congenital heart disease after initiation of advanced therapy. *J Am Coll Cardiol.* 2012;59(13):E1595. *Exclude - Not a full publication*

Varga J. Endothelin-I receptor antagonist for the treatment of pulmonary arterial hypertension in systemic sclerosis. *Curr Rheumatol Rep.* 2003;5(2):145-6. PMID: 12628045. *Exclude - Not a full publication*

Vargas-Origel A, Gomez-Rodriguez G, Aldana-Valenzuela C, et al. The use of sildenafil in persistent pulmonary hypertension of the newborn. *Am J Perinatol.* 2010;27(3):225-30. PMID: 19866403. *Exclude - no primary or secondary outcomes of interest*

Vassallo FG, Kodric M, Scarduelli C, et al. Bosentan for patients with chronic thromboembolic pulmonary hypertension. *Eur J Intern Med.* 2009;20(1):24-9. PMID: 19237088. *Exclude - No study population of interest*

- Vassalos A, Peng E, Young D, et al. Pre-operative sildenafil and pulmonary endothelial-related complications following cardiopulmonary bypass: a randomised trial in children undergoing cardiac surgery. *Anaesthesia*. 2011;66(6):472-80. PMID: 21457152. *Exclude - Does not include intervention of interest*
- Vegh J, Szodoray P, Kappelmayer J, et al. Clinical and immunoserological characteristics of mixed connective tissue disease associated with pulmonary arterial hypertension. *Scand J Immunol*. 2006;64(1):69-76. PMID: 16784493. *Exclude - Does not include intervention of interest*
- Vida VL, Gaitan G, Quezada E, et al. Low-dose oral sildenafil for patients with pulmonary hypertension: a cost-effective solution in countries with limited resources. *Cardiol Young*. 2007;17(1):72-7. PMID: 17184573. *Exclude - no primary or secondary outcomes of interest*
- Vijay P, Szekeley L, Sharp TG, et al. Adrenomedullin in patients at high risk for pulmonary hypertension. *Ann Thorac Surg*. 1998;66(2):500-5. PMID: 9725392. *Exclude - Does not include intervention of interest*
- Vijlbrief DC, Benders MJ, Kemperman H, et al. B-Type Natriuretic Peptide and Rebound during Treatment for Persistent Pulmonary Hypertension. *J Pediatr*. 2012;160(1):111-115 e1. PMID: 21839472. *Exclude - no primary or secondary outcomes of interest*
- Villalba WO, Sampaio-Barros PD, Pereira MC, et al. Six-minute walk test for the evaluation of pulmonary disease severity in scleroderma patients. *Chest*. 2007;131(1):217-22. PMID: 17218579. *Exclude - no primary or secondary outcomes of interest*
- Villegas FA, Sanchez TS, Palenciano CG. Diagnostic techniques of pulmonary hypertension in candidates for liver transplant. *Gastroenterol Hepatol Continuada*. 2007;6(5):237-241. *Exclude - Not available in English*
- Vis JC, Duffels MG, Mulder P, et al. Prolonged beneficial effect of bosentan treatment and 4-year survival rates in adult patients with pulmonary arterial hypertension associated with congenital heart disease. *Int J Cardiol*. 2011. PMID: 21723630. *Exclude - No comparisons of interest*
- Vizza CD, Badagliacca R, Poscia R, et al. Prognostic factors in severe pulmonary hypertension patients who need parenteral prostanoid therapy: The impact of late referral. *Chest*. 2011;140(4). *Exclude - Not a full publication*
- Vizza CD, Badagliacca R, Sciomer S, et al. Mid-term efficacy of beraprost, an oral prostacyclin analog, in the treatment of distal CTEPH: a case control study. *Cardiology*. 2006;106(3):168-73. 16645271. *Exclude - No study population of interest*
- Vizza CD, Rocca GD, Roma AD, et al. Acute hemodynamic effects of inhaled nitric oxide, dobutamine and a combination of the two in patients with mild to moderate secondary pulmonary hypertension. *Crit Care*. 2001;5(6):355-61. PMID: 11737925. *Exclude - No study population of interest*
- Vizza CD, Sciomer S, Morelli S, et al. Long term treatment of pulmonary arterial hypertension with beraprost, an oral prostacyclin analogue. *Heart*. 2001;86(6):661-5. PMID: 11711462. *Exclude - No comparisons of interest*
- Vogel-Claussen J, Skrok J, Shehata ML, et al. Right and left ventricular myocardial perfusion reserves correlate with right ventricular function and pulmonary hemodynamics in patients with pulmonary arterial hypertension. *Radiology*. 2011;258(1):119-27. PMID: 20971775. *Exclude - Does not include intervention of interest*
- von Haehling S, von Bardeleben RS, Kramm T, et al. Inflammation in right ventricular dysfunction due to thromboembolic pulmonary hypertension. *Int J Cardiol*. 2010;144(2):206-11. PMID: 19411119. *Exclude - No study population of interest*
- Voskaridou E, Tsetsos G, Tsoutsias A, et al. Pulmonary hypertension in patients with sickle cell/beta thalassemia: incidence and correlation with serum N-terminal pro-brain natriuretic peptide concentrations. *Haematologica*. 2007;92(6):738-43. PMID: 17550845. *Exclude - No comparisons of interest*
- Voswinckel R, Enke B, Reichenberger F, et al. Favorable effects of inhaled treprostinil in severe pulmonary hypertension: results from randomized controlled pilot studies. *J Am Coll Cardiol*. 2006;48(8):1672-81. PMID: 17045906. *Exclude - No comparisons of interest*
- Voswinckel R, Reichenberger F, Enke B, et al. Acute effects of the combination of sildenafil and inhaled treprostinil on haemodynamics and gas exchange in pulmonary hypertension. *Pulm Pharmacol Ther*. 2008;21(5):824-32. PMID: 18657627. *Exclude - no primary or secondary outcomes of interest*

Voswinckel R, Reichenberger F, Gall H, et al. Metered dose inhaler delivery of treprostinil for the treatment of pulmonary hypertension. *Pulm Pharmacol Ther.* 2009;22(1):50-6. PMID: 19071225. *Exclude - no primary or secondary outcomes of interest*

Wahl A, Praz F, Schwerzmann M, et al. Assessment of right ventricular systolic function: Comparison between cardiac magnetic resonance derived ejection fraction and pulsed-wave tissue Doppler imaging of the tricuspid annulus. *Int J Cardiol.* 2011;151(1):58-62. *Exclude - no primary or secondary outcomes of interest*

Walkey AJ, Fein D, Horbowicz KJ, et al. Differential response to intravenous prostacyclin analog therapy in patients with pulmonary arterial hypertension. *Pulm Pharmacol Ther.* 2011;24(4):421-5. PMID: 21251994. *Exclude - no primary or secondary outcomes of interest*

Wang T, Li SX, Zhang XQ, et al. Study on the effect of adrenomedullin and urotensin-II on pulmonary hypertension of patients with congenital heart disease. *Nat Med J China.* 2005;85(38):2691-2695. *Exclude - Not available in English.*

Wang X, Mendelsohn L, Alien D, et al. Levels of placental growth factor and endothelin-1 in adults with sickle cell disease are linked to markers of hemolysis, inflammation, iron overload and pulmonary hypertension. *Am J Hematol.* 2010;85(8):E19. *Exclude - Not a full publication*

Warrell C, Dobarro D, Handler C, et al. Predictors of bosentan monotherapy discontinuation in SSc-pah patients. *Rheumatology (Oxford).* 2012;51:ii49-ii50. *Exclude - Not a full publication*

Warwick G, Thomas PS, Yates DH. Biomarkers in pulmonary hypertension. *Eur Respir J.* 2008;32(2):503-12. PMID: 18669790. *Exclude - Background Other*

Wasielewski S. Phosphodiesterase 5 inhibitor: Sildenafil lowers pulmonary hypertension. *Dtsch Apoth Ztg.* 2003;143(1-2):46-48. *Exclude - Not available in English.*

Watanabe H. A potential role of sildenafil, a selective PDE-5 inhibitor, in the management of pulmonary hypertension. *Respir Circ.* 2003;51(9):881-886. *Exclude - Not available in English.*

Wax D, Garofano R, Barst RJ. Effects of long-term infusion of prostacyclin on exercise performance in patients with primary pulmonary hypertension. *Chest.* 1999;116(4):914-20. PMID: 10531153. *Exclude - No comparisons of interest*

Wensel R, Opitz CF, Ewert R, et al. Effects of iloprost inhalation on exercise capacity and ventilatory efficiency in patients with primary pulmonary hypertension. *Circulation.* 2000;101(20):2388-92. PMID: 10821815. *Exclude - no primary or secondary outcomes of interest*

Widimsky J. Calcium antagonists in the vasodilatory treatment of primary pulmonary hypertension. *Cor Vasa.* 1990;32(2 Suppl):73-80. PMID: 2143462. *Exclude - not a full publication*

Wiedemann R, Ghofrani HA, Weissmann N, et al. Atrial natriuretic peptide in severe primary and nonprimary pulmonary hypertension: response to iloprost inhalation. *J Am Coll Cardiol.* 2001;38(4):1130-6. PMID: 11583893. *Exclude - no primary or secondary outcomes of interest*

Wierzbicki K, Przybylowski P, Sobczyk D, et al. Markers of pulmonary hypertension in potential candidates to heart transplantation. *Przegl Lek.* 2006;63(12):1263-8. PMID: 17642136. *Exclude - No study population of interest*

Wierzbicki K, Sobczyk D, Bochenek M, et al. Analysis of correlations between N-terminal pro-B-type natriuretic peptide levels and markers of venous pulmonary hypertension in patients referred for heart transplantation. *Pol Arch Med Wewn.* 2012;122(6):291-297. *Exclude - No study population of interest*

Wilkens H, Bauer M, Forestier N, et al. Influence of inhaled iloprost on transpulmonary gradient of big endothelin in patients with pulmonary hypertension. *Circulation.* 2003;107(11):1509-13. PMID: 12654608. *Exclude - no primary or secondary outcomes of interest*

Wilkens H, Guth A, Konig J, et al. Effect of inhaled iloprost plus oral sildenafil in patients with primary pulmonary hypertension. *Circulation.* 2001;104(11):1218-22. PMID: 11551870. *Exclude - no primary or secondary outcomes of interest*

Williams MH, Das C, Handler CE, et al. Systemic sclerosis associated pulmonary hypertension: improved survival in the current era. *Heart.* 2006;92(7):926-32. PMID: 16339813. *Exclude - Does not include intervention of interest.*

Williamson DJ, Wallman LL, Jones R, et al. Hemodynamic effects of Bosentan, an endothelin receptor antagonist, in patients with pulmonary hypertension. *Circulation.* 2000;102(4):411-8. PMID: 10908213. *Exclude - no primary or secondary outcomes of interest*

- Winslow TM, Ossipov MA, Fazio GP, et al. Five-year follow-up study of the prevalence and progression of pulmonary hypertension in systemic lupus erythematosus. *Am Heart J.* 1995;129(3):510-5. PMID: 7872181. *Exclude - no primary or secondary outcomes of interest*
- Winterhalter M, Simon A, Fischer S, et al. Comparison of inhaled iloprost and nitric oxide in patients with pulmonary hypertension during weaning from cardiopulmonary bypass in cardiac surgery: a prospective randomized trial. *J Cardiothorac Vasc Anesth.* 2008;22(3):406-13. PMID: 18503929. *Exclude - no primary or secondary outcomes of interest*
- Wolff B, Lodziewski S, Bollmann T, et al. Impaired peripheral endothelial function in severe idiopathic pulmonary hypertension correlates with the pulmonary vascular response to inhaled iloprost. *Am Heart J.* 2007;153(6):1088 e1-7. PMID: 17540215. *Exclude - Does not include intervention of interest*
- Wong HA, Yan S, McGlothlin DP, et al. Comparative effectiveness of endothelin receptor antagonists for the treatment of pulmonary arterial hypertension (a pilot study). *Pharmacotherapy.* 2011;31(10):321e. *Exclude - Not a full publication*
- Wong RC, Koh GM, Choong PH, et al. Oral sildenafil therapy improves health-related quality of life and functional status in pulmonary arterial hypertension. *Int J Cardiol.* 2007;119(3):400-2. PMID: 17064789. *Exclude - No comparisons of interest*
- Woodmansey PA, O'Toole L, Channer KS, et al. Acute pulmonary vasodilatory properties of amlodipine in humans with pulmonary hypertension. *Heart.* 1996;75(2):171-3. PMID: 8673756. *Exclude - No study population of interest*
- Wylie BJ, Epps KC, Gaddipati S, et al. Correlation of transthoracic echocardiography and right heart catheterization in pregnancy. *J Perinat Med.* 2007;35(6):497-502. PMID: 18052837. *Exclude - No study population of interest*
- Xiong CM, Lu XL, Shan GL, et al. Oral Sildenafil Therapy for Chinese Patients With Pulmonary Arterial Hypertension: A Multicenter Study. *J Clin Pharmacol.* 2011. PMID: 21415281. *Exclude - No comparisons of interest*
- Xiong CM, Lu XL, Shan GL, et al. Oral sildenafil therapy for Chinese patients with pulmonary arterial hypertension: a multicenter study. *J Clin Pharmacol.* 2012;52(3):425-31. PMID: 21415281. *Exclude - No comparisons of interest*
- Xu XQ, Jing ZC, Zhang JH, et al. The efficacy and safety of sildenafil in Chinese patients with pulmonary arterial hypertension. *Hypertens Res.* 2009;32(10):911-5. PMID: 19644505. *Exclude - No comparisons of interest*
- Yadav R, Anandaraja S, Bhargava B, et al. Acute hemodynamic effects of nicorandil in patients with primary pulmonary arterial hypertension. *Indian Heart J.* 2005;57(6):666-9. PMID: 16521635. *Exclude - Does not include intervention of interest*
- Yamakawa H, Shiomi T, Sasanabe R, et al. Pulmonary hypertension in patients with severe obstructive sleep apnea. *Psychiatry Clin Neurosci.* 2002;56(3):311-2. PMID: 12047610. *Exclude - No study population of interest*
- Yamane K, Ihn H, Asano Y, et al. Clinical and laboratory features of scleroderma patients with pulmonary hypertension. *Rheumatology (Oxford).* 2000;39(11):1269-71. PMID: 11085808. *Exclude - Does not include intervention of interest*
- Yeager ME, Colvin KL, Everett AD, et al. Plasma proteomics of differential outcome to long-term therapy in children with idiopathic pulmonary arterial hypertension. *Proteomics - Clinical Applications.* 2012;6(5-6):257-267. *Exclude - Does not include intervention of interest*
- Yeo TC, Dujardin KS, Tei C, et al. Value of a Doppler-derived index combining systolic and diastolic time intervals in predicting outcome in primary pulmonary hypertension. *Am J Cardiol.* 1998;81(9):1157-61. PMID: 9605059. *Exclude - Does not include intervention of interest*
- Yigla M, Azzam Z, Rinkevich D, et al. Unexplained pulmonary hypertension in older patients: Clinical characteristics, follow-up, and prognosis. *J Cardiovasc Diagn Proc.* 1997;14(1):9-15. *Exclude - No comparisons of interest*
- Yilmaz N, Olgun S, Ahiskali R, et al. Serum and sputum caveolin-1, TGF-(beta) and et-1 levels in scleroderma patients. *Rheumatology (Oxford).* 2012;51:ii27. *Exclude - Not a full publication*
- Yinguang S, Lijiang T, Qinhua Z, et al. Assessment of right heart function in the patients with pulmonary arterial hypertension using 2D strain echocardiography. *Heart.* 2011;97:A197. *Exclude - Not a full publication*
- Yoshida S, Shirato K, Shimamura R, et al. Efficacy, safety, and pharmacokinetics of ambrisentan in Japanese adults with pulmonary arterial hypertension. *Curr Med Res Opin.* 2011;27(9):1827-34. PMID: 21812736. *Exclude - No comparisons of interest*

You XD, Pu ZX, Peng XJ, et al. Tissue Doppler imaging study of right ventricular myocardial systolic activation in subjects with pulmonary arterial hypertension. *Chin Med J (Engl)*. 2007;120(13):1172-5. PMID: 17637247. *Exclude - no primary or secondary outcomes of interest*

Yung D, Widlitz AC, Rosenzweig EB, et al. Outcomes in children with idiopathic pulmonary arterial hypertension. *Circulation*. 2004;110(6):660-5. PMID: 15289375. *Exclude - No comparisons of interest.*

Zafir B, Shehadeh W, Salman N, et al. Prognostic factors in pulmonary hypertension: The obesity paradox. *J Am Coll Cardiol*. 2012;59(13):E1592. *Exclude - Not a full publication*

Zhang DZ, Zhu XY, Meng J, et al. Acute hemodynamic responses to adenosine and iloprost in patients with congenital heart defects and severe pulmonary arterial hypertension. *Int J Cardiol*. 2011;147(3):433-7. PMID: 20537740. *Exclude - Does not include intervention of interest*

Zhang J, Zhang Y, Li N, et al. Potential diagnostic biomarkers in serum of idiopathic pulmonary arterial hypertension. *Respir Med*. 2009;103(12):1801-6. PMID: 19703762. *Exclude - Does not include intervention of interest*

Zhang R, Dai LZ, Xie WP, et al. Survival of Chinese patients with pulmonary arterial hypertension in the modern treatment era. *Chest*. 2011;140(2):301-9. PMID: 21330386. *Exclude - No comparisons of interest*

Zhang ZN, Jiang X, Zhang R, et al. Oral sildenafil treatment for Eisenmenger syndrome: A prospective, open-label, multicentre study. *Heart*. 2011;97(22):1876-1881. *Exclude - No comparisons of interest*

Zhu H, Wang GY, Xue H. Therapeutic effect of ambrisentan on congenital heart disease associated with PAH. *Am J Cardiol*. 2012;109(7):136S. *Exclude - Not a full publication*

Ziegler JW, Ivy DD, Wiggins JW, et al. Effects of dipyridamole and inhaled nitric oxide in pediatric patients with pulmonary hypertension. *Am J Respir Crit Care Med*. 1998;158(5 Pt 1):1388-95. PMID: 9817684. *Exclude - Does not include intervention of interest*

Zimbarra Cabrita I, Ruisanchez C, Dawson D, et al. Right ventricular function in patients with pulmonary hypertension; the value of myocardial performance index measured by tissue Doppler imaging. *Eur J Echocardiogr*. 2010;11(8):719-24. PMID: 20410189. *Exclude - no primary or secondary outcomes of interest*

Zompatori M, Battaglia M, Rimondi MR, et al. Hemodynamic estimation of chronic cor pulmonale by Doppler echocardiography. Clinical value and comparison with other noninvasive imaging techniques. *Rays*. 1997;22(1):73-93. PMID: 9145016. *Exclude - Not available in English.*

Zuo XR, Zhang R, Jiang X, et al. Usefulness of intravenous adenosine in idiopathic pulmonary arterial hypertension as a screening agent for identifying long-term responders to calcium channel blockers. *Am J Cardiol*. 2012;109(12):1801-1806. *Exclude - No comparisons of interest*



## Appendix F. Study Characteristics Tables (KQ 1 and KQ 2)

*Note: The study characteristics table for KQ 3 is in the main report.*

**Table F-1. Study characteristics table for KQ 1**

Study	Population Total N	Test Measures	Study Objectives	Quality
Ajami, 2011 <sup>1</sup>	Children and young adults with congenital heart disease referred for RHC N=20	TRV/VTI <sub>RVOT</sub>	Accuracy of TRV/VTI <sub>RVOT</sub> for diagnosing elevated PVR	Good
Allanore, 2008 <sup>2</sup>	SSc patients with echocardiography sPAP<40 mmHg and no NYHA III/IV symptoms N=101	NT-proBNP, plasma sPAP	Screening for prospective development of PAH (predicting development of PAH in at-risk population)	Good
Arcasoy 2003 <sup>3</sup>	Patients with advanced lung disease undergoing evaluation for lung transplantation N=374	sPAP RAP	Estimate performance characteristics of echocardiography compared with RHC in determining sPAP and diagnosing PH	Good
Bogdan, 1998 <sup>4</sup>	PAH patients and controls N=19	cGMP, urine	Test association of PAH with urine cGMP	Poor
Bonderman, 2011 <sup>5</sup>	Referred for evaluation of suspected PAH; more than half had NYHA III/IV symptoms N=372	NT-proBNP sPAP RA size RV size TAPSE	Diagnostic accuracy for distinguishing PAH from secondary PH Precision/calibration of echocardiographic measures	Good
Cavagna, 2010 <sup>6</sup>	SSc patients; symptoms not described N=135	BNP NT-proBNP	Screening for PAH Discrimination between PAH or not Reference standard based on echocardiography sPAP screening with RHC verification of positives	Good
Cevik, 2012 <sup>7</sup>	Children with pulmonary hypertension, with and without congenital heart disease N=70	RIMP/MPI/Tei index mPAP S' TAPSE TRV/VTI <sub>RVOT</sub>	Evaluation of RV function using transthoracic echocardiography	Fair
Ciurzynski, 2011 <sup>8</sup>	SSc patients. Patients with signs or symptoms of heart or lung disease excluded N=71	Transtricuspid gradient rest/exercise	Association with diagnosis of PAH	Good
Colle, 2003 <sup>9</sup>	Liver transplant candidates N=165	sPAP	Screening for portopulmonary hypertension	Good

Study	Population Total N	Test Measures	Study Objectives	Quality
Condliffe, 2011 <sup>10</sup>	SSc patients with suspected PAH; symptoms not described N=89	Tricuspid gradient	Discrimination between PAH or not Reference standard=RHC	Fair
Dahiya, 2010 <sup>11</sup>	Referred for evaluation of suspected PH; all patients had dyspnea N=114	TRV/VTI <sub>RVOT</sub>	Diagnostic accuracy, calibration, and precision of echocardiography estimation of elevated PVR	Good
Denton, 1997 <sup>12</sup>	SSc patients suspected of PAH, most due to reduced DLCO N=93	RV size sPAP	Diagnostic accuracy, discrimination of echocardiography for diagnosing PAH	Fair
Farber, 2011 <sup>13</sup>	Patients with PAH N=1883	sPAP RAP	Accuracy of echocardiography for sPAP and RAP	Fair
Fisher, 2009 <sup>14</sup>	Patients undergoing RHC for known or suspected PAH; symptoms not described N=65	sPAP Transticuspid gradient	Precision/calibration of echocardiography for mPAP, sPAP compared with RHC	Good
Fitzgerald, 2012 <sup>15</sup>	Sickle cell disease with TRV $\geq 2.5$ m/s and RHC N=75	TRV mPAP	Comparison of TRV measurement to RHC for diagnosing PH	Poor
Fonseca, 2012 <sup>16</sup>	Sickle cell disease; symptoms not described N=80	TRV Uric acid	Screening for PAH Echocardiography screening of TRV with RHC verification of positives	Fair
Frea, 2011 <sup>17</sup>	SSc patients with no signs or symptoms of PAH N=76	NT-proBNP FAC RIMP/MPI/Tei index RV size TRV/VTI <sub>RVOT</sub> TAPSE	Screening for prospective development of PAH (Predicting development of PAH in at-risk population)	Fair
Fukuda, 2011 <sup>18</sup>	Patients with known PH N=67	FAC TAPSE RIMP/MPI/Tei index sPAP	Correlation between echocardiography and RHC hemodynamics in patient with elevated mPAP	Fair
Ghio, 2004 <sup>19</sup>	HIV and confirmed PAH. Controls with HIV and no known cardiac or pulmonary disease N=93	NT-proBNP	Diagnostic accuracy for NT-proBNP for discriminating HIV-positive PAH patients from HIV-positive controls	Fair
Gialafos, 2008 <sup>20</sup>	SSc patients. Some were symptomatic N=106	NT-proBNP RIMP/MPI/Tei index	Association with diagnosis of PAH	Fair
Hachulla, 2005 <sup>21</sup>	SSc patients; some symptomatic N=599	TRV	Screening for PAH in at-risk population	Poor
Hammerstingl, 2012 <sup>22</sup>	Patients with PH undergoing RHC and transthoracic echocardiography N=155	sPAP mPAP	Diagnosis of PH and differentiating between pre- and postcapillary PH	Fair
Hsu, 2008 <sup>23</sup>	SSc patients with dyspnea or other clinical features suggestive of PAH N=49	sPAP	Diagnostic accuracy for diagnosing PAH	Good

Study	Population Total N	Test Measures	Study Objectives	Quality
Hua, 2009 <sup>24</sup>	Liver transplant candidates N=105	sPAP	Diagnostic accuracy for portopulmonary hypertension	Good
Jansa, 2012 <sup>25</sup>	SSc patients some with dyspnea N=203	TRV	Screening for PAH in at-risk population	Fair
Kovacs, 2010 <sup>26</sup>	Patients with CVD some with symptoms N=52	sPAP rest and exercise	Screening for PAH in at-risk population	Good
Lindqvist, 2011 <sup>27</sup>	Patients with PH undergoing RHC N=30	TRV/VTI <sub>RVOT</sub>	Accuracy for diagnosis of elevated PVR Precision/calibration of echocardiography estimate of PVR	Fair
Low, 2011 <sup>28</sup>	Referred for evaluation of suspected or definite PAH, most with symptoms N=200	Transticuspid gradient	Diagnostic accuracy for diagnosing PAH	Poor
Machado, 2006 <sup>29</sup>	Sickle cell disease N=416	NT-proBNP	Association between biomarker and hemodynamic measures. Diagnosis based on echocardiography screen with partial verification by RHC of some test positives.	Poor
McLean, 2007 <sup>30</sup>	Referred for echocardiography with adequate TR jet on Doppler, nearly all with symptoms N=108	RV end-diastolic diameter (RVD) time to peak (RV tricuspid annular motion by TDI, time from beginning of IC to first systolic myocardial peak)	Correlation between echocardiography RVD/time to peak and RHC PASP	Poor
Mourani, 2008 <sup>31</sup>	Children under 2 years of age undergoing RHC for chronic lung disease N=25	RA size RV size Transticuspid gradient	Asses echocardiography feasibility, calibration for estimating hemodynamics, and accuracy for diagnosis of PAH	Fair
Mukerjee, 2004 <sup>32</sup>	SSc patients with suspected PAH, symptoms of exercise limitation and reduced DLCO N=137	sPAP	Accuracy of echocardiography sPAP at different thresholds for diagnosis of PAH	Fair
Murata, 1997 <sup>33</sup>	SSc patients. Symptoms not described, but most had reduced DLCO N=135	sPAP	Precision/calibration of echocardiography for estimating invasive pulmonary hemodynamics	Fair
Nakayama, 1998 <sup>34</sup>	Patients with known, symptomatic CTEPH or PPH N=35	sPAP mPAP	Accuracy of echocardiography for discrimination between CTEPH and PPH	Fair
Nogami, 2009 <sup>35</sup>	Suspected pulmonary hypertension; all patients symptomatic N=29	sPAP	Precision/calibration of echocardiography for estimating invasive pulmonary hemodynamics	Good

Study	Population Total N	Test Measures	Study Objectives	Quality
Phung, 2009 <sup>36</sup>	SSc patient referred with or without suspicion of PAH; 10% had NYHA III/IV symptoms N=184	sPAP	Accuracy of echocardiography sPAP for diagnosing PAH	Good
Pilatis, 2000 <sup>37</sup>	Liver transplant candidates N=55	RV size sPAP	Accuracy of echocardiography for diagnosing portopulmonary hypertension	Fair
Rajagopalan, 2008 <sup>38</sup> Rajagopalan, 2007 <sup>39</sup>	Known pulmonary hypertension N=52	TRV/VTI <sub>RVOT</sub> sPAP S'	Accuracy of echocardiography for estimating PVR in PH patients Calibration/precision of echocardiography for estimating RHC hemodynamics	Fair
Rajaram, 2012 <sup>40</sup>	Connective tissue disease patients with suspected PH N=81	sPAP mPAP Pericardial effusion	Comparison of magnetic resonance imaging, computed tomography, and echocardiography for diagnosing PAH	Fair
Rich, 2011 <sup>41</sup>	Patients with both RHC and Doppler echo N=183	sPAP	Calibration/precision of echocardiography for estimating RHC hemodynamics	Good
Roeleveld, 2005 <sup>42</sup>	Known PH N=47	sPAP	Calibration/precision of echocardiography for estimating RHC hemodynamics	Fair
Roule, 2010 <sup>43</sup>	Known PH N=37	TRV TRV/VTI <sub>RVOT</sub>	Calibration/precision for estimating RHC hemodynamics at elevated PA pressures Accuracy for diagnosing elevated PVR in PH patients	Good
Ruan, 2007 <sup>44</sup>	Known PAH and healthy controls N=180	FAC RV size sPAP	Diagnostic accuracy of echocardiography for discriminating PAH and control patients	Fair
Ruiz-Irastorza, 2012 <sup>45</sup>	Systemic lupus erythematosus patients with or without suspicion of PAH N=245	sPAP mPAP	Prevalence of and strategy for diagnosing PH in patients with lupus	Fair
Sanli, 2012 <sup>46</sup>	Congenital heart disease with and without known PAH N=70	RV size mPAP Nitric oxide RIMP/MPI/Tei index TAPSE	Relationship between biomarkers and hemodynamic measurements	Fair
Selby, 2012 <sup>47</sup>	Patients with HIV infection with or without suspicion of PAH N=129	sPAP	Comparison of sPAP measured by echocardiography versus RHC	Fair
Selimovic, 2007 <sup>48</sup>	Patients with suspected pulmonary vascular disease. 37/42 NYHA III/IV N=42	sPAP mPAP	Calibration/precision of echocardiography for estimating RHC hemodynamics	Good
Simeoni, 2008 <sup>49</sup>	Known SSc-associated PAH and controls with SSc but no PAH N=20	NT-proBNP	Diagnostic accuracy of NT-proBNP for discriminating PAH and control patients	Poor

Study	Population Total N	Test Measures	Study Objectives	Quality
Steen, 2008 <sup>50</sup>	SSc patients with suspected PAH based on symptoms or signs N=54	sPAP rest/exercise	Accuracy of rest/exercise echocardiography to diagnose PAH	Fair
Takatsuki, 2012 <sup>51</sup>	Children with idiopathic PAH N=102	S' mPAP	Assessing disease severity and prognostic value with tissue Doppler imaging	Fair
Tei, 1996 <sup>52</sup>	Known PPH and health controls N=53	RIMP/MPI/Tei index	Association of Tei index with PPH versus normal controls	Poor
Thakkar, 2012 <sup>53</sup>	SSc patients with known PAH, high risk for PAH, interstitial lung disease, or no cardiopulmonary disease N=94	sPAP NT-proBNP	NT-proBNP as a replacement for transthoracic echocardiography in screening for SSc-related PAH	Fair
Tian, 2011 <sup>54</sup>	Suspected PH based on symptoms N=42	sPAP mPAP	Calibration/precision of echocardiography for estimating RHC hemodynamics	Fair
Torregrosa, 2001 <sup>55</sup>	Liver transplant candidates N=94	sPAP	Accuracy for diagnosing portopulmonary hypertension	Fair
Toyono, 2008 <sup>56</sup>	Children with VSD and severe PH N=24	BNP	Correlation between BNP levels and invasive PVR	Good
Tutar, 1999 <sup>57</sup>	Children with left-to-right shunt and health controls N=23	Endothelin-1, plasma	Association of endothelin-1 levels and pulmonary hypertension	Fair
Vlahos, 2007 <sup>58</sup>	Known or suspected pulmonary hypertension N=12	TRV/VTI <sub>RVOT</sub>	Accuracy of echocardiography for diagnosing elevated PVR	Poor
Vonk, 2007 <sup>59</sup>	Connective tissue diseases. One-third NYHA III/IV N=98	RIMP/MPI/Tei index sPAP	Accuracy for diagnosis of PAH or not	Fair
Willens, 2008 <sup>60</sup>	Patients with known PH and elevated sPAP and controls with CHF and elevated sPAP N=47	sPAP	Association of sPAP with PH versus CHF	Fair
Williams, 2006 <sup>61</sup>	SSc patients with PAH and controls with SSc but without PAH N=109	NT-proBNP	Accuracy for diagnosis of PAH	Fair

Abbreviations: BNP=brain natriuretic peptide; CHF=congestive heart failure; CTEPH=chronic thromboembolic pulmonary hypertension; CVD=collagen vascular disease; DLCO=diffusion capacity of the lung for carbon monoxide; FAC=fractional area change; mPAP=mean pulmonary artery pressure; MPI=myocardial performance index; NT-proBNP=N-terminal pro-B-type natriuretic peptide; NYHA=New York Heart Association; PAH=pulmonary arterial hypertension; PH=pulmonary hypertension; PPH=primary pulmonary hypertension; PVR=pulmonary vascular resistance; RA=right atrium; RHC=right heart catheterization; RIMP=right index of myocardial performance; RV=right ventricle; S'=tricuspid lateral annular systolic velocity; sPAP=systolic pulmonary artery pressure; SSc=systemic sclerosis; TAPSE=tricuspid annular plane systolic excursion; TDI=tissue Doppler imaging; TRV=tricuspid regurgitant jet velocity; VSD=ventricular septal defect; VTI<sub>RVOT</sub>=velocity-time integral of right ventricular outflow tract

**Table F-2. Study characteristics table for KQ 2**

Andreassen, 2006 <sup>62</sup> Europe	Adults with suspected chronic precapillary PH N=61 42:19	BNP	Cardiac index Functional class RHC-mPAP RHC-PVR RHC-sPAP RAP	Correlation	Good
		BNP	Mortality	Odds ratio	
Badesch, 2012 <sup>63</sup> Badesch 2011 <sup>64</sup> US/Canada	Adults with PAH N=224 156:68	BNP		Mean change from baseline in response to treatment (ambrisentan)	Good
Barst, 1996 <sup>65</sup> US/Canada	Adults with PPH N=81 59:22	mPAP		Change in mean from baseline in response to therapy (epoprostenol)	Good
Bendayan, 2002 <sup>66</sup> Asia	Adults and children with PAH N=29 25:4	Uric acid	6MWD (absolute) Functional class Mortality RHC-CO RHC-mPAP	Correlation	Good
Benza, 2010 <sup>67</sup> US	Adults with PAH N=2716 NR	BNP >180 BNP <50 Pericardial effusion	Mortality	HR	Good
Bernus, 2009 <sup>68</sup> US	Children with PAH N=78 42:26	BNP	Cardiac index Peak TRV PCWP RHC-mPAP RHC-PVR Right atrial pressure RV size TRV	Correlation	Good
Bharani, 2007 <sup>69</sup> Asia	Adults and children with suspected or symptomatic PAH N=8 4:4	sPAP		Change in mean in response to therapy (tadalafil)	Fair

Borges, 2006 <sup>70</sup> Europe	Chronic PAH N=37 24:13	RIMP/MPI/Tei index TAPSE  TAPSE RV size	6MWD (absolute) RHC-PVR	Correlation  Change in mean in response to therapy (bosentan ± beraprost or iloprost)	Good
Brierre, 2010 <sup>71</sup> Europe	Adults with PAH N=79 36:43	mPAP mPAP ≥ 49 Pericardial effusion RIMP/MPI/Tei index RIMP/MPI/Tei index ≥0.98 TAPSE	Mortality	HR	Good
Bustamante-Labarta, 2002 <sup>72</sup> South America	Adults with PPH N=25 19:6	RA size	Survival free from lung transplant	HR	Good
Campana, 2004 <sup>73</sup> Europe	Adults with pre-capillary PH N=22 14:8	BNP Cardiac index  FAC BNP RV size TAPSE	mPAP Right atrial pressure RVEF TAPSE	Correlation  Changes in means in response to therapy (epoprostenol)	Good
Cella, 2009 <sup>74</sup> Europe	Adults with PAH associated with CTD N=18 13:5	RVSP  Nitric oxide	6MWD (change)	Correlation  Change in mean over time in response to therapy (bosentan)	Good
Channick, 2001 <sup>75</sup> Badesch 2002 <sup>76</sup> US/Europe	Adults with PPH or PAH associated with scleroderma N=32 28:4	mPAP		Change in mean from baseline in response to therapy (bosentan)	Good

Chin, 2007 <sup>77</sup> US	Epoprostenol-treated patients with pulmonary hypertension N=27 19:8	BNP	6MWD (absolute) PCWP RHC-CO RHC-mPAP RHC-PVR Right atrial pressure	Correlation	Good
Dimitroulas, 2007 <sup>78</sup> Europe	Adults with PAH associated with scleroderma N=10 9:1	BNP		Change in median over time in response to therapy (Bosentan)	Good
D'Alto, 2010 <sup>79</sup> Europe	Adults with PAH due to CHD N=32 18:14	BNP		Change in mean in response to therapy (bosentan + sildenafil)	Fair
Dyer, 2006 <sup>80</sup> US	Children with IPAH N=12 NR	RIMP/MPI/Tei index	RHC-mPAP	Correlation	Fair
Elstein, 2004 <sup>81</sup> Asia	Adults and children with Gaucher disease N=47 27:20	BNP	Tricuspid insufficiency	Correlation with stratified TI values	Good
Fahmy Elnoamany, 2007 <sup>82</sup> Africa	Adults with arterial PH with different cardiac pathologies N=53 8:45	Endothelin-1  sPAP	RHC-sPAP RIMP/MPI/Tei Index RVEF sPAP  RHC-sPAP	Correlation	Fair
Feliciano, 2005 <sup>83</sup> Europe	Adults with severe PAH N=11 9:2	RIMP/MPI/Tei index		Change in mean in response to therapy (bosentan or Iloprost)	Good



Fijalkowska, 2006 <sup>84</sup> Europe	Adults with PH N=55 43:12	BNP          FAC BNP BNP Pericardial effusion RA size RIMP/MPI/Tei index RV size Troponin T	6MWD (absolute) Cardiac index Functional class Peak TRV Pericardial effusion RHC-mPAP RHC-PVR Right atrial pressure RIMP/MPI/Tei Index RV size Troponin  Mortality	Correlation          HR	Good
Filusch, 2010 <sup>85</sup> Europe	Adults with PAH N=55 33:22	cTroponin T hsTroponin T BNP	Mortality WHO class	Sensitivity Specificity NPV PPV	Good
Forfia, 2006 <sup>86</sup> US	Adults with PH N=63 52:11	TAPSE  TAPSE	RHC-PVR  Mortality	Correlation  HR	Good
Friedberg, 2006 <sup>87</sup> US	Adults and children who had undergone RHC N=112 48:64	mPAP BNP  sPAP	RHC-mPAP  RHC-sPAP	Correlation	Good
Galie, 2008 <sup>88</sup> Oudiz 2009 <sup>89</sup> Shapiro 2012 <sup>90</sup>  US/Europe/Mexico/ South America/ Australia/NZ	Adults with PAH N=201 168:33	BNP		Change in mean in response to therapy (ambrisentan)	Good

Gan, 2006 <sup>91</sup> Europe	Adults with PH N=30 22:8	BNP	6MWD (absolute) Cardiac index RHC-mPAP RHC-PVR Right atrial pressure RVEF	Correlation	Good
Ghio, 2010 <sup>92</sup> Europe	Adults with IPAH N=59 37:22	FAC Pericardial effusion RIMP/MPI/Tei index sPAP TAPSE	Mortality	HR	Good
Ghofrani, 2002 <sup>93</sup> Europe	Adults with severe precapillary PH. N=20 (36 tests) NR	BNP  cGMP	RHC-PVR Cyclic guanosine monophosphate  RHC-PVR	Correlation	Fair
Goto, 2010 <sup>94</sup> Asia	Adults with PAH N=46 34:12	BNP  sPAP	RHC-mPAP  RHC-sPAP	Correlation	Good
Grapsa, 2007 <sup>95</sup> UK	Adults with PH N=93 50:43	RIMP/MPI/Tei index	Pericardial effusion RA size TRV	Correlation	Good
Grubstein, 2008 <sup>96</sup> Asia	Adults with PH N=38 27:11	sPAP	RHC-sPAP	Correlation	Fair
Haddad, 2009 <sup>97</sup> US	Adults with PAH N=51 35:16	mPAP  sPAP	RHC-mPAP  RHC-sPAP	Correlation	Good
Halank, 2011 <sup>98</sup> Europe	Adults with portopulmonary hypertension N=14 9:5	BNP	Median	Change in median over time in response to therapy (ambrisentan)	Fair
Hampole, 2009 <sup>99</sup> US	Adults with PH N=162 126:36	BNP	Mortality	HR	Good
Heresi, 2012 <sup>100</sup> US	Adults with PAH N=68 62:6	cTnI (detectable vs. nondetectable)	BNP NYHA class RA size 6MWD	Correlation	Good

Heresi, 2010 <sup>101</sup> US	Adults with PPH N=40 37:3	BNP	6MWD (absolute) Cardiac index RHC-mPAP RHC-PVR Right atrial pressure  Mortality	Correlation     HR	Good
Hinderliter, 1997 <sup>102</sup> Other	Adults with PPH N=81 59:22	FAC  Pericardial effusion  RV size  sPAP  RV size FAC TRV	6MWD (absolute) Cardiac index RHC-mPAP Right atrial pressure  6MWD (absolute) Cardiac index (CI) RHC-mPAP Right atrial pressure  6MWD (absolute) Cardiac index RHC-mPAP Right atrial pressure  RHC-sPAP	Correlation  Correlation  Correlation  Correlation  Change in mean from baseline in response to therapy (epoprostenol)	Fair
Hiramoto, 2009 <sup>103</sup> Asia	Adults with PAH N=16 11:5	BNP	Endothelin-1	Changes in mean stratified by % change in ET-1	Fair
Ho, 2009 <sup>104</sup> Asia	Adults with PAH N=6 4:2	RIMP/MPI/Tei Index FAC BNP sPAP RVEF		Changes in median in response to therapy (bosentan)	Good
Homma, 2001 <sup>105</sup> US	Adults with PH N=8 5:3	sPAP	RHC-sPAP	Correlation	Good

Jacobs, 2009 <sup>106</sup> Europe	Adults with idiopathic PAH N=16 13:3	BNP		Change in mean in response to therapy	Fair
Kaya, 2012 <sup>107</sup> NR	Adults and children with Eisenmenger syndrome N=23 13:10	RV size RA size sPAP s-prime		Change in mean over time in response to therapy (bosentan)	Good
Keogh, 2011 <sup>108</sup> Australia/NZ	Adults with PAH N=112 89:23	sPAP		Change in mean in response to therapy (monotherapy vs. combination therapy)	Fair
Knirsch, 2011 <sup>109</sup> Europe	Children with heart disease N=103 NR	BNP		Changes in mean in response to therapy (standardized protocol)	Good
Kopec, 2012 <sup>110</sup> Europe	Adults with Eisenmenger syndrome N=7 4:3	BNP ET-1		Change in median over time in response to therapy (bosentan)	Fair
Lammers, 2009 <sup>111</sup> UK	Children with PH N=50 18:32	BNP	6MWD (absolute) Functional class	Correlation	Good
Langleben, 1999 <sup>112</sup> US/Canada	Patients with PPH N=18 NR	Endothelin-1		Change in mean in response to therapy	Good
Leuchte, 2005 <sup>113</sup> Europe	Adults with PAH N=30 18:12	Change in BNP  BNP	6MWD (absolute) Cardiac index RHC-CO RHC-mPAP RHC-PVR Right atrial pressure	Correlation  Changes in mean levels over time (no specific therapy)	Good
Lorenzen, 2011 <sup>114</sup> Europe	Adults with PAH N=70 48:22	BNP Uric acid	Mortality	HR	Good

Machado, 2006 <sup>29</sup> US	Patients with sickle cell disease N=230 138:92	BNP  BNP ≥160, unadjusted ≥160, adjusted log10, adjusted log10, unadjusted	6MWD (absolute) mPAP PCWP RA size RHC-CO RHC-dPAP RHC-PVR RHC-sPAP RV size TRV  Mortality	Correlation        HR	Poor
Machado, 2004 <sup>115</sup> US	Patients with PAH N=17 17:0	Nitric oxide  sPAP	mPAP  RHC-sPAP	Correlation	Fair
Mahapatra, 2006 <sup>116</sup> US	Adults with PH N=54 41:13	RIMP/MPI/Tei Index RVSP	Mortality	HR	Fair
Mathai, 2011 <sup>117</sup> US	Adults with known or suspected PAH N=50 49:1	FAC Peak TRV Pericardial effusion RA size TAPSE	Mortality	HR	Fair
Mauritz, 2011 <sup>118</sup> Europe	Adults with PAH N=198 149:49	BNP		Baseline means only	Good
McLaughlin, 2010 <sup>119</sup> Frantz, 2012 <sup>120</sup> US/Europe	Adults with PH N=235 191:44	BNP		Median change from baseline in response to treatment (treprostinil)	Good
Michelakis, 2002 <sup>121</sup> Canada	Adults with PH N=13 9:4	cGMP		Acute change in mean levels after dose of various vasodilators (iNO, sildenafil, iNO + sildenafil)	Fair

Minniti, 2009 <sup>122</sup> US	Adults with SCD and PH N=14 10:4	BNP TRV		Change in mean in response to therapy (ambrisentan)	Poor
Montani, 2007 <sup>123</sup> Europe	Adults with PAH N=33 21:12	Endothelin-1	Cardiac index RHC-PVR Right atrial pressure	Correlation	Fair
Morishita, 2009 <sup>124</sup> Asia	Adults and children with PAH N=7 6:1	Pericardial effusion RA size  RA size BNP	Functional class BNP	Correlation  Changes in mean in response to therapy (epoprostenol)	Good
Mukerjee, 2003 <sup>125</sup> Europe	Adults with systemic sclerosis N=23 21:2	BNP	RHC-mPAP RHC-PVR	Correlation	Good
Nagaya, 2000 <sup>126</sup> Asia	Patients with PPH N=60 42:18	ANP  ANP  BNP    BNP	PCWP RHC-CO RHC-mPAP Right atrial pressure  Mortality  PCWP RHC-CO RHC-mPAP RHC-mPAP RHC-PVR Right atrial pressure RV size  Mortality	Correlation  HR  Correlation   HR	Good
Nakayama, 2007 <sup>127</sup> Asia	Children with IPAH N=31 15:16	BNP BNP		Change in mean in response to therapy (epoprostenol)	Fair

Nath, 2005 <sup>128</sup> US	Adults with PPH N=20 16:4	Peak TRV RIMP/MPI/Tei Index RV size  RIMP/MPI/Tei Index RV size sPAP TRV	Functional class	Correlation  Mean changes over time in response to therapy (epoprostenol)	Good
Nickel, 2012 <sup>129</sup> NR	Adults with IPAH N=109 85:24	BNP Uric acid	Mortality	HR	Fair
Nickel, 2008 <sup>130</sup> Europe	Adults with IPAH N=76 52:24	BNP Uric acid	Composite outcome (death or lung transplantation)	HR	Fair
Njama, 2007 <sup>131</sup> Asia	Adults with PH N=90 77:13	Uric acid	Mortality	HR stratified by uric acid levels	Good
Ogawa, 2012 <sup>132</sup> Asia	Adults with pulmonary veno-occlusive or pulmonary capillary hemangiomatosis N=8 4:4	BNP		Change in mean over time in response to therapy (epoprostenol)	Fair
Park, 2004 <sup>133</sup> US	Adults with PAH N=20 16:4	sPAP BNP	Clinical event	Mean levels at baseline and over time stratified by patients with event vs patients without event	Fair
Pyxaras, 2011 <sup>134</sup> Europe	Adults and children with PAH N=60 36:24	sPAP mPAP	RHC-sPAP RHC-mPAP	Correlation	Good
Raymond, 2002 <sup>135</sup> Not reported/Unclear	Adults with PPH N=81 59:22	FAC Peak TRV Pericardial effusion RA size	Mortality Composite outcome (death or transplantation)	HR	Fair

Rhodes, 2011 <sup>136</sup> Europe	Adults with IPAH N=139 98:41	BNP	6MWD (absolute) Cardiac index PCWP RHC-PVR Right atrial pressure  Mortality	Correlation    HR	Good
Sadushi-Kolici, 2012 <sup>137</sup> NR	Adults with PH N=111 77:39	Pericardial effusion	Mortality	HR	Fair
Schumann, 2010 <sup>138</sup> Europe	Adults with PH N=36 17:19	BNP	sPAP	BNP levels stratified by different levels of disease severity	Good
Sebbag, 2001 <sup>139</sup> Canada	Adults and children with PPH N=16 13:3	RIMP/MPI/Tei Index  SPAP		Changes in mean in response to therapy (epoprostenol)	Good
Shimony, 2012 <sup>140</sup> Canada	Adults with PAH N=154 129:25	Pericardial effusion (prevalent v incident)	Mortality	% patients with outcome	Fair
Simeoni, 2008 <sup>49</sup> Europe	Adults with systemic sclerosis and PH N=20 18:2	BNP		Changes in mean in response to therapy (bosentan)	Good
Soon, 2011 <sup>141</sup> UK	Adults with PH N=63 42:21	BNP		Determination of most accurate log transformed dichotomous BNP variables to predict events	Good
Souza, 2007 <sup>142</sup> Not reported/Unclear	Adults with IPAH N=42 10:32	BNP	6MWD (absolute) Cardiac index Functional class RHC-mPAP RHC-PVR Right atrial pressure	Correlation	Good



Taguchi, 2012 <sup>143</sup> Asia	Adults and children with IPAH N=65 51:14	BNP		Change in mean over time in response to combination therapy	Good
Takatsuki, 2012 <sup>144</sup> US	Children with PAH N=33 22:11	TRJv RV size BNP		Change in mean over time in response to therapy (tadalafil)	Good
Takatsuki, 2012 <sup>145</sup> US	Children with PAH N=38 19:19	BNP		Change in mean over time in response to therapy (transition to or addition of ambrisentan)	Good
Takatsuki, 2012 <sup>146</sup> US	Children with PAH N=88 46:42	BNP (BNP and NT-proBNP)	6MWD RHC-mPAP RHC-RAP RHC-PVR RHC-CI TRJv	Correlation	Good
Takeda, 2010 <sup>147</sup> Asia	Adults with PAH N=37 29:8	BNP	Mortality	HR	Good
Torbicki, 2003 <sup>148</sup> Europe	Adults with PAH N=56 43:13	FAC BNP Pericardial effusion RA size Troponin T	Mortality	HR	Good
Utsunomiya, 2011 <sup>149</sup> Asia	Adults with PH N=50 39:11	BNP RA size RIMP/MPI/Tei Index	Mortality	HR	Fair
Utsunomiya, 2009 <sup>150</sup> Asia	Adults with chronic PH N=50 39:11	RA size	Right atrial pressure RIMP/MPI/Tei Index	Correlation	Good

Van Albada, 2008 <sup>151</sup> Europe	Children with PAH N=29 18:11	BNP  Uric acid	6MWD (absolute) 6MWD (change) Functional class Mortality Cardiac index RHC-mPAP RHC-PVR Mortality	Correlation	Good
Vizza, 2012 <sup>152</sup> Europe	Adults with IPAH N=44 37:7	ET-1  BNP	WHO FC BNP RHC-mPAP RHC-CI RHC-PVR Clinical worsening Clinical worsening	Correlation  OR	Good
Vizza, 2008 <sup>153</sup> Europe	Adults with PAH associated with CTD N=25 21:4	Endothelin-1	BNP	Correlation	Good
Voelkel, 2000 <sup>154</sup> US	Patients with PH N=191 NR	Uric acid	RHC-mPAP Right atrial pressure	Correlation	Good
Williams, 2006 <sup>61</sup> UK	Adults with systemic sclerosis N=109 88:21	BNP  BNP 10-fold increase baseline levels 10-fold increase baseline levels	Cardiac index RHC-mPAP RHC-PVR Right atrial pressure  Mortality	Correlation  HR	Fair
Wilkins, 2005 <sup>155</sup> UK	Adults with IPAH or PAH associated with CTD N=26 21:5	RV size Cardiac index RIMP/MPI/Tei Index RA size BNP		Change in mean from baseline in response to therapy (bosentan)	Good

Yamada, 2012 <sup>156</sup> Asia	Adults and children with IPAH N=41 29:12	BNP Uric acid	Mortality Hospitalization	HR	Good
Yanagisawa, 2012 <sup>157</sup> Asia	Adults with PAH N=46 38:8	BNP	Mortality	HR	Good
Yang, 2012 <sup>158</sup> Asia	Adults and children with Eisenmenger syndrome N=12 9:3	RV size mPAP		Change in mean over time in response to therapy (iloprost)	Fair
Yoshida, 2012 <sup>159</sup> Asia	Adults with PAH N=21 18:3	BNP mPAP		Mean change from baseline in response to treatment (ambrisentan)	Fair
Zafir, 2007 <sup>160</sup> Asia	Adults with PPH +/- collagen vascular disease N=29 22:7	RA size  RIMP/MPI/Tei Index  RVEF	6MWD (absolute) Functional class  6MWD (absolute)  Functional class	Correlation	Good
Zeng, 2011 <sup>161</sup> Asia	Adults and children with IPAH N=95 61:34	BNP		Means stratified by survivor/nonsurvivor	Good
Zhao, 2012 <sup>162</sup> Asia	Adults and children with IPAH N=76 56:20	Uric acid	Mortality	HR	Good

Abbreviations: 6MWD=6-minute walk distance; BNP=brain natriuretic peptide; CHD=congenital heart disease; CHF=congestive heart failure; CI=cardiac index; CTD=connective tissue disease; CTEPH=chronic thromboembolic pulmonary hypertension; CVD=collagen vascular disease; DLCO=diffusion capacity of the lung for carbon monoxide; FAC=fractional area change; HR=hazard ratio; IPAH=idiopathic pulmonary arterial hypertension; mPAP=mean pulmonary artery pressure; MPI=myocardial performance index; NPV=negative predictive value; NT-proBNP=N-terminal pro-B-type natriuretic peptide; NYHA=New York Heart Association; PAH=pulmonary arterial hypertension; PH=pulmonary hypertension; PPH=primary pulmonary hypertension; PPV=positive predictive value; PVR=pulmonary vascular resistance; RA=right atrium; RHC=right heart catheterization; RIMP=right index of myocardial performance; RV=right ventricle; S'=tricuspid lateral annular systolic velocity; RVEF= right ventricular ejection fraction ; sPAP=systolic pulmonary artery pressure; SSc=systemic sclerosis; TAPSE=tricuspid annular plane systolic excursion; TDI=tissue Doppler imaging; TRV=tricuspid regurgitant jet velocity; VSD=ventricular septal defect; VTI<sub>RVOT</sub>=velocity-time integral of right ventricular outflow tract

## References Cited in Appendix F

1. Ajami GH, Cheriki S, Amoozgar H, et al. Accuracy of doppler-derived estimation of pulmonary vascular resistance in congenital heart disease: An index of operability. *Pediatr Cardiol.* 2011;32(8):1168-1174. PMID: 21779967.
2. Allanore Y, Borderie D, Avouac J, et al. High N-terminal pro-brain natriuretic peptide levels and low diffusing capacity for carbon monoxide as independent predictors of the occurrence of precapillary pulmonary arterial hypertension in patients with systemic sclerosis. *Arthritis Rheum.* 2008;58(1):284-91. PMID: 18163505.
3. Arcasoy SM, Christie JD, Ferrari VA, et al. Echocardiographic assessment of pulmonary hypertension in patients with advanced lung disease. *Am J Respir Crit Care Med.* 2003;167(5):735-40. PMID: 12480614.
4. Bogdan M, Humbert M, Francoual J, et al. Urinary cGMP concentrations in severe primary pulmonary hypertension. *Thorax.* 1998;53(12):1059-62. PMID: 10195079.
5. Bonderman D, Wexberg P, Martischnig AM, et al. A noninvasive algorithm to exclude pre-capillary pulmonary hypertension. *Eur Respir J.* 2011;37(5):1096-103. PMID: 20693249.
6. Cavagna L, Caporali R, Klersy C, et al. Comparison of brain natriuretic peptide (BNP) and NT-proBNP in screening for pulmonary arterial hypertension in patients with systemic sclerosis. *J Rheumatol.* 2010;37(10):2064-70. PMID: 20634241.
7. Cevik A, Kula S, Olgunturk R, et al. Quantitative Evaluation of Right Ventricle Function by Transthoracic Echocardiography in Childhood Congenital Heart Disease Patients with Pulmonary Hypertension. *Echocardiography.* 2012. PMID: 22494051.
8. Ciurzynski M, Bienias P, Irzyk K, et al. Usefulness of echocardiography in the identification of an excessive increase in pulmonary arterial pressure in patients with systemic sclerosis. *Kardiol Pol.* 2011;69(1):9-15. PMID: 21267956.
9. Colle IO, Moreau R, Godinho E, et al. Diagnosis of portopulmonary hypertension in candidates for liver transplantation: a prospective study. *Hepatology.* 2003;37(2):401-9. PMID: 12540791.
10. Condliffe R, Radon M, Hurdman J, et al. CT pulmonary angiography combined with echocardiography in suspected systemic sclerosis-associated pulmonary arterial hypertension. *Rheumatology (Oxford).* 2011;50(8):1480-6. PMID: 21447566.
11. Dahiya A, Vollbon W, Jellis C, et al. Echocardiographic assessment of raised pulmonary vascular resistance: application to diagnosis and follow-up of pulmonary hypertension. *Heart.* 2010;96(24):2005-9. PMID: 21088122.
12. Denton CP, Cailes JB, Phillips GD, et al. Comparison of Doppler echocardiography and right heart catheterization to assess pulmonary hypertension in systemic sclerosis. *Br J Rheumatol.* 1997;36(2):239-43. PMID: 9133938.
13. Farber HW, Foreman AJ, Miller DP, et al. REVEAL Registry: correlation of right heart catheterization and echocardiography in patients with pulmonary arterial hypertension. *Congest Heart Fail.* 2011;17(2):56-64. PMID: 21449993.
14. Fisher MR, Forfia PR, Chamera E, et al. Accuracy of Doppler echocardiography in the hemodynamic assessment of pulmonary hypertension. *Am J Respir Crit Care Med.* 2009;179(7):615-21. PMID: 19164700.
15. Fitzgerald M, Fagan K, Herbert DE, et al. Misclassification of pulmonary hypertension in adults with sickle hemoglobinopathies using doppler echocardiography. *South Med J.* 2012;105(6):300-305. PMID: 22665152.
16. Fonseca GH, Souza R, Salemi VM, et al. Pulmonary hypertension diagnosed by right heart catheterisation in sickle cell disease. *Eur Respir J.* 2012;39(1):112-8. PMID: 21778170.
17. Frea S, Capriolo M, Marra WG, et al. Echo Doppler predictors of pulmonary artery hypertension in patients with systemic sclerosis. *Echocardiography.* 2011;28(8):860-9. PMID: 21906161.

18. Fukuda Y, Tanaka H, Sugiyama D, et al. Utility of right ventricular free wall speckle-tracking strain for evaluation of right ventricular performance in patients with pulmonary hypertension. *J Am Soc Echocardiogr.* 2011;24(10):1101-1108. PMID: 21775102.
19. Ghio S, Matteo AD, Scelsi L, et al. Plasma brain natriuretic peptide is a marker of right ventricular overload in pulmonary hypertension associated to HIV infection. *Eur Heart J Suppl.* 2004;6(6):F35-F39.
20. Gialafos EJ, Moyssakis I, Psaltopoulou T, et al. Circulating tissue inhibitor of matrix metalloproteinase-4 (TIMP-4) in systemic sclerosis patients with elevated pulmonary arterial pressure. *Mediators Inflamm.* 2008;2008.
21. Hachulla E, Gressin V, Guillemin L, et al. Early detection of pulmonary arterial hypertension in systemic sclerosis: a French nationwide prospective multicenter study. *Arthritis Rheum.* 2005;52(12):3792-800. PMID: 16320330.
22. Hammerstingl C, Schueler R, Bors L, et al. Diagnostic value of echocardiography in the diagnosis of pulmonary hypertension. *PLoS ONE.* 2012;7(6). PMID: 22685577.
23. Hsu VM, Moreyra AE, Wilson AC, et al. Assessment of pulmonary arterial hypertension in patients with systemic sclerosis: comparison of noninvasive tests with results of right-heart catheterization. *J Rheumatol.* 2008;35(3):458-65. PMID: 18203320.
24. Hua R, Sun YW, Wu ZY, et al. Role of 2-dimensional Doppler echo-cardiography in screening portopulmonary hypertension in portal hypertension patients. *Hepatobiliary Pancreat Dis Int.* 2009;8(2):157-61. PMID: 19357029.
25. Jansa P, Becvar R, Ambroz D, et al. Pulmonary arterial hypertension associated with systemic sclerosis in the Czech Republic. *Clin Rheumatol.* 2012;31(3):557-61. PMID: 22105781.
26. Kovacs G, Maier R, Aberer E, et al. Assessment of pulmonary arterial pressure during exercise in collagen vascular disease: echocardiography vs right-sided heart catheterization. *Chest.* 2010;138(2):270-8. PMID: 20418368.
27. Lindqvist P, Soderberg S, Gonzalez MC, et al. Echocardiography based estimation of pulmonary vascular resistance in patients with pulmonary hypertension: a simultaneous Doppler echocardiography and cardiac catheterization study. *Eur J Echocardiogr.* 2011;12(12):961-6. PMID: 22011836.
28. Low AJ, Fowler D, Manghani MK, et al. Screening and Treating Pulmonary Arterial Hypertension in a Tertiary Hospital -based Multidisciplinary Clinic - The First 200 Patients. *Intern Med J.* 2011. PMID: 22032309.
29. Machado RF, Anthi A, Steinberg MH, et al. N-terminal pro-brain natriuretic peptide levels and risk of death in sickle cell disease. *JAMA.* 2006;296(3):310-8. PMID: 16849664.
30. McLean AS, Ting I, Huang SJ, et al. The use of the right ventricular diameter and tricuspid annular tissue Doppler velocity parameter to predict the presence of pulmonary hypertension. *Eur J Echocardiogr.* 2007;8(2):128-36. PMID: 16672193.
31. Mourani PM, Sontag MK, Younoszai A, et al. Clinical utility of echocardiography for the diagnosis and management of pulmonary vascular disease in young children with chronic lung disease. *Pediatrics.* 2008;121(2):317-25. PMID: 18245423.
32. Mukerjee D, St George D, Knight C, et al. Echocardiography and pulmonary function as screening tests for pulmonary arterial hypertension in systemic sclerosis. *Rheumatology (Oxford).* 2004;43(4):461-6. PMID: 15024134.
33. Murata I, Takenaka K, Yoshinoya S, et al. Clinical evaluation of pulmonary hypertension in systemic sclerosis and related disorders. A Doppler echocardiographic study of 135 Japanese patients. *Chest.* 1997;111(1):36-43. PMID: 8995990.
34. Nakayama Y, Sugimachi M, Nakanishi N, et al. Noninvasive differential diagnosis between chronic pulmonary thromboembolism and primary pulmonary hypertension by means of Doppler ultrasound measurement. *J Am Coll Cardiol.* 1998;31(6):1367-71. PMID: 9581735.

35. Nogami M, Ohno Y, Koyama H, et al. Utility of phase contrast MR imaging for assessment of pulmonary flow and pressure estimation in patients with pulmonary hypertension: comparison with right heart catheterization and echocardiography. *J Magn Reson Imaging*. 2009;30(5):973-80. PMID: 19856412.
36. Phung S, Strange G, Chung LP, et al. Prevalence of pulmonary arterial hypertension in an Australian scleroderma population: screening allows for earlier diagnosis. *Intern Med J*. 2009;39(10):682-91. PMID: 19220532.
37. Pilatis ND, Jacobs LE, Rerkpattanapipat P, et al. Clinical predictors of pulmonary hypertension in patients undergoing liver transplant evaluation. *Liver Transpl*. 2000;6(1):85-91. PMID: 10648583.
38. Rajagopalan N, Simon MA, Suffoletto MS, et al. Noninvasive estimation of pulmonary vascular resistance in pulmonary hypertension. *Echocardiography*. 2009;26(5):489-94. PMID: 19054039.
39. Rajagopalan N, Saxena N, Simon MA, et al. Correlation of tricuspid annular velocities with invasive hemodynamics in pulmonary hypertension. *Congest Heart Fail*. 2007;13(4):200-4. PMID: 17673871.
40. Rajaram S, Swift AJ, Capener D, et al. Comparison of the diagnostic utility of cardiac magnetic resonance imaging, computed tomography, and echocardiography in assessment of suspected pulmonary arterial hypertension in patients with connective tissue disease. *J Rheumatol*. 2012;39(6):1265-1274. PMID: 22589263.
41. Rich JD, Shah SJ, Swamy RS, et al. Inaccuracy of Doppler echocardiographic estimates of pulmonary artery pressures in patients with pulmonary hypertension: implications for clinical practice. *Chest*. 2011;139(5):988-93. PMID: 20864617.
42. Roeleveld RJ, Marcus JT, Boonstra A, et al. A comparison of noninvasive MRI-based methods of estimating pulmonary artery pressure in pulmonary hypertension. *J Magn Reson Imaging*. 2005;22(1):67-72. PMID: 15971176.
43. Roule V, Labombarda F, Pellissier A, et al. Echocardiographic assessment of pulmonary vascular resistance in pulmonary arterial hypertension. *Cardiovasc Ultrasound*. 2010;8:21. PMID: 20529278.
44. Ruan Q, Nagueh SF. Clinical application of tissue Doppler imaging in patients with idiopathic pulmonary hypertension. *Chest*. 2007;131(2):395-401. PMID: 17296639.
45. Ruiz-Irastorza G, Garmendia M, Villar I, et al. Pulmonary hypertension in systemic lupus erythematosus: prevalence, predictors and diagnostic strategy. *Autoimmunity Reviews*. 2012. PMID: 22841984.
46. Sanli C, Oguz D, Olgunturk R, et al. Elevated Homocysteine and Asymmetric Dimethyl Arginine Levels in Pulmonary Hypertension Associated With Congenital Heart Disease. *Pediatr Cardiol*. 2012;1-9. PMID: 22526220.
47. Selby VN, Scherzer R, Barnett CF, et al. Doppler echocardiography does not accurately estimate pulmonary artery systolic pressure in HIV-infected patients. *AIDS*. 2012. PMID: 22781217.
48. Selimovic N, Rundqvist B, Bergh CH, et al. Assessment of pulmonary vascular resistance by Doppler echocardiography in patients with pulmonary arterial hypertension. *J Heart Lung Transplant*. 2007;26(9):927-34. PMID: 17845932.
49. Simeoni S, Lippi G, Puccetti A, et al. N-terminal pro-BNP in sclerodermic patients on bosentan therapy for PAH. *Rheumatol Int*. 2008;28(7):657-60. PMID: 18092166.
50. Steen V, Chou M, Shanmugam V, et al. Exercise-induced pulmonary arterial hypertension in patients with systemic sclerosis. *Chest*. 2008;134(1):146-51. PMID: 18403670.
51. Takatsuki S, Nakayama T, Jone PN, et al. Tissue Doppler Imaging Predicts Adverse Outcome in Children with Idiopathic Pulmonary Arterial Hypertension. *J Pediatr*. 2012. PMID: 33748515.
52. Tei C, Dujardin KS, Hodge DO, et al. Doppler echocardiographic index for assessment of global right ventricular function. *J Am Soc Echocardiogr*. 1996;9(6):838-47. PMID: 8943444.

53. Thakkar V, Stevens WM, Prior D, et al. N-terminal pro-brain natriuretic peptide in a novel screening algorithm for pulmonary arterial hypertension in systemic sclerosis: A case-control study. *Arthritis Research and Therapy*. 2012;14(3). PMID: 22691291.
54. Tian Z, Liu YT, Fang Q, et al. Hemodynamic parameters obtained by transthoracic echocardiography and right heart catheterization: a comparative study in patients with pulmonary hypertension. *Chin Med J (Engl)*. 2011;124(12):1796-801. PMID: 21740835.
55. Torregrosa M, Genesca J, Gonzalez A, et al. Role of Doppler echocardiography in the assessment of portopulmonary hypertension in liver transplantation candidates. *Transplantation*. 2001;71(4):572-4. PMID: 11258439.
56. Toyono M, Harada K, Tamura M, et al. Paradoxical relationship between B-type natriuretic peptide and pulmonary vascular resistance in patients with ventricular septal defect and concomitant severe pulmonary hypertension. *Pediatr Cardiol*. 2008;29(1):65-9. PMID: 17786380.
57. Tutar HE, Imamoglu A, Atalay S, et al. Plasma endothelin-1 levels in patients with left-to-right shunt with or without pulmonary hypertension. *Int J Cardiol*. 1999;70(1):57-62. PMID: 10402046.
58. Vlahos AP, Feinstein JA, Schiller NB, et al. Extension of Doppler-derived echocardiographic measures of pulmonary vascular resistance to patients with moderate or severe pulmonary vascular disease. *J Am Soc Echocardiogr*. 2008;21(6):711-4. PMID: 18187297.
59. Vonk MC, Sander MH, van den Hoogen FH, et al. Right ventricle Tei-index: a tool to increase the accuracy of non-invasive detection of pulmonary arterial hypertension in connective tissue diseases. *Eur J Echocardiogr*. 2007;8(5):317-21. PMID: 16846757.
60. Willens HJ, Chirinos JA, Gomez-Marin O, et al. Noninvasive differentiation of pulmonary arterial and venous hypertension using conventional and Doppler tissue imaging echocardiography. *J Am Soc Echocardiogr*. 2008;21(6):715-9. PMID: 18325734.
61. Williams MH, Handler CE, Akram R, et al. Role of N-terminal brain natriuretic peptide (N-TproBNP) in scleroderma-associated pulmonary arterial hypertension. *Eur Heart J*. 2006;27(12):1485-94. PMID: 16682379.
62. Andreassen AK, Wergeland R, Simonsen S, et al. N-terminal pro-B-type natriuretic peptide as an indicator of disease severity in a heterogeneous group of patients with chronic precapillary pulmonary hypertension. *Am J Cardiol*. 2006;98(4):525-9. PMID: 16893710.
63. Badesch DB, Feldman J, Keogh A, et al. ARIES-3: ambrisentan therapy in a diverse population of patients with pulmonary hypertension. *Cardiovasc Ther*. 2012;30(2):93-9. PMID: 21884013.
64. Badesch DB, Feldman J, Keogh A, et al. ARIES-3: Ambrisentan Therapy in a Diverse Population of Patients with Pulmonary Hypertension. *Cardiovasc Ther*. 2011. PMID: 21884013.
65. Barst RJ, Rubin LJ, Long WA, et al. A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension. The Primary Pulmonary Hypertension Study Group. *N Engl J Med*. 1996;334(5):296-302. PMID: 8532025.
66. Bendayan D, Shitrit D, Ygla M, et al. Hyperuricemia as a prognostic factor in pulmonary arterial hypertension. *Respir Med*. 2003;97(2):130-3. PMID: 12587962.
67. Benza RL, Miller DP, Gomberg-Maitland M, et al. Predicting survival in pulmonary arterial hypertension: insights from the Registry to Evaluate Early and Long-Term Pulmonary Arterial Hypertension Disease Management (REVEAL). *Circulation*. 2010;122(2):164-72. PMID: 20585012.
68. Bernus A, Wagner BD, Accurso F, et al. Brain natriuretic peptide levels in managing pediatric patients with pulmonary arterial hypertension. *Chest*. 2009;135(3):745-51. PMID: 18849405.
69. Bharani A, Patel A, Saraf J, et al. Efficacy and safety of PDE-5 inhibitor tadalafil in pulmonary arterial hypertension. *Indian Heart J*. 2007;59(4):323-8. PMID: 19126937.

70. Borges AC, Knebel F, Eddicks S, et al. Right ventricular function assessed by two-dimensional strain and tissue Doppler echocardiography in patients with pulmonary arterial hypertension and effect of vasodilator therapy. *Am J Cardiol.* 2006;98(4):530-4. PMID: 16893711.
71. Brierre G, Blot-Souletie N, Degano B, et al. New echocardiographic prognostic factors for mortality in pulmonary arterial hypertension. *Eur J Echocardiogr.* 2010;11(6):516-22. PMID: 20185528.
72. Bustamante-Labarta M, Perrone S, De La Fuente RL, et al. Right atrial size and tricuspid regurgitation severity predict mortality or transplantation in primary pulmonary hypertension. *J Am Soc Echocardiogr.* 2002;15(10 Pt 2):1160-4. PMID: 12411899.
73. Campana C, Pasotti M, Monti L, et al. The evaluation of right ventricular performance in different clinical models of heart failure. *Eur Heart J Suppl.* 2004;6(6):F61-F67.
74. Cella G, Vianello F, Cozzi F, et al. Effect of bosentan on plasma markers of endothelial cell activity in patients with secondary pulmonary hypertension related to connective tissue diseases. *J Rheumatol.* 2009;36(4):760-7. PMID: 19208592.
75. Channick RN, Simonneau G, Sitbon O, et al. Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: a randomised placebo-controlled study. *Lancet.* 2001;358(9288):1119-23. PMID: 11597664.
76. Badesch DB, Bodin F, Channick RN, et al. Complete results of the first randomized, placebo-controlled study of bosentan, a dual endothelin receptor antagonist, in pulmonary arterial hypertension. *Curr Ther Res Clin Exp.* 2002;63(4):227-246.
77. Chin KM, Channick RN, Kim NH, et al. Central venous blood oxygen saturation monitoring in patients with chronic pulmonary arterial hypertension treated with continuous IV epoprostenol: correlation with measurements of hemodynamics and plasma brain natriuretic peptide levels. *Chest.* 2007;132(3):786-92. PMID: 17646224.
78. Dimitroulas T, Giannakoulas G, Karvounis H, et al. N-terminal probrain natriuretic peptide as a biochemical marker in the evaluation of bosentan treatment in systemic-sclerosis-related pulmonary arterial hypertension. *Clin Rheumatol.* 2008;27(5):655-8. PMID: 18204995.
79. D'Alto M, Romeo E, Argiento P, et al. Bosentan-sildenafil association in patients with congenital heart disease-related pulmonary arterial hypertension and Eisenmenger physiology. *Int J Cardiol.* 2010. PMID: 21081251.
80. Dyer KL, Pauliks LB, Das B, et al. Use of myocardial performance index in pediatric patients with idiopathic pulmonary arterial hypertension. *J Am Soc Echocardiogr.* 2006;19(1):21-7. PMID: 16423665.
81. Elstein D, Nir A, Klutstein M, et al. N-brain natriuretic peptide: correlation with tricuspid insufficiency in Gaucher disease. *Pulm Pharmacol Ther.* 2004;17(5):319-23. PMID: 15477128.
82. Fahmy Elnoamany M, Abdelraouf Dawood A. Right ventricular myocardial isovolumic relaxation time as novel method for evaluation of pulmonary hypertension: correlation with endothelin-1 levels. *J Am Soc Echocardiogr.* 2007;20(5):462-9. PMID: 17484984.
83. Feliciano J, Cacela D, Agapito A, et al. Selective pulmonary vasodilators for severe pulmonary hypertension: comparison between endpoints. *Rev Port Cardiol.* 2005;24(3):399-404. PMID: 15929623.
84. Fijalkowska A, Kurzyna M, Torbicki A, et al. Serum N-terminal brain natriuretic peptide as a prognostic parameter in patients with pulmonary hypertension. *Chest.* 2006;129(5):1313-21. PMID: 16685024.
85. Filusch A, Giannitsis E, Katus HA, et al. High-sensitive troponin T: a novel biomarker for prognosis and disease severity in patients with pulmonary arterial hypertension. *Clin Sci (Lond).* 2010;119(5):207-13. PMID: 20412051.
86. Forfia PR, Fisher MR, Mathai SC, et al. Tricuspid annular displacement predicts survival in pulmonary hypertension. *Am J Respir Crit Care Med.* 2006;174(9):1034-41. PMID: 16888289.



87. Friedberg MK, Feinstein JA, Rosenthal DN. A novel echocardiographic Doppler method for estimation of pulmonary arterial pressures. *J Am Soc Echocardiogr*. 2006;19(5):559-62. PMID: 16644441.
88. Galie N, Olschewski H, Oudiz RJ, et al. Ambrisentan for the treatment of pulmonary arterial hypertension: results of the ambrisentan in pulmonary arterial hypertension, randomized, double-blind, placebo-controlled, multicenter, efficacy (ARIES) study 1 and 2. *Circulation*. 2008;117(23):3010-9. PMID: 18506008.
89. Oudiz RJ, Galie N, Olschewski H, et al. Long-term ambrisentan therapy for the treatment of pulmonary arterial hypertension. *J Am Coll Cardiol*. 2009;54(21):1971-81. PMID: 19909879.
90. Shapiro S, Pollock DM, Gillies H, et al. Frequency of Edema in Patients With Pulmonary Arterial Hypertension Receiving Ambrisentan. *Am J Cardiol*. 2012. PMID: 22858181.
91. Gan CT, McCann GP, Marcus JT, et al. NT-proBNP reflects right ventricular structure and function in pulmonary hypertension. *Eur Respir J*. 2006;28(6):1190-4. PMID: 16971413.
92. Ghio S, Klersy C, Magrini G, et al. Prognostic relevance of the echocardiographic assessment of right ventricular function in patients with idiopathic pulmonary arterial hypertension. *Int J Cardiol*. 2010;140(3):272-8. PMID: 19070379.
93. Ghofrani HA, Wiedemann R, Rose F, et al. Lung cGMP release subsequent to NO inhalation in pulmonary hypertension: responders versus nonresponders. *Eur Respir J*. 2002;19(4):664-71. PMID: 11998996.
94. Goto K, Arai M, Watanabe A, et al. Utility of echocardiography versus BNP level for the prediction of pulmonary arterial pressure in patients with pulmonary arterial hypertension. *Int Heart J*. 2010;51(5):343-7. PMID: 20966607.
95. Grapsa I, Pavlopoulos H, Dawson D, et al. Retrospective study of pulmonary hypertensive patients: is right ventricular myocardial performance index a vital prognostic factor? *Hellenic J Cardiol*. 2007;48(3):152-60. PMID: 17629178.
96. Grubstein A, Benjaminov O, Dayan DB, et al. Computed tomography angiography in pulmonary hypertension. *Isr Med Assoc J*. 2008;10(2):117-20. PMID: 18432023.
97. Haddad F, Zamanian R, Beraud AS, et al. A novel non-invasive method of estimating pulmonary vascular resistance in patients with pulmonary arterial hypertension. *J Am Soc Echocardiogr*. 2009;22(5):523-9. PMID: 19307098.
98. Halank M, Knudsen L, Seyfarth HJ, et al. Ambrisentan improves exercise capacity and symptoms in patients with portopulmonary hypertension. *Z Gastroenterol*. 2011;49(9):1258-62. PMID: 21887662.
99. Hampole CV, Mehrotra AK, Thenappan T, et al. Usefulness of red cell distribution width as a prognostic marker in pulmonary hypertension. *Am J Cardiol*. 2009;104(6):868-72. PMID: 19733726.
100. Heresi GA, Tang WH, Aytekin M, et al. Sensitive cardiac troponin I predicts poor outcomes in pulmonary arterial hypertension. *Eur Respir J*. 2012;39(4):939-44. PMID: 21885398.
101. Heresi GA, Aytekin M, Newman J, et al. CXC-chemokine ligand 10 in idiopathic pulmonary arterial hypertension: marker of improved survival. *Lung*. 2010;188(3):191-7. PMID: 20186422.
102. Hinderliter AL, Willis PWt, Barst RJ, et al. Effects of long-term infusion of prostacyclin (epoprostenol) on echocardiographic measures of right ventricular structure and function in primary pulmonary hypertension. Primary Pulmonary Hypertension Study Group. *Circulation*. 1997;95(6):1479-86. PMID: 9118516.
103. Hiramoto Y, Shioyama W, Higuchi K, et al. Clinical significance of plasma endothelin-1 level after bosentan administration in pulmonary arterial hypertension. *J Cardiol*. 2009;53(3):374-80. PMID: 19477379.

104. Ho WJ, Hsu TS, Tsay PK, et al. Serial plasma brain natriuretic peptide testing in clinical management of pulmonary arterial hypertension. *Acta Cardiol Sin.* 2009;25(3):147-153.
105. Homma A, Anzueto A, Peters JJ, et al. Pulmonary artery systolic pressures estimated by echocardiogram vs cardiac catheterization in patients awaiting lung transplantation. *J Heart Lung Transplant.* 2001;20(8):833-9. PMID: 11502405.
106. Jacobs W, Boonstra A, Marcus JT, et al. Addition of prostanoids in pulmonary hypertension deteriorating on oral therapy. *J Heart Lung Transplant.* 2009;28(3):280-4. PMID: 19285621.
107. Kaya MG, Lam YY, Erer B, et al. Long-term effect of bosentan therapy on cardiac function and symptomatic benefits in adult patients with Eisenmenger syndrome. *J Card Fail.* 2012;18(5):379-384. PMID: 22555267.
108. Keogh A, Strange G, Kotlyar E, et al. Survival after the initiation of combination therapy in patients with pulmonary arterial hypertension: an Australian collaborative report. *Intern Med J.* 2011;41(3):235-44. PMID: 21118410.
109. Knirsch W, Hausermann E, Fasnacht M, et al. Plasma B-type natriuretic peptide levels in children with heart disease. *Acta Paediatr Int J Paediatr.* 2011;100(9):1213-1216.
110. Kopeck G, Tyrka A, Miszalski-Jamka T, et al. Changes in Exercise Capacity and Cardiac Performance in a Series of Patients with Eisenmenger's Syndrome Transitioned from Selective to Dual Endothelin Receptor Antagonist. *Heart Lung and Circulation.* 2012. PMID: 22819097.
111. Lammers AE, Hislop AA, Haworth SG. Prognostic value of B-type natriuretic peptide in children with pulmonary hypertension. *Int J Cardiol.* 2009;135(1):21-6. PMID: 18599134.
112. Langleben D, Barst RJ, Badesch D, et al. Continuous infusion of epoprostenol improves the net balance between pulmonary endothelin-1 clearance and release in primary pulmonary hypertension. *Circulation.* 1999;99(25):3266-71. PMID: 10385501.
113. Leuchte HH, Holzapfel M, Baumgartner RA, et al. Characterization of brain natriuretic peptide in long-term follow-up of pulmonary arterial hypertension. *Chest.* 2005;128(4):2368-74. PMID: 16236896.
114. Lorenzen JM, Nickel N, Kramer R, et al. Osteopontin in patients with idiopathic pulmonary hypertension. *Chest.* 2011;139(5):1010-7. PMID: 20947652.
115. Machado RF, Londhe Nerkar MV, Dweik RA, et al. Nitric oxide and pulmonary arterial pressures in pulmonary hypertension. *Free Radic Biol Med.* 2004;37(7):1010-7. PMID: 15336317.
116. Mahapatra S, Nishimura RA, Oh JK, et al. The prognostic value of pulmonary vascular capacitance determined by Doppler echocardiography in patients with pulmonary arterial hypertension. *J Am Soc Echocardiogr.* 2006;19(8):1045-50. PMID: 16880101.
117. Mathai SC, Sibley CT, Forfia PR, et al. Tricuspid annular plane systolic excursion is a robust outcome measure in systemic sclerosis-associated pulmonary arterial hypertension. *J Rheumatol.* 2011;38(11):2410-8. PMID: 21965638.
118. Mauritz GJ, Rizopoulos D, Groepenhoff H, et al. Usefulness of serial N-terminal ProB-type natriuretic peptide measurements for determining prognosis in patients with pulmonary arterial hypertension. *Am J Cardiol.* 2011;108(11):1645-1650. PMID: 21890089.
119. McLaughlin VV, Benza RL, Rubin LJ, et al. Addition of inhaled treprostinil to oral therapy for pulmonary arterial hypertension: a randomized controlled clinical trial. *J Am Coll Cardiol.* 2010;55(18):1915-22. PMID: 20430262.
120. Frantz RP, McDevitt S, Walker S. Baseline NT-proBNP correlates with change in 6-minute walk distance in patients with pulmonary arterial hypertension in the pivotal inhaled treprostinil study TRIUMPH-1. *J Heart Lung Transplant.* 2012;31(8):811-816. PMID: 22759797.

121. Michelakis E, Tymchak W, Lien D, et al. Oral sildenafil is an effective and specific pulmonary vasodilator in patients with pulmonary arterial hypertension: comparison with inhaled nitric oxide. *Circulation*. 2002;105(20):2398-403. PMID: 12021227.
122. Minniti CP, Machado RF, Coles WA, et al. Endothelin receptor antagonists for pulmonary hypertension in adult patients with sickle cell disease. *Br J Haematol*. 2009;147(5):737-43. PMID: 19775299.
123. Montani D, Souza R, Binkert C, et al. Endothelin-1/endothelin-3 ratio: a potential prognostic factor of pulmonary arterial hypertension. *Chest*. 2007;131(1):101-8. PMID: 17218562.
124. Morishita T, Miyaji K, Akao I, et al. The ratio of the atrial areas reflects the clinical status of patients with pulmonary arterial hypertension. *J Med Ultrason*. 2009;36(4):201-206.
125. Mukerjee D, Yap LB, Holmes AM, et al. Significance of plasma N-terminal pro-brain natriuretic peptide in patients with systemic sclerosis-related pulmonary arterial hypertension. *Respir Med*. 2003;97(11):1230-6. PMID: 14635979.
126. Nagaya N, Nishikimi T, Uematsu M, et al. Plasma brain natriuretic peptide as a prognostic indicator in patients with primary pulmonary hypertension. *Circulation*. 2000;102(8):865-70. PMID: 10952954.
127. Nakayama T, Shimada H, Takatsuki S, et al. Efficacy and limitations of continuous intravenous epoprostenol therapy for idiopathic pulmonary arterial hypertension in Japanese children. *Circ J*. 2007;71(11):1785-90. PMID: 17965503.
128. Nath J, Demarco T, Hourigan L, et al. Correlation between right ventricular indices and clinical improvement in epoprostenol treated pulmonary hypertension patients. *Echocardiography*. 2005;22(5):374-9. PMID: 15901287.
129. Nickel N, Golpon H, Greer M, et al. The prognostic impact of follow-up assessments in patients with idiopathic pulmonary arterial hypertension. *Eur Respir J*. 2012;39(3):589-96. PMID: 21885392.
130. Nickel N, Kempf T, Tapken H, et al. Growth differentiation factor-15 in idiopathic pulmonary arterial hypertension. *Am J Respir Crit Care Med*. 2008;178(5):534-41. PMID: 18565955.
131. Njaman W, Iesaki T, Iwama Y, et al. Serum uric Acid as a prognostic predictor in pulmonary arterial hypertension with connective tissue disease. *Int Heart J*. 2007;48(4):523-32. PMID: 17827824.
132. Ogawa A, Miyaji K, Yamadori I, et al. Safety and efficacy of epoprostenol therapy in pulmonary veno-occlusive disease and pulmonary capillary hemangiomatosis. *Circulation Journal*. 2012;76(7):1729-1736. PMID: 22481098.
133. Park MH, Scott RL, Uber PA, et al. Usefulness of B-type natriuretic peptide as a predictor of treatment outcome in pulmonary arterial hypertension. *Congest Heart Fail*. 2004;10(5):221-5. PMID: 15470298.
134. Pyxaras SA, Pinamonti B, Barbati G, et al. Echocardiographic evaluation of systolic and mean pulmonary artery pressure in the follow-up of patients with pulmonary hypertension. *Eur J Echocardiogr*. 2011;12(9):696-701. PMID: 21821609.
135. Raymond RJ, Hinderliter AL, Willis PW, et al. Echocardiographic predictors of adverse outcomes in primary pulmonary hypertension. *J Am Coll Cardiol*. 2002;39(7):1214-9. PMID: 11923049.
136. Rhodes CJ, Wharton J, Howard LS, et al. Red cell distribution width outperforms other potential circulating biomarkers in predicting survival in idiopathic pulmonary arterial hypertension. *Heart*. 2011;97(13):1054-60. PMID: 21558476.
137. Sadushi-Kolici R, Skoro-Sajer N, Zimmer D, et al. Long-term treatment, tolerability, and survival with sub-cutaneous treprostinil for severe pulmonary hypertension. *J Heart Lung Transplant*. 2012;31(7):735-743. PMID: 22480725.
138. Schumann C, Lepper PM, Frank H, et al. Circulating biomarkers of tissue remodelling in pulmonary hypertension. *Biomarkers*. 2010;15(6):523-32. PMID: 20528622.

139. Sebbag I, Rudski LG, Therrien J, et al. Effect of chronic infusion of epoprostenol on echocardiographic right ventricular myocardial performance index and its relation to clinical outcome in patients with primary pulmonary hypertension. *Am J Cardiol*. 2001;88(9):1060-3. PMID: 11704014.
140. Shimony A, Fox BD, Langleben D, et al. Incidence and Significance of Pericardial Effusion in Patients With Pulmonary Arterial Hypertension. *Can J Cardiol*. 2012. PMID: 22717247.
141. Soon E, Doughty NJ, Treacy CM, et al. Log-transformation improves the prognostic value of serial NT-proBNP levels in apparently stable pulmonary arterial hypertension. *Pulm Circ*. 2011;1(2):244-9. PMID: 22034610.
142. Souza R, Jardim C, Julio Cesar Fernandes C, et al. NT-proBNP as a tool to stratify disease severity in pulmonary arterial hypertension. *Respir Med*. 2007;101(1):69-75. PMID: 16781131.
143. Taguchi H, Kataoka M, Yanagisawa R, et al. Platelet level as a new prognostic factor for idiopathic pulmonary arterial hypertension in the era of combination therapy. *Circulation Journal*. 2012;76(6):1494-1500. PMID: 22447010.
144. Takatsuki S, Calderbank M, Ivy DD. Initial experience with tadalafil in pediatric pulmonary arterial hypertension. *Pediatr Cardiol*. 2012;33(5):683-688. PMID: 22402804.
145. Takatsuki S, Rosenzweig EB, Zuckerman W, et al. Clinical safety, pharmacokinetics, and efficacy of ambrisentan therapy in children with pulmonary arterial hypertension. *Pediatr Pulmonol*. 2012. PMID: 22511577.
146. Takatsuki S, Wagner BD, Ivy DD. B-type Natriuretic Peptide and Amino-terminal Pro-B-type Natriuretic Peptide in Pediatric Patients with Pulmonary Arterial Hypertension. *Congenital Heart Disease*. 2012;7(3):259-267. PMID: 22325151.
147. Takeda Y, Tomimoto S, Tani T, et al. Bilirubin as a prognostic marker in patients with pulmonary arterial hypertension. *BMC Pulm Med*. 2010;10:22. PMID: 20412580.
148. Torbicki A, Kurzyna M, Kuca P, et al. Detectable serum cardiac troponin T as a marker of poor prognosis among patients with chronic precapillary pulmonary hypertension. *Circulation*. 2003;108(7):844-8. PMID: 12900346.
149. Utsunomiya H, Nakatani S, Okada T, et al. A simple method to predict impaired right ventricular performance and disease severity in chronic pulmonary hypertension using strain rate imaging. *Int J Cardiol*. 2011;147(1):88-94. PMID: 19747741.
150. Utsunomiya H, Nakatani S, Nishihira M, et al. Value of estimated right ventricular filling pressure in predicting cardiac events in chronic pulmonary arterial hypertension. *J Am Soc Echocardiogr*. 2009;22(12):1368-74. PMID: 19944957.
151. Van Albada ME, Loot FG, Fokkema R, et al. Biological serum markers in the management of pediatric pulmonary arterial hypertension. *Pediatr Res*. 2008;63(3):321-7. PMID: 18287971.
152. Vizza CD, Letizia C, Badagliacca R, et al. Relationship between baseline ET-1 plasma levels and outcome in patients with idiopathic pulmonary hypertension treated with bosentan. *Int J Cardiol*. 2012. PMID: 22265324.
153. Vizza CD, Letizia C, Petramala L, et al. Venous endotelin-1 (ET-1) and brain natriuretic peptide (BNP) plasma levels during 6-month bosentan treatment for pulmonary arterial hypertension. *Regul Pept*. 2008;151(1-3):48-53. PMID: 18796317.
154. Voelkel MA, Wynne KM, Badesch DB, et al. Hyperuricemia in severe pulmonary hypertension. *Chest*. 2000;117(1):19-24. PMID: 10631193.
155. Wilkins MR, Paul GA, Strange JW, et al. Sildenafil versus Endothelin Receptor Antagonist for Pulmonary Hypertension (SERAPH) study. *Am J Respir Crit Care Med*. 2005;171(11):1292-7. PMID: 15750042.
156. Yamada Y, Okuda S, Kataoka M, et al. Prognostic value of cardiac magnetic resonance imaging for idiopathic pulmonary arterial hypertension before initiating intravenous prostacyclin therapy. *Circulation Journal*. 2012;76(7):1737-1743. PMID: 22498565.

157. Yanagisawa R, Kataoka M, Taguchi H, et al. Impact of First-Line Sildenafil Monotreatment for Pulmonary Arterial Hypertension. *Circ J*. 2012;76(5):1245-1252. PMID: 22333215.
158. Yang SI, Chung WJ, Jung SH, et al. Effects of inhaled iloprost on congenital heart disease with eisenmenger syndrome. *Pediatr Cardiol*. 2012;33(5):744-748. PMID: 22349672.
159. Yoshida S, Shirato K, Shimamura R, et al. Long-term safety and efficacy of ambrisentan in Japanese adults with pulmonary arterial hypertension. *Curr Med Res Opin*. 2012;28(6):1069-1076. PMID: 22506623.
160. Zafirir N, Zingerman B, Solodky A, et al. Use of noninvasive tools in primary pulmonary hypertension to assess the correlation of right ventricular function with functional capacity and to predict outcome. *Int J Cardiovasc Imaging*. 2007;23(2):209-15. PMID: 16972146.
161. Zeng WJ, Sun YJ, Xiong CM, et al. Prognostic value of echocardiographic right/left ventricular end-diastolic diameter ratio in idiopathic pulmonary arterial hypertension. *Chin Med J (Engl)*. 2011;124(11):1672-7. PMID: 21740775.
162. Zhao QH, Peng FH, Wei H, et al. Serum high-density lipoprotein cholesterol levels as a prognostic indicator in patients with idiopathic pulmonary arterial hypertension. *Am J Cardiol*. 2012;110(3):433-439. PMID: 22560769.

## Appendix G. Correlation Table for KQ 2

Table G-1. Correlation table for KQ 2 (management of PAH)

Andreassen, 2006 <sup>1</sup>	NR for total cohort	Baseline	BNP	Cardiac index	61	-0.58	<0.001
			BNP	Functional class	61	0.27	0.047
			BNP	RHC-mPAP	61	0.47	<0.001
			BNP	RHC-PVR	61	0.66	<0.001
			BNP	RHC-PVR	17	0.55	0.041
			BNP	RHC-sPAP	61	-0.29	0.028
			BNP	Right atrial pressure	61	0.47	<0.001
Bendayan, 2002 <sup>2</sup>	Mean 54.9 (Range 16 to 80)	Baseline	Uric acid	6MWD (absolute)	29	-0.35	0.03
			Uric acid	Functional class	29	0.66	0.001
			Uric acid	Mortality	29	0.66	0.001
			Uric acid	RHC-CO	29	0.06	0.72
			Uric acid	RHC-mPAP	29	0.19	0.17
Bernus, 2009 <sup>3</sup>	Median 9.3 (Range 5.2 to 14.2)	Baseline	BNP	Cardiac index	52	-0.08	NS
			BNP	Peak TRV	47	0.23	NS
			BNP	PCWP	56	0.26	<0.05
			BNP	RHC-mPAP	57	0.16	NS
			BNP	RHC-PVR	56	0.06	NS
			BNP	Right atrial pressure	56	0.34	p<0.05
			BNP	RV size	42	0.23	NS
Borges, 2006 <sup>4</sup>	Mean 56.4 (SD 11)	Baseline	RIMP/MPI/ Tei Index	6MWD (absolute)	37	-0.73	0.661
			RIMP/MPI/ Tei Index	RHC-PVR	37	0.172	0.47
			TAPSE	6MWD (absolute)	37	0.36	0.028
			TAPSE	RHC-PVR	37	-0.072	0.53

Campana, 2004 <sup>5</sup>	Mean 50 (SD 11)	Baseline	BNP	Cardiac index	22	$r^2=0.2$ (negative correlation)	
			BNP	RHC-mPAP	22	$r^2=0.1$	
			BNP	Right atrial pressure	22	$r^2=0.09$	
			BNP	RVEF	22	$r^2=0.46$ (negative correlation)	
			BNP	TAPSE	22	$r^2=0.005$	
Cella, 2009 <sup>6</sup>	Mean 53.8 (SD 13.1)	1 year	Change in RVSP	6MWD (change)	18	$R^2=0.5355$	0.0006
Chin, 2007 <sup>7</sup>	NR	Baseline	BNP	6MWD (absolute)	27	-0.59	0.04
			BNP	PCWP	27	0.32	0.10
			BNP	RHC-CO	27	-0.25	0.19
			BNP	RHC-mPAP	27	0.29	0.14
			BNP	RHC-PVR	27	0.28	0.15
			BNP	Right atrial pressure	27	0.66	<0.001
Dyer, 2006 <sup>8</sup>	Mean 9.6 (SD 4.8)	Baseline	RIMP/MPI/Tei Index	RHC-mPAP	12	0.94	<0.001
		Intermediate	RIMP/MPI/Tei Index	RHC-mPAP	12	0.90	<0.001
Fahmy Elnoamany, 2007 <sup>9</sup>	Mean 55.3 (SD 10.39)	Baseline	Endothelin-1	RHC-sPAP	53	0.94	<0.001
			sPAP	RHC-sPAP	53	0.92	<0.001
Fijalkowska, 2006 <sup>10</sup>	Mean 41 (SD 15.1)	Baseline	BNP	6MWD (absolute)	55	-0.60	<0.001
			BNP	Cardiac index	55	-0.65	<0.001
			BNP	Functional class	55	0.45	<0.001
			BNP	Peak TRV	55	0.08	NS
			BNP	RHC-mPAP	55	0.21	NS
			BNP	RHC-PVR	55	0.43	<0.001
			BNP	Right atrial pressure	55	0.45	<0.001
Forfia, 2006 <sup>11</sup>	Mean 55 (SD 15)	Baseline	TAPSE	RHC-PVR	63	-0.52	<0.0001

Friedberg, 2006 <sup>12</sup>	NR	Baseline	mPAP	RHC-mPAP	17	0.85	<0.0001
			mPAP	RHC-mPAP	17	0.85	<0.0001
			sPAP	RHC-sPAP	17	0.88	<0.0001
			sPAP	RHC-sPAP	17	0.88	<0.0001
Gan, 2006 <sup>13</sup>	Mean 48 (Range 21 to 80)	Baseline	BNP	6MWD (absolute)	30	-0.51	0.008
			BNP	Cardiac index	30	-0.45	0.019
			BNP	RHC-mPAP	30	0.28	0.143
			BNP	RHC-PVR	30	0.30	0.122
			BNP	Right atrial pressure	30	0.49	0.008
Ghofrani, 2002 <sup>14</sup>	Mean 48.3 (SEM 3.7)	Baseline	ANP	RHC-PVR	20	0.66	<0.0001
			cGMP	RHC-PVR	36	0.139	NS
Goto, 2010 <sup>15</sup>	Mean 64.07 (SD 12.28)	Baseline	BNP	RHC-mPAP	46	0.508	0.044
			sPAP	RHC-sPAP	46	0.505	<0.01
Grubstein, 2008 <sup>16</sup>	Mean 52 (Range 20 to 80)	Baseline	sPAP	RHC-sPAP	38	0.6	0.001
Haddad, 2009 <sup>17</sup>	Mean 49 (SD 11)	Baseline	mPAP	RHC-mPAP	51	0.94	0.90-0.97
			sPAP	RHC-sPAP	48	0.97	0.94-0.98
Heresi, 2010 <sup>18</sup>	Mean 44 (SD 14)	Baseline	BNP	6MWD (absolute)	40	-0.58	<0.001
			BNP	Cardiac index	40	-0.31	0.07
			BNP	RHC-mPAP	40	0.26	0.10
			BNP	RHC-PVR	40	0.15	0.36
			BNP	Right atrial pressure	40	0.49	0.001
Heresi, 2012 <sup>19</sup>	Mean 47 (SD 13)	Baseline	cTnl (detectable)	6MWD (absolute)	68	-0.29	0.020
				Functional class	68	0.36	0.002
				BNP	68	0.45	0.001
				RA size	68	0.36	0.010



Hinderliter, 1997 <sup>20</sup>	NR for total cohort	Baseline	FAC	6MWD (absolute)	75	0.08	
			FAC	Cardiac index	75	-0.01	
			FAC	RHC-mPAP	75	-0.37	<0.01
			FAC	Right atrial pressure	75	-0.01	
			Pericardial effusion	6MWD (absolute)	75	-0.50	<0.01
			Pericardial effusion	Cardiac index	75	-0.40	<0.001
			Pericardial effusion	RHC-mPAP	75	0.22	
			Pericardial effusion	Right atrial pressure	75	0.50	<0.001
			RV size	6MWD (absolute)	75	-0.24	<0.05
			RV size	Cardiac index	75	-0.16	
			RV size	RHC-mPAP	75	0.25	
			RV size	Right atrial pressure	75	0.45	<0.001
			sPAP	RHC-sPAP	75	0.57	<0.001
Homma, 2001 <sup>21</sup>	Mean 45.0 (SD 10.6)	Baseline	sPAP	RHC-sPAP	8	$r^2=0.11$	
Leuchte, 2005 <sup>22</sup>	Mean 46.93 (SEM 2.8)	Mean followup 12.6 ± 1.5 months	Change in BNP	Change in 6MWD	30	-0.74	<0.001
			Change in BNP	Change in cardiac index	30	-0.49	<0.01
			Change in BNP	Change in RHC-CO	30	-0.48	<0.01
			Change in BNP	Change in RHC-mPAP	30	0.54	<0.01
			Change in BNP	Change in RHC-PVR	30	0.55	<0.01
			Change in BNP	Change in right atrial pressure	30	0.78	<0.001
Machado, 2006 <sup>23</sup>	NR for total cohort	Baseline	BNP	6MWD (absolute)	34	-0.54	0.001
			BNP	PCWP	37	0.30	0.07
			BNP	RA size	211	0.21	0.002
			BNP	RHC-CO	37	-0.43	0.006
			BNP	RHC-dPAP	37	0.37	0.02
			BNP	RHC-mPAP	37	0.43	0.006
			BNP	RHC-PVR	37	0.51	0.001
			BNP	RHC-sPAP	37	0.59	
Machado, 2004 <sup>24</sup>	NR for total cohort	Baseline	Nitric oxide	RHC-mPAP	12	0.56	0.054
			sPAP	RHC-sPAP	17	0.794	<0.001

Montani, 2007 <sup>25</sup>	Mean 43.8 (Range 33.8-56.6)	Baseline	Endothelin-1	Cardiac index	33	-0.47	<0.008
			Endothelin-1	RHC-PVR	33	0.55	<0.05
			Endothelin-1	Right atrial pressure	33	0.46	0.01
Morishita, 2009 <sup>26</sup>	Mean 32.6 (Range 15-49)	Baseline	Pericardial effusion	Functional class	7	0.34	<0.05
			RA size	Functional class	7	0.33	NS
Mukerjee, 2003 <sup>27</sup>	Mean 57 (Range 34-80)	Baseline	BNP	RHC-mPAP	23	$r^2=0.28$	<0.05
			BNP	RHC-PVR	23	$r^2=0.24$	<0.05
Nagaya, 2000 <sup>28</sup>	NR for total cohort	Baseline	ANP	PCWP	60	0.22	NS
			ANP	RHC-CO	60	-0.49	<0.001
			ANP	RHC-mPAP	60	0.42	<0.001
			ANP	Right atrial pressure	60	0.55	<0.001
		Baseline	BNP	PCWP	60	0.16	
			BNP	RHC-CO	60	-0.51	<0.001
			BNP	RHC-mPAP	60	0.42	
			BNP	RHC-mPAP	60	0.43	<0.05
			BNP	RHC-PVR	60	0.59	<0.001
			BNP	Right atrial pressure	60	0.55	<0.001
Nath, 2005 <sup>29</sup>	Mean 46 (SD 11)	Long-term >1 year	Peak TRV	Functional class	20	0.26	0.29
			Peak TRV	Functional class	20	0.23	0.33
			Peak TRV	Functional class	20	0.38	0.10
Nickel, 2008 <sup>30</sup>	Mean 47.6 (SD 15.8)	Baseline	BNP	6MWD (absolute)	139	-0.217	0.028
			BNP	Cardiac index	139	-0.378	0.001
			BNP	PCWP	139	-0.027	0.9
			BNP	RHC-PVR	139	0.321	0.006
			BNP	Right atrial pressure	139	0.283	0.008
Pyxaras, 2011 <sup>31</sup>	Mean 55 (SD 19)	Baseline	sPAP	RHC-sPAP	60	0.457	0.002
			mPAP	RHC-mPAP	60	0.451	0.006

Souza, 2007 <sup>32</sup>	Mean 37 (SEM 2)	Baseline	BNP	6MWD (absolute)	42	-0.31	0.052
			BNP	Cardiac index	42	-0.70	<0.001
			BNP	Functional class	42	0.81	<0.001
			BNP	RHC-mPAP	42	0.58	<0.001
			BNP	RHC-PVR	42	0.80	<0.001
			BNP	Right atrial pressure	42	0.68	0.004
Takatsuki, 2012 <sup>33</sup>	Median 10 (Range 5-15)	Baseline	BNP	6MWD (absolute)	41	-0.32	0.04
			BNP	RHC-mPAP	47	0.34	0.02
			BNP	Right atrial pressure	45	0.48	<0.01
			BNP	RHC-PVRi	46	0.30	0.04
			BNP	RHC-CI	41	-0.22	0.16
			BNP	TRJv	69	0.36	<0.01
			BNP	WHO FC	36	0.32	0.06
			NT-proBNP	6MWD (absolute)	41	-0.49	<0.01
			NT-proBNP	RHC-mPAP	47	0.28	0.06
			NT-proBNP	Right atrial pressure	45	0.48	<0.01
			NT-proBNP	RHC-PVRi	46	0.23	0.12
			NT-proBNP	RHC-CI	41	-0.01	0.93
			NT-proBNP	TRJv	69	0.41	<0.01
			NT-proBNP	WHO FC	36	0.35	0.04
Utsunomiya, 2009 <sup>34</sup>	Mean 46 (SD 13)	Baseline	RA size	Right atrial pressure	50	0.31	0.03
Van Albada, 2008 <sup>35</sup>	Median 7.0 (Range 0.1-17.3)	Baseline	BNP	6MWD (absolute)	29	-0.527	<0.001
		Long-term >1 year	BNP	6MWD (change)	20	-0.63	0.04
		Baseline	BNP	Functional class	29	0.34	0.04
		Long-term >1 year	BNP	Functional class	20	0.72	0.02
		Long-term >1 year	BNP	Mortality	29	9.93	0.002
		Baseline	Uric acid	Cardiac index	16	-0.65	0.007
		Long-term >1 year	Uric acid	Mortality	29	5.93	0.015
		Baseline	Uric acid	RHC-mPAP	16	0.63	0.01
		Baseline	Uric acid	RHC-PVR	16	0.71	0.03

Vizza, 2012 <sup>36</sup>	Mean 53 (SD 17)	Baseline	ET-1	WHO FC	44	0.35	0.02
				BNP	44	0.51	0.001
				RHC-mPAP	44	0.38	0.01
				RHC-CI	44	-0.43	0.004
				RHC-PVR	44	0.48	0.001
Voelkel, 2000 <sup>37</sup>	NR for total cohort	Baseline	Uric acid	RHC-mPAP	191	0.41	<0.0001
			Uric acid	Right atrial pressure	191	0.486	<0.0001
Williams, 2006 <sup>38</sup>	Mean 60 (SD 11)	Baseline	BNP	Cardiac index	68	-0.5	<0.0001
			BNP	RHC-mPAP	68	0.62	<0.0001
			BNP	RHC-PVR	68	0.81	<0.0001
			BNP	Right atrial pressure	68	0.53	<0.0001
Zafir, 2007 <sup>39</sup>	Mean 51 (SD 14.7)	Baseline	RA size	6MWD (absolute)	29	-0.42	0.02
				Functional class	29	0.39	0.04
			RIMP/MPI/Tei Index	6MWD (absolute)	29	-0.25	0.18
			RVEF	Functional class	29	-0.45	0.019

Abbreviations: 6MWD=6-minute walk distance; ANP=A-type natriuretic peptide; BNP=B-type natriuretic peptide ; CO=cardiac output; CVD=collagen vascular disease; FAC=fractional area change; mPAP=mean pulmonary artery pressure; MPI=myocardial performance index; NR=not reported; PCWP=pulmonary capillary wedge pressure; PVR=pulmonary vascular resistance; RA=right atrium; RIMP=right index of myocardial performance; RV=right ventricle; RVEF=right ventricular ejection fraction; SD=standard deviation; SEM=standard error of the mean; sPAP=systolic pulmonary artery pressure; TAPSE=tricuspid annular plane systolic excursion; TRV=tricuspid regurgitant jet velocity

## References Cited in Appendix G

1. Andreassen AK, Wergeland R, Simonsen S, et al. N-terminal pro-B-type natriuretic peptide as an indicator of disease severity in a heterogeneous group of patients with chronic precapillary pulmonary hypertension. *Am J Cardiol.* 2006;98(4):525-9. PMID: 16893710.
2. Bendayan D, Shitrit D, Ygla M, et al. Hyperuricemia as a prognostic factor in pulmonary arterial hypertension. *Respir Med.* 2003;97(2):130-3. PMID: 12587962.
3. Bernus A, Wagner BD, Accurso F, et al. Brain natriuretic peptide levels in managing pediatric patients with pulmonary arterial hypertension. *Chest.* 2009;135(3):745-51. PMID: 18849405.
4. Borges AC, Knebel F, Eddicks S, et al. Right ventricular function assessed by two-dimensional strain and tissue Doppler echocardiography in patients with pulmonary arterial hypertension and effect of vasodilator therapy. *Am J Cardiol.* 2006;98(4):530-4. PMID: 16893711.
5. Campana C, Pasotti M, Monti L, et al. The evaluation of right ventricular performance in different clinical models of heart failure. *Eur Heart J Suppl.* 2004;6(6):F61-F67.
6. Cella G, Vianello F, Cozzi F, et al. Effect of bosentan on plasma markers of endothelial cell activity in patients with secondary pulmonary hypertension related to connective tissue diseases. *J Rheumatol.* 2009;36(4):760-7. PMID: 19208592.
7. Chin KM, Channick RN, Kim NH, et al. Central venous blood oxygen saturation monitoring in patients with chronic pulmonary arterial hypertension treated with continuous IV epoprostenol: correlation with measurements of hemodynamics and plasma brain natriuretic peptide levels. *Chest.* 2007;132(3):786-92. PMID: 17646224.
8. Dyer KL, Pauliks LB, Das B, et al. Use of myocardial performance index in pediatric patients with idiopathic pulmonary arterial hypertension. *J Am Soc Echocardiogr.* 2006;19(1):21-7. PMID: 16423665.
9. Fahmy Elnoamany M, Abdelraouf Dawood A. Right ventricular myocardial isovolumic relaxation time as novel method for evaluation of pulmonary hypertension: correlation with endothelin-1 levels. *J Am Soc Echocardiogr.* 2007;20(5):462-9. PMID: 17484984.
10. Fijalkowska A, Kurzyna M, Torbicki A, et al. Serum N-terminal brain natriuretic peptide as a prognostic parameter in patients with pulmonary hypertension. *Chest.* 2006;129(5):1313-21. PMID: 16685024.
11. Forfia PR, Fisher MR, Mathai SC, et al. Tricuspid annular displacement predicts survival in pulmonary hypertension. *Am J Respir Crit Care Med.* 2006;174(9):1034-41. PMID: 16888289.
12. Friedberg MK, Feinstein JA, Rosenthal DN. A novel echocardiographic Doppler method for estimation of pulmonary arterial pressures. *J Am Soc Echocardiogr.* 2006;19(5):559-62. PMID: 16644441.
13. Gan CT, McCann GP, Marcus JT, et al. NT-proBNP reflects right ventricular structure and function in pulmonary hypertension. *Eur Respir J.* 2006;28(6):1190-4. PMID: 16971413.
14. Ghofrani HA, Wiedemann R, Rose F, et al. Lung cGMP release subsequent to NO inhalation in pulmonary hypertension: responders versus nonresponders. *Eur Respir J.* 2002;19(4):664-71. PMID: 11998996.
15. Goto K, Arai M, Watanabe A, et al. Utility of echocardiography versus BNP level for the prediction of pulmonary arterial pressure in patients with pulmonary arterial hypertension. *Int Heart J.* 2010;51(5):343-7. PMID: 20966607.
16. Grubstein A, Benjaminov O, Dayan DB, et al. Computed tomography angiography in pulmonary hypertension. *Isr Med Assoc J.* 2008;10(2):117-20. PMID: 18432023.

17. Haddad F, Zamanian R, Beraud AS, et al. A novel non-invasive method of estimating pulmonary vascular resistance in patients with pulmonary arterial hypertension. *J Am Soc Echocardiogr*. 2009;22(5):523-9. PMID: 19307098.
18. Heresi GA, Aytekin M, Newman J, et al. CXC-chemokine ligand 10 in idiopathic pulmonary arterial hypertension: marker of improved survival. *Lung*. 2010;188(3):191-7. PMID: 20186422.
19. Heresi GA, Tang WH, Aytekin M, et al. Sensitive cardiac troponin I predicts poor outcomes in pulmonary arterial hypertension. *Eur Respir J*. 2012;39(4):939-44. PMID: 21885398.
20. Hinderliter AL, Willis PWt, Barst RJ, et al. Effects of long-term infusion of prostacyclin (epoprostenol) on echocardiographic measures of right ventricular structure and function in primary pulmonary hypertension. Primary Pulmonary Hypertension Study Group. *Circulation*. 1997;95(6):1479-86. PMID: 9118516.
21. Homma A, Anzueto A, Peters JL, et al. Pulmonary artery systolic pressures estimated by echocardiogram vs cardiac catheterization in patients awaiting lung transplantation. *J Heart Lung Transplant*. 2001;20(8):833-9. PMID: 11502405.
22. Leuchte HH, Holzapfel M, Baumgartner RA, et al. Characterization of brain natriuretic peptide in long-term follow-up of pulmonary arterial hypertension. *Chest*. 2005;128(4):2368-74. PMID: 16236896.
23. Machado RF, Anthi A, Steinberg MH, et al. N-terminal pro-brain natriuretic peptide levels and risk of death in sickle cell disease. *JAMA*. 2006;296(3):310-8. PMID: 16849664.
24. Machado RF, Londhe Nerkar MV, Dweik RA, et al. Nitric oxide and pulmonary arterial pressures in pulmonary hypertension. *Free Radic Biol Med*. 2004;37(7):1010-7. PMID: 15336317.
25. Montani D, Souza R, Binkert C, et al. Endothelin-1/endothelin-3 ratio: a potential prognostic factor of pulmonary arterial hypertension. *Chest*. 2007;131(1):101-8. PMID: 17218562.
26. Morishita T, Miyaji K, Akao I, et al. The ratio of the atrial areas reflects the clinical status of patients with pulmonary arterial hypertension. *J Med Ultrason*. 2009;36(4):201-206.
27. Mukerjee D, Yap LB, Holmes AM, et al. Significance of plasma N-terminal pro-brain natriuretic peptide in patients with systemic sclerosis-related pulmonary arterial hypertension. *Respir Med*. 2003;97(11):1230-6. PMID: 14635979.
28. Nagaya N, Nishikimi T, Uematsu M, et al. Plasma brain natriuretic peptide as a prognostic indicator in patients with primary pulmonary hypertension. *Circulation*. 2000;102(8):865-70. PMID: 10952954.
29. Nath J, Demarco T, Hourigan L, et al. Correlation between right ventricular indices and clinical improvement in epoprostenol treated pulmonary hypertension patients. *Echocardiography*. 2005;22(5):374-9. PMID: 15901287.
30. Nickel N, Kempf T, Tapken H, et al. Growth differentiation factor-15 in idiopathic pulmonary arterial hypertension. *Am J Respir Crit Care Med*. 2008;178(5):534-41. PMID: 18565955.
31. Pyxaras SA, Pinamonti B, Barbati G, et al. Echocardiographic evaluation of systolic and mean pulmonary artery pressure in the follow-up of patients with pulmonary hypertension. *Eur J Echocardiogr*. 2011;12(9):696-701. PMID: 21821609.
32. Souza R, Jardim C, Julio Cesar Fernandes C, et al. NT-proBNP as a tool to stratify disease severity in pulmonary arterial hypertension. *Respir Med*. 2007;101(1):69-75. PMID: 16781131.
33. Takatsuki S, Wagner BD, Ivy DD. B-type Natriuretic Peptide and Amino-terminal Pro-B-type Natriuretic Peptide in Pediatric Patients with Pulmonary Arterial Hypertension. *Congenital Heart Disease*. 2012;7(3):259-267. PMID: 22325151.
34. Utsunomiya H, Nakatani S, Nishihira M, et al. Value of estimated right ventricular filling pressure in predicting cardiac events in chronic pulmonary arterial hypertension. *J Am Soc Echocardiogr*. 2009;22(12):1368-74. PMID: 19944957.

35. Van Albada ME, Loot FG, Fokkema R, et al. Biological serum markers in the management of pediatric pulmonary arterial hypertension. *Pediatr Res*. 2008;63(3):321-7. PMID: 18287971.
36. Vizza CD, Letizia C, Badagliacca R, et al. Relationship between baseline ET-1 plasma levels and outcome in patients with idiopathic pulmonary hypertension treated with bosentan. *Int J Cardiol*. 2012. PMID: 22265324.
37. Voelkel MA, Wynne KM, Badesch DB, et al. Hyperuricemia in severe pulmonary hypertension. *Chest*. 2000;117(1):19-24. PMID: 10631193.
38. Williams MH, Handler CE, Akram R, et al. Role of N-terminal brain natriuretic peptide (N-TproBNP) in scleroderma-associated pulmonary arterial hypertension. *Eur Heart J*. 2006;27(12):1485-94. PMID: 16682379.
39. Zafrir N, Zingerman B, Solodky A, et al. Use of noninvasive tools in primary pulmonary hypertension to assess the correlation of right ventricular function with functional capacity and to predict outcome. *Int J Cardiovasc Imaging*. 2007;23(2):209-15. PMID: 1697214.